

Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelssystem.org.

Overview for Request: cder_mpl1r_wp077, Report 1 of 3

Request ID: cder_mpl1p_wp077

Request Description: In this report, we describe the incidence rate of hospitalized tachyarrhythmia, defined as tachyarrhythmia, overall and by subtype, that occurred from May 13, 2022 (the approval date of Mounjaro (tirzepatide) in the U.S.) to June 30, 2023, in type 2 diabetes mellitus (T2DM) patients who newly initiated Mounjaro (tirzepatide) or other long-acting glucagon-like peptide-1 (LA GLP-1) receptor agonists (RAs), by product and patient characteristics including race/ethnicity groups.

This is report 1 of 3 and contains the results from the primary analysis. For the primary analysis, the lookback period for enrollment, inclusion or exclusion criteria, and most covariates was 365 days in length, and patients were excluded from the analysis if an event occurred on the index date (i.e., the blackout period is set to 1 day). Reports 2 and 3 contain the results from two sensitivity analyses. For the first sensitivity analysis, the lookback period was 183 days in length. For the second sensitivity analysis, events were allowed to occur on the index date.

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis (CIDA) module, version 12.1.2 with custom programming.

Data Source: We distributed this query to seven Sentinel Data Partners (DPs) on September 28, 2023. Six of these Data Partners are a subset of the SDD that rapidly refresh to provide freshest feasible data. The study period included data from May 13, 2022 through June 30, 2023. See Appendix A for a list of dates of available data for each DP.

Study Design: We identified all individuals with incident use of tirzepatide or other LA GLP-1 RAs and evaluated the occurrence of hospitalized tachyarrhythmia within each LA GLP-1 RA exposure cohorts.

In addition to the overall exposure cohorts, analyses were also conducted by the following subgroups:

- Age groups (0-40, 41-64, 65-74, 75-84, 85 years of age or greater)
- Sex (male, female)
- Calendar year of index date
- Race (White, Black or African American, Asian, American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, Unknown, Multi-Racial)
- Calendar year * race
- Age group * race
- Other cardiac disease at baseline (heart failure, ischemic heart disease/coronary artery disease/myocardial infarction, hypertension, valvular disease, obstructive sleep apnea, and hypertrophic cardiomyopathy)

For the primary analysis, the lookback period for enrollment, inclusion or exclusion criteria, and most covariates was 365 days in length, and patients were excluded from the analysis if an event occurred on the index date (i.e., the blackout period is set to 1 day). Two sensitivity analyses were conducted. For the first sensitivity analysis, the lookback period was 183 days in length. For the second sensitivity analysis, events were allowed to occur on the index date.

This is a Type 2 analysis with custom programming in the Query Request Package (QRP) documentation.

Exposures of Interest: Our exposures of interest were defined as the first qualifying dispensing of one of the following LA GLP-1 RA brand names, each as its own separate cohort: Mounjaro (tirzepatide), Bydureon or Bydureon BCISE (exenatide synthetic), Ozempic (semaglutide), Rybelsus (semaglutide), Wegovy (semaglutide), Saxenda (liraglutide), Victoza (liraglutide), Trulicity (dulaglutide) or Xultophy (insulin degludec/liraglutide). We defined exposures using National Drug Codes (NDCs). Only the first qualifying (index) dispensings of the exposures of interest were included; cohort re-entry was not allowed. See Appendix B for generic and brand names of medical products used to define exposures of interest.

Stockpiling Rules: Brand names within a single exposure definition were stockpiled together, and dispensing dates were not adjusted in case of early refills. If multiple dispensings occurred on the same day, the maximum value for days supply and amount supply among these dispensings were taken to be days supply and amount supply values on that day.

Overview for Request: cder_mpl1r_wp077, Report 1 of 3

Outcomes of Interest: The following health outcomes of interest (HOI) were evaluated for each of the exposure definitions:

- Hospitalized tachyarrhythmia (defined as the presence of any of the conditions below)
- Atrial fibrillation and flutter
- Sinus tachycardia
- Supraventricular tachycardia
- Other tachycardia
- Cardiac arrest
- Ventricular fibrillation and flutter
- Ventricular tachycardia

Outcomes were defined in the inpatient caresetting in principal position (IPP) and in the emergency department caresetting (ED*).

We defined outcomes using International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes. See Appendix C for diagnosis codes used to define the outcome.

Cohort Eligibility Criteria: We required eligible members to be continuously enrolled in health plans with medical and drug coverage for at least 365 days prior to the index date, during which gaps in coverage of up to 45 days were allowed. We defined new use as no evidence use of the index-defining exposure or any other LA GLP-1 RA in the 365 days prior to index date.

Inclusion Criteria: We required exposure episodes to have a T2DM diagnosis and usage of any oral anti-diabetic drug in the 365 days prior to index date.

Exclusion Criteria: We excluded exposure episodes with a T1DM diagnosis, gestational diabetes, other secondary diabetes illnesses, use of any short-acting (SA) GLP-1 RAs, pregnancy, or insulin-only use (defined as evidence of insulin use without evidence of use of any other anti-diabetic drug) in the 365 days prior to the index date.

We defined inclusion and exclusion criteria using NDCs, ICD-10-CM diagnosis and procedure codes, Healthcare Common Procedure Coding System (HCPCS), Level II codes, and Current Procedural Terminology, Fourth Edition (CPT-4) codes.

See Appendix D for diagnosis or procedure codes used to define inclusion and exclusion characteristics and Appendix E for generic and brand names of medical products.

Follow-up Time: We created exposure episodes based on the number of days of product supplied per dispensing in the outpatient pharmacy dispensing data. We bridged together episodes less than 5 days apart and added 5 days to the end of each episode.

Outcome evaluation began on the day after index date and continued until the earliest occurrence of the following:

- Outcome
- Treatment discontinuation
- Disenrollment
- Death (except for when all-cause mortality is the outcome)
- End of DP data
- Pregnancy
- Inpatient (IP*) or ED* encounter (other than the HOI-defining hospitalized tachyarrhythmia)
- Non-index LA GLP-1 RA

Baseline Characteristics: The following demographic and clinical characteristics of our study population were ascertained on index date: continuous age, age groups (0-40, 41-64, 65-74, 75-84, 85 years of age or greater), sex (male, female), race (American Indian or Alaska native, Asian, Black or African American, Native Hawaiian or other Pacific Islander, White, Unknown, Multi-racial), calendar year of treatment initiation, tachyarrhythmia, hospitalized tachyarrhythmia, drugs with a known risk of prolonged QT and torsades de pointes, drugs with a known or possible or conditional risk of prolonged QT and torsades de pointes.

Overview for Request: cder_mpl1r_wp077, Report 1 of 3

The following clinical characteristics were ascertained in the 365 days prior to cohort entry in the primary analysis and second sensitivity analysis or in the 183 days prior to cohort entry in the first sensitivity analysis: alcohol use or abuse, obesity, tobacco use, arrhythmia, cerebrovascular disease or stroke or transient ischemic attack, chronic kidney disease, chronic obstructive pulmonary disease, congenital heart disease, heart failure, hyperlipidemia, hypertensive disease, thyroid disease, ischemic heart disease or coronary artery disease or myocardial infarction, left ventricular hypertrophy, peripheral artery disease, valvular or mitral valve disease, disease of veins and lymphatics and other diseases of the circulatory system, obstructive sleep apnea, hypertrophic cardiomyopathy, other cardiac disease (heart failure, ischemic heart disease/coronary artery disease/myocardial infarction, hypertension, valvular disease, obstructive sleep apnea or hypertrophic cardiomyopathy), history of serious hypoglycemia (ED* or IP*), antidiabetic drugs [alpha-glucosidase inhibitors, amylin analogs, dipeptidyl peptidase 4 (DPP-4) inhibitors, incretin mimetics, meglitinides, insulin, biguanides, sodium-glucose cotransporter-2 (SGLT2) inhibitors, sulfonylureas, and thiazolidinediones], no baseline use of any of the previous antidiabetic drugs, other antidiabetic drugs (bromocriptine, mifepristone), antiarrhythmic agents [sodium channel blocker, beta blocker, potassium channel blockers or openers, non-dihydropyridine calcium channel blockers, digoxin, other antiarrhythmic agents], any of the previous antiarrhythmic agents, antihypertensives [angiotensin-converting-enzyme (ACE) inhibitor, angiotensin II receptor blockers (ARB), dihydropyridines, diuretics, other antihypertensives], any of the previous antihypertensives, cardiac medications [oral anticoagulants, vitamin K antagonists, other cardiac medications (not including oral anticoagulants or vitamin K antagonists)], any of previous cardiac medications, lipid lowering therapy, drugs with a known risk of prolonged QT and torsades de pointes, drugs with a known or possible or conditional risk of prolonged QT and torsades de pointes, health care services and drug utilization metrics, continuous Charlson/Elixhauser combined comorbidity index¹ (CCI), CCI groups (0, 1-2, 3-4, 5 or greater), continuous adapted diabetes complications severity index² (ADCSI), and ADCSI groups (0, 1-2, 3-4, 5 or greater). These characteristics were defined using NDCs; ICD-10-CM diagnosis codes; ICD-10-PCS procedure codes; HCPCS, Level II codes; CPT-4, Category I; and CPT-4, Category III codes. See Appendix F for diagnosis or procedure codes used to define baseline characteristics and Appendix G for generic and brand names of medical products.

Please see Appendices H-J for the specifications of parameters used in this request.

Please see Appendix K for a diagram detailing the design of this request.

Limitations: Algorithms to define exposures, outcomes, inclusion and exclusion criteria, and covariates are imperfect and may be misclassified. Therefore, data should be interpreted with this limitation in mind.

Notes: Please contact the Sentinel Operations Center (info@sentinelssystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (<https://dev.sentinelssystem.org/projects/SENTINEL/repos/sentinel-routine-querying-tool-documentation/browse>).

¹Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

²Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

**Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module***

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.

Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded.

Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

Code Days - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.

Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.

Computed Start Marketing Date - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.

Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."

Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

**Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module***

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.

Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.

Query Period - period in which the modular program looks for exposures and outcomes of interest.

Switch Evaluation Step Value - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).

Switch Gap Inclusion Indicator - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.

Switch Pattern Cohort Inclusion Date - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

Switch Pattern Cohort Inclusion Strategy - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

Table of Contents

<u>Glossary (CIDA)</u>	List of Terms to Define the Cohort Identification and Descriptive Analysis (CIDA) Found in this Report
<u>Table 1a</u>	Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1b</u>	Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1c</u>	Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1d</u>	Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1e</u>	Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1f</u>	Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1g</u>	Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1h</u>	Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1i</u>	Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1j</u>	Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1k</u>	Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1l</u>	Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1m</u>	Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1n</u>	Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1o</u>	Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1p</u>	Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1q</u>	Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1r</u>	Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table of Contents

<u>Table 1s</u>	Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1t</u>	Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1u</u>	Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1v</u>	Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1w</u>	Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1x</u>	Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1y</u>	Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1z</u>	Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1aa</u>	Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1ab</u>	Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1ac</u>	Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1ad</u>	Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1ae</u>	Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1af</u>	Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1ag</u>	Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1ah</u>	Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1ai</u>	Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table of Contents

<u>Table 1aj</u>	Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1ak</u>	Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1al</u>	Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1am</u>	Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1an</u>	Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1ao</u>	Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1ap</u>	Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1aq</u>	Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1ar</u>	Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1as</u>	Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1at</u>	Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1au</u>	Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1av</u>	Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1aw</u>	Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1ax</u>	Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1ay</u>	Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1az</u>	Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table of Contents

<u>Table 1ba</u>	Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1bb</u>	Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1bc</u>	Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1bd</u>	Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1be</u>	Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1bf</u>	Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1bg</u>	Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1bh</u>	Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1bi</u>	Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1bj</u>	Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1bk</u>	Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1bl</u>	Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1bm</u>	Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1bn</u>	Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1bo</u>	Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1bp</u>	Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1bq</u>	Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table of Contents

<u>Table 1br</u>	Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1bs</u>	Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 1bt</u>	Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 2</u>	Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 3</u>	Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Sex
<u>Table 4</u>	Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group
<u>Table 5</u>	Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Year
<u>Table 6</u>	Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race
<u>Table 7</u>	Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Other Cardiac Disease
<u>Table 8</u>	Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group
<u>Table 9</u>	Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year
<u>Table 10</u>	Summary of Time to End of At-Risk Period for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 11</u>	Summary of Time to End of At-Risk Period due to End of Exposure Episode for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 12</u>	Summary of Time to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 13</u>	Summary of Time to End of At-Risk Period due to Occurrence of User-Defined Censoring Criteria for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 14</u>	Summary of Time to End of At-Risk Period due to Evidence of Death for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 15</u>	Summary of Time to End of At-Risk Period due to Disenrollment for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 16</u>	Summary of Time to End of At-Risk Period due to End of Data for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 17</u>	Summary of Time to End of At-Risk Period due to End of Study Period for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Table of Contents

<u>Table 18</u>	Summary of Time to End of Observable Data for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 19</u>	Summary of Time to End of Observable Data due to Evidence of Death for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 20</u>	Summary of Time to End of Observable Data due to Disenrollment for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 21</u>	Summary of Time to End of Observable Data due to End of Data for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 22</u>	Summary of Time to End of Observable Data due to End of Study Period for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023
<u>Table 23a</u>	Full Code Distribution of Bydureon, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23b</u>	Total Code Counts of Bydureon, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23c</u>	Full Code Distribution of Mounjaro, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23d</u>	Total Code Counts of Mounjaro, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23e</u>	Full Code Distribution of Ozempic, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23f</u>	Total Code Counts of Ozempic, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23g</u>	Full Code Distribution of Rybelsus, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23h</u>	Total Code Counts of Rybelsus, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23i</u>	Full Code Distribution of Saxenda, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23j</u>	Total Code Counts of Saxenda, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23k</u>	Full Code Distribution of Trulicity, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23l</u>	Total Code Counts of Trulicity, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23m</u>	Full Code Distribution of Victoza, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23n</u>	Total Code Counts of Victoza, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23o</u>	Full Code Distribution of Wegovy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23p</u>	Total Code Counts of Wegovy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Table of Contents

<u>Table 23q</u>	Full Code Distribution of Xultophy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23r</u>	Total Code Counts of Xultophy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23s</u>	Full Code Distribution of Mounjaro, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23t</u>	Total Code Counts of Mounjaro, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23u</u>	Full Code Distribution of Bydureon, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23v</u>	Total Code Counts of Bydureon, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23w</u>	Full Code Distribution of Ozempic, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23x</u>	Total Code Counts of Ozempic, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23y</u>	Full Code Distribution of Rybelsus, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23z</u>	Total Code Counts of Rybelsus, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23aa</u>	Full Code Distribution of Wegovy, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23ab</u>	Total Code Counts of Wegovy, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23ac</u>	Full Code Distribution of Saxenda, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23ad</u>	Total Code Counts of Saxenda, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23ae</u>	Full Code Distribution of Victoza, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23af</u>	Total Code Counts of Victoza, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23ag</u>	Full Code Distribution of Trulicity, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23ah</u>	Total Code Counts of Trulicity, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23ai</u>	Full Code Distribution of Xultophy, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23aj</u>	Total Code Counts of Xultophy, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23ak</u>	Full Code Distribution of Mounjaro, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Page 13 of 1023

Table of Contents

<u>Table 23bi</u>	Full Code Distribution of Rybelsus, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23bj</u>	Total Code Counts of Rybelsus, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23bk</u>	Full Code Distribution of Wegovy, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23bl</u>	Total Code Counts of Wegovy, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23bm</u>	Full Code Distribution of Saxenda, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23bn</u>	Total Code Counts of Saxenda, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23bo</u>	Full Code Distribution of Victoza, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23bp</u>	Total Code Counts of Victoza, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23bq</u>	Full Code Distribution of Trulicity, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23br</u>	Total Code Counts of Trulicity, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23bs</u>	Full Code Distribution of Xultophy, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23bt</u>	Total Code Counts of Xultophy, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23bu</u>	Full Code Distribution of Mounjaro, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23bv</u>	Total Code Counts of Mounjaro, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23bw</u>	Full Code Distribution of Bydureon, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23bx</u>	Total Code Counts of Bydureon, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23by</u>	Full Code Distribution of Ozempic, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23bz</u>	Total Code Counts of Ozempic, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23ca</u>	Full Code Distribution of Rybelsus, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23cb</u>	Total Code Counts of Rybelsus, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23cc</u>	Full Code Distribution of Wegovy, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Table of Contents

<u>Table 23cd</u>	Total Code Counts of Wegovy, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23ce</u>	Full Code Distribution of Saxenda, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23cf</u>	Total Code Counts of Saxenda, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23cg</u>	Full Code Distribution of Victoza, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23ch</u>	Total Code Counts of Victoza, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23ci</u>	Full Code Distribution of Trulicity, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23cj</u>	Total Code Counts of Trulicity, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23ck</u>	Full Code Distribution of Xultophy, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23cl</u>	Total Code Counts of Xultophy, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23cm</u>	Full Code Distribution of Mounjaro, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23cn</u>	Total Code Counts of Mounjaro, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23co</u>	Full Code Distribution of Bydureon, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23cp</u>	Total Code Counts of Bydureon, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23cq</u>	Full Code Distribution of Ozempic, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23cr</u>	Total Code Counts of Ozempic, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23cs</u>	Full Code Distribution of Rybelsus, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23ct</u>	Total Code Counts of Rybelsus, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23cu</u>	Full Code Distribution of Wegovy, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23cv</u>	Total Code Counts of Wegovy, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23cw</u>	Full Code Distribution of Saxenda, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23cx</u>	Total Code Counts of Saxenda, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Table of Contents

<u>Table 23cy</u>	Full Code Distribution of Victoza, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23cz</u>	Total Code Counts of Victoza, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23da</u>	Full Code Distribution of Trulicity, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23db</u>	Total Code Counts of Trulicity, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23dc</u>	Full Code Distribution of Xultophy, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23dd</u>	Total Code Counts of Xultophy, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23de</u>	Full Code Distribution of Mounjaro, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23df</u>	Total Code Counts of Mounjaro, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23dg</u>	Full Code Distribution of Bydureon, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23dh</u>	Total Code Counts of Bydureon, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23di</u>	Full Code Distribution of Ozempic, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23dj</u>	Total Code Counts of Ozempic, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23dk</u>	Full Code Distribution of Rybelsus, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23dl</u>	Total Code Counts of Rybelsus, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23dm</u>	Full Code Distribution of Wegovy, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23dn</u>	Total Code Counts of Wegovy, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23do</u>	Full Code Distribution of Saxenda, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23dp</u>	Total Code Counts of Saxenda, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23dq</u>	Full Code Distribution of Victoza, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23dr</u>	Total Code Counts of Victoza, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation
<u>Table 23ds</u>	Full Code Distribution of Trulicity, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Page 17 of 1023

Table of Contents

Table 24 Summary of Patient Level Cohort Attrition in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Appendix A Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (September 28, 2023)

Appendix B Generic and Brand Names of Medical Products Used to Define Exposures or Exposure Washout in this Request

Appendix C List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Tachyarrhythmia in this Request

Appendix D List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Appendix E Generic and Brand Names of Medical Products Used to Define Inclusion or Exclusion Criteria in this Request

Appendix F List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Appendix G Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Appendix H Specifications Defining Parameters for this Request (Primary Analysis)

Appendix I Specifications Defining Parameters for Baseline Characteristics in this Request (Primary Analysis)

Appendix J Specifications Defining Combination Code Parameters Used in this Request (Primary Analysis)

Appendix K Design Diagram Detailing this Request

Table 1a. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Unique patients	1,321	N/A
Demographic Characteristics		
Age (years)	64.0	10.2
Age		
0-40 years	78	5.9%
41-64 years	498	37.7%
65-74 years	535	40.5%
75-84 years	195	14.8%
≥ 85 years	15	1.1%
Sex		
Female	675	51.1%
Male	646	48.9%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	44	3.3%
Black or African American	165	12.5%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	234	18.5%
White	833	63.1%
Hispanic origin		
Yes	76	5.8%
No	960	72.7%
Unknown	285	21.6%
Year		
2022	1,075	81.4%
2023	236	18.6%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.0	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	429	32.5%
1-2	462	35.0%
3-4	262	19.8%
5+	168	12.7%
Combined comorbidity score ⁴	2.5	2.6
Combined comorbidity score categories ⁴		
<0	53	4.0%
0	252	19.1%
1-2	507	38.4%
3-4	254	19.2%
5+	255	19.3%

Table 1a. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	31	2.3%
Obesity	722	54.7%
Tobacco use	358	27.1%
Arrhythmia	335	25.4%
Cerebrovascular disease/stroke/transient ischemic attack	179	13.6%
Chronic kidney disease	250	18.9%
Chronic obstructive pulmonary disease	164	12.4%
Congenital heart disease	164	12.4%
Heart failure	173	13.1%
Hyperlipidemia	1,052	79.6%
Hypertensive disease	1,105	83.6%
Thyroid disease	292	22.1%
Ischemic heart disease/coronary artery disease/myocardial infarction	334	25.3%
Left ventricular hypertrophy	66	5.0%
Peripheral artery disease	66	5.0%
Valvular/mitral valve disease	54	4.1%
Diseases of veins and lymphatics, and other diseases of circulatory system	175	13.2%
Obstructive sleep apnea	339	25.7%
Hypertrophic cardiomyopathy	74	5.6%
Other cardiac disease	597	45.2%
Tachyarrhythmia day 0	15	1.1%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	15	1.1%
Medical Product Use		
Alpha-glucosidase inhibitors	*****	*****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	198	15.0%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	16	1.2%
Insulin	444	33.6%
Biguanides (metformin, phenformin, etc.)	1,093	82.7%
SGLT2 inhibitors	436	33.0%
Sulfonylurea	549	41.6%
Thiazolidinedione	148	11.2%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	*****	*****
Sodium channel blockers	*****	*****
Beta blockers	545	41.3%
Potassium channel blockers/openers	15	1.1%
Non-dihydropyridine calcium channel blockers	*****	*****
Digoxin	13	1.0%
Other antiarrhythmic agents	0	0.0%

Table 1a. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	555	42.0%
Angiotensin-converting-enzyme (ACE) inhibitor	550	41.6%
Angiotensin ii receptor blockers (ARBs)	460	34.8%
Dihydropyridines	323	23.50%
Diuretics	511	38.7%
Other antihypertensives	102	7.7%
Antihypertensives (any of the above antihypertensives)	1,101	83.3%
Oral anticoagulants	141	10.7%
Vitamin K antagonists	25	1.9%
Other cardiac medications not mentioned above	84	6.4%
Other cardiac medications (any of the other cardiac medications)	223	16.9%
Lipid lowering therapy	1,111	84.1%
Baseline known risk of prolonged QT and torsades de pointes	579	43.8%
Baseline possible risk of prolonged QT and torsades de pointes	1,130	85.5%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	179	13.6%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	20.9	17.6
Mean number of emergency room encounters	0.6	1.5
Mean number of inpatient hospital encounters	0.2	0.7
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	6.7	14.7
Mean number of filled prescriptions	48.5	36.7
Mean number of generics dispensed	12.9	6.3
Mean number of unique drug classes dispensed	11.2	5.5

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1b. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	234	N/A
Demographic Characteristics		
Age (years)	62.2	11.2
Age		
0-40 years	*****	*****
41-64 years	118	48.4%
65-74 years	87	35.7%
75-84 years	26	10.7%
≥ 85 years	*****	*****
Sex		
Female	117	48.0%
Male	127	52.0%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	234	100.0%
White	0	0.0%
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	181	74.2%
Year		
2022	179	73.4%
2023	65	26.6%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.9	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	85	34.8%
1-2	88	36.1%
3-4	43	17.6%
5+	28	11.5%
Combined comorbidity score ⁴	2.1	2.5
Combined comorbidity score categories ⁴		
<0	11	4.5%
0	59	23.20%
1-2	98	40.2%
3-4	42	17.2%
5+	34	13.9%

Table 1b. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	*****	*****
Obesity	128	52.5%
Tobacco use	54	22.1%
Arrhythmia	55	22.5%
Cerebrovascular disease/stroke/transient ischemic attack	34	13.9%
Chronic kidney disease	36	14.8%
Chronic obstructive pulmonary disease	21	8.6%
Congenital heart disease	21	8.6%
Heart failure	26	10.7%
Hyperlipidemia	194	79.5%
Hypertensive disease	202	82.8%
Thyroid disease	43	17.6%
Ischemic heart disease/coronary artery disease/myocardial infarction	53	21.7%
Left ventricular hypertrophy	13	5.3%
Peripheral artery disease	13	5.3%
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	32	13.1%
Obstructive sleep apnea	55	22.5%
Hypertrophic cardiomyopathy	11	4.5%
Other cardiac disease	96	39.3%
Tachyarrhythmia day 0	*****	*****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	36	14.8%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	85	34.8%
Biguanides (metformin, phenformin, etc.)	203	83.2%
SGLT2 inhibitors	91	37.3%
Sulfonylurea	99	40.6%
Thiazolidinedione	26	10.7%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	*****	*****
Sodium channel blockers	*****	*****
Beta blockers	101	41.4%
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	*****	*****
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%

Table 1b. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	102	41.8%
Angiotensin-converting-enzyme (ACE) inhibitor	103	42.2%
Angiotensin ii receptor blockers (ARBs)	76	31.1%
Dihydropyridines	56	23.0%
Diuretics	84	34.4%
Other antihypertensives	16	6.6%
Antihypertensives (any of the above antihypertensives)	197	80.7%
Oral anticoagulants	23	9.4%
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	13	5.3%
Other cardiac medications (any of the other cardiac medications)	36	14.8%
Lipid lowering therapy	209	85.7%
Baseline known risk of prolonged QT and torsades de pointes	99	40.6%
Baseline possible risk of prolonged QT and torsades de pointes	192	78.7%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	31	12.7%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	18.1	15.7
Mean number of emergency room encounters	0.5	1.3
Mean number of inpatient hospital encounters	0.2	0.9
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	5.0	7.2
Mean number of filled prescriptions	43.4	32.4
Mean number of generics dispensed	12.3	6.4
Mean number of unique drug classes dispensed	10.6	5.7

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1c. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	*****	N/A
Demographic Characteristics		
Age (years)	57.8	7.4
Age		
0-40 years	0	0.0%
41-64 years	*****	66.7%
65-74 years	*****	33.3%
75-84 years	0	0.0%
≥ 85 years	0	0.0%
Sex		
Female	*****	66.7%
Male	*****	33.3%
Race ²		
American Indian or Alaska Native	*****	100.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	*****	16.7%
No	*****	83.3%
Unknown	0	0.0%
Year		
2022	*****	50.0%
2023	*****	50.0%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.2	0.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	*****	66.7%
1-2	0	0.0%
3-4	*****	33.3%
5+	0	0.0%
Combined comorbidity score ⁴	0.8	1.0
Combined comorbidity score categorie ⁴		
<0	*****	16.7%
0	*****	16.7%
1-2	*****	66.7%
3-4	0	0.0%
5+	0	0.0%

Table 1c. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	0	0.0%
Obesity	*****	50.0%
Tobacco use	*****	33.3%
Arrhythmia	0	0.0%
Cerebrovascular disease/stroke/transient ischemic attack	0	0.0%
Chronic kidney disease	0	0.0%
Chronic obstructive pulmonary disease	*****	16.7%
Congenital heart disease	*****	16.7%
Heart failure	0	0.0%
Hyperlipidemia	*****	50.0%
Hypertensive disease	*****	66.7%
Thyroid disease	*****	16.7%
Ischemic heart disease/coronary artery disease/myocardial infarction	*****	16.7%
Left ventricular hypertrophy	0	0.0%
Peripheral artery disease	0	0.0%
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	0	0.0%
Obstructive sleep apnea	*****	16.7%
Hypertrophic cardiomyopathy	0	0.0%
Other cardiac disease	*****	33.3%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	*****	50.0%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	*****	33.3%
Biguanides (metformin, phenformin, etc.)	*****	83.3%
SGLT2 inhibitors	*****	33.3%
Sulfonylurea	*****	50.0%
Thiazolidinedione	0	0.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	*****	16.7%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%

Table 1c. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	*****	16.7%
Angiotensin-converting-enzyme (ACE) inhibitor	*****	33.3%
Angiotensin ii receptor blockers (ARBs)	*****	50.0%
Dihydropyridines	*****	33.3%
Diuretics	*****	16.7%
Other antihypertensives	0	0.0%
Antihypertensives (any of the above antihypertensives)	*****	66.7%
Oral anticoagulants	0	0.0%
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	0	0.0%
Other cardiac medications (any of the other cardiac medications)	0	0.0%
Lipid lowering therapy	*****	100.0%
Baseline known risk of prolonged QT and torsades de pointes	*****	16.7%
Baseline possible risk of prolonged QT and torsades de pointes	*****	100.0%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	0	0.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	9.8	4.9
Mean number of emergency room encounters	0.5	0.4
Mean number of inpatient hospital encounters	0.0	NaN
Mean number of non-acute institutional encounters	0.3	0.0
Mean number of other ambulatory encounters	2.5	1.4
Mean number of filled prescriptions	48.0	16.8
Mean number of generics dispensed	11.2	2.3
Mean number of unique drug classes dispensed	9.5	2.3

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a number

N/A: Not applicable

Table 1d. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	44	N/A
Demographic Characteristics		
Age (years)	57.2	10.6
Age		
0-40 years	11	25.0%
41-64 years	17	38.6%
65-74 years	*****	*****
75-84 years	*****	*****
≥ 85 years	*****	*****
Sex		
Female	27	61.4%
Male	17	38.6%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	44	100.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	*****	*****
Unknown	*****	*****
Year		
2022	29	65.9%
2023	15	34.1%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.2	1.6
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	22	50.0%
1-2	*****	*****
3-4	*****	*****
5+	*****	*****
Combined comorbidity score ⁴	1.8	1.8
Combined comorbidity score categories ⁴		
<0	*****	*****
0	12	27.3%
1-2	16	36.4%
3-4	*****	*****
5+	*****	*****

Table 1d. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	*****	*****
Obesity	15	34.1%
Tobacco use	*****	*****
Arrhythmia	*****	*****
Cerebrovascular disease/stroke/transient ischemic attack	*****	*****
Chronic kidney disease	*****	*****
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	*****	*****
Hyperlipidemia	23	54.5%
Hypertensive disease	27	61.4%
Thyroid disease	*****	*****
Ischemic heart disease/coronary artery disease/myocardial infarction	*****	*****
Left ventricular hypertrophy	0	0.0%
Peripheral artery disease	0	0.0%
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	*****
Obstructive sleep apnea	*****	*****
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	15	34.1%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	13	29.5%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	17	38.6%
Biguanides (metformin, phenformin, etc.)	41	93.2%
SGLT2 inhibitors	14	31.8%
Sulfonylurea	20	45.5%
Thiazolidinedione	*****	*****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	11	25.0%
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%

Table 1d. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	11	25.0%
Angiotensin-converting-enzyme (ACE) inhibitor	12	27.3%
Angiotensin ii receptor blockers (ARBs)	18	40.9%
Dihydropyridines	11	25.0%
Diuretics	12	27.3%
Other antihypertensives	*****	*****
Antihypertensives (any of the above antihypertensives)	32	72.7%
Oral anticoagulants	*****	*****
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	*****	*****
Other cardiac medications (any of the other cardiac medications)	*****	*****
Lipid lowering therapy	32	72.7%
Baseline known risk of prolonged QT and torsades de pointes	15	34.1%
Baseline possible risk of prolonged QT and torsades de pointes	29	65.9%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	14.1	16.2
Mean number of emergency room encounters	0.3	0.4
Mean number of inpatient hospital encounters	0.0	0.1
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	2.8	3.0
Mean number of filled prescriptions	42.6	29.7
Mean number of generics dispensed	10.2	4.9
Mean number of unique drug classes dispensed	8.6	4.5

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a number

N/A: Not applicable

Table 1e. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	165	N/A
Demographic Characteristics		
Age (years)	58.9	11.2
Age		
0-40 years	14	8.5%
41-64 years	88	53.3%
65-74 years	49	29.7%
75-84 years	*****	*****
≥ 85 years	*****	*****
Sex		
Female	99	60.0%
Male	66	40.0%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	165	100.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	*****	*****
No	152	92.1%
Unknown	*****	*****
Year		
2022	120	72.7%
2023	45	27.3%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.7	1.8
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	56	33.9%
1-2	64	38.8%
3-4	27	16.4%
5+	18	10.9%
Combined comorbidity score ⁴	2.2	2.4
Combined comorbidity score categories ⁴		
<0	*****	*****
0	35	21.2%
1-2	77	46.7%
3-4	*****	*****
5+	32	19.4%

Table 1e. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	*****	*****
Obesity	95	57.6%
Tobacco use	38	23.0%
Arrhythmia	35	21.2%
Cerebrovascular disease/stroke/transient ischemic attack	19	11.5%
Chronic kidney disease	25	15.2%
Chronic obstructive pulmonary disease	16	9.7%
Congenital heart disease	16	9.7%
Heart failure	21	12.7%
Hyperlipidemia	114	69.1%
Hypertensive disease	139	84.2%
Thyroid disease	20	12.1%
Ischemic heart disease/coronary artery disease/myocardial infarction	31	18.8%
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	12	7.3%
Obstructive sleep apnea	38	23.0%
Hypertrophic cardiomyopathy	14	8.5%
Other cardiac disease	69	41.8%
Tachyarrhythmia day 0	*****	*****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	26	15.8%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	64	38.8%
Biguanides (metformin, phenformin, etc.)	137	83.0%
SGLT2 inhibitors	56	33.9%
Sulfonylurea	75	45.5%
Thiazolidinedione	*****	*****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	*****	*****
Beta blockers	66	40.0%
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%

Table 1e. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	67	40.6%
Angiotensin-converting-enzyme (ACE) inhibitor	58	35.2%
Angiotensin ii receptor blockers (ARBs)	68	41.2%
Dihydropyridines	56	33.9%
Diuretics	61	37.0%
Other antihypertensives	26	15.8%
Antihypertensives (any of the above antihypertensives)	136	82.4%
Oral anticoagulants	*****	*****
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	12	7.3%
Other cardiac medications (any of the other cardiac medications)	19	11.5%
Lipid lowering therapy	130	78.8%
Baseline known risk of prolonged QT and torsades de pointes	62	37.6%
Baseline possible risk of prolonged QT and torsades de pointes	137	83.0%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	14	8.5%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	20.6	17.3
Mean number of emergency room encounters	0.8	2.1
Mean number of inpatient hospital encounters	0.2	0.8
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	6.6	11.6
Mean number of filled prescriptions	44.0	32.3
Mean number of generics dispensed	12.7	5.6
Mean number of unique drug classes dispensed	11.0	4.9

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1f. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Unique patients	*****	N/A
Demographic Characteristics		
Age (years)	84.8	NaN
Age		
0-40 years	0	0.0%
41-64 years	0	0.0%
65-74 years	0	0.0%
75-84 years	*****	*****
≥ 85 years	0	0.0%
Sex		
Female	0	0.0%
Male	*****	*****
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	*****	*****
Unknown	0	0.0%
Year		
2022	*****	*****
2023	0	0.0%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.0	NaN
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	0	0.0%
1-2	*****	*****
3-4	0	0.0%
5+	0	0.0%
Combined comorbidity score ⁴	1.0	NaN
Combined comorbidity score categories ⁴		
<0	0	0.0%
0	0	0.0%
1-2	*****	*****
3-4	0	0.0%
5+	0	0.0%

Table 1f. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Alcohol use or abuse	0	0.0%
Obesity	0	0.0%
Tobacco use	0	0.0%
Arrhythmia	0	0.0%
Cerebrovascular disease/stroke/transient ischemic attack	0	0.0%
Chronic kidney disease	0	0.0%
Chronic obstructive pulmonary disease	0	0.0%
Congenital heart disease	0	0.0%
Heart failure	0	0.0%
Hyperlipidemia	*****	*****
Hypertensive disease	*****	*****
Thyroid disease	0	0.0%
Ischemic heart disease/coronary artery disease/myocardial infarction	0	0.0%
Left ventricular hypertrophy	0	0.0%
Peripheral artery disease	0	0.0%
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	0	0.0%
Obstructive sleep apnea	0	0.0%
Hypertrophic cardiomyopathy	0	0.0%
Other cardiac disease	0	0.0%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	0	0.0%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	*****	*****
Biguanides (metformin, phenformin, etc.)	*****	*****
SGLT2 inhibitors	0	0.0%
Sulfonylurea	0	0.0%
Thiazolidinedione	0	0.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	0	0.0%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%

Table 1f. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	0	0.0%
Angiotensin-converting-enzyme (ACE) inhibitor	*****	*****
Angiotensin ii receptor blockers (ARBs)	*****	*****
Dihydropyridines	0	0.0%
Diuretics	*****	*****
Other antihypertensives	0	0.0%
Antihypertensives (any of the above antihypertensives)	*****	*****
Oral anticoagulants	0	0.0%
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	0	0.0%
Other cardiac medications (any of the other cardiac medications)	0	0.0%
Lipid lowering therapy	0	0.0%
Baseline known risk of prolonged QT and torsades de pointes	0	0.0%
Baseline possible risk of prolonged QT and torsades de pointes	0	0.0%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	0	0.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	8.0	NaN
Mean number of emergency room encounters	0.0	NaN
Mean number of inpatient hospital encounters	0.0	NaN
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	0.0	NaN
Mean number of filled prescriptions	21.0	NaN
Mean number of generics dispensed	12.0	NaN
Mean number of unique drug classes dispensed	9.0	NaN

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a number

N/A: Not applicable

Table 1g. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	833	N/A
Demographic Characteristics		
Age (years)	66.4	9.4
Age		
0-40 years	34	4.1%
41-64 years	251	30.1%
65-74 years	387	46.5%
75-84 years	149	17.9%
≥ 85 years	12	1.4%
Sex		
Female	410	49.2%
Male	423	50.8%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	833	100.0%
Hispanic origin		
Yes	12	1.4%
No	744	89.3%
Unknown	77	9.2%
Year		
2022	723	86.8%
2023	110	13.2%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.1	2.1
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	239	29.9%
1-2	285	34.2%
3-4	180	21.6%
5+	119	14.3%
Combined comorbidity score ⁴	2.8	2.7
Combined comorbidity score categories ⁴		
<0	33	4.0%
0	137	16.4%
1-2	300	36.0%
3-4	181	21.7%
5+	182	21.8%

Table 1g. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	23	2.8%
Obesity	467	56.1%
Tobacco use	255	30.6%
Arrhythmia	233	28.0%
Cerebrovascular disease/stroke/transient ischemic attack	118	14.2%
Chronic kidney disease	181	21.7%
Chronic obstructive pulmonary disease	122	14.6%
Congenital heart disease	122	14.6%
Heart failure	122	14.6%
Hyperlipidemia	697	83.7%
Hypertensive disease	716	86.0%
Thyroid disease	218	26.2%
Ischemic heart disease/coronary artery disease/myocardial infarction	230	28.8%
Left ventricular hypertrophy	44	5.3%
Peripheral artery disease	44	5.3%
Valvular/mitral valve disease	42	5.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	125	15.0%
Obstructive sleep apnea	230	27.6%
Hypertrophic cardiomyopathy	48	5.8%
Other cardiac disease	406	48.7%
Tachyarrhythmia day 0	13	1.6%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	1.1%
Medical Product Use		
Alpha-glucosidase inhibitors	*****	0.4%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	116	13.9%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	0.7%
Insulin	266	31.9%
Biguanides (metformin, phenformin, etc.)	680	81.6%
SGLT2 inhibitors	267	32.1%
Sulfonylurea	345	41.4%
Thiazolidinedione	110	13.2%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	*****	0.1%
Sodium channel blockers	*****	0.6%
Beta blockers	359	43.1%
Potassium channel blockers/openers	*****	1.0%
Non-dihydropyridine calcium channel blockers	*****	0.6%
Digoxin	*****	1.2%
Other antiarrhythmic agents	0	0.0%

Table 1g. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	367	44.1%
Angiotensin-converting-enzyme (ACE) inhibitor	366	43.9%
Angiotensin ii receptor blockers (ARBs)	289	34.7%
Dihydropyridines	196	23.5%
Diuretics	348	41.8%
Other antihypertensives	57	6.8%
Antihypertensives (any of the above antihypertensives)	716	86.0%
Oral anticoagulants	111	13.3%
Vitamin K antagonists	18	2.2%
Other cardiac medications not mentioned above	57	6.8%
Other cardiac medications (any of the other cardiac medications)	165	19.8%
Lipid lowering therapy	714	85.7%
Baseline known risk of prolonged QT and torsades de pointes	394	47.3%
Baseline possible risk of prolonged QT and torsades de pointes	741	89.0%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	131	15.7%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	22.3	18.3
Mean number of emergency room encounters	0.6	1.4
Mean number of inpatient hospital encounters	0.2	0.7
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	7.6	17.3
Mean number of filled prescriptions	51.2	39.0
Mean number of generics dispensed	13.2	6.4
Mean number of unique drug classes dispensed	11.6	5.6

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1h. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	*****	N/A
Demographic Characteristics		
Age (years)	48.7	12.5
Age		
0-40 years	*****	25.0%
41-64 years	*****	71.4%
65-74 years	*****	3.6%
75-84 years	0	0.0%
≥ 85 years	0	0.0%
Sex		
Female	*****	64.3%
Male	*****	35.7%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	*****	100.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	*****	17.9%
No	17	60.7%
Unknown	*****	21.4%
Year		
2022	*****	71.4%
2023	*****	28.6%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.0	1.2
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	*****	46.4%
1-2	*****	39.3%
3-4	*****	14.3%
5+	0	0.0%
Combined comorbidity score ⁴	1.9	1.9
Combined comorbidity score categories ⁴		
<0	0	0.0%
0	*****	28.6%
1-2	11	39.3%
3-4	*****	21.4%
5+	*****	10.7%

Table 1h. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	0	0.0%
Obesity	14	50.0%
Tobacco use	*****	14.3%
Arrhythmia	*****	21.4%
Cerebrovascular disease/stroke/transient ischemic attack	*****	7.1%
Chronic kidney disease	*****	7.1%
Chronic obstructive pulmonary disease	*****	7.1%
Congenital heart disease	*****	7.1%
Heart failure	*****	3.6%
Hyperlipidemia	19	67.9%
Hypertensive disease	16	57.1%
Thyroid disease	*****	17.9%
Ischemic heart disease/coronary artery disease/myocardial infarction	*****	10.7%
Left ventricular hypertrophy	0	0.0%
Peripheral artery disease	0	0.0%
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	14.3%
Obstructive sleep apnea	*****	25.0%
Hypertrophic cardiomyopathy	0	0.0%
Other cardiac disease	*****	32.1%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	3.6%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	*****	14.3%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	*****	32.1%
Biguanides (metformin, phenformin, etc.)	26	92.9%
SGLT2 inhibitors	*****	21.4%
Sulfonylurea	*****	25.0%
Thiazolidinedione	*****	3.6%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	*****	25.0%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%

Table 1h. Aggregated Characteristics of Bydureon, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	*****	25.0%
Angiotensin-converting-enzyme (ACE) inhibitor	*****	28.6%
Angiotensin ii receptor blockers (ARBs)	*****	17.9%
Dihydropyridines	*****	10.7%
Diuretics	*****	14.3%
Other antihypertensives	*****	3.6%
Antihypertensives (any of the above antihypertensives)	15	53.6%
Oral anticoagulants	0	0.0%
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	0	0.0%
Other cardiac medications (any of the other cardiac medications)	0	0.0%
Lipid lowering therapy	20	71.4%
Baseline known risk of prolonged QT and torsades de pointes	*****	28.6%
Baseline possible risk of prolonged QT and torsades de pointes	25	89.3%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	*****	3.6%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	19.0	16.8
Mean number of emergency room encounters	0.9	0.9
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	3.4	3.6
Mean number of filled prescriptions	48.0	37.9
Mean number of generics dispensed	12.5	7.3
Mean number of unique drug classes dispensed	11.2	6.3

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a number

N/A: Not applicable

Table 1i. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Unique patients	18,842	N/A
Demographic Characteristics		
Age (years)	61.6	10.0
Age		
0-40 years	1,034	5.5%
41-64 years	9,239	49.1%
65-74 years	6,597	35.0%
75-84 years	1,867	9.9%
≥ 85 years	95	0.5%
Sex		
Female	10,809	57.4%
Male	8,033	42.6%
Race ²		
American Indian or Alaska Native	32	0.2%
Asian	108	0.6%
Black or African American	1,640	8.7%
Multi-racial	60	0.3%
Native Hawaiian or Other Pacific Islander	57	0.3%
Unknown	8,006	42.5%
White	8,939	47.4%
Hispanic origin		
Yes	321	1.7%
No	10,283	54.6%
Unknown	8,238	43.7%
Year		
2022	9,509	50.5%
2023	9,333	49.5%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.6	1.8
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	7,429	39.4%
1-2	6,577	34.9%
3-4	3,152	16.7%
5+	1,684	8.9%
Combined comorbidity score ⁴	2.2	2.4
Combined comorbidity score categories ⁴		
<0	1,478	7.8%
0	3,997	21.2%
1-2	6,850	36.4%
3-4	3,475	18.4%
5+	3,042	16.1%

Table 1i. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Alcohol use or abuse	328	1.7%
Obesity	12,882	68.4%
Tobacco use	4,423	23.5%
Arrhythmia	4,370	23.2%
Cerebrovascular disease/stroke/transient ischemic attack	1,945	10.3%
Chronic kidney disease	3,057	16.2%
Chronic obstructive pulmonary disease	2,074	11.0%
Congenital heart disease	2,074	11.0%
Heart failure	2,190	11.6%
Hyperlipidemia	15,602	82.8%
Hypertensive disease	16,145	85.7%
Thyroid disease	4,723	25.1%
Ischemic heart disease/coronary artery disease/myocardial infarction	4,259	22.6%
Left ventricular hypertrophy	992	5.3%
Peripheral artery disease	992	5.3%
Valvular/mitral valve disease	688	3.7%
Diseases of veins and lymphatics, and other diseases of circulatory system	2,291	12.2%
Obstructive sleep apnea	5,977	31.7%
Hypertrophic cardiomyopathy	785	4.2%
Other cardiac disease	8,953	47.5%
Tachyarrhythmia day 0	250	1.3%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	116	0.6%
Medical Product Use		
Alpha-glucosidase inhibitors	55	0.3%
Amylin analogs (pramlintide)	*****	0.0%
DPP-4 inhibitors	2,215	11.8%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	123	0.7%
Insulin	4,501	23.9%
Biguanides (metformin, phenformin, etc.)	15,590	82.7%
SGLT2 inhibitors	5,037	26.7%
Sulfonylurea	5,321	28.2%
Thiazolidinedione	1,730	9.2%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	*****	0.0%
Sodium channel blockers	148	0.8%
Beta blockers	7,323	38.9%
Potassium channel blockers/openers	239	1.3%
Non-dihydropyridine calcium channel blockers	28	0.1%
Digoxin	103	0.5%
Other antiarrhythmic agents	0	0.0%

Table 1i. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	7,421	39.4%
Angiotensin-converting-enzyme (ACE) inhibitor	6,967	37.0%
Angiotensin ii receptor blockers (ARBs)	7,089	37.6%
Dihydropyridines	4,713	25.0%
Diuretics	6,901	36.6%
Other antihypertensives	1,620	8.6%
Antihypertensives (any of the above antihypertensives)	15,654	83.1%
Oral anticoagulants	1,441	7.6%
Vitamin K antagonists	288	1.5%
Other cardiac medications not mentioned above	1,140	6.1%
Other cardiac medications (any of the other cardiac medications)	2,609	13.8%
Lipid lowering therapy	15,018	79.7%
Baseline known risk of prolonged QT and torsades de pointes	9,532	50.6%
Baseline possible risk of prolonged QT and torsades de pointes	16,298	86.5%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	3,159	16.8%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	20.2	16.7
Mean number of emergency room encounters	0.6	1.7
Mean number of inpatient hospital encounters	0.1	0.5
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	4.7	9.4
Mean number of filled prescriptions	46.1	32.0
Mean number of generics dispensed	13.6	6.6
Mean number of unique drug classes dispensed	11.9	5.7

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1j. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	8,006	N/A
Demographic Characteristics		
Age (years)	54.2	10.3
Age		
0-40 years	855	10.7%
41-64 years	6,086	76.0%
65-74 years	898	11.2%
75-84 years	*****	*****
≥ 85 years	*****	*****
Sex		
Female	4,326	54.0%
Male	3,680	46.0%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	8,006	100.0%
White	0	0.0%
Hispanic origin		
Yes	300	3.7%
No	0	0.0%
Unknown	7,706	96.3%
Year		
2022	4,058	50.7%
2023	3,948	49.3%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.9	1.4
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	4,656	58.2%
1-2	2,388	29.8%
3-4	716	8.9%
5+	236	3.1%
Combined comorbidity score ⁴	1.2	1.9
Combined comorbidity score categories ⁴		
<0	951	11.9%
0	2,360	29.5%
1-2	3,192	39.9%
3-4	1,018	12.7%
5+	485	6.1%

Table 1j. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	112	1.4%
Obesity	5,158	64.4%
Tobacco use	1,209	15.1%
Arrhythmia	1,234	15.5%
Cerebrovascular disease/stroke/transient ischemic attack	376	4.7%
Chronic kidney disease	608	7.6%
Chronic obstructive pulmonary disease	309	3.9%
Congenital heart disease	309	3.9%
Heart failure	374	4.7%
Hyperlipidemia	6,070	75.8%
Hypertensive disease	6,177	77.2%
Thyroid disease	1,596	19.9%
Ischemic heart disease/coronary artery disease/myocardial infarction	1,007	12.6%
Left ventricular hypertrophy	262	3.3%
Peripheral artery disease	262	3.3%
Valvular/mitral valve disease	144	1.8%
Diseases of veins and lymphatics, and other diseases of circulatory system	614	7.7%
Obstructive sleep apnea	2,196	27.4%
Hypertrophic cardiomyopathy	181	2.3%
Other cardiac disease	2,932	36.6%
Tachyarrhythmia day 0	37	0.5%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	23	0.3%
Medical Product Use		
Alpha-glucosidase inhibitors	21	0.3%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	855	10.7%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	32	0.4%
Insulin	1,521	19.0%
Biguanides (metformin, phenformin, etc.)	6,960	86.9%
SGLT2 inhibitors	2,202	27.5%
Sulfonylurea	1,798	22.5%
Thiazolidinedione	570	7.1%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	*****	*****
Sodium channel blockers	43	0.5%
Beta blockers	2,233	28.0%
Potassium channel blockers/openers	50	0.6%
Non-dihydropyridine calcium channel blockers	*****	*****
Digoxin	16	0.2%
Other antiarrhythmic agents	0	0.0%

Table 1j. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	2,266	28.3%
Angiotensin-converting-enzyme (ACE) inhibitor	2,902	36.2%
Angiotensin ii receptor blockers (ARBs)	2,613	32.6%
Dihydropyridines	1,533	19.1%
Diuretics	2,098	26.2%
Other antihypertensives	432	5.4%
Antihypertensives (any of the above antihypertensives)	6,061	75.7%
Oral anticoagulants	357	4.5%
Vitamin K antagonists	57	0.7%
Other cardiac medications not mentioned above	251	3.1%
Other cardiac medications (any of the other cardiac medications)	621	7.8%
Lipid lowering therapy	5,705	71.3%
Baseline known risk of prolonged QT and torsades de pointes	3,732	46.6%
Baseline possible risk of prolonged QT and torsades de pointes	6,450	80.6%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	1,076	13.4%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	15.6	14.7
Mean number of emergency room encounters	0.3	1.0
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	4.2	7.1
Mean number of filled prescriptions	38.0	29.0
Mean number of generics dispensed	11.5	6.3
Mean number of unique drug classes dispensed	10.1	5.5

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1k. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	32	N/A
Demographic Characteristics		
Age (years)	62.2	12.7
Age		
0-40 years	*****	*****
41-64 years	15	46.9%
65-74 years	*****	*****
75-84 years	*****	*****
≥ 85 years	0	0.0%
Sex		
Female	18	56.3%
Male	14	43.8%
Race ²		
American Indian or Alaska Native	32	100.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	*****	*****
Unknown	*****	*****
Year		
2022	*****	*****
2023	*****	*****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.9	2.3
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	13	40.6%
1-2	*****	*****
3-4	*****	*****
5+	*****	*****
Combined comorbidity score ⁴	3.2	2.8
Combined comorbidity score categories ⁴		
<0	*****	*****
0	*****	*****
1-2	*****	*****
3-4	*****	*****
5+	11	34.4%

Table 1k. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	*****	*****
Obesity	*****	*****
Tobacco use	*****	*****
Arrhythmia	*****	*****
Cerebrovascular disease/stroke/transient ischemic attack	*****	*****
Chronic kidney disease	*****	*****
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	*****	*****
Hyperlipidemia	*****	*****
Hypertensive disease	*****	*****
Thyroid disease	*****	*****
Ischemic heart disease/coronary artery disease/myocardial infarction	*****	*****
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	*****
Obstructive sleep apnea	*****	*****
Hypertrophic cardiomyopathy	0	0.0%
Other cardiac disease	14	43.8%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	*****	*****
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	*****	*****
Biguanides (metformin, phenformin, etc.)	*****	*****
SGLT2 inhibitors	*****	*****
Sulfonylurea	*****	*****
Thiazolidinedione	*****	*****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	12	37.5%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%

Table 1k. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	12	37.5%
Angiotensin-converting-enzyme (ACE) inhibitor	*****	*****
Angiotensin ii receptor blockers (ARBs)	14	43.8%
Dihydropyridines	*****	*****
Diuretics	12	37.5%
Other antihypertensives	*****	*****
Antihypertensives (any of the above antihypertensives)	*****	*****
Oral anticoagulants	0	0.0%
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	0	0.0%
Other cardiac medications (any of the other cardiac medications)	0	0.0%
Lipid lowering therapy	26	81.3%
Baseline known risk of prolonged QT and torsades de pointes	16	50.0%
Baseline possible risk of prolonged QT and torsades de pointes	30	93.8%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	23.3	19.2
Mean number of emergency room encounters	1.0	1.7
Mean number of inpatient hospital encounters	0.3	0.8
Mean number of non-acute institutional encounters	0.1	0.2
Mean number of other ambulatory encounters	6.6	8.3
Mean number of filled prescriptions	53.4	38.3
Mean number of generics dispensed	14.5	6.6
Mean number of unique drug classes dispensed	12.9	5.7

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 11. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	108	N/A
Demographic Characteristics		
Age (years)	65.1	10.6
Age		
0-40 years	*****	*****
41-64 years	29	26.9%
65-74 years	53	49.1%
75-84 years	*****	*****
≥ 85 years	*****	*****
Sex		
Female	55	50.9%
Male	53	49.1%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	108	100.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	86	79.6%
Unknown	22	20.4%
Year		
2022	68	63.0%
2023	40	37.0%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.8	1.7
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	35	32.4%
1-2	42	38.9%
3-4	*****	*****
5+	*****	*****
Combined comorbidity score ⁴	2.4	2.6
Combined comorbidity score categories ⁴		
<0	*****	*****
0	25	23.1%
1-2	41	38.0%
3-4	23	21.3%
5+	*****	*****

Table 11. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	*****	*****
Obesity	47	43.5%
Tobacco use	17	15.7%
Arrhythmia	16	14.8%
Cerebrovascular disease/stroke/transient ischemic attack	16	14.8%
Chronic kidney disease	17	15.7%
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	*****	*****
Hyperlipidemia	97	89.8%
Hypertensive disease	95	88.0%
Thyroid disease	29	26.9%
Ischemic heart disease/coronary artery disease/myocardial infarction	29	26.9%
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	16	14.8%
Obstructive sleep apnea	16	14.8%
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	41	38.0%
Tachyarrhythmia day 0	*****	*****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	33	30.6%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	34	31.5%
Biguanides (metformin, phenformin, etc.)	81	75.0%
SGLT2 inhibitors	36	33.3%
Sulfonylurea	38	35.2%
Thiazolidinedione	22	20.4%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	*****	*****
Beta blockers	43	39.8%
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%

Table 1I. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	43	39.8%
Angiotensin-converting-enzyme (ACE) inhibitor	33	30.6%
Angiotensin ii receptor blockers (ARBs)	54	50.0%
Dihydropyridines	29	26.9%
Diuretics	31	28.7%
Other antihypertensives	*****	*****
Antihypertensives (any of the above antihypertensives)	*****	*****
Oral anticoagulants	*****	*****
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	*****	*****
Other cardiac medications (any of the other cardiac medications)	15	13.9%
Lipid lowering therapy	95	88.0%
Baseline known risk of prolonged QT and torsades de pointes	40	37.0%
Baseline possible risk of prolonged QT and torsades de pointes	85	78.7%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	20.0	16.2
Mean number of emergency room encounters	0.3	0.8
Mean number of inpatient hospital encounters	0.1	0.7
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	5.2	8.1
Mean number of filled prescriptions	46.1	34.5
Mean number of generics dispensed	13.3	7.0
Mean number of unique drug classes dispensed	11.3	6.2

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1m. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	1,640	N/A
Demographic Characteristics		
Age (years)	64.8	9.7
Age		
0-40 years	*****	*****
41-64 years	671	40.9%
65-74 years	744	45.4%
75-84 years	173	10.5%
≥ 85 years	*****	*****
Sex		
Female	1,199	73.1%
Male	441	26.9%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	1,640	100.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	1,572	95.9%
Unknown	68	4.1%
Year		
2022	634	38.7%
2023	1,006	61.3%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.3	2.1
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	370	22.6%
1-2	636	38.8%
3-4	368	22.4%
5+	266	16.2%
Combined comorbidity score ⁴	3.0	2.8
Combined comorbidity score categories ⁴		
<0	68	4.1%
0	252	15.4%
1-2	522	31.8%
3-4	363	22.1%
5+	435	26.5%

Table 1m. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	23	1.5%
Obesity	1,316	80.2%
Tobacco use	432	26.3%
Arrhythmia	404	23.60%
Cerebrovascular disease/stroke/transient ischemic attack	250	15.2%
Chronic kidney disease	445	27.1%
Chronic obstructive pulmonary disease	235	14.3%
Congenital heart disease	235	14.3%
Heart failure	329	20.1%
Hyperlipidemia	1,419	86.5%
Hypertensive disease	1,579	96.3%
Thyroid disease	282	17.2%
Ischemic heart disease/coronary artery disease/myocardial infarction	401	23.50%
Left ventricular hypertrophy	145	8.8%
Peripheral artery disease	145	8.8%
Valvular/mitral valve disease	67	4.1%
Diseases of veins and lymphatics, and other diseases of circulatory system	251	15.3%
Obstructive sleep apnea	512	31.2%
Hypertrophic cardiomyopathy	117	7.1%
Other cardiac disease	834	50.9%
Tachyarrhythmia day 0	18	1.1%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	19	1.2%
Medical Product Use		
Alpha-glucosidase inhibitors	*****	*****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	186	11.3%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	493	30.1%
Biguanides (metformin, phenformin, etc.)	1,273	77.6%
SGLT2 inhibitors	433	26.4%
Sulfonylurea	482	29.4%
Thiazolidinedione	128	7.8%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	*****	*****
Beta blockers	798	48.7%
Potassium channel blockers/openers	16	1.0%
Non-dihydropyridine calcium channel blockers	*****	*****
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%

Table 1m. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	806	49.1%
Angiotensin-converting-enzyme (ACE) inhibitor	483	29.5%
Angiotensin ii receptor blockers (ARBs)	829	50.5%
Dihydropyridines	759	46.3%
Diuretics	905	55.2%
Other antihypertensives	287	17.5%
Antihypertensives (any of the above antihypertensives)	1,536	93.7%
Oral anticoagulants	132	8.0%
Vitamin K antagonists	22	1.3%
Other cardiac medications not mentioned above	118	7.2%
Other cardiac medications (any of the other cardiac medications)	230	14.6%
Lipid lowering therapy	1,400	85.4%
Baseline known risk of prolonged QT and torsades de pointes	804	49.0%
Baseline possible risk of prolonged QT and torsades de pointes	1,510	92.1%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	233	14.2%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	23.2	19.1
Mean number of emergency room encounters	1.2	3.0
Mean number of inpatient hospital encounters	0.1	0.6
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	4.8	11.0
Mean number of filled prescriptions	50.5	32.7
Mean number of generics dispensed	15.4	7.0
Mean number of unique drug classes dispensed	13.6	5.9

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1n. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	57	N/A
Demographic Characteristics		
Age (years)	71.4	6.6
Age		
0-40 years	0	0.0%
41-64 years	*****	*****
65-74 years	38	66.7%
75-84 years	*****	*****
≥ 85 years	*****	*****
Sex		
Female	26	45.6%
Male	31	54.4%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	57	100.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	57	100.0%
Unknown	0	0.0%
Year		
2022	19	33.3%
2023	38	66.7%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.2	1.8
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	*****	*****
1-2	25	43.9%
3-4	16	28.1%
5+	*****	*****
Combined comorbidity score ⁴	2.9	2.9
Combined comorbidity score categories ⁴		
<0	*****	*****
0	*****	*****
1-2	18	31.6%
3-4	11	19.3%
5+	15	26.3%

Table 1n. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	*****	*****
Obesity	33	57.9%
Tobacco use	*****	*****
Arrhythmia	12	21.1%
Cerebrovascular disease/stroke/transient ischemic attack	*****	*****
Chronic kidney disease	22	38.6%
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	*****	*****
Hyperlipidemia	*****	*****
Hypertensive disease	*****	*****
Thyroid disease	14	23.60%
Ischemic heart disease/coronary artery disease/myocardial infarction	17	29.8%
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	11	19.3%
Obstructive sleep apnea	12	21.1%
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	23	40.4%
Tachyarrhythmia day 0	*****	*****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	*****	*****
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	17	29.8%
Biguanides (metformin, phenformin, etc.)	46	80.7%
SGLT2 inhibitors	16	28.1%
Sulfonylurea	20	35.1%
Thiazolidinedione	12	21.1%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	26	45.6%
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%

Table 1n. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	26	45.6%
Angiotensin-converting-enzyme (ACE) inhibitor	23	40.4%
Angiotensin ii receptor blockers (ARBs)	26	45.6%
Dihydropyridines	19	33.3%
Diuretics	20	35.1%
Other antihypertensives	*****	*****
Antihypertensives (any of the above antihypertensives)	*****	*****
Oral anticoagulants	*****	*****
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	*****	*****
Other cardiac medications (any of the other cardiac medications)	*****	*****
Lipid lowering therapy	*****	*****
Baseline known risk of prolonged QT and torsades de pointes	27	47.4%
Baseline possible risk of prolonged QT and torsades de pointes	*****	*****
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	11	19.3%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	21.9	19.6
Mean number of emergency room encounters	0.5	1.3
Mean number of inpatient hospital encounters	0.1	0.6
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	1.9	5.1
Mean number of filled prescriptions	40.6	22.7
Mean number of generics dispensed	13.5	6.6
Mean number of unique drug classes dispensed	11.5	5.5

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1o. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	8,939	N/A
Demographic Characteristics		
Age (years)	67.5	8.9
Age		
0-40 years	115	1.3%
41-64 years	2,394	26.8%
65-74 years	4,850	54.3%
75-84 years	1,505	16.8%
≥ 85 years	75	0.8%
Sex		
Female	5,154	57.7%
Male	3,785	42.3%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	8,939	100.0%
Hispanic origin		
Yes	*****	*****
No	8,538	95.5%
Unknown	*****	*****
Year		
2022	4,671	52.3%
2023	4,268	47.7%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.1	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	2,304	25.8%
1-2	3,461	38.7%
3-4	2,022	22.6%
5+	1,152	12.9%
Combined comorbidity score ⁴	2.8	2.7
Combined comorbidity score categories ⁴		
<0	446	5.0%
0	1,322	14.8%
1-2	3,050	34.1%
3-4	2,045	22.9%
5+	2,076	23.2%

Table 1o. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	185	2.1%
Obesity	6,268	70.1%
Tobacco use	2,740	30.7%
Arrhythmia	2,678	30.0%
Cerebrovascular disease/stroke/transient ischemic attack	1,296	14.5%
Chronic kidney disease	1,953	21.8%
Chronic obstructive pulmonary disease	1,511	16.9%
Congenital heart disease	1,511	16.9%
Heart failure	1,467	16.4%
Hyperlipidemia	7,892	88.3%
Hypertensive disease	8,165	91.3%
Thyroid disease	2,777	31.1%
Ischemic heart disease/coronary artery disease/myocardial infarction	2,798	31.3%
Left ventricular hypertrophy	564	6.3%
Peripheral artery disease	564	6.3%
Valvular/mitral valve disease	466	5.2%
Diseases of veins and lymphatics, and other diseases of circulatory system	1,393	15.6%
Obstructive sleep apnea	3,214	36.0%
Hypertrophic cardiomyopathy	478	5.3%
Other cardiac disease	5,089	56.9%
Tachyarrhythmia day 0	191	2.1%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	70	0.8%
Medical Product Use		
Alpha-glucosidase inhibitors	29	0.3%
Amylin analogs (pramlintide)	*****	*****
DPP-4 inhibitors	1,121	12.5%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	78	0.9%
Insulin	2,422	27.1%
Biguanides (metformin, phenformin, etc.)	7,149	80.0%
SGLT2 inhibitors	2,329	26.1%
Sulfonylurea	2,962	33.1%
Thiazolidinedione	989	11.1%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	*****	*****
Sodium channel blockers	97	1.1%
Beta blockers	4,189	46.9%
Potassium channel blockers/openers	176	2.0%
Non-dihydropyridine calcium channel blockers	20	0.2%
Digoxin	81	0.9%
Other antiarrhythmic agents	0	0.0%

Table 1o. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	4,256	47.6%
Angiotensin-converting-enzyme (ACE) inhibitor	3,497	39.1%
Angiotensin ii receptor blockers (ARBs)	3,536	39.6%
Dihydropyridines	2,361	26.4%
Diuretics	3,826	42.8%
Other antihypertensives	880	9.8%
Antihypertensives (any of the above antihypertensives)	7,839	87.7%
Oral anticoagulants	941	10.5%
Vitamin K antagonists	205	2.3%
Other cardiac medications not mentioned above	761	8.5%
Other cardiac medications (any of the other cardiac medications)	1,723	19.3%
Lipid lowering therapy	7,700	86.1%
Baseline known risk of prolonged QT and torsades de pointes	4,894	54.7%
Baseline possible risk of prolonged QT and torsades de pointes	8,129	90.9%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	1,822	20.4%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	23.5	17.7
Mean number of emergency room encounters	0.7	1.8
Mean number of inpatient hospital encounters	0.2	0.5
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	5.1	10.8
Mean number of filled prescriptions	52.6	33.9
Mean number of generics dispensed	15.1	6.7
Mean number of unique drug classes dispensed	13.3	5.8

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1p. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	60	N/A
Demographic Characteristics		
Age (years)	53.2	10.6
Age		
0-40 years	*****	*****
41-64 years	46	76.7%
65-74 years	*****	*****
75-84 years	*****	*****
≥ 85 years	0	0.0%
Sex		
Female	31	51.7%
Male	29	48.3%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	60	100.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	41	68.3%
Year		
2022	34	56.7%
2023	26	43.3%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.6	1.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	41	68.3%
1-2	*****	*****
3-4	*****	*****
5+	0	0.0%
Combined comorbidity score ⁴	1.3	1.9
Combined comorbidity score categories ⁴		
<0	*****	*****
0	22	36.7%
1-2	18	30.0%
3-4	*****	*****
5+	*****	*****

Table 1p. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	*****	*****
Obesity	35	58.3%
Tobacco use	*****	*****
Arrhythmia	*****	*****
Cerebrovascular disease/stroke/transient ischemic attack	*****	*****
Chronic kidney disease	*****	*****
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	*****	*****
Hyperlipidemia	48	80.0%
Hypertensive disease	45	75.0%
Thyroid disease	15	25.0%
Ischemic heart disease/coronary artery disease/myocardial infarction	*****	*****
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	*****
Obstructive sleep apnea	17	28.3%
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	20	33.3%
Tachyarrhythmia day 0	*****	*****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	*****	*****
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	*****	*****
Biguanides (metformin, phenformin, etc.)	*****	*****
SGLT2 inhibitors	17	28.3%
Sulfonylurea	11	18.3%
Thiazolidinedione	*****	*****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	12	20.0%
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%

Table 1p. Aggregated Characteristics of Mounjaro, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	12	20.0%
Angiotensin-converting-enzyme (ACE) inhibitor	21	35.0%
Angiotensin ii receptor blockers (ARBs)	17	28.3%
Dihydropyridines	*****	*****
Diuretics	*****	*****
Other antihypertensives	*****	*****
Antihypertensives (any of the above antihypertensives)	41	68.3%
Oral anticoagulants	*****	*****
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	0	0.0%
Other cardiac medications (any of the other cardiac medications)	*****	*****
Lipid lowering therapy	40	66.7%
Baseline known risk of prolonged QT and torsades de pointes	19	31.7%
Baseline possible risk of prolonged QT and torsades de pointes	43	71.7%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	15.7	10.7
Mean number of emergency room encounters	0.4	0.6
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	2.7	3.5
Mean number of filled prescriptions	33.8	23.7
Mean number of generics dispensed	9.9	4.4
Mean number of unique drug classes dispensed	8.5	3.9

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a number

N/A: Not applicable

Table 1q. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Unique patients	117,008	N/A
Demographic Characteristics		
Age (years)	63.2	10.2
Age		
0-40 years	5,493	4.7%
41-64 years	50,784	43.4%
65-74 years	44,381	37.9%
75-84 years	15,103	12.9%
≥ 85 years	1,237	1.1%
Sex		
Female	65,494	56.0%
Male	51,514	44.0%
Race ²		
American Indian or Alaska Native	826	0.7%
Asian	1,393	1.2%
Black or African American	9,832	8.4%
Multi-racial	816	0.7%
Native Hawaiian or Other Pacific Islander	333	0.3%
Unknown	45,367	38.8%
White	58,441	49.9%
Hispanic origin		
Yes	3,235	2.8%
No	62,161	53.1%
Unknown	51,602	44.1%
Year		
2022	79,091	67.6%
2023	37,917	32.4%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.7	1.9
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	43,316	37.0%
1-2	41,147	35.2%
3-4	20,519	17.5%
5+	12,026	10.3%
Combined comorbidity score ⁴	2.3	2.5
Combined comorbidity score categories ⁴		
<0	8,676	7.4%
0	23,129	20.6%
1-2	41,625	35.6%
3-4	22,050	18.8%
5+	20,528	17.5%

Table 1q. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Alcohol use or abuse	2,056	1.8%
Obesity	72,913	62.3%
Tobacco use	28,078	23.00%
Arrhythmia	29,326	25.1%
Cerebrovascular disease/stroke/transient ischemic attack	14,018	12.0%
Chronic kidney disease	20,745	17.7%
Chronic obstructive pulmonary disease	12,960	11.1%
Congenital heart disease	12,960	11.1%
Heart failure	14,535	12.4%
Hyperlipidemia	96,908	82.8%
Hypertensive disease	100,211	85.6%
Thyroid disease	26,991	23.1%
Ischemic heart disease/coronary artery disease/myocardial infarction	29,134	23.90%
Left ventricular hypertrophy	6,816	5.8%
Peripheral artery disease	6,816	5.8%
Valvular/mitral valve disease	4,608	3.9%
Diseases of veins and lymphatics, and other diseases of circulatory system	15,132	12.9%
Obstructive sleep apnea	34,548	29.5%
Hypertrophic cardiomyopathy	5,772	4.9%
Other cardiac disease	55,966	47.8%
Tachyarrhythmia day 0	1,942	1.7%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	916	0.8%
Medical Product Use		
Alpha-glucosidase inhibitors	403	0.3%
Amylin analogs (pramlintide)	*****	*****
DPP-4 inhibitors	16,890	14.4%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	1,021	0.9%
Insulin	29,144	23.90%
Biguanides (metformin, phenformin, etc.)	97,762	83.6%
SGLT2 inhibitors	30,413	26.0%
Sulfonylurea	36,658	31.3%
Thiazolidinedione	9,450	8.1%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	31	0.0%
Sodium channel blockers	841	0.7%
Beta blockers	48,316	41.3%
Potassium channel blockers/openers	1,789	1.5%
Non-dihydropyridine calcium channel blockers	157	0.1%
Digoxin	843	0.7%
Other antiarrhythmic agents	0	0.0%

Table 1q. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	48,852	41.8%
Angiotensin-converting-enzyme (ACE) inhibitor	44,027	37.6%
Angiotensin ii receptor blockers (ARBs)	42,983	36.7%
Dihydropyridines	30,487	26.1%
Diuretics	43,232	37.0%
Other antihypertensives	9,664	8.3%
Antihypertensives (any of the above antihypertensives)	97,051	82.9%
Oral anticoagulants	10,151	8.7%
Vitamin K antagonists	2,185	1.9%
Other cardiac medications not mentioned above	8,054	6.9%
Other cardiac medications (any of the other cardiac medications)	18,420	15.7%
Lipid lowering therapy	94,793	81.0%
Baseline known risk of prolonged QT and torsades de pointes	54,758	46.8%
Baseline possible risk of prolonged QT and torsades de pointes	99,693	85.2%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	17,852	15.3%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	20.9	18.6
Mean number of emergency room encounters	0.6	1.6
Mean number of inpatient hospital encounters	0.2	0.5
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	5.5	10.7
Mean number of filled prescriptions	45.5	33.7
Mean number of generics dispensed	13.0	6.4
Mean number of unique drug classes dispensed	11.4	5.6

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1r. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	45,367	N/A
Demographic Characteristics		
Age (years)	56.4	10.8
Age		
0-40 years	4,021	8.9%
41-64 years	31,654	69.8%
65-74 years	7,739	17.1%
75-84 years	1,811	4.0%
≥ 85 years	142	0.3%
Sex		
Female	23,280	53.5%
Male	21,087	46.5%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	45,367	100.0%
White	0	0.0%
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	42,385	93.4%
Year		
2022	27,580	60.8%
2023	17,787	39.2%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.1	1.5
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	23,400	53.8%
1-2	14,252	31.4%
3-4	4,665	10.3%
5+	2,050	4.5%
Combined comorbidity score ⁴	1.4	2.0
Combined comorbidity score categories ⁴		
<0	5,069	11.2%
0	12,821	28.3%
1-2	17,633	38.9%
3-4	6,145	13.5%
5+	3,699	8.2%

Table 1r. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	634	1.4%
Obesity	27,400	60.4%
Tobacco use	7,631	16.8%
Arrhythmia	7,913	17.4%
Cerebrovascular disease/stroke/transient ischemic attack	2,899	6.4%
Chronic kidney disease	4,294	9.5%
Chronic obstructive pulmonary disease	2,435	5.4%
Congenital heart disease	2,435	5.4%
Heart failure	2,911	6.4%
Hyperlipidemia	34,725	76.5%
Hypertensive disease	35,654	78.6%
Thyroid disease	8,262	18.2%
Ischemic heart disease/coronary artery disease/myocardial infarction	6,787	15.0%
Left ventricular hypertrophy	1,736	3.8%
Peripheral artery disease	1,736	3.8%
Valvular/mitral valve disease	980	2.2%
Diseases of veins and lymphatics, and other diseases of circulatory system	3,881	8.6%
Obstructive sleep apnea	11,872	26.2%
Hypertrophic cardiomyopathy	1,369	3.0%
Other cardiac disease	17,100	37.7%
Tachyarrhythmia day 0	419	0.9%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	184	0.4%
Medical Product Use		
Alpha-glucosidase inhibitors	129	0.3%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	6,063	13.4%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	286	0.6%
Insulin	8,721	19.2%
Biguanides (metformin, phenformin, etc.)	39,797	87.7%
SGLT2 inhibitors	11,723	25.8%
Sulfonylurea	11,723	25.8%
Thiazolidinedione	2,842	6.3%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	12	0.0%
Sodium channel blockers	220	0.5%
Beta blockers	14,273	31.5%
Potassium channel blockers/openers	334	0.7%
Non-dihydropyridine calcium channel blockers	40	0.1%
Digoxin	162	0.4%
Other antiarrhythmic agents	0	0.0%

Table 1r. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	14,390	31.7%
Angiotensin-converting-enzyme (ACE) inhibitor	16,623	36.6%
Angiotensin ii receptor blockers (ARBs)	14,940	32.9%
Dihydropyridines	9,599	21.2%
Diuretics	12,858	28.3%
Other antihypertensives	2,592	5.7%
Antihypertensives (any of the above antihypertensives)	34,827	76.8%
Oral anticoagulants	2,380	5.2%
Vitamin K antagonists	431	1.0%
Other cardiac medications not mentioned above	1,857	4.1%
Other cardiac medications (any of the other cardiac medications)	4,318	9.5%
Lipid lowering therapy	33,518	73.9%
Baseline known risk of prolonged QT and torsades de pointes	19,695	43.4%
Baseline possible risk of prolonged QT and torsades de pointes	36,173	79.7%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	5,808	12.8%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	16.5	16.6
Mean number of emergency room encounters	0.4	1.0
Mean number of inpatient hospital encounters	0.1	0.5
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	4.6	7.1
Mean number of filled prescriptions	38.5	29.9
Mean number of generics dispensed	11.5	6.2
Mean number of unique drug classes dispensed	10.1	5.4

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1s. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	826	N/A
Demographic Characteristics		
Age (years)	67.1	10.9
Age		
0-40 years	23	2.8%
41-64 years	259	31.4%
65-74 years	361	43.7%
75-84 years	165	20.0%
≥ 85 years	18	2.2%
Sex		
Female	474	57.4%
Male	352	42.6%
Race ²		
American Indian or Alaska Native	826	100.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	*****	*****
No	771	93.3%
Unknown	*****	*****
Year		
2022	695	84.1%
2023	131	15.9%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.9	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	274	33.2%
1-2	276	33.4%
3-4	186	22.5%
5+	90	10.9%
Combined comorbidity score ⁴	2.5	2.6
Combined comorbidity score categories ⁴		
<0	48	5.8%
0	153	18.5%
1-2	289	35.0%
3-4	183	22.2%
5+	153	18.5%

Table 1s. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	21	2.5%
Obesity	376	45.5%
Tobacco use	256	31.0%
Arrhythmia	205	23.80%
Cerebrovascular disease/stroke/transient ischemic attack	104	12.6%
Chronic kidney disease	180	21.8%
Chronic obstructive pulmonary disease	120	14.5%
Congenital heart disease	120	14.5%
Heart failure	126	15.3%
Hyperlipidemia	591	71.5%
Hypertensive disease	694	84.0%
Thyroid disease	186	22.5%
Ischemic heart disease/coronary artery disease/myocardial infarction	227	27.5%
Left ventricular hypertrophy	47	5.7%
Peripheral artery disease	47	5.7%
Valvular/mitral valve disease	40	4.8%
Diseases of veins and lymphatics, and other diseases of circulatory system	121	14.6%
Obstructive sleep apnea	190	23.0%
Hypertrophic cardiomyopathy	46	5.6%
Other cardiac disease	367	44.4%
Tachyarrhythmia day 0	20	2.4%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	13	1.6%
Medical Product Use		
Alpha-glucosidase inhibitors	*****	*****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	163	19.7%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	370	44.8%
Biguanides (metformin, phenformin, etc.)	653	79.1%
SGLT2 inhibitors	223	27.0%
Sulfonylurea	277	33.5%
Thiazolidinedione	94	11.4%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	*****	*****
Beta blockers	329	39.8%
Potassium channel blockers/openers	14	1.7%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%

Table 1s. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	332	40.2%
Angiotensin-converting-enzyme (ACE) inhibitor	358	43.3%
Angiotensin ii receptor blockers (ARBs)	305	36.9%
Dihydropyridines	225	27.2%
Diuretics	343	41.5%
Other antihypertensives	81	9.8%
Antihypertensives (any of the above antihypertensives)	716	86.7%
Oral anticoagulants	92	11.1%
Vitamin K antagonists	20	2.4%
Other cardiac medications not mentioned above	73	8.8%
Other cardiac medications (any of the other cardiac medications)	163	19.7%
Lipid lowering therapy	681	82.4%
Baseline known risk of prolonged QT and torsades de pointes	376	45.5%
Baseline possible risk of prolonged QT and torsades de pointes	706	85.5%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	99	12.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	19.8	15.0
Mean number of emergency room encounters	0.8	1.9
Mean number of inpatient hospital encounters	0.2	0.7
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	5.0	9.8
Mean number of filled prescriptions	69.3	47.4
Mean number of generics dispensed	13.6	6.2
Mean number of unique drug classes dispensed	12.1	5.4

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1t. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	1,393	N/A
Demographic Characteristics		
Age (years)	65.9	10.3
Age		
0-40 years	79	5.7%
41-64 years	360	25.8%
65-74 years	655	47.0%
75-84 years	251	18.0%
≥ 85 years	48	3.4%
Sex		
Female	777	55.8%
Male	616	44.2%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	1,393	100.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	*****	*****
No	1,051	75.4%
Unknown	*****	*****
Year		
2022	1,022	73.4%
2023	371	26.6%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.9	1.9
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	461	33.1%
1-2	492	35.3%
3-4	267	19.2%
5+	173	12.4%
Combined comorbidity score ⁴	2.4	2.5
Combined comorbidity score categories ⁴		
<0	85	6.1%
0	273	19.6%
1-2	487	35.0%
3-4	277	19.9%
5+	271	19.5%

Table 1t. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	16	1.1%
Obesity	507	36.4%
Tobacco use	183	13.1%
Arrhythmia	299	21.5%
Cerebrovascular disease/stroke/transient ischemic attack	174	12.5%
Chronic kidney disease	344	23.70%
Chronic obstructive pulmonary disease	97	7.0%
Congenital heart disease	97	7.0%
Heart failure	177	12.7%
Hyperlipidemia	1,210	86.9%
Hypertensive disease	1,182	84.9%
Thyroid disease	328	23.5%
Ischemic heart disease/coronary artery disease/myocardial infarction	383	27.5%
Left ventricular hypertrophy	79	5.7%
Peripheral artery disease	79	5.7%
Valvular/mitral valve disease	49	3.5%
Diseases of veins and lymphatics, and other diseases of circulatory system	147	10.6%
Obstructive sleep apnea	204	14.6%
Hypertrophic cardiomyopathy	57	4.1%
Other cardiac disease	570	40.9%
Tachyarrhythmia day 0	14	1.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	13	0.9%
Medical Product Use		
Alpha-glucosidase inhibitors	21	1.5%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	298	21.4%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	30	2.2%
Insulin	455	32.7%
Biguanides (metformin, phenformin, etc.)	1,189	85.4%
SGLT2 inhibitors	478	34.3%
Sulfonylurea	513	36.8%
Thiazolidinedione	153	11.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	*****	*****
Sodium channel blockers	*****	*****
Beta blockers	589	42.3%
Potassium channel blockers/openers	17	1.2%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%

Table 1t. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	592	42.5%
Angiotensin-converting-enzyme (ACE) inhibitor	401	28.8%
Angiotensin ii receptor blockers (ARBs)	696	50.0%
Dihydropyridines	464	33.3%
Diuretics	381	27.4%
Other antihypertensives	130	9.3%
Antihypertensives (any of the above antihypertensives)	1,155	82.9%
Oral anticoagulants	81	5.8%
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	119	8.5%
Other cardiac medications (any of the other cardiac medications)	196	14.1%
Lipid lowering therapy	1,193	85.6%
Baseline known risk of prolonged QT and torsades de pointes	523	37.5%
Baseline possible risk of prolonged QT and torsades de pointes	1,056	75.8%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	142	10.2%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	19.9	20.1
Mean number of emergency room encounters	0.4	0.9
Mean number of inpatient hospital encounters	0.1	0.5
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	5.7	10.4
Mean number of filled prescriptions	42.6	33.7
Mean number of generics dispensed	12.4	6.2
Mean number of unique drug classes dispensed	10.6	5.4

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1u. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Unique patients	9,832	N/A
Demographic Characteristics		
Age (years)	64.6	10.3
Age		
0-40 years	313	3.2%
41-64 years	3,802	38.7%
65-74 years	4,502	45.8%
75-84 years	1,113	11.3%
≥ 85 years	102	1.0%
Sex		
Female	7,071	71.9%
Male	2,761	28.1%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	9,832	100.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	8,627	87.7%
Unknown	1,205	12.3%
Year		
2022	6,058	61.6%
2023	3,774	38.4%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.3	2.1
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	2,332	23.7%
1-2	3,571	36.3%
3-4	2,353	23.9%
5+	1,576	16.0%
Combined comorbidity score ⁴	3.0	2.8
Combined comorbidity score categories ⁴		
<0	456	4.6%
0	1,463	14.9%
1-2	3,023	30.8%
3-4	2,254	22.9%
5+	2,635	26.8%

Table 1u. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	199	2.0%
Obesity	7,118	72.4%
Tobacco use	2,661	27.1%
Arrhythmia	2,642	26.9%
Cerebrovascular disease/stroke/transient ischemic attack	1,519	15.4%
Chronic kidney disease	2,747	27.9%
Chronic obstructive pulmonary disease	1,297	13.2%
Congenital heart disease	1,297	13.2%
Heart failure	1,998	20.3%
Hyperlipidemia	8,355	85.0%
Hypertensive disease	9,306	94.7%
Thyroid disease	1,527	15.5%
Ischemic heart disease/coronary artery disease/myocardial infarction	2,439	23.80%
Left ventricular hypertrophy	794	8.1%
Peripheral artery disease	794	8.1%
Valvular/mitral valve disease	386	3.9%
Diseases of veins and lymphatics, and other diseases of circulatory system	1,461	14.9%
Obstructive sleep apnea	2,961	30.1%
Hypertrophic cardiomyopathy	739	7.5%
Other cardiac disease	4,983	50.7%
Tachyarrhythmia day 0	126	1.3%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	142	1.4%
Medical Product Use		
Alpha-glucosidase inhibitors	40	0.4%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	1,565	15.9%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	75	0.8%
Insulin	3,206	32.6%
Biguanides (metformin, phenformin, etc.)	7,565	76.9%
SGLT2 inhibitors	2,533	25.8%
Sulfonylurea	3,231	33.0%
Thiazolidinedione	685	7.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	*****	*****
Sodium channel blockers	51	0.5%
Beta blockers	4,761	48.4%
Potassium channel blockers/openers	122	1.2%
Non-dihydropyridine calcium channel blockers	13	0.1%
Digoxin	68	0.7%
Other antiarrhythmic agents	0	0.0%

Table 1u. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	4,788	48.7%
Angiotensin-converting-enzyme (ACE) inhibitor	3,144	32.0%
Angiotensin ii receptor blockers (ARBs)	4,656	47.4%
Dihydropyridines	4,536	46.1%
Diuretics	5,129	52.2%
Other antihypertensives	1,551	15.8%
Antihypertensives (any of the above antihypertensives)	9,048	92.0%
Oral anticoagulants	794	8.1%
Vitamin K antagonists	157	1.6%
Other cardiac medications not mentioned above	752	7.6%
Other cardiac medications (any of the other cardiac medications)	1,537	15.6%
Lipid lowering therapy	8,239	83.9%
Baseline known risk of prolonged QT and torsades de pointes	4,455	45.3%
Baseline possible risk of prolonged QT and torsades de pointes	8,860	90.1%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	1,302	13.2%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	23.6	20.6
Mean number of emergency room encounters	1.0	2.2
Mean number of inpatient hospital encounters	0.2	0.6
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	6.1	13.7
Mean number of filled prescriptions	49.1	34.6
Mean number of generics dispensed	14.3	6.5
Mean number of unique drug classes dispensed	12.6	5.7

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1v. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	333	N/A
Demographic Characteristics		
Age (years)	69.1	8.3
Age		
0-40 years	*****	*****
41-64 years	*****	*****
65-74 years	184	55.3%
75-84 years	81	23.30%
≥ 85 years	*****	*****
Sex		
Female	158	47.4%
Male	175	52.6%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	333	100.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	315	94.6%
Unknown	18	5.4%
Year		
2022	156	46.8%
2023	177	53.2%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.3	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	83	23.90%
1-2	114	34.2%
3-4	87	26.1%
5+	49	14.7%
Combined comorbidity score ⁴	2.7	2.7
Combined comorbidity score categories ⁴		
<0	14	4.2%
0	55	16.5%
1-2	122	36.6%
3-4	75	22.5%
5+	67	20.1%

Table 1v. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	*****	*****
Obesity	177	53.2%
Tobacco use	72	21.6%
Arrhythmia	72	21.6%
Cerebrovascular disease/stroke/transient ischemic attack	57	17.1%
Chronic kidney disease	98	29.4%
Chronic obstructive pulmonary disease	26	7.8%
Congenital heart disease	26	7.8%
Heart failure	50	15.0%
Hyperlipidemia	306	91.9%
Hypertensive disease	302	90.7%
Thyroid disease	73	21.9%
Ischemic heart disease/coronary artery disease/myocardial infarction	92	27.6%
Left ventricular hypertrophy	20	6.0%
Peripheral artery disease	20	6.0%
Valvular/mitral valve disease	14	4.2%
Diseases of veins and lymphatics, and other diseases of circulatory system	35	10.5%
Obstructive sleep apnea	64	19.2%
Hypertrophic cardiomyopathy	22	6.6%
Other cardiac disease	149	44.7%
Tachyarrhythmia day 0	*****	*****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	*****	*****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	44	13.2%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	111	33.3%
Biguanides (metformin, phenformin, etc.)	281	84.4%
SGLT2 inhibitors	90	27.0%
Sulfonylurea	135	40.5%
Thiazolidinedione	43	12.9%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	146	43.8%
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%

Table 1v. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	147	44.1%
Angiotensin-converting-enzyme (ACE) inhibitor	131	39.3%
Angiotensin ii receptor blockers (ARBs)	148	44.4%
Dihydropyridines	112	33.6%
Diuretics	113	33.9%
Other antihypertensives	26	7.8%
Antihypertensives (any of the above antihypertensives)	293	88.0%
Oral anticoagulants	23	6.9%
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	17	5.1%
Other cardiac medications (any of the other cardiac medications)	43	12.9%
Lipid lowering therapy	299	89.8%
Baseline known risk of prolonged QT and torsades de pointes	125	37.5%
Baseline possible risk of prolonged QT and torsades de pointes	270	81.1%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	31	9.3%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	19.9	14.2
Mean number of emergency room encounters	0.5	1.1
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	2.8	7.5
Mean number of filled prescriptions	40.7	27.7
Mean number of generics dispensed	13.0	5.8
Mean number of unique drug classes dispensed	11.2	5.0

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1w. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	58,441	N/A
Demographic Characteristics		
Age (years)	68.2	9.2
Age		
0-40 years	930	1.6%
41-64 years	14,028	23.00%
65-74 years	30,872	52.8%
75-84 years	11,675	20.0%
≥ 85 years	936	1.6%
Sex		
Female	32,293	55.3%
Male	26,148	44.7%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	58,441	100.0%
Hispanic origin		
Yes	26	0.0%
No	51,332	87.8%
Unknown	7,083	12.1%
Year		
2022	43,173	73.9%
2023	15,268	26.1%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.2	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	15,256	26.1%
1-2	22,228	38.0%
3-4	12,890	22.1%
5+	8,067	13.8%
Combined comorbidity score ⁴	2.8	2.8
Combined comorbidity score categories ⁴		
<0	2,907	5.0%
0	9,121	15.6%
1-2	19,737	33.8%
3-4	13,017	22.3%
5+	13,659	23.4%

Table 1w. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	1,169	2.0%
Obesity	36,835	63.0%
Tobacco use	17,167	29.4%
Arrhythmia	18,063	30.9%
Cerebrovascular disease/stroke/transient ischemic attack	9,229	15.8%
Chronic kidney disease	13,019	22.3%
Chronic obstructive pulmonary disease	8,971	15.4%
Congenital heart disease	8,971	15.4%
Heart failure	9,238	15.8%
Hyperlipidemia	51,110	87.5%
Hypertensive disease	52,488	89.8%
Thyroid disease	16,473	28.2%
Ischemic heart disease/coronary artery disease/myocardial infarction	19,111	32.7%
Left ventricular hypertrophy	4,121	7.1%
Peripheral artery disease	4,121	7.1%
Valvular/mitral valve disease	3,131	5.4%
Diseases of veins and lymphatics, and other diseases of circulatory system	9,431	16.1%
Obstructive sleep apnea	19,040	32.6%
Hypertrophic cardiomyopathy	3,518	6.0%
Other cardiac disease	32,519	55.6%
Tachyarrhythmia day 0	1,351	2.3%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	556	1.0%
Medical Product Use		
Alpha-glucosidase inhibitors	204	0.3%
Amylin analogs (pramlintide)	*****	*****
DPP-4 inhibitors	8,680	14.9%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	621	1.1%
Insulin	16,115	27.6%
Biguanides (metformin, phenformin, etc.)	47,548	81.4%
SGLT2 inhibitors	15,159	25.9%
Sulfonylurea	20,602	35.3%
Thiazolidinedione	5,590	9.6%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	16	0.0%
Sodium channel blockers	556	1.0%
Beta blockers	28,013	47.9%
Potassium channel blockers/openers	1,292	2.2%
Non-dihydropyridine calcium channel blockers	104	0.2%
Digoxin	595	1.0%
Other antiarrhythmic agents	0	0.0%

Table 1w. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	28,398	48.6%
Angiotensin-converting-enzyme (ACE) inhibitor	23,080	39.5%
Angiotensin ii receptor blockers (ARBs)	21,968	37.6%
Dihydropyridines	15,399	26.3%
Diuretics	23,233	41.5%
Other antihypertensives	5,235	9.0%
Antihypertensives (any of the above antihypertensives)	50,423	86.3%
Oral anticoagulants	6,750	11.6%
Vitamin K antagonists	1,557	2.7%
Other cardiac medications not mentioned above	5,211	8.9%
Other cardiac medications (any of the other cardiac medications)	12,108	20.7%
Lipid lowering therapy	50,285	86.0%
Baseline known risk of prolonged QT and torsades de pointes	29,264	50.1%
Baseline possible risk of prolonged QT and torsades de pointes	52,029	89.0%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	10,394	17.8%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	23.9	19.7
Mean number of emergency room encounters	0.7	1.8
Mean number of inpatient hospital encounters	0.2	0.6
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	6.2	12.3
Mean number of filled prescriptions	50.2	35.8
Mean number of generics dispensed	13.9	6.4
Mean number of unique drug classes dispensed	12.3	5.6

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1x. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	816	N/A
Demographic Characteristics		
Age (years)	52.5	10.1
Age		
0-40 years	118	14.5%
41-64 years	623	76.3%
65-74 years	*****	*****
75-84 years	*****	*****
≥ 85 years	0	0.0%
Sex		
Female	441	54.0%
Male	375	46.0%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	816	100.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	239	29.3%
No	61	7.5%
Unknown	516	63.2%
Year		
2022	407	49.9%
2023	409	50.1%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.8	1.3
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	510	62.5%
1-2	214	26.2%
3-4	71	8.7%
5+	21	2.6%
Combined comorbidity score ⁴	1.2	1.8
Combined comorbidity score categories ⁴		
<0	97	11.9%
0	233	29.8%
1-2	333	40.8%
3-4	99	12.1%
5+	44	5.4%

Table 1x. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	11	1.3%
Obesity	500	61.3%
Tobacco use	108	13.2%
Arrhythmia	132	16.2%
Cerebrovascular disease/stroke/transient ischemic attack	36	4.4%
Chronic kidney disease	63	7.7%
Chronic obstructive pulmonary disease	14	1.7%
Congenital heart disease	14	1.7%
Heart failure	35	4.3%
Hyperlipidemia	611	74.9%
Hypertensive disease	585	71.7%
Thyroid disease	142	17.4%
Ischemic heart disease/coronary artery disease/myocardial infarction	95	11.6%
Left ventricular hypertrophy	19	2.3%
Peripheral artery disease	19	2.3%
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	56	6.9%
Obstructive sleep apnea	217	26.6%
Hypertrophic cardiomyopathy	21	2.6%
Other cardiac disease	278	34.1%
Tachyarrhythmia day 0	*****	*****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	*****	*****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	77	9.4%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	166	20.3%
Biguanides (metformin, phenformin, etc.)	729	89.3%
SGLT2 inhibitors	207	25.4%
Sulfonylurea	167	20.5%
Thiazolidinedione	43	5.3%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	*****	*****
Beta blockers	205	25.1%
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%

Table 1x. Aggregated Characteristics of Ozempic, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	205	25.1%
Angiotensin-converting-enzyme (ACE) inhibitor	289	35.4%
Angiotensin ii receptor blockers (ARBs)	270	33.1%
Dihydropyridines	152	18.6%
Diuretics	185	22.7%
Other antihypertensives	39	4.8%
Antihypertensives (any of the above antihypertensives)	589	72.2%
Oral anticoagulants	31	3.8%
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	25	3.1%
Other cardiac medications (any of the other cardiac medications)	55	6.7%
Lipid lowering therapy	568	69.6%
Baseline known risk of prolonged QT and torsades de pointes	320	39.2%
Baseline possible risk of prolonged QT and torsades de pointes	599	73.4%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	76	9.3%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	16.3	15.7
Mean number of emergency room encounters	0.5	1.3
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	3.5	6.6
Mean number of filled prescriptions	34.3	25.4
Mean number of generics dispensed	10.3	5.5
Mean number of unique drug classes dispensed	9.1	4.8

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1y. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Unique patients	34,058	N/A
Demographic Characteristics		
Age (years)	65.8	10.2
Age		
0-40 years	1,132	3.3%
41-64 years	12,264	36.0%
65-74 years	13,680	40.2%
75-84 years	6,100	17.9%
≥ 85 years	882	2.6%
Sex		
Female	17,466	51.3%
Male	16,592	48.7%
Race ²		
American Indian or Alaska Native	68	0.2%
Asian	1,087	3.2%
Black or African American	3,392	10.0%
Multi-racial	181	0.5%
Native Hawaiian or Other Pacific Islander	128	0.4%
Unknown	12,788	37.5%
White	16,414	48.2%
Hispanic origin		
Yes	1,271	3.7%
No	18,712	54.9%
Unknown	14,075	41.3%
Year		
2022	25,230	74.1%
2023	8,818	25.9%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.7	1.8
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	12,947	38.0%
1-2	12,115	35.6%
3-4	5,837	17.1%
5+	3,159	9.3%
Combined comorbidity score ⁴	2.1	2.5
Combined comorbidity score categories ⁴		
<0	2,836	8.3%
0	7,571	22.2%
1-2	12,116	35.6%
3-4	6,165	18.1%
5+	5,370	15.8%

Table 1y. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Alcohol use or abuse	514	1.5%
Obesity	16,968	49.8%
Tobacco use	7,048	20.7%
Arrhythmia	7,648	22.5%
Cerebrovascular disease/stroke/transient ischemic attack	4,055	11.9%
Chronic kidney disease	6,315	18.5%
Chronic obstructive pulmonary disease	3,131	9.2%
Congenital heart disease	3,131	9.2%
Heart failure	3,547	10.4%
Hyperlipidemia	28,660	84.2%
Hypertensive disease	29,230	85.9%
Thyroid disease	6,972	20.5%
Ischemic heart disease/coronary artery disease/myocardial infarction	7,664	22.5%
Left ventricular hypertrophy	1,658	4.9%
Peripheral artery disease	1,658	4.9%
Valvular/mitral valve disease	1,255	3.7%
Diseases of veins and lymphatics, and other diseases of circulatory system	3,868	11.4%
Obstructive sleep apnea	7,094	20.8%
Hypertrophic cardiomyopathy	1,421	4.2%
Other cardiac disease	13,748	40.4%
Tachyarrhythmia day 0	510	1.5%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	218	0.6%
Medical Product Use		
Alpha-glucosidase inhibitors	180	0.5%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	6,790	19.9%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	478	1.4%
Insulin	4,352	12.8%
Biguanides (metformin, phenformin, etc.)	28,279	83.0%
SGLT2 inhibitors	11,336	33.3%
Sulfonylurea	13,337	39.2%
Thiazolidinedione	3,445	10.1%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	*****	*****
Sodium channel blockers	199	0.6%
Beta blockers	13,213	38.8%
Potassium channel blockers/openers	441	1.3%
Non-dihydropyridine calcium channel blockers	45	0.1%
Digoxin	239	0.7%
Other antiarrhythmic agents	0	0.0%

Table 1y. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	13,369	39.3%
Angiotensin-converting-enzyme (ACE) inhibitor	13,334	39.2%
Angiotensin ii receptor blockers (ARBs)	12,334	36.2%
Dihydropyridines	9,144	26.8%
Diuretics	10,973	32.2%
Other antihypertensives	2,606	7.7%
Antihypertensives (any of the above antihypertensives)	28,268	83.0%
Oral anticoagulants	2,698	7.9%
Vitamin K antagonists	534	1.6%
Other cardiac medications not mentioned above	1,898	5.6%
Other cardiac medications (any of the other cardiac medications)	4,672	13.7%
Lipid lowering therapy	28,502	83.7%
Baseline known risk of prolonged QT and torsades de pointes	13,708	40.2%
Baseline possible risk of prolonged QT and torsades de pointes	27,233	80.0%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	3,991	11.7%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	18.6	16.7
Mean number of emergency room encounters	0.5	1.3
Mean number of inpatient hospital encounters	0.1	0.5
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	4.6	8.4
Mean number of filled prescriptions	40.8	30.5
Mean number of generics dispensed	11.7	5.7
Mean number of unique drug classes dispensed	10.1	5.0

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1z. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	12,788	N/A
Demographic Characteristics		
Age (years)	59.4	10.9
Age		
0-40 years	773	6.0%
41-64 years	7,936	62.1%
65-74 years	3,034	23.7%
75-84 years	894	7.0%
≥ 85 years	151	1.2%
Sex		
Female	6,020	47.1%
Male	6,768	52.9%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	12,788	100.0%
White	0	0.0%
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	11,568	90.5%
Year		
2022	8,899	69.6%
2023	3,889	30.4%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.1	1.5
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	6,767	52.9%
1-2	4,064	31.8%
3-4	1,388	10.9%
5+	569	4.4%
Combined comorbidity score ⁴	1.4	2.1
Combined comorbidity score categories ⁴		
<0	1,530	12.0%
0	3,760	29.4%
1-2	4,838	37.8%
3-4	1,617	12.6%
5+	1,043	8.2%

Table 1z. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Alcohol use or abuse	157	1.2%
Obesity	6,210	48.6%
Tobacco use	1,820	14.2%
Arrhythmia	2,011	15.7%
Cerebrovascular disease/stroke/transient ischemic attack	897	7.0%
Chronic kidney disease	1,377	10.8%
Chronic obstructive pulmonary disease	612	4.8%
Congenital heart disease	612	4.8%
Heart failure	730	5.7%
Hyperlipidemia	10,163	79.5%
Hypertensive disease	10,134	79.2%
Thyroid disease	2,099	16.4%
Ischemic heart disease/coronary artery disease/myocardial infarction	1,834	14.3%
Left ventricular hypertrophy	395	3.1%
Peripheral artery disease	395	3.1%
Valvular/mitral valve disease	268	2.1%
Diseases of veins and lymphatics, and other diseases of circulatory system	1,043	8.2%
Obstructive sleep apnea	2,425	19.0%
Hypertrophic cardiomyopathy	335	2.6%
Other cardiac disease	4,057	31.7%
Tachyarrhythmia day 0	111	0.9%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	46	0.4%
Medical Product Use		
Alpha-glucosidase inhibitors	52	0.4%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	2,328	18.2%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	121	0.9%
Insulin	1,349	10.5%
Biguanides (metformin, phenformin, etc.)	11,140	87.1%
SGLT2 inhibitors	4,347	34.0%
Sulfonylurea	4,259	33.3%
Thiazolidinedione	1,119	8.8%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	54	0.4%
Beta blockers	3,747	29.3%
Potassium channel blockers/openers	95	0.7%
Non-dihydropyridine calcium channel blockers	*****	*****
Digoxin	50	0.4%
Other antiarrhythmic agents	0	0.0%

Table 1z. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	3,774	29.5%
Angiotensin-converting-enzyme (ACE) inhibitor	4,897	38.3%
Angiotensin ii receptor blockers (ARBs)	4,260	33.3%
Dihydropyridines	2,817	22.0%
Diuretics	3,193	25.0%
Other antihypertensives	659	5.2%
Antihypertensives (any of the above antihypertensives)	9,915	77.5%
Oral anticoagulants	637	5.0%
Vitamin K antagonists	112	0.9%
Other cardiac medications not mentioned above	455	3.6%
Other cardiac medications (any of the other cardiac medications)	1,122	8.8%
Lipid lowering therapy	10,144	79.3%
Baseline known risk of prolonged QT and torsades de pointes	4,752	37.2%
Baseline possible risk of prolonged QT and torsades de pointes	9,439	73.8%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	1,193	9.3%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	14.8	14.7
Mean number of emergency room encounters	0.3	0.9
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	4.0	6.0
Mean number of filled prescriptions	35.3	27.1
Mean number of generics dispensed	10.5	5.6
Mean number of unique drug classes dispensed	9.0	4.9

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1aa. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	68	N/A
Demographic Characteristics		
Age (years)	61.3	13.6
Age		
0-40 years	*****	*****
41-64 years	25	36.8%
65-74 years	23	35.3%
75-84 years	*****	*****
≥ 85 years	*****	*****
Sex		
Female	41	60.3%
Male	27	39.7%
Race ²		
American Indian or Alaska Native	68	100.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	*****	*****
Year		
2022	*****	*****
2023	*****	*****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.5	1.9
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	27	39.7%
1-2	26	38.2%
3-4	*****	*****
5+	*****	*****
Combined comorbidity score ⁴	2.2	2.2
Combined comorbidity score categories ⁴		
<0	*****	*****
0	12	17.6%
1-2	30	44.1%
3-4	*****	*****
5+	15	22.1%

Table 1aa. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	*****	*****
Obesity	38	55.9%
Tobacco use	18	26.5%
Arrhythmia	13	19.1%
Cerebrovascular disease/stroke/transient ischemic attack	*****	*****
Chronic kidney disease	*****	*****
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	*****	*****
Hyperlipidemia	51	75.0%
Hypertensive disease	52	76.5%
Thyroid disease	16	23.5%
Ischemic heart disease/coronary artery disease/myocardial infarction	14	20.6%
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	*****
Obstructive sleep apnea	*****	*****
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	20	29.4%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	19	27.9%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	12	17.6%
Biguanides (metformin, phenformin, etc.)	58	85.3%
SGLT2 inhibitors	18	26.5%
Sulfonylurea	25	36.8%
Thiazolidinedione	*****	*****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	25	36.8%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%

Table 1aa. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	25	36.8%
Angiotensin-converting-enzyme (ACE) inhibitor	31	45.6%
Angiotensin ii receptor blockers (ARBs)	14	20.6%
Dihydropyridines	15	22.1%
Diuretics	19	27.9%
Other antihypertensives	*****	*****
Antihypertensives (any of the above antihypertensives)	53	77.9%
Oral anticoagulants	*****	*****
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	*****	*****
Other cardiac medications (any of the other cardiac medications)	*****	*****
Lipid lowering therapy	55	80.9%
Baseline known risk of prolonged QT and torsades de pointes	34	50.0%
Baseline possible risk of prolonged QT and torsades de pointes	61	89.7%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	15.9	11.2
Mean number of emergency room encounters	0.9	2.0
Mean number of inpatient hospital encounters	0.2	0.5
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	7.0	14.7
Mean number of filled prescriptions	61.9	45.9
Mean number of generics dispensed	12.9	5.5
Mean number of unique drug classes dispensed	11.1	4.8

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1ab. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	1,087	N/A
Demographic Characteristics		
Age (years)	70.6	9.9
Age		
0-40 years	26	2.4%
41-64 years	173	15.9%
65-74 years	523	48.2%
75-84 years	292	26.9%
≥ 85 years	72	6.6%
Sex		
Female	601	55.3%
Male	486	44.7%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	1,087	100.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	*****	*****
No	931	85.6%
Unknown	*****	*****
Year		
2022	923	84.9%
2023	164	15.1%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.8	1.9
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	361	33.2%
1-2	401	36.9%
3-4	207	19.0%
5+	118	10.9%
Combined comorbidity score ⁴	2.4	2.6
Combined comorbidity score categories ⁴		
<0	66	6.1%
0	222	20.4%
1-2	382	35.1%
3-4	225	20.7%
5+	192	17.7%

Table 1ab. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	*****	*****
Obesity	251	23.1%
Tobacco use	121	11.1%
Arrhythmia	220	20.2%
Cerebrovascular disease/stroke/transient ischemic attack	148	13.6%
Chronic kidney disease	306	28.2%
Chronic obstructive pulmonary disease	85	7.8%
Congenital heart disease	85	7.8%
Heart failure	115	10.6%
Hyperlipidemia	955	87.9%
Hypertensive disease	951	87.5%
Thyroid disease	206	19.0%
Ischemic heart disease/coronary artery disease/myocardial infarction	267	23.60%
Left ventricular hypertrophy	43	4.0%
Peripheral artery disease	43	4.0%
Valvular/mitral valve disease	42	3.9%
Diseases of veins and lymphatics, and other diseases of circulatory system	91	8.4%
Obstructive sleep apnea	87	8.0%
Hypertrophic cardiomyopathy	41	3.8%
Other cardiac disease	376	34.6%
Tachyarrhythmia day 0	15	1.4%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	25	2.3%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	338	31.1%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	35	3.2%
Insulin	158	14.5%
Biguanides (metformin, phenformin, etc.)	915	84.2%
SGLT2 inhibitors	492	45.3%
Sulfonylurea	503	46.3%
Thiazolidinedione	172	15.8%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	*****	*****
Beta blockers	440	40.5%
Potassium channel blockers/openers	13	1.2%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%

Table 1ab. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	446	41.0%
Angiotensin-converting-enzyme (ACE) inhibitor	294	27.0%
Angiotensin ii receptor blockers (ARBs)	577	53.1%
Dihydropyridines	397	36.5%
Diuretics	259	23.8%
Other antihypertensives	101	9.3%
Antihypertensives (any of the above antihypertensives)	933	85.8%
Oral anticoagulants	67	6.2%
Vitamin K antagonists	11	1.0%
Other cardiac medications not mentioned above	106	9.8%
Other cardiac medications (any of the other cardiac medications)	166	15.3%
Lipid lowering therapy	989	91.0%
Baseline known risk of prolonged QT and torsades de pointes	344	31.6%
Baseline possible risk of prolonged QT and torsades de pointes	778	71.6%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	79	7.3%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	17.6	18.8
Mean number of emergency room encounters	0.3	0.7
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	5.2	8.7
Mean number of filled prescriptions	42.9	32.7
Mean number of generics dispensed	11.9	6.0
Mean number of unique drug classes dispensed	9.9	5.2

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1ac. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	3,392	N/A
Demographic Characteristics		
Age (years)	67.1	10.3
Age		
0-40 years	88	2.6%
41-64 years	984	29.0%
65-74 years	1,680	49.5%
75-84 years	564	16.6%
≥ 85 years	76	2.2%
Sex		
Female	2,238	66.3%
Male	1,144	33.7%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	3,392	100.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	*****	*****
No	2,987	88.1%
Unknown	*****	*****
Year		
2022	2,336	68.9%
2023	1,056	31.1%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.1	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	937	27.6%
1-2	1,294	38.1%
3-4	728	21.5%
5+	433	12.8%
Combined comorbidity score ⁴	2.6	2.7
Combined comorbidity score categories ⁴		
<0	208	6.1%
0	615	18.1%
1-2	1,123	33.1%
3-4	753	22.2%
5+	693	20.4%

Table 1ac. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Alcohol use or abuse	73	2.2%
Obesity	1,998	58.9%
Tobacco use	836	23.60%
Arrhythmia	734	21.6%
Cerebrovascular disease/stroke/transient ischemic attack	440	13.0%
Chronic kidney disease	896	26.4%
Chronic obstructive pulmonary disease	370	10.9%
Congenital heart disease	370	10.9%
Heart failure	501	14.8%
Hyperlipidemia	2,885	85.1%
Hypertensive disease	3,191	94.1%
Thyroid disease	469	13.8%
Ischemic heart disease/coronary artery disease/myocardial infarction	685	20.2%
Left ventricular hypertrophy	232	6.8%
Peripheral artery disease	232	6.8%
Valvular/mitral valve disease	126	3.7%
Diseases of veins and lymphatics, and other diseases of circulatory system	442	13.0%
Obstructive sleep apnea	665	19.6%
Hypertrophic cardiomyopathy	184	5.4%
Other cardiac disease	1,352	39.9%
Tachyarrhythmia day 0	31	0.9%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	44	1.3%
Medical Product Use		
Alpha-glucosidase inhibitors	19	0.6%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	687	20.3%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	44	1.3%
Insulin	551	16.2%
Biguanides (metformin, phenformin, etc.)	2,627	77.4%
SGLT2 inhibitors	1,012	29.8%
Sulfonylurea	1,408	41.5%
Thiazolidinedione	307	9.1%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	*****	*****
Beta blockers	1,454	42.9%
Potassium channel blockers/openers	26	0.8%
Non-dihydropyridine calcium channel blockers	*****	*****
Digoxin	13	0.4%
Other antiarrhythmic agents	0	0.0%

Table 1ac. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	1,470	43.3%
Angiotensin-converting-enzyme (ACE) inhibitor	1,196	35.3%
Angiotensin ii receptor blockers (ARBs)	1,502	44.3%
Dihydropyridines	1,511	44.5%
Diuretics	1,554	45.8%
Other antihypertensives	469	13.8%
Antihypertensives (any of the above antihypertensives)	3,101	91.4%
Oral anticoagulants	211	6.2%
Vitamin K antagonists	40	1.2%
Other cardiac medications not mentioned above	188	5.5%
Other cardiac medications (any of the other cardiac medications)	402	11.9%
Lipid lowering therapy	2,844	83.8%
Baseline known risk of prolonged QT and torsades de pointes	1,332	39.3%
Baseline possible risk of prolonged QT and torsades de pointes	2,915	85.9%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	327	9.6%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	20.2	17.7
Mean number of emergency room encounters	0.8	1.9
Mean number of inpatient hospital encounters	0.1	0.6
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	4.7	10.8
Mean number of filled prescriptions	42.2	29.0
Mean number of generics dispensed	12.4	5.9
Mean number of unique drug classes dispensed	10.9	5.2

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1ad. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Unique patients	128	N/A
Demographic Characteristics		
Age (years)	71.4	7.6
Age		
0-40 years	*****	*****
41-64 years	*****	*****
65-74 years	66	51.6%
75-84 years	35	27.3%
≥ 85 years	*****	*****
Sex		
Female	53	41.4%
Male	75	58.6%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	128	100.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	*****	*****
Unknown	*****	*****
Year		
2022	70	54.7%
2023	58	45.3%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.2	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	33	25.8%
1-2	49	38.3%
3-4	26	20.3%
5+	20	15.6%
Combined comorbidity score ⁴	2.5	2.7
Combined comorbidity score categories ⁴		
<0	15	11.7%
0	19	14.8%
1-2	34	26.6%
3-4	37	28.9%
5+	23	18.0%

Table 1ad. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Alcohol use or abuse	*****	*****
Obesity	50	39.1%
Tobacco use	19	14.8%
Arrhythmia	35	27.3%
Cerebrovascular disease/stroke/transient ischemic attack	16	12.5%
Chronic kidney disease	43	33.6%
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	17	13.3%
Hyperlipidemia	116	90.6%
Hypertensive disease	116	90.6%
Thyroid disease	22	17.2%
Ischemic heart disease/coronary artery disease/myocardial infarction	33	25.8%
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	*****
Obstructive sleep apnea	16	12.5%
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	50	39.1%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	26	20.3%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	17	13.3%
Biguanides (metformin, phenformin, etc.)	106	82.8%
SGLT2 inhibitors	41	32.0%
Sulfonylurea	71	55.5%
Thiazolidinedione	26	20.3%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	*****	*****
Sodium channel blockers	0	0.0%
Beta blockers	56	43.8%
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%

Table 1ad. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	57	44.5%
Angiotensin-converting-enzyme (ACE) inhibitor	45	35.2%
Angiotensin ii receptor blockers (ARBs)	58	45.3%
Dihydropyridines	39	30.5%
Diuretics	38	29.7%
Other antihypertensives	11	8.6%
Antihypertensives (any of the above antihypertensives)	114	89.1%
Oral anticoagulants	*****	*****
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	*****	*****
Other cardiac medications (any of the other cardiac medications)	17	13.3%
Lipid lowering therapy	112	87.5%
Baseline known risk of prolonged QT and torsades de pointes	42	32.8%
Baseline possible risk of prolonged QT and torsades de pointes	93	72.7%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	11	8.6%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	17.1	13.6
Mean number of emergency room encounters	0.5	1.1
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	1.9	6.9
Mean number of filled prescriptions	33.2	18.4
Mean number of generics dispensed	11.2	5.0
Mean number of unique drug classes dispensed	9.3	4.3

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1ae. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	16,414	N/A
Demographic Characteristics		
Age (years)	70.2	9.3
Age		
0-40 years	209	1.3%
41-64 years	2,999	18.3%
65-74 years	8,327	50.7%
75-84 years	4,305	26.2%
≥ 85 years	574	3.5%
Sex		
Female	8,414	51.3%
Male	8,000	48.7%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	16,414	100.0%
Hispanic origin		
Yes	*****	*****
No	14,602	89.0%
Unknown	*****	*****
Year		
2022	12,838	78.2%
2023	3,576	21.8%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.0	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	4,705	28.7%
1-2	6,231	38.0%
3-4	3,466	21.1%
5+	2,012	12.3%
Combined comorbidity score ⁴	2.6	2.7
Combined comorbidity score categories ⁴		
<0	988	6.0%
0	2,893	17.6%
1-2	5,628	34.3%
3-4	3,510	21.4%
5+	3,395	20.7%

Table 1ae. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	264	1.6%
Obesity	8,321	50.7%
Tobacco use	4,209	25.6%
Arrhythmia	4,607	28.1%
Cerebrovascular disease/stroke/transient ischemic attack	2,539	15.5%
Chronic kidney disease	3,673	22.4%
Chronic obstructive pulmonary disease	2,049	12.5%
Congenital heart disease	2,049	12.5%
Heart failure	2,171	13.2%
Hyperlipidemia	14,358	87.5%
Hypertensive disease	14,663	89.3%
Thyroid disease	4,135	25.2%
Ischemic heart disease/coronary artery disease/myocardial infarction	4,812	29.3%
Left ventricular hypertrophy	973	5.9%
Peripheral artery disease	973	5.9%
Valvular/mitral valve disease	809	4.9%
Diseases of veins and lymphatics, and other diseases of circulatory system	2,266	13.8%
Obstructive sleep apnea	3,854	23.5%
Hypertrophic cardiomyopathy	852	5.2%
Other cardiac disease	7,838	47.8%
Tachyarrhythmia day 0	352	2.1%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	119	0.7%
Medical Product Use		
Alpha-glucosidase inhibitors	84	0.5%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	3,372	20.5%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	275	1.7%
Insulin	2,256	13.7%
Biguanides (metformin, phenformin, etc.)	13,271	80.9%
SGLT2 inhibitors	5,370	32.7%
Sulfonylurea	7,012	42.7%
Thiazolidinedione	1,796	10.9%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	*****	*****
Sodium channel blockers	135	0.8%
Beta blockers	7,450	45.4%
Potassium channel blockers/openers	305	1.9%
Non-dihydropyridine calcium channel blockers	28	0.2%
Digoxin	176	1.1%
Other antiarrhythmic agents	0	0.0%

Table 1ae. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	7,556	46.0%
Angiotensin-converting-enzyme (ACE) inhibitor	6,803	41.4%
Angiotensin ii receptor blockers (ARBs)	5,867	35.7%
Dihydropyridines	4,331	26.4%
Diuretics	5,874	35.8%
Other antihypertensives	1,356	8.3%
Antihypertensives (any of the above antihypertensives)	14,018	85.4%
Oral anticoagulants	1,766	10.8%
Vitamin K antagonists	363	2.2%
Other cardiac medications not mentioned above	1,130	6.9%
Other cardiac medications (any of the other cardiac medications)	2,945	17.9%
Lipid lowering therapy	14,229	86.7%
Baseline known risk of prolonged QT and torsades de pointes	7,140	43.5%
Baseline possible risk of prolonged QT and torsades de pointes	13,830	84.3%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	2,366	14.4%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	21.4	17.8
Mean number of emergency room encounters	0.5	1.4
Mean number of inpatient hospital encounters	0.1	0.5
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	5.1	9.5
Mean number of filled prescriptions	44.7	32.9
Mean number of generics dispensed	12.4	5.8
Mean number of unique drug classes dispensed	10.8	5.1

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1af. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	181	N/A
Demographic Characteristics		
Age (years)	53.3	10.7
Age		
0-40 years	25	13.8%
41-64 years	129	71.3%
65-74 years	*****	*****
75-84 years	*****	*****
≥ 85 years	0	0.0%
Sex		
Female	89	49.2%
Male	92	50.8%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	181	100.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	46	25.4%
No	12	6.6%
Unknown	123	68.0%
Year		
2022	111	61.3%
2023	70	38.7%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.6	1.1
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	117	64.6%
1-2	50	27.6%
3-4	*****	*****
5+	*****	*****
Combined comorbidity score ⁴	1.0	1.8
Combined comorbidity score categories ⁴		
<0	26	14.4%
0	50	27.6%
1-2	81	44.8%
3-4	*****	*****
5+	*****	*****

Table 1af. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	*****	*****
Obesity	100	55.2%
Tobacco use	25	13.8%
Arrhythmia	28	15.5%
Cerebrovascular disease/stroke/transient ischemic attack	*****	*****
Chronic kidney disease	12	6.6%
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	*****	*****
Hyperlipidemia	132	72.9%
Hypertensive disease	133	73.5%
Thyroid disease	25	13.8%
Ischemic heart disease/coronary artery disease/myocardial infarction	19	10.5%
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	*****
Obstructive sleep apnea	38	21.0%
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	55	30.4%
Tachyarrhythmia day 0	*****	*****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	20	11.0%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	*****	*****
Biguanides (metformin, phenformin, etc.)	162	89.5%
SGLT2 inhibitors	56	30.9%
Sulfonylurea	59	32.6%
Thiazolidinedione	16	8.8%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	41	22.7%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%

Table 1af. Aggregated Characteristics of Rybelsus, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	41	22.7%
Angiotensin-converting-enzyme (ACE) inhibitor	68	37.6%
Angiotensin ii receptor blockers (ARBs)	56	30.9%
Dihydropyridines	34	18.8%
Diuretics	36	19.9%
Other antihypertensives	*****	*****
Antihypertensives (any of the above antihypertensives)	134	74.0%
Oral anticoagulants	*****	*****
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	*****	*****
Other cardiac medications (any of the other cardiac medications)	14	7.7%
Lipid lowering therapy	129	71.3%
Baseline known risk of prolonged QT and torsades de pointes	64	35.4%
Baseline possible risk of prolonged QT and torsades de pointes	127	70.2%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	14.0	10.7
Mean number of emergency room encounters	0.4	1.0
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	1.3	2.3
Mean number of filled prescriptions	30.3	20.0
Mean number of generics dispensed	9.6	4.6
Mean number of unique drug classes dispensed	8.1	3.9

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a number

N/A: Not applicable

Table 1ag. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Unique patients	386	N/A
Demographic Characteristics		
Age (years)	50.6	10.0
Age		
0-40 years	70	18.1%
41-64 years	292	75.6%
65-74 years	*****	*****
75-84 years	*****	*****
≥ 85 years	0	0.0%
Sex		
Female	294	76.2%
Male	92	23.8%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	342	88.6%
White	31	8.0%
Hispanic origin		
Yes	0	0.0%
No	13	3.4%
Unknown	373	96.6%
Year		
2022	333	86.3%
2023	53	13.7%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.6	1.1
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	276	71.5%
1-2	88	22.8%
3-4	*****	*****
5+	*****	*****
Combined comorbidity score ⁴	1.2	1.9
Combined comorbidity score categories ⁴		
<0	44	11.4%
0	123	31.9%
1-2	144	37.3%
3-4	53	13.7%
5+	22	5.7%

Table 1ag. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Alcohol use or abuse	*****	*****
Obesity	332	86.0%
Tobacco use	50	13.0%
Arrhythmia	67	17.4%
Cerebrovascular disease/stroke/transient ischemic attack	*****	*****
Chronic kidney disease	18	4.7%
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	14	3.6%
Hyperlipidemia	257	66.6%
Hypertensive disease	274	71.0%
Thyroid disease	105	27.2%
Ischemic heart disease/coronary artery disease/myocardial infarction	25	6.5%
Left ventricular hypertrophy	12	3.1%
Peripheral artery disease	12	3.1%
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	38	9.8%
Obstructive sleep apnea	137	35.5%
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	159	41.2%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	*****	*****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	21	5.4%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	18	4.7%
Biguanides (metformin, phenformin, etc.)	358	92.7%
SGLT2 inhibitors	47	12.2%
Sulfonylurea	39	10.1%
Thiazolidinedione	*****	*****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	115	29.8%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%

Table 1ag. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	115	29.8%
Angiotensin-converting-enzyme (ACE) inhibitor	101	26.2%
Angiotensin ii receptor blockers (ARBs)	106	27.5%
Dihydropyridines	72	18.7%
Diuretics	152	39.4%
Other antihypertensives	26	6.7%
Antihypertensives (any of the above antihypertensives)	281	72.8%
Oral anticoagulants	16	4.1%
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	*****	*****
Other cardiac medications (any of the other cardiac medications)	21	5.4%
Lipid lowering therapy	206	53.4%
Baseline known risk of prolonged QT and torsades de pointes	213	55.2%
Baseline possible risk of prolonged QT and torsades de pointes	345	89.4%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	68	17.6%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	20.0	16.9
Mean number of emergency room encounters	0.5	1.2
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	5.2	5.2
Mean number of filled prescriptions	38.7	26.9
Mean number of generics dispensed	12.7	6.4
Mean number of unique drug classes dispensed	11.5	5.6

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1ah. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	342	N/A
Demographic Characteristics		
Age (years)	50.0	9.9
Age		
0-40 years	64	18.7%
41-64 years	266	77.8%
65-74 years	12	3.5%
75-84 years	0	0.0%
≥ 85 years	0	0.0%
Sex		
Female	263	76.9%
Male	79	23.1%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	342	100.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	0	0.0%
Unknown	342	100.0%
Year		
2022	298	87.1%
2023	44	12.9%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.6	1.1
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	234	71.3%
1-2	78	22.8%
3-4	*****	*****
5+	*****	*****
Combined comorbidity score ⁴	1.2	1.9
Combined comorbidity score categories ⁴		
<0	39	11.4%
0	112	32.7%
1-2	127	37.1%
3-4	45	13.2%
5+	19	5.6%

Table 1ah. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	*****	*****
Obesity	296	86.5%
Tobacco use	40	11.7%
Arrhythmia	56	16.4%
Cerebrovascular disease/stroke/transient ischemic attack	*****	*****
Chronic kidney disease	16	4.7%
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	13	3.8%
Hyperlipidemia	220	64.3%
Hypertensive disease	235	71.6%
Thyroid disease	93	27.2%
Ischemic heart disease/coronary artery disease/myocardial infarction	21	6.1%
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	32	9.4%
Obstructive sleep apnea	119	34.8%
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	136	39.8%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	*****	*****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	19	5.6%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	14	4.1%
Biguanides (metformin, phenformin, etc.)	318	93.0%
SGLT2 inhibitors	39	11.4%
Sulfonylurea	29	8.5%
Thiazolidinedione	*****	*****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	99	28.9%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%

Table 1ah. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	99	28.9%
Angiotensin-converting-enzyme (ACE) inhibitor	93	27.2%
Angiotensin ii receptor blockers (ARBs)	94	27.5%
Dihydropyridines	61	17.8%
Diuretics	133	38.9%
Other antihypertensives	23	7.0%
Antihypertensives (any of the above antihypertensives)	250	73.1%
Oral anticoagulants	13	3.8%
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	*****	*****
Other cardiac medications (any of the other cardiac medications)	16	4.7%
Lipid lowering therapy	179	52.3%
Baseline known risk of prolonged QT and torsades de pointes	192	56.1%
Baseline possible risk of prolonged QT and torsades de pointes	305	89.2%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	59	17.3%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	19.4	16.8
Mean number of emergency room encounters	0.4	0.9
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	5.5	5.1
Mean number of filled prescriptions	37.9	26.2
Mean number of generics dispensed	12.6	6.4
Mean number of unique drug classes dispensed	11.4	5.6

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1ai. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	0	N/A
Demographic Characteristics		
Age (years)	.	.
Age		
0-40 years	.	.
41-64 years	.	.
65-74 years	.	.
75-84 years	.	.
≥ 85 years	.	.
Sex		
Female	.	.
Male	.	.
Race ²		
American Indian or Alaska Native	.	.
Asian	.	.
Black or African American	.	.
Multi-racial	.	.
Native Hawaiian or Other Pacific Islander	.	.
Unknown	.	.
White	.	.
Hispanic origin		
Yes	.	.
No	.	.
Unknown	.	.
Year		
2022	.	.
2023	.	.
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	.	.
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	.	.
0	.	.
1-2	.	.
3-4	.	.
5+	.	.
Combined comorbidity score ⁴	.	.
Combined comorbidity score categories ⁴		
<0	.	.
0	.	.
1-2	.	.
3-4	.	.
5+	.	.

Table 1ai. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	.	.
Obesity	.	.
Tobacco use	.	.
Arrhythmia	.	.
Cerebrovascular disease/stroke/transient ischemic attack	.	.
Chronic kidney disease	.	.
Chronic obstructive pulmonary disease	.	.
Congenital heart disease	.	.
Heart failure	.	.
Hyperlipidemia	.	.
Hypertensive disease	.	.
Thyroid disease	.	.
Ischemic heart disease/coronary artery disease/myocardial infarction	.	.
Left ventricular hypertrophy	.	.
Peripheral artery disease	.	.
Valvular/mitral valve disease	.	.
Diseases of veins and lymphatics, and other diseases of circulatory system	.	.
Obstructive sleep apnea	.	.
Hypertrophic cardiomyopathy	.	.
Other cardiac disease	.	.
Tachyarrhythmia day 0	.	.
Hospitalized tachyarrhythmia day 0	.	.
History of serious hypoglycemia (ED and/or IP)	.	.
Medical Product Use		
Alpha-glucosidase inhibitors	.	.
Amylin analogs (pramlintide)	.	.
DPP-4 inhibitors	.	.
Incretin mimetics (albiglutide, dulaglutide, etc.)	.	.
Meglitinides	.	.
Insulin	.	.
Biguanides (metformin, phenformin, etc.)	.	.
SGLT2 inhibitors	.	.
Sulfonylurea	.	.
Thiazolidinedione	.	.
No baseline use of any of the above antidiabetic drugs	.	.
Other antidiabetics	.	.
Sodium channel blockers	.	.
Beta blockers	.	.
Potassium channel blockers/openers	.	.
Non-dihydropyridine calcium channel blockers	.	.
Digoxin	.	.
Other antiarrhythmic agents	.	.

Table 1ai. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	.	.
Angiotensin-converting-enzyme (ACE) inhibitor	.	.
Angiotensin ii receptor blockers (ARBs)	.	.
Dihydropyridines	.	.
Diuretics	.	.
Other antihypertensives	.	.
Antihypertensives (any of the above antihypertensives)	.	.
Oral anticoagulants	.	.
Vitamin K antagonists	.	.
Other cardiac medications not mentioned above	.	.
Other cardiac medications (any of the other cardiac medications)	.	.
Lipid lowering therapy	.	.
Baseline known risk of prolonged QT and torsades de pointes	.	.
Baseline possible risk of prolonged QT and torsades de pointes	.	.
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	.	.
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	.	.
Mean number of emergency room encounters	.	.
Mean number of inpatient hospital encounters	.	.
Mean number of non-acute institutional encounters	.	.
Mean number of other ambulatory encounters	.	.
Mean number of filled prescriptions	.	.
Mean number of generics dispensed	.	.
Mean number of unique drug classes dispensed	.	.

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

Data presented by a dash, asterisk, or period represent missing information. This table may not use all data representations.

N/A: Not applicable

Table 1aj. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	0	N/A
Demographic Characteristics		
Age (years)	.	.
Age		
0-40 years	.	.
41-64 years	.	.
65-74 years	.	.
75-84 years	.	.
≥ 85 years	.	.
Sex		
Female	.	.
Male	.	.
Race ²		
American Indian or Alaska Native	.	.
Asian	.	.
Black or African American	.	.
Multi-racial	.	.
Native Hawaiian or Other Pacific Islander	.	.
Unknown	.	.
White	.	.
Hispanic origin		
Yes	.	.
No	.	.
Unknown	.	.
Year		
2022	.	.
2023	.	.
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	.	.
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	.	.
0	.	.
1-2	.	.
3-4	.	.
5+	.	.
Combined comorbidity score ⁴	.	.
Combined comorbidity score categories ⁴		
<0	.	.
0	.	.
1-2	.	.
3-4	.	.
5+	.	.

Table 1aj. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	.	.
Obesity	.	.
Tobacco use	.	.
Arrhythmia	.	.
Cerebrovascular disease/stroke/transient ischemic attack	.	.
Chronic kidney disease	.	.
Chronic obstructive pulmonary disease	.	.
Congenital heart disease	.	.
Heart failure	.	.
Hyperlipidemia	.	.
Hypertensive disease	.	.
Thyroid disease	.	.
Ischemic heart disease/coronary artery disease/myocardial infarction	.	.
Left ventricular hypertrophy	.	.
Peripheral artery disease	.	.
Valvular/mitral valve disease	.	.
Diseases of veins and lymphatics, and other diseases of circulatory system	.	.
Obstructive sleep apnea	.	.
Hypertrophic cardiomyopathy	.	.
Other cardiac disease	.	.
Tachyarrhythmia day 0	.	.
Hospitalized tachyarrhythmia day 0	.	.
History of serious hypoglycemia (ED and/or IP)	.	.
Medical Product Use		
Alpha-glucosidase inhibitors	.	.
Amylin analogs (pramlintide)	.	.
DPP-4 inhibitors	.	.
Incretin mimetics (albiglutide, dulaglutide, etc.)	.	.
Meglitinides	.	.
Insulin	.	.
Biguanides (metformin, phenformin, etc.)	.	.
SGLT2 inhibitors	.	.
Sulfonylurea	.	.
Thiazolidinedione	.	.
No baseline use of any of the above antidiabetic drugs	.	.
Other antidiabetics	.	.
Sodium channel blockers	.	.
Beta blockers	.	.
Potassium channel blockers/openers	.	.
Non-dihydropyridine calcium channel blockers	.	.
Digoxin	.	.
Other antiarrhythmic agents	.	.

Table 1aj. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	.	.
Angiotensin-converting-enzyme (ACE) inhibitor	.	.
Angiotensin ii receptor blockers (ARBs)	.	.
Dihydropyridines	.	.
Diuretics	.	.
Other antihypertensives	.	.
Antihypertensives (any of the above antihypertensives)	.	.
Oral anticoagulants	.	.
Vitamin K antagonists	.	.
Other cardiac medications not mentioned above	.	.
Other cardiac medications (any of the other cardiac medications)	.	.
Lipid lowering therapy	.	.
Baseline known risk of prolonged QT and torsades de pointes	.	.
Baseline possible risk of prolonged QT and torsades de pointes	.	.
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	.	.
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	.	.
Mean number of emergency room encounters	.	.
Mean number of inpatient hospital encounters	.	.
Mean number of non-acute institutional encounters	.	.
Mean number of other ambulatory encounters	.	.
Mean number of filled prescriptions	.	.
Mean number of generics dispensed	.	.
Mean number of unique drug classes dispensed	.	.

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

Data presented by a dash, asterisk, or period represent missing information. This table may not use all data representations.

N/A: Not applicable

Table 1ak. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	*****	N/A
Demographic Characteristics		
Age (years)	51.1	10.1
Age		
0-40 years	*****	*****
41-64 years	*****	*****
65-74 years	0	0.0%
75-84 years	0	0.0%
≥ 85 years	0	0.0%
Sex		
Female	*****	*****
Male	*****	*****
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	*****	100.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	*****	*****
Unknown	*****	*****
Year		
2022	*****	*****
2023	*****	*****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.2	0.7
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	*****	*****
1-2	*****	*****
3-4	0	0.0%
5+	0	0.0%
Combined comorbidity score ⁴	0.8	1.5
Combined comorbidity score categories ⁴		
<0	*****	*****
0	*****	*****
1-2	*****	*****
3-4	*****	*****
5+	0	0.0%

Table 1ak. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	0	0.0%
Obesity	*****	100.0%
Tobacco use	0	0.0%
Arrhythmia	0	0.0%
Cerebrovascular disease/stroke/transient ischemic attack	0	0.0%
Chronic kidney disease	*****	*****
Chronic obstructive pulmonary disease	0	0.0%
Congenital heart disease	0	0.0%
Heart failure	0	0.0%
Hyperlipidemia	*****	*****
Hypertensive disease	*****	*****
Thyroid disease	*****	*****
Ischemic heart disease/coronary artery disease/myocardial infarction	0	0.0%
Left ventricular hypertrophy	0	0.0%
Peripheral artery disease	0	0.0%
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	0	0.0%
Obstructive sleep apnea	*****	*****
Hypertrophic cardiomyopathy	0	0.0%
Other cardiac disease	*****	*****
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	0	0.0%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	0	0.0%
Biguanides (metformin, phenformin, etc.)	*****	100.0%
SGLT2 inhibitors	0	0.0%
Sulfonylurea	0	0.0%
Thiazolidinedione	0	0.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	*****	*****
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%

Table 1ak. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	*****	*****
Angiotensin-converting-enzyme (ACE) inhibitor	0	0.0%
Angiotensin ii receptor blockers (ARBs)	*****	*****
Dihydropyridines	0	0.0%
Diuretics	*****	*****
Other antihypertensives	0	0.0%
Antihypertensives (any of the above antihypertensives)	*****	*****
Oral anticoagulants	0	0.0%
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	*****	*****
Other cardiac medications (any of the other cardiac medications)	*****	*****
Lipid lowering therapy	*****	*****
Baseline known risk of prolonged QT and torsades de pointes	*****	*****
Baseline possible risk of prolonged QT and torsades de pointes	*****	*****
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	22.8	23.8
Mean number of emergency room encounters	0.9	1.5
Mean number of inpatient hospital encounters	0.0	NaN
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	3.4	8.0
Mean number of filled prescriptions	29.4	20.9
Mean number of generics dispensed	10.1	5.6
Mean number of unique drug classes dispensed	9.4	4.7

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a number

N/A: Not applicable

Table 1a. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Unique patients	0	N/A
Demographic Characteristics		
Age (years)	.	.
Age		
0-40 years	.	.
41-64 years	.	.
65-74 years	.	.
75-84 years	.	.
≥ 85 years	.	.
Sex		
Female	.	.
Male	.	.
Race ²		
American Indian or Alaska Native	.	.
Asian	.	.
Black or African American	.	.
Multi-racial	.	.
Native Hawaiian or Other Pacific Islander	.	.
Unknown	.	.
White	.	.
Hispanic origin		
Yes	.	.
No	.	.
Unknown	.	.
Year		
2022	.	.
2023	.	.
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	.	.
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	.	.
0	.	.
1-2	.	.
3-4	.	.
5+	.	.
Combined comorbidity score ⁴	.	.
Combined comorbidity score categories ⁴		
<0	.	.
0	.	.
1-2	.	.
3-4	.	.
5+	.	.

Table 1a. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Alcohol use or abuse	.	.
Obesity	.	.
Tobacco use	.	.
Arrhythmia	.	.
Cerebrovascular disease/stroke/transient ischemic attack	.	.
Chronic kidney disease	.	.
Chronic obstructive pulmonary disease	.	.
Congenital heart disease	.	.
Heart failure	.	.
Hyperlipidemia	.	.
Hypertensive disease	.	.
Thyroid disease	.	.
Ischemic heart disease/coronary artery disease/myocardial infarction	.	.
Left ventricular hypertrophy	.	.
Peripheral artery disease	.	.
Valvular/mitral valve disease	.	.
Diseases of veins and lymphatics, and other diseases of circulatory system	.	.
Obstructive sleep apnea	.	.
Hypertrophic cardiomyopathy	.	.
Other cardiac disease	.	.
Tachyarrhythmia day 0	.	.
Hospitalized tachyarrhythmia day 0	.	.
History of serious hypoglycemia (ED and/or IP)	.	.
Medical Product Use		
Alpha-glucosidase inhibitors	.	.
Amylin analogs (pramlintide)	.	.
DPP-4 inhibitors	.	.
Incretin mimetics (albiglutide, dulaglutide, etc.)	.	.
Meglitinides	.	.
Insulin	.	.
Biguanides (metformin, phenformin, etc.)	.	.
SGLT2 inhibitors	.	.
Sulfonylurea	.	.
Thiazolidinedione	.	.
No baseline use of any of the above antidiabetic drugs	.	.
Other antidiabetics	.	.
Sodium channel blockers	.	.
Beta blockers	.	.
Potassium channel blockers/openers	.	.
Non-dihydropyridine calcium channel blockers	.	.
Digoxin	.	.
Other antiarrhythmic agents	.	.

Table 1a. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	.	.
Angiotensin-converting-enzyme (ACE) inhibitor	.	.
Angiotensin ii receptor blockers (ARBs)	.	.
Dihydropyridines	.	.
Diuretics	.	.
Other antihypertensives	.	.
Antihypertensives (any of the above antihypertensives)	.	.
Oral anticoagulants	.	.
Vitamin K antagonists	.	.
Other cardiac medications not mentioned above	.	.
Other cardiac medications (any of the other cardiac medications)	.	.
Lipid lowering therapy	.	.
Baseline known risk of prolonged QT and torsades de pointes	.	.
Baseline possible risk of prolonged QT and torsades de pointes	.	.
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	.	.
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	.	.
Mean number of emergency room encounters	.	.
Mean number of inpatient hospital encounters	.	.
Mean number of non-acute institutional encounters	.	.
Mean number of other ambulatory encounters	.	.
Mean number of filled prescriptions	.	.
Mean number of generics dispensed	.	.
Mean number of unique drug classes dispensed	.	.

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

Data presented by a dash, asterisk, or period represent missing information. This table may not use all data representations.

N/A: Not applicable

Table 1am. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	31	N/A
Demographic Characteristics		
Age (years)	57.2	10.6
Age		
0-40 years	*****	*****
41-64 years	14	45.2%
65-74 years	*****	*****
75-84 years	*****	*****
≥ 85 years	0	0.0%
Sex		
Female	20	64.5%
Male	11	35.5%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	31	100.0%
Hispanic origin		
Yes	0	0.0%
No	12	38.7%
Unknown	19	61.3%
Year		
2022	*****	*****
2023	*****	*****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.6	1.1
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	*****	*****
1-2	*****	*****
3-4	*****	*****
5+	*****	*****
Combined comorbidity score ⁴	1.7	2.1
Combined comorbidity score categories ⁴		
<0	*****	*****
0	*****	*****
1-2	14	45.2%
3-4	*****	*****
5+	*****	*****

Table 1am. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	0	0.0%
Obesity	*****	*****
Tobacco use	*****	*****
Arrhythmia	11	35.5%
Cerebrovascular disease/stroke/transient ischemic attack	*****	*****
Chronic kidney disease	*****	*****
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	*****	*****
Hyperlipidemia	*****	*****
Hypertensive disease	*****	*****
Thyroid disease	*****	*****
Ischemic heart disease/coronary artery disease/myocardial infarction	*****	*****
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	*****
Obstructive sleep apnea	13	41.9%
Hypertrophic cardiomyopathy	0	0.0%
Other cardiac disease	18	58.1%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	*****	*****
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	*****	*****
Biguanides (metformin, phenformin, etc.)	*****	*****
SGLT2 inhibitors	*****	*****
Sulfonylurea	*****	*****
Thiazolidinedione	*****	*****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	15	48.4%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%

Table 1am. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	15	48.4%
Angiotensin-converting-enzyme (ACE) inhibitor	*****	*****
Angiotensin ii receptor blockers (ARBs)	11	35.5%
Dihydropyridines	*****	*****
Diuretics	16	51.6%
Other antihypertensives	*****	*****
Antihypertensives (any of the above antihypertensives)	*****	*****
Oral anticoagulants	*****	*****
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	*****	*****
Other cardiac medications (any of the other cardiac medications)	*****	*****
Lipid lowering therapy	*****	*****
Baseline known risk of prolonged QT and torsades de pointes	18	58.1%
Baseline possible risk of prolonged QT and torsades de pointes	*****	*****
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	23.8	16.3
Mean number of emergency room encounters	0.9	3.0
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.1	0.5
Mean number of other ambulatory encounters	3.8	5.1
Mean number of filled prescriptions	51.4	35.5
Mean number of generics dispensed	15.2	6.8
Mean number of unique drug classes dispensed	13.3	5.7

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1an. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	*****	N/A
Demographic Characteristics		
Age (years)	47.7	6.3
Age		
0-40 years	0	0.0%
41-64 years	*****	100.0%
65-74 years	0	0.0%
75-84 years	0	0.0%
≥ 85 years	0	0.0%
Sex		
Female	*****	100.0%
Male	0	0.0%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	*****	100.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	0	0.0%
Unknown	*****	100.0%
Year		
2022	*****	*****
2023	*****	*****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.0	1.2
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	*****	*****
1-2	*****	*****
3-4	0	0.0%
5+	0	0.0%
Combined comorbidity score ⁴	1.8	2.1
Combined comorbidity score categories ⁴		
<0	0	0.0%
0	*****	*****
1-2	0	0.0%
3-4	*****	*****
5+	0	0.0%

Table 1an. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	0	0.0%
Obesity	*****	100.0%
Tobacco use	*****	*****
Arrhythmia	0	0.0%
Cerebrovascular disease/stroke/transient ischemic attack	0	0.0%
Chronic kidney disease	0	0.0%
Chronic obstructive pulmonary disease	0	0.0%
Congenital heart disease	0	0.0%
Heart failure	0	0.0%
Hyperlipidemia	*****	*****
Hypertensive disease	*****	*****
Thyroid disease	0	0.0%
Ischemic heart disease/coronary artery disease/myocardial infarction	0	0.0%
Left ventricular hypertrophy	0	0.0%
Peripheral artery disease	0	0.0%
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	0	0.0%
Obstructive sleep apnea	*****	*****
Hypertrophic cardiomyopathy	0	0.0%
Other cardiac disease	*****	*****
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	0	0.0%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	*****	*****
Biguanides (metformin, phenformin, etc.)	*****	*****
SGLT2 inhibitors	*****	*****
Sulfonylurea	*****	*****
Thiazolidinedione	0	0.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	0	0.0%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%

Table 1an. Aggregated Characteristics of Saxenda, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	0	0.0%
Angiotensin-converting-enzyme (ACE) inhibitor	*****	*****
Angiotensin ii receptor blockers (ARBs)	0	0.0%
Dihydropyridines	*****	*****
Diuretics	*****	*****
Other antihypertensives	0	0.0%
Antihypertensives (any of the above antihypertensives)	*****	*****
Oral anticoagulants	0	0.0%
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	0	0.0%
Other cardiac medications (any of the other cardiac medications)	0	0.0%
Lipid lowering therapy	*****	*****
Baseline known risk of prolonged QT and torsades de pointes	*****	*****
Baseline possible risk of prolonged QT and torsades de pointes	*****	100.0%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	0	0.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	32.5	20.1
Mean number of emergency room encounters	1.3	0.5
Mean number of inpatient hospital encounters	0.5	0.6
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	3.0	2.8
Mean number of filled prescriptions	26.8	17.0
Mean number of generics dispensed	11.0	6.3
Mean number of unique drug classes dispensed	9.5	4.7

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a number

N/A: Not applicable

Table 1ao. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Unique patients	66,978	N/A
Demographic Characteristics		
Age (years)	65.7	10.5
Age		
0-40 years	2,425	3.6%
41-64 years	23,743	35.4%
65-74 years	27,390	40.9%
75-84 years	11,847	17.7%
≥ 85 years	1,573	2.3%
Sex		
Female	34,815	52.0%
Male	32,163	48.0%
Race ²		
American Indian or Alaska Native	258	0.4%
Asian	1,202	1.8%
Black or African American	6,428	9.6%
Multi-racial	293	0.4%
Native Hawaiian or Other Pacific Islander	238	0.4%
Unknown	21,774	32.5%
White	36,775	54.9%
Hispanic origin		
Yes	2,477	3.7%
No	40,947	61.1%
Unknown	23,554	35.2%
Year		
2022	52,917	79.0%
2023	14,061	21.0%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.0	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	21,378	31.9%
1-2	23,333	34.8%
3-4	13,032	19.5%
5+	9,235	13.8%
Combined comorbidity score ⁴	2.7	2.8
Combined comorbidity score categories ⁴		
<0	3,992	6.0%
0	12,482	18.6%
1-2	22,773	34.0%
3-4	13,084	19.5%
5+	14,647	21.9%

Table 1ao. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Alcohol use or abuse	1,370	2.0%
Obesity	35,956	53.7%
Tobacco use	17,593	26.3%
Arrhythmia	17,988	26.9%
Cerebrovascular disease/stroke/transient ischemic attack	9,793	14.6%
Chronic kidney disease	14,796	22.1%
Chronic obstructive pulmonary disease	8,288	12.4%
Congenital heart disease	8,288	12.4%
Heart failure	9,669	14.4%
Hyperlipidemia	56,189	83.9%
Hypertensive disease	58,287	87.0%
Thyroid disease	14,775	22.1%
Ischemic heart disease/coronary artery disease/myocardial infarction	18,264	27.3%
Left ventricular hypertrophy	4,264	6.4%
Peripheral artery disease	4,264	6.4%
Valvular/mitral valve disease	2,932	4.4%
Diseases of veins and lymphatics, and other diseases of circulatory system	9,323	13.9%
Obstructive sleep apnea	16,638	23.80%
Hypertrophic cardiomyopathy	3,676	5.5%
Other cardiac disease	31,389	46.9%
Tachyarrhythmia day 0	1,233	1.9%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	893	1.3%
Medical Product Use		
Alpha-glucosidase inhibitors	273	0.4%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	12,181	18.2%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	905	1.4%
Insulin	20,294	30.3%
Biguanides (metformin, phenformin, etc.)	54,620	81.5%
SGLT2 inhibitors	19,602	29.3%
Sulfonylurea	26,616	39.7%
Thiazolidinedione	6,286	9.4%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	11	0.0%
Sodium channel blockers	369	0.6%
Beta blockers	28,774	43.0%
Potassium channel blockers/openers	1,081	1.6%
Non-dihydropyridine calcium channel blockers	95	0.1%
Digoxin	606	0.9%
Other antiarrhythmic agents	0	0.0%

Table 1ao. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	29,096	43.4%
Angiotensin-converting-enzyme (ACE) inhibitor	27,314	40.8%
Angiotensin ii receptor blockers (ARBs)	23,305	34.8%
Dihydropyridines	18,425	27.5%
Diuretics	23,675	36.8%
Other antihypertensives	5,845	8.7%
Antihypertensives (any of the above antihypertensives)	56,405	84.2%
Oral anticoagulants	6,376	9.5%
Vitamin K antagonists	1,474	2.2%
Other cardiac medications not mentioned above	4,986	7.4%
Other cardiac medications (any of the other cardiac medications)	11,459	17.1%
Lipid lowering therapy	56,298	84.1%
Baseline known risk of prolonged QT and torsades de pointes	29,700	44.3%
Baseline possible risk of prolonged QT and torsades de pointes	56,429	84.3%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	9,950	14.9%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	20.8	19.4
Mean number of emergency room encounters	0.6	1.7
Mean number of inpatient hospital encounters	0.2	0.6
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	6.8	14.8
Mean number of filled prescriptions	47.2	37.4
Mean number of generics dispensed	12.8	6.2
Mean number of unique drug classes dispensed	11.1	5.5

¹Characteristics in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁵Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

N/A: Not applicable

Table 1ap. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	21,774	N/A
Demographic Characteristics		
Age (years)	58.8	11.3
Age		
0-40 years	1,577	7.2%
41-64 years	13,585	62.4%
65-74 years	4,882	22.4%
75-84 years	1,533	7.0%
≥ 85 years	197	0.9%
Sex		
Female	10,589	48.6%
Male	11,185	51.4%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	21,774	100.0%
White	0	0.0%
Hispanic origin		
Yes	*****	10.9%
No	*****	0.0%
Unknown	19,400	89.1%
Year		
2022	15,411	70.8%
2023	6,363	29.2%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.3	1.7
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	10,552	48.5%
1-2	7,054	32.4%
3-4	2,659	12.2%
5+	1,509	6.9%
Combined comorbidity score ⁴	1.7	2.3
Combined comorbidity score categories ⁴		
<0	2,075	9.5%
0	5,955	27.3%
1-2	8,259	37.9%
3-4	3,115	14.3%
5+	2,370	10.9%

Table 1ap. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	331	1.5%
Obesity	11,145	51.2%
Tobacco use	3,994	18.3%
Arrhythmia	3,977	18.3%
Cerebrovascular disease/stroke/transient ischemic attack	1,788	8.2%
Chronic kidney disease	2,755	12.7%
Chronic obstructive pulmonary disease	1,393	6.4%
Congenital heart disease	1,393	6.4%
Heart failure	1,697	7.8%
Hyperlipidemia	16,962	77.9%
Hypertensive disease	17,377	79.8%
Thyroid disease	3,610	16.6%
Ischemic heart disease/coronary artery disease/myocardial infarction	3,653	16.8%
Left ventricular hypertrophy	886	4.1%
Peripheral artery disease	886	4.1%
Valvular/mitral valve disease	528	2.4%
Diseases of veins and lymphatics, and other diseases of circulatory system	1,952	9.0%
Obstructive sleep apnea	4,719	21.7%
Hypertrophic cardiomyopathy	711	3.3%
Other cardiac disease	7,752	35.6%
Tachyarrhythmia day 0	234	1.1%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	157	0.7%
Medical Product Use		
Alpha-glucosidase inhibitors	71	0.3%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	3,737	17.2%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	188	0.9%
Insulin	5,567	25.6%
Biguanides (metformin, phenformin, etc.)	18,674	85.8%
SGLT2 inhibitors	6,491	29.8%
Sulfonylurea	7,649	35.1%
Thiazolidinedione	1,749	8.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	*****	0.0%
Sodium channel blockers	87	0.4%
Beta blockers	6,978	32.0%
Potassium channel blockers/openers	196	0.9%
Non-dihydropyridine calcium channel blockers	23	0.1%
Digoxin	119	0.5%
Other antiarrhythmic agents	0	0.0%

Table 1ap. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	7,050	32.4%
Angiotensin-converting-enzyme (ACE) inhibitor	8,887	40.8%
Angiotensin ii receptor blockers (ARBs)	6,743	31.0%
Dihydropyridines	4,841	22.2%
Diuretics	6,071	27.9%
Other antihypertensives	1,321	6.1%
Antihypertensives (any of the above antihypertensives)	17,073	78.4%
Oral anticoagulants	1,237	5.7%
Vitamin K antagonists	221	1.0%
Other cardiac medications not mentioned above	997	4.6%
Other cardiac medications (any of the other cardiac medications)	2,250	10.3%
Lipid lowering therapy	17,082	78.5%
Baseline known risk of prolonged QT and torsades de pointes	8,626	39.6%
Baseline possible risk of prolonged QT and torsades de pointes	16,829	77.3%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	2,569	11.8%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	16.0	17.6
Mean number of emergency room encounters	0.4	1.1
Mean number of inpatient hospital encounters	0.2	0.6
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	4.9	9.4
Mean number of filled prescriptions	39.0	31.1
Mean number of generics dispensed	11.3	6.1
Mean number of unique drug classes dispensed	9.7	5.3

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1a. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	258	N/A
Demographic Characteristics		
Age (years)	64.8	11.8
Age		
0-40 years	*****	*****
41-64 years	100	38.8%
65-74 years	95	36.8%
75-84 years	43	16.7%
≥ 85 years	*****	*****
Sex		
Female	147	57.0%
Male	111	43.0%
Race ²		
American Indian or Alaska Native	258	100.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	230	93.0%
Unknown	18	7.0%
Year		
2022	234	90.7%
2023	23	9.3%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.1	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	72	27.9%
1-2	96	37.2%
3-4	49	19.0%
5+	41	15.9%
Combined comorbidity score ⁴	2.6	2.5
Combined comorbidity score categories ⁴		
<0	13	5.0%
0	40	15.5%
1-2	97	37.6%
3-4	59	22.9%
5+	49	19.0%

Table 1a. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	13	5.0%
Obesity	116	45.0%
Tobacco use	85	32.9%
Arrhythmia	59	22.9%
Cerebrovascular disease/stroke/transient ischemic attack	43	16.7%
Chronic kidney disease	53	20.5%
Chronic obstructive pulmonary disease	29	11.2%
Congenital heart disease	29	11.2%
Heart failure	35	13.6%
Hyperlipidemia	201	77.9%
Hypertensive disease	225	87.2%
Thyroid disease	55	21.3%
Ischemic heart disease/coronary artery disease/myocardial infarction	67	26.0%
Left ventricular hypertrophy	15	5.8%
Peripheral artery disease	15	5.8%
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	35	13.6%
Obstructive sleep apnea	57	22.1%
Hypertrophic cardiomyopathy	14	5.4%
Other cardiac disease	107	41.5%
Tachyarrhythmia day 0	*****	*****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	55	21.3%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	117	45.3%
Biguanides (metformin, phenformin, etc.)	210	81.4%
SGLT2 inhibitors	66	25.6%
Sulfonylurea	96	37.2%
Thiazolidinedione	26	10.1%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	92	35.7%
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%

Table 1a. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	93	36.0%
Angiotensin-converting-enzyme (ACE) inhibitor	135	52.3%
Angiotensin ii receptor blockers (ARBs)	73	28.3%
Dihydropyridines	64	23.80%
Diuretics	87	33.7%
Other antihypertensives	27	10.5%
Antihypertensives (any of the above antihypertensives)	221	85.7%
Oral anticoagulants	18	7.0%
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	20	7.8%
Other cardiac medications (any of the other cardiac medications)	35	13.6%
Lipid lowering therapy	215	83.3%
Baseline known risk of prolonged QT and torsades de pointes	119	46.1%
Baseline possible risk of prolonged QT and torsades de pointes	220	85.3%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	42	16.3%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	19.8	18.8
Mean number of emergency room encounters	0.8	1.7
Mean number of inpatient hospital encounters	0.2	0.8
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	10.1	31.0
Mean number of filled prescriptions	62.9	49.5
Mean number of generics dispensed	13.4	6.6
Mean number of unique drug classes dispensed	11.6	5.7

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1ar. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	1,202	N/A
Demographic Characteristics		
Age (years)	69.3	10.7
Age		
0-40 years	46	3.8%
41-64 years	221	18.4%
65-74 years	570	47.4%
75-84 years	297	23.70%
≥ 85 years	68	5.7%
Sex		
Female	630	52.4%
Male	572	47.6%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	1,202	100.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	1,046	87.0%
Unknown	156	13.0%
Year		
2022	1,045	86.9%
2023	157	13.1%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.2	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	312	26.0%
1-2	441	36.7%
3-4	275	22.9%
5+	174	14.5%
Combined comorbidity score ⁴	2.9	2.8
Combined comorbidity score categories ⁴		
<0	29	2.4%
0	210	17.5%
1-2	414	34.4%
3-4	256	21.3%
5+	293	23.40%

Table 1ar. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	18	1.5%
Obesity	306	25.5%
Tobacco use	177	14.7%
Arrhythmia	312	26.0%
Cerebrovascular disease/stroke/transient ischemic attack	203	16.9%
Chronic kidney disease	371	30.9%
Chronic obstructive pulmonary disease	97	8.1%
Congenital heart disease	97	8.1%
Heart failure	179	14.9%
Hyperlipidemia	1,047	87.1%
Hypertensive disease	1,050	87.4%
Thyroid disease	271	22.5%
Ischemic heart disease/coronary artery disease/myocardial infarction	347	28.9%
Left ventricular hypertrophy	63	5.2%
Peripheral artery disease	63	5.2%
Valvular/mitral valve disease	50	4.2%
Diseases of veins and lymphatics, and other diseases of circulatory system	144	12.0%
Obstructive sleep apnea	148	12.3%
Hypertrophic cardiomyopathy	61	5.1%
Other cardiac disease	497	41.3%
Tachyarrhythmia day 0	20	1.7%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	20	1.7%
Medical Product Use		
Alpha-glucosidase inhibitors	31	2.6%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	359	29.9%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	43	3.6%
Insulin	437	36.4%
Biguanides (metformin, phenformin, etc.)	982	81.7%
SGLT2 inhibitors	475	39.5%
Sulfonylurea	549	45.7%
Thiazolidinedione	137	11.4%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	*****	*****
Beta blockers	531	44.2%
Potassium channel blockers/openers	18	1.5%
Non-dihydropyridine calcium channel blockers	*****	*****
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%

Table 1ar. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	535	44.5%
Angiotensin-converting-enzyme (ACE) inhibitor	359	29.9%
Angiotensin ii receptor blockers (ARBs)	596	49.6%
Dihydropyridines	421	35.0%
Diuretics	346	28.8%
Other antihypertensives	131	10.9%
Antihypertensives (any of the above antihypertensives)	1,030	85.7%
Oral anticoagulants	97	8.1%
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	105	8.7%
Other cardiac medications (any of the other cardiac medications)	193	16.1%
Lipid lowering therapy	1,095	91.1%
Baseline known risk of prolonged QT and torsades de pointes	430	35.8%
Baseline possible risk of prolonged QT and torsades de pointes	933	77.6%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	141	11.7%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	19.9	26.0
Mean number of emergency room encounters	0.4	1.1
Mean number of inpatient hospital encounters	0.2	0.6
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	7.2	15.4
Mean number of filled prescriptions	45.4	35.2
Mean number of generics dispensed	12.4	6.0
Mean number of unique drug classes dispensed	10.5	5.2

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1as. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	6,428	N/A
Demographic Characteristics		
Age (years)	66.1	10.8
Age		
0-40 years	218	3.4%
41-64 years	2,117	32.9%
65-74 years	2,953	45.9%
75-84 years	1,022	15.9%
≥ 85 years	118	1.8%
Sex		
Female	4,237	65.9%
Male	2,191	34.1%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	6,428	100.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	5,794	90.1%
Unknown	634	9.9%
Year		
2022	4,894	76.1%
2023	1,534	23.9%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.6	2.2
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	1,346	20.9%
1-2	2,277	35.4%
3-4	1,531	23.8%
5+	1,274	19.8%
Combined comorbidity score ⁴	3.3	3.0
Combined comorbidity score categories ⁴		
<0	228	3.5%
0	859	13.4%
1-2	2,002	31.1%
3-4	1,438	22.4%
5+	1,901	29.6%

Table 1as. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Alcohol use or abuse	152	2.4%
Obesity	3,922	61.0%
Tobacco use	1,926	30.0%
Arrhythmia	1,771	27.6%
Cerebrovascular disease/stroke/transient ischemic attack	1,207	18.8%
Chronic kidney disease	2,014	31.3%
Chronic obstructive pulmonary disease	888	13.8%
Congenital heart disease	888	13.8%
Heart failure	1,303	20.3%
Hyperlipidemia	5,482	85.3%
Hypertensive disease	6,054	94.2%
Thyroid disease	992	15.4%
Ischemic heart disease/coronary artery disease/myocardial infarction	1,691	26.3%
Left ventricular hypertrophy	566	8.8%
Peripheral artery disease	566	8.8%
Valvular/mitral valve disease	272	4.2%
Diseases of veins and lymphatics, and other diseases of circulatory system	1,028	16.0%
Obstructive sleep apnea	1,496	23.3%
Hypertrophic cardiomyopathy	463	7.2%
Other cardiac disease	3,052	47.5%
Tachyarrhythmia day 0	81	1.3%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	163	2.5%
Medical Product Use		
Alpha-glucosidase inhibitors	23	0.4%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	1,223	19.0%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	95	1.5%
Insulin	2,549	39.7%
Biguanides (metformin, phenformin, etc.)	4,822	75.0%
SGLT2 inhibitors	1,813	28.2%
Sulfonylurea	2,505	39.0%
Thiazolidinedione	488	7.6%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	21	0.3%
Beta blockers	3,075	47.8%
Potassium channel blockers/openers	72	1.1%
Non-dihydropyridine calcium channel blockers	*****	*****
Digoxin	33	0.5%
Other antiarrhythmic agents	0	0.0%

Table 1as. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	3,097	48.2%
Angiotensin-converting-enzyme (ACE) inhibitor	2,225	34.6%
Angiotensin ii receptor blockers (ARBs)	2,839	44.2%
Dihydropyridines	3,069	47.7%
Diuretics	3,145	48.9%
Other antihypertensives	1,030	16.0%
Antihypertensives (any of the above antihypertensives)	5,919	92.1%
Oral anticoagulants	576	9.0%
Vitamin K antagonists	118	1.8%
Other cardiac medications not mentioned above	517	8.0%
Other cardiac medications (any of the other cardiac medications)	1,073	16.7%
Lipid lowering therapy	5,508	85.7%
Baseline known risk of prolonged QT and torsades de pointes	2,734	42.5%
Baseline possible risk of prolonged QT and torsades de pointes	5,684	88.4%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	826	12.9%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	22.6	21.5
Mean number of emergency room encounters	1.0	2.2
Mean number of inpatient hospital encounters	0.2	0.7
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	8.2	18.6
Mean number of filled prescriptions	50.4	38.9
Mean number of generics dispensed	13.7	6.4
Mean number of unique drug classes dispensed	12.0	5.5

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1at. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Unique patients	238	N/A
Demographic Characteristics		
Age (years)	71.0	7.3
Age		
0-40 years	*****	*****
41-64 years	39	15.7%
65-74 years	136	54.8%
75-84 years	62	25.0%
≥ 85 years	*****	*****
Sex		
Female	116	46.8%
Male	132	53.2%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	238	100.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	*****	*****
Year		
2022	145	58.5%
2023	103	41.5%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.2	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	59	23.8%
1-2	99	39.9%
3-4	59	23.8%
5+	31	12.5%
Combined comorbidity score ⁴	2.7	2.7
Combined comorbidity score categories ⁴		
<0	13	5.2%
0	40	16.1%
1-2	92	37.1%
3-4	51	20.6%
5+	52	21.0%

Table 1at. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Alcohol use or abuse	*****	*****
Obesity	108	43.5%
Tobacco use	59	23.8%
Arrhythmia	48	19.4%
Cerebrovascular disease/stroke/transient ischemic attack	39	15.7%
Chronic kidney disease	85	34.3%
Chronic obstructive pulmonary disease	23	9.3%
Congenital heart disease	23	9.3%
Heart failure	33	13.3%
Hyperlipidemia	217	87.5%
Hypertensive disease	221	89.1%
Thyroid disease	34	13.7%
Ischemic heart disease/coronary artery disease/myocardial infarction	64	25.8%
Left ventricular hypertrophy	11	4.4%
Peripheral artery disease	11	4.4%
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	28	11.3%
Obstructive sleep apnea	36	14.5%
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	91	36.7%
Tachyarrhythmia day 0	*****	*****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	*****	*****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	46	18.5%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	82	33.1%
Biguanides (metformin, phenformin, etc.)	204	82.3%
SGLT2 inhibitors	71	28.6%
Sulfonylurea	125	50.4%
Thiazolidinedione	32	12.9%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	103	41.5%
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%

Table 1at. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	103	41.5%
Angiotensin-converting-enzyme (ACE) inhibitor	114	46.0%
Angiotensin ii receptor blockers (ARBs)	97	39.1%
Dihydropyridines	84	33.9%
Diuretics	74	29.8%
Other antihypertensives	23	9.7%
Antihypertensives (any of the above antihypertensives)	220	88.7%
Oral anticoagulants	18	7.3%
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	18	7.3%
Other cardiac medications (any of the other cardiac medications)	35	14.1%
Lipid lowering therapy	223	89.9%
Baseline known risk of prolonged QT and torsades de pointes	89	35.9%
Baseline possible risk of prolonged QT and torsades de pointes	200	80.6%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	13	5.2%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	19.0	17.0
Mean number of emergency room encounters	0.6	1.4
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	2.3	5.9
Mean number of filled prescriptions	35.9	20.3
Mean number of generics dispensed	12.4	5.3
Mean number of unique drug classes dispensed	10.4	4.7

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1au. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Unique patients	36,775	N/A
Demographic Characteristics		
Age (years)	69.6	9.6
Age		
0-40 years	536	1.5%
41-64 years	7,457	20.3%
65-74 years	18,730	50.9%
75-84 years	8,880	23.10%
≥ 85 years	1,172	3.2%
Sex		
Female	18,955	51.5%
Male	17,820	48.5%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	36,775	100.0%
Hispanic origin		
Yes	*****	0.0%
No	33,614	91.4%
Unknown	*****	8.6%
Year		
2022	30,998	84.3%
2023	5,777	15.7%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.4	2.2
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	8,863	23.10%
1-2	13,277	36.1%
3-4	8,437	22.9%
5+	6,198	16.9%
Combined comorbidity score ⁴	3.1	3.0
Combined comorbidity score categories ⁴		
<0	1,613	4.4%
0	5,293	14.4%
1-2	11,771	32.0%
3-4	8,131	22.1%
5+	9,967	27.1%

Table 1au. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Alcohol use or abuse	849	2.3%
Obesity	20,204	54.9%
Tobacco use	11,323	30.8%
Arrhythmia	11,776	32.0%
Cerebrovascular disease/stroke/transient ischemic attack	6,500	17.7%
Chronic kidney disease	9,494	25.8%
Chronic obstructive pulmonary disease	5,854	15.9%
Congenital heart disease	5,854	15.9%
Heart failure	6,412	17.4%
Hyperlipidemia	32,059	87.2%
Hypertensive disease	33,158	90.2%
Thyroid disease	9,774	26.6%
Ischemic heart disease/coronary artery disease/myocardial infarction	12,417	33.8%
Left ventricular hypertrophy	2,714	7.4%
Peripheral artery disease	2,714	7.4%
Valvular/mitral valve disease	2,063	5.6%
Diseases of veins and lymphatics, and other diseases of circulatory system	6,119	16.6%
Obstructive sleep apnea	10,119	27.5%
Hypertrophic cardiomyopathy	2,412	6.6%
Other cardiac disease	19,808	53.9%
Tachyarrhythmia day 0	903	2.5%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	544	1.5%
Medical Product Use		
Alpha-glucosidase inhibitors	144	0.4%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	6,718	18.3%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	573	1.6%
Insulin	11,478	31.2%
Biguanides (metformin, phenformin, etc.)	29,464	80.1%
SGLT2 inhibitors	10,598	28.8%
Sulfonylurea	15,591	42.4%
Thiazolidinedione	3,831	10.4%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	*****	0.0%
Sodium channel blockers	256	0.7%
Beta blockers	17,931	48.8%
Potassium channel blockers/openers	785	2.1%
Non-dihydropyridine calcium channel blockers	63	0.2%
Digoxin	438	1.2%
Other antiarrhythmic agents	0	0.0%

Table 1au. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	18,153	49.4%
Angiotensin-converting-enzyme (ACE) inhibitor	15,495	42.1%
Angiotensin ii receptor blockers (ARBs)	12,862	35.0%
Dihydropyridines	9,899	26.9%
Diuretics	14,887	40.5%
Other antihypertensives	3,296	9.0%
Antihypertensives (any of the above antihypertensives)	31,739	86.3%
Oral anticoagulants	4,418	12.0%
Vitamin K antagonists	1,119	3.0%
Other cardiac medications not mentioned above	3,318	9.0%
Other cardiac medications (any of the other cardiac medications)	7,848	21.3%
Lipid lowering therapy	31,958	86.9%
Baseline known risk of prolonged QT and torsades de pointes	17,592	47.8%
Baseline possible risk of prolonged QT and torsades de pointes	32,360	88.0%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	6,330	17.2%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	23.5	19.8
Mean number of emergency room encounters	0.7	1.8
Mean number of inpatient hospital encounters	0.2	0.7
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	7.8	16.5
Mean number of filled prescriptions	51.5	40.4
Mean number of generics dispensed	13.5	6.3
Mean number of unique drug classes dispensed	11.8	5.5

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1av. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	293	N/A
Demographic Characteristics		
Age (years)	53.7	10.8
Age		
0-40 years	35	11.9%
41-64 years	223	76.5%
65-74 years	*****	*****
75-84 years	*****	*****
≥ 85 years	0	0.0%
Sex		
Female	141	48.1%
Male	152	51.9%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	293	100.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	95	32.4%
No	12	4.1%
Unknown	186	63.5%
Year		
2022	190	64.8%
2023	103	35.2%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.8	1.3
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	174	59.4%
1-2	89	30.4%
3-4	*****	*****
5+	*****	*****
Combined comorbidity score ⁴	1.3	2.0
Combined comorbidity score categories ⁴		
<0	21	7.2%
0	85	29.0%
1-2	138	47.1%
3-4	34	11.6%
5+	15	5.1%

Table 1av. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	*****	*****
Obesity	155	52.9%
Tobacco use	28	9.6%
Arrhythmia	45	15.4%
Cerebrovascular disease/stroke/transient ischemic attack	13	4.4%
Chronic kidney disease	23	8.2%
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	*****	*****
Hyperlipidemia	221	75.4%
Hypertensive disease	202	68.9%
Thyroid disease	39	13.3%
Ischemic heart disease/coronary artery disease/myocardial infarction	25	8.5%
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	17	5.8%
Obstructive sleep apnea	63	21.5%
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	82	28.0%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	43	14.7%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	64	21.8%
Biguanides (metformin, phenformin, etc.)	264	90.1%
SGLT2 inhibitors	88	30.0%
Sulfonylurea	101	34.5%
Thiazolidinedione	23	7.8%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	64	21.8%
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	*****	*****
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%

Table 1av. Aggregated Characteristics of Trulicity, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	65	22.2%
Angiotensin-converting-enzyme (ACE) inhibitor	99	33.8%
Angiotensin ii receptor blockers (ARBs)	95	32.4%
Dihydropyridines	47	16.0%
Diuretics	65	22.2%
Other antihypertensives	16	5.5%
Antihypertensives (any of the above antihypertensives)	203	69.3%
Oral anticoagulants	12	4.1%
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	11	3.8%
Other cardiac medications (any of the other cardiac medications)	25	8.5%
Lipid lowering therapy	217	74.1%
Baseline known risk of prolonged QT and torsades de pointes	110	37.5%
Baseline possible risk of prolonged QT and torsades de pointes	203	69.3%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	29	9.9%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	16.2	14.8
Mean number of emergency room encounters	0.5	2.8
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	2.7	7.6
Mean number of filled prescriptions	32.8	27.9
Mean number of generics dispensed	9.7	5.7
Mean number of unique drug classes dispensed	8.4	4.9

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1aw. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Unique patients	5,354	N/A
Demographic Characteristics		
Age (years)	63.6	11.4
Age		
0-40 years	308	5.8%
41-64 years	2,151	40.2%
65-74 years	2,042	38.1%
75-84 years	754	14.1%
≥ 85 years	99	1.8%
Sex		
Female	3,117	58.2%
Male	2,237	41.8%
Race ²		
American Indian or Alaska Native	59	1.1%
Asian	92	1.7%
Black or African American	556	10.4%
Multi-racial	67	1.3%
Native Hawaiian or Other Pacific Islander	14	0.3%
Unknown	1,435	26.8%
White	3,131	58.5%
Hispanic origin		
Yes	223	4.2%
No	3,491	65.2%
Unknown	1,640	30.6%
Year		
2022	4,105	76.7%
2023	1,239	23.3%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.1	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	1,647	30.8%
1-2	1,892	35.3%
3-4	1,075	20.1%
5+	740	13.8%
Combined comorbidity score ⁴	2.8	2.8
Combined comorbidity score categories ⁴		
<0	231	4.5%
0	900	16.8%
1-2	1,825	34.1%
3-4	1,181	22.1%
5+	1,207	22.5%

Table 1aw. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Alcohol use or abuse	145	2.7%
Obesity	3,218	60.1%
Tobacco use	1,538	28.7%
Arrhythmia	1,442	26.9%
Cerebrovascular disease/stroke/transient ischemic attack	695	13.0%
Chronic kidney disease	1,196	22.3%
Chronic obstructive pulmonary disease	714	13.3%
Congenital heart disease	714	13.3%
Heart failure	843	15.7%
Hyperlipidemia	4,199	78.4%
Hypertensive disease	4,519	84.4%
Thyroid disease	1,164	21.7%
Ischemic heart disease/coronary artery disease/myocardial infarction	1,402	26.2%
Left ventricular hypertrophy	354	6.6%
Peripheral artery disease	354	6.6%
Valvular/mitral valve disease	216	4.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	766	14.3%
Obstructive sleep apnea	1,522	28.4%
Hypertrophic cardiomyopathy	285	5.3%
Other cardiac disease	2,610	48.7%
Tachyarrhythmia day 0	65	1.2%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	89	1.7%
Medical Product Use		
Alpha-glucosidase inhibitors	25	0.5%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	714	13.3%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	69	1.3%
Insulin	2,046	38.2%
Biguanides (metformin, phenformin, etc.)	4,363	81.5%
SGLT2 inhibitors	1,415	26.4%
Sulfonylurea	1,817	33.9%
Thiazolidinedione	447	8.3%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	*****	*****
Sodium channel blockers	41	0.8%
Beta blockers	2,311	43.2%
Potassium channel blockers/openers	79	1.5%
Non-dihydropyridine calcium channel blockers	*****	*****
Digoxin	50	0.9%
Other antiarrhythmic agents	0	0.0%

Table 1aw. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	2,339	43.7%
Angiotensin-converting-enzyme (ACE) inhibitor	2,168	40.5%
Angiotensin ii receptor blockers (ARBs)	1,827	34.1%
Dihydropyridines	1,457	27.2%
Diuretics	2,167	40.5%
Other antihypertensives	498	9.3%
Antihypertensives (any of the above antihypertensives)	4,490	83.9%
Oral anticoagulants	464	8.7%
Vitamin K antagonists	155	2.9%
Other cardiac medications not mentioned above	439	8.2%
Other cardiac medications (any of the other cardiac medications)	946	17.7%
Lipid lowering therapy	4,394	82.1%
Baseline known risk of prolonged QT and torsades de pointes	2,479	46.3%
Baseline possible risk of prolonged QT and torsades de pointes	4,646	86.8%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	815	15.2%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	22.2	22.5
Mean number of emergency room encounters	0.8	2.4
Mean number of inpatient hospital encounters	0.2	0.6
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	8.5	18.2
Mean number of filled prescriptions	50.9	41.1
Mean number of generics dispensed	13.5	6.6
Mean number of unique drug classes dispensed	11.9	5.7

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1ax. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Unique patients	1,435	N/A
Demographic Characteristics		
Age (years)	58.1	12.8
Age		
0-40 years	140	9.8%
41-64 years	848	59.1%
65-74 years	337	23.5%
75-84 years	93	6.5%
≥ 85 years	17	1.2%
Sex		
Female	853	59.4%
Male	582	40.6%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	1,435	100.0%
White	0	0.0%
Hispanic origin		
Yes	193	13.4%
No	0	0.0%
Unknown	1,232	86.6%
Year		
2022	1,026	71.5%
2023	409	28.5%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.4	1.8
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	670	46.7%
1-2	463	32.3%
3-4	185	12.9%
5+	117	8.2%
Combined comorbidity score ⁴	1.9	2.4
Combined comorbidity score categories ⁴		
<0	109	7.6%
0	341	23.8%
1-2	560	39.0%
3-4	255	17.8%
5+	170	11.8%

Table 1ax. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Alcohol use or abuse	22	1.5%
Obesity	851	59.3%
Tobacco use	293	20.4%
Arrhythmia	271	18.9%
Cerebrovascular disease/stroke/transient ischemic attack	116	8.1%
Chronic kidney disease	196	13.7%
Chronic obstructive pulmonary disease	111	7.7%
Congenital heart disease	111	7.7%
Heart failure	125	8.7%
Hyperlipidemia	1,037	72.3%
Hypertensive disease	1,111	77.4%
Thyroid disease	256	17.8%
Ischemic heart disease/coronary artery disease/myocardial infarction	232	16.9%
Left ventricular hypertrophy	57	4.0%
Peripheral artery disease	57	4.0%
Valvular/mitral valve disease	33	2.3%
Diseases of veins and lymphatics, and other diseases of circulatory system	122	8.5%
Obstructive sleep apnea	336	23.4%
Hypertrophic cardiomyopathy	60	4.2%
Other cardiac disease	523	36.4%
Tachyarrhythmia day 0	11	0.8%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	*****	*****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	179	12.5%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	16	1.1%
Insulin	467	32.5%
Biguanides (metformin, phenformin, etc.)	1,216	84.7%
SGLT2 inhibitors	390	27.2%
Sulfonylurea	436	30.4%
Thiazolidinedione	103	7.2%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	*****	*****
Beta blockers	479	33.4%
Potassium channel blockers/openers	13	0.9%
Non-dihydropyridine calcium channel blockers	*****	*****
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%

Table 1ax. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	485	33.8%
Angiotensin-converting-enzyme (ACE) inhibitor	566	39.4%
Angiotensin ii receptor blockers (ARBs)	459	32.0%
Dihydropyridines	309	21.5%
Diuretics	457	31.8%
Other antihypertensives	91	6.3%
Antihypertensives (any of the above antihypertensives)	1,123	78.3%
Oral anticoagulants	78	5.4%
Vitamin K antagonists	19	1.3%
Other cardiac medications not mentioned above	76	5.3%
Other cardiac medications (any of the other cardiac medications)	162	11.3%
Lipid lowering therapy	1,091	76.0%
Baseline known risk of prolonged QT and torsades de pointes	631	44.0%
Baseline possible risk of prolonged QT and torsades de pointes	1,165	81.2%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	196	13.7%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	18.2	23.3
Mean number of emergency room encounters	0.5	1.1
Mean number of inpatient hospital encounters	0.2	0.6
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	5.6	8.8
Mean number of filled prescriptions	42.3	35.4
Mean number of generics dispensed	12.2	6.5
Mean number of unique drug classes dispensed	10.7	5.7

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1ay. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	59	N/A
Demographic Characteristics		
Age (years)	62.7	10.5
Age		
0-40 years	*****	*****
41-64 years	27	45.8%
65-74 years	20	33.9%
75-84 years	*****	*****
≥ 85 years	0	0.0%
Sex		
Female	31	52.5%
Male	28	47.5%
Race ²		
American Indian or Alaska Native	59	100.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	*****	*****
Year		
2022	*****	*****
2023	*****	*****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.3	1.6
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	25	42.4%
1-2	*****	*****
3-4	*****	*****
5+	*****	*****
Combined comorbidity score ⁴	1.9	2.2
Combined comorbidity score categories ⁴		
<0	*****	*****
0	12	20.3%
1-2	23	40.7%
3-4	*****	*****
5+	*****	*****

Table 1ay. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	*****	*****
Obesity	26	44.1%
Tobacco use	18	30.5%
Arrhythmia	*****	*****
Cerebrovascular disease/stroke/transient ischemic attack	*****	*****
Chronic kidney disease	*****	*****
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	*****	*****
Hyperlipidemia	38	64.4%
Hypertensive disease	44	74.6%
Thyroid disease	*****	*****
Ischemic heart disease/coronary artery disease/myocardial infarction	*****	*****
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	*****
Obstructive sleep apnea	*****	*****
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	16	27.1%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	*****	*****
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	28	47.5%
Biguanides (metformin, phenformin, etc.)	48	81.4%
SGLT2 inhibitors	17	28.8%
Sulfonylurea	13	22.0%
Thiazolidinedione	*****	*****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	21	35.6%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%

Table 1ay. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	21	35.6%
Angiotensin-converting-enzyme (ACE) inhibitor	28	47.5%
Angiotensin ii receptor blockers (ARBs)	16	27.1%
Dihydropyridines	16	27.1%
Diuretics	19	32.2%
Other antihypertensives	*****	*****
Antihypertensives (any of the above antihypertensives)	47	79.7%
Oral anticoagulants	*****	*****
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	*****	*****
Other cardiac medications (any of the other cardiac medications)	*****	*****
Lipid lowering therapy	42	71.2%
Baseline known risk of prolonged QT and torsades de pointes	23	40.7%
Baseline possible risk of prolonged QT and torsades de pointes	48	81.4%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	18.9	15.0
Mean number of emergency room encounters	0.7	1.5
Mean number of inpatient hospital encounters	0.3	0.7
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	5.0	11.3
Mean number of filled prescriptions	56.9	47.7
Mean number of generics dispensed	12.0	6.4
Mean number of unique drug classes dispensed	10.6	5.4

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1az. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	92	N/A
Demographic Characteristics		
Age (years)	63.1	12.1
Age		
0-40 years	*****	*****
41-64 years	34	37.0%
65-74 years	30	32.6%
75-84 years	17	18.5%
≥ 85 years	*****	*****
Sex		
Female	58	63.0%
Male	34	37.0%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	92	100.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	78	84.8%
Unknown	14	15.2%
Year		
2022	74	80.4%
2023	18	19.6%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.3	2.4
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	30	32.6%
1-2	30	32.6%
3-4	12	13.0%
5+	20	21.7%
Combined comorbidity score ⁴	2.7	2.7
Combined comorbidity score categories ⁴		
<0	*****	*****
0	20	21.7%
1-2	30	32.6%
3-4	*****	*****
5+	21	22.8%

Table 1az. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	*****	*****
Obesity	30	32.6%
Tobacco use	*****	*****
Arrhythmia	25	27.2%
Cerebrovascular disease/stroke/transient ischemic attack	17	18.5%
Chronic kidney disease	23	25.0%
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	16	17.4%
Hyperlipidemia	69	75.0%
Hypertensive disease	76	82.6%
Thyroid disease	18	19.6%
Ischemic heart disease/coronary artery disease/myocardial infarction	20	21.7%
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	*****
Obstructive sleep apnea	14	15.2%
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	37	40.2%
Tachyarrhythmia day 0	*****	*****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	*****	*****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	18	19.6%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	54	58.7%
Biguanides (metformin, phenformin, etc.)	67	72.8%
SGLT2 inhibitors	27	29.3%
Sulfonylurea	33	35.9%
Thiazolidinedione	12	13.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	*****	*****
Beta blockers	45	48.9%
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%

Table 1az. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	47	51.1%
Angiotensin-converting-enzyme (ACE) inhibitor	33	35.9%
Angiotensin ii receptor blockers (ARBs)	38	41.3%
Dihydropyridines	31	33.7%
Diuretics	33	35.9%
Other antihypertensives	*****	*****
Antihypertensives (any of the above antihypertensives)	75	81.5%
Oral anticoagulants	*****	*****
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	*****	*****
Other cardiac medications (any of the other cardiac medications)	13	14.1%
Lipid lowering therapy	81	88.0%
Baseline known risk of prolonged QT and torsades de pointes	33	35.9%
Baseline possible risk of prolonged QT and torsades de pointes	69	75.0%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	22.1	35.7
Mean number of emergency room encounters	0.5	0.9
Mean number of inpatient hospital encounters	0.3	0.8
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	8.5	11.1
Mean number of filled prescriptions	44.7	35.4
Mean number of generics dispensed	12.1	6.6
Mean number of unique drug classes dispensed	10.6	5.4

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1ba. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	556	N/A
Demographic Characteristics		
Age (years)	61.7	11.0
Age		
0-40 years	39	7.0%
41-64 years	250	45.0%
65-74 years	223	40.1%
75-84 years	*****	*****
≥ 85 years	*****	*****
Sex		
Female	359	64.6%
Male	197	35.4%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	556	100.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	*****	*****
No	502	90.3%
Unknown	*****	*****
Year		
2022	397	71.4%
2023	159	28.6%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.5	2.2
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	141	25.4%
1-2	176	31.7%
3-4	137	23.60%
5+	102	18.3%
Combined comorbidity score ⁴	3.3	3.0
Combined comorbidity score categories ⁴		
<0	23	4.1%
0	83	14.9%
1-2	163	29.3%
3-4	131	23.6%
5+	156	28.1%

Table 1ba. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	18	3.2%
Obesity	370	66.5%
Tobacco use	186	33.5%
Arrhythmia	142	25.5%
Cerebrovascular disease/stroke/transient ischemic attack	90	16.2%
Chronic kidney disease	160	28.8%
Chronic obstructive pulmonary disease	89	16.0%
Congenital heart disease	89	16.0%
Heart failure	127	22.8%
Hyperlipidemia	430	77.3%
Hypertensive disease	503	90.5%
Thyroid disease	69	12.4%
Ischemic heart disease/coronary artery disease/myocardial infarction	140	25.2%
Left ventricular hypertrophy	63	11.3%
Peripheral artery disease	63	11.3%
Valvular/mitral valve disease	19	3.4%
Diseases of veins and lymphatics, and other diseases of circulatory system	71	12.8%
Obstructive sleep apnea	154	27.7%
Hypertrophic cardiomyopathy	41	7.4%
Other cardiac disease	282	50.7%
Tachyarrhythmia day 0	*****	*****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	17	3.1%
Medical Product Use		
Alpha-glucosidase inhibitors	*****	*****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	90	16.2%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	250	45.0%
Biguanides (metformin, phenformin, etc.)	439	79.0%
SGLT2 inhibitors	134	23.10%
Sulfonylurea	188	33.8%
Thiazolidinedione	35	6.3%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	*****	*****
Beta blockers	263	47.3%
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	*****	*****
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%

Table 1ba. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	265	47.7%
Angiotensin-converting-enzyme (ACE) inhibitor	196	35.3%
Angiotensin ii receptor blockers (ARBs)	236	42.4%
Dihydropyridines	251	45.1%
Diuretics	282	50.7%
Other antihypertensives	89	16.0%
Antihypertensives (any of the above antihypertensives)	504	90.6%
Oral anticoagulants	55	9.9%
Vitamin K antagonists	18	3.2%
Other cardiac medications not mentioned above	53	9.5%
Other cardiac medications (any of the other cardiac medications)	104	18.7%
Lipid lowering therapy	472	84.9%
Baseline known risk of prolonged QT and torsades de pointes	252	45.3%
Baseline possible risk of prolonged QT and torsades de pointes	505	90.8%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	60	10.8%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	23.8	27.4
Mean number of emergency room encounters	1.4	5.6
Mean number of inpatient hospital encounters	0.3	0.6
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	8.7	15.3
Mean number of filled prescriptions	52.8	41.2
Mean number of generics dispensed	14.4	6.5
Mean number of unique drug classes dispensed	12.7	5.6

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1bb. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	14	N/A
Demographic Characteristics		
Age (years)	67.4	10.0
Age		
0-40 years	0	0.0%
41-64 years	*****	*****
65-74 years	*****	*****
75-84 years	*****	*****
≥ 85 years	*****	*****
Sex		
Female	*****	*****
Male	*****	*****
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	14	100.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	14	100.0%
Unknown	0	0.0%
Year		
2022	*****	*****
2023	*****	*****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.7	2.3
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	*****	*****
1-2	*****	*****
3-4	*****	*****
5+	*****	*****
Combined comorbidity score ⁴	3.4	2.6
Combined comorbidity score categories ⁴		
<0	0	0.0%
0	*****	*****
1-2	*****	*****
3-4	*****	*****
5+	*****	*****

Table 1bb. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	0	0.0%
Obesity	*****	*****
Tobacco use	*****	*****
Arrhythmia	*****	*****
Cerebrovascular disease/stroke/transient ischemic attack	*****	*****
Chronic kidney disease	*****	*****
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	*****	*****
Hyperlipidemia	*****	*****
Hypertensive disease	*****	*****
Thyroid disease	*****	*****
Ischemic heart disease/coronary artery disease/myocardial infarction	*****	*****
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	*****
Obstructive sleep apnea	*****	*****
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	*****	*****
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	0	0.0%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	*****	*****
Biguanides (metformin, phenformin, etc.)	*****	*****
SGLT2 inhibitors	*****	*****
Sulfonylurea	*****	*****
Thiazolidinedione	*****	*****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	*****	*****
Beta blockers	*****	*****
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%

Table 1bb. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	*****	*****
Angiotensin-converting-enzyme (ACE) inhibitor	*****	*****
Angiotensin ii receptor blockers (ARBs)	*****	*****
Dihydropyridines	*****	*****
Diuretics	*****	*****
Other antihypertensives	0	0.0%
Antihypertensives (any of the above antihypertensives)	*****	*****
Oral anticoagulants	*****	*****
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	*****	*****
Other cardiac medications (any of the other cardiac medications)	*****	*****
Lipid lowering therapy	*****	*****
Baseline known risk of prolonged QT and torsades de pointes	*****	*****
Baseline possible risk of prolonged QT and torsades de pointes	*****	*****
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	18.8	9.6
Mean number of emergency room encounters	0.6	1.0
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	1.5	4.2
Mean number of filled prescriptions	42.1	31.6
Mean number of generics dispensed	13.6	8.3
Mean number of unique drug classes dispensed	12.1	7.1

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a number

N/A: Not applicable

Table 1bc. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	3,131	N/A
Demographic Characteristics		
Age (years)	66.8	10.4
Age		
0-40 years	95	3.0%
41-64 years	947	30.2%
65-74 years	1,420	45.4%
75-84 years	597	19.1%
≥ 85 years	72	2.3%
Sex		
Female	1,762	56.3%
Male	1,369	43.7%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	3,131	100.0%
Hispanic origin		
Yes	15	0.5%
No	2,808	89.7%
Unknown	308	9.8%
Year		
2022	2,510	80.2%
2023	621	19.8%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.3	2.1
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	734	23.4%
1-2	1,177	37.6%
3-4	726	23.2%
5+	494	15.8%
Combined comorbidity score ⁴	3.2	3.0
Combined comorbidity score categories ⁴		
<0	101	3.2%
0	432	13.8%
1-2	1,010	32.3%
3-4	748	23.9%
5+	840	26.8%

Table 1bc. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	98	3.1%
Obesity	1,886	60.2%
Tobacco use	1,007	32.2%
Arrhythmia	979	31.3%
Cerebrovascular disease/stroke/transient ischemic attack	466	14.9%
Chronic kidney disease	804	25.7%
Chronic obstructive pulmonary disease	498	15.9%
Congenital heart disease	498	15.9%
Heart failure	558	17.8%
Hyperlipidemia	2,573	82.2%
Hypertensive disease	2,743	87.6%
Thyroid disease	795	25.4%
Ischemic heart disease/coronary artery disease/myocardial infarction	985	31.5%
Left ventricular hypertrophy	221	7.1%
Peripheral artery disease	221	7.1%
Valvular/mitral valve disease	161	5.1%
Diseases of veins and lymphatics, and other diseases of circulatory system	558	17.8%
Obstructive sleep apnea	994	31.7%
Hypertrophic cardiomyopathy	173	5.5%
Other cardiac disease	1,723	55.1%
Tachyarrhythmia day 0	43	1.4%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	65	2.1%
Medical Product Use		
Alpha-glucosidase inhibitors	17	0.5%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	411	13.1%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	43	1.4%
Insulin	1,216	38.8%
Biguanides (metformin, phenformin, etc.)	2,523	80.6%
SGLT2 inhibitors	827	26.4%
Sulfonylurea	1,131	36.1%
Thiazolidinedione	291	9.3%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	*****	*****
Sodium channel blockers	31	1.0%
Beta blockers	1,476	47.1%
Potassium channel blockers/openers	55	1.8%
Non-dihydropyridine calcium channel blockers	*****	*****
Digoxin	40	1.3%
Other antiarrhythmic agents	0	0.0%

Table 1bc. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	1,494	47.7%
Angiotensin-converting-enzyme (ACE) inhibitor	1,320	42.2%
Angiotensin ii receptor blockers (ARBs)	1,057	33.8%
Dihydropyridines	832	26.6%
Diuretics	1,350	43.1%
Other antihypertensives	296	9.5%
Antihypertensives (any of the above antihypertensives)	2,686	85.8%
Oral anticoagulants	322	10.3%
Vitamin K antagonists	114	3.6%
Other cardiac medications not mentioned above	294	9.4%
Other cardiac medications (any of the other cardiac medications)	653	20.9%
Lipid lowering therapy	2,650	84.6%
Baseline known risk of prolonged QT and torsades de pointes	1,503	48.0%
Baseline possible risk of prolonged QT and torsades de pointes	2,793	89.2%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	531	17.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	23.7	20.8
Mean number of emergency room encounters	0.8	1.8
Mean number of inpatient hospital encounters	0.2	0.6
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	9.8	21.7
Mean number of filled prescriptions	54.8	43.4
Mean number of generics dispensed	13.9	6.5
Mean number of unique drug classes dispensed	12.3	5.7

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1bd. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	67	N/A
Demographic Characteristics		
Age (years)	46.6	13.4
Age		
0-40 years	*****	*****
41-64 years	41	61.2%
65-74 years	*****	*****
75-84 years	*****	*****
≥ 85 years	0	0.0%
Sex		
Female	49	73.1%
Male	18	26.9%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	67	100.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	13	19.4%
No	35	52.2%
Unknown	19	28.4%
Year		
2022	37	55.2%
2023	30	44.8%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.7	1.2
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	45	67.2%
1-2	*****	*****
3-4	*****	*****
5+	*****	*****
Combined comorbidity score ⁴	2.2	2.2
Combined comorbidity score categories ⁴		
<0	*****	*****
0	*****	*****
1-2	33	49.3%
3-4	14	20.9%
5+	*****	*****

Table 1bd. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	*****	*****
Obesity	44	65.7%
Tobacco use	21	31.3%
Arrhythmia	12	17.9%
Cerebrovascular disease/stroke/transient ischemic attack	*****	*****
Chronic kidney disease	*****	*****
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	*****	*****
Hyperlipidemia	40	59.7%
Hypertensive disease	30	44.8%
Thyroid disease	13	19.4%
Ischemic heart disease/coronary artery disease/myocardial infarction	*****	*****
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	*****
Obstructive sleep apnea	11	16.4%
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	19	28.4%
Tachyarrhythmia day 0	*****	*****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	*****	*****
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	28	41.8%
Biguanides (metformin, phenformin, etc.)	59	88.1%
SGLT2 inhibitors	16	23.9%
Sulfonylurea	11	16.4%
Thiazolidinedione	*****	*****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	20	29.9%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%

Table 1bd. Aggregated Characteristics of Victoza, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	20	29.9%
Angiotensin-converting-enzyme (ACE) inhibitor	20	29.9%
Angiotensin ii receptor blockers (ARBs)	12	17.9%
Dihydropyridines	15	22.4%
Diuretics	19	28.4%
Other antihypertensives	*****	*****
Antihypertensives (any of the above antihypertensives)	43	64.2%
Oral anticoagulants	0	0.0%
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	*****	*****
Other cardiac medications (any of the other cardiac medications)	*****	*****
Lipid lowering therapy	46	68.7%
Baseline known risk of prolonged QT and torsades de pointes	30	44.8%
Baseline possible risk of prolonged QT and torsades de pointes	56	83.6%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	23.8	18.9
Mean number of emergency room encounters	1.0	2.6
Mean number of inpatient hospital encounters	0.1	0.5
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	11.1	18.4
Mean number of filled prescriptions	47.5	39.7
Mean number of generics dispensed	13.2	6.3
Mean number of unique drug classes dispensed	11.9	5.6

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1be. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Unique patients	828	N/A
Demographic Characteristics		
Age (years)	52.1	10.3
Age		
0-40 years	132	15.9%
41-64 years	621	75.0%
65-74 years	64	7.7%
75-84 years	*****	*****
≥ 85 years	*****	*****
Sex		
Female	570	68.8%
Male	258	31.2%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	37	4.5%
Multi-racial	18	2.2%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	663	80.1%
White	110	13.3%
Hispanic origin		
Yes	15	1.8%
No	58	7.0%
Unknown	755	91.2%
Year		
2022	72	8.7%
2023	756	91.3%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.7	1.1
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	531	64.1%
1-2	234	28.3%
3-4	49	5.9%
5+	14	1.7%
Combined comorbidity score ⁴	1.2	1.9
Combined comorbidity score categories ⁴		
<0	123	14.9%
0	232	29.2%
1-2	312	37.7%
3-4	99	12.0%
5+	52	6.3%

Table 1be. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Alcohol use or abuse	*****	*****
Obesity	681	82.2%
Tobacco use	131	15.8%
Arrhythmia	169	20.4%
Cerebrovascular disease/stroke/transient ischemic attack	41	5.0%
Chronic kidney disease	53	6.4%
Chronic obstructive pulmonary disease	23	2.9%
Congenital heart disease	23	2.9%
Heart failure	52	6.3%
Hyperlipidemia	539	65.1%
Hypertensive disease	615	74.3%
Thyroid disease	198	23.9%
Ischemic heart disease/coronary artery disease/myocardial infarction	98	11.8%
Left ventricular hypertrophy	25	3.0%
Peripheral artery disease	25	3.0%
Valvular/mitral valve disease	17	2.1%
Diseases of veins and lymphatics, and other diseases of circulatory system	69	8.3%
Obstructive sleep apnea	287	34.7%
Hypertrophic cardiomyopathy	28	3.4%
Other cardiac disease	343	41.4%
Tachyarrhythmia day 0	*****	*****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	*****	*****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	39	4.7%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	41	5.0%
Biguanides (metformin, phenformin, etc.)	736	88.9%
SGLT2 inhibitors	127	15.3%
Sulfonylurea	79	9.5%
Thiazolidinedione	21	2.5%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	*****	*****
Beta blockers	233	29.3%
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%

Table 1be. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	234	29.5%
Angiotensin-converting-enzyme (ACE) inhibitor	226	27.3%
Angiotensin ii receptor blockers (ARBs)	265	32.0%
Dihydropyridines	167	20.2%
Diuretics	280	33.8%
Other antihypertensives	42	5.1%
Antihypertensives (any of the above antihypertensives)	598	72.2%
Oral anticoagulants	40	4.8%
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	26	3.1%
Other cardiac medications (any of the other cardiac medications)	69	8.3%
Lipid lowering therapy	447	54.0%
Baseline known risk of prolonged QT and torsades de pointes	420	50.7%
Baseline possible risk of prolonged QT and torsades de pointes	714	86.2%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	131	15.8%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	19.6	16.0
Mean number of emergency room encounters	0.4	1.0
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	4.9	7.5
Mean number of filled prescriptions	37.1	29.0
Mean number of generics dispensed	12.2	6.9
Mean number of unique drug classes dispensed	11.0	6.0

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1bf. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	663	N/A
Demographic Characteristics		
Age (years)	50.9	10.3
Age		
0-40 years	113	17.0%
41-64 years	520	78.4%
65-74 years	*****	*****
75-84 years	*****	*****
≥ 85 years	0	0.0%
Sex		
Female	465	70.1%
Male	198	29.9%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	663	100.0%
White	0	0.0%
Hispanic origin		
Yes	13	2.0%
No	0	0.0%
Unknown	650	98.0%
Year		
2022	62	9.4%
2023	601	90.6%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.6	1.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	448	67.6%
1-2	181	27.3%
3-4	*****	*****
5+	*****	*****
Combined comorbidity score ⁴	1.0	1.8
Combined comorbidity score categories ⁴		
<0	105	15.8%
0	207	31.2%
1-2	232	36.5%
3-4	74	11.2%
5+	35	5.3%

Table 1bf. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	*****	*****
Obesity	542	81.7%
Tobacco use	102	15.4%
Arrhythmia	130	19.6%
Cerebrovascular disease/stroke/transient ischemic attack	27	4.1%
Chronic kidney disease	37	5.6%
Chronic obstructive pulmonary disease	16	2.4%
Congenital heart disease	16	2.4%
Heart failure	37	5.6%
Hyperlipidemia	428	64.6%
Hypertensive disease	499	75.3%
Thyroid disease	160	23.10%
Ischemic heart disease/coronary artery disease/myocardial infarction	70	10.6%
Left ventricular hypertrophy	21	3.2%
Peripheral artery disease	21	3.2%
Valvular/mitral valve disease	13	2.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	48	7.2%
Obstructive sleep apnea	211	31.8%
Hypertrophic cardiomyopathy	23	3.5%
Other cardiac disease	252	38.0%
Tachyarrhythmia day 0	*****	*****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	*****	*****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	30	4.5%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	26	3.9%
Biguanides (metformin, phenformin, etc.)	599	90.3%
SGLT2 inhibitors	99	14.9%
Sulfonylurea	55	8.3%
Thiazolidinedione	12	1.8%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	*****	*****
Beta blockers	187	28.2%
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%

Table 1bf. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	188	28.4%
Angiotensin-converting-enzyme (ACE) inhibitor	187	28.2%
Angiotensin ii receptor blockers (ARBs)	209	31.5%
Dihydropyridines	133	20.1%
Diuretics	216	32.6%
Other antihypertensives	30	4.5%
Antihypertensives (any of the above antihypertensives)	481	72.5%
Oral anticoagulants	28	4.2%
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	21	3.2%
Other cardiac medications (any of the other cardiac medications)	50	7.5%
Lipid lowering therapy	344	51.9%
Baseline known risk of prolonged QT and torsades de pointes	353	53.2%
Baseline possible risk of prolonged QT and torsades de pointes	575	86.7%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	110	16.6%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	18.5	15.0
Mean number of emergency room encounters	0.4	0.9
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	4.8	6.0
Mean number of filled prescriptions	35.1	25.2
Mean number of generics dispensed	12.0	6.5
Mean number of unique drug classes dispensed	10.9	5.7

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a number

N/A: Not applicable

Table 1bg. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	0	N/A
Demographic Characteristics		
Age (years)	.	.
Age		
0-40 years	.	.
41-64 years	.	.
65-74 years	.	.
75-84 years	.	.
≥ 85 years	.	.
Sex		
Female	.	.
Male	.	.
Race ²		
American Indian or Alaska Native	.	.
Asian	.	.
Black or African American	.	.
Multi-racial	.	.
Native Hawaiian or Other Pacific Islander	.	.
Unknown	.	.
White	.	.
Hispanic origin		
Yes	.	.
No	.	.
Unknown	.	.
Year		
2022	.	.
2023	.	.
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	.	.
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	.	.
0	.	.
1-2	.	.
3-4	.	.
5+	.	.
Combined comorbidity score ⁴	.	.
Combined comorbidity score categories ⁴		
<0	.	.
0	.	.
1-2	.	.
3-4	.	.
5+	.	.

Table 1bg. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	.	.
Obesity	.	.
Tobacco use	.	.
Arrhythmia	.	.
Cerebrovascular disease/stroke/transient ischemic attack	.	.
Chronic kidney disease	.	.
Chronic obstructive pulmonary disease	.	.
Congenital heart disease	.	.
Heart failure	.	.
Hyperlipidemia	.	.
Hypertensive disease	.	.
Thyroid disease	.	.
Ischemic heart disease/coronary artery disease/myocardial infarction	.	.
Left ventricular hypertrophy	.	.
Peripheral artery disease	.	.
Valvular/mitral valve disease	.	.
Diseases of veins and lymphatics, and other diseases of circulatory system	.	.
Obstructive sleep apnea	.	.
Hypertrophic cardiomyopathy	.	.
Other cardiac disease	.	.
Tachyarrhythmia day 0	.	.
Hospitalized tachyarrhythmia day 0	.	.
History of serious hypoglycemia (ED and/or IP)	.	.
Medical Product Use		
Alpha-glucosidase inhibitors	.	.
Amylin analogs (pramlintide)	.	.
DPP-4 inhibitors	.	.
Incretin mimetics (albiglutide, dulaglutide, etc.)	.	.
Meglitinides	.	.
Insulin	.	.
Biguanides (metformin, phenformin, etc.)	.	.
SGLT2 inhibitors	.	.
Sulfonylurea	.	.
Thiazolidinedione	.	.
No baseline use of any of the above antidiabetic drugs	.	.
Other antidiabetics	.	.
Sodium channel blockers	.	.
Beta blockers	.	.
Potassium channel blockers/openers	.	.
Non-dihydropyridine calcium channel blockers	.	.
Digoxin	.	.
Other antiarrhythmic agents	.	.

Table 1bg. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	.	.
Angiotensin-converting-enzyme (ACE) inhibitor	.	.
Angiotensin ii receptor blockers (ARBs)	.	.
Dihydropyridines	.	.
Diuretics	.	.
Other antihypertensives	.	.
Antihypertensives (any of the above antihypertensives)	.	.
Oral anticoagulants	.	.
Vitamin K antagonists	.	.
Other cardiac medications not mentioned above	.	.
Other cardiac medications (any of the other cardiac medications)	.	.
Lipid lowering therapy	.	.
Baseline known risk of prolonged QT and torsades de pointes	.	.
Baseline possible risk of prolonged QT and torsades de pointes	.	.
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	.	.
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	.	.
Mean number of emergency room encounters	.	.
Mean number of inpatient hospital encounters	.	.
Mean number of non-acute institutional encounters	.	.
Mean number of other ambulatory encounters	.	.
Mean number of filled prescriptions	.	.
Mean number of generics dispensed	.	.
Mean number of unique drug classes dispensed	.	.

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

Data presented by a dash, asterisk, or period represent missing information. This table may not use all data representations.

N/A: Not applicable

Table 1bh. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	0	N/A
Demographic Characteristics		
Age (years)	.	.
Age		
0-40 years	.	.
41-64 years	.	.
65-74 years	.	.
75-84 years	.	.
≥ 85 years	.	.
Sex		
Female	.	.
Male	.	.
Race ²		
American Indian or Alaska Native	.	.
Asian	.	.
Black or African American	.	.
Multi-racial	.	.
Native Hawaiian or Other Pacific Islander	.	.
Unknown	.	.
White	.	.
Hispanic origin		
Yes	.	.
No	.	.
Unknown	.	.
Year		
2022	.	.
2023	.	.
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	.	.
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	.	.
0	.	.
1-2	.	.
3-4	.	.
5+	.	.
Combined comorbidity score ⁴	.	.
Combined comorbidity score categories ⁴		
<0	.	.
0	.	.
1-2	.	.
3-4	.	.
5+	.	.

Table 1bh. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	.	.
Obesity	.	.
Tobacco use	.	.
Arrhythmia	.	.
Cerebrovascular disease/stroke/transient ischemic attack	.	.
Chronic kidney disease	.	.
Chronic obstructive pulmonary disease	.	.
Congenital heart disease	.	.
Heart failure	.	.
Hyperlipidemia	.	.
Hypertensive disease	.	.
Thyroid disease	.	.
Ischemic heart disease/coronary artery disease/myocardial infarction	.	.
Left ventricular hypertrophy	.	.
Peripheral artery disease	.	.
Valvular/mitral valve disease	.	.
Diseases of veins and lymphatics, and other diseases of circulatory system	.	.
Obstructive sleep apnea	.	.
Hypertrophic cardiomyopathy	.	.
Other cardiac disease	.	.
Tachyarrhythmia day 0	.	.
Hospitalized tachyarrhythmia day 0	.	.
History of serious hypoglycemia (ED and/or IP)	.	.
Medical Product Use		
Alpha-glucosidase inhibitors	.	.
Amylin analogs (pramlintide)	.	.
DPP-4 inhibitors	.	.
Incretin mimetics (albiglutide, dulaglutide, etc.)	.	.
Meglitinides	.	.
Insulin	.	.
Biguanides (metformin, phenformin, etc.)	.	.
SGLT2 inhibitors	.	.
Sulfonylurea	.	.
Thiazolidinedione	.	.
No baseline use of any of the above antidiabetic drugs	.	.
Other antidiabetics	.	.
Sodium channel blockers	.	.
Beta blockers	.	.
Potassium channel blockers/openers	.	.
Non-dihydropyridine calcium channel blockers	.	.
Digoxin	.	.
Other antiarrhythmic agents	.	.

Table 1bh. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	.	.
Angiotensin-converting-enzyme (ACE) inhibitor	.	.
Angiotensin ii receptor blockers (ARBs)	.	.
Dihydropyridines	.	.
Diuretics	.	.
Other antihypertensives	.	.
Antihypertensives (any of the above antihypertensives)	.	.
Oral anticoagulants	.	.
Vitamin K antagonists	.	.
Other cardiac medications not mentioned above	.	.
Other cardiac medications (any of the other cardiac medications)	.	.
Lipid lowering therapy	.	.
Baseline known risk of prolonged QT and torsades de pointes	.	.
Baseline possible risk of prolonged QT and torsades de pointes	.	.
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	.	.
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	.	.
Mean number of emergency room encounters	.	.
Mean number of inpatient hospital encounters	.	.
Mean number of non-acute institutional encounters	.	.
Mean number of other ambulatory encounters	.	.
Mean number of filled prescriptions	.	.
Mean number of generics dispensed	.	.
Mean number of unique drug classes dispensed	.	.

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

Data presented by a dash, asterisk, or period represent missing information. This table may not use all data representations.

N/A: Not applicable

Table 1bi. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	37	N/A
Demographic Characteristics		
Age (years)	56.2	9.6
Age		
0-40 years	*****	*****
41-64 years	23	62.2%
65-74 years	*****	*****
75-84 years	*****	*****
≥ 85 years	0	0.0%
Sex		
Female	*****	*****
Male	*****	*****
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	37	100.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	14	37.8%
Unknown	23	62.2%
Year		
2022	*****	*****
2023	*****	*****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.0	1.3
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	19	51.4%
1-2	*****	*****
3-4	*****	*****
5+	*****	*****
Combined comorbidity score ⁴	1.4	1.9
Combined comorbidity score categories ⁴		
<0	*****	*****
0	*****	*****
1-2	14	37.8%
3-4	*****	*****
5+	*****	*****

Table 1bi. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	*****	*****
Obesity	*****	*****
Tobacco use	*****	*****
Arrhythmia	*****	*****
Cerebrovascular disease/stroke/transient ischemic attack	*****	*****
Chronic kidney disease	*****	*****
Chronic obstructive pulmonary disease	0	0.0%
Congenital heart disease	0	0.0%
Heart failure	*****	*****
Hyperlipidemia	*****	*****
Hypertensive disease	*****	*****
Thyroid disease	*****	*****
Ischemic heart disease/coronary artery disease/myocardial infarction	*****	*****
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	*****
Obstructive sleep apnea	11	29.7%
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	13	35.1%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	*****	*****
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	*****	*****
Biguanides (metformin, phenformin, etc.)	*****	*****
SGLT2 inhibitors	*****	*****
Sulfonylurea	*****	*****
Thiazolidinedione	*****	*****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	12	32.4%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%

Table 1bi. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	12	32.4%
Angiotensin-converting-enzyme (ACE) inhibitor	*****	*****
Angiotensin ii receptor blockers (ARBs)	19	51.4%
Dihydropyridines	12	32.4%
Diuretics	16	43.2%
Other antihypertensives	*****	*****
Antihypertensives (any of the above antihypertensives)	*****	*****
Oral anticoagulants	*****	*****
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	0	0.0%
Other cardiac medications (any of the other cardiac medications)	*****	*****
Lipid lowering therapy	20	54.1%
Baseline known risk of prolonged QT and torsades de pointes	13	35.1%
Baseline possible risk of prolonged QT and torsades de pointes	*****	*****
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	19.3	14.1
Mean number of emergency room encounters	0.6	1.3
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	2.8	4.7
Mean number of filled prescriptions	34.1	35.4
Mean number of generics dispensed	11.6	6.6
Mean number of unique drug classes dispensed	10.4	5.7

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

NaN: Not a number

N/A: Not applicable

Table 1bj. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	0	N/A
Demographic Characteristics		
Age (years)	.	.
Age		
0-40 years	.	.
41-64 years	.	.
65-74 years	.	.
75-84 years	.	.
≥ 85 years	.	.
Sex		
Female	.	.
Male	.	.
Race ²		
American Indian or Alaska Native	.	.
Asian	.	.
Black or African American	.	.
Multi-racial	.	.
Native Hawaiian or Other Pacific Islander	.	.
Unknown	.	.
White	.	.
Hispanic origin		
Yes	.	.
No	.	.
Unknown	.	.
Year		
2022	.	.
2023	.	.
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	.	.
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	.	.
0	.	.
1-2	.	.
3-4	.	.
5+	.	.
Combined comorbidity score ⁴	.	.
Combined comorbidity score categories ⁴		
<0	.	.
0	.	.
1-2	.	.
3-4	.	.
5+	.	.

Table 1bj. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Alcohol use or abuse	.	.
Obesity	.	.
Tobacco use	.	.
Arrhythmia	.	.
Cerebrovascular disease/stroke/transient ischemic attack	.	.
Chronic kidney disease	.	.
Chronic obstructive pulmonary disease	.	.
Congenital heart disease	.	.
Heart failure	.	.
Hyperlipidemia	.	.
Hypertensive disease	.	.
Thyroid disease	.	.
Ischemic heart disease/coronary artery disease/myocardial infarction	.	.
Left ventricular hypertrophy	.	.
Peripheral artery disease	.	.
Valvular/mitral valve disease	.	.
Diseases of veins and lymphatics, and other diseases of circulatory system	.	.
Obstructive sleep apnea	.	.
Hypertrophic cardiomyopathy	.	.
Other cardiac disease	.	.
Tachyarrhythmia day 0	.	.
Hospitalized tachyarrhythmia day 0	.	.
History of serious hypoglycemia (ED and/or IP)	.	.
Medical Product Use		
Alpha-glucosidase inhibitors	.	.
Amylin analogs (pramlintide)	.	.
DPP-4 inhibitors	.	.
Incretin mimetics (albiglutide, dulaglutide, etc.)	.	.
Meglitinides	.	.
Insulin	.	.
Biguanides (metformin, phenformin, etc.)	.	.
SGLT2 inhibitors	.	.
Sulfonylurea	.	.
Thiazolidinedione	.	.
No baseline use of any of the above antidiabetic drugs	.	.
Other antidiabetics	.	.
Sodium channel blockers	.	.
Beta blockers	.	.
Potassium channel blockers/openers	.	.
Non-dihydropyridine calcium channel blockers	.	.
Digoxin	.	.
Other antiarrhythmic agents	.	.

Table 1bj. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	.	.
Angiotensin-converting-enzyme (ACE) inhibitor	.	.
Angiotensin ii receptor blockers (ARBs)	.	.
Dihydropyridines	.	.
Diuretics	.	.
Other antihypertensives	.	.
Antihypertensives (any of the above antihypertensives)	.	.
Oral anticoagulants	.	.
Vitamin K antagonists	.	.
Other cardiac medications not mentioned above	.	.
Other cardiac medications (any of the other cardiac medications)	.	.
Lipid lowering therapy	.	.
Baseline known risk of prolonged QT and torsades de pointes	.	.
Baseline possible risk of prolonged QT and torsades de pointes	.	.
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	.	.
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	.	.
Mean number of emergency room encounters	.	.
Mean number of inpatient hospital encounters	.	.
Mean number of non-acute institutional encounters	.	.
Mean number of other ambulatory encounters	.	.
Mean number of filled prescriptions	.	.
Mean number of generics dispensed	.	.
Mean number of unique drug classes dispensed	.	.

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

Data presented by a dash, asterisk, or period represent missing information. This table may not use all data representations.

N/A: Not applicable

Table 1bk. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	110	N/A
Demographic Characteristics		
Age (years)	58.5	10.1
Age		
0-40 years	*****	*****
41-64 years	64	58.2%
65-74 years	29	26.4%
75-84 years	*****	*****
≥ 85 years	*****	*****
Sex		
Female	63	57.3%
Male	47	42.7%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	110	100.0%
Hispanic origin		
Yes	0	0.0%
No	41	37.3%
Unknown	69	62.7%
Year		
2022	*****	*****
2023	*****	*****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.3	1.5
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	53	48.2%
1-2	35	31.8%
3-4	*****	*****
5+	*****	*****
Combined comorbidity score ⁴	1.8	2.3
Combined comorbidity score categories ⁴		
<0	*****	*****
0	21	19.1%
1-2	49	44.5%
3-4	19	17.3%
5+	*****	*****

Table 1bk. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Alcohol use or abuse	*****	*****
Obesity	92	83.6%
Tobacco use	23	20.9%
Arrhythmia	27	23.50%
Cerebrovascular disease/stroke/transient ischemic attack	12	10.9%
Chronic kidney disease	*****	*****
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	13	11.8%
Hyperlipidemia	74	67.3%
Hypertensive disease	74	67.3%
Thyroid disease	25	22.7%
Ischemic heart disease/coronary artery disease/myocardial infarction	25	22.7%
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	15	13.6%
Obstructive sleep apnea	58	52.7%
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	70	63.6%
Tachyarrhythmia day 0	*****	*****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	*****	*****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	*****	*****
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	*****	*****
Biguanides (metformin, phenformin, etc.)	90	81.8%
SGLT2 inhibitors	20	18.2%
Sulfonylurea	17	15.5%
Thiazolidinedione	*****	*****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	39	35.5%
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%

Table 1bk. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	39	35.5%
Angiotensin-converting-enzyme (ACE) inhibitor	29	26.4%
Angiotensin ii receptor blockers (ARBs)	33	30.0%
Dihydropyridines	18	16.4%
Diuretics	42	38.2%
Other antihypertensives	*****	*****
Antihypertensives (any of the above antihypertensives)	75	68.2%
Oral anticoagulants	*****	*****
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	*****	*****
Other cardiac medications (any of the other cardiac medications)	16	14.5%
Lipid lowering therapy	72	65.5%
Baseline known risk of prolonged QT and torsades de pointes	47	42.7%
Baseline possible risk of prolonged QT and torsades de pointes	94	85.5%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	14	12.7%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	25.3	20.3
Mean number of emergency room encounters	0.6	1.5
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	6.2	13.3
Mean number of filled prescriptions	47.6	38.3
Mean number of generics dispensed	13.7	7.7
Mean number of unique drug classes dispensed	12.1	6.6

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1bl. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	18	N/A
Demographic Characteristics		
Age (years)	49.6	9.0
Age		
0-40 years	*****	*****
41-64 years	*****	*****
65-74 years	0	0.0%
75-84 years	0	0.0%
≥ 85 years	0	0.0%
Sex		
Female	*****	*****
Male	*****	*****
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	18	100.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	*****	*****
Year		
2022	*****	*****
2023	*****	*****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.1	1.5
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	*****	*****
1-2	*****	*****
3-4	*****	*****
5+	*****	*****
Combined comorbidity score ⁴	1.8	2.2
Combined comorbidity score categories ⁴		
<0	*****	*****
0	*****	*****
1-2	*****	*****
3-4	*****	*****
5+	*****	*****

Table 1bl. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	*****	*****
Obesity	*****	*****
Tobacco use	*****	*****
Arrhythmia	*****	*****
Cerebrovascular disease/stroke/transient ischemic attack	*****	*****
Chronic kidney disease	*****	*****
Chronic obstructive pulmonary disease	0	0.0%
Congenital heart disease	0	0.0%
Heart failure	0	0.0%
Hyperlipidemia	*****	*****
Hypertensive disease	*****	*****
Thyroid disease	*****	*****
Ischemic heart disease/coronary artery disease/myocardial infarction	*****	*****
Left ventricular hypertrophy	0	0.0%
Peripheral artery disease	0	0.0%
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	*****
Obstructive sleep apnea	*****	*****
Hypertrophic cardiomyopathy	0	0.0%
Other cardiac disease	*****	*****
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	0	0.0%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	*****	*****
Biguanides (metformin, phenformin, etc.)	*****	*****
SGLT2 inhibitors	*****	*****
Sulfonylurea	*****	*****
Thiazolidinedione	0	0.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	*****	*****
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%

Table 1bl. Aggregated Characteristics of Wegovy, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	*****	*****
Angiotensin-converting-enzyme (ACE) inhibitor	*****	*****
Angiotensin ii receptor blockers (ARBs)	*****	*****
Dihydropyridines	*****	*****
Diuretics	*****	*****
Other antihypertensives	*****	*****
Antihypertensives (any of the above antihypertensives)	*****	*****
Oral anticoagulants	*****	*****
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	0	0.0%
Other cardiac medications (any of the other cardiac medications)	*****	*****
Lipid lowering therapy	*****	*****
Baseline known risk of prolonged QT and torsades de pointes	*****	*****
Baseline possible risk of prolonged QT and torsades de pointes	*****	*****
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	23.9	22.0
Mean number of emergency room encounters	0.9	1.6
Mean number of inpatient hospital encounters	0.2	0.7
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	5.3	10.7
Mean number of filled prescriptions	52.1	61.1
Mean number of generics dispensed	13.8	12.7
Mean number of unique drug classes dispensed	12.1	11.2

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

NaN: Not a number

N/A: Not applicable

Table 1bm. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Unique patients	364	N/A
Demographic Characteristics		
Age (years)	69.5	8.8
Age		
0-40 years	*****	*****
41-64 years	74	20.3%
65-74 years	183	50.3%
75-84 years	87	23.9%
≥ 85 years	*****	*****
Sex		
Female	172	47.3%
Male	192	52.7%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	40	11.0%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	63	17.3%
White	237	67.9%
Hispanic origin		
Yes	11	3.0%
No	274	75.3%
Unknown	79	21.7%
Year		
2022	217	59.6%
2023	147	40.4%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.8	2.3
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	68	18.7%
1-2	109	29.9%
3-4	106	29.1%
5+	81	22.3%
Combined comorbidity score ⁴	3.2	2.7
Combined comorbidity score categories ⁴		
<0	*****	*****
0	*****	*****
1-2	121	33.2%
3-4	80	22.0%
5+	103	28.3%

Table 1bm. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation¹
Alcohol use or abuse	*****	*****
Obesity	169	46.4%
Tobacco use	91	25.0%
Arrhythmia	101	27.7%
Cerebrovascular disease/stroke/transient ischemic attack	78	21.4%
Chronic kidney disease	109	29.9%
Chronic obstructive pulmonary disease	50	13.7%
Congenital heart disease	50	13.7%
Heart failure	70	19.2%
Hyperlipidemia	328	90.1%
Hypertensive disease	327	89.8%
Thyroid disease	89	23.50%
Ischemic heart disease/coronary artery disease/myocardial infarction	123	34.1%
Left ventricular hypertrophy	26	7.1%
Peripheral artery disease	26	7.1%
Valvular/mitral valve disease	22	6.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	61	16.8%
Obstructive sleep apnea	94	25.8%
Hypertrophic cardiomyopathy	34	9.3%
Other cardiac disease	186	51.1%
Tachyarrhythmia day 0	*****	*****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	*****	*****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	56	15.4%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	215	59.1%
Biguanides (metformin, phenformin, etc.)	291	79.9%
SGLT2 inhibitors	95	26.1%
Sulfonylurea	161	44.2%
Thiazolidinedione	54	14.8%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	*****	*****
Beta blockers	173	47.5%
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	*****	*****
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%

Table 1bm. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	174	47.8%
Angiotensin-converting-enzyme (ACE) inhibitor	178	48.9%
Angiotensin ii receptor blockers (ARBs)	136	37.4%
Dihydropyridines	106	29.1%
Diuretics	132	36.3%
Other antihypertensives	37	10.2%
Antihypertensives (any of the above antihypertensives)	323	89.0%
Oral anticoagulants	30	8.2%
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	30	8.2%
Other cardiac medications (any of the other cardiac medications)	63	17.3%
Lipid lowering therapy	330	90.7%
Baseline known risk of prolonged QT and torsades de pointes	146	40.1%
Baseline possible risk of prolonged QT and torsades de pointes	303	83.2%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	44	12.1%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	20.7	16.4
Mean number of emergency room encounters	0.8	1.6
Mean number of inpatient hospital encounters	0.2	0.5
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	4.7	8.0
Mean number of filled prescriptions	41.3	23.9
Mean number of generics dispensed	12.6	5.4
Mean number of unique drug classes dispensed	10.9	4.8

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1bn. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	63	N/A
Demographic Characteristics		
Age (years)	62.8	10.6
Age		
0-40 years	*****	*****
41-64 years	27	42.9%
65-74 years	22	34.9%
75-84 years	*****	*****
≥ 85 years	0	0.0%
Sex		
Female	28	44.4%
Male	35	55.6%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	63	100.0%
White	0	0.0%
Hispanic origin		
Yes	11	17.5%
No	0	0.0%
Unknown	52	82.5%
Year		
2022	38	60.3%
2023	25	39.7%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	1.9	2.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	21	33.3%
1-2	20	31.7%
3-4	*****	*****
5+	*****	*****
Combined comorbidity score ⁴	1.9	2.0
Combined comorbidity score categories ⁴		
<0	*****	*****
0	12	19.0%
1-2	32	50.8%
3-4	*****	*****
5+	*****	*****

Table 1bn. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	0	0.0%
Obesity	30	47.6%
Tobacco use	11	17.5%
Arrhythmia	15	23.8%
Cerebrovascular disease/stroke/transient ischemic attack	*****	*****
Chronic kidney disease	*****	*****
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	*****	*****
Hyperlipidemia	*****	*****
Hypertensive disease	49	77.8%
Thyroid disease	14	22.2%
Ischemic heart disease/coronary artery disease/myocardial infarction	17	27.0%
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	*****
Obstructive sleep apnea	18	28.6%
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	30	47.6%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	1.6%
Medical Product Use		
Alpha-glucosidase inhibitors	*****	*****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	*****	*****
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	36	57.1%
Biguanides (metformin, phenformin, etc.)	51	81.0%
SGLT2 inhibitors	17	27.0%
Sulfonylurea	26	41.3%
Thiazolidinedione	*****	*****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	*****	*****
Beta blockers	26	41.3%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	*****	*****
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%

Table 1bn. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Unknown in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	27	42.9%
Angiotensin-converting-enzyme (ACE) inhibitor	37	58.7%
Angiotensin ii receptor blockers (ARBs)	15	23.8%
Dihydropyridines	12	19.0%
Diuretics	16	25.4%
Other antihypertensives	*****	*****
Antihypertensives (any of the above antihypertensives)	52	82.5%
Oral anticoagulants	*****	*****
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	*****	*****
Other cardiac medications (any of the other cardiac medications)	*****	*****
Lipid lowering therapy	*****	*****
Baseline known risk of prolonged QT and torsades de pointes	23	36.5%
Baseline possible risk of prolonged QT and torsades de pointes	48	76.2%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	16.0	11.8
Mean number of emergency room encounters	0.6	0.9
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	4.2	6.3
Mean number of filled prescriptions	36.1	25.5
Mean number of generics dispensed	11.6	5.9
Mean number of unique drug classes dispensed	10.2	5.2

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1bo. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	*****	N/A
Demographic Characteristics		
Age (years)	70.8	6.4
Age		
0-40 years	0	0.0%
41-64 years	0	0.0%
65-74 years	*****	*****
75-84 years	*****	*****
≥ 85 years	0	0.0%
Sex		
Female	0	0.0%
Male	*****	100.0%
Race ²		
American Indian or Alaska Native	*****	100.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	*****	100.0%
Unknown	0	0.0%
Year		
2022	0	0.0%
2023	*****	100.0%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.0	0.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	0	0.0%
1-2	*****	100.0%
3-4	0	0.0%
5+	0	0.0%
Combined comorbidity score ⁴	1.5	0.7
Combined comorbidity score categories ⁴		
<0	0	0.0%
0	0	0.0%
1-2	*****	100.0%
3-4	0	0.0%
5+	0	0.0%

Table 1bo. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	0	0.0%
Obesity	0	0.0%
Tobacco use	0	0.0%
Arrhythmia	0	0.0%
Cerebrovascular disease/stroke/transient ischemic attack	0	0.0%
Chronic kidney disease	*****	*****
Chronic obstructive pulmonary disease	0	0.0%
Congenital heart disease	0	0.0%
Heart failure	0	0.0%
Hyperlipidemia	*****	100.0%
Hypertensive disease	*****	100.0%
Thyroid disease	0	0.0%
Ischemic heart disease/coronary artery disease/myocardial infarction	0	0.0%
Left ventricular hypertrophy	0	0.0%
Peripheral artery disease	0	0.0%
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	*****
Obstructive sleep apnea	0	0.0%
Hypertrophic cardiomyopathy	0	0.0%
Other cardiac disease	0	0.0%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	0	0.0%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	*****	*****
Biguanides (metformin, phenformin, etc.)	*****	100.0%
SGLT2 inhibitors	0	0.0%
Sulfonylurea	*****	*****
Thiazolidinedione	0	0.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	0	0.0%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%

Table 1bo. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=American Indian or Alaska Native in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	0	0.0%
Angiotensin-converting-enzyme (ACE) inhibitor	*****	100.0%
Angiotensin ii receptor blockers (ARBs)	0	0.0%
Dihydropyridines	*****	*****
Diuretics	*****	*****
Other antihypertensives	0	0.0%
Antihypertensives (any of the above antihypertensives)	*****	100.0%
Oral anticoagulants	0	0.0%
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	0	0.0%
Other cardiac medications (any of the other cardiac medications)	0	0.0%
Lipid lowering therapy	*****	100.0%
Baseline known risk of prolonged QT and torsades de pointes	*****	*****
Baseline possible risk of prolonged QT and torsades de pointes	*****	100.0%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	0	0.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	10.5	3.5
Mean number of emergency room encounters	0.0	NaN
Mean number of inpatient hospital encounters	0.0	NaN
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	0.0	NaN
Mean number of filled prescriptions	34.5	20.5
Mean number of generics dispensed	13.5	4.9
Mean number of unique drug classes dispensed	11.0	1.4

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a number

N/A: Not applicable

Table 1bp. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	*****	N/A
Demographic Characteristics		
Age (years)	74.8	6.8
Age		
0-40 years	0	0.0%
41-64 years	0	0.0%
65-74 years	*****	*****
75-84 years	*****	*****
≥ 85 years	*****	*****
Sex		
Female	*****	*****
Male	*****	*****
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	*****	100.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	*****	*****
Unknown	*****	*****
Year		
2022	*****	*****
2023	*****	*****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	2.0	2.6
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	*****	*****
1-2	*****	*****
3-4	*****	*****
5+	*****	*****
Combined comorbidity score ⁴	3.2	3.2
Combined comorbidity score categories ⁴		
<0	0	0.0%
0	*****	*****
1-2	*****	*****
3-4	*****	*****
5+	*****	*****

Table 1bp. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	0	0.0%
Obesity	0	0.0%
Tobacco use	0	0.0%
Arrhythmia	*****	*****
Cerebrovascular disease/stroke/transient ischemic attack	*****	*****
Chronic kidney disease	*****	*****
Chronic obstructive pulmonary disease	0	0.0%
Congenital heart disease	0	0.0%
Heart failure	*****	*****
Hyperlipidemia	*****	*****
Hypertensive disease	*****	*****
Thyroid disease	*****	*****
Ischemic heart disease/coronary artery disease/myocardial infarction	*****	*****
Left ventricular hypertrophy	0	0.0%
Peripheral artery disease	0	0.0%
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	*****
Obstructive sleep apnea	*****	*****
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	*****	*****
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	*****	*****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	*****	*****
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	*****	*****
Biguanides (metformin, phenformin, etc.)	*****	*****
SGLT2 inhibitors	*****	*****
Sulfonylurea	*****	*****
Thiazolidinedione	*****	*****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	*****	*****
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%

Table 1bp. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Asian in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	*****	*****
Angiotensin-converting-enzyme (ACE) inhibitor	*****	*****
Angiotensin ii receptor blockers (ARBs)	*****	*****
Dihydropyridines	*****	*****
Diuretics	*****	*****
Other antihypertensives	*****	*****
Antihypertensives (any of the above antihypertensives)	*****	*****
Oral anticoagulants	*****	*****
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	*****	*****
Other cardiac medications (any of the other cardiac medications)	*****	*****
Lipid lowering therapy	*****	100.0%
Baseline known risk of prolonged QT and torsades de pointes	*****	*****
Baseline possible risk of prolonged QT and torsades de pointes	*****	*****
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	0	0.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	23.4	27.7
Mean number of emergency room encounters	0.2	0.7
Mean number of inpatient hospital encounters	0.3	1.0
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	7.8	14.2
Mean number of filled prescriptions	35.6	21.1
Mean number of generics dispensed	10.6	5.3
Mean number of unique drug classes dispensed	9.1	4.6

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a number

N/A: Not applicable

Table 1bq. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	40	N/A
Demographic Characteristics		
Age (years)	70.1	5.5
Age		
0-40 years	*****	*****
41-64 years	*****	*****
65-74 years	27	67.5%
75-84 years	*****	*****
≥ 85 years	*****	*****
Sex		
Female	25	62.5%
Male	15	37.5%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	40	100.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	*****	*****
Unknown	*****	*****
Year		
2022	18	45.0%
2023	22	55.0%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	3.0	2.2
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	*****	*****
1-2	*****	*****
3-4	16	40.0%
5+	*****	*****
Combined comorbidity score ⁴	3.1	2.7
Combined comorbidity score categories ⁴		
<0	*****	*****
0	*****	*****
1-2	11	27.5%
3-4	11	27.5%
5+	*****	*****

Table 1bq. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	0	0.0%
Obesity	15	37.5%
Tobacco use	*****	*****
Arrhythmia	12	30.0%
Cerebrovascular disease/stroke/transient ischemic attack	*****	*****
Chronic kidney disease	11	27.5%
Chronic obstructive pulmonary disease	*****	*****
Congenital heart disease	*****	*****
Heart failure	11	27.5%
Hyperlipidemia	*****	*****
Hypertensive disease	*****	*****
Thyroid disease	*****	*****
Ischemic heart disease/coronary artery disease/myocardial infarction	13	32.5%
Left ventricular hypertrophy	*****	*****
Peripheral artery disease	*****	*****
Valvular/mitral valve disease	*****	*****
Diseases of veins and lymphatics, and other diseases of circulatory system	*****	*****
Obstructive sleep apnea	*****	*****
Hypertrophic cardiomyopathy	*****	*****
Other cardiac disease	22	55.0%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	*****	*****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	*****	*****
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	26	65.0%
Biguanides (metformin, phenformin, etc.)	*****	*****
SGLT2 inhibitors	13	32.5%
Sulfonylurea	16	40.0%
Thiazolidinedione	*****	*****
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	23	60.0%
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%

Table 1bq. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Black or African American in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	23	60.0%
Angiotensin-converting-enzyme (ACE) inhibitor	15	37.5%
Angiotensin ii receptor blockers (ARBs)	16	40.0%
Dihydropyridines	21	52.5%
Diuretics	18	45.0%
Other antihypertensives	*****	*****
Antihypertensives (any of the above antihypertensives)	*****	*****
Oral anticoagulants	*****	*****
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	*****	*****
Other cardiac medications (any of the other cardiac medications)	*****	*****
Lipid lowering therapy	*****	*****
Baseline known risk of prolonged QT and torsades de pointes	14	35.0%
Baseline possible risk of prolonged QT and torsades de pointes	*****	*****
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	22.2	23.3
Mean number of emergency room encounters	0.5	1.1
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	2.9	4.0
Mean number of filled prescriptions	34.2	16.3
Mean number of generics dispensed	12.3	5.7
Mean number of unique drug classes dispensed	10.6	4.9

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1br. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	*****	N/A
Demographic Characteristics		
Age (years)	32.8	NaN
Age		
0-40 years	*****	100.0%
41-64 years	0	0.0%
65-74 years	0	0.0%
75-84 years	0	0.0%
≥ 85 years	0	0.0%
Sex		
Female	0	0.0%
Male	*****	100.0%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	*****	100.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	*****	100.0%
Unknown	0	0.0%
Year		
2022	*****	100.0%
2023	0	0.0%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.0	NaN
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	*****	100.0%
1-2	0	0.0%
3-4	0	0.0%
5+	0	0.0%
Combined comorbidity score ⁴	2.0	NaN
Combined comorbidity score categories ⁴		
<0	0	0.0%
0	0	0.0%
1-2	*****	100.0%
3-4	0	0.0%
5+	0	0.0%

Table 1br. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	0	0.0%
Obesity	*****	100.0%
Tobacco use	*****	100.0%
Arrhythmia	0	0.0%
Cerebrovascular disease/stroke/transient ischemic attack	0	0.0%
Chronic kidney disease	0	0.0%
Chronic obstructive pulmonary disease	0	0.0%
Congenital heart disease	0	0.0%
Heart failure	0	0.0%
Hyperlipidemia	*****	100.0%
Hypertensive disease	0	0.0%
Thyroid disease	0	0.0%
Ischemic heart disease/coronary artery disease/myocardial infarction	0	0.0%
Left ventricular hypertrophy	0	0.0%
Peripheral artery disease	0	0.0%
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	0	0.0%
Obstructive sleep apnea	*****	100.0%
Hypertrophic cardiomyopathy	0	0.0%
Other cardiac disease	*****	100.0%
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	0	0.0%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	*****	100.0%
Biguanides (metformin, phenformin, etc.)	*****	100.0%
SGLT2 inhibitors	0	0.0%
Sulfonylurea	0	0.0%
Thiazolidinedione	0	0.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	0	0.0%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%

Table 1br. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Native Hawaiian or Other Pacific Islander in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	0	0.0%
Angiotensin-converting-enzyme (ACE) inhibitor	0	0.0%
Angiotensin ii receptor blockers (ARBs)	0	0.0%
Dihydropyridines	0	0.0%
Diuretics	0	0.0%
Other antihypertensives	0	0.0%
Antihypertensives (any of the above antihypertensives)	0	0.0%
Oral anticoagulants	0	0.0%
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	0	0.0%
Other cardiac medications (any of the other cardiac medications)	0	0.0%
Lipid lowering therapy	*****	100.0%
Baseline known risk of prolonged QT and torsades de pointes	*****	100.0%
Baseline possible risk of prolonged QT and torsades de pointes	*****	100.0%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	*****	100.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	49.0	NaN
Mean number of emergency room encounters	9.0	NaN
Mean number of inpatient hospital encounters	0.0	NaN
Mean number of non-acute institutional encounters	1.0	NaN
Mean number of other ambulatory encounters	14.0	NaN
Mean number of filled prescriptions	85.0	NaN
Mean number of generics dispensed	13.0	NaN
Mean number of unique drug classes dispensed	12.0	NaN

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a number

N/A: Not applicable

Table 1bs. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	237	N/A
Demographic Characteristics		
Age (years)	71.2	8.2
Age		
0-40 years	*****	*****
41-64 years	42	17.0%
65-74 years	127	51.4%
75-84 years	66	26.7%
≥ 85 years	*****	*****
Sex		
Female	113	45.7%
Male	134	54.3%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	237	100.0%
Hispanic origin		
Yes	0	0.0%
No	229	92.7%
Unknown	18	7.3%
Year		
2022	153	61.9%
2023	94	38.1%
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	3.1	2.3
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	35	14.2%
1-2	74	30.0%
3-4	74	30.0%
5+	64	25.9%
Combined comorbidity score ⁴	3.5	2.9
Combined comorbidity score categories ⁴		
<0	*****	*****
0	*****	*****
1-2	70	28.3%
3-4	58	23.5%
5+	83	33.6%

Table 1bs. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	*****	*****
Obesity	123	49.8%
Tobacco use	69	27.9%
Arrhythmia	72	29.1%
Cerebrovascular disease/stroke/transient ischemic attack	64	25.9%
Chronic kidney disease	85	34.4%
Chronic obstructive pulmonary disease	46	18.6%
Congenital heart disease	46	18.6%
Heart failure	53	21.5%
Hyperlipidemia	226	91.5%
Hypertensive disease	229	92.7%
Thyroid disease	64	25.9%
Ischemic heart disease/coronary artery disease/myocardial infarction	91	36.8%
Left ventricular hypertrophy	23	9.3%
Peripheral artery disease	23	9.3%
Valvular/mitral valve disease	19	7.7%
Diseases of veins and lymphatics, and other diseases of circulatory system	46	18.6%
Obstructive sleep apnea	66	26.7%
Hypertrophic cardiomyopathy	25	10.1%
Other cardiac disease	129	52.2%
Tachyarrhythmia day 0	*****	*****
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	*****	*****
Medical Product Use		
Alpha-glucosidase inhibitors	*****	*****
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	34	13.8%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	*****	*****
Insulin	148	59.9%
Biguanides (metformin, phenformin, etc.)	195	78.9%
SGLT2 inhibitors	62	25.1%
Sulfonylurea	113	45.7%
Thiazolidinedione	37	15.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	*****	*****
Beta blockers	121	49.0%
Potassium channel blockers/openers	*****	*****
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	*****	*****
Other antiarrhythmic agents	0	0.0%

Table 1bs. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=White in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	121	49.0%
Angiotensin-converting-enzyme (ACE) inhibitor	123	49.8%
Angiotensin ii receptor blockers (ARBs)	97	39.3%
Dihydropyridines	70	28.3%
Diuretics	95	38.5%
Other antihypertensives	25	10.1%
Antihypertensives (any of the above antihypertensives)	225	91.1%
Oral anticoagulants	23	9.3%
Vitamin K antagonists	*****	*****
Other cardiac medications not mentioned above	20	8.1%
Other cardiac medications (any of the other cardiac medications)	45	18.2%
Lipid lowering therapy	222	89.9%
Baseline known risk of prolonged QT and torsades de pointes	104	42.1%
Baseline possible risk of prolonged QT and torsades de pointes	212	85.8%
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	34	13.8%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	21.6	15.4
Mean number of emergency room encounters	0.9	1.7
Mean number of inpatient hospital encounters	0.2	0.5
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	5.0	8.6
Mean number of filled prescriptions	44.0	25.8
Mean number of generics dispensed	12.9	5.3
Mean number of unique drug classes dispensed	11.3	4.7

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not applicable

Table 1bt. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Unique patients	*****	N/A
Demographic Characteristics		
Age (years)	53.0	0.0
Age		
0-40 years	0	0.0%
41-64 years	*****	100.0%
65-74 years	0	0.0%
75-84 years	0	0.0%
≥ 85 years	0	0.0%
Sex		
Female	*****	100.0%
Male	0	0.0%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	*****	100.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	0	0.0%
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	0	0.0%
Unknown	*****	100.0%
Year		
2022	*****	*****
2023	*****	*****
Health Characteristics		
Adapted Diabetes Complications Severity Index (aDCSI) ³	0.5	0.0
Adapted Diabetes Complications Severity Index (aDCSI) categories ³		
<0	0	0.0%
0	*****	*****
1-2	*****	*****
3-4	0	0.0%
5+	0	0.0%
Combined comorbidity score ⁴	0.5	0.0
Combined comorbidity score categories ⁴		
<0	0	0.0%
0	*****	*****
1-2	*****	*****
3-4	0	0.0%
5+	0	0.0%

Table 1bt. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Alcohol use or abuse	0	0.0%
Obesity	0	0.0%
Tobacco use	0	0.0%
Arrhythmia	0	0.0%
Cerebrovascular disease/stroke/transient ischemic attack	0	0.0%
Chronic kidney disease	0	0.0%
Chronic obstructive pulmonary disease	0	0.0%
Congenital heart disease	0	0.0%
Heart failure	0	0.0%
Hyperlipidemia	*****	*****
Hypertensive disease	*****	*****
Thyroid disease	*****	*****
Ischemic heart disease/coronary artery disease/myocardial infarction	*****	*****
Left ventricular hypertrophy	0	0.0%
Peripheral artery disease	0	0.0%
Valvular/mitral valve disease	0	0.0%
Diseases of veins and lymphatics, and other diseases of circulatory system	0	0.0%
Obstructive sleep apnea	0	0.0%
Hypertrophic cardiomyopathy	0	0.0%
Other cardiac disease	*****	*****
Tachyarrhythmia day 0	0	0.0%
Hospitalized tachyarrhythmia day 0	0	0.0%
History of serious hypoglycemia (ED and/or IP)	0	0.0%
Medical Product Use		
Alpha-glucosidase inhibitors	0	0.0%
Amylin analogs (pramlintide)	0	0.0%
DPP-4 inhibitors	0	0.0%
Incretin mimetics (albiglutide, dulaglutide, etc.)	0	0.0%
Meglitinides	0	0.0%
Insulin	0	0.0%
Biguanides (metformin, phenformin, etc.)	*****	100.0%
SGLT2 inhibitors	0	0.0%
Sulfonylurea	*****	*****
Thiazolidinedione	0	0.0%
No baseline use of any of the above antidiabetic drugs	0	0.0%
Other antidiabetics	0	0.0%
Sodium channel blockers	0	0.0%
Beta blockers	0	0.0%
Potassium channel blockers/openers	0	0.0%
Non-dihydropyridine calcium channel blockers	0	0.0%
Digoxin	0	0.0%
Other antiarrhythmic agents	0	0.0%

Table 1bt. Aggregated Characteristics of Xultophy, Hospitalized Tachyarrhythmia, Race=Multi-racial in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/Standard Deviation ¹
Antiarrhythmic agents (any of the above antiarrhythmic agents)	0	0.0%
Angiotensin-converting-enzyme (ACE) inhibitor	0	0.0%
Angiotensin ii receptor blockers (ARBs)	*****	*****
Dihydropyridines	0	0.0%
Diuretics	0	0.0%
Other antihypertensives	0	0.0%
Antihypertensives (any of the above antihypertensives)	*****	*****
Oral anticoagulants	0	0.0%
Vitamin K antagonists	0	0.0%
Other cardiac medications not mentioned above	0	0.0%
Other cardiac medications (any of the other cardiac medications)	0	0.0%
Lipid lowering therapy	*****	*****
Baseline known risk of prolonged QT and torsades de pointes	0	0.0%
Baseline possible risk of prolonged QT and torsades de pointes	*****	*****
Concomitant use of medical products with a known risk of prolonged QT and torsades de pointes	0	0.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	17.5	0.0
Mean number of emergency room encounters	0.5	0.0
Mean number of inpatient hospital encounters	0.0	NaN
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	0.0	NaN
Mean number of filled prescriptions	19.5	0.0
Mean number of generics dispensed	8.0	0.0
Mean number of unique drug classes dispensed	7.5	0.0

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

³Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012 Nov;18(11):721-6

⁴Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a number

N/A: Not applicable

Table 2. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same- Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Bydureon, Hospitalized Tachyarrhythmia</i>	1,321	1,321	*****	*****	*****	*****	392.98 (187.35, 823.34)	2,069	2,069	518.3
<i>Mounjaro, Hospitalized Tachyarrhythmia</i>	18,842	18,842	102	0.54 (0.44, 0.65)	2,159.0	788,592	472.43 (389.09, 573.62)	31,173	31,585	5,238.20
<i>Ozempic, Hospitalized Tachyarrhythmia</i>	117,008	117,008	793	0.68 (0.63, 0.72)	16,235.0	5,929,844	488.45 (455.61, 523.66)	174,434	174,950	42,322.8
<i>Rybelsus, Hospitalized Tachyarrhythmia</i>	34,058	34,058	178	0.52 (0.45, 0.60)	4,668.5	1,705,183	381.28 (329.18, 441.61)	49,962	51,042	12,854.5
<i>Saxenda, Hospitalized Tachyarrhythmia</i>	386	386	*****	*****	*****	*****	199.10 (28.04, 1,413.48)	587	587	195.2
<i>Trulicity, Hospitalized Tachyarrhythmia</i>	66,978	66,978	496	0.74 (0.68, 0.81)	9,902.2	3,616,783	500.90 (458.70, 546.98)	117,542	118,288	25,876.5
<i>Victoza, Hospitalized Tachyarrhythmia</i>	5,354	5,354	45	0.84 (0.60, 1.09)	748.6	273,417	601.14 (448.83, 805.14)	7,722	7,723	2,071.3
<i>Wegovy, Hospitalized Tachyarrhythmia</i>	828	828	*****	*****	*****	*****	137.10 (19.31, 973.29)	1,299	1,323	137.3
<i>Xultophy, Hospitalized Tachyarrhythmia</i>	364	364	*****	*****	*****	*****	349.71 (87.46, 1,398.31)	484	484	131.2
<i>Mounjaro, Atrial Fibrillation and Flutter</i>	18,842	18,842	64	0.34 (0.26, 0.42)	2,159.0	788,592	296.43 (232.01, 378.72)	31,173	31,585	5,238.20
<i>Bydureon, Atrial Fibrillation and Flutter</i>	1,321	1,321	*****	*****	*****	*****	280.70 (116.83, 674.41)	2,069	2,069	518.3
<i>Ozempic, Atrial Fibrillation and Flutter</i>	117,008	117,008	506	0.43 (0.39, 0.47)	16,235.0	5,929,844	311.67 (285.66, 340.05)	174,434	174,950	42,322.8

Table 2. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Rybelsus, Atrial Fibrillation and Flutter</i>	34,058	34,058	123	0.36 (0.30, 0.43)	4,668.5	1,705,183	265.61 (222.74, 316.73)	49,962	51,042	12,854.5
<i>Wegovy, Atrial Fibrillation and Flutter</i>	828	828	*****	*****	*****	*****	137.10 (19.31, 973.29)	1,299	1,323	137.3
<i>Saxenda, Atrial Fibrillation and Flutter</i>	386	386	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	587	587	195.2
<i>Victoza, Atrial Fibrillation and Flutter</i>	5,354	5,354	27	0.50 (0.31, 0.69)	748.6	273,417	360.69 (237.35, 525.95)	7,722	7,723	2,071.3
<i>Trulicity, Atrial Fibrillation and Flutter</i>	66,978	66,978	344	0.51 (0.46, 0.57)	9,902.2	3,616,783	347.40 (312.56, 386.12)	117,542	118,288	25,876.5
<i>Xultophy, Atrial Fibrillation and Flutter</i>	364	364	*****	*****	*****	*****	174.85 (23.63, 1,231.34)	484	484	131.2
<i>Mounjaro, Sinus Tachycardia</i>	18,842	18,842	30	0.16 (0.10, 0.22)	2,159.0	788,592	138.95 (97.15, 198.73)	31,173	31,585	5,238.20
<i>Bydureon, Sinus Tachycardia</i>	1,321	1,321	*****	*****	*****	*****	56.14 (7.91, 398.56)	2,069	2,069	518.3
<i>Ozempic, Sinus</i>	117,008	117,008	182	0.16 (0.13, 0.18)	16,235.0	5,929,844	112.10 (96.94, 129.63)	174,434	174,950	42,322.8
<i>Rybelsus, Sinus</i>	34,058	34,058	45	0.13 (0.09, 0.17)	4,668.5	1,705,183	96.39 (71.97, 129.10)	49,962	51,042	12,854.5
<i>Wegovy, Sinus</i>	828	828	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,299	1,323	137.3
<i>Saxenda, Sinus</i>	386	386	*****	*****	*****	*****	199.10 (28.04, 1,413.48)	587	587	195.2
<i>Victoza, Sinus</i>	5,354	5,354	15	0.28 (0.14, 0.42)	748.6	273,417	200.38 (120.80, 332.38)	7,722	7,723	2,071.3
<i>Trulicity, Sinus</i>	66,978	66,978	108	0.16 (0.13, 0.19)	9,902.2	3,616,783	109.07 (90.32, 131.70)	117,542	118,288	25,876.5
<i>Xultophy, Sinus Tachycardia</i>	364	364	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	484	484	131.2

Table 2. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Mounjaro, Supraventricular</i>	18,842	18,842	*****	*****	*****	*****	37.05 (18.53, 74.09)	31,173	31,585	5,238.20
<i>Bydureon, Supraventricular</i>	1,321	1,321	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,069	2,069	518.3
<i>Ozempic, Supraventricular</i>	117,008	117,008	70	0.06 (0.05, 0.07)	16,235.0	5,929,844	43.12 (34.11, 54.50)	174,434	174,950	42,322.8
<i>Rybelsus, Supraventricular</i>	34,058	34,058	16	0.05 (0.02, 0.07)	4,668.5	1,705,183	34.27 (21.00, 55.94)	49,962	51,042	12,854.5
<i>Wegovy, Supraventricular Tachycardia</i>	828	828	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,299	1,323	137.3
<i>Saxenda, Supraventricular</i>	386	386	*****	*****	*****	*****	199.10 (28.04, 1,413.48)	587	587	195.2
<i>Victoza, Supraventricular Tachycardia</i>	5,354	5,354	*****	*****	*****	*****	66.79 (27.80, 160.48)	7,722	7,723	2,071.3
<i>Trulicity, Supraventricular Tachycardia</i>	66,978	66,978	41	0.06 (0.04, 0.08)	9,902.2	3,616,783	41.40 (30.49, 56.23)	117,542	118,288	25,876.5
<i>Xultophy, Supraventricular</i>	364	364	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	484	484	131.2
<i>Mounjaro, Other Tachycardia</i>	18,842	18,842	*****	*****	*****	*****	23.16 (9.64, 55.64)	31,173	31,585	5,238.20
<i>Bydureon, Other Tachycardia</i>	1,321	1,321	*****	*****	*****	*****	112.28 (28.08, 448.96)	2,069	2,069	518.3
<i>Ozempic, Other</i>	117,008	117,008	53	0.05 (0.03, 0.06)	16,235.0	5,929,844	32.65 (23.94, 42.73)	174,434	174,950	42,322.8

Table 2. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Rybelsus, Other Tachycardia</i>	34,058	34,058	*****	*****	*****	*****	10.71 (4.46, 25.73)	49,962	51,042	12,854.5
<i>Wegovy, Other</i>	828	828	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,299	1,323	137.3
<i>Saxenda, Other Tachycardia</i>	386	386	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	587	587	195.2
<i>Victoza, Other</i>	5,354	5,354	*****	*****	*****	*****	40.08 (12.93, 123.26)	7,722	7,723	2,071.3
<i>Trulicity, Other</i>	66,978	66,978	21	0.03 (0.02, 0.04)	9,902.2	3,616,783	21.21 (13.83, 32.53)	117,542	118,288	25,876.5
<i>Xultophy, Other Tachycardia</i>	364	364	*****	*****	*****	*****	174.85 (23.63, 1,231.34)	484	484	131.2
<i>Mounjaro, Cardiac Arrest</i>	18,842	18,842	0	0.00 (0.00, 0.00)	2,159.0	788,592	0.00 (0.00, 0.00)	31,173	31,585	5,238.20
<i>Bydureon, Cardiac Arrest</i>	1,321	1,321	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,069	2,069	518.3
<i>Ozempic, Cardiac Arrest</i>	117,008	117,008	18	0.02 (0.01, 0.02)	16,235.0	5,929,844	11.09 (6.99, 17.60)	174,434	174,950	42,322.8
<i>Rybelsus, Cardiac Arrest</i>	34,058	34,058	*****	*****	*****	*****	4.28 (1.07, 17.13)	49,962	51,042	12,854.5
<i>Wegovy, Cardiac Arrest</i>	828	828	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,299	1,323	137.3
<i>Saxenda, Cardiac Arrest</i>	386	386	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	587	587	195.2
<i>Victoza, Cardiac Arrest</i>	5,354	5,354	*****	*****	*****	*****	40.08 (12.93, 123.26)	7,722	7,723	2,071.3
<i>Trulicity, Cardiac Arrest</i>	66,978	66,978	12	0.02 (0.01, 0.03)	9,902.2	3,616,783	12.12 (6.88, 21.34)	117,542	118,288	25,876.5
<i>Xultophy, Cardiac Arrest</i>	364	364	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	484	484	131.2
<i>Mounjaro, Ventricular Tachycardia</i>	18,842	18,842	0	0.00 (0.00, 0.00)	2,159.0	788,592	0.00 (0.00, 0.00)	31,173	31,585	5,238.20
<i>Bydureon, Ventricular Tachycardia</i>	1,321	1,321	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,069	2,069	518.3
<i>Ozempic, Ventricular Tachycardia</i>	117,008	117,008	*****	*****	*****	*****	4.31 (2.06, 9.04)	174,434	174,950	42,322.8

Table 2. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Rybelsus, Ventricular Tachycardia</i>	34,058	34,058	0	0.00 (0.00, 0.00)	4,668.5	1,705,183	0.00 (0.00, 0.00)	49,962	51,042	12,854.5
<i>Wegovy, Ventricular Tachycardia</i>	828	828	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,299	1,323	137.3
<i>Saxenda, Ventricular Tachycardia</i>	386	386	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	587	587	195.2
<i>Victoza, Ventricular Tachycardia</i>	5,354	5,354	0	0.00 (0.00, 0.00)	748.6	273,417	0.00 (0.00, 0.00)	7,722	7,723	2,071.3
<i>Trulicity, Ventricular Tachycardia</i>	66,978	66,978	*****	*****	*****	*****	3.03 (0.98, 9.39)	117,542	118,288	25,876.5
<i>Xultophy, Ventricular Tachycardia</i>	364	364	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	484	484	131.2
<i>Mounjaro, Ventricular Fibrillation and Flutter</i>	18,842	18,842	*****	*****	*****	*****	4.63 (0.65, 32.88)	31,173	31,585	5,238.20
<i>Bydureon, Ventricular Fibrillation and Flutter</i>	1,321	1,321	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,069	2,069	518.3
<i>Ozempic, Ventricular Fibrillation and Flutter</i>	117,008	117,008	*****	*****	*****	*****	2.46 (0.92, 6.56)	174,434	174,950	42,322.8
<i>Rybelsus, Ventricular Fibrillation and Flutter</i>	34,058	34,058	0	0.00 (0.00, 0.00)	4,668.5	1,705,183	0.00 (0.00, 0.00)	49,962	51,042	12,854.5
<i>Wegovy, Ventricular Fibrillation and Flutter</i>	828	828	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,299	1,323	137.3
<i>Saxenda, Ventricular Fibrillation and Flutter</i>	386	386	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	587	587	195.2

Table 2. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same- Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Victoza, Ventricular Fibrillation and Flutter</i>	5,354	5,354	0	0.00 (0.00, 0.00)	748.6	273,417	0.00 (0.00, 0.00)	7,722	7,723	2,071.3
<i>Trulicity, Ventricular Fibrillation and Flutter</i>	66,978	66,978	*****	*****	*****	*****	5.05 (2.10, 12.13)	117,542	118,288	25,876.5
<i>Xultophy, Ventricular Fibrillation and Flutter</i>	364	364	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	484	484	131.2

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 3. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Sex

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Bydureon, Hospitalized Tachyarrhythmia										
Female	675	675	*****	*****	*****	*****	339.17 (109.39, 1,051.64)	1,071	1,071	266.7
Male	646	646	*****	*****	*****	*****	446.07 (167.41, 1,188.52)	998	998	251.7
Mounjaro, Hospitalized Tachyarrhythmia										
Female	10,809	10,809	*****	*****	*****	*****	381.12 (286.35, 507.25)	17,975	18,222	3,009.5
Male	8,033	8,033	*****	*****	*****	*****	594.06 (456.09, 773.76)	13,198	13,363	2,238.6
Ozempic, Hospitalized Tachyarrhythmia										
Female	65,494	65,494	*****	*****	*****	*****	473.98 (431.23, 520.96)	98,213	98,479	23,828.9
Male	51,514	51,514	*****	*****	*****	*****	506.78 (457.23, 561.69)	76,221	76,471	18,494.0
Rybelsus, Hospitalized Tachyarrhythmia										
Female	17,466	17,466	*****	*****	*****	*****	352.48 (284.25, 437.09)	25,490	25,984	6,620.4
Male	16,592	16,592	*****	*****	*****	*****	410.58 (335.79, 502.03)	23,472	25,058	6,234.1
Saxenda, Hospitalized Tachyarrhythmia										
Female	294	294	*****	*****	*****	*****	265.69 (37.43, 1,886.25)	447	447	145.2
Male	92	92	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	140	140	49.9
Trulicity, Hospitalized Tachyarrhythmia										
Female	34,815	34,815	*****	*****	*****	*****	448.64 (394.13, 510.68)	61,129	61,503	13,487.5
Male	32,163	32,163	*****	*****	*****	*****	556.50 (493.59, 627.42)	56,413	56,785	12,389.0
Victoza, Hospitalized Tachyarrhythmia										
Female	3,117	3,117	*****	*****	*****	*****	556.80 (373.20, 830.72)	4,488	4,489	1,214.8
Male	2,237	2,237	*****	*****	*****	*****	661.33 (431.19, 1,014.31)	3,234	3,234	856.5
Wegovy, Hospitalized Tachyarrhythmia										
Female	570	570	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	885	899	94.4
Male	258	258	*****	*****	*****	*****	417.91 (58.87, 2,966.85)	414	425	42.9
Xultophy, Hospitalized Tachyarrhythmia										
Female	172	172	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	234	234	63.6
Male	192	192	*****	*****	*****	*****	701.19 (175.36, 2,803.74)	250	250	67.6

Table 3. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Sex

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Mounjaro, Atrial Fibrillation and Flutter										
Female	10,809	10,809	*****	*****	*****	*****	202.72 (136.98, 300.02)	17,975	18,222	3,009.5
Male	8,033	8,033	*****	*****	*****	*****	421.23 (307.77, 576.54)	13,198	13,363	2,238.6
Bydureon, Atrial Fibrillation and Flutter										
Female	675	675	*****	*****	*****	*****	339.17 (109.39, 1,051.64)	1,071	1,071	266.7
Male	646	646	*****	*****	*****	*****	223.03 (55.78, 891.81)	998	998	251.7
Ozempic, Atrial Fibrillation and Flutter										
Female	65,494	65,494	*****	*****	*****	*****	282.18 (239.65, 318.96)	98,213	98,479	23,828.9
Male	51,514	51,514	*****	*****	*****	*****	349.02 (308.33, 395.08)	76,221	76,471	18,494.0
Rybelsus, Atrial Fibrillation and Flutter										
Female	17,466	17,466	*****	*****	*****	*****	229.33 (175.64, 299.43)	25,490	25,984	6,620.4
Male	16,592	16,592	*****	*****	*****	*****	302.53 (239.35, 382.39)	23,472	25,058	6,234.1
Wegovy, Atrial Fibrillation and Flutter										
Female	570	570	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	885	899	94.4
Male	258	258	*****	*****	*****	*****	417.91 (58.87, 2,966.85)	414	425	42.9
Saxenda, Atrial Fibrillation and Flutter										
Female	294	294	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	447	447	145.2
Male	92	92	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	140	140	49.9
Victoza, Atrial Fibrillation and Flutter										
Female	3,117	3,117	*****	*****	*****	*****	255.20 (141.33, 460.82)	4,488	4,489	1,214.8
Male	2,237	2,237	*****	*****	*****	*****	503.87 (308.68, 822.48)	3,234	3,234	856.5
Trulicity, Atrial Fibrillation and Flutter										
Female	34,815	34,815	*****	*****	*****	*****	293.87 (250.41, 344.87)	61,129	61,503	13,487.5
Male	32,163	32,163	*****	*****	*****	*****	404.35 (351.27, 465.44)	56,413	56,785	12,389.0
Xultophy, Atrial Fibrillation and Flutter										
Female	172	172	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	234	234	63.6
Male	192	192	*****	*****	*****	*****	350.60 (49.38, 2,488.99)	250	250	67.6

Table 3. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Sex

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Mounjaro, Sinus Tachycardia										
Female	10,809	10,809	*****	*****	*****	*****	129.74 (79.48, 211.78)	17,975	18,222	3,009.5
Male	8,033	8,033	*****	*****	*****	*****	151.21 (89.56, 255.32)	13,198	13,363	2,238.6
Bydureon, Sinus Tachycardia										
Female	675	675	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,071	1,071	266.7
Male	646	646	*****	*****	*****	*****	111.52 (15.71, 791.69)	998	998	251.7
Ozempic, Sinus Tachycardia										
Female	65,494	65,494	*****	*****	*****	*****	130.07 (108.60, 155.79)	98,213	98,479	23,828.9
Male	51,514	51,514	*****	*****	*****	*****	89.35 (69.93, 114.15)	76,221	76,471	18,494.0
Rybelsus, Sinus Tachycardia										
Female	17,466	17,466	*****	*****	*****	*****	97.68 (64.91, 146.99)	25,490	25,984	6,620.4
Male	16,592	16,592	*****	*****	*****	*****	95.08 (62.61, 144.40)	23,472	25,058	6,234.1
Wegovy, Sinus Tachycardia										
Female	570	570	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	885	899	94.4
Male	258	258	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	414	425	42.9
Saxenda, Sinus Tachycardia										
Female	294	294	*****	*****	*****	*****	265.69 (37.43, 1,886.25)	447	447	145.2
Male	92	92	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	140	140	49.9
Victoza, Sinus Tachycardia										
Female	3,117	3,117	*****	*****	*****	*****	208.80 (108.64, 401.30)	4,488	4,489	1,214.8
Male	2,237	2,237	*****	*****	*****	*****	188.95 (84.89, 420.59)	3,234	3,234	856.5
Trulicity, Sinus Tachycardia										
Female	34,815	34,815	*****	*****	*****	*****	109.71 (84.43, 142.56)	61,129	61,503	13,487.5
Male	32,163	32,163	*****	*****	*****	*****	108.38 (82.59, 142.23)	56,413	56,785	12,389.0
Xultophy, Sinus Tachycardia										
Female	172	172	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	234	234	63.6
Male	192	192	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	250	250	67.6

Table 3. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Sex

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Mounjaro, Supraventricular Tachycardia										
Female	10,809	10,809	*****	*****	*****	*****	40.54 (16.88, 97.41)	17,975	18,222	3,009.5
Male	8,033	8,033	*****	*****	*****	*****	32.40 (10.45, 100.47)	13,198	13,363	2,238.6
Bydureon, Supraventricular Tachycardia										
Female	675	675	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,071	1,071	266.7
Male	646	646	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	998	998	251.7
Ozempic, Supraventricular Tachycardia										
Female	65,494	65,494	*****	*****	*****	*****	42.99 (31.41, 58.84)	98,213	98,479	23,828.9
Male	51,514	51,514	*****	*****	*****	*****	43.28 (30.44, 61.54)	76,221	76,471	18,494.0
Rybelsus, Supraventricular Tachycardia										
Female	17,466	17,466	*****	*****	*****	*****	33.97 (16.99, 67.94)	25,490	25,984	6,620.4
Male	16,592	16,592	*****	*****	*****	*****	34.57 (17.29, 69.14)	23,472	25,058	6,234.1
Wegovy, Supraventricular Tachycardia										
Female	570	570	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	885	899	94.4
Male	258	258	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	414	425	42.9
Saxenda, Supraventricular Tachycardia										
Female	294	294	*****	*****	*****	*****	265.69 (37.43, 1,886.25)	447	447	145.2
Male	92	92	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	140	140	49.9
Victoza, Supraventricular Tachycardia										
Female	3,117	3,117	*****	*****	*****	*****	23.20 (3.27, 164.70)	4,488	4,489	1,214.8
Male	2,237	2,237	*****	*****	*****	*****	125.97 (47.28, 335.64)	3,234	3,234	856.5
Trulicity, Supraventricular Tachycardia										
Female	34,815	34,815	*****	*****	*****	*****	35.26 (22.22, 55.97)	61,129	61,503	13,487.5
Male	32,163	32,163	*****	*****	*****	*****	47.94 (31.86, 72.14)	56,413	56,785	12,389.0
Xultophy, Supraventricular Tachycardia										
Female	172	172	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	234	234	63.6
Male	192	192	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	250	250	67.6

Table 3. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Sex

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Mounjaro, Other Tachycardia										
Female	10,809	10,809	*****	*****	*****	*****	16.22 (4.06, 64.85)	17,975	18,222	3,009.5
Male	8,033	8,033	*****	*****	*****	*****	32.40 (10.45, 100.47)	13,198	13,363	2,238.6
Bydureon, Other Tachycardia										
Female	675	675	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,071	1,071	266.7
Male	646	646	*****	*****	*****	*****	223.03 (55.78, 891.81)	998	998	251.7
Ozempic, Other Tachycardia										
Female	65,494	65,494	*****	*****	*****	*****	36.38 (25.86, 51.17)	98,213	98,479	23,828.9
Male	51,514	51,514	*****	*****	*****	*****	27.92 (18.01, 43.28)	76,221	76,471	18,494.0
Rybelsus, Other Tachycardia										
Female	17,466	17,466	*****	*****	*****	*****	4.25 (0.60, 30.15)	25,490	25,984	6,620.4
Male	16,592	16,592	*****	*****	*****	*****	17.29 (6.49, 46.06)	23,472	25,058	6,234.1
Wegovy, Other Tachycardia										
Female	570	570	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	885	899	94.4
Male	258	258	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	414	425	42.9
Saxenda, Other Tachycardia										
Female	294	294	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	447	447	145.2
Male	92	92	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	140	140	49.9
Victoza, Other Tachycardia										
Female	3,117	3,117	*****	*****	*****	*****	23.20 (3.27, 164.70)	4,488	4,489	1,214.8
Male	2,237	2,237	*****	*****	*****	*****	62.98 (15.75, 251.84)	3,234	3,234	856.5
Trulicity, Other Tachycardia										
Female	34,815	34,815	*****	*****	*****	*****	23.51 (13.35, 41.40)	61,129	61,503	13,487.5
Male	32,163	32,163	*****	*****	*****	*****	18.76 (9.76, 36.05)	56,413	56,785	12,389.0
Xultophy, Other Tachycardia										
Female	172	172	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	234	234	63.6
Male	192	192	*****	*****	*****	*****	350.60 (49.38, 2,488.99)	250	250	67.6

Table 3. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Sex

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Mounjaro, Cardiac Arrest										
Female	10,809	10,809	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17,975	18,222	3,009.5
Male	8,033	8,033	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13,198	13,363	2,238.6
Bydureon, Cardiac Arrest										
Female	675	675	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,071	1,071	266.7
Male	646	646	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	998	998	251.7
Ozempic, Cardiac Arrest										
Female	65,494	65,494	*****	*****	*****	*****	11.02 (5.93, 20.49)	98,213	98,479	23,828.9
Male	51,514	51,514	*****	*****	*****	*****	11.17 (5.59, 22.33)	76,221	76,471	18,494.0
Rybelsus, Cardiac Arrest										
Female	17,466	17,466	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25,490	25,984	6,620.4
Male	16,592	16,592	*****	*****	*****	*****	8.64 (2.16, 34.56)	23,472	25,058	6,234.1
Wegovy, Cardiac Arrest										
Female	570	570	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	885	899	94.4
Male	258	258	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	414	425	42.9
Saxenda, Cardiac Arrest										
Female	294	294	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	447	447	145.2
Male	92	92	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	140	140	49.9
Victoza, Cardiac Arrest										
Female	3,117	3,117	*****	*****	*****	*****	69.60 (22.45, 215.80)	4,488	4,489	1,214.8
Male	2,237	2,237	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	3,234	3,234	856.5
Trulicity, Cardiac Arrest										
Female	34,815	34,815	*****	*****	*****	*****	9.80 (4.08, 23.53)	61,129	61,503	13,487.5
Male	32,163	32,163	*****	*****	*****	*****	14.59 (6.96, 30.60)	56,413	56,785	12,389.0
Xultophy, Cardiac Arrest										
Female	172	172	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	234	234	63.6
Male	192	192	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	250	250	67.6

Table 3. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Sex

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Mounjaro, Ventricular Tachycardia										
Female	10,809	10,809	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17,975	18,222	3,009.5
Male	8,033	8,033	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13,198	13,363	2,238.6
Bydureon, Ventricular Tachycardia										
Female	675	675	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,071	1,071	266.7
Male	646	646	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	998	998	251.7
Ozempic, Ventricular Tachycardia										
Female	65,494	65,494	*****	*****	*****	*****	4.41 (1.65, 11.75)	98,213	98,479	23,828.9
Male	51,514	51,514	*****	*****	*****	*****	4.19 (1.35, 12.99)	76,221	76,471	18,494.0
Rybelsus, Ventricular Tachycardia										
Female	17,466	17,466	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25,490	25,984	6,620.4
Male	16,592	16,592	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	23,472	25,058	6,234.1
Wegovy, Ventricular Tachycardia										
Female	570	570	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	885	899	94.4
Male	258	258	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	414	425	42.9
Saxenda, Ventricular Tachycardia										
Female	294	294	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	447	447	145.2
Male	92	92	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	140	140	49.9
Victoza, Ventricular Tachycardia										
Female	3,117	3,117	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,488	4,489	1,214.8
Male	2,237	2,237	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	3,234	3,234	856.5
Trulicity, Ventricular Tachycardia										
Female	34,815	34,815	*****	*****	*****	*****	1.96 (0.28, 13.91)	61,129	61,503	13,487.5
Male	32,163	32,163	*****	*****	*****	*****	4.17 (1.04, 16.67)	56,413	56,785	12,389.0
Xultophy, Ventricular Tachycardia										
Female	172	172	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	234	234	63.6
Male	192	192	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	250	250	67.6

Table 3. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Sex

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Mounjaro, Ventricular Fibrillation and Flutter										
Female	10,809	10,809	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17,975	18,222	3,009.5
Male	8,033	8,033	*****	*****	*****	*****	10.80 (1.52, 76.68)	13,198	13,363	2,238.6
Bydureon, Ventricular Fibrillation and Flutter										
Female	675	675	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,071	1,071	266.7
Male	646	646	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	998	998	251.7
Ozempic, Ventricular Fibrillation and Flutter										
Female	65,494	65,494	*****	*****	*****	*****	2.20 (0.55, 8.81)	98,213	98,479	23,828.9
Male	51,514	51,514	*****	*****	*****	*****	2.79 (0.70, 11.16)	76,221	76,471	18,494.0
Rybelsus, Ventricular Fibrillation and Flutter										
Female	17,466	17,466	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25,490	25,984	6,620.4
Male	16,592	16,592	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	23,472	25,058	6,234.1
Wegovy, Ventricular Fibrillation and Flutter										
Female	570	570	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	885	899	94.4
Male	258	258	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	414	425	42.9
Saxenda, Ventricular Fibrillation and Flutter										
Female	294	294	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	447	447	145.2
Male	92	92	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	140	140	49.9
Victoza, Ventricular Fibrillation and Flutter										
Female	3,117	3,117	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,488	4,489	1,214.8
Male	2,237	2,237	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	3,234	3,234	856.5
Trulicity, Ventricular Fibrillation and Flutter										
Female	34,815	34,815	*****	*****	*****	*****	3.92 (0.98, 15.67)	61,129	61,503	13,487.5
Male	32,163	32,163	*****	*****	*****	*****	6.25 (2.02, 19.39)	56,413	56,785	12,389.0
Xultophy, Ventricular Fibrillation and Flutter										
Female	172	172	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	234	234	63.6
Male	192	192	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	250	250	67.6

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Bydureon, Hospitalized Tachyarrhythmia										
0-40 years	78	78	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	108	36.9
41-64 years	498	498	*****	*****	*****	*****	478.43 (154.30, 1,483.44)	767	767	198.2
65-74 years	535	535	*****	*****	*****	*****	121.44 (17.11, 862.16)	891	891	210.7
75-84 years	195	195	*****	*****	*****	*****	815.93 (204.06, 3,262.52)	282	282	67.7
≥ 85 years	15	15	*****	*****	*****	*****	9,200.25 (1,295.93, 65,315.60)	21	21	4.7
Mounjaro, Hospitalized Tachyarrhythmia										
0-40 years	1,034	1,034	*****	*****	*****	*****	173.79 (43.46, 694.91)	1,749	1,770	282.9
41-64 years	9,239	9,239	*****	*****	*****	*****	359.03 (262.32, 491.40)	15,849	16,034	2,687.4
65-74 years	6,597	6,597	*****	*****	*****	*****	601.68 (449.23, 805.85)	10,587	10,749	1,774.2
75-84 years	1,867	1,867	*****	*****	*****	*****	697.13 (412.87, 1,177.09)	2,852	2,894	483.0
≥ 85 years	95	95	*****	*****	*****	*****	2,225.78 (556.65, 8,899.86)	136	138	20.7
Ozempic, Hospitalized Tachyarrhythmia										
0-40 years	5,493	5,493	*****	*****	*****	*****	260.71 (164.26, 413.81)	8,123	8,149	1,972.9
41-64 years	50,784	50,784	*****	*****	*****	*****	335.37 (294.96, 381.32)	77,302	77,553	18,891.3
65-74 years	44,381	44,381	*****	*****	*****	*****	523.50 (471.09, 583.98)	65,755	65,935	15,718.1
75-84 years	15,103	15,103	*****	*****	*****	*****	891.86 (772.47, 1,029.70)	21,493	21,550	5,301.5
≥ 85 years	1,237	1,237	*****	*****	*****	*****	1,414.29 (939.83, 2,128.29)	1,761	1,763	439.1
Rybelsus, Hospitalized Tachyarrhythmia										
0-40 years	1,132	1,132	*****	*****	*****	*****	284.78 (106.88, 758.80)	1,632	1,665	416.8

Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	12,264	12,264	*****	*****	*****	*****	232.94 (170.20, 318.83)	18,110	18,551	4,911.3
65-74 years	13,680	13,680	*****	*****	*****	*****	314.57 (234.25, 405.15)	19,963	20,392	5,048.6
75-84 years	6,100	6,100	*****	*****	*****	*****	747.25 (582.58, 958.45)	8,935	9,099	2,172.3
≥ 85 years	882	882	*****	*****	*****	*****	1,112.99 (646.26, 1,916.80)	1,322	1,335	305.6
Saxenda, Hospitalized Tachyarrhythmia										
0-40 years	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	107	33.9
41-64 years	292	292	*****	*****	*****	*****	259.32 (36.53, 1,840.99)	442	442	146.5
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	12.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Trulicity, Hospitalized Tachyarrhythmia										
0-40 years	2,425	2,425	*****	*****	*****	*****	299.74 (161.28, 557.09)	4,289	4,319	940.8
41-64 years	23,743	23,743	*****	*****	*****	*****	315.97 (262.76, 379.94)	43,189	43,507	9,622.6
65-74 years	27,390	27,390	*****	*****	*****	*****	497.44 (433.51, 570.80)	47,354	47,631	10,357.6
75-84 years	11,847	11,847	*****	*****	*****	*****	843.38 (716.29, 993.03)	19,976	20,087	4,408.1
≥ 85 years	1,573	1,573	*****	*****	*****	*****	1,274.65 (867.87, 1,872.09)	2,734	2,744	547.5
Victoza, Hospitalized Tachyarrhythmia										
0-40 years	308	308	*****	*****	*****	*****	236.03 (34.65, 1,746.62)	471	471	125.5
41-64 years	2,151	2,151	*****	*****	*****	*****	508.55 (306.59, 843.57)	3,187	3,188	871.2
65-74 years	2,042	2,042	*****	*****	*****	*****	440.23 (255.62, 758.18)	2,892	2,892	767.9

Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	754	754	*****	*****	*****	*****	1,505.64 (922.40, 2,457.68)	1,038	1,038	270.5
≥ 85 years	99	99	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	134	134	36.2
Wegovy, Hospitalized Tachyarrhythmia										
0-40 years	132	132	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	196	203	18.6
41-64 years	621	621	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	973	986	104.4
65-74 years	64	64	*****	*****	*****	*****	1,597.77 (225.06, 11,343.08)	108	112	11.4
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
Xultophy, Hospitalized Tachyarrhythmia										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.7
41-64 years	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	102	102	26.2
65-74 years	183	183	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	238	238	69.8
75-84 years	87	87	*****	*****	*****	*****	1,492.64 (373.30, 5,968.40)	120	120	26.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.2
Mounjaro, Atrial Fibrillation and Flutter										
0-40 years	1,034	1,034	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,749	1,770	282.9
41-64 years	9,239	9,239	*****	*****	*****	*****	211.74 (140.70, 318.63)	15,849	16,034	2,687.4
65-74 years	6,597	6,597	*****	*****	*****	*****	374.38 (258.49, 542.22)	10,587	10,749	1,774.2
75-84 years	1,867	1,867	*****	*****	*****	*****	597.54 (339.34, 1,052.18)	2,852	2,894	483.0
≥ 85 years	95	95	*****	*****	*****	*****	1,112.89 (156.76, 7,900.76)	136	138	20.7

Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Bydureon, Atrial Fibrillation and Flutter										
0-40 years	78	78	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	108	36.9
41-64 years	498	498	*****	*****	*****	*****	478.43 (154.30, 1,483.44)	767	767	198.2
65-74 years	535	535	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	891	891	210.7
75-84 years	195	195	*****	*****	*****	*****	407.96 (57.47, 2,896.27)	282	282	67.7
≥ 85 years	15	15	*****	*****	*****	*****	9,200.25 (1,295.93, 65,315.60)	21	21	4.7
Ozempic, Atrial Fibrillation and Flutter										
0-40 years	5,493	5,493	*****	*****	*****	*****	28.97 (7.23, 115.83)	8,123	8,149	1,972.9
41-64 years	50,784	50,784	*****	*****	*****	*****	165.52 (137.88, 198.72)	77,302	77,553	18,891.3
65-74 years	44,381	44,381	*****	*****	*****	*****	351.23 (308.04, 400.51)	65,755	65,935	15,718.1
75-84 years	15,103	15,103	*****	*****	*****	*****	704.85 (599.64, 828.53)	21,493	21,550	5,301.5
≥ 85 years	1,237	1,237	*****	*****	*****	*****	1,168.33 (745.22, 1,831.67)	1,761	1,763	439.1
Rybelsus, Atrial Fibrillation and Flutter										
0-40 years	1,132	1,132	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,632	1,665	416.8
41-64 years	12,264	12,264	*****	*****	*****	*****	125.43 (81.78, 192.38)	18,110	18,551	4,911.3
65-74 years	13,680	13,680	*****	*****	*****	*****	235.93 (176.15, 315.99)	19,963	20,392	5,048.6
75-84 years	6,100	6,100	*****	*****	*****	*****	566.46 (425.60, 753.93)	8,935	9,099	2,172.3
≥ 85 years	882	882	*****	*****	*****	*****	941.76 (521.54, 1,700.57)	1,322	1,335	305.6
Wegovy, Atrial Fibrillation and Flutter										
0-40 years	132	132	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	196	203	18.6

Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	621	621	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	973	986	104.4
65-74 years	64	64	*****	*****	*****	*****	1,597.77 (225.06, 11,343.08)	108	112	11.4
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
Saxenda, Atrial Fibrillation and Flutter										
0-40 years	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	107	33.9
41-64 years	292	292	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	442	442	146.5
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	12.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Atrial Fibrillation and Flutter										
0-40 years	308	308	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	471	471	125.5
41-64 years	2,151	2,151	*****	*****	*****	*****	169.52 (70.56, 407.28)	3,187	3,188	871.2
65-74 years	2,042	2,042	*****	*****	*****	*****	270.91 (135.48, 541.73)	2,892	2,892	767.9
75-84 years	754	754	*****	*****	*****	*****	1,317.44 (780.25, 2,223.47)	1,038	1,038	270.5
≥ 85 years	99	99	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	134	134	36.2
Trulicity, Atrial Fibrillation and Flutter										
0-40 years	2,425	2,425	*****	*****	*****	*****	89.92 (29.00, 278.82)	4,289	4,319	940.8
41-64 years	23,743	23,743	*****	*****	*****	*****	150.99 (115.64, 197.15)	43,189	43,507	9,622.6
65-74 years	27,390	27,390	*****	*****	*****	*****	365.12 (310.95, 428.71)	47,354	47,631	10,357.6

Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	11,847	11,847	*****	*****	*****	*****	667.68 (555.70, 802.22)	19,976	20,087	4,408.1
≥ 85 years	1,573	1,573	*****	*****	*****	*****	1,176.60 (788.63, 1,755.42)	2,734	2,744	547.5
Xultophy, Atrial Fibrillation and Flutter										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.7
41-64 years	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	102	102	26.2
65-74 years	183	183	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	238	238	69.8
75-84 years	87	87	*****	*****	*****	*****	746.32 (105.13, 5,298.38)	120	120	26.4
≥ 85 years	13	13	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.2
Mounjaro, Sinus Tachycardia										
0-40 years	1,034	1,034	*****	*****	*****	*****	173.79 (43.46, 694.91)	1,749	1,770	282.9
41-64 years	9,239	9,239	*****	*****	*****	*****	138.09 (83.25, 229.06)	15,849	16,034	2,687.4
65-74 years	6,597	6,597	*****	*****	*****	*****	133.71 (71.94, 238.50)	10,587	10,749	1,774.2
75-84 years	1,867	1,867	*****	*****	*****	*****	99.59 (23.91, 398.21)	2,852	2,894	483.0
≥ 85 years	95	95	*****	*****	*****	*****	1,112.89 (156.76, 7,900.76)	136	138	20.7
Bydureon, Sinus Tachycardia										
0-40 years	78	78	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	108	36.9
41-64 years	498	498	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	767	767	198.2
65-74 years	535	535	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	891	891	210.7
75-84 years	195	195	*****	*****	*****	*****	407.96 (57.47, 2,896.27)	282	282	67.7
≥ 85 years	15	15	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	21	21	4.7

Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Ozempic, Sinus Tachycardia										
0-40 years	5,493	5,493	*****	*****	*****	*****	217.26 (130.98, 360.39)	8,123	8,149	1,972.9
41-64 years	50,784	50,784	*****	*****	*****	*****	122.34 (98.91, 151.33)	77,302	77,553	18,891.3
65-74 years	44,381	44,381	*****	*****	*****	*****	97.66 (76.14, 125.26)	65,755	65,935	15,718.1
75-84 years	15,103	15,103	*****	*****	*****	*****	95.90 (61.87, 148.64)	21,493	21,550	5,301.5
≥ 85 years	1,237	1,237	*****	*****	*****	*****	0.00 (0.00, 0.00)	1,761	1,763	439.1
Rybelsus, Sinus Tachycardia										
0-40 years	1,132	1,132	*****	*****	*****	*****	284.78 (106.88, 758.80)	1,632	1,665	416.8
41-64 years	12,264	12,264	*****	*****	*****	*****	101.54 (63.12, 163.34)	18,110	18,551	4,911.3
65-74 years	13,680	13,680	*****	*****	*****	*****	62.91 (35.73, 110.78)	19,963	20,392	5,048.6
75-84 years	6,100	6,100	*****	*****	*****	*****	144.63 (82.13, 254.67)	8,935	9,099	2,172.3
≥ 85 years	882	882	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,322	1,335	305.6
Wegovy, Sinus Tachycardia										
0-40 years	132	132	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	196	203	18.6
41-64 years	621	621	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	973	986	104.4
65-74 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	112	11.4
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
Saxenda, Sinus Tachycardia										
0-40 years	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	107	33.9

Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	292	292	*****	*****	*****	*****	259.32 (36.53, 1,840.99)	442	442	146.5
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	12.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Sinus Tachycardia										
0-40 years	308	308	*****	*****	*****	*****	236.03 (34.65, 1,746.62)	471	471	125.5
41-64 years	2,151	2,151	*****	*****	*****	*****	271.23 (135.64, 542.36)	3,187	3,188	871.2
65-74 years	2,042	2,042	*****	*****	*****	*****	101.59 (32.77, 315.00)	2,892	2,892	767.9
75-84 years	754	754	*****	*****	*****	*****	282.31 (91.05, 875.33)	1,038	1,038	270.5
≥ 85 years	99	99	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	134	134	36.2
Trulicity, Sinus Tachycardia										
0-40 years	2,425	2,425	*****	*****	*****	*****	179.85 (80.80, 400.32)	4,289	4,319	940.8
41-64 years	23,743	23,743	*****	*****	*****	*****	131.42 (98.74, 174.91)	43,189	43,507	9,622.6
65-74 years	27,390	27,390	*****	*****	*****	*****	95.57 (69.82, 130.80)	47,354	47,631	10,357.6
75-84 years	11,847	11,847	*****	*****	*****	*****	93.71 (57.41, 152.96)	19,976	20,087	4,408.1
≥ 85 years	1,573	1,573	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,734	2,744	547.5
Kultophy, Sinus Tachycardia										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.7
41-64 years	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	102	102	26.2
65-74 years	183	183	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	238	238	69.8

Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	87	87	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	120	120	26.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.2
Mounjaro, Supraventricular Tachycardia										
0-40 years	1,034	1,034	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,749	1,770	282.9
41-64 years	9,239	9,239	*****	*****	*****	*****	27.62 (8.91, 85.63)	15,849	16,034	2,687.4
65-74 years	6,597	6,597	*****	*****	*****	*****	66.85 (27.83, 160.62)	10,587	10,749	1,774.2
75-84 years	1,867	1,867	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,852	2,894	483.0
≥ 85 years	95	95	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	136	138	20.7
Bydureon, Supraventricular Tachycardia										
0-40 years	78	78	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	108	36.9
41-64 years	498	498	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	767	767	198.2
65-74 years	535	535	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	891	891	210.7
75-84 years	195	195	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	282	282	67.7
≥ 85 years	15	15	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	21	21	4.7
Ozempic, Supraventricular Tachycardia										
0-40 years	5,493	5,493	*****	*****	*****	*****	14.48 (2.04, 102.83)	8,123	8,149	1,972.9
41-64 years	50,784	50,784	*****	*****	*****	*****	23.03 (14.11, 37.59)	77,302	77,553	18,891.3
65-74 years	44,381	44,381	*****	*****	*****	*****	59.85 (43.55, 82.26)	65,755	65,935	15,718.1
75-84 years	15,103	15,103	*****	*****	*****	*****	67.13 (39.76, 113.35)	21,493	21,550	5,301.5
≥ 85 years	1,237	1,237	*****	*****	*****	*****	61.49 (8.66, 436.54)	1,761	1,763	439.1

Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Rybelsus, Supraventricular Tachycardia										
0-40 years	1,132	1,132	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,632	1,665	416.8
41-64 years	12,264	12,264	*****	*****	*****	*****	23.89 (8.97, 63.66)	18,110	18,551	4,911.3
65-74 years	13,680	13,680	*****	*****	*****	*****	26.21 (10.91, 62.98)	19,963	20,392	5,048.6
75-84 years	6,100	6,100	*****	*****	*****	*****	60.26 (25.08, 144.78)	8,935	9,099	2,172.3
≥ 85 years	882	882	*****	*****	*****	*****	171.23 (42.82, 684.67)	1,322	1,335	305.6
Wegovy, Supraventricular Tachycardia										
0-40 years	132	132	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	196	203	18.6
41-64 years	621	621	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	973	986	104.4
65-74 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	112	11.4
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
Saxenda, Supraventricular Tachycardia										
0-40 years	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	107	33.9
41-64 years	292	292	*****	*****	*****	*****	259.32 (36.53, 1,840.99)	442	442	146.5
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	12.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Supraventricular Tachycardia										
0-40 years	308	308	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	471	471	125.5

Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	2,151	2,151	*****	*****	*****	*****	67.81 (16.96, 271.13)	3,187	3,188	871.2
65-74 years	2,042	2,042	*****	*****	*****	*****	33.86 (4.77, 230.41)	2,892	2,892	767.9
75-84 years	754	754	*****	*****	*****	*****	188.21 (47.07, 752.55)	1,038	1,038	270.5
≥ 85 years	99	99	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	134	134	36.2
Trulicity, Supraventricular Tachycardia										
0-40 years	2,425	2,425	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,289	4,319	940.8
41-64 years	23,743	23,743	*****	*****	*****	*****	30.76 (17.03, 55.54)	43,189	43,507	9,622.6
65-74 years	27,390	27,390	*****	*****	*****	*****	36.76 (22.16, 60.97)	47,354	47,631	10,357.6
75-84 years	11,847	11,847	*****	*****	*****	*****	70.28 (39.91, 123.76)	19,976	20,087	4,408.1
≥ 85 years	1,573	1,573	*****	*****	*****	*****	147.07 (47.43, 456.02)	2,734	2,744	547.5
Xultophy, Supraventricular Tachycardia										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.7
41-64 years	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	102	102	26.2
65-74 years	183	183	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	238	238	69.8
75-84 years	87	87	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	120	120	26.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.2
Mounjaro, Other Tachycardia										
0-40 years	1,034	1,034	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,749	1,770	282.9
41-64 years	9,239	9,239	*****	*****	*****	*****	9.21 (1.30, 65.36)	15,849	16,034	2,687.4
65-74 years	6,597	6,597	*****	*****	*****	*****	53.48 (20.07, 142.50)	10,587	10,749	1,774.2

Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	1,867	1,867	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,852	2,894	483.0
≥ 85 years	95	95	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	136	138	20.7
Bydureon, Other Tachycardia										
0-40 years	78	78	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	108	36.9
41-64 years	498	498	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	767	767	198.2
65-74 years	535	535	*****	*****	*****	*****	121.44 (17.11, 862.16)	891	891	210.7
75-84 years	195	195	*****	*****	*****	*****	407.96 (57.47, 2,896.27)	282	282	67.7
≥ 85 years	15	15	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	21	21	4.7
Ozempic, Other Tachycardia										
0-40 years	5,493	5,493	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	8,123	8,149	1,972.9
41-64 years	50,784	50,784	*****	*****	*****	*****	23.03 (14.11, 37.59)	77,302	77,553	18,891.3
65-74 years	44,381	44,381	*****	*****	*****	*****	37.80 (25.34, 56.40)	65,755	65,935	15,718.1
75-84 years	15,103	15,103	*****	*****	*****	*****	47.95 (25.80, 89.12)	21,493	21,550	5,301.5
≥ 85 years	1,237	1,237	*****	*****	*****	*****	184.47 (59.50, 571.98)	1,761	1,763	439.1
Rybelsus, Other Tachycardia										
0-40 years	1,132	1,132	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,632	1,665	416.8
41-64 years	12,264	12,264	*****	*****	*****	*****	5.97 (0.84, 42.40)	18,110	18,551	4,911.3
65-74 years	13,680	13,680	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	19,963	20,392	5,048.6
75-84 years	6,100	6,100	*****	*****	*****	*****	36.16 (11.66, 112.11)	8,935	9,099	2,172.3
≥ 85 years	882	882	*****	*****	*****	*****	85.61 (12.06, 607.81)	1,322	1,335	305.6

Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Wegovy, Other Tachycardia										
0-40 years	132	132	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	196	203	18.6
41-64 years	621	621	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	973	986	104.4
65-74 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	112	11.4
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
Saxenda, Other Tachycardia										
0-40 years	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	107	33.9
41-64 years	292	292	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	442	442	146.5
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	12.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Other Tachycardia										
0-40 years	308	308	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	471	471	125.5
41-64 years	2,151	2,151	*****	*****	*****	*****	33.90 (4.78, 230.69)	3,187	3,188	871.2
65-74 years	2,042	2,042	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,892	2,892	767.9
75-84 years	754	754	*****	*****	*****	*****	188.21 (47.07, 752.55)	1,038	1,038	270.5
≥ 85 years	99	99	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	134	134	36.2
Trulicity, Other Tachycardia										
0-40 years	2,425	2,425	*****	*****	*****	*****	59.95 (14.99, 239.71)	4,289	4,319	940.8

Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	23,743	23,743	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	43,189	43,507	9,622.6
65-74 years	27,390	27,390	*****	*****	*****	*****	36.76 (22.16, 60.97)	47,354	47,631	10,357.6
75-84 years	11,847	11,847	*****	*****	*****	*****	23.43 (8.79, 62.42)	19,976	20,087	4,408.1
≥ 85 years	1,573	1,573	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,734	2,744	547.5
Xultophy, Other Tachycardia										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.7
41-64 years	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	102	102	26.2
65-74 years	183	183	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	238	238	69.8
75-84 years	87	87	*****	*****	*****	*****	746.32 (105.13, 5,298.38)	120	120	26.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.2
Mounjaro, Cardiac Arrest										
0-40 years	1,034	1,034	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,749	1,770	282.9
41-64 years	9,239	9,239	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	15,849	16,034	2,687.4
65-74 years	6,597	6,597	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	10,587	10,749	1,774.2
75-84 years	1,867	1,867	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,852	2,894	483.0
≥ 85 years	95	95	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	136	138	20.7
Bydureon, Cardiac Arrest										
0-40 years	78	78	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	108	36.9
41-64 years	498	498	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	767	767	198.2
65-74 years	535	535	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	891	891	210.7

Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	195	195	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	282	282	67.7
≥ 85 years	15	15	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	21	21	4.7
Ozempic, Cardiac Arrest										
0-40 years	5,493	5,493	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	8,123	8,149	1,972.9
41-64 years	50,784	50,784	*****	*****	*****	*****	10.08 (4.80, 21.13)	77,302	77,553	18,891.3
65-74 years	44,381	44,381	*****	*****	*****	*****	11.03 (5.26, 23.13)	65,755	65,935	15,718.1
75-84 years	15,103	15,103	*****	*****	*****	*****	14.38 (4.64, 44.60)	21,493	21,550	5,301.5
≥ 85 years	1,237	1,237	*****	*****	*****	*****	61.49 (8.66, 436.54)	1,761	1,763	439.1
Rybelsus, Cardiac Arrest										
0-40 years	1,132	1,132	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,632	1,665	416.8
41-64 years	12,264	12,264	*****	*****	*****	*****	5.97 (0.84, 42.40)	18,110	18,551	4,911.3
65-74 years	13,680	13,680	*****	*****	*****	*****	5.23 (0.74, 37.22)	19,963	20,392	5,048.6
75-84 years	6,100	6,100	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	8,935	9,099	2,172.3
≥ 85 years	882	882	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,322	1,335	305.6
Wegovy, Cardiac Arrest										
0-40 years	132	132	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	196	203	18.6
41-64 years	621	621	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	973	986	104.4
65-74 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	112	11.4
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0

Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Saxenda, Cardiac Arrest										
0-40 years	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	107	33.9
41-64 years	292	292	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	442	442	146.5
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	12.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Cardiac Arrest										
0-40 years	308	308	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	471	471	125.5
41-64 years	2,151	2,151	*****	*****	*****	*****	33.90 (4.78, 230.69)	3,187	3,188	871.2
65-74 years	2,042	2,042	*****	*****	*****	*****	67.73 (16.94, 270.82)	2,892	2,892	767.9
75-84 years	754	754	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,038	1,038	270.5
≥ 85 years	99	99	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	134	134	36.2
Trulicity, Cardiac Arrest										
0-40 years	2,425	2,425	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,289	4,319	940.8
41-64 years	23,743	23,743	*****	*****	*****	*****	5.59 (1.40, 22.36)	43,189	43,507	9,622.6
65-74 years	27,390	27,390	*****	*****	*****	*****	9.80 (3.68, 26.12)	47,354	47,631	10,357.6
75-84 years	11,847	11,847	*****	*****	*****	*****	35.14 (15.79, 78.22)	19,976	20,087	4,408.1
≥ 85 years	1,573	1,573	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,734	2,744	547.5
Xultophy, Cardiac Arrest										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.7

Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	102	102	26.2
65-74 years	183	183	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	238	238	69.8
75-84 years	87	87	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	120	120	26.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.2
Mounjaro, Ventricular Tachycardia										
0-40 years	1,034	1,034	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,749	1,770	282.9
41-64 years	9,239	9,239	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	15,849	16,034	2,687.4
65-74 years	6,597	6,597	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	10,587	10,749	1,774.2
75-84 years	1,867	1,867	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,852	2,894	483.0
≥ 85 years	95	95	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	136	138	20.7
Bydureon, Ventricular Tachycardia										
0-40 years	78	78	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	108	36.9
41-64 years	498	498	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	767	767	198.2
65-74 years	535	535	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	891	891	210.7
75-84 years	195	195	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	282	282	67.7
≥ 85 years	15	15	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	21	21	4.7
Ozempic, Ventricular Tachycardia										
0-40 years	5,493	5,493	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	8,123	8,149	1,972.9
41-64 years	50,784	50,784	*****	*****	*****	*****	1.44 (0.20, 10.22)	77,302	77,553	18,891.3
65-74 years	44,381	44,381	*****	*****	*****	*****	6.30 (2.36, 16.79)	65,755	65,935	15,718.1

Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	15,103	15,103	*****	*****	*****	*****	9.59 (2.40, 38.35)	21,493	21,550	5,301.5
≥ 85 years	1,237	1,237	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,761	1,763	439.1
Rybelsus, Ventricular Tachycardia										
0-40 years	1,132	1,132	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,632	1,665	416.8
41-64 years	12,264	12,264	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18,110	18,551	4,911.3
65-74 years	13,680	13,680	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	19,963	20,392	5,048.6
75-84 years	6,100	6,100	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	8,935	9,099	2,172.3
≥ 85 years	882	882	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,322	1,335	305.6
Wegovy, Ventricular Tachycardia										
0-40 years	132	132	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	196	203	18.6
41-64 years	621	621	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	973	986	104.4
65-74 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	112	11.4
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
Saxenda, Ventricular Tachycardia										
0-40 years	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	107	33.9
41-64 years	292	292	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	442	442	146.5
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	12.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Victoza, Ventricular Tachycardia										
0-40 years	308	308	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	471	471	125.5
41-64 years	2,151	2,151	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	3,187	3,188	871.2
65-74 years	2,042	2,042	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,892	2,892	767.9
75-84 years	754	754	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,038	1,038	270.5
≥ 85 years	99	99	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	134	134	36.2
Trulicity, Ventricular Tachycardia										
0-40 years	2,425	2,425	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,289	4,319	940.8
41-64 years	23,743	23,743	*****	*****	*****	*****	5.59 (1.40, 22.36)	43,189	43,507	9,622.6
65-74 years	27,390	27,390	*****	*****	*****	*****	2.45 (0.35, 17.40)	47,354	47,631	10,357.6
75-84 years	11,847	11,847	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	19,976	20,087	4,408.1
≥ 85 years	1,573	1,573	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,734	2,744	547.5
Xultophy, Ventricular Tachycardia										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.7
41-64 years	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	102	102	26.2
65-74 years	183	183	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	238	238	69.8
75-84 years	87	87	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	120	120	26.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.2
Mounjaro, Ventricular Fibrillation and Flutter										
0-40 years	1,034	1,034	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,749	1,770	282.9

Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	9,239	9,239	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	15,849	16,034	2,687.4
65-74 years	6,597	6,597	*****	*****	*****	*****	13.37 (1.88, 94.92)	10,587	10,749	1,774.2
75-84 years	1,867	1,867	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,852	2,894	483.0
≥ 85 years	95	95	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	136	138	20.7
Bydureon, Ventricular Fibrillation and Flutter										
0-40 years	78	78	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	108	36.9
41-64 years	498	498	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	767	767	198.2
65-74 years	535	535	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	891	891	210.7
75-84 years	195	195	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	282	282	67.7
≥ 85 years	15	15	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	21	21	4.7
Ozempic, Ventricular Fibrillation and Flutter										
0-40 years	5,493	5,493	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	8,123	8,149	1,972.9
41-64 years	50,784	50,784	*****	*****	*****	*****	2.88 (0.72, 11.51)	77,302	77,553	18,891.3
65-74 years	44,381	44,381	*****	*****	*****	*****	3.15 (0.79, 12.60)	65,755	65,935	15,718.1
75-84 years	15,103	15,103	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	21,493	21,550	5,301.5
≥ 85 years	1,237	1,237	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,761	1,763	439.1
Rybelsus, Ventricular Fibrillation and Flutter										
0-40 years	1,132	1,132	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,632	1,665	416.8
41-64 years	12,264	12,264	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18,110	18,551	4,911.3
65-74 years	13,680	13,680	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	19,963	20,392	5,048.6

Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	6,100	6,100	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	8,935	9,099	2,172.3
≥ 85 years	882	882	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,322	1,335	305.6
Wegovy, Ventricular Fibrillation and Flutter										
0-40 years	132	132	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	196	203	18.6
41-64 years	621	621	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	973	986	104.4
65-74 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	112	11.4
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
Saxenda, Ventricular Fibrillation and Flutter										
0-40 years	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	107	33.9
41-64 years	292	292	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	442	442	146.5
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	12.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Ventricular Fibrillation and Flutter										
0-40 years	308	308	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	471	471	125.5
41-64 years	2,151	2,151	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	3,187	3,188	871.2
65-74 years	2,042	2,042	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,892	2,892	767.9
75-84 years	754	754	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,038	1,038	270.5
≥ 85 years	99	99	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	134	134	36.2

Table 4. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Trulicity, Ventricular Fibrillation and Flutter										
0-40 years	2,425	2,425	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,289	4,319	940.8
41-64 years	23,743	23,743	*****	*****	*****	*****	5.59 (1.40, 22.36)	43,189	43,507	9,622.6
65-74 years	27,390	27,390	*****	*****	*****	*****	4.90 (1.23, 19.60)	47,354	47,631	10,357.6
75-84 years	11,847	11,847	*****	*****	*****	*****	5.86 (0.82, 41.58)	19,976	20,087	4,408.1
≥ 85 years	1,573	1,573	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,734	2,744	547.5
Xultophy, Ventricular Fibrillation and Flutter										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.7
41-64 years	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	102	102	26.2
65-74 years	183	183	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	238	238	69.8
75-84 years	87	87	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	120	120	26.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.2

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

*NaN: Not a number

Table 5. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Year

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Bydureon, Hospitalized Tachyarrhythmia										
2022	1,075	1,075	*****	*****	*****	*****	325.46 (135.46, 781.94)	1,732	1,732	473.5
2023	236	236	*****	*****	*****	*****	816.47 (204.19, 3,264.71)	337	337	44.9
Mounjaro, Hospitalized Tachyarrhythmia										
2022	9,509	9,509	*****	*****	*****	*****	417.45 (317.26, 549.29)	16,430	16,616	3,676.3
2023	9,333	9,333	*****	*****	*****	*****	544.09 (413.50, 715.92)	14,743	14,969	1,571.8
Ozempic, Hospitalized Tachyarrhythmia										
2022	79,091	79,091	*****	*****	*****	*****	497.95 (460.11, 538.91)	123,021	123,332	36,506.4
2023	37,917	37,917	*****	*****	*****	*****	458.23 (395.63, 530.75)	50,413	50,618	5,816.4
Rybelsus, Hospitalized Tachyarrhythmia										
2022	25,230	25,230	*****	*****	*****	*****	363.53 (307.29, 430.07)	38,417	39,148	11,337.8
2023	8,818	8,818	*****	*****	*****	*****	452.83 (334.65, 612.75)	11,545	11,894	1,516.7
Saxenda, Hospitalized Tachyarrhythmia										
2022	333	333	*****	*****	*****	*****	220.73 (31.09, 1,567.07)	516	516	187.1
2023	53	53	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	71	71	8.1
Trulicity, Hospitalized Tachyarrhythmia										
2022	52,917	52,917	*****	*****	*****	*****	500.60 (454.78, 551.02)	96,127	96,694	23,372.2
2023	14,061	14,061	*****	*****	*****	*****	502.50 (403.06, 626.48)	21,415	21,594	2,504.3
Victoza, Hospitalized Tachyarrhythmia										
2022	4,105	4,105	*****	*****	*****	*****	560.05 (400.17, 783.81)	6,092	6,093	1,829.6
2023	1,239	1,239	*****	*****	*****	*****	777.46 (430.55, 1,403.88)	1,630	1,630	231.7
Wegovy, Hospitalized Tachyarrhythmia										
2022	72	72	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	110	110	41.1
2023	756	756	*****	*****	*****	*****	152.89 (21.54, 1,085.40)	1,189	1,214	96.2
Xultophy, Hospitalized Tachyarrhythmia										
2022	217	217	*****	*****	*****	*****	265.93 (37.46, 1,887.90)	292	292	101.7
2023	147	147	*****	*****	*****	*****	510.55 (71.92, 3,623.59)	192	192	29.5

Table 5. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Year

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Mounjaro, Atrial Fibrillation and Flutter										
2022	9,509	9,509	*****	*****	*****	*****	270.12 (192.03, 379.95)	16,430	16,616	3,676.3
2023	9,333	9,333	*****	*****	*****	*****	330.72 (232.58, 470.26)	14,743	14,969	1,571.8
Bydureon, Atrial Fibrillation and Flutter										
2022	1,075	1,075	*****	*****	*****	*****	195.28 (62.98, 605.48)	1,732	1,732	473.5
2023	236	236	*****	*****	*****	*****	816.47 (204.19, 3,264.71)	337	337	44.9
Ozempic, Atrial Fibrillation and Flutter										
2022	79,091	79,091	*****	*****	*****	*****	329.54 (299.03, 363.16)	123,021	123,332	36,506.4
2023	37,917	37,917	*****	*****	*****	*****	254.86 (209.29, 310.35)	50,413	50,618	5,816.4
Rybelsus, Atrial Fibrillation and Flutter										
2022	25,230	25,230	*****	*****	*****	*****	259.29 (212.50, 316.38)	38,417	39,148	11,337.8
2023	8,818	8,818	*****	*****	*****	*****	291.11 (199.63, 423.49)	11,545	11,894	1,516.7
Wegovy, Atrial Fibrillation and Flutter										
2022	72	72	0	*****	*****	2,752	0.00 (0.00, 0.00)	110	110	41.1
2023	756	756	*****	*****	*****	*****	152.89 (21.54, 1,085.40)	1,189	1,214	96.2
Saxenda, Atrial Fibrillation and Flutter										
2022	333	333	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	516	516	187.1
2023	53	53	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	71	71	8.1
Victoza, Atrial Fibrillation and Flutter										
2022	4,105	4,105	*****	*****	*****	*****	345.91 (225.54, 530.54)	6,092	6,093	1,829.6
2023	1,239	1,239	*****	*****	*****	*****	423.07 (190.51, 943.94)	1,630	1,630	231.7
Trulicity, Atrial Fibrillation and Flutter										
2022	52,917	52,917	*****	*****	*****	*****	354.14 (315.95, 396.95)	96,127	96,694	23,372.2
2023	14,061	14,061	*****	*****	*****	*****	311.68 (235.56, 412.39)	21,415	21,594	2,504.3
Xultophy, Atrial Fibrillation and Flutter										
2022	217	217	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	292	292	101.7
2023	147	147	*****	*****	*****	*****	510.55 (71.92, 3,623.59)	192	192	29.5

Table 5. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Year

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Mounjaro, Sinus Tachycardia										
2022	9,509	9,509	*****	*****	*****	*****	114.59 (67.87, 193.49)	16,430	16,616	3,676.3
2023	9,333	9,333	*****	*****	*****	*****	170.69 (104.57, 278.63)	14,743	14,969	1,571.8
Bydureon, Sinus Tachycardia										
2022	1,075	1,075	*****	*****	*****	*****	65.09 (9.17, 462.11)	1,732	1,732	473.5
2023	236	236	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	337	337	44.9
Ozempic, Sinus Tachycardia										
2022	79,091	79,091	*****	*****	*****	*****	107.69 (90.86, 127.64)	123,021	123,332	36,506.4
2023	37,917	37,917	*****	*****	*****	*****	126.14 (95.34, 166.90)	50,413	50,618	5,816.4
Rybelsus, Sinus Tachycardia										
2022	25,230	25,230	*****	*****	*****	*****	90.88 (64.94, 127.19)	38,417	39,148	11,337.8
2023	8,818	8,818	*****	*****	*****	*****	118.60 (65.68, 214.16)	11,545	11,894	1,516.7
Wegovy, Sinus Tachycardia										
2022	72	72	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	110	110	41.1
2023	756	756	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,189	1,214	96.2
Saxenda, Sinus Tachycardia										
2022	333	333	*****	*****	*****	*****	220.73 (31.09, 1,567.07)	516	516	187.1
2023	53	53	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	71	71	8.1
Victoza, Sinus Tachycardia										
2022	4,105	4,105	*****	*****	*****	*****	164.72 (88.63, 306.14)	6,092	6,093	1,829.6
2023	1,239	1,239	*****	*****	*****	*****	353.39 (147.09, 849.04)	1,630	1,630	231.7
Trulicity, Sinus Tachycardia										
2022	52,917	52,917	*****	*****	*****	*****	103.23 (83.57, 127.54)	96,127	96,694	23,372.2
2023	14,061	14,061	*****	*****	*****	*****	139.94 (92.14, 212.53)	21,415	21,594	2,504.3
Kulthophy, Sinus Tachycardia										
2022	217	217	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	292	292	101.7
2023	147	147	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	192	192	29.5

Table 5. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Year

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Mounjaro, Supraventricular Tachycardia										
2022	9,509	9,509	*****	*****	*****	*****	23.56 (7.92, 76.14)	16,430	16,616	3,676.3
2023	9,333	9,333	*****	*****	*****	*****	53.34 (22.20, 128.16)	14,743	14,969	1,571.8
Bydureon, Supraventricular Tachycardia										
2022	1,075	1,075	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,732	1,732	473.5
2023	236	236	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	337	337	44.9
Ozempic, Supraventricular Tachycardia										
2022	79,091	79,091	*****	*****	*****	*****	39.67 (29.99, 52.49)	123,021	123,332	36,506.4
2023	37,917	37,917	*****	*****	*****	*****	54.06 (35.25, 82.92)	50,413	50,618	5,816.4
Rybelsus, Supraventricular Tachycardia										
2022	25,230	25,230	*****	*****	*****	*****	29.40 (16.28, 53.09)	38,417	39,148	11,337.8
2023	8,818	8,818	*****	*****	*****	*****	53.91 (22.44, 129.52)	11,545	11,894	1,516.7
Wegovy, Supraventricular Tachycardia										
2022	72	72	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	110	110	41.1
2023	756	756	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,189	1,214	96.2
Saxenda, Supraventricular Tachycardia										
2022	333	333	*****	*****	*****	*****	220.73 (31.09, 1,567.07)	516	516	187.1
2023	53	53	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	71	71	8.1
Victoza, Supraventricular Tachycardia										
2022	4,105	4,105	*****	*****	*****	*****	82.36 (34.28, 197.88)	6,092	6,093	1,829.6
2023	1,239	1,239	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,630	1,630	231.7
Trulicity, Supraventricular Tachycardia										
2022	52,917	52,917	*****	*****	*****	*****	42.02 (30.17, 58.52)	96,127	96,694	23,372.2
2023	14,061	14,061	*****	*****	*****	*****	38.16 (17.15, 84.95)	21,415	21,594	2,504.3
Xultophy, Supraventricular Tachycardia										
2022	217	217	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	292	292	101.7
2023	147	147	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	192	192	29.5

Table 5. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Year

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Mounjaro, Other Tachycardia										
2022	9,509	9,509	*****	*****	*****	*****	8.19 (1.15, 58.11)	16,430	16,616	3,676.3
2023	9,333	9,333	*****	*****	*****	*****	42.67 (16.02, 113.70)	14,743	14,969	1,571.8
Bydureon, Other Tachycardia										
2022	1,075	1,075	*****	*****	*****	*****	130.18 (32.56, 520.54)	1,732	1,732	473.5
2023	236	236	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	337	337	44.9
Ozempic, Other Tachycardia										
2022	79,091	79,091	*****	*****	*****	*****	29.15 (21.03, 40.41)	123,021	123,332	36,506.4
2023	37,917	37,917	*****	*****	*****	*****	43.76 (27.21, 70.40)	50,413	50,618	5,816.4
Rybelsus, Other Tachycardia										
2022	25,230	25,230	*****	*****	*****	*****	2.67 (0.38, 18.98)	38,417	39,148	11,337.8
2023	8,818	8,818	*****	*****	*****	*****	43.13 (16.19, 114.91)	11,545	11,894	1,516.7
Wegovy, Other Tachycardia										
2022	72	72	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	110	110	41.1
2023	756	756	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,189	1,214	96.2
Saxenda, Other Tachycardia										
2022	333	333	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	516	516	187.1
2023	53	53	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	71	71	8.1
Victoza, Other Tachycardia										
2022	4,105	4,105	*****	*****	*****	*****	32.94 (8.23, 131.73)	6,092	6,093	1,829.6
2023	1,239	1,239	*****	*****	*****	*****	70.68 (9.96, 501.77)	1,630	1,630	231.7
Trulicity, Other Tachycardia										
2022	52,917	52,917	*****	*****	*****	*****	19.21 (11.77, 31.35)	96,127	96,694	23,372.2
2023	14,061	14,061	*****	*****	*****	*****	31.80 (13.23, 76.41)	21,415	21,594	2,504.3
Xultophy, Other Tachycardia										
2022	217	217	*****	*****	*****	*****	265.93 (37.46, 1,887.90)	292	292	101.7
2023	147	147	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	192	192	29.5

Table 5. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Year

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Mounjaro, Cardiac Arrest										
2022	9,509	9,509	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16,430	16,616	3,676.3
2023	9,333	9,333	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14,743	14,969	1,571.8
Bydureon, Cardiac Arrest										
2022	1,075	1,075	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,732	1,732	473.5
2023	236	236	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	337	337	44.9
Ozempic, Cardiac Arrest										
2022	79,091	79,091	*****	*****	*****	*****	12.95 (7.94, 21.15)	123,021	123,332	36,506.4
2023	37,917	37,917	*****	*****	*****	*****	5.15 (1.29, 20.59)	50,413	50,618	5,816.4
Rybelsus, Cardiac Arrest										
2022	25,230	25,230	*****	*****	*****	*****	5.35 (1.34, 21.38)	38,417	39,148	11,337.8
2023	8,818	8,818	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	11,545	11,894	1,516.7
Wegovy, Cardiac Arrest										
2022	72	72	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	110	110	41.1
2023	756	756	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,189	1,214	96.2
Saxenda, Cardiac Arrest										
2022	333	333	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	516	516	187.1
2023	53	53	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	71	71	8.1
Victoza, Cardiac Arrest										
2022	4,105	4,105	*****	*****	*****	*****	49.42 (15.94, 153.22)	6,092	6,093	1,829.6
2023	1,239	1,239	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,630	1,630	231.7
Trulicity, Cardiac Arrest										
2022	52,917	52,917	*****	*****	*****	*****	13.21 (7.31, 23.84)	96,127	96,694	23,372.2
2023	14,061	14,061	*****	*****	*****	*****	6.36 (0.90, 45.16)	21,415	21,594	2,504.3
Kultophy, Cardiac Arrest										
2022	217	217	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	292	292	101.7
2023	147	147	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	192	192	29.5

Table 5. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Year

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Mounjaro, Ventricular Tachycardia										
2022	9,509	9,509	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16,430	16,616	3,676.3
2023	9,333	9,333	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14,743	14,969	1,571.8
Bydureon, Ventricular Tachycardia										
2022	1,075	1,075	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,732	1,732	473.5
2023	236	236	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	337	337	44.9
Ozempic, Ventricular Tachycardia										
2022	79,091	79,091	*****	*****	*****	*****	5.67 (2.70, 11.89)	123,021	123,332	36,506.4
2023	37,917	37,917	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	50,413	50,618	5,816.4
Rybelsus, Ventricular Tachycardia										
2022	25,230	25,230	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38,417	39,148	11,337.8
2023	8,818	8,818	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	11,545	11,894	1,516.7
Wegovy, Ventricular Tachycardia										
2022	72	72	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	110	110	41.1
2023	756	756	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,189	1,214	96.2
Saxenda, Ventricular Tachycardia										
2022	333	333	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	516	516	187.1
2023	53	53	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	71	71	8.1
Victoza, Ventricular Tachycardia										
2022	4,105	4,105	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	6,092	6,093	1,829.6
2023	1,239	1,239	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,630	1,630	231.7
Trulicity, Ventricular Tachycardia										
2022	52,917	52,917	*****	*****	*****	*****	3.60 (1.16, 11.17)	96,127	96,694	23,372.2
2023	14,061	14,061	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	21,415	21,594	2,504.3
Xultophy, Ventricular Tachycardia										
2022	217	217	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	292	292	101.7
2023	147	147	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	192	192	29.5

Table 5. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Year

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Mounjaro, Ventricular Fibrillation and Flutter										
2022	9,509	9,509	*****	*****	*****	*****	8.19 (1.15, 58.11)	16,430	16,616	3,676.3
2023	9,333	9,333	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14,743	14,969	1,571.8
Bydureon, Ventricular Fibrillation and Flutter										
2022	1,075	1,075	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,732	1,732	473.5
2023	236	236	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	337	337	44.9
Ozempic, Ventricular Fibrillation and Flutter										
2022	79,091	79,091	*****	*****	*****	*****	2.43 (0.78, 7.53)	123,021	123,332	36,506.4
2023	37,917	37,917	*****	*****	*****	*****	2.57 (0.36, 18.28)	50,413	50,618	5,816.4
Rybelsus, Ventricular Fibrillation and Flutter										
2022	25,230	25,230	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38,417	39,148	11,337.8
2023	8,818	8,818	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	11,545	11,894	1,516.7
Wegovy, Ventricular Fibrillation and Flutter										
2022	72	72	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	110	110	41.1
2023	756	756	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,189	1,214	96.2
Saxenda, Ventricular Fibrillation and Flutter										
2022	333	333	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	516	516	187.1
2023	53	53	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	71	71	8.1
Victoza, Ventricular Fibrillation and Flutter										
2022	4,105	4,105	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	6,092	6,093	1,829.6
2023	1,239	1,239	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,630	1,630	231.7
Trulicity, Ventricular Fibrillation and Flutter										
2022	52,917	52,917	*****	*****	*****	*****	4.80 (1.80, 12.79)	96,127	96,694	23,372.2
2023	14,061	14,061	*****	*****	*****	*****	6.36 (0.90, 45.16)	21,415	21,594	2,504.3
Xultophy, Ventricular Fibrillation and Flutter										
2022	217	217	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	292	292	101.7
2023	147	147	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	192	192	29.5

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Bydureon, Hospitalized Tachyarrhythmia										
American Indian or Alaska Native	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.7
Asian	44	44	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	75	75	18.7
Black or African American	165	165	****	****	****	****	450.48 (63.45, 3,198.11)	255	255	73.0
Multi-racial	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	15.8
Native Hawaiian or Other Pacific Islander	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
Unknown	234	5,354	****	****	****	****	295.44 (41.61, 2,097.41)	346	346	89.3
White	833	833	****	****	****	****	444.90 (185.17, 1,068.89)	1,336	1,336	318.3
Mounjaro, Hospitalized Tachyarrhythmia										
American Indian or Alaska Native	32	32	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	56	56	8.9
Asian	108	108	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	162	163	28.1
Black or African American	1,640	1,640	****	****	****	****	452.36 (226.22, 904.55)	2,494	2,537	467.1
Multi-racial	60	60	****	****	****	****	1,360.34 (191.61, 9,657.46)	112	113	23.5
Native Hawaiian or Other Pacific Islander	57	57	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	86	87	17.3
Unknown	8,006	8,006	****	****	****	****	237.60 (156.45, 360.85)	13,643	13,787	2,230.00
White	8,939	8,939	****	****	****	****	692.12 (548.48, 873.38)	14,620	14,842	2,463.4
Ozempic, Hospitalized Tachyarrhythmia										
American Indian or Alaska Native	826	826	****	****	****	****	1,173.23 (666.29, 2,065.92)	1,270	1,275	282.9
Asian	1,393	1,393	****	****	****	****	441.73 (229.83, 848.97)	2,121	2,125	488.2
Black or African American	9,832	9,832	****	****	****	****	526.22 (417.01, 664.03)	14,096	14,145	3,611.6
Multi-racial	816	816	****	****	****	****	379.89 (142.58, 1,012.21)	1,239	1,254	316.0
Native Hawaiian or Other Pacific Islander	333	333	****	****	****	****	400.08 (100.06, 1,599.72)	452	452	138.0

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Unknown	45,367	45,367	*****	*****	*****	*****	236.92 (201.45, 278.65)	68,462	68,668	16,633.7
White	58,441	58,441	*****	*****	*****	*****	664.48 (611.15, 722.45)	86,784	87,031	20,852.5
Rybelsus, Hospitalized Tachyarrhythmia										
American Indian or Alaska Native	68	68	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	110	27.8
Asian	1,087	1,087	*****	*****	*****	*****	120.51 (30.14, 481.87)	1,655	1,684	387.9
Black or African American	3,392	3,392	*****	*****	*****	*****	400.12 (252.09, 635.07)	4,686	4,789	1,311.4
Multi-racial	181	181	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	274	281	78.9
Native Hawaiian or Other Pacific Islander	128	128	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	170	178	61.8
Unknown	12,788	12,788	*****	*****	*****	*****	207.77 (149.87, 288.04)	18,631	19,067	5,022.6
White	16,414	16,414	*****	*****	*****	*****	538.58 (451.01, 643.16)	23,439	23,933	5,964.1
Saxenda, Hospitalized Tachyarrhythmia										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.0
Multi-racial	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
Native Hawaiian or Other Pacific Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	342	342	*****	*****	*****	*****	222.89 (31.40, 1,582.37)	526	526	171.9
White	31	31	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45	45	16.6
Trulicity, Hospitalized Tachyarrhythmia										
American Indian or Alaska Native	258	258	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	479	482	91.9
Asian	1,202	1,202	*****	*****	*****	*****	213.52 (80.14, 568.93)	2,047	2,055	439.7
Black or African American	6,428	6,428	*****	*****	*****	*****	491.73 (365.93, 660.77)	10,496	10,571	2,588.8
Multi-racial	293	293	*****	*****	*****	*****	402.77 (100.73, 1,610.48)	600	605	131.5
Native Hawaiian or Other Pacific Islander	238	238	*****	*****	*****	*****	518.45 (129.66, 2,073.05)	400	406	121.2

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Unknown	21,774	21,774	*****	*****	*****	*****	322.82 (267.10, 390.16)	39,329	39,602	8,747.9
White	36,775	36,775	*****	*****	*****	*****	626.10 (562.70, 696.65)	64,191	64,567	13,755.5
Victoza, Hospitalized Tachyarrhythmia										
American Indian or Alaska Native	59	59	*****	*****	*****	*****	1,592.89 (223.37, 11,308.46)	82	82	22.6
Asian	92	92	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	120	120	35.9
Black or African American	556	556	*****	*****	*****	*****	549.31 (206.16, 1,463.61)	749	749	227.0
Multi-racial	67	67	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	103	103	27.9
Native Hawaiian or Other Pacific Islander	14	14	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18	18	7.1
Unknown	1,435	1,435	*****	*****	*****	*****	511.14 (275.02, 949.99)	2,076	2,077	576.9
White	3,131	3,131	*****	*****	*****	*****	665.13 (465.04, 951.29)	4,574	4,574	1,173.9
Wegovy, Hospitalized Tachyarrhythmia										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	37	37	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	55	57	7.0
Multi-racial	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	28	28	3.6
Native Hawaiian or Other Pacific Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	663	663	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,023	1,044	104.6
White	110	110	*****	*****	*****	*****	859.21 (121.03, 6,099.81)	192	195	22.2
Xultophy, Hospitalized Tachyarrhythmia										
American Indian or Alaska Native	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
Asian	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.3
Black or African American	40	40	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	53	53	15.5
Multi-racial	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Native Hawaiian or Other Pacific Islander	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.9
Unknown	63	63	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	84	84	23
White	237	237	****	****	****	****	521.52 (130.43, 2,085.34)	328	328	86.6
Mounjaro, Atrial Fibrillation and Flutter										
American Indian or Alaska Native	32	32	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	56	56	8.9
Asian	108	108	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	162	163	28.1
Black or African American	1,640	1,640	****	****	****	****	339.27 (152.42, 755.18)	2,494	2,537	467.1
Multi-racial	60	60	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	112	113	23.5
Native Hawaiian or Other Pacific Islander	57	57	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	86	87	17.3
Unknown	8,006	8,006	****	****	****	****	129.60 (73.60, 228.21)	13,643	13,787	2,230.00
White	8,939	8,939	****	****	****	****	448.42 (335.87, 598.67)	14,620	14,842	2,463.4
Bydureon, Atrial Fibrillation and Flutter										
American Indian or Alaska Native	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	2.7
Asian	44	44	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	75	75	18.7
Black or African American	165	165	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	255	255	73.0
Multi-racial	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	15.8
Native Hawaiian or Other Pacific Islander	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.5
Unknown	234	234	****	****	****	****	295.44 (41.61, 2,097.41)	346	346	89.3
White	833	833	****	****	****	****	355.92 (133.58, 948.32)	1,336	1,336	318.3
Ozempic, Atrial Fibrillation and Flutter										
American Indian or Alaska Native	826	826	****	****	****	****	879.93 (457.84, 1,691.17)	1,270	1,275	282.9
Asian	1,393	1,393	****	****	****	****	147.23 (47.49, 456.55)	2,121	2,125	488.2
Black or African American	9,832	9,832	****	****	****	****	266.82 (192.46, 369.90)	14,096	14,145	3,611.6
Multi-racial	816	816	****	****	****	****	189.95 (47.50, 759.51)	1,239	1,254	316.0

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Native Hawaiian or Other Pacific Islander	333	333	*****	*****	*****	*****	400.08 (100.06, 1,599.72)	452	452	138.0
Unknown	45,367	45,367	*****	*****	*****	*****	136.31 (110.07, 168.81)	68,462	68,668	16,633.7
White	58,441	58,441	*****	*****	*****	*****	447.83 (404.44, 495.86)	86,784	87,031	20,852.5
Rybelsus, Atrial Fibrillation and Flutter										
American Indian or Alaska Native	68	68	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	110	27.8
Asian	1,087	1,087	*****	*****	*****	*****	60.26 (8.49, 427.78)	1,655	1,684	387.9
Black or African American	3,392	3,392	*****	*****	*****	*****	234.52 (135.41, 441.53)	4,686	4,789	1,311.4
Multi-racial	181	181	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	274	281	78.9
Native Hawaiian or Other Pacific Islander	128	128	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	170	178	61.8
Unknown	12,788	12,788	*****	*****	*****	*****	109.66 (69.94, 171.91)	18,631	19,067	5,022.6
White	16,414	16,414	*****	*****	*****	*****	410.56 (335.05, 503.08)	23,439	23,933	5,964.1
Wegovy, Atrial Fibrillation and Flutter										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	37	37	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	55	57	7.0
Multi-racial	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	28	28	3.6
Native Hawaiian or Other Pacific Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	663	663	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,023	1,044	104.6
White	110	110	*****	*****	*****	*****	859.21 (121.03, 6,099.81)	192	195	22.2
Saxenda, Atrial Fibrillation and Flutter										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.0
Multi-racial	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Native Hawaiian or Other Pacific Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	342	342	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	526	526	171.9
White	31	31	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45	45	16.6
Victoza, Atrial Fibrillation and Flutter										
American Indian or Alaska Native	59	59	*****	*****	*****	*****	1,592.89 (223.37, 11,308.46)	82	82	22.6
Asian	92	92	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	120	120	35.9
Black or African American	556	556	*****	*****	*****	*****	274.66 (68.69, 1,098.22)	749	749	227.0
Multi-racial	67	67	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	103	103	27.9
Native Hawaiian or Other Pacific Islander	14	14	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18	18	7.1
Unknown	1,435	1,435	*****	*****	*****	*****	204.46 (76.73, 544.76)	2,076	2,077	576.9
White	3,131	3,131	*****	*****	*****	*****	443.42 (286.07, 687.31)	4,574	4,574	1,173.9
Trulicity, Atrial Fibrillation and Flutter										
American Indian or Alaska Native	258	258	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	479	482	91.9
Asian	1,202	1,202	*****	*****	*****	*****	160.14 (51.65, 496.55)	2,047	2,055	439.7
Black or African American	6,428	6,428	*****	*****	*****	*****	234.69 (153.02, 359.95)	10,496	10,571	2,588.8
Multi-racial	293	293	*****	*****	*****	*****	201.38 (28.37, 1,429.69)	600	605	131.5
Native Hawaiian or Other Pacific Islander	238	238	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	400	406	121.2
Unknown	21,774	21,774	*****	*****	*****	*****	190.07 (148.48, 233.31)	39,329	39,602	8,747.9
White	36,775	36,775	*****	*****	*****	*****	475.62 (420.78, 537.60)	64,191	64,567	13,755.5
Xultophy, Atrial Fibrillation and Flutter										
American Indian or Alaska Native	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
Asian	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.3
Black or African American	40	40	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	53	53	15.5

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Multi-racial	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
Native Hawaiian or Other Pacific Islander	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
Unknown	63	63	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	84	23
White	237	237	*****	*****	*****	*****	260.76 (36.73, 1,851.23)	328	328	86.6
Mounjaro, Sinus Tachycardia										
American Indian or Alaska Native	32	32	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	8.9
Asian	108	108	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	162	163	28.1
Black or African American	1,640	1,640	*****	*****	*****	*****	113.09 (28.28, 452.19)	2,494	2,537	467.1
Multi-racial	60	60	*****	*****	*****	*****	1,360.34 (191.61, 9,657.46)	112	113	23.5
Native Hawaiian or Other Pacific Islander	57	57	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	86	87	17.3
Unknown	8,006	8,006	*****	*****	*****	*****	86.40 (43.21, 172.77)	13,643	13,787	2,230.00
White	8,939	8,939	*****	*****	*****	*****	185.22 (118.14, 290.37)	14,620	14,842	2,463.4
Bydureon, Sinus Tachycardia										
American Indian or Alaska Native	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.7
Asian	44	44	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	75	75	18.7
Black or African American	165	165	*****	*****	*****	*****	450.48 (63.45, 3,198.11)	255	255	73.0
Multi-racial	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	15.8
Native Hawaiian or Other Pacific Islander	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
Unknown	234	234	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	346	346	89.3
White	833	833	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,336	1,336	318.3
Ozempic, Sinus Tachycardia										
American Indian or Alaska Native	826	826	*****	*****	*****	*****	195.54 (48.90, 781.88)	1,270	1,275	282.9
Asian	1,393	1,393	*****	*****	*****	*****	98.16 (23.55, 392.50)	2,121	2,125	488.2
Black or African American	9,832	9,832	*****	*****	*****	*****	177.88 (119.23, 265.39)	14,096	14,145	3,611.6

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Multi-racial	816	816	*****	*****	*****	*****	94.97 (13.38, 674.25)	1,239	1,254	316.0
Native Hawaiian or Other Pacific Islander	333	333	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	452	452	138.0
Unknown	45,367	45,367	*****	*****	*****	*****	64.91 (47.61, 88.49)	68,462	68,668	16,633.7
White	58,441	58,441	*****	*****	*****	*****	136.77 (113.74, 164.46)	86,784	87,031	20,852.5
Rybelsus, Sinus Tachycardia										
American Indian or Alaska Native	68	68	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	110	27.8
Asian	1,087	1,087	*****	*****	*****	*****	60.26 (8.49, 427.78)	1,655	1,684	387.9
Black or African American	3,392	3,392	*****	*****	*****	*****	133.37 (59.92, 296.88)	4,686	4,789	1,311.4
Multi-racial	181	181	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	274	281	78.9
Native Hawaiian or Other Pacific Islander	128	128	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	170	178	61.8
Unknown	12,788	12,788	*****	*****	*****	*****	80.80 (47.85, 136.43)	18,631	19,067	5,022.6
White	16,414	16,414	*****	*****	*****	*****	105.95 (71.01, 158.07)	23,439	23,933	5,964.1
Wegovy, Sinus Tachycardia										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	37	37	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	55	57	7.0
Multi-racial	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	28	28	3.6
Native Hawaiian or Other Pacific Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	663	663	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,023	1,044	104.6
White	110	110	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	192	195	22.2
Saxenda, Sinus Tachycardia										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.0

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Multi-racial	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.7
Native Hawaiian or Other Pacific Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	342	342	****	****	****	****	222.89 (31.40, 1,582.37)	526	526	171.9
White	31	31	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	45	45	16.6
Victoza, Sinus Tachycardia										
American Indian or Alaska Native	59	59	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	82	82	22.6
Asian	92	92	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	120	120	35.9
Black or African American	556	556	****	****	****	****	274.66 (68.69, 1,098.22)	749	749	227.0
Multi-racial	67	67	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	103	103	27.9
Native Hawaiian or Other Pacific Islander	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	18	18	7.1
Unknown	1,435	1,435	****	****	****	****	357.80 (170.57, 750.53)	2,076	2,077	576.9
White	3,131	3,131	****	****	****	****	133.03 (59.76, 296.10)	4,574	4,574	1,173.9
Trulicity, Sinus Tachycardia										
American Indian or Alaska Native	258	258	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	479	482	91.9
Asian	1,202	1,202	****	****	****	****	53.38 (7.52, 378.97)	2,047	2,055	439.7
Black or African American	6,428	6,428	****	****	****	****	201.16 (126.74, 319.28)	10,496	10,571	2,588.8
Multi-racial	293	293	****	****	****	****	201.38 (28.37, 1,429.69)	600	605	131.5
Native Hawaiian or Other Pacific Islander	238	238	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	400	406	121.2
Unknown	21,774	21,774	****	****	****	****	102.58 (73.29, 143.56)	39,329	39,602	8,747.9
White	36,775	36,775	****	****	****	****	100.33 (76.84, 130.99)	64,191	64,567	13,755.5
Xultophy, Sinus Tachycardia										
American Indian or Alaska Native	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Asian	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.3
Black or African American	40	40	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	53	53	15.5

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Multi-racial	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
Native Hawaiian or Other Pacific Islander	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
Unknown	63	63	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	84	23
White	237	237	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	328	328	86.6
Mounjaro, Supraventricular Tachycardia										
American Indian or Alaska Native	32	32	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	8.9
Asian	108	108	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	162	163	28.1
Black or African American	1,640	1,640	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,494	2,537	467.1
Multi-racial	60	60	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	112	113	23.5
Native Hawaiian or Other Pacific Islander	57	57	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	86	87	17.3
Unknown	8,006	8,006	*****	*****	*****	*****	21.60 (5.40, 86.37)	13,643	13,787	2,230.00
White	8,939	8,939	*****	*****	*****	*****	58.49 (26.28, 130.19)	14,620	14,842	2,463.4
Bydureon, Supraventricular Tachycardia										
American Indian or Alaska Native	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.7
Asian	44	44	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	75	75	18.7
Black or African American	165	165	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	255	255	73.0
Multi-racial	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	15.8
Native Hawaiian or Other Pacific Islander	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
Unknown	234	234	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	346	346	89.3
White	833	833	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,336	1,336	318.3
Ozempic, Supraventricular Tachycardia										
American Indian or Alaska Native	826	826	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,270	1,275	282.9
Asian	1,393	1,393	*****	*****	*****	*****	49.08 (6.91, 348.44)	2,121	2,125	488.2
Black or African American	9,832	9,832	*****	*****	*****	*****	51.88 (23.73, 108.83)	14,096	14,145	3,611.6

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Multi-racial	816	816	*****	*****	*****	*****	94.97 (13.38, 674.25)	1,239	1,254	316.0
Native Hawaiian or Other Pacific Islander	333	333	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	452	452	138.0
Unknown	45,367	45,367	*****	*****	*****	*****	29.21 (18.40, 46.36)	68,462	68,668	16,633.7
White	58,441	58,441	*****	*****	*****	*****	52.04 (38.60, 70.18)	86,784	87,031	20,852.5
Rybelsus, Supraventricular Tachycardia										
American Indian or Alaska Native	68	68	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	110	27.8
Asian	1,087	1,087	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,655	1,684	387.9
Black or African American	3,392	3,392	*****	*****	*****	*****	22.23 (3.13, 157.81)	4,686	4,789	1,311.4
Multi-racial	181	181	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	274	281	78.9
Native Hawaiian or Other Pacific Islander	128	128	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	170	178	61.8
Unknown	12,788	12,788	*****	*****	*****	*****	17.31 (5.58, 53.68)	18,631	19,067	5,022.6
White	16,414	16,414	*****	*****	*****	*****	52.98 (30.08, 93.28)	23,439	23,933	5,964.1
Wegovy, Supraventricular Tachycardia										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	37	37	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	55	57	7.0
Multi-racial	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	28	28	3.6
Native Hawaiian or Other Pacific Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	663	663	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,023	1,044	104.6
White	110	110	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	192	195	22.2
Saxenda, Supraventricular Tachycardia										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.0

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Multi-racial	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.7
Native Hawaiian or Other Pacific Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	342	342	****	****	****	****	222.89 (31.40, 1,582.37)	526	526	171.9
White	31	31	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	45	45	16.6
Victoza, Supraventricular Tachycardia										
American Indian or Alaska Native	59	59	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	82	82	22.6
Asian	92	92	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	120	120	35.9
Black or African American	556	556	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	749	749	227.0
Multi-racial	67	67	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	103	103	27.9
Native Hawaiian or Other Pacific Islander	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	18	18	7.1
Unknown	1,435	1,435	****	****	****	****	102.23 (25.57, 408.76)	2,076	2,077	576.9
White	3,131	3,131	****	****	****	****	66.51 (21.45, 206.23)	4,574	4,574	1,173.9
Trulicity, Supraventricular Tachycardia										
American Indian or Alaska Native	258	258	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	479	482	91.9
Asian	1,202	1,202	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,047	2,055	439.7
Black or African American	6,428	6,428	****	****	****	****	22.35 (5.59, 89.37)	10,496	10,571	2,588.8
Multi-racial	293	293	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	600	605	131.5
Native Hawaiian or Other Pacific Islander	238	238	****	****	****	****	259.23 (36.51, 1,840.33)	400	406	121.2
Unknown	21,774	21,774	****	****	****	****	30.17 (16.23, 56.07)	39,329	39,602	8,747.9
White	36,775	36,775	****	****	****	****	52.02 (35.92, 75.34)	64,191	64,567	13,755.5
Xultophy, Supraventricular Tachycardia										
American Indian or Alaska Native	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Asian	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.3
Black or African American	40	40	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	53	53	15.5

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Multi-racial	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
Native Hawaiian or Other Pacific Islander	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
Unknown	63	63	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	84	23
White	237	237	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	328	328	86.6
Mounjaro, Other Tachycardia										
American Indian or Alaska Native	32	32	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	8.9
Asian	108	108	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	162	163	28.1
Black or African American	1,640	1,640	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,494	2,537	467.1
Multi-racial	60	60	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	112	113	23.5
Native Hawaiian or Other Pacific Islander	57	57	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	86	87	17.3
Unknown	8,006	8,006	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13,643	13,787	2,230.00
White	8,939	8,939	*****	*****	*****	*****	48.74 (20.29, 117.10)	14,620	14,842	2,463.4
Bydureon, Other Tachycardia										
American Indian or Alaska Native	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.7
Asian	44	44	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	75	75	18.7
Black or African American	165	165	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	255	255	73.0
Multi-racial	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	15.8
Native Hawaiian or Other Pacific Islander	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
Unknown	234	234	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	346	346	89.3
White	833	833	*****	*****	*****	*****	177.96 (44.51, 711.57)	1,336	1,336	318.3
Ozempic, Other Tachycardia										
American Indian or Alaska Native	826	826	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,270	1,275	282.9
Asian	1,393	1,393	*****	*****	*****	*****	98.16 (23.55, 392.50)	2,121	2,125	488.2
Black or African American	9,832	9,832	*****	*****	*****	*****	59.29 (29.65, 118.56)	14,096	14,145	3,611.6

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Multi-racial	816	816	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,239	1,254	316.0
Native Hawaiian or Other Pacific Islander	333	333	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	452	452	138.0
Unknown	45,367	45,367	*****	*****	*****	*****	8.11 (3.38, 19.49)	68,462	68,668	16,633.7
White	58,441	58,441	*****	*****	*****	*****	45.99 (33.47, 63.21)	86,784	87,031	20,852.5
Rybelsus, Other Tachycardia										
American Indian or Alaska Native	68	68	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	110	27.8
Asian	1,087	1,087	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,655	1,684	387.9
Black or African American	3,392	3,392	*****	*****	*****	*****	22.23 (3.13, 157.81)	4,686	4,789	1,311.4
Multi-racial	181	181	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	274	281	78.9
Native Hawaiian or Other Pacific Islander	128	128	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	170	178	61.8
Unknown	12,788	12,788	*****	*****	*****	*****	5.77 (0.81, 40.97)	18,631	19,067	5,022.6
White	16,414	16,414	*****	*****	*****	*****	13.23 (4.27, 41.06)	23,439	23,933	5,964.1
Wegovy, Other Tachycardia										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	37	37	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	55	57	7.0
Multi-racial	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	28	28	3.6
Native Hawaiian or Other Pacific Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	663	663	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,023	1,044	104.6
White	110	110	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	192	195	22.2
Saxenda, Other Tachycardia										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.0

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Multi-racial	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.7
Native Hawaiian or Other Pacific Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	342	342	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	526	526	171.9
White	31	31	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	45	45	16.6
Victoza, Other Tachycardia										
American Indian or Alaska Native	59	59	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	82	82	22.6
Asian	92	92	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	120	120	35.9
Black or African American	556	556	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	749	749	227.0
Multi-racial	67	67	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	103	103	27.9
Native Hawaiian or Other Pacific Islander	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	18	18	7.1
Unknown	1,435	1,435	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,076	2,077	576.9
White	3,131	3,131	****	****	****	****	66.51 (21.45, 206.23)	4,574	4,574	1,173.9
Trulicity, Other Tachycardia										
American Indian or Alaska Native	258	258	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	479	482	91.9
Asian	1,202	1,202	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,047	2,055	439.7
Black or African American	6,428	6,428	****	****	****	****	22.35 (5.59, 89.37)	10,496	10,571	2,588.8
Multi-racial	293	293	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	600	605	131.5
Native Hawaiian or Other Pacific Islander	238	238	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	400	406	121.2
Unknown	21,774	21,774	****	****	****	****	6.03 (1.51, 23.13)	39,329	39,602	8,747.9
White	36,775	36,775	****	****	****	****	31.58 (19.63, 50.81)	64,191	64,567	13,755.5
Xultophy, Other Tachycardia										
American Indian or Alaska Native	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Asian	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.3
Black or African American	40	40	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	53	53	15.5

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Multi-racial	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
Native Hawaiian or Other Pacific Islander	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
Unknown	63	63	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	84	23
White	237	237	*****	*****	*****	*****	260.76 (36.73, 1,851.23)	328	328	86.6
Mounjaro, Cardiac Arrest										
American Indian or Alaska Native	32	32	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	8.9
Asian	108	108	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	162	163	28.1
Black or African American	1,640	1,640	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,494	2,537	467.1
Multi-racial	60	60	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	112	113	23.5
Native Hawaiian or Other Pacific Islander	57	57	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	86	87	17.3
Unknown	8,006	8,006	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13,643	13,787	2,230.00
White	8,939	8,939	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14,620	14,842	2,463.4
Bydureon, Cardiac Arrest										
American Indian or Alaska Native	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.7
Asian	44	44	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	75	75	18.7
Black or African American	165	165	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	255	255	73.0
Multi-racial	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	15.8
Native Hawaiian or Other Pacific Islander	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
Unknown	234	234	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	346	346	89.3
White	833	833	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,336	1,336	318.3
Ozempic, Cardiac Arrest										
American Indian or Alaska Native	826	826	*****	*****	*****	*****	97.77 (13.77, 694.10)	1,270	1,275	282.9
Asian	1,393	1,393	*****	*****	*****	*****	49.08 (6.91, 348.44)	2,121	2,125	488.2
Black or African American	9,832	9,832	*****	*****	*****	*****	7.41 (1.04, 52.62)	14,096	14,145	3,611.6

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Multi-racial	816	816	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,239	1,254	316.0
Native Hawaiian or Other Pacific Islander	333	333	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	452	452	138.0
Unknown	45,367	45,367	*****	*****	*****	*****	4.87 (1.57, 15.09)	68,462	68,668	16,633.7
White	58,441	58,441	*****	*****	*****	*****	14.52 (8.25, 25.57)	86,784	87,031	20,852.5
Rybelsus, Cardiac Arrest										
American Indian or Alaska Native	68	68	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	110	27.8
Asian	1,087	1,087	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,655	1,684	387.9
Black or African American	3,392	3,392	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,686	4,789	1,311.4
Multi-racial	181	181	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	274	281	78.9
Native Hawaiian or Other Pacific Islander	128	128	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	170	178	61.8
Unknown	12,788	12,788	*****	*****	*****	*****	5.77 (0.81, 40.97)	18,631	19,067	5,022.6
White	16,414	16,414	*****	*****	*****	*****	4.41 (0.62, 31.34)	23,439	23,933	5,964.1
Wegovy, Cardiac Arrest										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	37	37	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	55	57	7.0
Multi-racial	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	28	28	3.6
Native Hawaiian or Other Pacific Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	663	663	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,023	1,044	104.6
White	110	110	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	192	195	22.2
Saxenda, Cardiac Arrest										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.0

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Multi-racial	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.7
Native Hawaiian or Other Pacific Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	342	342	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	526	526	171.9
White	31	31	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	45	45	16.6
Victoza, Cardiac Arrest										
American Indian or Alaska Native	59	59	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	82	82	22.6
Asian	92	92	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	120	120	35.9
Black or African American	556	556	****	****	****	****	137.33 (19.34, 974.93)	749	749	227.0
Multi-racial	67	67	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	103	103	27.9
Native Hawaiian or Other Pacific Islander	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	18	18	7.1
Unknown	1,435	1,435	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,076	2,077	576.9
White	3,131	3,131	****	****	****	****	44.34 (11.09, 177.30)	4,574	4,574	1,173.9
Trulicity, Cardiac Arrest										
American Indian or Alaska Native	258	258	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	479	482	91.9
Asian	1,202	1,202	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,047	2,055	439.7
Black or African American	6,428	6,428	****	****	****	****	11.18 (1.57, 79.34)	10,496	10,571	2,588.8
Multi-racial	293	293	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	600	605	131.5
Native Hawaiian or Other Pacific Islander	238	238	****	****	****	****	259.23 (36.51, 1,840.33)	400	406	121.2
Unknown	21,774	21,774	****	****	****	****	3.02 (0.42, 21.42)	39,329	39,602	8,747.9
White	36,775	36,775	****	****	****	****	16.72 (8.70, 32.14)	64,191	64,567	13,755.5
Xultophy, Cardiac Arrest										
American Indian or Alaska Native	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Asian	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.3
Black or African American	40	40	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	53	53	15.5

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Multi-racial	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
Native Hawaiian or Other Pacific Islander	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
Unknown	63	63	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	84	23
White	237	237	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	328	328	86.6
Mounjaro, Ventricular Tachycardia										
American Indian or Alaska Native	32	32	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	8.9
Asian	108	108	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	162	163	28.1
Black or African American	1,640	1,640	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,494	2,537	467.1
Multi-racial	60	60	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	112	113	23.5
Native Hawaiian or Other Pacific Islander	57	57	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	86	87	17.3
Unknown	8,006	8,006	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13,643	13,787	2,230.00
White	8,939	8,939	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14,620	14,842	2,463.4
Bydureon, Ventricular Tachycardia										
American Indian or Alaska Native	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.7
Asian	44	44	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	75	75	18.7
Black or African American	165	165	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	255	255	73.0
Multi-racial	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	15.8
Native Hawaiian or Other Pacific Islander	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
Unknown	234	234	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	346	346	89.3
White	833	833	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,336	1,336	318.3
Ozempic, Ventricular Tachycardia										
American Indian or Alaska Native	826	826	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,270	1,275	282.9
Asian	1,393	1,393	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,121	2,125	488.2
Black or African American	9,832	9,832	*****	*****	*****	*****	14.82 (3.71, 59.27)	14,096	14,145	3,611.6

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Multi-racial	816	816	*****	*****	*****	*****	94.97 (13.38, 674.25)	1,239	1,254	316.0
Native Hawaiian or Other Pacific Islander	333	333	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	452	452	138.0
Unknown	45,367	45,367	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	68,462	68,668	16,633.7
White	58,441	58,441	*****	*****	*****	*****	4.84 (1.82, 12.90)	86,784	87,031	20,852.5
Rybelsus, Ventricular Tachycardia										
American Indian or Alaska Native	68	68	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	110	27.8
Asian	1,087	1,087	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,655	1,684	387.9
Black or African American	3,392	3,392	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,686	4,789	1,311.4
Multi-racial	181	181	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	274	281	78.9
Native Hawaiian or Other Pacific Islander	128	128	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	170	178	61.8
Unknown	12,788	12,788	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18,631	19,067	5,022.6
White	16,414	16,414	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	23,439	23,933	5,964.1
Wegovy, Ventricular Tachycardia										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	37	37	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	55	57	7.0
Multi-racial	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	28	28	3.6
Native Hawaiian or Other Pacific Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	663	663	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,023	1,044	104.6
White	110	110	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	192	195	22.2
Saxenda, Ventricular Tachycardia										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.0

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Multi-racial	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.7
Native Hawaiian or Other Pacific Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	342	342	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	526	526	171.9
White	31	31	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	45	45	16.6
Victoza, Ventricular Tachycardia										
American Indian or Alaska Native	59	59	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	82	82	22.6
Asian	92	92	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	120	120	35.9
Black or African American	556	556	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	749	749	227.0
Multi-racial	67	67	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	103	103	27.9
Native Hawaiian or Other Pacific Islander	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	18	18	7.1
Unknown	1,435	1,435	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,076	2,077	576.9
White	3,131	3,131	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,574	4,574	1,173.9
Trulicity, Ventricular Tachycardia										
American Indian or Alaska Native	258	258	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	479	482	91.9
Asian	1,202	1,202	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,047	2,055	439.7
Black or African American	6,428	6,428	****	****	****	****	11.18 (1.57, 79.34)	10,496	10,571	2,588.8
Multi-racial	293	293	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	600	605	131.5
Native Hawaiian or Other Pacific Islander	238	238	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	400	406	121.2
Unknown	21,774	21,774	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	39,329	39,602	8,747.9
White	36,775	36,775	****	****	****	****	3.72 (0.93, 14.86)	64,191	64,567	13,755.5
Xultophy, Ventricular Tachycardia										
American Indian or Alaska Native	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Asian	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.3
Black or African American	40	40	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	53	53	15.5

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Multi-racial	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
Native Hawaiian or Other Pacific Islander	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
Unknown	63	63	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	84	23
White	237	237	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	328	328	86.6
Mounjaro, Ventricular Fibrillation and Flutter										
American Indian or Alaska Native	32	32	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	8.9
Asian	108	108	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	162	163	28.1
Black or African American	1,640	1,640	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,494	2,537	467.1
Multi-racial	60	60	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	112	113	23.5
Native Hawaiian or Other Pacific Islander	57	57	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	86	87	17.3
Unknown	8,006	8,006	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13,643	13,787	2,230.00
White	8,939	8,939	*****	*****	*****	*****	9.75 (1.37, 69.21)	14,620	14,842	2,463.4
Bydureon, Ventricular Fibrillation and Flutter										
American Indian or Alaska Native	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.7
Asian	44	44	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	75	75	18.7
Black or African American	165	165	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	255	255	73.0
Multi-racial	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	15.8
Native Hawaiian or Other Pacific Islander	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
Unknown	234	234	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	346	346	89.3
White	833	833	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,336	1,336	318.3
Ozempic, Ventricular Fibrillation and Flutter										
American Indian or Alaska Native	826	826	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,270	1,275	282.9
Asian	1,393	1,393	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,121	2,125	488.2
Black or African American	9,832	9,832	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14,096	14,145	3,611.6

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Multi-racial	816	816	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,239	1,254	316.0
Native Hawaiian or Other Pacific Islander	333	333	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	452	452	138.0
Unknown	45,367	45,367	*****	*****	*****	*****	1.62 (0.23, 11.52)	68,462	68,668	16,633.7
White	58,441	58,441	*****	*****	*****	*****	3.63 (1.17, 11.26)	86,784	87,031	20,852.5
Rybelsus, Ventricular Fibrillation and Flutter										
American Indian or Alaska Native	68	68	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	110	27.8
Asian	1,087	1,087	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,655	1,684	387.9
Black or African American	3,392	3,392	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,686	4,789	1,311.4
Multi-racial	181	181	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	274	281	78.9
Native Hawaiian or Other Pacific Islander	128	128	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	170	178	61.8
Unknown	12,788	12,788	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18,631	19,067	5,022.6
White	16,414	16,414	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	23,439	23,933	5,964.1
Wegovy, Ventricular Fibrillation and Flutter										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	37	37	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	55	57	7.0
Multi-racial	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	28	28	3.6
Native Hawaiian or Other Pacific Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	663	663	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,023	1,044	104.6
White	110	110	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	192	195	22.2
Saxenda, Ventricular Fibrillation and Flutter										
American Indian or Alaska Native	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Black or African American	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.0

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Multi-racial	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	1.7
Native Hawaiian or Other Pacific Islander	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Unknown	342	342	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	526	526	171.9
White	31	31	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	45	45	16.6
Victoza, Ventricular Fibrillation and Flutter										
American Indian or Alaska Native	59	59	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	82	82	22.6
Asian	92	92	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	120	120	35.9
Black or African American	556	556	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	749	749	227.0
Multi-racial	67	67	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	103	103	27.9
Native Hawaiian or Other Pacific Islander	14	14	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	18	18	7.1
Unknown	1,435	1,435	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,076	2,077	576.9
White	3,131	3,131	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	4,574	4,574	1,173.9
Trulicity, Ventricular Fibrillation and Flutter										
American Indian or Alaska Native	258	258	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	479	482	91.9
Asian	1,202	1,202	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	2,047	2,055	439.7
Black or African American	6,428	6,428	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	10,496	10,571	2,588.8
Multi-racial	293	293	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	600	605	131.5
Native Hawaiian or Other Pacific Islander	238	238	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	400	406	121.2
Unknown	21,774	21,774	****	****	****	****	6.03 (1.51, 23.13)	39,329	39,602	8,747.9
White	36,775	36,775	****	****	****	****	5.57 (1.80, 17.28)	64,191	64,567	13,755.5
Xultophy, Ventricular Fibrillation and Flutter										
American Indian or Alaska Native	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	0.4
Asian	****	****	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	****	****	3.3
Black or African American	40	40	0	0.00 (0.00, 0.00)	****	****	0.00 (0.00, 0.00)	53	53	15.5

Table 6. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining- Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining- Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Multi-racial	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
Native Hawaiian or Other Pacific Islander	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
Unknown	63	63	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	84	23
White	237	237	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	328	328	86.6

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

*NaN: Not a number

Table 7. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Other cardiac disease

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Bydureon, Hospitalized Tachyarrhythmia										
Evidence of Other cardiac disease	597	597	*****	*****	*****	*****	744.29 (334.38, 1,656.73)	935	935	233.0
No evidence of Other cardiac disease	723	723	*****	*****	*****	*****	102.55 (14.45, 728.05)	1,134	1,134	285.4
Mounjaro, Hospitalized Tachyarrhythmia										
Evidence of Other cardiac disease	8,953	8,953	*****	*****	*****	*****	788.80 (633.57, 982.05)	14,710	14,908	2,489.2
No evidence of Other cardiac disease	9,889	9,889	*****	*****	*****	*****	192.17 (126.53, 291.85)	16,463	16,677	2,759.0
Ozempic, Hospitalized Tachyarrhythmia										
Evidence of Other cardiac disease	55,966	55,966	*****	*****	*****	*****	789.15 (728.89, 854.38)	83,193	83,455	20,067.1
No evidence of Other cardiac disease	61,042	61,042	*****	*****	*****	*****	216.02 (186.95, 239.60)	91,231	91,495	22,255.7
Rybelsus, Hospitalized Tachyarrhythmia										
Evidence of Other cardiac disease	13,748	13,748	*****	*****	*****	*****	719.61 (607.52, 852.37)	20,288	20,718	5,100.9
No evidence of Other cardiac disease	20,310	20,310	*****	*****	*****	*****	156.78 (116.67, 210.68)	29,674	30,323	7,753.6
Saxenda, Hospitalized Tachyarrhythmia										
Evidence of Other cardiac disease	159	159	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	239	239	82.3
No evidence of Other cardiac disease	227	227	*****	*****	*****	*****	347.10 (48.89, 2,464.15)	348	348	112.9
Trulicity, Hospitalized Tachyarrhythmia										
Evidence of Other cardiac disease	31,389	31,389	*****	*****	*****	*****	793.33 (715.47, 879.67)	54,555	54,896	11,979.8
No evidence of Other cardiac disease	35,589	35,589	*****	*****	*****	*****	253.52 (214.30, 299.92)	62,987	63,392	13,896.7
Victoza, Hospitalized Tachyarrhythmia										
Evidence of Other cardiac disease	2,610	2,610	*****	*****	*****	*****	1,022.36 (740.74, 1,411.05)	3,723	3,723	999.2
No evidence of Other cardiac disease	2,744	2,744	*****	*****	*****	*****	206.90 (103.47, 413.72)	3,998	3,999	1,072.0
Wegovy, Hospitalized Tachyarrhythmia										
Evidence of Other cardiac disease	343	343	*****	*****	*****	*****	314.92 (44.36, 2,235.76)	562	578	57.4
No evidence of Other cardiac disease	485	485	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	737	746	79.9
Kultophy, Hospitalized Tachyarrhythmia										

Table 7. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Other cardiac disease

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Evidence of Other cardiac disease	186	186	*****	*****	*****	*****	677.39 (169.41, 2,708.58)	255	255	65.6
No evidence of Other cardiac disease	178	178	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	229	229	65.6
Mounjaro, Atrial Fibrillation and Flutter										
Evidence of Other cardiac disease	8,953	8,953	*****	*****	*****	*****	552.16 (423.93, 717.48)	14,710	14,908	2,489.2
No evidence of Other cardiac disease	9,889	9,889	*****	*****	*****	*****	69.88 (34.95, 139.73)	16,463	16,677	2,759.0
Bydureon, Atrial Fibrillation and Flutter										
Evidence of Other cardiac disease	597	597	*****	*****	*****	*****	496.20 (186.23, 1,322.09)	935	935	233.0
No evidence of Other cardiac disease	723	723	*****	*****	*****	*****	102.55 (14.45, 728.05)	1,134	1,134	285.4
Ozempic, Atrial Fibrillation and Flutter										
Evidence of Other cardiac disease	55,966	55,966	*****	*****	*****	*****	563.68 (513.12, 619.22)	83,193	83,455	20,067.1
No evidence of Other cardiac disease	61,042	61,042	*****	*****	*****	*****	83.35 (66.06, 105.18)	91,231	91,495	22,255.7
Rybelsus, Atrial Fibrillation and Flutter										
Evidence of Other cardiac disease	13,748	13,748	*****	*****	*****	*****	563.87 (465.70, 682.73)	20,288	20,718	5,100.9
No evidence of Other cardiac disease	20,310	20,310	*****	*****	*****	*****	67.70 (43.18, 106.14)	29,674	30,323	7,753.6
Wegovy, Atrial Fibrillation and Flutter										
Evidence of Other cardiac disease	343	343	*****	*****	*****	*****	314.92 (44.36, 2,235.76)	562	578	57.4
No evidence of Other cardiac disease	485	485	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	737	746	79.9
Saxenda, Atrial Fibrillation and Flutter										
Evidence of Other cardiac disease	159	159	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	239	239	82.3
No evidence of Other cardiac disease	227	227	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	348	348	112.9
Victoza, Atrial Fibrillation and Flutter										
Evidence of Other cardiac disease	2,610	2,610	*****	*****	*****	*****	663.15 (444.49, 989.39)	3,723	3,723	999.2
No evidence of Other cardiac disease	2,744	2,744	*****	*****	*****	*****	77.59 (25.02, 230.57)	3,998	3,999	1,072.0
Trulicity, Atrial Fibrillation and Flutter										
Evidence of Other cardiac disease	31,389	31,389	*****	*****	*****	*****	606.02 (538.46, 682.05)	54,555	54,896	11,979.8
No evidence of Other cardiac disease	35,589	35,589	*****	*****	*****	*****	128.63 (101.59, 162.86)	62,987	63,392	13,896.7

Table 7. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Other cardiac disease

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Kultophy, Atrial Fibrillation and Flutter										
Evidence of Other cardiac disease	186	186	*****	*****	*****	*****	338.70 (47.71, 2,404.52)	255	255	65.6
No evidence of Other cardiac disease	178	178	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	229	229	65.6
Mounjaro, Sinus Tachycardia										
Evidence of Other cardiac disease	8,953	8,953	*****	*****	*****	*****	157.76 (96.65, 257.51)	14,710	14,908	2,489.2
No evidence of Other cardiac disease	9,889	9,889	*****	*****	*****	*****	122.29 (72.42, 206.48)	16,463	16,677	2,759.0
Bydureon, Sinus Tachycardia										
Evidence of Other cardiac disease	597	597	*****	*****	*****	*****	123.05 (17.47, 880.66)	935	935	233.0
No evidence of Other cardiac disease	723	723	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,134	1,134	285.4
Ozempic, Sinus Tachycardia										
Evidence of Other cardiac disease	55,966	55,966	*****	*****	*****	*****	128.28 (105.35, 156.22)	83,193	83,455	20,067.1
No evidence of Other cardiac disease	61,042	61,042	*****	*****	*****	*****	97.44 (78.58, 120.83)	91,231	91,495	22,255.7
Rybelsus, Sinus Tachycardia										
Evidence of Other cardiac disease	13,748	13,748	*****	*****	*****	*****	123.51 (82.08, 185.87)	20,288	20,718	5,100.9
No evidence of Other cardiac disease	20,310	20,310	*****	*****	*****	*****	78.39 (51.62, 119.06)	29,674	30,323	7,753.6
Wegovy, Sinus Tachycardia										
Evidence of Other cardiac disease	343	343	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	562	578	57.4
No evidence of Other cardiac disease	485	485	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	737	746	79.9
Saxenda, Sinus Tachycardia										
Evidence of Other cardiac disease	159	159	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	239	239	82.3
No evidence of Other cardiac disease	227	227	*****	*****	*****	*****	347.10 (48.89, 2,464.15)	348	348	112.9
Victoza, Sinus Tachycardia										
Evidence of Other cardiac disease	2,610	2,610	*****	*****	*****	*****	238.68 (129.39, 477.95)	3,723	3,723	999.2
No evidence of Other cardiac disease	2,744	2,744	*****	*****	*****	*****	155.17 (69.71, 345.40)	3,998	3,999	1,072.0
Trulicity, Sinus Tachycardia										

Table 7. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Other cardiac disease

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Evidence of Other cardiac disease	31,389	31,389	*****	*****	*****	*****	127.82 (98.81, 165.33)	54,555	54,896	11,979.8
No evidence of Other cardiac disease	35,589	35,589	*****	*****	*****	*****	93.21 (70.64, 122.98)	62,987	63,392	13,896.7
Xultophy, Sinus Tachycardia										
Evidence of Other cardiac disease	186	186	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	255	255	65.6
No evidence of Other cardiac disease	178	178	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	229	229	65.6
Mounjaro, Supraventricular Tachycardia										
Evidence of Other cardiac disease	8,953	8,953	*****	*****	*****	*****	78.88 (39.45, 157.73)	14,710	14,908	2,489.2
No evidence of Other cardiac disease	9,889	9,889	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16,463	16,677	2,759.0
Bydureon, Supraventricular Tachycardia										
Evidence of Other cardiac disease	597	597	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	935	935	233.0
No evidence of Other cardiac disease	723	723	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,134	1,134	285.4
Ozempic, Supraventricular Tachycardia										
Evidence of Other cardiac disease	55,966	55,966	*****	*****	*****	*****	63.49 (47.99, 84.01)	83,193	83,455	20,067.1
No evidence of Other cardiac disease	61,042	61,042	*****	*****	*****	*****	23.65 (16.07, 37.81)	91,231	91,495	22,255.7
Rybelsus, Supraventricular Tachycardia										
Evidence of Other cardiac disease	13,748	13,748	*****	*****	*****	*****	59.07 (32.71, 106.67)	20,288	20,718	5,100.9
No evidence of Other cardiac disease	20,310	20,310	*****	*****	*****	*****	17.82 (7.42, 42.80)	29,674	30,323	7,753.6
Wegovy, Supraventricular Tachycardia										
Evidence of Other cardiac disease	343	343	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	562	578	57.4
No evidence of Other cardiac disease	485	485	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	737	746	79.9
Saxenda, Supraventricular Tachycardia										
Evidence of Other cardiac disease	159	159	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	239	239	82.3
No evidence of Other cardiac disease	227	227	*****	*****	*****	*****	347.10 (48.89, 2,464.15)	348	348	112.9
Victoza, Supraventricular Tachycardia										
Evidence of Other cardiac disease	2,610	2,610	*****	*****	*****	*****	138.16 (57.50, 331.93)	3,723	3,723	999.2
No evidence of Other cardiac disease	2,744	2,744	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	3,998	3,999	1,072.0

Table 7. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Other cardiac disease

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Trulicity, Supraventricular Tachycardia										
Evidence of Other cardiac disease	31,389	31,389	*****	*****	*****	*****	59.50 (40.80, 86.76)	54,555	54,896	11,979.8
No evidence of Other cardiac disease	35,589	35,589	*****	*****	*****	*****	26.10 (15.46, 44.07)	62,987	63,392	13,896.7
Xultophy, Supraventricular Tachycardia										
Evidence of Other cardiac disease	186	186	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	255	255	65.6
No evidence of Other cardiac disease	178	178	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	229	229	65.6
Mounjaro, Other Tachycardia										
Evidence of Other cardiac disease	8,953	8,953	*****	*****	*****	*****	39.44 (14.80, 105.09)	14,710	14,908	2,489.2
No evidence of Other cardiac disease	9,889	9,889	*****	*****	*****	*****	8.73 (1.23, 62.01)	16,463	16,677	2,759.0
Bydureon, Other Tachycardia										
Evidence of Other cardiac disease	597	597	*****	*****	*****	*****	238.10 (62.05, 992.03)	935	935	233.0
No evidence of Other cardiac disease	723	723	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,134	1,134	285.4
Ozempic, Other Tachycardia										
Evidence of Other cardiac disease	55,966	55,966	*****	*****	*****	*****	50.54 (36.92, 69.17)	83,193	83,455	20,067.1
No evidence of Other cardiac disease	61,042	61,042	*****	*****	*****	*****	16.44 (9.73, 27.75)	91,231	91,495	22,255.7
Rybelsus, Other Tachycardia										
Evidence of Other cardiac disease	13,748	13,748	*****	*****	*****	*****	16.11 (5.20, 49.95)	20,288	20,718	5,100.9
No evidence of Other cardiac disease	20,310	20,310	*****	*****	*****	*****	7.13 (1.78, 28.50)	29,674	30,323	7,753.6
Wegovy, Other Tachycardia										
Evidence of Other cardiac disease	343	343	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	562	578	57.4
No evidence of Other cardiac disease	485	485	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	737	746	79.9
Saxenda, Other Tachycardia										
Evidence of Other cardiac disease	159	159	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	239	239	82.3
No evidence of Other cardiac disease	227	227	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	348	348	112.9
Victoza, Other Tachycardia										

Table 7. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Other cardiac disease

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Evidence of Other cardiac disease	2,610	2,610	*****	*****	*****	*****	82.89 (26.73, 257.02)	3,723	3,723	999.2
No evidence of Other cardiac disease	2,744	2,744	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	3,998	3,999	1,072.0
Trulicity, Other Tachycardia										
Evidence of Other cardiac disease	31,389	31,389	*****	*****	*****	*****	30.85 (18.27, 52.09)	54,555	54,896	11,979.8
No evidence of Other cardiac disease	35,589	35,589	*****	*****	*****	*****	13.05 (6.22, 27.37)	62,987	63,392	13,896.7
Xultophy, Other Tachycardia										
Evidence of Other cardiac disease	186	186	*****	*****	*****	*****	338.70 (47.71, 2,404.52)	255	255	65.6
No evidence of Other cardiac disease	178	178	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	229	229	65.6
Mounjaro, Cardiac Arrest										
Evidence of Other cardiac disease	8,953	8,953	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14,710	14,908	2,489.2
No evidence of Other cardiac disease	9,889	9,889	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16,463	16,677	2,759.0
Bydureon, Cardiac Arrest										
Evidence of Other cardiac disease	597	597	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	935	935	233.0
No evidence of Other cardiac disease	723	723	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,134	1,134	285.4
Ozempic, Cardiac Arrest										
Evidence of Other cardiac disease	55,966	55,966	*****	*****	*****	*****	15.55 (8.83, 27.38)	83,193	83,455	20,067.1
No evidence of Other cardiac disease	61,042	61,042	*****	*****	*****	*****	7.04 (3.16, 15.68)	91,231	91,495	22,255.7
Rybelsus, Cardiac Arrest										
Evidence of Other cardiac disease	13,748	13,748	*****	*****	*****	*****	10.74 (2.69, 42.95)	20,288	20,718	5,100.9
No evidence of Other cardiac disease	20,310	20,310	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	29,674	30,323	7,753.6
Wegovy, Cardiac Arrest										
Evidence of Other cardiac disease	343	343	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	562	578	57.4
No evidence of Other cardiac disease	485	485	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	737	746	79.9
Saxenda, Cardiac Arrest										
Evidence of Other cardiac disease	159	159	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	239	239	82.3
No evidence of Other cardiac disease	227	227	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	348	348	112.9

Table 7. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Other cardiac disease

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Victoza, Cardiac Arrest										
Evidence of Other cardiac disease	2,610	2,610	*****	*****	*****	*****	82.89 (26.73, 257.02)	3,723	3,723	999.2
No evidence of Other cardiac disease	2,744	2,744	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	3,998	3,999	1,072.0
Trulicity, Cardiac Arrest										
Evidence of Other cardiac disease	31,389	31,389	*****	*****	*****	*****	19.83 (10.32, 38.12)	54,555	54,896	11,979.8
No evidence of Other cardiac disease	35,589	35,589	*****	*****	*****	*****	5.59 (1.80, 17.34)	62,987	63,392	13,896.7
Xultophy, Cardiac Arrest										
Evidence of Other cardiac disease	186	186	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	255	255	65.6
No evidence of Other cardiac disease	178	178	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	229	229	65.6
Mounjaro, Ventricular Tachycardia										
Evidence of Other cardiac disease	8,953	8,953	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14,710	14,908	2,489.2
No evidence of Other cardiac disease	9,889	9,889	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16,463	16,677	2,759.0
Bydureon, Ventricular Tachycardia										
Evidence of Other cardiac disease	597	597	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	935	935	233.0
No evidence of Other cardiac disease	723	723	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,134	1,134	285.4
Ozempic, Ventricular Tachycardia										
Evidence of Other cardiac disease	55,966	55,966	*****	*****	*****	*****	6.48 (2.70, 15.57)	83,193	83,455	20,067.1
No evidence of Other cardiac disease	61,042	61,042	*****	*****	*****	*****	2.35 (0.59, 9.39)	91,231	91,495	22,255.7
Rybelsus, Ventricular Tachycardia										
Evidence of Other cardiac disease	13,748	13,748	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	20,288	20,718	5,100.9
No evidence of Other cardiac disease	20,310	20,310	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	29,674	30,323	7,753.6
Wegovy, Ventricular Tachycardia										
Evidence of Other cardiac disease	343	343	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	562	578	57.4
No evidence of Other cardiac disease	485	485	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	737	746	79.9
Saxenda, Ventricular Tachycardia										

Table 7. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Other cardiac disease

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Evidence of Other cardiac disease	159	159	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	239	239	82.3
No evidence of Other cardiac disease	227	227	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	348	348	112.9
Victoza, Ventricular Tachycardia										
Evidence of Other cardiac disease	2,610	2,610	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	3,723	3,723	999.2
No evidence of Other cardiac disease	2,744	2,744	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	3,998	3,999	1,072.0
Trulicity, Ventricular Tachycardia										
Evidence of Other cardiac disease	31,389	31,389	*****	*****	*****	*****	6.61 (2.13, 20.50)	54,555	54,896	11,979.8
No evidence of Other cardiac disease	35,589	35,589	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	62,987	63,392	13,896.7
Xultophy, Ventricular Tachycardia										
Evidence of Other cardiac disease	186	186	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	255	255	65.6
No evidence of Other cardiac disease	178	178	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	229	229	65.6
Mounjaro, Ventricular Fibrillation and Flutter										
Evidence of Other cardiac disease	8,953	8,953	*****	*****	*****	*****	9.86 (1.39, 70.00)	14,710	14,908	2,489.2
No evidence of Other cardiac disease	9,889	9,889	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16,463	16,677	2,759.0
Bydureon, Ventricular Fibrillation and Flutter										
Evidence of Other cardiac disease	597	597	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	935	935	233.0
No evidence of Other cardiac disease	723	723	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,134	1,134	285.4
Ozempic, Ventricular Fibrillation and Flutter										
Evidence of Other cardiac disease	55,966	55,966	*****	*****	*****	*****	5.18 (1.95, 13.81)	83,193	83,455	20,067.1
No evidence of Other cardiac disease	61,042	61,042	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	91,231	91,495	22,255.7
Rybelsus, Ventricular Fibrillation and Flutter										
Evidence of Other cardiac disease	13,748	13,748	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	20,288	20,718	5,100.9
No evidence of Other cardiac disease	20,310	20,310	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	29,674	30,323	7,753.6
Wegovy, Ventricular Fibrillation and Flutter										
Evidence of Other cardiac disease	343	343	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	562	578	57.4
No evidence of Other cardiac disease	485	485	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	737	746	79.9

Table 7. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Other cardiac disease

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Saxenda, Ventricular Fibrillation and Flutter										
Evidence of Other cardiac disease	159	159	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	239	239	82.3
No evidence of Other cardiac disease	227	227	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	348	348	112.9
Victoza, Ventricular Fibrillation and Flutter										
Evidence of Other cardiac disease	2,610	2,610	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	3,723	3,723	999.2
No evidence of Other cardiac disease	2,744	2,744	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	3,998	3,999	1,072.0
Trulicity, Ventricular Fibrillation and Flutter										
Evidence of Other cardiac disease	31,389	31,389	*****	*****	*****	*****	8.81 (3.31, 23.49)	54,555	54,896	11,979.8
No evidence of Other cardiac disease	35,589	35,589	*****	*****	*****	*****	1.86 (0.26, 13.23)	62,987	63,392	13,896.7
Xultophy, Ventricular Fibrillation and Flutter										
Evidence of Other cardiac disease	186	186	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	255	255	65.6
No evidence of Other cardiac disease	178	178	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	229	229	65.6

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Bydureon, Hospitalized Tachyarrhythmia										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.5
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	0.1	54	0.00 (0.00, 0.00)	*****	*****	1.2
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	5,354	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	11	11	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14	14	5.4
41-64 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	6.2
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	28	28	4.4
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Black or African American</i>										
0-40 years	14	14	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	23	23	6.9
41-64 years	88	88	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	139	139	38.2
65-74 years	49	49	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	76	76	22.9
75-84 years	*****	*****	*****	*****	*****	*****	6,330.16 (891.66, 44,939.85)	*****	*****	4.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.3
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	35	11.1
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	6.3
41-64 years	118	118	*****	*****	*****	*****	626.18 (88.20, 4,445.45)	160	160	42.5
65-74 years	87	87	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	130	130	29.7
75-84 years	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	10.5
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.3
<i>White</i>										
0-40 years	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45	45	14.0
41-64 years	251	251	*****	*****	*****	*****	635.05 (158.82, 2,539.28)	404	404	98.6
65-74 years	387	387	*****	*****	*****	*****	169.91 (23.93, 1,206.23)	654	654	152.2
75-84 years	149	149	*****	*****	*****	*****	546.54 (76.98, 3,880.04)	217	217	49.5
≥ 85 years	12	12	*****	*****	*****	*****	12,726.48 (1,792.63, 90,349.45)	16	16	3.9
Mounjaro, Hospitalized Tachyarrhythmia										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	4.9
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	19	19	2.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Asian</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
41-64 years	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	53	9.6
65-74 years	53	53	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	71	71	12.5
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	4.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	70	73	13.0
41-64 years	671	671	*****	*****	*****	*****	809.69 (363.76, 1,802.29)	1,074	1,085	198.4
65-74 years	744	744	*****	*****	*****	*****	251.47 (62.89, 1,005.52)	1,100	1,125	209.6
75-84 years	173	173	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	235	239	44.1
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	15	15	2.0
<i>Multi-racial</i>										
0-40 years	*****	*****	*****	*****	*****	*****	7,423.78 (1,045.70, 52,703.85)	20	20	3.7
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	81	81	17.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17	17	1.6
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	55	56	12.1
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Unknown</i>										

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	855	855	*****	*****	*****	*****	107.06 (15.08, 760.06)	1,423	1,439	231.3
41-64 years	6,086	6,086	*****	*****	*****	*****	181.35 (105.30, 312.32)	10,484	10,593	1,733.2
65-74 years	898	898	*****	*****	*****	*****	706.07 (336.60, 1,481.08)	1,474	1,489	233.3
75-84 years	*****	*****	*****	*****	*****	*****	633.89 (89.29, 4,500.22)	239	253	40.5
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	1.7
<i>White</i>										
0-40 years	115	115	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	215	217	32.5
41-64 years	2,394	2,394	20	0.84 (0.47, 1.20)	*****	*****	706.41 (455.74, 1,094.95)	4,115	4,179	722.7
65-74 years	4,850	4,850	36	0.74 (0.50, 0.98)	*****	*****	646.92 (466.64, 896.85)	7,859	7,979	1,301.9
75-84 years	1,505	1,505	*****	*****	*****	*****	787.73 (457.39, 1,356.63)	2,325	2,359	389.7
≥ 85 years	75	75	*****	*****	*****	*****	2,912.68 (728.44, 11,646.47)	106	108	16.6
Ozempic, Hospitalized Tachyarrhythmia										
<i>American Indian or Alaska Native</i>										
0-40 years	23	23	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	31	31	7.5
41-64 years	259	259	*****	*****	*****	*****	1,180.42 (443.02, 3,145.16)	409	411	89.4
65-74 years	361	361	*****	*****	*****	*****	666.64 (215.00, 2,066.99)	566	569	120.7
75-84 years	165	165	*****	*****	*****	*****	2,563.52 (1,066.99, 6,159.03)	239	239	59.4
≥ 85 years	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25	25	5.8
<i>Asian</i>										
0-40 years	79	79	*****	*****	*****	*****	2,097.93 (523.67, 8,388.67)	111	111	29.8
41-64 years	360	360	*****	*****	*****	*****	190.21 (26.79, 1,350.40)	563	563	137.7

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	655	655	*****	*****	*****	*****	417.72 (156.77, 1,112.98)	982	985	217.5
75-84 years	251	251	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	385	386	86.5
≥ 85 years	48	48	*****	*****	*****	*****	2,778.62 (694.91, 11,110.44)	80	80	16.7
<i>Black or African American</i>										
0-40 years	313	313	*****	*****	*****	*****	508.14 (127.08, 2,031.81)	434	436	110.9
41-64 years	3,802	3,802	30	0.79 (0.51, 1.07)	*****	*****	581.94 (406.88, 832.31)	5,615	5,642	1,405.5
65-74 years	4,502	4,502	30	0.67 (0.43, 0.90)	*****	*****	478.93 (334.86, 684.98)	6,369	6,383	1,649.8
75-84 years	1,113	1,113	*****	*****	*****	*****	579.26 (301.39, 1,113.30)	1,538	1,543	408.1
≥ 85 years	102	102	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	140	141	37.2
<i>Multi-racial</i>										
0-40 years	118	118	*****	*****	*****	*****	704.84 (99.28, 5,003.92)	171	172	42.9
41-64 years	623	623	*****	*****	*****	*****	123.68 (17.56, 885.11)	953	957	230.4
65-74 years	*****	*****	*****	*****	*****	*****	1,057.47 (148.95, 7,507.32)	108	108	30.3
75-84 years	*****	*****	*****	*****	*****	*****	6,943.92 (978.11, 49,297.13)	17	17	2.4
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.2
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	92	92	23.2
65-74 years	184	184	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	236	236	77.6
75-84 years	81	81	*****	*****	*****	*****	1,683.96 (421.14, 6,733.36)	100	100	31.0
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Unknown</i>										
0-40 years	4,021	4,021	*****	*****	*****	*****	160.92 (80.48, 321.78)	5,878	5,895	1,434.7
41-64 years	31,654	31,654	90	0.28 (0.23, 0.34)	*****	*****	208.49 (169.57, 256.33)	48,223	48,372	11,753.2
65-74 years	7,739	7,739	32	0.41 (0.27, 0.56)	*****	*****	295.61 (209.05, 418.02)	11,555	11,590	2,750.4
75-84 years	1,811	1,811	*****	*****	*****	*****	646.43 (396.02, 1,055.18)	2,610	2,616	646.6
≥ 85 years	142	142	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	195	195	48.8
<i>White</i>										
0-40 years	930	930	*****	*****	*****	*****	394.42 (164.17, 947.62)	1,485	1,491	342.8
41-64 years	14,028	14,028	107	0.76 (0.62, 0.91)	*****	*****	551.83 (456.58, 666.95)	21,446	21,516	5,230.80
65-74 years	30,872	30,872	263	0.85 (0.75, 0.95)	*****	*****	589.31 (522.23, 665.02)	45,929	46,054	10,871.6
75-84 years	11,675	11,675	153	1.31 (1.10, 1.52)	*****	*****	949.63 (810.47, 1,112.69)	16,604	16,649	4,067.5
≥ 85 years	936	936	*****	*****	*****	*****	1,715.63 (1,118.60, 2,631.33)	1,320	1,321	329.8
Rybelsus, Hospitalized Tachyarrhythmia										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.4
41-64 years	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	37	12.1
65-74 years	23	23	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	30	30	8.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	19	19	2.7
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
<i>Asian</i>										
0-40 years	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38	39	10.9
41-64 years	173	173	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	284	293	67.3
65-74 years	523	523	*****	*****	*****	*****	130.84 (18.43, 928.90)	759	770	187.7
75-84 years	292	292	*****	*****	*****	*****	218.10 (30.72, 1,548.35)	457	465	98.6
≥ 85 years	72	72	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	117	117	23.4

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Black or African American</i>										
0-40 years	88	88	*****	*****	*****	*****	1,949.04 (487.44, 7,793.31)	127	131	29.2
41-64 years	984	984	*****	*****	*****	*****	158.19 (39.56, 632.51)	1,405	1,436	392.4
65-74 years	1,680	1,680	*****	*****	*****	*****	480.99 (266.37, 868.53)	2,298	2,352	650.1
75-84 years	564	564	*****	*****	*****	*****	269.91 (67.50, 1,079.23)	749	760	211.0
≥ 85 years	76	76	*****	*****	*****	*****	963.72 (135.75, 6,841.77)	107	110	28.7
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	9.5
41-64 years	129	129	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	190	195	56.0
65-74 years	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	41	12.6
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	8.5
65-74 years	66	66	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	80	84	32.6
75-84 years	35	35	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	55	57	16.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.9
<i>Unknown</i>										
0-40 years	773	773	*****	*****	*****	*****	102.82 (14.48, 729.96)	1,106	1,127	291.8
41-64 years	7,936	7,936	*****	*****	*****	*****	195.55 (127.50, 299.92)	11,573	11,866	3,217.6
65-74 years	3,034	3,034	*****	*****	*****	*****	213.87 (111.28, 411.05)	4,404	4,501	1,126.7
75-84 years	894	894	*****	*****	*****	*****	250.36 (80.74, 776.27)	1,316	1,338	330.7
≥ 85 years	151	151	*****	*****	*****	*****	957.28 (239.41, 3,827.72)	232	235	55.8
<i>White</i>										

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	209	209	*****	*****	*****	*****	408.37 (57.52, 2,899.18)	303	309	70.2
41-64 years	2,999	2,999	16	0.53 (0.27, 0.79)	*****	*****	379.96 (232.77, 620.21)	4,598	4,697	1,157.3
65-74 years	8,327	8,327	39	0.47 (0.32, 0.62)	*****	*****	334.69 (234.53, 458.08)	12,353	12,614	3,030.6
75-84 years	4,305	4,305	56	1.30 (0.96, 1.64)	*****	*****	963.03 (741.12, 1,251.37)	6,332	6,453	1,511.7
≥ 85 years	574	574	*****	*****	*****	*****	1,372.29 (738.36, 2,550.50)	853	860	194.4
Saxenda, Hospitalized Tachyarrhythmia										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.9
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Multi-racial</i>										

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	100	100	32.2
41-64 years	266	266	*****	*****	*****	*****	280.47 (39.51, 1,991.12)	410	410	132.1
65-74 years	12	12	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	7.5
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17	17	7.8
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	5.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Trulicity, Hospitalized Tachyarrhythmia										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	31	31	5.3

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	100	100	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	175	177	38.7
65-74 years	95	95	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	194	195	32.2
75-84 years	43	43	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	67	67	14.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12	12	1.2
<i>Asian</i>										
0-40 years	46	46	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	85	20.2
41-64 years	221	221	*****	*****	*****	*****	332.41 (46.82, 2,359.87)	366	366	84.8
65-74 years	570	570	*****	*****	*****	*****	215.05 (53.78, 859.88)	973	978	208.1
75-84 years	297	297	*****	*****	*****	*****	216.10 (30.44, 1,534.16)	495	497	105.0
≥ 85 years	68	68	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	129	129	21.6
<i>Black or African American</i>										
0-40 years	218	218	*****	*****	*****	*****	335.86 (47.31, 2,384.39)	376	377	83.7
41-64 years	2,117	2,117	16	0.76 (0.39, 1.12)	*****	*****	548.94 (336.29, 896.04)	3,613	3,644	839.2
65-74 years	2,953	2,953	12	0.41 (0.18, 0.64)	*****	*****	289.86 (164.61, 510.41)	4,729	4,762	1,204.7
75-84 years	1,022	1,022	*****	*****	*****	*****	826.61 (469.43, 1,455.54)	1,592	1,601	416.7
≥ 85 years	118	118	*****	*****	*****	*****	2,083.17 (671.85, 6,459.16)	186	187	44.5
<i>Multi-racial</i>										
0-40 years	35	35	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	68	68	12.7
41-64 years	223	223	*****	*****	*****	*****	527.47 (131.92, 2,109.13)	469	473	100.4
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45	45	13.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18	19	5.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
41-64 years	39	39	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	65	67	18.4

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	136	136	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	230	234	66.3
75-84 years	62	62	*****	*****	*****	*****	2,313.91 (578.69, 9,252.23)	90	90	30.0
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.7
Unknown										
0-40 years	1,577	1,577	*****	*****	*****	*****	422.23 (219.69, 811.50)	2,730	2,751	632.6
41-64 years	13,585	13,585	45	0.33 (0.23, 0.43)	*****	*****	212.40 (158.58, 284.47)	25,059	25,238	5,589.0
65-74 years	4,882	4,882	32	0.66 (0.43, 0.88)	*****	*****	433.93 (306.86, 613.61)	8,576	8,623	1,863.4
75-84 years	1,533	1,533	18	1.17 (0.63, 1.71)	*****	*****	817.14 (514.83, 1,296.98)	2,637	2,652	594.5
≥ 85 years	197	197	*****	*****	*****	*****	1,198.85 (386.65, 3,717.20)	327	328	68.5
White										
0-40 years	536	536	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	999	1,006	185.5
41-64 years	7,457	7,457	49	0.66 (0.47, 0.84)	*****	*****	453.55 (342.78, 600.10)	13,442	13,532	2,952.2
65-74 years	18,730	18,730	157	0.84 (0.71, 0.97)	*****	*****	562.08 (480.69, 657.25)	32,607	32,794	6,969.6
75-84 years	8,880	8,880	111	1.25 (1.02, 1.48)	*****	*****	866.57 (719.46, 1,043.75)	15,077	15,161	3,232.30
≥ 85 years	1,172	1,172	20	1.71 (0.96, 2.45)	*****	*****	1,318.81 (850.83, 2,044.18)	2,066	2,074	406.0
Victoza, Hospitalized Tachyarrhythmia										
American Indian or Alaska Native										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.0
41-64 years	27	27	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	37	37	11.9
65-74 years	20	20	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	6.4
75-84 years	*****	*****	*****	*****	*****	*****	10,742.65 (1,513.19, 76,265.57)	*****	*****	2.2

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.0
41-64 years	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	43	43	14.2
65-74 years	30	30	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	9.7
75-84 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	23	23	6.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
<i>Black or African American</i>										
0-40 years	39	39	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	14.9
41-64 years	250	250	*****	*****	*****	*****	930.65 (300.15, 2,885.61)	342	342	100.5
65-74 years	223	223	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	300	300	94.9
75-84 years	*****	*****	*****	*****	*****	*****	2,261.61 (318.57, 16,055.91)	*****	*****	15.0
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.5
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	7.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	66	66	19.1
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Unknown</i>										
0-40 years	140	140	*****	*****	*****	*****	539.35 (75.97, 3,829.04)	201	201	55.5
41-64 years	848	848	*****	*****	*****	*****	420.68 (175.10, 1,010.71)	1,269	1,270	356.5
65-74 years	337	337	*****	*****	*****	*****	657.36 (212.01, 2,038.23)	462	462	126.0
75-84 years	93	93	*****	*****	*****	*****	955.15 (134.54, 6,780.93)	118	118	32.5
≥ 85 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	6.5
<i>White</i>										
0-40 years	95	95	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	164	164	41.2
41-64 years	947	947	*****	*****	*****	*****	533.27 (254.22, 1,118.60)	1,423	1,423	367.4
65-74 years	1,420	1,420	*****	*****	*****	*****	475.91 (256.06, 884.51)	2,051	2,051	525.2
75-84 years	597	597	13	2.18 (1.01, 3.35)	*****	*****	1,492.60 (866.68, 2,570.56)	839	839	213.7
≥ 85 years	72	72	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	96	96	26.3
Wegovy, Hospitalized Tachyarrhythmia										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	30	30	4.6
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.8
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	113	113	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	165	170	14.9
41-64 years	520	520	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	804	817	84.2
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	21	21	2.3

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	116	116	12.8
65-74 years	29	29	*****	*****	*****	*****	4,363.80 (614.68, 30,980.04)	42	45	4.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.1
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
Kultophy, Hospitalized Tachyarrhythmia										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.5
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	11.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Multi-racial</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.8
41-64 years	27	27	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	11.6
65-74 years	22	22	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	29	29	6.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.3
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
41-64 years	42	42	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	13.3
65-74 years	127	127	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	161	161	49.4
75-84 years	66	66	*****	*****	*****	*****	1,991.55 (498.07, 7,963.29)	95	95	19.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.6
Mounjaro, Atrial Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	4.9
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	19	19	2.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
41-64 years	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	53	9.6
65-74 years	53	53	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	71	71	12.5
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	4.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	70	73	13.0
41-64 years	671	671	*****	*****	*****	*****	674.74 (280.84, 1,621.11)	1,074	1,085	198.4
65-74 years	744	744	*****	*****	*****	*****	125.74 (17.71, 892.64)	1,100	1,125	209.6
75-84 years	173	173	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	235	239	44.1
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	15	15	2.0
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	20	20	3.7
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	81	81	17.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17	17	1.6
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	55	56	12.1

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Unknown</i>										
0-40 years	855	855	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,423	1,439	231.3
41-64 years	6,086	6,086	*****	*****	*****	*****	97.65 (46.55, 204.83)	10,484	10,593	1,733.2
65-74 years	898	898	*****	*****	*****	*****	403.47 (151.43, 1,075.02)	1,474	1,489	233.3
75-84 years	*****	*****	*****	*****	*****	*****	633.89 (89.29, 4,500.22)	239	253	40.5
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	1.7
<i>White</i>										
0-40 years	115	115	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	215	217	32.5
41-64 years	2,394	2,394	11	0.46 (0.19, 0.73)	*****	*****	388.53 (215.16, 701.57)	4,115	4,179	722.7
65-74 years	4,850	4,850	23	0.47 (0.28, 0.67)	*****	*****	413.31 (274.65, 621.97)	7,859	7,979	1,301.9
75-84 years	1,505	1,505	*****	*****	*****	*****	666.54 (369.12, 1,203.58)	2,325	2,359	389.7
≥ 85 years	75	75	*****	*****	*****	*****	1,456.34 (205.14, 10,339.03)	106	108	16.6
Bydureon, Atrial Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.5
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.2
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	11	11	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14	14	5.4
41-64 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	6.2
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	28	28	4.4

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Black or African American</i>										
0-40 years	14	14	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	23	23	6.9
41-64 years	88	88	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	139	139	38.2
65-74 years	49	49	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	76	76	22.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.3
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	35	11.1
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	6.3
41-64 years	118	118	*****	*****	*****	*****	626.18 (88.20, 4,445.45)	160	160	42.5
65-74 years	87	87	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	130	130	29.7
75-84 years	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	10.5
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.3

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>White</i>										
0-40 years	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45	45	14.0
41-64 years	251	251	*****	*****	*****	*****	635.05 (158.82, 2,539.28)	404	404	98.6
65-74 years	387	387	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	654	654	152.2
75-84 years	149	149	*****	*****	*****	*****	546.54 (76.98, 3,880.04)	217	217	49.5
≥ 85 years	12	12	*****	*****	*****	*****	12,726.48 (1,792.63, 90,349.45)	16	16	3.9
Ozempic, Atrial Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
0-40 years	23	23	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	31	31	7.5
41-64 years	259	259	*****	*****	*****	*****	590.21 (147.61, 2,359.97)	409	411	89.4
65-74 years	361	361	*****	*****	*****	*****	444.42 (111.15, 1,777.05)	566	569	120.7
75-84 years	165	165	*****	*****	*****	*****	2,563.52 (1,066.99, 6,159.03)	239	239	59.4
≥ 85 years	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25	25	5.8
<i>Asian</i>										
0-40 years	79	79	*****	*****	*****	*****	1,048.97 (147.76, 7,446.95)	111	111	29.8
41-64 years	360	360	*****	*****	*****	*****	190.21 (26.79, 1,350.40)	563	563	137.7
65-74 years	655	655	*****	*****	*****	*****	104.43 (14.71, 741.37)	982	985	217.5
75-84 years	251	251	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	385	386	86.5
≥ 85 years	48	48	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	80	80	16.7
<i>Black or African American</i>										
0-40 years	313	313	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	434	436	110.9
41-64 years	3,802	3,802	*****	*****	*****	*****	271.57 (160.84, 458.54)	5,615	5,642	1,405.5

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	4,502	4,502	16	0.36 (0.18, 0.53)	*****	*****	255.43 (156.48, 416.94)	6,369	6,383	1,649.8
75-84 years	1,113	1,113	*****	*****	*****	*****	386.17 (173.49, 859.59)	1,538	1,543	408.1
≥ 85 years	102	102	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	140	141	37.2
<i>Multi-racial</i>										
0-40 years	118	118	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	171	172	42.9
41-64 years	623	623	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	953	957	230.4
65-74 years	*****	*****	*****	*****	*****	*****	1,057.47 (148.95, 7,507.32)	108	108	30.3
75-84 years	*****	*****	*****	*****	*****	*****	6,943.92 (978.11, 49,297.13)	17	17	2.4
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.2
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	92	92	23.2
65-74 years	184	184	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	236	236	77.6
75-84 years	81	81	*****	*****	*****	*****	1,683.96 (421.14, 6,733.36)	100	100	31.0
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
<i>Unknown</i>										
0-40 years	4,021	4,021	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	5,878	5,895	1,434.7
41-64 years	31,654	31,654	47	0.15 (0.11, 0.19)	*****	*****	108.88 (81.80, 144.91)	48,223	48,372	11,753.2
65-74 years	7,739	7,739	22	0.28 (0.17, 0.40)	*****	*****	203.23 (133.82, 308.66)	11,555	11,590	2,750.4
75-84 years	1,811	1,811	15	0.83 (0.41, 1.25)	*****	*****	606.03 (365.35, 1,005.26)	2,610	2,616	646.6
≥ 85 years	142	142	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	195	195	48.8
<i>White</i>										

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	930	930	*****	*****	*****	*****	78.88 (11.11, 560.03)	1,485	1,491	342.8
41-64 years	14,028	14,028	51	0.36 (0.26, 0.46)	*****	*****	263.02 (199.89, 346.09)	21,446	21,516	5,230.80
65-74 years	30,872	30,872	181	0.59 (0.50, 0.67)	*****	*****	405.57 (350.59, 469.18)	45,929	46,054	10,871.6
75-84 years	11,675	11,675	118	1.01 (0.83, 1.19)	*****	*****	732.40 (611.48, 877.22)	16,604	16,649	4,067.5
≥ 85 years	936	936	*****	*****	*****	*****	1,552.23 (990.09, 2,433.56)	1,320	1,321	329.8
Rybelsus, Atrial Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.4
41-64 years	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	37	12.1
65-74 years	23	23	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	30	30	8.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	19	19	2.7
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
<i>Asian</i>										
0-40 years	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38	39	10.9
41-64 years	173	173	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	284	293	67.3
65-74 years	523	523	*****	*****	*****	*****	130.84 (18.43, 928.90)	759	770	187.7
75-84 years	292	292	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	457	465	98.6
≥ 85 years	72	72	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	117	117	23.4
<i>Black or African American</i>										
0-40 years	88	88	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	127	131	29.2
41-64 years	984	984	*****	*****	*****	*****	79.09 (11.14, 561.50)	1,405	1,436	392.4
65-74 years	1,680	1,680	*****	*****	*****	*****	393.54 (204.76, 756.35)	2,298	2,352	650.1
75-84 years	564	564	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	749	760	211.0
≥ 85 years	76	76	*****	*****	*****	*****	963.72 (135.75, 6,841.77)	107	110	28.7
<i>Multi-racial</i>										

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	9.5
41-64 years	129	129	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	190	195	56.0
65-74 years	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	41	12.6
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	8.5
65-74 years	66	66	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	80	84	32.6
75-84 years	35	35	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	55	57	16.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.9
<i>Unknown</i>										
0-40 years	773	773	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,106	1,127	291.8
41-64 years	7,936	7,936	*****	*****	*****	*****	102.43 (56.72, 184.96)	11,573	11,866	3,217.6
65-74 years	3,034	3,034	*****	*****	*****	*****	95.06 (35.68, 253.27)	4,404	4,501	1,126.7
75-84 years	894	894	*****	*****	*****	*****	250.36 (80.74, 776.27)	1,316	1,338	330.7
≥ 85 years	151	151	*****	*****	*****	*****	478.64 (67.42, 3,398.02)	232	235	55.8
<i>White</i>										
0-40 years	209	209	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	303	309	70.2
41-64 years	2,999	2,999	*****	*****	*****	*****	213.73 (111.20, 410.77)	4,598	4,697	1,157.3
65-74 years	8,327	8,327	31	0.37 (0.23, 0.50)	*****	*****	266.04 (187.09, 378.29)	12,353	12,614	3,030.6
75-84 years	4,305	4,305	44	1.02 (0.72, 1.32)	*****	*****	756.66 (563.09, 1,016.78)	6,332	6,453	1,511.7
≥ 85 years	574	574	*****	*****	*****	*****	1,235.07 (642.62, 2,373.72)	853	860	194.4
Wegovy, Atrial Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	30	30	4.6
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.8
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	113	113	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	165	170	14.9
41-64 years	520	520	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	804	817	84.2
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	21	21	2.3
41-64 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	116	116	12.8
65-74 years	29	29	*****	*****	*****	*****	4,363.80 (614.68, 30,980.04)	42	45	4.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.1
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
Saxenda, Atrial Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.9
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Multi-racial</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	100	100	32.2
41-64 years	266	266	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	410	410	132.1
65-74 years	12	12	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	7.5
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17	17	7.8
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	5.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Atrial Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.0
41-64 years	27	27	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	37	37	11.9
65-74 years	20	20	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	6.4
75-84 years	*****	*****	*****	*****	*****	*****	10,742.65 (1,513.19, 76,265.57)	*****	*****	2.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.0
41-64 years	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	43	43	14.2
65-74 years	30	30	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	9.7
75-84 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	23	23	6.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
<i>Black or African American</i>										
0-40 years	39	39	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	14.9
41-64 years	250	250	*****	*****	*****	*****	310.22 (43.70, 2,202.33)	342	342	100.5
65-74 years	223	223	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	300	300	94.9

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	*****	*****	*****	*****	*****	*****	2,261.61 (318.57, 16,055.91)	*****	*****	15.0
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.5
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	7.0
41-64 years	41	41	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	19.1
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
<i>Unknown</i>										
0-40 years	140	140	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	201	201	55.5
41-64 years	848	848	*****	*****	*****	*****	84.14 (11.85, 597.31)	1,269	1,270	356.5
65-74 years	337	337	*****	*****	*****	*****	438.23 (109.60, 1,752.31)	462	462	126.0
75-84 years	93	93	*****	*****	*****	*****	955.15 (134.54, 6,780.93)	118	118	32.5
≥ 85 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	6.5
<i>White</i>										
0-40 years	95	95	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	164	164	41.2
41-64 years	947	947	*****	*****	*****	*****	228.54 (73.71, 708.63)	1,423	1,423	367.4
65-74 years	1,420	1,420	*****	*****	*****	*****	285.54 (128.28, 635.60)	2,051	2,051	525.2

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	597	597	*****	*****	*****	*****	1,262.97 (699.42, 2,280.57)	839	839	213.7
≥ 85 years	72	72	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	96	96	26.3
Trulicity, Atrial Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	31	31	5.3
41-64 years	100	100	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	175	177	38.7
65-74 years	95	95	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	194	195	32.2
75-84 years	43	43	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	67	67	14.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12	12	1.2
<i>Asian</i>										
0-40 years	46	46	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	85	20.2
41-64 years	221	221	*****	*****	*****	*****	332.41 (46.82, 2,359.87)	366	366	84.8
65-74 years	570	570	*****	*****	*****	*****	107.52 (15.15, 763.35)	973	978	208.1
75-84 years	297	297	*****	*****	*****	*****	216.10 (30.44, 1,534.16)	495	497	105.0
≥ 85 years	68	68	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	129	129	21.6
<i>Black or African American</i>										
0-40 years	218	218	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	376	377	83.7
41-64 years	2,117	2,117	*****	*****	*****	*****	274.47 (137.26, 548.84)	3,613	3,644	839.2
65-74 years	2,953	2,953	*****	*****	*****	*****	144.93 (65.11, 322.60)	4,729	4,762	1,204.7
75-84 years	1,022	1,022	*****	*****	*****	*****	344.42 (143.35, 827.49)	1,592	1,601	416.7
≥ 85 years	118	118	*****	*****	*****	*****	1,388.78 (347.32, 5,553.11)	186	187	44.5
<i>Multi-racial</i>										
0-40 years	35	35	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	68	68	12.7

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	223	223	*****	*****	*****	*****	263.74 (37.15, 1,872.36)	469	473	100.4
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45	45	13.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18	19	5.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
41-64 years	39	39	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	65	67	18.4
65-74 years	136	136	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	230	234	66.3
75-84 years	62	62	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	90	90	30.0
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.7
<i>Unknown</i>										
0-40 years	1,577	1,577	*****	*****	*****	*****	140.74 (45.39, 436.40)	2,730	2,751	632.6
41-64 years	13,585	13,585	21	0.15 (0.09, 0.22)	*****	*****	99.12 (64.63, 152.02)	25,059	25,238	5,589.0
65-74 years	4,882	4,882	21	0.43 (0.25, 0.61)	*****	*****	284.76 (185.67, 436.75)	8,576	8,623	1,863.4
75-84 years	1,533	1,533	*****	*****	*****	*****	726.35 (444.98, 1,185.63)	2,637	2,652	594.5
≥ 85 years	197	197	*****	*****	*****	*****	799.23 (199.88, 3,195.77)	327	328	68.5
<i>White</i>										
0-40 years	536	536	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	999	1,006	185.5
41-64 years	7,457	7,457	23	0.31 (0.18, 0.43)	*****	*****	212.89 (141.47, 320.37)	13,442	13,532	2,952.2
65-74 years	18,730	18,730	121	0.65 (0.53, 0.76)	*****	*****	433.19 (362.49, 517.69)	32,607	32,794	6,969.6
75-84 years	8,880	8,880	92	1.04 (0.83, 1.25)	*****	*****	718.23 (585.49, 881.07)	15,077	15,161	3,232.30
≥ 85 years	1,172	1,172	20	1.71 (0.96, 2.45)	*****	*****	1,318.81 (850.83, 2,044.18)	2,066	2,074	406.0
Xultophy, Atrial Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.5
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	11.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Multi-racial</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.8
41-64 years	27	27	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	11.6
65-74 years	22	22	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	29	29	6.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.3
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
41-64 years	42	42	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	13.3
65-74 years	127	127	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	161	161	49.4
75-84 years	66	66	*****	*****	*****	*****	995.77 (140.26, 7,069.33)	95	95	19.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.6
Mounjaro, Sinus Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	4.9
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	19	19	2.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
41-64 years	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	53	9.6
65-74 years	53	53	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	71	71	12.5
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	4.2

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	70	73	13.0
41-64 years	671	671	*****	*****	*****	*****	134.95 (19.01, 958.04)	1,074	1,085	198.4
65-74 years	744	744	*****	*****	*****	*****	125.74 (17.71, 892.64)	1,100	1,125	209.6
75-84 years	173	173	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	235	239	44.1
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	15	15	2.0
<i>Multi-racial</i>										
0-40 years	*****	*****	*****	*****	*****	*****	7,423.78 (1,045.70, 52,703.85)	20	20	3.7
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	81	81	17.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	55	56	12.1
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	3.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Unknown</i>										
0-40 years	855	855	*****	*****	*****	*****	107.06 (15.08, 760.06)	1,423	1,439	231.3
41-64 years	6,086	6,086	*****	*****	*****	*****	69.75 (29.03, 167.58)	10,484	10,593	1,733.2
65-74 years	898	898	*****	*****	*****	*****	201.73 (50.45, 806.64)	1,474	1,489	233.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	239	253	40.5
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	1.7

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>White</i>										
0-40 years	115	115	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	215	217	32.5
41-64 years	2,394	2,394	*****	*****	*****	*****	317.89 (165.40, 610.96)	4,115	4,179	722.7
65-74 years	4,850	4,850	*****	*****	*****	*****	125.79 (59.97, 263.86)	7,859	7,979	1,301.9
75-84 years	1,505	1,505	*****	*****	*****	*****	121.19 (30.31, 484.58)	2,325	2,359	389.7
≥ 85 years	75	75	*****	*****	*****	*****	1,456.34 (205.14, 10,339.03)	106	108	16.6
Bydureon, Sinus Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.5
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.2
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	11	11	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14	14	5.4
41-64 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	6.2
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	28	28	4.4
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Black or African American</i>										
0-40 years	14	14	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	23	23	6.9
41-64 years	88	88	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	139	139	38.2
65-74 years	49	49	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	76	76	22.9

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	*****	*****	*****	*****	*****	*****	6,330.16 (891.66, 44,939.85)	*****	*****	4.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.3
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	35	11.1
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	6.3
41-64 years	118	118	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	160	160	42.5
65-74 years	87	87	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	130	130	29.7
75-84 years	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	10.5
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.3
<i>White</i>										
0-40 years	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45	45	14.0
41-64 years	251	251	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	404	404	98.6
65-74 years	387	387	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	654	654	152.2
75-84 years	149	149	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	217	217	49.5

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
≥ 85 years	12	12	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	3.9
Ozempic, Sinus Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	23	23	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	31	31	7.5
41-64 years	259	259	*****	*****	*****	*****	295.10 (41.57, 2,095.04)	409	411	89.4
65-74 years	361	361	*****	*****	*****	*****	222.21 (31.30, 1,577.56)	566	569	120.7
75-84 years	165	165	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	239	239	59.4
≥ 85 years	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25	25	5.8
<i>Asian</i>										
0-40 years	79	79	*****	*****	*****	*****	1,048.97 (147.76, 7,446.95)	111	111	29.8
41-64 years	360	360	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	563	563	137.7
65-74 years	655	655	*****	*****	*****	*****	104.43 (14.71, 741.37)	982	985	217.5
75-84 years	251	251	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	385	386	86.5
≥ 85 years	48	48	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	80	80	16.7
<i>Black or African American</i>										
0-40 years	313	313	*****	*****	*****	*****	508.14 (127.08, 2,031.81)	434	436	110.9
41-64 years	3,802	3,802	*****	*****	*****	*****	232.78 (132.19, 409.89)	5,615	5,642	1,405.5
65-74 years	4,502	4,502	*****	*****	*****	*****	143.68 (74.76, 276.14)	6,369	6,383	1,649.8
75-84 years	1,113	1,113	*****	*****	*****	*****	64.36 (9.07, 456.93)	1,538	1,543	408.1
≥ 85 years	102	102	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	140	141	37.2
<i>Multi-racial</i>										
0-40 years	118	118	*****	*****	*****	*****	704.84 (99.28, 5,003.92)	171	172	42.9
41-64 years	623	623	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	953	957	230.4
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	108	30.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17	17	2.4

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.2
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	92	92	23.2
65-74 years	184	184	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	236	236	77.6
75-84 years	81	81	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	100	100	31.0
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
<i>Unknown</i>										
0-40 years	4,021	4,021	*****	*****	*****	*****	140.81 (67.13, 295.36)	5,878	5,895	1,434.7
41-64 years	31,654	31,654	*****	*****	*****	*****	64.86 (44.78, 93.94)	48,223	48,372	11,753.2
65-74 years	7,739	7,739	*****	*****	*****	*****	36.95 (13.87, 98.46)	11,555	11,590	2,750.4
75-84 years	1,811	1,811	*****	*****	*****	*****	40.40 (5.69, 286.83)	2,610	2,616	646.6
≥ 85 years	142	142	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	195	195	48.8
<i>White</i>										
0-40 years	930	930	*****	*****	*****	*****	315.54 (118.42, 840.73)	1,485	1,491	342.8
41-64 years	14,028	14,028	44	0.31 (0.22, 0.41)	*****	*****	226.92 (168.87, 304.93)	21,446	21,516	5,230.80
65-74 years	30,872	30,872	47	0.15 (0.11, 0.20)	*****	*****	105.31 (79.13, 140.17)	45,929	46,054	10,871.6
75-84 years	11,675	11,675	*****	*****	*****	*****	111.72 (70.39, 177.33)	16,604	16,649	4,067.5
≥ 85 years	936	936	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,320	1,321	329.8
Rybelsus, Sinus Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.4
41-64 years	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	37	12.1
65-74 years	23	23	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	30	30	8.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	19	19	2.7
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Asian</i>										
0-40 years	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38	39	10.9
41-64 years	173	173	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	284	293	67.3
65-74 years	523	523	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	759	770	187.7
75-84 years	292	292	*****	*****	*****	*****	218.10 (30.72, 1,548.35)	457	465	98.6
≥ 85 years	72	72	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	117	117	23.4
<i>Black or African American</i>										
0-40 years	88	88	*****	*****	*****	*****	1,949.04 (487.44, 7,793.31)	127	131	29.2
41-64 years	984	984	*****	*****	*****	*****	79.09 (11.14, 561.50)	1,405	1,436	392.4
65-74 years	1,680	1,680	*****	*****	*****	*****	87.45 (21.87, 349.68)	2,298	2,352	650.1
75-84 years	564	564	*****	*****	*****	*****	134.95 (19.01, 958.07)	749	760	211.0
≥ 85 years	76	76	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	110	28.7
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	9.5
41-64 years	129	129	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	190	195	56.0
65-74 years	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	41	12.6
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	8.5
65-74 years	66	66	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	80	84	32.6
75-84 years	35	35	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	55	57	16.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.9
<i>Unknown</i>										

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	773	773	*****	*****	*****	*****	102.82 (14.48, 729.96)	1,106	1,127	291.8
41-64 years	7,936	7,936	*****	*****	*****	*****	83.81 (43.60, 161.07)	11,573	11,866	3,217.6
65-74 years	3,034	3,034	*****	*****	*****	*****	95.06 (35.68, 253.27)	4,404	4,501	1,126.7
75-84 years	894	894	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,316	1,338	330.7
≥ 85 years	151	151	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	232	235	55.8
<i>White</i>										
0-40 years	209	209	*****	*****	*****	*****	408.37 (57.52, 2,899.18)	303	309	70.2
41-64 years	2,999	2,999	*****	*****	*****	*****	166.23 (79.25, 348.69)	4,598	4,697	1,157.3
65-74 years	8,327	8,327	*****	*****	*****	*****	51.49 (23.13, 114.61)	12,353	12,614	3,030.6
75-84 years	4,305	4,305	*****	*****	*****	*****	171.97 (92.53, 319.62)	6,332	6,453	1,511.7
≥ 85 years	574	574	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	853	860	194.4
Wegovy, Sinus Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	30	30	4.6
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
≥ 85 years	*****	*****	0	NaN	0.0	0	NaN	0	0	0.0
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.8
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	113	113	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	165	170	14.9
41-64 years	520	520	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	804	817	84.2
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	21	21	2.3
41-64 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	116	116	12.8
65-74 years	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	42	45	4.9

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.1
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
Saxenda, Sinus Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.9
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Multi-racial</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	100	100	32.2
41-64 years	266	266	*****	*****	*****	*****	280.47 (39.51, 1,991.12)	410	410	132.1
65-74 years	12	12	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	7.5
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17	17	7.8
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	5.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Sinus Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.0
41-64 years	27	27	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	37	37	11.9
65-74 years	20	20	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	6.4
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Asian</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.0
41-64 years	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	43	43	14.2
65-74 years	30	30	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	9.7
75-84 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	23	23	6.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
<i>Black or African American</i>										
0-40 years	39	39	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	14.9
41-64 years	250	250	*****	*****	*****	*****	310.22 (43.70, 2,202.33)	342	342	100.5
65-74 years	223	223	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	300	300	94.9
75-84 years	*****	*****	*****	*****	*****	*****	2,261.61 (318.57, 16,055.91)	*****	*****	15.0
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.5
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	7.0
41-64 years	41	41	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	66	66	19.1
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
<i>Unknown</i>										

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	140	140	*****	*****	*****	*****	539.35 (75.97, 3,829.04)	201	201	55.5
41-64 years	848	848	*****	*****	*****	*****	336.54 (126.31, 896.70)	1,269	1,270	356.5
65-74 years	337	337	*****	*****	*****	*****	219.12 (30.86, 1,555.60)	462	462	126.0
75-84 years	93	93	*****	*****	*****	*****	955.15 (134.54, 6,780.93)	118	118	32.5
≥ 85 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	6.5
White										
0-40 years	95	95	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	164	164	41.2
41-64 years	947	947	*****	*****	*****	*****	228.54 (73.71, 708.63)	1,423	1,423	367.4
65-74 years	1,420	1,420	*****	*****	*****	*****	95.18 (23.80, 380.59)	2,051	2,051	525.2
75-84 years	597	597	*****	*****	*****	*****	114.82 (16.17, 815.11)	839	839	213.7
≥ 85 years	72	72	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	96	96	26.3
Trulicity, Sinus Tachycardia										
American Indian or Alaska Native										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	31	31	5.3
41-64 years	100	100	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	175	177	38.7
65-74 years	95	95	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	194	195	32.2
75-84 years	43	43	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	67	67	14.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12	12	1.2
Asian										
0-40 years	46	46	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	85	20.2
41-64 years	221	221	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	366	366	84.8
65-74 years	570	570	*****	*****	*****	*****	107.52 (15.15, 763.35)	973	978	208.1
75-84 years	297	297	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	495	497	105.0
≥ 85 years	68	68	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	129	129	21.6
Black or African American										
0-40 years	218	218	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	376	377	83.7

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	2,117	2,117	*****	*****	*****	*****	230.16 (114.49, 503.77)	3,613	3,644	839.2
65-74 years	2,953	2,953	*****	*****	*****	*****	144.93 (65.11, 322.60)	4,729	4,762	1,204.7
75-84 years	1,022	1,022	*****	*****	*****	*****	344.42 (143.35, 827.49)	1,592	1,601	416.7
≥ 85 years	118	118	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	186	187	44.5
<i>Multi-racial</i>										
0-40 years	35	35	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	68	68	12.7
41-64 years	223	223	*****	*****	*****	*****	263.74 (37.15, 1,872.36)	469	473	100.4
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45	45	13.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18	19	5.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
41-64 years	39	39	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	65	67	18.4
65-74 years	136	136	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	230	234	66.3
75-84 years	62	62	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	90	90	30.0
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.7
<i>Unknown</i>										
0-40 years	1,577	1,577	*****	*****	*****	*****	281.49 (126.46, 626.57)	2,730	2,751	632.6
41-64 years	13,585	13,585	*****	*****	*****	*****	89.68 (57.20, 140.60)	25,059	25,238	5,589.0
65-74 years	4,882	4,882	*****	*****	*****	*****	122.04 (63.50, 234.56)	8,576	8,623	1,863.4
75-84 years	1,533	1,533	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,637	2,652	594.5
≥ 85 years	197	197	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	327	328	68.5
<i>White</i>										
0-40 years	536	536	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	999	1,006	185.5
41-64 years	7,457	7,457	20	0.27 (0.15, 0.39)	*****	*****	185.12 (119.43, 286.94)	13,442	13,532	2,952.2
65-74 years	18,730	18,730	23	0.12 (0.07, 0.17)	*****	*****	82.34 (54.72, 123.91)	32,607	32,794	6,969.6

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	8,880	8,880	11	0.12 (0.05, 0.20)	*****	*****	85.88 (47.56, 155.07)	15,077	15,161	3,232.30
≥ 85 years	1,172	1,172	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,066	2,074	406.0
Xultophy, Sinus Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.5
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	11.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Multi-racial</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.8
41-64 years	27	27	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	11.6
65-74 years	22	22	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	29	29	6.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.3
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
41-64 years	42	42	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	13.3
65-74 years	127	127	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	161	161	49.4
75-84 years	66	66	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	95	95	19.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.6
Mounjaro, Supraventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	4.9
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	19	19	2.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Asian</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
41-64 years	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	53	9.6
65-74 years	53	53	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	71	71	12.5
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	4.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	70	73	13.0
41-64 years	671	671	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,074	1,085	198.4
65-74 years	744	744	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,100	1,125	209.6
75-84 years	173	173	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	235	239	44.1
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	15	15	2.0
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	20	20	3.7
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	81	81	17.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17	17	1.6
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	55	56	12.1
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Unknown</i>										
0-40 years	855	855	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,423	1,439	231.3

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	6,086	6,086	*****	*****	*****	*****	13.95 (1.96, 99.04)	10,484	10,593	1,733.2
65-74 years	898	898	*****	*****	*****	*****	100.87 (14.21, 716.09)	1,474	1,489	233.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	239	253	40.5
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	1.7
<i>White</i>										
0-40 years	115	115	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	215	217	32.5
41-64 years	2,394	2,394	*****	*****	*****	*****	70.64 (17.67, 282.46)	4,115	4,179	722.7
65-74 years	4,850	4,850	*****	*****	*****	*****	71.88 (26.98, 191.52)	7,859	7,979	1,301.9
75-84 years	1,505	1,505	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,325	2,359	389.7
≥ 85 years	75	75	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	106	108	16.6
Bydureon, Supraventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.5
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.2
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	11	11	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14	14	5.4
41-64 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	6.2
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	28	28	4.4
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Black or African American</i>										
0-40 years	14	14	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	23	23	6.9
41-64 years	88	88	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	139	139	38.2

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	49	49	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	76	76	22.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.3
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	35	11.1
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	6.3
41-64 years	118	118	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	160	160	42.5
65-74 years	87	87	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	130	130	29.7
75-84 years	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	10.5
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.3
<i>White</i>										
0-40 years	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45	45	14.0
41-64 years	251	251	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	404	404	98.6
65-74 years	387	387	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	654	654	152.2
75-84 years	149	149	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	217	217	49.5

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
≥ 85 years	12	12	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	3.9
Ozempic, Supraventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	23	23	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	31	31	7.5
41-64 years	259	259	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	409	411	89.4
65-74 years	361	361	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	566	569	120.7
75-84 years	165	165	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	239	239	59.4
≥ 85 years	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25	25	5.8
<i>Asian</i>										
0-40 years	79	79	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	111	111	29.8
41-64 years	360	360	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	563	563	137.7
65-74 years	655	655	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	982	985	217.5
75-84 years	251	251	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	385	386	86.5
≥ 85 years	48	48	*****	*****	*****	*****	1,389.31 (195.70, 9,863.18)	80	80	16.7
<i>Black or African American</i>										
0-40 years	313	313	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	434	436	110.9
41-64 years	3,802	3,802	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	5,615	5,642	1,405.5
65-74 years	4,502	4,502	*****	*****	*****	*****	63.86 (23.97, 170.14)	6,369	6,383	1,649.8
75-84 years	1,113	1,113	*****	*****	*****	*****	193.09 (62.27, 598.69)	1,538	1,543	408.1
≥ 85 years	102	102	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	140	141	37.2
<i>Multi-racial</i>										
0-40 years	118	118	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	171	172	42.9
41-64 years	623	623	*****	*****	*****	*****	123.68 (17.56, 885.11)	953	957	230.4
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	108	30.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17	17	2.4

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.2
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	92	92	23.2
65-74 years	184	184	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	236	236	77.6
75-84 years	81	81	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	100	100	31.0
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
<i>Unknown</i>										
0-40 years	4,021	4,021	*****	*****	*****	*****	20.12 (2.83, 142.80)	5,878	5,895	1,434.7
41-64 years	31,654	31,654	*****	*****	*****	*****	23.17 (12.46, 43.05)	48,223	48,372	11,753.2
65-74 years	7,739	7,739	*****	*****	*****	*****	64.67 (30.83, 135.64)	11,555	11,590	2,750.4
75-84 years	1,811	1,811	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,610	2,616	646.6
≥ 85 years	142	142	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	195	195	48.8
<i>White</i>										
0-40 years	930	930	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,485	1,491	342.8
41-64 years	14,028	14,028	*****	*****	*****	*****	25.79 (10.73, 61.95)	21,446	21,516	5,230.80
65-74 years	30,872	30,872	27	0.09 (0.05, 0.12)	*****	*****	60.50 (41.49, 88.22)	45,929	46,054	10,871.6
75-84 years	11,675	11,675	*****	*****	*****	*****	68.27 (37.81, 123.28)	16,604	16,649	4,067.5
≥ 85 years	936	936	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,320	1,321	329.8
Rybelsus, Supraventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.4
41-64 years	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	37	12.1
65-74 years	23	23	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	30	30	8.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	19	19	2.7
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Asian</i>										
0-40 years	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38	39	10.9
41-64 years	173	173	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	284	293	67.3
65-74 years	523	523	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	759	770	187.7
75-84 years	292	292	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	457	465	98.6
≥ 85 years	72	72	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	117	117	23.4
<i>Black or African American</i>										
0-40 years	88	88	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	127	131	29.2
41-64 years	984	984	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,405	1,436	392.4
65-74 years	1,680	1,680	*****	*****	*****	*****	43.73 (6.16, 310.43)	2,298	2,352	650.1
75-84 years	564	564	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	749	760	211.0
≥ 85 years	76	76	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	110	28.7
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	9.5
41-64 years	129	129	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	190	195	56.0
65-74 years	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	41	12.6
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	8.5
65-74 years	66	66	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	80	84	32.6
75-84 years	35	35	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	55	57	16.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.9
<i>Unknown</i>										
0-40 years	773	773	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,106	1,127	291.8

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	7,936	7,936	*****	*****	*****	*****	18.62 (4.66, 74.47)	11,573	11,866	3,217.6
65-74 years	3,034	3,034	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,404	4,501	1,126.7
75-84 years	894	894	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,316	1,338	330.7
≥ 85 years	151	151	*****	*****	*****	*****	478.64 (67.42, 3.398.02)	232	235	55.8
<i>White</i>										
0-40 years	209	209	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	303	309	70.2
41-64 years	2,999	2,999	*****	*****	*****	*****	47.49 (11.88, 189.91)	4,598	4,697	1,157.3
65-74 years	8,327	8,327	*****	*****	*****	*****	34.33 (12.88, 91.46)	12,353	12,614	3,030.6
75-84 years	4,305	4,305	*****	*****	*****	*****	85.98 (35.79, 206.58)	6,332	6,453	1,511.7
≥ 85 years	574	574	*****	*****	*****	*****	137.23 (19.33, 974.23)	853	860	194.4
Wegovy, Supraventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	30	30	4.6

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.8
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	113	113	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	165	170	14.9
41-64 years	520	520	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	804	817	84.2
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	21	21	2.3
41-64 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	116	116	12.8
65-74 years	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	42	45	4.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.1

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
Saxenda, Supraventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.9
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Multi-racial</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	100	100	32.2
41-64 years	266	266	*****	*****	*****	*****	280.47 (39.51, 1,991.12)	410	410	132.1
65-74 years	12	12	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	7.5
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17	17	7.8
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	5.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Supraventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.0
41-64 years	27	27	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	37	37	11.9
65-74 years	20	20	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	6.4
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.0
41-64 years	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	43	43	14.2
65-74 years	30	30	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	9.7
75-84 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	23	23	6.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
<i>Black or African American</i>										
0-40 years	39	39	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	14.9
41-64 years	250	250	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	342	342	100.5
65-74 years	223	223	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	300	300	94.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	15.0
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.5
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	7.0
41-64 years	41	41	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	19.1
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
<i>Unknown</i>										
0-40 years	140	140	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	201	201	55.5
41-64 years	848	848	*****	*****	*****	*****	84.14 (11.85, 597.31)	1,269	1,270	356.5

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	337	337	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	462	462	126.0
75-84 years	93	93	*****	*****	*****	*****	955.15 (134.54, 6,780.93)	118	118	32.5
≥ 85 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	6.5
<i>White</i>										
0-40 years	95	95	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	164	164	41.2
41-64 years	947	947	*****	*****	*****	*****	76.18 (10.73, 540.83)	1,423	1,423	367.4
65-74 years	1,420	1,420	*****	*****	*****	*****	47.59 (6.70, 337.86)	2,051	2,051	525.2
75-84 years	597	597	*****	*****	*****	*****	114.82 (16.17, 815.11)	839	839	213.7
≥ 85 years	72	72	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	96	96	26.3
Trulicity, Supraventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	31	31	5.3
41-64 years	100	100	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	175	177	38.7
65-74 years	95	95	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	194	195	32.2
75-84 years	43	43	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	67	67	14.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12	12	1.2
<i>Asian</i>										
0-40 years	46	46	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	85	20.2
41-64 years	221	221	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	366	366	84.8
65-74 years	570	570	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	973	978	208.1
75-84 years	297	297	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	495	497	105.0
≥ 85 years	68	68	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	129	129	21.6
<i>Black or African American</i>										
0-40 years	218	218	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	376	377	83.7
41-64 years	2,117	2,117	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	3,613	3,644	839.2
65-74 years	2,953	2,953	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,729	4,762	1,204.7

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	1,022	1,022	*****	*****	*****	*****	68.88 (9.70, 489.03)	1,592	1,601	416.7
≥ 85 years	118	118	*****	*****	*****	*****	694.39 (97.81, 4,929.71)	186	187	44.5
<i>Multi-racial</i>										
0-40 years	35	35	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	68	68	12.7
41-64 years	223	223	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	469	473	100.4
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45	45	13.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18	19	5.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
41-64 years	39	39	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	65	67	18.4
65-74 years	136	136	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	230	234	66.3
75-84 years	62	62	*****	*****	*****	*****	1,156.95 (162.97, 8,213.59)	90	90	30.0
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.7
<i>Unknown</i>										
0-40 years	1,577	1,577	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,730	2,751	632.6
41-64 years	13,585	13,585	*****	*****	*****	*****	18.88 (7.09, 50.30)	25,059	25,238	5,589.0
65-74 years	4,882	4,882	*****	*****	*****	*****	54.23 (20.36, 144.52)	8,576	8,623	1,863.4
75-84 years	1,533	1,533	*****	*****	*****	*****	45.40 (6.39, 322.29)	2,637	2,652	594.5
≥ 85 years	197	197	*****	*****	*****	*****	399.62 (56.29, 2,837.01)	327	328	68.5
<i>White</i>										
0-40 years	536	536	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	999	1,006	185.5
41-64 years	7,457	7,457	*****	*****	*****	*****	64.79 (30.89, 135.91)	13,442	13,532	2,952.2
65-74 years	18,730	18,730	*****	*****	*****	*****	39.38 (21.81, 71.11)	32,607	32,794	6,969.6
75-84 years	8,880	8,880	*****	*****	*****	*****	70.26 (36.56, 135.04)	15,077	15,161	3,232.30

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
≥ 85 years	1,172	1,172	*****	*****	*****	*****	65.94 (9.29, 468.13)	2,066	2,074	406.0
Xultophy, Supraventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.5
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	11.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Multi-racial</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.8
41-64 years	27	27	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	11.6
65-74 years	22	22	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	29	29	6.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12	12	4.3
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
41-64 years	42	42	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	13.3
65-74 years	127	127	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	161	161	49.4
75-84 years	66	66	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	95	95	19.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14	14	4.6
Mounjaro, Other Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	4.9
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	19	19	2.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
41-64 years	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	53	9.6
65-74 years	53	53	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	71	71	12.5
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	4.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	70	73	13.0
41-64 years	671	671	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,074	1,085	198.4
65-74 years	744	744	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,100	1,125	209.6
75-84 years	173	173	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	235	239	44.1
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	15	15	2.0
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	20	20	3.7
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	81	81	17.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17	17	1.6
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	55	56	12.1
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Unknown</i>										
0-40 years	855	855	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,423	1,439	231.3
41-64 years	6,086	6,086	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	10,484	10,593	1,733.2

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	898	898	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,474	1,489	233.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	239	253	40.5
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	1.7
<i>White</i>										
0-40 years	115	115	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	215	217	32.5
41-64 years	2,394	2,394	*****	*****	*****	*****	35.32 (4.98, 250.75)	4,115	4,179	722.7
65-74 years	4,850	4,850	*****	*****	*****	*****	71.88 (26.98, 191.52)	7,859	7,979	1,301.9
75-84 years	1,505	1,505	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,325	2,359	389.7
≥ 85 years	75	75	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	106	108	16.6
Bydureon, Other Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.5
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.2
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	11	11	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14	14	5.4
41-64 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	6.2
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	28	28	4.4
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Black or African American</i>										
0-40 years	14	14	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	23	23	6.9
41-64 years	88	88	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	139	139	38.2
65-74 years	49	49	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	76	76	22.9

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	0.0	9	0.00 (0.00, 0.00)	*****	*****	0.1
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.3
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	35	11.1
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	6.3
41-64 years	118	118	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	160	160	42.5
65-74 years	87	87	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	130	130	29.7
75-84 years	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	10.5
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.3
<i>White</i>										
0-40 years	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45	45	14.0
41-64 years	251	251	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	404	404	98.6
65-74 years	387	387	*****	*****	*****	*****	169.91 (23.93, 1,206.23)	654	654	152.2
75-84 years	149	149	*****	*****	*****	*****	546.54 (76.98, 3,880.04)	217	217	49.5
≥ 85 years	12	12	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	3.9

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Ozempic, Other Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	23	23	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	31	31	7.5
41-64 years	259	259	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	409	411	89.4
65-74 years	361	361	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	566	569	120.7
75-84 years	165	165	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	239	239	59.4
≥ 85 years	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25	25	5.8
<i>Asian</i>										
0-40 years	79	79	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	111	111	29.8
41-64 years	360	360	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	563	563	137.7
65-74 years	655	655	*****	*****	*****	*****	208.86 (52.23, 835.13)	982	985	217.5
75-84 years	251	251	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	385	386	86.5
≥ 85 years	48	48	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	80	80	16.7
<i>Black or African American</i>										
0-40 years	313	313	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	434	436	110.9
41-64 years	3,802	3,802	*****	*****	*****	*****	96.99 (40.37, 233.02)	5,615	5,642	1,405.5
65-74 years	4,502	4,502	*****	*****	*****	*****	47.89 (15.45, 148.50)	6,369	6,383	1,649.8
75-84 years	1,113	1,113	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,538	1,543	408.1
≥ 85 years	102	102	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	140	141	37.2
<i>Multi-racial</i>										
0-40 years	118	118	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	171	172	42.9
41-64 years	623	623	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	953	957	230.4
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	108	30.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17	17	2.4
≥ 85 years	0	0	0	NaN	*****	*****	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.2
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	92	92	23.2
65-74 years	184	184	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	236	236	77.6
75-84 years	81	81	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	100	100	31.0
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
Unknown										
0-40 years	4,021	4,021	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	5,878	5,895	1,434.7
41-64 years	31,654	31,654	*****	*****	*****	*****	9.27 (3.48, 23.69)	48,223	48,372	11,753.2
65-74 years	7,739	7,739	*****	*****	*****	*****	9.23 (1.30, 65.58)	11,555	11,590	2,750.4
75-84 years	1,811	1,811	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,610	2,616	646.6
≥ 85 years	142	142	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	195	195	48.8
White										
0-40 years	930	930	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,485	1,491	342.8
41-64 years	14,028	14,028	*****	*****	*****	*****	36.10 (17.21, 75.73)	21,446	21,516	5,230.80
65-74 years	30,872	30,872	*****	*****	*****	*****	40.33 (25.41, 64.02)	45,929	46,054	10,871.6
75-84 years	11,675	11,675	*****	*****	*****	*****	62.07 (33.40, 115.36)	16,604	16,649	4,067.5
≥ 85 years	936	936	*****	*****	*****	*****	235.09 (79.05, 759.94)	1,320	1,321	329.8
Rybelsus, Other Tachycardia										
American Indian or Alaska Native										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.4
41-64 years	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	37	12.1
65-74 years	23	23	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	30	30	8.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	19	19	2.7
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
Asian										
0-40 years	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38	39	10.9

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	173	173	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	284	293	67.3
65-74 years	523	523	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	759	770	187.7
75-84 years	292	292	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	457	465	98.6
≥ 85 years	72	72	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	117	117	23.4
<i>Black or African American</i>										
0-40 years	88	88	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	127	131	29.2
41-64 years	984	984	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,405	1,436	392.4
65-74 years	1,680	1,680	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,298	2,352	650.1
75-84 years	564	564	*****	*****	*****	*****	134.95 (19.01, 958.07)	749	760	211.0
≥ 85 years	76	76	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	110	28.7
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	9.5
41-64 years	129	129	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	190	195	56.0
65-74 years	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	41	12.6
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	8.5
65-74 years	66	66	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	80	84	32.6
75-84 years	35	35	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	55	57	16.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.9
<i>Unknown</i>										
0-40 years	773	773	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,106	1,127	291.8
41-64 years	7,936	7,936	*****	*****	*****	*****	9.31 (1.31, 66.11)	11,573	11,866	3,217.6
65-74 years	3,034	3,034	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,404	4,501	1,126.7

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	894	894	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,316	1,338	330.7
≥ 85 years	151	151	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	232	235	55.8
<i>White</i>										
0-40 years	209	209	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	303	309	70.2
41-64 years	2,999	2,999	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,598	4,697	1,157.3
65-74 years	8,327	8,327	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12,353	12,614	3,030.6
75-84 years	4,305	4,305	*****	*****	*****	*****	34.39 (8.60, 137.52)	6,332	6,453	1,511.7
≥ 85 years	574	574	*****	*****	*****	*****	137.23 (19.33, 974.23)	853	860	194.4
Wegovy, Other Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	30	30	4.6
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.8
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	113	113	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	165	170	14.9
41-64 years	520	520	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	804	817	84.2
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	21	21	2.3
41-64 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	116	116	12.8
65-74 years	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	42	45	4.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.1
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
Saxenda, Other Tachycardia										

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.9
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Multi-racial</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	100	100	32.2
41-64 years	266	266	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	410	410	132.1
65-74 years	12	12	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	7.5
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17	17	7.8
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	5.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Other Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.0
41-64 years	27	27	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	37	37	11.9
65-74 years	20	20	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	6.4
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.0
41-64 years	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	43	43	14.2

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	30	30	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	9.7
75-84 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	23	23	6.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
<i>Black or African American</i>										
0-40 years	39	39	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	14.9
41-64 years	250	250	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	342	342	100.5
65-74 years	223	223	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	300	300	94.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	15.0
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.5
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	7.0
41-64 years	41	41	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	66	66	19.1
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
<i>Unknown</i>										
0-40 years	140	140	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	201	201	55.5
41-64 years	848	848	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,269	1,270	356.5
65-74 years	337	337	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	462	462	126.0
75-84 years	93	93	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	118	118	32.5

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
≥ 85 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	6.5
<i>White</i>										
0-40 years	95	95	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	164	164	41.2
41-64 years	947	947	*****	*****	*****	*****	76.18 (10.73, 540.83)	1,423	1,423	367.4
65-74 years	1,420	1,420	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,051	2,051	525.2
75-84 years	597	597	*****	*****	*****	*****	229.63 (57.43, 918.19)	839	839	213.7
≥ 85 years	72	72	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	96	96	26.3
Trulicity, Other Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	31	31	5.3
41-64 years	100	100	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	175	177	38.7
65-74 years	95	95	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	194	195	32.2
75-84 years	43	43	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	67	67	14.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12	12	1.2
<i>Asian</i>										
0-40 years	46	46	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	85	20.2
41-64 years	221	221	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	366	366	84.8
65-74 years	570	570	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	973	978	208.1
75-84 years	297	297	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	495	497	105.0
≥ 85 years	68	68	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	129	129	21.6
<i>Black or African American</i>										
0-40 years	218	218	*****	*****	*****	*****	335.86 (47.31, 2,384.39)	376	377	83.7
41-64 years	2,117	2,117	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	3,613	3,644	839.2
65-74 years	2,953	2,953	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,729	4,762	1,204.7
75-84 years	1,022	1,022	*****	*****	*****	*****	68.88 (9.70, 489.03)	1,592	1,601	416.7
≥ 85 years	118	118	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	186	187	44.5

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Multi-racial</i>										
0-40 years	35	35	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	68	68	12.7
41-64 years	223	223	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	469	473	100.4
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45	45	13.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18	19	5.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
41-64 years	39	39	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	65	67	18.4
65-74 years	136	136	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	230	234	66.3
75-84 years	62	62	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	90	90	30.0
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.7
<i>Unknown</i>										
0-40 years	1,577	1,577	*****	*****	*****	*****	46.91 (6.61, 333.06)	2,730	2,751	632.6
41-64 years	13,585	13,585	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25,059	25,238	5,589.0
65-74 years	4,882	4,882	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	8,576	8,623	1,863.4
75-84 years	1,533	1,533	*****	*****	*****	*****	45.40 (6.39, 322.29)	2,637	2,652	594.5
≥ 85 years	197	197	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	327	328	68.5
<i>White</i>										
0-40 years	536	536	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	999	1,006	185.5
41-64 years	7,457	7,457	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13,442	13,532	2,952.2
65-74 years	18,730	18,730	*****	*****	*****	*****	53.70 (32.37, 89.08)	32,607	32,794	6,969.6
75-84 years	8,880	8,880	*****	*****	*****	*****	15.61 (3.90, 62.43)	15,077	15,161	3,232.30
≥ 85 years	1,172	1,172	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,066	2,074	406.0

Xultophy, Other Tachycardia

American Indian or Alaska Native

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.5
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	11.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Multi-racial</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.8
41-64 years	27	27	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	11.6
65-74 years	22	22	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	29	29	6.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.3
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
41-64 years	42	42	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	13.3
65-74 years	127	127	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	161	161	49.4
75-84 years	66	66	*****	*****	*****	*****	995.77 (140.26, 7,069.33)	95	95	19.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.6
Mounjaro, Cardiac Arrest										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	4.9
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	19	19	2.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
41-64 years	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	53	9.6
65-74 years	53	53	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	71	71	12.5

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	4.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	70	73	13.0
41-64 years	671	671	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,074	1,085	198.4
65-74 years	744	744	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,100	1,125	209.6
75-84 years	173	173	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	235	239	44.1
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	15	15	2.0
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	20	20	3.7
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	81	81	17.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	55	56	12.1
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	3.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Unknown</i>										
0-40 years	855	855	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,423	1,439	231.3
41-64 years	6,086	6,086	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	10,484	10,593	1,733.2
65-74 years	898	898	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,474	1,489	233.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	239	253	40.5
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	1.7

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
White										
0-40 years	115	115	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	215	217	32.5
41-64 years	2,394	2,394	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,115	4,179	722.7
65-74 years	4,850	4,850	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	7,859	7,979	1,301.9
75-84 years	1,505	1,505	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,325	2,359	389.7
≥ 85 years	75	75	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	106	108	16.6
Bydureon, Cardiac Arrest										
American Indian or Alaska Native										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.5
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.2
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Asian										
0-40 years	11	11	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14	14	5.4
41-64 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	6.2
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	28	28	4.4
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
Black or African American										
0-40 years	14	14	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	23	23	6.9
41-64 years	88	88	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	139	139	38.2
65-74 years	49	49	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	76	76	22.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
Multi-racial										

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.3
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	35	11.1
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	6.3
41-64 years	118	118	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	160	160	42.5
65-74 years	87	87	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	130	130	29.7
75-84 years	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	10.5
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.3
<i>White</i>										
0-40 years	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45	45	14.0
41-64 years	251	251	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	404	404	98.6
65-74 years	387	387	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	654	654	152.2
75-84 years	149	149	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	217	217	49.5
≥ 85 years	12	12	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	3.9
Ozempic, Cardiac Arrest										
<i>American Indian or Alaska Native</i>										
0-40 years	23	23	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	31	31	7.5

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	259	259	*****	*****	*****	*****	295.10 (41.57, 2,095.04)	409	411	89.4
65-74 years	361	361	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	566	569	120.7
75-84 years	165	165	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	239	239	59.4
≥ 85 years	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25	25	5.8
<i>Asian</i>										
0-40 years	79	79	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	111	111	29.8
41-64 years	360	360	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	563	563	137.7
65-74 years	655	655	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	982	985	217.5
75-84 years	251	251	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	385	386	86.5
≥ 85 years	48	48	*****	*****	*****	*****	1,389.31 (195.70, 9,863.18)	80	80	16.7
<i>Black or African American</i>										
0-40 years	313	313	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	434	436	110.9
41-64 years	3,802	3,802	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	5,615	5,642	1,405.5
65-74 years	4,502	4,502	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	6,369	6,383	1,649.8
75-84 years	1,113	1,113	*****	*****	*****	*****	64.36 (9.07, 456.93)	1,538	1,543	408.1
≥ 85 years	102	102	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	140	141	37.2
<i>Multi-racial</i>										
0-40 years	118	118	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	171	172	42.9
41-64 years	623	623	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	953	957	230.4
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	108	30.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17	17	2.4
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.2
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	92	92	23.2

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	184	184	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	236	236	77.6
75-84 years	81	81	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	100	100	31.0
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
<i>Unknown</i>										
0-40 years	4,021	4,021	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	5,878	5,895	1,434.7
41-64 years	31,654	31,654	*****	*****	*****	*****	6.95 (2.23, 21.55)	48,223	48,372	11,753.2
65-74 years	7,739	7,739	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	11,555	11,590	2,750.4
75-84 years	1,811	1,811	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,610	2,616	646.6
≥ 85 years	142	142	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	195	195	48.8
<i>White</i>										
0-40 years	930	930	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,485	1,491	342.8
41-64 years	14,028	14,028	*****	*****	*****	*****	15.47 (4.99, 47.97)	21,446	21,516	5,230.80
65-74 years	30,872	30,872	*****	*****	*****	*****	15.69 (7.48, 32.90)	45,929	46,054	10,871.6
75-84 years	11,675	11,675	*****	*****	*****	*****	12.41 (3.10, 49.64)	16,604	16,649	4,067.5
≥ 85 years	936	936	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,320	1,321	329.8
Rybelsus, Cardiac Arrest										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.4
41-64 years	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	37	12.1
65-74 years	23	23	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	30	30	8.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	19	19	2.7
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
<i>Asian</i>										
0-40 years	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38	39	10.9
41-64 years	173	173	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	284	293	67.3
65-74 years	523	523	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	759	770	187.7

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	292	292	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	457	465	98.6
≥ 85 years	72	72	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	117	117	23.4
<i>Black or African American</i>										
0-40 years	88	88	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	127	131	29.2
41-64 years	984	984	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,405	1,436	392.4
65-74 years	1,680	1,680	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,298	2,352	650.1
75-84 years	564	564	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	749	760	211.0
≥ 85 years	76	76	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	110	28.7
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	9.5
41-64 years	129	129	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	190	195	56.0
65-74 years	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	41	12.6
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	8.5
65-74 years	66	66	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	80	84	32.6
75-84 years	35	35	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	55	57	16.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.9
<i>Unknown</i>										
0-40 years	773	773	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,106	1,127	291.8
41-64 years	7,936	7,936	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	11,573	11,866	3,217.6
65-74 years	3,034	3,034	*****	*****	*****	*****	23.76 (3.35, 168.71)	4,404	4,501	1,126.7
75-84 years	894	894	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,316	1,338	330.7
≥ 85 years	151	151	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	232	235	55.8

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>White</i>										
0-40 years	209	209	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	303	309	70.2
41-64 years	2,999	2,999	*****	*****	*****	*****	23.75 (3.35, 168.59)	4,598	4,697	1,157.3
65-74 years	8,327	8,327	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12,353	12,614	3,030.6
75-84 years	4,305	4,305	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	6,332	6,453	1,511.7
≥ 85 years	574	574	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	853	860	194.4
Wegovy, Cardiac Arrest										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	30	30	4.6
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Multi-racial</i>										

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
41-64 years	14	14	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.8
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	113	113	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	165	170	14.9
41-64 years	520	520	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	804	817	84.2
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	21	21	2.3
41-64 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	116	116	12.8
65-74 years	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	42	45	4.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.1
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
Saxenda, Cardiac Arrest										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>41-64 years</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>65-74 years</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>75-84 years</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>≥ 85 years</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
<i>0-40 years</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>41-64 years</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>65-74 years</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>75-84 years</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>≥ 85 years</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
<i>0-40 years</i>	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
<i>41-64 years</i>	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.9
<i>65-74 years</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>75-84 years</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>≥ 85 years</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Multi-racial</i>										
<i>0-40 years</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>41-64 years</i>	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
<i>65-74 years</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>75-84 years</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>≥ 85 years</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
<i>0-40 years</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>41-64 years</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>65-74 years</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	100	100	32.2
41-64 years	266	266	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	410	410	132.1
65-74 years	12	12	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	7.5
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17	17	7.8
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	5.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Cardiac Arrest										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.0
41-64 years	27	27	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	37	37	11.9
65-74 years	20	20	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	6.4
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.0
41-64 years	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	43	43	14.2
65-74 years	30	30	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	9.7
75-84 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	23	23	6.2

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
<i>Black or African American</i>										
0-40 years	39	39	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	14.9
41-64 years	250	250	*****	*****	*****	*****	310.22 (43.70, 2,202.33)	342	342	100.5
65-74 years	223	223	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	300	300	94.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	15.0
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.5
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	30	30	7.0
41-64 years	41	41	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	66	66	19.1
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
<i>Unknown</i>										
0-40 years	140	140	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	201	201	55.5
41-64 years	848	848	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,269	1,270	356.5
65-74 years	337	337	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	462	462	126.0
75-84 years	93	93	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	118	118	32.5
≥ 85 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	6.5
<i>White</i>										

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	95	95	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	164	164	41.2
41-64 years	947	947	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,423	1,423	367.4
65-74 years	1,420	1,420	*****	*****	*****	*****	95.18 (23.80, 380.59)	2,051	2,051	525.2
75-84 years	597	597	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	839	839	213.7
≥ 85 years	72	72	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	96	96	26.3
Trulicity, Cardiac Arrest										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	31	31	5.3
41-64 years	100	100	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	175	177	38.7
65-74 years	95	95	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	194	195	32.2
75-84 years	43	43	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	67	67	14.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12	12	1.2
<i>Asian</i>										
0-40 years	46	46	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	85	20.2
41-64 years	221	221	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	366	366	84.8
65-74 years	570	570	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	973	978	208.1
75-84 years	297	297	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	495	497	105.0
≥ 85 years	68	68	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	129	129	21.6
<i>Black or African American</i>										
0-40 years	218	218	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	376	377	83.7
41-64 years	2,117	2,117	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	3,613	3,644	839.2
65-74 years	2,953	2,953	*****	*****	*****	*****	23.16 (3.40, 171.49)	4,729	4,762	1,204.7
75-84 years	1,022	1,022	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,592	1,601	416.7
≥ 85 years	118	118	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	186	187	44.5
<i>Multi-racial</i>										
0-40 years	35	35	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	68	68	12.7

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	223	223	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	469	473	100.4
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45	45	13.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18	19	5.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
41-64 years	39	39	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	65	67	18.4
65-74 years	136	136	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	230	234	66.3
75-84 years	62	62	*****	*****	*****	*****	1,156.95 (162.97, 8,213.59)	90	90	30.0
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.7
<i>Unknown</i>										
0-40 years	1,577	1,577	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,730	2,751	632.6
41-64 years	13,585	13,585	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25,059	25,238	5,589.0
65-74 years	4,882	4,882	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	8,576	8,623	1,863.4
75-84 years	1,533	1,533	*****	*****	*****	*****	45.40 (6.39, 322.29)	2,637	2,652	594.5
≥ 85 years	197	197	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	327	328	68.5
<i>White</i>										
0-40 years	536	536	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	999	1,006	185.5
41-64 years	7,457	7,457	*****	*****	*****	*****	18.51 (4.63, 74.02)	13,442	13,532	2,952.2
65-74 years	18,730	18,730	*****	*****	*****	*****	10.74 (3.46, 33.30)	32,607	32,794	6,969.6
75-84 years	8,880	8,880	*****	*****	*****	*****	31.23 (11.72, 83.20)	15,077	15,161	3,232.30
≥ 85 years	1,172	1,172	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,066	2,074	406.0
Xultophy, Cardiac Arrest										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.5
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	11.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Multi-racial</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.8
41-64 years	27	27	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	11.6
65-74 years	22	22	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	29	29	6.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.3
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
41-64 years	42	42	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	13.3
65-74 years	127	127	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	161	161	49.4
75-84 years	66	66	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	95	95	19.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.6
Mounjaro, Ventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	4.9
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	19	19	2.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
41-64 years	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	53	9.6
65-74 years	53	53	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	71	71	12.5
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	4.2

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	70	73	13.0
41-64 years	671	671	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,074	1,085	198.4
65-74 years	744	744	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,100	1,125	209.6
75-84 years	173	173	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	235	239	44.1
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	15	15	2.0
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	20	20	3.7
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	81	81	17.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17	17	1.6
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	55	56	12.1
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Unknown</i>										
0-40 years	855	855	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,423	1,439	231.3
41-64 years	6,086	6,086	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	10,484	10,593	1,733.2
65-74 years	898	898	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,474	1,489	233.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	239	253	40.5
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	1.7
<i>White</i>										

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	115	115	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	215	217	32.5
41-64 years	2,394	2,394	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,115	4,179	722.7
65-74 years	4,850	4,850	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	7,859	7,979	1,301.9
75-84 years	1,505	1,505	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,325	2,359	389.7
≥ 85 years	75	75	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	106	108	16.6
Bydureon, Ventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.5
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.2
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	11	11	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14	14	5.4
41-64 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	6.2
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	28	28	4.4
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Black or African American</i>										
0-40 years	14	14	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	23	23	6.9
41-64 years	88	88	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	139	139	38.2
65-74 years	49	49	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	76	76	22.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.3

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	11.1
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	6.3
41-64 years	118	118	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	160	160	42.5
65-74 years	87	87	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	130	130	29.7
75-84 years	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	10.5
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.3
<i>White</i>										
0-40 years	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45	45	14.0
41-64 years	251	251	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	404	404	98.6
65-74 years	387	387	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	654	654	152.2
75-84 years	149	149	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	217	217	49.5
≥ 85 years	12	12	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	3.9
Ozempic, Ventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	23	23	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	31	31	7.5
41-64 years	259	259	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	409	411	89.4

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	361	361	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	566	569	120.7
75-84 years	165	165	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	239	239	59.4
≥ 85 years	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25	25	5.8
<i>Asian</i>										
0-40 years	79	79	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	111	111	29.8
41-64 years	360	360	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	563	563	137.7
65-74 years	655	655	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	982	985	217.5
75-84 years	251	251	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	385	386	86.5
≥ 85 years	48	48	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	80	80	16.7
<i>Black or African American</i>										
0-40 years	313	313	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	434	436	110.9
41-64 years	3,802	3,802	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	5,615	5,642	1,405.5
65-74 years	4,502	4,502	*****	*****	*****	*****	31.93 (7.99, 127.67)	6,369	6,383	1,649.8
75-84 years	1,113	1,113	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,538	1,543	408.1
≥ 85 years	102	102	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	140	141	37.2
<i>Multi-racial</i>										
0-40 years	118	118	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	171	172	42.9
41-64 years	623	623	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	953	957	230.4
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	108	30.3
75-84 years	*****	*****	*****	*****	*****	*****	6,943.92 (978.11, 49,297.13)	17	17	2.4
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.2
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	92	92	23.2
65-74 years	184	184	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	236	236	77.6

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	81	81	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	100	100	31.0
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
<i>Unknown</i>										
0-40 years	4,021	4,021	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	5,878	5,895	1,434.7
41-64 years	31,654	31,654	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	48,223	48,372	11,753.2
65-74 years	7,739	7,739	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	11,555	11,590	2,750.4
75-84 years	1,811	1,811	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,610	2,616	646.6
≥ 85 years	142	142	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	195	195	48.8
<i>White</i>										
0-40 years	930	930	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,485	1,491	342.8
41-64 years	14,028	14,028	*****	*****	*****	*****	5.16 (0.73, 36.61)	21,446	21,516	5,230.80
65-74 years	30,872	30,872	*****	*****	*****	*****	4.48 (1.12, 17.92)	45,929	46,054	10,871.6
75-84 years	11,675	11,675	*****	*****	*****	*****	6.21 (0.87, 44.06)	16,604	16,649	4,067.5
≥ 85 years	936	936	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,320	1,321	329.8
Rybelsus, Ventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.4
41-64 years	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	37	12.1
65-74 years	23	23	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	30	30	8.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	19	19	2.7
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
<i>Asian</i>										
0-40 years	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38	39	10.9
41-64 years	173	173	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	284	293	67.3
65-74 years	523	523	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	759	770	187.7
75-84 years	292	292	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	457	465	98.6

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
≥ 85 years	72	72	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	117	117	23.4
<i>Black or African American</i>										
0-40 years	88	88	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	127	131	29.2
41-64 years	984	984	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,405	1,436	392.4
65-74 years	1,680	1,680	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,298	2,352	650.1
75-84 years	564	564	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	749	760	211.0
≥ 85 years	76	76	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	110	28.7
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	9.5
41-64 years	129	129	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	190	195	56.0
65-74 years	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	41	12.6
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	8.5
65-74 years	66	66	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	80	84	32.6
75-84 years	35	35	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	55	57	16.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.9
<i>Unknown</i>										
0-40 years	773	773	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,106	1,127	291.8
41-64 years	7,936	7,936	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	11,573	11,866	3,217.6
65-74 years	3,034	3,034	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,404	4,501	1,126.7
75-84 years	894	894	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,316	1,338	330.7
≥ 85 years	151	151	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	232	235	55.8
<i>White</i>										

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	209	209	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	303	309	70.2
41-64 years	2,999	2,999	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,598	4,697	1,157.3
65-74 years	8,327	8,327	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12,353	12,614	3,030.6
75-84 years	4,305	4,305	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	6,332	6,453	1,511.7
≥ 85 years	574	574	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	853	860	194.4
Wegovy, Ventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.6
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.8
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	113	113	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	165	170	14.9
41-64 years	520	520	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	804	817	84.2
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	21	21	2.3
41-64 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	116	116	12.8
65-74 years	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	42	45	4.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.1
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
Saxenda, Ventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>65-74 years</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>75-84 years</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>≥ 85 years</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
<i>0-40 years</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>41-64 years</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>65-74 years</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>75-84 years</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>≥ 85 years</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
<i>0-40 years</i>	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
<i>41-64 years</i>	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.9
<i>65-74 years</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>75-84 years</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>≥ 85 years</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Multi-racial</i>										
<i>0-40 years</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>41-64 years</i>	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
<i>65-74 years</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>75-84 years</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>≥ 85 years</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
<i>0-40 years</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>41-64 years</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>65-74 years</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>75-84 years</i>	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	100	100	32.2
41-64 years	266	266	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	410	410	132.1
65-74 years	12	12	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	7.5
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17	17	7.8
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	5.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Ventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.0
41-64 years	27	27	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	37	37	11.9
65-74 years	20	20	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	6.4
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.0
41-64 years	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	43	43	14.2
65-74 years	30	30	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	9.7
75-84 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	23	23	6.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Black or African American</i>										
0-40 years	39	39	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	14.9
41-64 years	250	250	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	342	342	100.5
65-74 years	223	223	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	300	300	94.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	15.0
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.5
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	7.0
41-64 years	41	41	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	19.1
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
<i>Unknown</i>										
0-40 years	140	140	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	201	201	55.5
41-64 years	848	848	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,269	1,270	356.5
65-74 years	337	337	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	462	462	126.0
75-84 years	93	93	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	118	118	32.5
≥ 85 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	6.5
<i>White</i>										
0-40 years	95	95	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	164	164	41.2

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	947	947	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,423	1,423	367.4
65-74 years	1,420	1,420	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,051	2,051	525.2
75-84 years	597	597	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	839	839	213.7
≥ 85 years	72	72	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	96	96	26.3
Trulicity, Ventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	31	31	5.3
41-64 years	100	100	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	175	177	38.7
65-74 years	95	95	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	194	195	32.2
75-84 years	43	43	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	67	67	14.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12	12	1.2
<i>Asian</i>										
0-40 years	46	46	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	85	20.2
41-64 years	221	221	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	366	366	84.8
65-74 years	570	570	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	973	978	208.1
75-84 years	297	297	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	495	497	105.0
≥ 85 years	68	68	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	129	129	21.6
<i>Black or African American</i>										
0-40 years	218	218	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	376	377	83.7
41-64 years	2,117	2,117	*****	*****	*****	*****	34.31 (4.83, 233.57)	3,613	3,644	839.2
65-74 years	2,953	2,953	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,729	4,762	1,204.7
75-84 years	1,022	1,022	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,592	1,601	416.7
≥ 85 years	118	118	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	186	187	44.5
<i>Multi-racial</i>										
0-40 years	35	35	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	68	68	12.7
41-64 years	223	223	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	469	473	100.4

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45	45	13.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18	19	5.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
41-64 years	39	39	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	65	67	18.4
65-74 years	136	136	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	230	234	66.3
75-84 years	62	62	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	90	90	30.0
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.7
<i>Unknown</i>										
0-40 years	1,577	1,577	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,730	2,751	632.6
41-64 years	13,585	13,585	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25,059	25,238	5,589.0
65-74 years	4,882	4,882	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	8,576	8,623	1,863.4
75-84 years	1,533	1,533	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,637	2,652	594.5
≥ 85 years	197	197	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	327	328	68.5
<i>White</i>										
0-40 years	536	536	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	999	1,006	185.5
41-64 years	7,457	7,457	*****	*****	*****	*****	9.26 (1.30, 65.71)	13,442	13,532	2,952.2
65-74 years	18,730	18,730	*****	*****	*****	*****	3.58 (0.50, 25.42)	32,607	32,794	6,969.6
75-84 years	8,880	8,880	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	15,077	15,161	3,232.30
≥ 85 years	1,172	1,172	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,066	2,074	406.0
Xultophy, Ventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.3

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.5
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	11.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Multi-racial</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Unknown</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.8
41-64 years	27	27	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	11.6
65-74 years	22	22	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	29	29	6.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.3
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
41-64 years	42	42	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	13.3
65-74 years	127	127	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	161	161	49.4
75-84 years	66	66	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	95	95	19.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.6
Mounjaro, Ventricular Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	4.9
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	19	19	2.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
41-64 years	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	53	9.6
65-74 years	53	53	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	71	71	12.5
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	4.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Black or African American</i>										

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	70	73	13.0
41-64 years	671	671	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,074	1,085	198.4
65-74 years	744	744	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,100	1,125	209.6
75-84 years	173	173	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	235	239	44.1
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	15	15	2.0
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	20	20	3.7
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	81	81	17.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17	17	1.6
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	55	56	12.1
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Unknown</i>										
0-40 years	855	855	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,423	1,439	231.3
41-64 years	6,086	6,086	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	10,484	10,593	1,733.2
65-74 years	898	898	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,474	1,489	233.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	239	253	40.5
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	1.7
<i>White</i>										
0-40 years	115	115	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	215	217	32.5
41-64 years	2,394	2,394	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,115	4,179	722.7

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	4,850	4,850	*****	*****	*****	*****	17.97 (2.53, 127.58)	7,859	7,979	1,301.9
75-84 years	1,505	1,505	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,325	2,359	389.7
≥ 85 years	75	75	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	106	108	16.6
Bydureon, Ventricular Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.5
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.2
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	11	11	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	14	14	5.4
41-64 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	6.2
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	28	28	4.4
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Black or African American</i>										
0-40 years	14	14	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	23	23	6.9
41-64 years	88	88	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	139	139	38.2
65-74 years	49	49	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	76	76	22.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	0.0	9	0.00 (0.00, 0.00)	*****	*****	0.1
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.3
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	35	11.1
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	6.3
41-64 years	118	118	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	160	160	42.5
65-74 years	87	87	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	130	130	29.7
75-84 years	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	10.5
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.3
<i>White</i>										
0-40 years	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45	45	14.0
41-64 years	251	251	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	404	404	98.6
65-74 years	387	387	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	654	654	152.2
75-84 years	149	149	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	217	217	49.5
≥ 85 years	12	12	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	3.9
Ozempic, Ventricular Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
0-40 years	23	23	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	31	31	7.5
41-64 years	259	259	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	409	411	89.4
65-74 years	361	361	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	566	569	120.7
75-84 years	165	165	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	239	239	59.4

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
≥ 85 years	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25	25	5.8
<i>Asian</i>										
0-40 years	79	79	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	111	111	29.8
41-64 years	360	360	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	563	563	137.7
65-74 years	655	655	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	982	985	217.5
75-84 years	251	251	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	385	386	86.5
≥ 85 years	48	48	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	80	80	16.7
<i>Black or African American</i>										
0-40 years	313	313	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	434	436	110.9
41-64 years	3,802	3,802	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	5,615	5,642	1,405.5
65-74 years	4,502	4,502	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	6,369	6,383	1,649.8
75-84 years	1,113	1,113	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,538	1,543	408.1
≥ 85 years	102	102	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	140	141	37.2
<i>Multi-racial</i>										
0-40 years	118	118	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	171	172	42.9
41-64 years	623	623	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	953	957	230.4
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	108	30.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17	17	2.4
≥ 85 years	0	0	0	NaN	*****	*****	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.2
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	92	92	23.2
65-74 years	184	184	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	236	236	77.6
75-84 years	81	81	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	100	100	31.0
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
<i>Unknown</i>										

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	4,021	4,021	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	5,878	5,895	1,434.7
41-64 years	31,654	31,654	*****	*****	*****	*****	2.32 (0.33, 16.45)	48,223	48,372	11,753.2
65-74 years	7,739	7,739	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	11,555	11,590	2,750.4
75-84 years	1,811	1,811	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,610	2,616	646.6
≥ 85 years	142	142	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	195	195	48.8
<i>White</i>										
0-40 years	930	930	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,485	1,491	342.8
41-64 years	14,028	14,028	*****	*****	*****	*****	5.16 (0.73, 36.61)	21,446	21,516	5,230.80
65-74 years	30,872	30,872	*****	*****	*****	*****	4.48 (1.12, 17.92)	45,929	46,054	10,871.6
75-84 years	11,675	11,675	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16,604	16,649	4,067.5
≥ 85 years	936	936	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,320	1,321	329.8
Rybelsus, Ventricular Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.4
41-64 years	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	37	12.1
65-74 years	23	23	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	30	30	8.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	19	19	2.7
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
<i>Asian</i>										
0-40 years	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	38	39	10.9
41-64 years	173	173	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	284	293	67.3
65-74 years	523	523	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	759	770	187.7
75-84 years	292	292	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	457	465	98.6
≥ 85 years	72	72	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	117	117	23.4
<i>Black or African American</i>										
0-40 years	88	88	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	127	131	29.2

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	984	984	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,405	1,436	392.4
65-74 years	1,680	1,680	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,298	2,352	650.1
75-84 years	564	564	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	749	760	211.0
≥ 85 years	76	76	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	107	110	28.7
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	9.5
41-64 years	129	129	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	190	195	56.0
65-74 years	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	41	12.6
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	8.5
65-74 years	66	66	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	80	84	32.6
75-84 years	35	35	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	55	57	16.9
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.9
<i>Unknown</i>										
0-40 years	773	773	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,106	1,127	291.8
41-64 years	7,936	7,936	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	11,573	11,866	3,217.6
65-74 years	3,034	3,034	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,404	4,501	1,126.7
75-84 years	894	894	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,316	1,338	330.7
≥ 85 years	151	151	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	232	235	55.8
<i>White</i>										
0-40 years	209	209	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	303	309	70.2
41-64 years	2,999	2,999	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,598	4,697	1,157.3
65-74 years	8,327	8,327	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12,353	12,614	3,030.6

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
75-84 years	4,305	4,305	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	6,332	6,453	1,511.7
≥ 85 years	574	574	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	853	860	194.4
Wegovy, Ventricular Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	30	30	4.6
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.8
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	113	113	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	165	170	14.9
41-64 years	520	520	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	804	817	84.2
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	21	21	2.3
41-64 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	116	116	12.8
65-74 years	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	42	45	4.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.1
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
Saxenda, Ventricular Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Asian</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.9
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Multi-racial</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	64	64	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	100	100	32.2

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
41-64 years	266	266	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	410	410	132.1
65-74 years	12	12	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	7.5
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	17	17	7.8
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	16	16	5.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
Victoza, Ventricular Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.0
41-64 years	27	27	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	37	37	11.9
65-74 years	20	20	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	6.4
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.0
41-64 years	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	43	43	14.2
65-74 years	30	30	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	9.7
75-84 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	23	23	6.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
<i>Black or African American</i>										
0-40 years	39	39	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	14.9
41-64 years	250	250	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	342	342	100.5

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	223	223	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	300	300	94.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	15.0
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.5
<i>Multi-racial</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	30	30	7.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	66	66	19.1
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.7
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.9
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
<i>Unknown</i>										
0-40 years	140	140	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	201	201	55.5
41-64 years	848	848	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,269	1,270	356.5
65-74 years	337	337	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	462	462	126.0
75-84 years	93	93	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	118	118	32.5
≥ 85 years	17	17	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	6.5
<i>White</i>										
0-40 years	95	95	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	164	164	41.2
41-64 years	947	947	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,423	1,423	367.4
65-74 years	1,420	1,420	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,051	2,051	525.2
75-84 years	597	597	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	839	839	213.7

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
≥ 85 years	72	72	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	96	96	26.3
Trulicity, Ventricular Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	31	31	5.3
41-64 years	100	100	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	175	177	38.7
65-74 years	95	95	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	194	195	32.2
75-84 years	43	43	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	67	67	14.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	12	12	1.2
<i>Asian</i>										
0-40 years	46	46	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	85	20.2
41-64 years	221	221	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	366	366	84.8
65-74 years	570	570	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	973	978	208.1
75-84 years	297	297	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	495	497	105.0
≥ 85 years	68	68	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	129	129	21.6
<i>Black or African American</i>										
0-40 years	218	218	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	376	377	83.7
41-64 years	2,117	2,117	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	3,613	3,644	839.2
65-74 years	2,953	2,953	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,729	4,762	1,204.7
75-84 years	1,022	1,022	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,592	1,601	416.7
≥ 85 years	118	118	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	186	187	44.5
<i>Multi-racial</i>										
0-40 years	35	35	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	68	68	12.7
41-64 years	223	223	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	469	473	100.4
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45	45	13.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	18	19	5.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
41-64 years	39	39	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	65	67	18.4
65-74 years	136	136	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	230	234	66.3
75-84 years	62	62	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	90	90	30.0
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.7
<i>Unknown</i>										
0-40 years	1,577	1,577	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,730	2,751	632.6
41-64 years	13,585	13,585	*****	*****	*****	*****	4.72 (0.66, 33.51)	25,059	25,238	5,589.0
65-74 years	4,882	4,882	*****	*****	*****	*****	13.56 (1.91, 96.27)	8,576	8,623	1,863.4
75-84 years	1,533	1,533	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,637	2,652	594.5
≥ 85 years	197	197	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	327	328	68.5
<i>White</i>										
0-40 years	536	536	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	999	1,006	185.5
41-64 years	7,457	7,457	*****	*****	*****	*****	9.26 (1.30, 65.71)	13,442	13,532	2,952.2
65-74 years	18,730	18,730	*****	*****	*****	*****	3.58 (0.50, 25.42)	32,607	32,794	6,969.6
75-84 years	8,880	8,880	*****	*****	*****	*****	7.81 (1.10, 55.42)	15,077	15,161	3,232.30
≥ 85 years	1,172	1,172	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,066	2,074	406.0
Xultophy, Ventricular Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.5
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Black or African American</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
65-74 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	11.2
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.3
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.2
<i>Multi-racial</i>										
0-40 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
41-64 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
41-64 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
65-74 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
75-84 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.8
41-64 years	27	27	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	11.6

Table 8. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Age Group¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
65-74 years	22	22	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	29	29	6.3
75-84 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.3
≥ 85 years	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>White</i>										
0-40 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.1
41-64 years	42	42	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	13.3
65-74 years	127	127	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	161	161	49.4
75-84 years	66	66	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	95	95	19.2
≥ 85 years	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.6

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

*NaN: Not a number

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Bydureon, Hospitalized Tachyarrhythmia										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.9
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
<i>Asian</i>										
2022	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	53	53	16.0
2023	15	5,354	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	2.7
<i>Black or African American</i>										
2022	120	120	*****	*****	*****	*****	559.77 (78.85, 3,973.99)	197	197	64.0
2023	45	45	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	58	58	9.0
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	34	34	14.3
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	1.5
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	179	179	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	262	262	79.8
2023	65	65	*****	*****	*****	*****	1,579.80 (222.53, 11,215.52)	84	84	9.5
<i>White</i>										
2022	723	723	*****	*****	*****	*****	396.27 (148.72, 1,055.84)	1,181	1,181	297.0
2023	110	110	*****	*****	*****	*****	873.80 (123.08, 6,203.42)	155	155	21.4

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
Mounjaro, Hospitalized Tachyarrhythmia										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	47	47	7.8
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.1
<i>Asian</i>										
2022	68	68	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	109	21.2
2023	40	40	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	54	54	6.9
<i>Black or African American</i>										
2022	634	634	*****	*****	*****	*****	402.07 (129.67, 1,236.66)	980	999	273.7
2023	1,006	1,006	*****	*****	*****	*****	489.06 (203.56, 1,175.00)	1,514	1,538	193.4
<i>Multi-racial</i>										
2022	34	34	*****	*****	*****	*****	2,219.02 (312.57, 15,753.52)	60	61	19.3
2023	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	52	4.2
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	19	19	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	10.5
2023	38	38	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	60	61	6.7
<i>Unknown</i>										
2022	4,058	4,058	*****	*****	*****	*****	268.21 (161.70, 444.90)	7,434	7,510	1,698.6
2023	3,948	3,948	*****	*****	*****	*****	190.91 (91.01, 400.45)	6,209	6,277	541.4
<i>White</i>										
2022	4,671	4,671	*****	*****	*****	*****	563.46 (398.46, 796.77)	7,775	7,864	1,645.2
2023	4,268	4,268	*****	*****	*****	*****	851.69 (622.27, 1,165.70)	6,845	6,978	818.2
Ozempic, Hospitalized Tachyarrhythmia										

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>American Indian or Alaska Native</i>										
2022	695	695	*****	*****	*****	*****	1,222.72 (677.14, 2,207.90)	1,100	1,102	260.8
2023	131	131	*****	*****	*****	*****	811.85 (114.36, 5,763.57)	170	173	22.1
<i>Asian</i>										
2022	1,022	1,022	*****	*****	*****	*****	311.17 (129.52, 747.60)	1,605	1,607	423.1
2023	371	371	*****	*****	*****	*****	928.92 (348.63, 2,475.06)	516	518	65.1
<i>Black or African American</i>										
2022	6,058	6,058	*****	*****	*****	*****	540.69 (409.80, 713.39)	9,102	9,130	2,926.5
2023	3,774	3,774	*****	*****	*****	*****	494.71 (322.55, 758.75)	4,994	5,015	685.0
<i>Multi-racial</i>										
2022	407	407	*****	*****	*****	*****	308.05 (77.04, 1,231.73)	690	692	253.6
2023	409	409	*****	*****	*****	*****	495.46 (123.91, 1,981.10)	559	562	62.4
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	156	156	*****	*****	*****	*****	691.76 (173.00, 2,766.04)	229	229	106.1
2023	177	177	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	223	223	31.8
<i>Unknown</i>										
2022	27,580	27,580	*****	*****	*****	*****	236.94 (205.36, 296.94)	45,223	45,337	14,467.1
2023	17,787	17,787	*****	*****	*****	*****	208.02 (147.89, 292.61)	23,239	23,331	2,166.6
<i>White</i>										
2022	43,173	43,173	*****	*****	*****	*****	664.07 (604.31, 729.74)	66,072	66,235	18,069.2
2023	15,268	15,268	*****	*****	*****	*****	665.99 (555.62, 798.30)	20,712	20,796	2,783.3
Rybelsus, Hospitalized Tachyarrhythmia										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	100	103	26.9

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
<i>Asian</i>										
2022	923	923	*****	*****	*****	*****	135.89 (33.99, 543.38)	1,445	1,471	355.0
2023	164	164	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	210	213	32.8
<i>Black or African American</i>										
2022	2,336	2,336	*****	*****	*****	*****	391.32 (227.22, 673.94)	3,335	3,398	1,106.2
2023	1,056	1,056	*****	*****	*****	*****	423.95 (176.87, 1,020.96)	1,351	1,391	205.2
<i>Multi-racial</i>										
2022	111	111	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	168	172	65.2
2023	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	106	109	13.8
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	96	98	48.4
2023	58	58	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	74	80	13.4
<i>Unknown</i>										
2022	8,899	8,899	*****	*****	*****	*****	196.27 (134.60, 286.20)	13,647	13,926	4,494.3
2023	3,889	3,889	*****	*****	*****	*****	252.06 (131.15, 484.44)	4,984	5,141	528.3
<i>White</i>										
2022	12,838	12,838	*****	*****	*****	*****	508.70 (415.59, 622.67)	19,626	19,980	5,231.90
2023	3,576	3,576	*****	*****	*****	*****	670.87 (463.21, 971.64)	4,813	4,953	722.2
Saxenda, Hospitalized Tachyarrhythmia										
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
2023	*****	*****	0	0.00 (0.00, 0.00)	0.0	16	0.00 (0.00, 0.00)	*****	*****	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	298	298	*****	*****	*****	*****	233.56 (34.31, 1,729.15)	470	470	165.4
2023	44	44	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	6.5
<i>White</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	35	15.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
Trulicity, Hospitalized Tachyarrhythmia										
<i>American Indian or Alaska Native</i>										
2022	234	234	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	440	443	86.9
2023	23	23	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	5.0
<i>Asian</i>										
2022	1,045	1,045	*****	*****	*****	*****	237.34 (89.08, 632.37)	1,825	1,831	408.0
2023	157	157	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	222	223	31.7

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Black or African American</i>										
2022	4,894	4,894	*****	*****	*****	*****	502.51 (362.47, 696.64)	8,231	8,302	2,271.0
2023	1,534	1,534	*****	*****	*****	*****	448.43 (223.26, 896.71)	2,255	2,269	317.8
<i>Multi-racial</i>										
2022	190	190	*****	*****	*****	*****	532.94 (133.28, 2,130.98)	426	430	114.0
2023	103	103	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	174	175	17.5
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	145	145	*****	*****	*****	*****	752.01 (188.07, 3,006.93)	236	250	100.6
2023	103	103	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	154	156	20.6
<i>Unknown</i>										
2022	15,411	15,411	81	0.53 (0.41, 0.64)	*****	*****	302.59 (233.37, 376.21)	29,665	29,856	7,853.5
2023	6,363	6,363	26	0.41 (0.25, 0.57)	*****	*****	407.73 (277.61, 598.84)	9,664	9,746	894.4
<i>White</i>										
2022	30,998	30,998	292	0.94 (0.83, 1.05)	*****	*****	625.00 (557.27, 700.96)	55,284	55,582	12,538.3
2023	5,777	5,777	45	0.78 (0.55, 1.01)	*****	*****	633.39 (472.91, 848.32)	8,907	8,985	1,217.2
Victoza, Hospitalized Tachyarrhythmia										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	*****	*****	*****	*****	1,683.96 (237.20, 11,954.95)	76	76	21.3
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.3
<i>Asian</i>										
2022	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	95	95	32.7
2023	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25	25	3.2
<i>Black or African American</i>										

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2022	397	397	*****	*****	*****	*****	540.10 (174.19, 1,674.64)	550	550	193.2
2023	159	159	*****	*****	*****	*****	578.93 (81.55, 4,110.05)	199	199	33.8
<i>Multi-racial</i>										
2022	37	37	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	57	57	22.5
2023	30	30	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	46	46	5.4
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.7
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.4
<i>Unknown</i>										
2022	1,026	1,026	*****	*****	*****	*****	384.16 (172.58, 855.10)	1,555	1,556	514.6
2023	409	409	*****	*****	*****	*****	1,013.81 (380.49, 2,701.25)	521	521	62.3
<i>White</i>										
2022	2,510	2,510	*****	*****	*****	*****	643.15 (431.08, 959.55)	3,751	3,751	1,039.7
2023	621	621	*****	*****	*****	*****	770.43 (346.12, 1,714.92)	823	823	134.2
Wegovy, Hospitalized Tachyarrhythmia										
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.4
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	50	52	4.6

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	3.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	62	62	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	96	96	34.4
2023	601	601	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	928	948	70.2
<i>White</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.8
2023	*****	*****	*****	*****	*****	*****	899.41 (126.69, 6,385.20)	185	188	18.4
Xultophy, Hospitalized Tachyarrhythmia										
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Asian</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
<i>Black or African American</i>										
2022	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	20	20	10.7
2023	22	22	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	33	33	4.8
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	38	38	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	52	19.7
2023	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	32	32	4.3
<i>White</i>										
2022	153	153	*****	*****	*****	*****	377.83 (53.22, 2,682.35)	207	207	67.3
2023	94	94	*****	*****	*****	*****	841.59 (118.55, 5,974.72)	121	121	19.3
Mounjaro, Atrial Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	47	47	7.8
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.1
<i>Asian</i>										
2022	68	68	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	109	21.2
2023	40	40	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	54	54	6.9
<i>Black or African American</i>										
2022	634	634	*****	*****	*****	*****	268.04 (67.04, 1,071.78)	980	999	273.7
2023	1,006	1,006	*****	*****	*****	*****	391.25 (146.84, 1,042.46)	1,514	1,538	193.4
<i>Multi-racial</i>										
2022	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	60	61	19.3
2023	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	52	4.2
<i>Native Hawaiian or Other Pacific Islander</i>										

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2022	19	19	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	10.5
2023	38	38	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	60	61	6.7
<i>Unknown</i>										
2022	4,058	4,058	*****	*****	*****	*****	125.17 (59.67, 262.55)	7,434	7,510	1,698.6
2023	3,948	3,948	*****	*****	*****	*****	136.36 (56.76, 327.62)	6,209	6,277	541.4
<i>White</i>										
2022	4,671	4,671	*****	*****	*****	*****	422.59 (283.25, 630.49)	7,775	7,864	1,645.2
2023	4,268	4,268	*****	*****	*****	*****	480.44 (316.35, 729.66)	6,845	6,978	818.2
Bydureon, Atrial Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.9
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
<i>Asian</i>										
2022	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	53	53	16.0
2023	15	15	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	2.7
<i>Black or African American</i>										
2022	120	120	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	197	197	64.0
2023	45	45	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	58	58	9.0
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	34	34	14.3
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	1.5
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Unknown</i>										
2022	179	179	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	262	262	79.8
2023	65	65	*****	*****	*****	*****	1,579.80 (222.53, 11.215.52)	84	84	9.5
<i>White</i>										
2022	723	723	*****	*****	*****	*****	297.20 (95.85, 921.51)	1,181	1,181	297.0
2023	110	110	*****	*****	*****	*****	873.80 (123.08, 6,203.42)	155	155	21.4
Ozempic, Atrial Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
2022	695	695	*****	*****	*****	*****	889.25 (444.71, 1,778.18)	1,100	1,102	260.8
2023	131	131	*****	*****	*****	*****	811.85 (114.36, 5,763.57)	170	173	22.1
<i>Asian</i>										
2022	1,022	1,022	*****	*****	*****	*****	123.47 (31.13, 497.69)	1,605	1,607	423.1
2023	371	371	*****	*****	*****	*****	232.23 (32.71, 1,648.67)	516	518	65.1
<i>Black or African American</i>										
2022	6,058	6,058	*****	*****	*****	*****	281.16 (191.43, 412.94)	9,102	9,130	2,926.5
2023	3,774	3,774	*****	*****	*****	*****	235.58 (126.75, 437.83)	4,994	5,015	685.0
<i>Multi-racial</i>										
2022	407	407	*****	*****	*****	*****	154.02 (21.70, 1,093.46)	690	692	253.6
2023	409	409	*****	*****	*****	*****	237.73 (34.89, 1,758.70)	559	562	62.4
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	156	156	*****	*****	*****	*****	691.76 (173.00, 2,766.04)	229	229	106.1
2023	177	177	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	223	223	31.8
<i>Unknown</i>										

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2022	27,580	27,580	*****	*****	*****	*****	146.42 (115.23, 186.03)	45,223	45,337	14,467.1
2023	17,787	17,787	*****	*****	*****	*****	107.16 (66.62, 172.38)	23,239	23,331	2,166.6
<i>White</i>										
2022	43,173	43,173	*****	*****	*****	*****	462.69 (413.27, 518.03)	66,072	66,235	18,069.2
2023	15,268	15,268	*****	*****	*****	*****	392.77 (310.21, 497.29)	20,712	20,796	2,783.3
Rybelsus, Atrial Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	100	103	26.9
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
<i>Asian</i>										
2022	923	923	*****	*****	*****	*****	67.95 (9.57, 482.38)	1,445	1,471	355.0
2023	164	164	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	210	213	32.8
<i>Black or African American</i>										
2022	2,336	2,336	*****	*****	*****	*****	230.81 (120.43, 481.54)	3,335	3,398	1,106.2
2023	1,056	1,056	*****	*****	*****	*****	254.97 (82.23, 790.56)	1,351	1,391	205.2
<i>Multi-racial</i>										
2022	111	111	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	168	172	65.2
2023	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	106	109	13.8
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	96	98	48.4
2023	58	58	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	74	80	13.4
<i>Unknown</i>										
2022	8,899	8,899	*****	*****	*****	*****	101.77 (60.27, 171.84)	13,647	13,926	4,494.3
2023	3,889	3,889	*****	*****	*****	*****	140.03 (58.28, 336.44)	4,984	5,141	528.3

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>White</i>										
2022	12,838	12,838	*****	*****	*****	*****	400.47 (318.87, 502.94)	19,626	19,980	5,231.90
2023	3,576	3,576	*****	*****	*****	*****	455.23 (290.37, 713.71)	4,813	4,953	722.2
Wegovy, Atrial Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.4
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	50	52	4.6
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	3.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	62	62	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	96	96	34.4
2023	601	601	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	928	948	70.2
<i>White</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.8

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023	*****	*****	*****	*****	*****	*****	899.41 (126.69, 6,385.20)	185	188	18.4
Saxenda, Atrial Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	298	298	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	470	470	165.4
2023	44	44	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	6.5
<i>White</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	35	15.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
Victoza, Atrial Fibrillation and Flutter										

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>American Indian or Alaska Native</i>										
2022	*****	*****	*****	*****	*****	*****	1,683.96 (237.20, 11,954.95)	76	76	21.3
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.3
<i>Asian</i>										
2022	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	95	95	32.7
2023	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25	25	3.2
<i>Black or African American</i>										
2022	397	397	*****	*****	*****	*****	180.03 (25.36, 1,278.11)	550	550	193.2
2023	159	159	*****	*****	*****	*****	578.93 (81.55, 4,110.05)	199	199	33.8
<i>Multi-racial</i>										
2022	37	37	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	57	57	22.5
2023	30	30	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	46	46	5.4
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.7
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.4
<i>Unknown</i>										
2022	1,026	1,026	*****	*****	*****	*****	128.05 (32.02, 512.02)	1,555	1,556	514.6
2023	409	409	*****	*****	*****	*****	506.90 (126.77, 2,026.88)	521	521	62.3
<i>White</i>										
2022	2,510	2,510	*****	*****	*****	*****	455.56 (283.20, 732.82)	3,751	3,751	1,039.7
2023	621	621	*****	*****	*****	*****	385.22 (123.23, 1,194.42)	823	823	134.2

Trulicity, Atrial Fibrillation and Flutter

American Indian or Alaska Native

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2022	234	234	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	440	443	86.9
2023	23	23	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	5.0
<i>Asian</i>										
2022	1,045	1,045	*****	*****	*****	*****	178.00 (57.41, 551.92)	1,825	1,831	408.0
2023	157	157	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	222	223	31.7
<i>Black or African American</i>										
2022	4,894	4,894	*****	*****	*****	*****	251.25 (158.30, 398.79)	8,231	8,302	2,271.0
2023	1,534	1,534	*****	*****	*****	*****	168.16 (54.23, 521.41)	2,255	2,269	317.8
<i>Multi-racial</i>										
2022	190	190	*****	*****	*****	*****	266.47 (37.53, 1,891.76)	426	430	114.0
2023	103	103	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	174	175	17.5
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	145	145	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	236	250	100.6
2023	103	103	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	154	156	20.6
<i>Unknown</i>										
2022	15,411	15,411	*****	*****	*****	*****	175.58 (131.92, 233.68)	29,665	29,856	7,853.5
2023	6,363	6,363	*****	*****	*****	*****	250.91 (153.71, 409.56)	9,664	9,746	894.4
<i>White</i>										
2022	30,998	30,998	*****	*****	*****	*****	483.73 (423.60, 551.09)	55,284	55,582	12,538.3
2023	5,777	5,777	*****	*****	*****	*****	422.26 (295.23, 603.93)	8,907	8,985	1,217.2
<u>Kulopathy, Atrial Fibrillation and Flutter</u>										
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Asian</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
<i>Black or African American</i>										
2022	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	20	20	10.7
2023	22	22	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	33	33	4.8
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	38	38	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	52	19.7
2023	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	32	32	4.3
<i>White</i>										
2022	153	153	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	207	207	67.3
2023	94	94	*****	*****	*****	*****	841.59 (118.55, 5,974.72)	121	121	19.3
Mounjaro, Sinus Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	47	47	7.8
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.1
<i>Asian</i>										
2022	68	68	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	109	21.2

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023	40	40	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	54	54	6.9
<i>Black or African American</i>										
2022	634	634	*****	*****	*****	*****	134.02 (18.88, 951.47)	980	999	273.7
2023	1,006	1,006	*****	*****	*****	*****	97.81 (13.78, 694.40)	1,514	1,538	193.4
<i>Multi-racial</i>										
2022	34	34	*****	*****	*****	*****	2,219.02 (312.57, 15,753.52)	60	61	19.3
2023	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	52	4.2
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	19	19	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	10.5
2023	38	38	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	60	61	6.7
<i>Unknown</i>										
2022	4,058	4,058	*****	*****	*****	*****	125.17 (59.67, 262.55)	7,434	7,510	1,698.6
2023	3,948	3,948	*****	*****	*****	*****	27.27 (3.84, 193.62)	6,209	6,277	541.4
<i>White</i>										
2022	4,671	4,671	*****	*****	*****	*****	88.04 (36.64, 211.52)	7,775	7,864	1,645.2
2023	4,268	4,268	*****	*****	*****	*****	305.74 (181.07, 516.23)	6,845	6,978	818.2
Bydureon, Sinus Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.9
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
<i>Asian</i>										
2022	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	53	53	16.0
2023	15	15	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	2.7

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Black or African American</i>										
2022	120	120	*****	*****	*****	*****	559.77 (78.85, 3,973.99)	197	197	64.0
2023	45	45	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	58	58	9.0
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	34	34	14.3
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	1.5
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	179	179	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	262	262	79.8
2023	65	65	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	84	9.5
<i>White</i>										
2022	723	723	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,181	1,181	297.0
2023	110	110	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	155	155	21.4
Ozempic, Sinus Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	695	695	*****	*****	*****	*****	222.31 (55.60, 888.93)	1,100	1,102	260.8
2023	131	131	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	170	173	22.1
<i>Asian</i>										
2022	1,022	1,022	*****	*****	*****	*****	62.23 (8.77, 441.82)	1,605	1,607	423.1
2023	371	371	*****	*****	*****	*****	232.23 (32.71, 1,648.67)	516	518	65.1
<i>Black or African American</i>										
2022	6,058	6,058	*****	*****	*****	*****	194.65 (122.64, 308.95)	9,102	9,130	2,926.5

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023	3,774	3,774	*****	*****	*****	*****	141.35 (63.50, 314.62)	4,994	5,015	685.0
<i>Multi-racial</i>										
2022	407	407	*****	*****	*****	*****	154.02 (21.70, 1,093.46)	690	692	253.6
2023	409	409	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	559	562	62.4
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	156	156	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	229	229	106.1
2023	177	177	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	223	223	31.8
<i>Unknown</i>										
2022	27,580	27,580	*****	*****	*****	*****	69.93 (49.45, 98.89)	45,223	45,337	14,467.1
2023	17,787	17,787	*****	*****	*****	*****	50.43 (25.22, 100.84)	23,239	23,331	2,166.6
<i>White</i>										
2022	43,173	43,173	*****	*****	*****	*****	121.44 (97.41, 151.40)	66,072	66,235	18,069.2
2023	15,268	15,268	*****	*****	*****	*****	193.54 (138.29, 270.86)	20,712	20,796	2,783.3
Rybelsus, Sinus Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	100	103	26.9
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
<i>Asian</i>										
2022	923	923	*****	*****	*****	*****	67.95 (9.57, 482.38)	1,445	1,471	355.0
2023	164	164	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	210	213	32.8
<i>Black or African American</i>										
2022	2,336	2,336	*****	*****	*****	*****	150.51 (62.65, 361.61)	3,335	3,398	1,106.2
2023	1,056	1,056	*****	*****	*****	*****	84.99 (11.97, 603.37)	1,351	1,391	205.2
<i>Multi-racial</i>										

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2022	111	111	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	168	172	65.2
2023	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	106	109	13.8
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	96	98	48.4
2023	58	58	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	74	80	13.4
<i>Unknown</i>										
2022	8,899	8,899	*****	*****	*****	*****	79.96 (44.28, 144.39)	13,647	13,926	4,494.3
2023	3,889	3,889	*****	*****	*****	*****	84.02 (27.10, 260.51)	4,984	5,141	528.3
<i>White</i>										
2022	12,838	12,838	*****	*****	*****	*****	92.00 (57.19, 147.99)	19,626	19,980	5,231.90
2023	3,576	3,576	*****	*****	*****	*****	167.72 (79.96, 351.81)	4,813	4,953	722.2
Wegovy, Sinus Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.4
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	50	52	4.6
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	3.0

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	62	62	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	96	96	34.4
2023	601	601	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	928	948	70.2
<i>White</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.8
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	185	188	18.4
<u>Saxenda, Sinus Tachycardia</u>										
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	298	298	*****	*****	*****	*****	233.56 (34.31, 1,729.15)	470	470	165.4
2023	44	44	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	6.5
<i>White</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	35	15.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
Victoza, Sinus Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	76	76	21.3
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.3
<i>Asian</i>										
2022	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	95	95	32.7
2023	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25	25	3.2
<i>Black or African American</i>										
2022	397	397	*****	*****	*****	*****	360.07 (90.05, 1,439.73)	550	550	193.2
2023	159	159	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	199	199	33.8
<i>Multi-racial</i>										
2022	37	37	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	57	57	22.5
2023	30	30	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	46	46	5.4
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.7
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.4
<i>Unknown</i>										

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2022	1,026	1,026	*****	*****	*****	*****	320.13 (133.25, 769.14)	1,555	1,556	514.6
2023	409	409	*****	*****	*****	*****	506.90 (126.77, 2,026.88)	521	521	62.3
<i>White</i>										
2022	2,510	2,510	*****	*****	*****	*****	80.39 (25.93, 239.27)	3,751	3,751	1,039.7
2023	621	621	*****	*****	*****	*****	385.22 (123.23, 1,194.42)	823	823	134.2
Trulicity, Sinus Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	234	234	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	440	443	86.9
2023	23	23	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	5.0
<i>Asian</i>										
2022	1,045	1,045	*****	*****	*****	*****	59.33 (8.36, 421.23)	1,825	1,831	408.0
2023	157	157	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	222	223	31.7
<i>Black or African American</i>										
2022	4,894	4,894	*****	*****	*****	*****	195.42 (115.74, 329.96)	8,231	8,302	2,271.0
2023	1,534	1,534	*****	*****	*****	*****	223.22 (84.15, 597.42)	2,255	2,269	317.8
<i>Multi-racial</i>										
2022	190	190	*****	*****	*****	*****	266.47 (37.53, 1,891.76)	426	430	114.0
2023	103	103	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	174	175	17.5
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	145	145	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	236	250	100.6
2023	103	103	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	154	156	20.6
<i>Unknown</i>										
2022	15,411	15,411	*****	*****	*****	*****	93.39 (63.11, 138.21)	29,665	29,856	7,853.5
2023	6,363	6,363	*****	*****	*****	*****	141.14 (73.43, 271.26)	9,664	9,746	894.4

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>White</i>										
2022	30,998	30,998	*****	*****	*****	*****	96.32 (71.91, 129.00)	55,284	55,582	12,538.3
2023	5,777	5,777	*****	*****	*****	*****	126.68 (65.91, 233.47)	8,907	8,985	1,217.2
Xultophy, Sinus Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Asian</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
<i>Black or African American</i>										
2022	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	20	20	10.7
2023	22	22	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	33	33	4.8
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	38	38	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	52	19.7
2023	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	32	32	4.3
<i>White</i>										
2022	153	153	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	207	207	67.3

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023	94	94	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	121	121	19.3
Mounjaro, Supraventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	47	47	7.8
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.1
<i>Asian</i>										
2022	68	68	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	109	21.2
2023	40	40	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	54	54	6.9
<i>Black or African American</i>										
2022	634	634	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	980	999	273.7
2023	1,006	1,006	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,514	1,538	193.4
<i>Multi-racial</i>										
2022	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	60	61	19.3
2023	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	52	4.2
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	19	19	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	10.5
2023	38	38	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	60	61	6.7
<i>Unknown</i>										
2022	4,058	4,058	*****	*****	*****	*****	17.88 (2.52, 126.94)	7,434	7,510	1,698.6
2023	3,948	3,948	*****	*****	*****	*****	27.27 (3.84, 193.62)	6,209	6,277	541.4
<i>White</i>										
2022	4,671	4,671	*****	*****	*****	*****	35.22 (8.81, 140.81)	7,775	7,864	1,645.2
2023	4,268	4,268	*****	*****	*****	*****	87.35 (32.78, 232.75)	6,845	6,978	818.2
Bydureon, Supraventricular Tachycardia										

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.9
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
<i>Asian</i>										
2022	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	53	53	16.0
2023	15	15	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	2.7
<i>Black or African American</i>										
2022	120	120	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	197	197	64.0
2023	45	45	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	58	58	9.0
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	34	34	14.3
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	1.5
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	179	179	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	262	262	79.8
2023	65	65	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	84	9.5
<i>White</i>										
2022	723	723	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,181	1,181	297.0
2023	110	110	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	155	155	21.4
Ozempic, Supraventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	695	695	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,100	1,102	260.8

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023	131	131	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	170	173	22.1
<i>Asian</i>										
2022	1,022	1,022	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,605	1,607	423.1
2023	371	371	*****	*****	*****	*****	232.23 (32.71, 1,648.67)	516	518	65.1
<i>Black or African American</i>										
2022	6,058	6,058	*****	*****	*****	*****	43.26 (16.23, 115.25)	9,102	9,130	2,926.5
2023	3,774	3,774	*****	*****	*****	*****	70.67 (22.79, 219.13)	4,994	5,015	685.0
<i>Multi-racial</i>										
2022	407	407	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	690	692	253.6
2023	409	409	*****	*****	*****	*****	237.73 (34.89, 1,758.70)	559	562	62.4
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	156	156	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	229	229	106.1
2023	177	177	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	223	223	31.8
<i>Unknown</i>										
2022	27,580	27,580	*****	*****	*****	*****	26.22 (14.89, 46.18)	45,223	45,337	14,467.1
2023	17,787	17,787	*****	*****	*****	*****	37.82 (16.99, 84.19)	23,239	23,331	2,166.6
<i>White</i>										
2022	43,173	43,173	*****	*****	*****	*****	50.73 (36.06, 71.35)	66,072	66,235	18,069.2
2023	15,268	15,268	*****	*****	*****	*****	56.92 (30.63, 105.79)	20,712	20,796	2,783.3
Rybelsus, Supraventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	100	103	26.9
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
<i>Asian</i>										

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2022	923	923	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,445	1,471	355.0
2023	164	164	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	210	213	32.8
<i>Black or African American</i>										
2022	2,336	2,336	*****	*****	*****	*****	30.10 (4.23, 213.70)	3,335	3,398	1,106.2
2023	1,056	1,056	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,351	1,391	205.2
<i>Multi-racial</i>										
2022	111	111	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	168	172	65.2
2023	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	106	109	13.8
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	96	98	48.4
2023	58	58	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	74	80	13.4
<i>Unknown</i>										
2022	8,899	8,899	*****	*****	*****	*****	14.54 (3.64, 58.13)	13,647	13,926	4,494.3
2023	3,889	3,889	*****	*****	*****	*****	28.01 (3.94, 198.83)	4,984	5,141	528.3
<i>White</i>										
2022	12,838	12,838	*****	*****	*****	*****	43.29 (21.65, 86.57)	19,626	19,980	5,231.90
2023	3,576	3,576	*****	*****	*****	*****	95.84 (35.97, 255.36)	4,813	4,953	722.2
Wegovy, Supraventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Black or African American</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.4
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.6
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	62	62	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	96	96	34.4
2023	601	601	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	928	948	70.2
<i>White</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.8
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	18.4
Saxenda, Supraventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.5

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	298	298	*****	*****	*****	*****	233.56 (34.31, 1,729.15)	470	470	165.4
2023	44	44	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	6.5
<i>White</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	35	15.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
Victoza, Supraventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	76	76	21.3
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.3
<i>Asian</i>										
2022	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	95	95	32.7
2023	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25	25	3.2
<i>Black or African American</i>										
2022	397	397	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	550	550	193.2
2023	159	159	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	199	199	33.8
<i>Multi-racial</i>										

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2022	37	37	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	57	57	22.5
2023	30	30	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	46	46	5.4
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.7
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.4
<i>Unknown</i>										
2022	1,026	1,026	*****	*****	*****	*****	128.05 (32.02, 512.02)	1,555	1,556	514.6
2023	409	409	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	521	521	62.3
<i>White</i>										
2022	2,510	2,510	*****	*****	*****	*****	80.39 (25.93, 239.27)	3,751	3,751	1,039.7
2023	621	621	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	823	823	134.2
Trulicity, Supraventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	234	234	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	440	443	86.9
2023	23	23	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	5.0
<i>Asian</i>										
2022	1,045	1,045	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,825	1,831	408.0
2023	157	157	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	222	223	31.7
<i>Black or African American</i>										
2022	4,894	4,894	*****	*****	*****	*****	13.96 (1.97, 99.10)	8,231	8,302	2,271.0
2023	1,534	1,534	*****	*****	*****	*****	56.05 (7.90, 397.95)	2,255	2,269	317.8
<i>Multi-racial</i>										
2022	190	190	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	426	430	114.0
2023	103	103	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	174	175	17.5

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	145	145	*****	*****	*****	*****	376.00 (52.96, 2,669.37)	236	250	100.6
2023	103	103	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	154	156	20.6
<i>Unknown</i>										
2022	15,411	15,411	*****	*****	*****	*****	33.62 (17.49, 64.62)	29,665	29,856	7,853.5
2023	6,363	6,363	*****	*****	*****	*****	15.68 (2.21, 111.33)	9,664	9,746	894.4
<i>White</i>										
2022	30,998	30,998	*****	*****	*****	*****	51.37 (34.43, 76.64)	55,284	55,582	12,538.3
2023	5,777	5,777	*****	*****	*****	*****	56.30 (21.13, 150.01)	8,907	8,985	1,217.2
<u>Xultophy, Supraventricular Tachycardia</u>										
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Asian</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
<i>Black or African American</i>										
2022	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	20	20	10.7
2023	22	22	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	33	33	4.8
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	38	38	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	52	19.7
2023	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	32	32	4.3
<i>White</i>										
2022	153	153	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	207	207	67.3
2023	94	94	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	121	121	19.3
Mounjaro, Other Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	47	47	7.8
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.1
<i>Asian</i>										
2022	68	68	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	109	21.2
2023	40	40	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	54	54	6.9
<i>Black or African American</i>										
2022	634	634	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	980	999	273.7
2023	1,006	1,006	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,514	1,538	193.4
<i>Multi-racial</i>										
2022	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	60	61	19.3
2023	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	52	4.2
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	19	19	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	10.5
2023	38	38	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	60	61	6.7
<i>Unknown</i>										

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2022	4,058	4,058	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	7,434	7,510	1,698.6
2023	3,948	3,948	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	6,209	6,277	541.4
<i>White</i>										
2022	4,671	4,671	*****	*****	*****	*****	17.61 (2.48, 125.01)	7,775	7,864	1,645.2
2023	4,268	4,268	*****	*****	*****	*****	87.35 (32.78, 232.75)	6,845	6,978	818.2
Bydureon, Other Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.9
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
<i>Asian</i>										
2022	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	53	53	16.0
2023	15	15	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	2.7
<i>Black or African American</i>										
2022	120	120	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	197	197	64.0
2023	45	45	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	58	58	9.0
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	34	34	14.3
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	1.5
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	179	179	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	262	262	79.8
2023	65	65	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	84	9.5

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>White</i>										
2022	723	723	*****	*****	*****	*****	198.13 (49.55, 792.25)	1,181	1,181	297.0
2023	110	110	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	155	155	21.4
Ozempic, Other Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	695	695	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,100	1,102	260.8
2023	131	131	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	170	173	22.1
<i>Asian</i>										
2022	1,022	1,022	*****	*****	*****	*****	62.23 (8.77, 441.82)	1,605	1,607	423.1
2023	371	371	*****	*****	*****	*****	232.23 (32.71, 1,648.67)	516	518	65.1
<i>Black or African American</i>										
2022	6,058	6,058	*****	*****	*****	*****	43.26 (16.23, 115.25)	9,102	9,130	2,926.5
2023	3,774	3,774	*****	*****	*****	*****	94.23 (35.37, 251.07)	4,994	5,015	685.0
<i>Multi-racial</i>										
2022	407	407	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	690	692	253.6
2023	409	409	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	559	562	62.4
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	156	156	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	229	229	106.1
2023	177	177	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	223	223	31.8
<i>Unknown</i>										
2022	27,580	27,580	*****	*****	*****	*****	8.74 (3.28, 23.29)	45,223	45,337	14,467.1
2023	17,787	17,787	*****	*****	*****	*****	6.30 (0.89, 44.75)	23,239	23,331	2,166.6
<i>White</i>										
2022	43,173	43,173	27	0.06 (0.04, 0.09)	*****	*****	41.50 (28.46, 60.52)	66,072	66,235	18,069.2

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023	15,268	15,268	11	0.07 (0.03, 0.11)	*****	*****	62.61 (34.68, 113.07)	20,712	20,796	2,783.3
Rybelsus, Other Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	100	103	26.9
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
<i>Asian</i>										
2022	923	923	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,445	1,471	355.0
2023	164	164	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	210	213	32.8
<i>Black or African American</i>										
2022	2,336	2,336	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	3,335	3,398	1,106.2
2023	1,056	1,056	*****	*****	*****	*****	84.99 (11.97, 603.37)	1,351	1,391	205.2
<i>Multi-racial</i>										
2022	111	111	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	168	172	65.2
2023	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	106	109	13.8
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	96	98	48.4
2023	58	58	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	74	80	13.4
<i>Unknown</i>										
2022	8,899	8,899	*****	*****	*****	*****	7.27 (1.02, 51.61)	13,647	13,926	4,494.3
2023	3,889	3,889	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,984	5,141	528.3
<i>White</i>										
2022	12,838	12,838	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	19,626	19,980	5,231.90
2023	3,576	3,576	*****	*****	*****	*****	71.88 (23.18, 222.87)	4,813	4,953	722.2
Wegovy, Other Tachycardia										

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.4
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	50	52	4.6
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	3.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	62	62	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	96	96	34.4
2023	601	601	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	928	948	70.2
<i>White</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.8
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	185	188	18.4
Saxenda, Other Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	298	298	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	470	470	165.4
2023	44	44	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	6.5
<i>White</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	35	15.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
Victoza, Other Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	76	76	21.3
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.3
<i>Asian</i>										

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2022	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	95	95	32.7
2023	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25	25	3.2
<i>Black or African American</i>										
2022	397	397	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	550	550	193.2
2023	159	159	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	199	199	33.8
<i>Multi-racial</i>										
2022	37	37	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	57	57	22.5
2023	30	30	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	46	46	5.4
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.7
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.4
<i>Unknown</i>										
2022	1,026	1,026	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,555	1,556	514.6
2023	409	409	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	521	521	62.3
<i>White</i>										
2022	2,510	2,510	*****	*****	*****	*****	53.60 (13.40, 214.30)	3,751	3,751	1,039.7
2023	621	621	*****	*****	*****	*****	128.41 (18.09, 911.59)	823	823	134.2
Trulicity, Other Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	234	234	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	440	443	86.9
2023	23	23	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	5.0
<i>Asian</i>										
2022	1,045	1,045	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,825	1,831	408.0
2023	157	157	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	222	223	31.7

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Black or African American</i>										
2022	4,894	4,894	*****	*****	*****	*****	27.92 (6.98, 111.63)	8,231	8,302	2,271.0
2023	1,534	1,534	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,255	2,269	317.8
<i>Multi-racial</i>										
2022	190	190	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	426	430	114.0
2023	103	103	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	174	175	17.5
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	145	145	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	236	250	100.6
2023	103	103	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	154	156	20.6
<i>Unknown</i>										
2022	15,411	15,411	*****	*****	*****	*****	7.47 (1.87, 29.87)	29,665	29,856	7,853.5
2023	6,363	6,363	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	9,664	9,746	894.4
<i>White</i>										
2022	30,998	30,998	*****	*****	*****	*****	25.68 (14.59, 45.23)	55,284	55,582	12,538.3
2023	5,777	5,777	*****	*****	*****	*****	70.38 (29.29, 169.08)	8,907	8,985	1,217.2
Xultophy, Other Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Asian</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
<i>Black or African American</i>										
2022	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	20	20	10.7

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023	22	22	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	33	33	4.8
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	38	38	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	52	19.7
2023	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	32	32	4.3
<i>White</i>										
2022	153	153	*****	*****	*****	*****	377.83 (53.22, 2,682.35)	207	207	67.3
2023	94	94	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	121	121	19.3
Mounjaro, Cardiac Arrest										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	47	47	7.8
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.1
<i>Asian</i>										
2022	68	68	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	109	21.2
2023	40	40	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	54	54	6.9
<i>Black or African American</i>										
2022	634	634	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	980	999	273.7
2023	1,006	1,006	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,514	1,538	193.4
<i>Multi-racial</i>										

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2022	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	60	61	19.3
2023	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	52	4.2
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	19	19	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	10.5
2023	38	38	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	60	61	6.7
<i>Unknown</i>										
2022	4,058	4,058	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	7,434	7,510	1,698.6
2023	3,948	3,948	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	6,209	6,277	541.4
<i>White</i>										
2022	4,671	4,671	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	7,775	7,864	1,645.2
2023	4,268	4,268	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	6,845	6,978	818.2
Bydureon, Cardiac Arrest										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.9
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
<i>Asian</i>										
2022	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	53	53	16.0
2023	15	15	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	2.7
<i>Black or African American</i>										
2022	120	120	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	197	197	64.0
2023	45	45	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	58	58	9.0
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	34	34	14.3
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	1.5

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	179	179	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	262	262	79.8
2023	65	65	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	84	9.5
<i>White</i>										
2022	723	723	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,181	1,181	297.0
2023	110	110	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	155	155	21.4
Ozempic, Cardiac Arrest										
<i>American Indian or Alaska Native</i>										
2022	695	695	*****	*****	*****	*****	111.16 (15.66, 789.14)	1,100	1,102	260.8
2023	131	131	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	170	173	22.1
<i>Asian</i>										
2022	1,022	1,022	*****	*****	*****	*****	62.23 (8.77, 441.82)	1,605	1,607	423.1
2023	371	371	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	516	518	65.1
<i>Black or African American</i>										
2022	6,058	6,058	*****	*****	*****	*****	10.81 (1.52, 76.77)	9,102	9,130	2,926.5
2023	3,774	3,774	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,994	5,015	685.0
<i>Multi-racial</i>										
2022	407	407	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	690	692	253.6
2023	409	409	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	559	562	62.4
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	156	156	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	229	229	106.1

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023	177	177	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	223	223	31.8
<i>Unknown</i>										
2022	27,580	27,580	*****	*****	*****	*****	4.37 (1.09, 17.48)	45,223	45,337	14,467.1
2023	17,787	17,787	*****	*****	*****	*****	6.30 (0.89, 44.75)	23,239	23,331	2,166.6
<i>White</i>										
2022	43,173	43,173	*****	*****	*****	*****	16.91 (9.36, 30.53)	66,072	66,235	18,069.2
2023	15,268	15,268	*****	*****	*****	*****	5.69 (0.80, 40.41)	20,712	20,796	2,783.3
Rybelsus, Cardiac Arrest										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	100	103	26.9
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
<i>Asian</i>										
2022	923	923	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,445	1,471	355.0
2023	164	164	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	210	213	32.8
<i>Black or African American</i>										
2022	2,336	2,336	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	3,335	3,398	1,106.2
2023	1,056	1,056	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,351	1,391	205.2
<i>Multi-racial</i>										
2022	111	111	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	168	172	65.2
2023	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	106	109	13.8
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	96	98	48.4
2023	58	58	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	74	80	13.4
<i>Unknown</i>										

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2022	8,899	8,899	*****	*****	*****	*****	7.27 (1.02, 51.61)	13,647	13,926	4,494.3
2023	3,889	3,889	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,984	5,141	528.3
<i>White</i>										
2022	12,838	12,838	*****	*****	*****	*****	5.41 (0.76, 38.42)	19,626	19,980	5,231.90
2023	3,576	3,576	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,813	4,953	722.2
Wegovy, Cardiac Arrest										
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.4
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	50	52	4.6
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	3.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	62	62	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	96	96	34.4
2023	601	601	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	928	948	70.2

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>White</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.8
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	185	188	18.4
Saxenda, Cardiac Arrest										
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	298	298	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	470	470	165.4
2023	44	44	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	6.5
<i>White</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	35	15.6

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
Victoza, Cardiac Arrest										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	76	76	21.3
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.3
<i>Asian</i>										
2022	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	95	95	32.7
2023	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25	25	3.2
<i>Black or African American</i>										
2022	397	397	*****	*****	*****	*****	180.03 (25.36, 1,278.11)	550	550	193.2
2023	159	159	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	199	199	33.8
<i>Multi-racial</i>										
2022	37	37	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	57	57	22.5
2023	30	30	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	46	46	5.4
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.7
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.4
<i>Unknown</i>										
2022	1,026	1,026	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,555	1,556	514.6
2023	409	409	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	521	521	62.3
<i>White</i>										
2022	2,510	2,510	*****	*****	*****	*****	53.60 (13.40, 214.30)	3,751	3,751	1,039.7
2023	621	621	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	823	823	134.2
Trulicity, Cardiac Arrest										

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>American Indian or Alaska Native</i>										
2022	234	234	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	440	443	86.9
2023	23	23	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	5.0
<i>Asian</i>										
2022	1,045	1,045	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,825	1,831	408.0
2023	157	157	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	222	223	31.7
<i>Black or African American</i>										
2022	4,894	4,894	*****	*****	*****	*****	13.96 (1.97, 99.10)	8,231	8,302	2,271.0
2023	1,534	1,534	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,255	2,269	317.8
<i>Multi-racial</i>										
2022	190	190	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	426	430	114.0
2023	103	103	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	174	175	17.5
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	145	145	*****	*****	*****	*****	376.00 (52.96, 2,669.37)	236	250	100.6
2023	103	103	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	154	156	20.6
<i>Unknown</i>										
2022	15,411	15,411	*****	*****	*****	*****	3.74 (0.53, 26.52)	29,665	29,856	7,853.5
2023	6,363	6,363	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	9,664	9,746	894.4
<i>White</i>										
2022	30,998	30,998	*****	*****	*****	*****	17.12 (8.56, 34.23)	55,284	55,582	12,538.3
2023	5,777	5,777	*****	*****	*****	*****	14.08 (1.98, 99.92)	8,907	8,985	1,217.2
Xultophy, Cardiac Arrest										
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Asian</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
<i>Black or African American</i>										
2022	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	20	20	10.7
2023	22	22	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	33	33	4.8
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	38	38	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	52	19.7
2023	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	32	32	4.3
<i>White</i>										
2022	153	153	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	207	207	67.3
2023	94	94	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	121	121	19.3
Mounjaro, Ventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	47	47	7.8
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.1
<i>Asian</i>										

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2022	68	68	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	109	21.2
2023	40	40	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	54	54	6.9
<i>Black or African American</i>										
2022	634	634	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	980	999	273.7
2023	1,006	1,006	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,514	1,538	193.4
<i>Multi-racial</i>										
2022	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	60	61	19.3
2023	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	52	4.2
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	19	19	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	10.5
2023	38	38	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	60	61	6.7
<i>Unknown</i>										
2022	4,058	4,058	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	7,434	7,510	1,698.6
2023	3,948	3,948	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	6,209	6,277	541.4
<i>White</i>										
2022	4,671	4,671	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	7,775	7,864	1,645.2
2023	4,268	4,268	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	6,845	6,978	818.2
Bydureon, Ventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.9
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
<i>Asian</i>										
2022	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	53	53	16.0
2023	15	15	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	2.7

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Black or African American</i>										
2022	120	120	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	197	197	64.0
2023	45	45	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	58	58	9.0
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	34	34	14.3
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	1.5
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	179	179	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	262	262	79.8
2023	65	65	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	84	9.5
<i>White</i>										
2022	723	723	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,181	1,181	297.0
2023	110	110	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	155	155	21.4
Ozempic, Ventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	695	695	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,100	1,102	260.8
2023	131	131	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	170	173	22.1
<i>Asian</i>										
2022	1,022	1,022	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,605	1,607	423.1
2023	371	371	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	516	518	65.1
<i>Black or African American</i>										
2022	6,058	6,058	*****	*****	*****	*****	21.63 (5.41, 86.48)	9,102	9,130	2,926.5

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023	3,774	3,774	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,994	5,015	685.0
<i>Multi-racial</i>										
2022	407	407	*****	*****	*****	*****	154.02 (21.70, 1,093.46)	690	692	253.6
2023	409	409	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	559	562	62.4
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	156	156	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	229	229	106.1
2023	177	177	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	223	223	31.8
<i>Unknown</i>										
2022	27,580	27,580	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	45,223	45,337	14,467.1
2023	17,787	17,787	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	23,239	23,331	2,166.6
<i>White</i>										
2022	43,173	43,173	*****	*****	*****	*****	6.15 (2.31, 16.38)	66,072	66,235	18,069.2
2023	15,268	15,268	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	20,712	20,796	2,783.3
Rybelsus, Ventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	100	103	26.9
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
<i>Asian</i>										
2022	923	923	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,445	1,471	355.0
2023	164	164	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	210	213	32.8
<i>Black or African American</i>										
2022	2,336	2,336	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	3,335	3,398	1,106.2
2023	1,056	1,056	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,351	1,391	205.2
<i>Multi-racial</i>										

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2022	111	111	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	168	172	65.2
2023	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	106	109	13.8
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	96	98	48.4
2023	58	58	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	74	80	13.4
<i>Unknown</i>										
2022	8,899	8,899	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13,647	13,926	4,494.3
2023	3,889	3,889	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,984	5,141	528.3
<i>White</i>										
2022	12,838	12,838	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	19,626	19,980	5,231.90
2023	3,576	3,576	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,813	4,953	722.2
Wegovy, Ventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.4
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	50	52	4.6
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	3.0

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	62	62	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	96	96	34.4
2023	601	601	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	928	948	70.2
<i>White</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.8
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	185	188	18.4
<u>Saxenda, Ventricular Tachycardia</u>										
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	298	298	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	470	470	165.4
2023	44	44	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	6.5
<i>White</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	35	35	15.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
Victoza, Ventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	76	76	21.3
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.3
<i>Asian</i>										
2022	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	95	95	32.7
2023	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25	25	3.2
<i>Black or African American</i>										
2022	397	397	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	550	550	193.2
2023	159	159	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	199	199	33.8
<i>Multi-racial</i>										
2022	37	37	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	57	57	22.5
2023	30	30	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	46	46	5.4
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.7
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.4
<i>Unknown</i>										

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2022	1,026	1,026	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,555	1,556	514.6
2023	409	409	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	521	521	62.3
<i>White</i>										
2022	2,510	2,510	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	3,751	3,751	1,039.7
2023	621	621	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	823	823	134.2
Trulicity, Ventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	234	234	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	440	443	86.9
2023	23	23	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	5.0
<i>Asian</i>										
2022	1,045	1,045	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,825	1,831	408.0
2023	157	157	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	222	223	31.7
<i>Black or African American</i>										
2022	4,894	4,894	*****	*****	*****	*****	13.96 (1.97, 99.10)	8,231	8,302	2,271.0
2023	1,534	1,534	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,255	2,269	317.8
<i>Multi-racial</i>										
2022	190	190	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	426	430	114.0
2023	103	103	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	174	175	17.5
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	145	145	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	236	250	100.6
2023	103	103	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	154	156	20.6
<i>Unknown</i>										
2022	15,411	15,411	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	29,665	29,856	7,853.5
2023	6,363	6,363	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	9,664	9,746	894.4

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>White</i>										
2022	30,998	30,998	*****	*****	*****	*****	4.28 (1.07, 17.12)	55,284	55,582	12,538.3
2023	5,777	5,777	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	8,907	8,985	1,217.2
Xultophy, Ventricular Tachycardia										
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Asian</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
<i>Black or African American</i>										
2022	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	20	20	10.7
2023	22	22	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	33	33	4.8
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	38	38	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	52	19.7
2023	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	32	32	4.3
<i>White</i>										
2022	153	153	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	207	207	67.3

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023	94	94	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	121	121	19.3
Mounjaro, Ventricular Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	47	47	7.8
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.1
<i>Asian</i>										
2022	68	68	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	108	109	21.2
2023	40	40	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	54	54	6.9
<i>Black or African American</i>										
2022	634	634	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	980	999	273.7
2023	1,006	1,006	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,514	1,538	193.4
<i>Multi-racial</i>										
2022	34	34	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	60	61	19.3
2023	26	26	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	52	4.2
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	19	19	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	10.5
2023	38	38	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	60	61	6.7
<i>Unknown</i>										
2022	4,058	4,058	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	7,434	7,510	1,698.6
2023	3,948	3,948	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	6,209	6,277	541.4
<i>White</i>										
2022	4,671	4,671	*****	*****	*****	*****	17.61 (2.48, 125.01)	7,775	7,864	1,645.2
2023	4,268	4,268	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	6,845	6,978	818.2
Bydureon, Ventricular Fibrillation and Flutter										

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.9
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.7
<i>Asian</i>										
2022	29	29	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	53	53	16.0
2023	15	15	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	22	22	2.7
<i>Black or African American</i>										
2022	120	120	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	197	197	64.0
2023	45	45	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	58	58	9.0
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	34	34	14.3
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13	13	1.5
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	179	179	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	262	262	79.8
2023	65	65	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	84	84	9.5
<i>White</i>										
2022	723	723	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,181	1,181	297.0
2023	110	110	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	155	155	21.4
Ozempic, Ventricular Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
2022	695	695	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,100	1,102	260.8

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023	131	131	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	170	173	22.1
<i>Asian</i>										
2022	1,022	1,022	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,605	1,607	423.1
2023	371	371	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	516	518	65.1
<i>Black or African American</i>										
2022	6,058	6,058	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	9,102	9,130	2,926.5
2023	3,774	3,774	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,994	5,015	685.0
<i>Multi-racial</i>										
2022	407	407	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	690	692	253.6
2023	409	409	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	559	562	62.4
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	156	156	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	229	229	106.1
2023	177	177	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	223	223	31.8
<i>Unknown</i>										
2022	27,580	27,580	*****	*****	*****	*****	2.19 (0.31, 15.51)	45,223	45,337	14,467.1
2023	17,787	17,787	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	23,239	23,331	2,166.6
<i>White</i>										
2022	43,173	43,173	*****	*****	*****	*****	3.07 (0.77, 12.29)	66,072	66,235	18,069.2
2023	15,268	15,268	*****	*****	*****	*****	5.69 (0.80, 40.41)	20,712	20,796	2,783.3
Rybelsus, Ventricular Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	100	103	26.9
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
<i>Asian</i>										

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2022	923	923	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,445	1,471	355.0
2023	164	164	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	210	213	32.8
<i>Black or African American</i>										
2022	2,336	2,336	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	3,335	3,398	1,106.2
2023	1,056	1,056	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,351	1,391	205.2
<i>Multi-racial</i>										
2022	111	111	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	168	172	65.2
2023	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	106	109	13.8
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	70	70	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	96	98	48.4
2023	58	58	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	74	80	13.4
<i>Unknown</i>										
2022	8,899	8,899	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	13,647	13,926	4,494.3
2023	3,889	3,889	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,984	5,141	528.3
<i>White</i>										
2022	12,838	12,838	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	19,626	19,980	5,231.90
2023	3,576	3,576	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	4,813	4,953	722.2
Wegovy, Ventricular Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Black or African American</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.4
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	50	52	4.6
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	26	26	3.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	62	62	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	96	96	34.4
2023	601	601	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	928	948	70.2
<i>White</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	3.8
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	185	188	18.4
Saxenda, Ventricular Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Asian</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Black or African American</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	4.5

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.6
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	298	298	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	470	470	165.4
2023	44	44	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	56	56	6.5
<i>White</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	15.6
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.0
Victoza, Ventricular Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	76	76	21.3
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.3
<i>Asian</i>										
2022	74	74	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	95	95	32.7
2023	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	25	25	3.2
<i>Black or African American</i>										
2022	397	397	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	550	550	193.2
2023	159	159	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	199	199	33.8
<i>Multi-racial</i>										

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2022	37	37	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	57	57	22.5
2023	30	30	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	46	46	5.4
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	5.7
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	1.4
<i>Unknown</i>										
2022	1,026	1,026	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,555	1,556	514.6
2023	409	409	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	521	521	62.3
<i>White</i>										
2022	2,510	2,510	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	3,751	3,751	1,039.7
2023	621	621	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	823	823	134.2
Trulicity, Ventricular Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
2022	234	234	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	440	443	86.9
2023	23	23	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	39	39	5.0
<i>Asian</i>										
2022	1,045	1,045	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	1,825	1,831	408.0
2023	157	157	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	222	223	31.7
<i>Black or African American</i>										
2022	4,894	4,894	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	8,231	8,302	2,271.0
2023	1,534	1,534	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	2,255	2,269	317.8
<i>Multi-racial</i>										
2022	190	190	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	426	430	114.0
2023	103	103	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	174	175	17.5

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	145	145	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	236	250	100.6
2023	103	103	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	154	156	20.6
<i>Unknown</i>										
2022	15,411	15,411	*****	*****	*****	*****	7.47 (1.87, 29.87)	29,665	29,856	7,853.5
2023	6,363	6,363	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	9,664	9,746	894.4
<i>White</i>										
2022	30,998	30,998	*****	*****	*****	*****	4.28 (1.07, 17.12)	55,284	55,582	12,538.3
2023	5,777	5,777	*****	*****	*****	*****	14.08 (1.98, 99.92)	8,907	8,985	1,217.2
Xultophy, Ventricular Fibrillation and Flutter										
<i>American Indian or Alaska Native</i>										
2022	0	0	0	NaN	0.0	0	NaN	0	0	0.0
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.4
<i>Asian</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	2.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.8
<i>Black or African American</i>										
2022	18	18	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	20	20	10.7
2023	22	22	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	33	33	4.8
<i>Multi-racial</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.5
2023	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.0
<i>Native Hawaiian or Other Pacific Islander</i>										
2022	*****	*****	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	*****	*****	0.9

Table 9. Summary of Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023, by Race and Year¹

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event	Number of Exposure Episodes with an Event per 100 Exposure Episodes (95% Confidence Interval)	Total Years at Risk	Total Days at Risk	Event Rate per 10,000 Patient-Years at Risk (95% Confidence Interval)	Number of Exposure Episode Defining-Dispensings (Adjusted for Same-Day Dispensings)	Number of Exposure Episode Defining-Dispensings (Not Adjusted for Same-Day Dispensings)	Total Observable Years
2023	0	0	0	NaN	0.0	0	NaN	0	0	0.0
<i>Unknown</i>										
2022	38	38	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	52	52	19.7
2023	25	25	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	32	32	4.3
<i>White</i>										
2022	153	153	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	207	207	67.3
2023	94	94	0	0.00 (0.00, 0.00)	*****	*****	0.00 (0.00, 0.00)	121	121	19.3

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

*NaN: Not a number

Table 10. Summary of Time to End of At-Risk Period for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

Total Number of Episodes	Number of Episodes by Episode Length														
	0-30 days		31-60 days		61-90 days		91-183 days		184-365 days		366-455 days		456+ days		
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	
Bydureon	1,321	727	55.0%	236	17.9%	223	16.9%	115	8.7%	20	1.5%	0	0.0%	0	0.0%
Mounjaro	18,842	10,973	58.2%	4,395	23.3%	2,202	11.7%	1,169	6.2%	103	0.5%	0	0.0%	0	0.0%
Ozempic	117,008	54,789	46.8%	30,804	26.3%	18,795	16.1%	10,850	9.3%	1,756	1.5%	14	0.0%	0	0.0%
Rybelsus	34,058	19,925	58.5%	5,505	16.2%	5,228	15.4%	2,835	8.3%	*****	1.6%	*****	0.0%	0	0.0%
Saxenda	386	5,354	58.3%	72	18.7%	53	13.7%	*****	8.5%	*****	0.8%	0	0.0%	0	0.0%
Trulicity	66,978	32,227	48.1%	14,173	21.2%	11,634	17.4%	7,509	11.2%	1,423	2.1%	12	0.0%	0	0.0%
Victoza	5,354	2,728	51.0%	1,213	22.7%	846	15.8%	481	9.0%	*****	1.6%	*****	0.0%	0	0.0%
Wegovy	828	554	66.9%	193	23.3%	*****	8.6%	*****	1.2%	0	0.0%	0	0.0%	0	0.0%
Xultophy	364	165	45.3%	62	17.0%	85	23.4%	*****	11.8%	*****	2.5%	0	0.0%	0	0.0%

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 10. Summary of Time to End of At-Risk Period for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 (Continued)

	Total Number of Episodes	Distribution of At-Risk Time in Days, by Episode						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard
<i>Bydureon</i>	1,321	1	27	28	70	344	49.3	40.4
<i>Mounjaro</i>	18,842	1	27	27	53	344	41.9	31.5
<i>Ozempic</i>	117,008	1	27	38	65	383	50.7	40.4
<i>Rybelsus</i>	34,058	1	29	29	62	380	50.1	41.5
<i>Saxenda</i>	386	2	29	29	58	277	47.5	36.9
<i>Trulicity</i>	66,978	5,354	27	36	77	383	54.0	44.5
<i>Victoza</i>	5,354	1	29	29	66	369	51.1	42.3
<i>Wegovy</i>	828	1	21	27	45	164	32.2	21.2
<i>Xultophy</i>	364	1	29	36	89	301	57.4	45.7

Table 11. Summary of Time to End of At-Risk Period due to End of Exposure Episode for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

			Number of Episodes Censored due to End of Exposure Episode by Episode Length													
			0-30 days		31-60 days		61-90 days		91-183 days		184-365 days		366-455 days		456+ days	
	Total Number of Episodes	Total Number of Episodes Censored due to End of Exposure Episode ¹	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Bydureon</i>	1,321	1,061	583	54.9%	185	17.4%	190	17.9%	88	8.3%	15	1.4%	0	0.0%	0	0.0%
<i>Mounjaro</i>	18,842	13,251	7,868	59.4%	3,028	22.9%	1,554	11.7%	768	5.8%	33	0.2%	0	0.0%	0	0.0%
<i>Ozempic</i>	117,008	85,708	38,597	45.0%	22,686	26.5%	15,146	17.7%	8,272	9.7%	*****	1.2%	*****	0.0%	0	0.0%
<i>Rybelsus</i>	34,058	27,065	16,334	60.4%	4,047	15.0%	4,287	15.8%	2,085	7.7%	312	1.2%	0	0.0%	0	0.0%
<i>Saxenda</i>	386	5354	193	59.9%	60	18.6%	44	13.7%	*****	7.5%	*****	0.3%	0	0.0%	0	0.0%
<i>Trulicity</i>	66,978	52,689	25,345	48.1%	10,857	20.6%	9,695	18.4%	5,948	11.3%	844	1.6%	0	0.0%	0	0.0%
<i>Victoza</i>	5,354	4,096	2,049	50.0%	955	23.3%	674	16.5%	362	8.8%	56	1.4%	0	0.0%	0	0.0%
<i>Wegovy</i>	828	403	268	66.5%	102	25.3%	*****	7.4%	*****	0.7%	0	0.0%	0	0.0%	0	0.0%
<i>Xultophy</i>	364	231	111	46.1%	39	16.2%	61	25.3%	*****	9.1%	*****	3.3%	0	0.0%	0	0.0%

¹Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 11. Summary of Time to End of At-Risk Period due to End of Exposure Episode for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 (Continued)

			Distribution of At-Risk Time in Days, by Episode						
	Total Number of Episodes	Total Number of Episodes Censored due to End of Exposure Episode ¹	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Bydureon	1,321	1,061	1	27	29	75	238	50.6	37.9
Mounjaro	18,842	13,251	1	27	27	53	344	43.1	27.9
Ozempic	117,008	85,708	1	27	41	69	383	53.3	37.4
Rybelsus	34,058	27,065	1	29	29	59	337	50.2	37.6
Saxenda	386	322	5	29	29	58	186	46.8	31.2
Trulicity	66,978	5,354	1	27	40	79	344	54.8	40.6
Victoza	5,354	4,096	1	29	30	70	302	53.0	39.6
Wegovy	828	403	1	27	27	48	164	36.7	17.6
Xultophy	364	231	2	29	37	89	231	60.0	44.9

¹Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing records, and episodes end after days supplied are exhausted or a pre-determined maximum episode duration is met. In point exposure analyses, exposure episodes end when a pre-determined maximum episode duration is met.

Table 12. Summary of Time to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Total Number of Episodes of Interest	Total Number of Episodes Censored due to Occurrence of Outcome of Interest ¹	Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length													
			0-30 days		31-60 days		61-90 days		91-183 days		184-365 days		366-455 days		456+ days	
			Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Bydureon, Hospitalized Tachyarrhythmia</i>	1,321	*****	*****	71.4%	*****	14.3%	0	0.0%	*****	14.3%	0	0.0%	0	0.0%	0	0.0%
<i>Mounjaro, Hospitalized Tachyarrhythmia</i>	18,842	102	66	64.7%	22	21.6%	*****	10.8%	*****	2.9%	0	0.0%	0	0.0%	0	0.0%
<i>Ozempic, Hospitalized Tachyarrhythmia</i>	117,008	793	435	54.9%	208	26.2%	85	10.7%	*****	6.9%	*****	1.3%	0	0.0%	0	0.0%
<i>Rybelsus, Hospitalized Tachyarrhythmia</i>	34,058	178	102	57.3%	47	26.4%	*****	10.7%	*****	5.6%	0	0.0%	0	0.0%	0	0.0%
<i>Saxenda, Hospitalized Tachyarrhythmia</i>	386	5354	*****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Trulicity, Hospitalized Tachyarrhythmia</i>	66,978	496	300	60.5%	99	20.0%	50	10.1%	*****	8.3%	*****	1.2%	0	0.0%	0	0.0%
<i>Victoza, Hospitalized Tachyarrhythmia</i>	5,354	45	25	55.6%	*****	17.8%	*****	8.9%	*****	17.8%	0	0.0%	0	0.0%	0	0.0%
<i>Wegovy, Hospitalized Tachyarrhythmia</i>	828	*****	0	0.0%	*****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Table 12. Summary of Time to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Total Number of Episodes of Interest	Total Number of Episodes Censored due to Occurrence of Outcome of Interest ¹	Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length													
			0-30 days		31-60 days		61-90 days		91-183 days		184-365 days		366-455 days		456+ days	
			Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Xultophy, Hospitalized Tachyarrhythmia</i>	364	*****	0	0.0%	*****	50.0%	0	0.0%	*****	50.0%	0	0.0%	0	0.0%	0	0.0%
<i>Mounjaro, Atrial Fibrillation and Flutter</i>	18,842	64	43	67.2%	*****	20.3%	*****	10.9%	*****	1.6%	0	0.0%	0	0.0%	0	0.0%
<i>Bydureon, Atrial Fibrillation and Flutter</i>	1,321	*****	*****	80.0%	*****	20.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Ozempic, Atrial Fibrillation and Flutter</i>	117,008	506	285	56.3%	125	0.237	49	9.7%	*****	7.7%	*****	1.6%	0	0.0%	0	0.0%
<i>Rybelsus, Atrial Fibrillation and Flutter</i>	34,058	123	71	57.3%	30	0.232	*****	11.3%	*****	7.3%	0	0.0%	0	0.0%	0	0.0%
<i>Wegovy, Atrial Fibrillation and Flutter</i>	828	*****	0	0.0%	*****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Saxenda, Atrial Fibrillation and Flutter</i>	386	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Victoza, Atrial Fibrillation and Flutter</i>	5,354	27	14	51.9%	*****	22.2%	*****	11.1%	*****	14.8%	0	0.0%	0	0.0%	0	0.0%

Table 12. Summary of Time to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Total Number of Episodes of Interest		Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length													
			0-30 days		31-60 days		61-90 days		91-183 days		184-365 days		366-455 days		456+ days	
	Number of Episodes	Number of Outcome of Interest ¹	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Trulicity, Atrial Fibrillation and Flutter</i>	66,978	344	223	65.1%	67	19.5%	32	9.3%	*****	5.2%	*****	0.9%	0	0.0%	0	0.0%
<i>Xultophy, Atrial Fibrillation and Flutter</i>	364	*****	0	0.0%	*****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Mounjaro, Sinus Tachycardia</i>	18,842	30	18	60.0%	*****	26.7%	*****	6.7%	*****	6.7%	0	0.0%	0	0.0%	0	0.0%
<i>Bydureon, Sinus Tachycardia</i>	1,321	*****	*****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Ozempic, Sinus Tachycardia</i>	117,008	182	100	54.9%	55	30.2%	*****	9.3%	*****	4.9%	*****	0.5%	0	0.0%	0	0.0%
<i>Rybelsus, Sinus Tachycardia</i>	34,058	45	23	53.3%	*****	33.3%	*****	8.9%	*****	4.4%	0	0.0%	0	0.0%	0	0.0%
<i>Wegovy, Sinus Tachycardia</i>	828	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Saxenda, Sinus Tachycardia</i>	386	*****	*****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Victoza, Sinus Tachycardia</i>	5,354	15	*****	80.0%	*****	13.3%	0	0.0%	*****	6.7%	0	0.0%	0	0.0%	0	0.0%
<i>Trulicity, Sinus Tachycardia</i>	66,978	108	52	48.1%	23	21.3%	16	14.8%	*****	14.8%	*****	0.9%	0	0.0%	0	0.0%
<i>Xultophy, Sinus Tachycardia</i>	364	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

Table 12. Summary of Time to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Total Number of Episodes	Total Number of Outcome of Interest ¹	Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length													
			0-30 days		31-60 days		61-90 days		91-183 days		184-365 days		366-455 days		456+ days	
			Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Mounjaro, Supraventricular Tachycardia</i>	18,842	*****	*****	62.5%	*****	12.5%	*****	25.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Bydureon, Supraventricular Tachycardia</i>	1,321	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Ozempic, Supraventricular Tachycardia</i>	117,008	70	34	48.6%	*****	37.1%	*****	12.9%	0	0.0%	*****	1.4%	0	0.0%	0	0.0%
<i>Rybelsus, Supraventricular Tachycardia</i>	34,058	16	*****	56.3%	*****	18.8%	*****	12.5%	*****	12.5%	0	0.0%	0	0.0%	0	0.0%
<i>Wegovy, Supraventricular Tachycardia</i>	828	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Saxenda, Supraventricular Tachycardia</i>	386	*****	*****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Victoza, Supraventricular Tachycardia</i>	5,354	*****	*****	40.0%	0	0.0%	0	0.0%	*****	60.0%	0	0.0%	0	0.0%	0	0.0%

Table 12. Summary of Time to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Total Number of Episodes of Interest		Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length													
			0-30 days		31-60 days		61-90 days		91-183 days		184-365 days		366-455 days		456+ days	
	Number of Episodes	of Outcome of Interest ¹	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Trulicity, Supraventricular Tachycardia</i>	66,978	41	25	61.0%	*****	22.0%	*****	9.8%	*****	7.3%	0	0.0%	0	0.0%	0	0.0%
<i>Xultophy, Supraventricular Tachycardia</i>	364	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Mounjaro, Other</i>	18,842	*****	*****	80.0%	0	0.0%	*****	20.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Bydureon, Other Tachycardia</i>	1,321	*****	*****	50.0%	0	0.0%	0	0.0%	*****	50.0%	0	0.0%	0	0.0%	0	0.0%
<i>Ozempic, Other Tachycardia</i>	117,008	53	28	52.8%	11	20.8%	*****	13.2%	*****	13.2%	0	0.0%	0	0.0%	0	0.0%
<i>Rybelsus, Other Tachycardia</i>	34,058	*****	*****	60.0%	*****	20.0%	0	0.0%	*****	20.0%	0	0.0%	0	0.0%	0	0.0%
<i>Wegovy, Other Tachycardia</i>	828	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Saxenda, Other Tachycardia</i>	386	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Victoza, Other Tachycardia</i>	5,354	*****	*****	66.7%	0	0.0%	*****	33.3%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Trulicity, Other Tachycardia</i>	66,978	21	*****	57.1%	*****	19.0%	0	0.0%	*****	19.0%	*****	4.8%	0	0.0%	0	0.0%
<i>Xultophy, Other Tachycardia</i>	364	*****	0	0.0%	0	0.0%	0	0.0%	*****	100.0%	0	0.0%	0	0.0%	0	0.0%

Table 12. Summary of Time to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Total Number of Episodes of Interest		Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length													
			0-30 days		31-60 days		61-90 days		91-183 days		184-365 days		366-455 days		456+ days	
	Number of Episodes	Number of Outcome of Interest ¹	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Mounjaro, Cardiac Arrest</i>	18,842	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Bydureon, Cardiac Arrest</i>	1,321	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Ozempic, Cardiac Arrest</i>	117,008	18	*****	50.0%	*****	16.7%	*****	16.7%	*****	16.7%	0	0.0%	0	0.0%	0	0.0%
<i>Rybelsus, Cardiac Arrest</i>	34,058	*****	*****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Wegovy, Cardiac Arrest</i>	828	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Saxenda, Cardiac Arrest</i>	386	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Victoza, Cardiac Arrest</i>	5,354	*****	0	0.0%	*****	33.3%	0	0.0%	*****	66.7%	0	0.0%	0	0.0%	0	0.0%
<i>Trulicity, Cardiac Arrest</i>	66,978	12	*****	41.7%	*****	25.0%	*****	16.7%	*****	8.3%	*****	8.3%	0	0.0%	0	0.0%
<i>Xultophy, Cardiac Arrest</i>	364	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Mounjaro, Ventricular Tachycardia</i>	18,842	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Bydureon, Ventricular Tachycardia</i>	1,321	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

Table 12. Summary of Time to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Total Number of Episodes of Interest	Total Number of Episodes Censored due to Occurrence of Outcome of Interest ¹	Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length													
			0-30 days		31-60 days		61-90 days		91-183 days		184-365 days		366-455 days		456+ days	
			Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Ozempic, Ventricular Tachycardia</i>	117,008	*****	*****	42.9%	*****	42.9%	*****	14.3%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Rybelsus, Ventricular Tachycardia</i>	34,058	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Wegovy, Ventricular Tachycardia</i>	828	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Saxenda, Ventricular Tachycardia</i>	386	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Victoza, Ventricular Tachycardia</i>	5,354	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Trulicity, Ventricular Tachycardia</i>	66,978	*****	*****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Xultophy, Ventricular Tachycardia</i>	364	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

Table 12. Summary of Time to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Total Number of Episodes of Interest	Total Number of Episodes Censored due to Occurrence of Outcome of Interest ¹	Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length													
			0-30 days		31-60 days		61-90 days		91-183 days		184-365 days		366-455 days		456+ days	
			Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Mounjaro, Ventricular Fibrillation and Flutter</i>	18,842	*****	0	0.0%	*****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Bydureon, Ventricular Fibrillation and Flutter</i>	1,321	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Ozempic, Ventricular Fibrillation and Flutter</i>	117,008	*****	*****	75.0%	*****	25.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Rybelsus, Ventricular Fibrillation and Flutter</i>	34,058	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Wegovy, Ventricular Fibrillation and Flutter</i>	828	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Saxenda, Ventricular Fibrillation and Flutter</i>	386	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

Table 12. Summary of Time to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Total Number of Episodes Censored due to Occurrence of Outcome of Interest ¹		Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length													
			0-30 days		31-60 days		61-90 days		91-183 days		184-365 days		366-455 days		456+ days	
			Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Victoza, Ventricular Fibrillation and Flutter</i>	5,354	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Trulicity, Ventricular Fibrillation and Flutter</i>	66,978	*****	*****	60.0%	*****	40.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Xultophy, Ventricular Fibrillation and Flutter</i>	364	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

¹Represents episodes censored due to occurrence of request-defined event.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a number

Table 12. Summary of Time to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 (Continued)

	Total Number of Episodes		Distribution of At-Risk Time in Days, by Episode						
	Total Number of Episodes	Censored due to Occurrence of Outcome of Interest ¹	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Bydureon, Hospitalized Tachyarrhythmia</i>	1,321	*****	2	10	19	33	94	28.1	30.6
<i>Mounjaro, Hospitalized Tachyarrhythmia</i>	18,842	102	1	8	20	36	166	28.9	30.1
<i>Ozempic, Hospitalized Tachyarrhythmia</i>	117,008	793	1	12	26	51	354	38.4	39.3
<i>Rybelsus, Hospitalized Tachyarrhythmia</i>	34,058	178	1	13	26	48	170	36.1	33.7
<i>Saxenda, Hospitalized Tachyarrhythmia</i>	386	*****	4	4	4	4	4	4.0	NaN
<i>Trulicity, Hospitalized Tachyarrhythmia</i>	66,978	496	1	9	23	49	326	37.0	41.7
<i>Victoza, Hospitalized Tachyarrhythmia</i>	5,354	45	1	11	22	78	174	45.9	48.2
<i>Wegovy, Hospitalized Tachyarrhythmia</i>	828	*****	34	34	34	34	34	34.0	NaN
<i>Xultophy, Hospitalized Tachyarrhythmia</i>	364	*****	38	38	77	116	116	77.0	55.2
<i>Mounjaro, Atrial Fibrillation and Flutter</i>	18,842	64	1	9	19	39	119	27.0	23.8
<i>Bydureon, Atrial Fibrillation and Flutter</i>	1,321	*****	2	10	17	19	33	16.2	11.5
<i>Ozempic, Atrial Fibrillation and Flutter</i>	117,008	506	1	11	25	51	261	38.7	40.7
<i>Rybelsus, Atrial Fibrillation and Flutter</i>	34,058	123	1	14	26	51	170	39.2	37.4
<i>Wegovy, Atrial Fibrillation and Flutter</i>	828	*****	34	34	34	34	34	34.0	NaN
<i>Saxenda, Atrial Fibrillation and Flutter</i>	386	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Victoza, Atrial Fibrillation and Flutter</i>	5,354	27	1	11	29	78	155	43.6	43.7
<i>Trulicity, Atrial Fibrillation and Flutter</i>	66,978	344	1	9	21	42	326	32.7	38.3
<i>Xultophy, Atrial Fibrillation and Flutter</i>	364	*****	38	38	38	38	38	38.0	NaN
<i>Mounjaro, Sinus Tachycardia</i>	18,842	30	1	9	23	34	166	32.3	39.3
<i>Bydureon, Sinus Tachycardia</i>	1,321	*****	22	22	22	22	22	22.0	NaN
<i>Ozempic, Sinus Tachycardia</i>	117,008	182	1	12	27	49	354	35.7	37.9
<i>Rybelsus, Sinus Tachycardia</i>	34,058	45	1	15	27	44	165	34.0	29.7
<i>Wegovy, Sinus Tachycardia</i>	828	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Saxenda, Sinus Tachycardia</i>	386	*****	4	4	4	4	4	4.0	NaN
<i>Victoza, Sinus Tachycardia</i>	5,354	15	2	9	12	25	113	23.2	28.1
<i>Trulicity, Sinus Tachycardia</i>	66,978	108	1	12	32	74	225	46.7	46.3
<i>Xultophy, Sinus Tachycardia</i>	364	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Mounjaro, Supraventricular Tachycardia</i>	18,842	*****	4	12	23	55	86	33.8	30.6

Table 12. Summary of Time to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 (Continued)

	Total Number of Episodes		Distribution of At-Risk Time in Days, by Episode						
	Total Number of Episodes	Censored due to Occurrence of Outcome of Interest ¹	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Bydureon, Supraventricular Tachycardia</i>	1,321	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Ozempic, Supraventricular Tachycardia</i>	117,008	70	1	14	32	52	189	35.5	29.2
<i>Rybelsus, Supraventricular Tachycardia</i>	34,058	16	1	16	23	60	170	45.6	51.5
<i>Wegovy, Supraventricular Tachycardia</i>	828	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Saxenda, Supraventricular Tachycardia</i>	386	*****	4	4	4	4	4	4.0	NaN
<i>Victoza, Supraventricular Tachycardia</i>	5,354	*****	6	8	121	138	174	89.4	77.6
<i>Trulicity, Supraventricular Tachycardia</i>	66,978	41	1	7	25	45	150	32.1	33.3
<i>Xultophy, Supraventricular Tachycardia</i>	364	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Mounjaro, Other Tachycardia</i>	18,842	*****	7	7	14	18	75	23.2	28.8
<i>Bydureon, Other Tachycardia</i>	1,321	*****	17	17	56	94	94	55.5	54.4
<i>Ozempic, Other Tachycardia</i>	117,008	53	1	10	29	61	155	42.3	38.1
<i>Rybelsus, Other Tachycardia</i>	34,058	*****	5	26	28	40	165	52.8	64.0
<i>Wegovy, Other Tachycardia</i>	828	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Saxenda, Other Tachycardia</i>	386	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Victoza, Other Tachycardia</i>	5,354	*****	8	8	15	80	80	34.3	39.7
<i>Trulicity, Other Tachycardia</i>	66,978	21	3	13	25	59	194	46.6	50.7
<i>Xultophy, Other Tachycardia</i>	364	*****	116	116	116	116	116	116.0	NaN
<i>Mounjaro, Cardiac Arrest</i>	18,842	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Bydureon, Cardiac Arrest</i>	1,321	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Ozempic, Cardiac Arrest</i>	117,008	18	4	6	34	80	165	46.7	44.8
<i>Rybelsus, Cardiac Arrest</i>	34,058	*****	2	2	10	18	18	10.0	11.3
<i>Wegovy, Cardiac Arrest</i>	828	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Saxenda, Cardiac Arrest</i>	386	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Victoza, Cardiac Arrest</i>	5,354	*****	39	39	133	142	142	104.7	57.0
<i>Trulicity, Cardiac Arrest</i>	66,978	12	1	13	49	65	192	53.6	53.9
<i>Xultophy, Cardiac Arrest</i>	364	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Mounjaro, Ventricular Tachycardia</i>	18,842	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Bydureon, Ventricular Tachycardia</i>	1,321	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 12. Summary of Time to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 (Continued)

	Total Number of Episodes		Distribution of At-Risk Time in Days, by Episode						
	Total Number of Episodes	Censored due to Occurrence of Outcome of Interest ¹	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Ozempic, Ventricular Tachycardia</i>	117,008	*****	1	3	34	51	71	31.4	23.9
<i>Rybelsus, Ventricular Tachycardia</i>	34,058	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Wegovy, Ventricular Tachycardia</i>	828	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Saxenda, Ventricular Tachycardia</i>	386	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Victoza, Ventricular Tachycardia</i>	5,354	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Trulicity, Ventricular Tachycardia</i>	66,978	*****	2	2	5	18	18	8.3	8.5
<i>Xultophy, Ventricular Tachycardia</i>	364	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Mounjaro, Ventricular Fibrillation and Flutter</i>	18,842	*****	33	33	33	33	33	33.0	NaN
<i>Bydureon, Ventricular Fibrillation and Flutter</i>	1,321	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Ozempic, Ventricular Fibrillation and Flutter</i>	117,008	*****	7	12	22	42	57	26.8	21.6
<i>Rybelsus, Ventricular Fibrillation and Flutter</i>	34,058	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Wegovy, Ventricular Fibrillation and Flutter</i>	828	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Saxenda, Ventricular Fibrillation and Flutter</i>	386	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Victoza, Ventricular Fibrillation and Flutter</i>	5,354	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Trulicity, Ventricular Fibrillation and Flutter</i>	66,978	*****	1	23	25	38	57	29.0	20.6
<i>Xultophy, Ventricular Fibrillation and Flutter</i>	364	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

¹Represents episodes censored due to occurrence of request-defined event.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

NaN: Not a number

Table 13. Summary of Time to End of At-Risk Period due to Occurrence of User-Defined Censoring Criteria for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

			Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length															
			0-30 days		31-60 days		61-90 days		91-183 days		184-365 days		366-455 days		456+ days			
	Total Number of Episodes	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria ¹	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Bydureon</i>	1,321	151	85	56.3%	31	20.5%	23	15.2%	*****	7.3%	*****	0.7%	0	0.0%	0	0.0%	0	0.0%
<i>Mounjaro</i>	18,842	1,259	843	67.0%	235	19.5%	120	9.5%	*****	3.7%	*****	0.3%	0	0.0%	0	0.0%	0	0.0%
<i>Ozempic</i>	117,008	10,001	5,642	56.4%	2,552	25.5%	1,023	10.2%	688	6.9%	96	1.0%	0	0.0%	0	0.0%	0	0.0%
<i>Rybelsus</i>	34,058	2,585	1,543	59.7%	514	19.9%	295	11.4%	213	8.2%	20	0.8%	0	0.0%	0	0.0%	0	0.0%
<i>Saxenda</i>	386	37	22	59.5%	*****	0.233	*****	10.8%	*****	5.4%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Trulicity</i>	66,978	6,761	3,968	58.7%	1,458	21.6%	726	10.7%	535	7.9%	74	1.1%	0	0.0%	0	0.0%	0	0.0%
<i>Victoza</i>	5,354	727	447	61.5%	140	19.3%	78	10.7%	*****	8.3%	*****	0.3%	0	0.0%	0	0.0%	0	0.0%
<i>Wegovy</i>	828	38	*****	81.6%	*****	15.8%	*****	2.6%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Xultophy</i>	364	46	23	50.0%	11	23.9%	*****	13.0%	*****	13.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

¹Represents episodes censored due to occurrence of additional user-defined criteria using drug, procedure, diagnosis, and/or laboratory codes.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 13. Summary of Time to End of At-Risk Period due to Occurrence of User-Defined Censoring Criteria for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 (Continued)

	Total Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria ¹		Distribution of At-Risk Time in Days, by Episode						
	Total Number of Episodes	Criteria ¹	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Bydureon</i>	1,321	151	1	12	26	56	344	39.2	41.1
<i>Mounjaro</i>	18,842	1,259	1	10	20	41	231	29.4	29.7
<i>Ozempic</i>	117,008	10,001	1	12	26	49	356	37.2	37.5
<i>Rybelsus</i>	34,058	2,585	1	13	23	53	329	38.2	38.4
<i>Saxenda</i>	386	37	2	10	28	50	166	34.6	35.7
<i>Trulicity</i>	66,978	6,761	1	11	23	51	337	37.6	39.8
<i>Victoza</i>	5,354	727	1	11	23	48	273	36.2	36.8
<i>Wegovy</i>	828	38	1	7	17	27	63	19.4	14.6
<i>Xultophy</i>	364	46	2	15	30	62	170	43.2	41.2

¹Represents episodes censored due to occurrence of additional user-defined criteria using drug, procedure, diagnosis, and/or laboratory codes.

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 14. Summary of Time to End of At-Risk Period due to Evidence of Death for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

			Number of Episodes Censored due to Evidence of Death by Episode Length															
			0-30 days		31-60 days		61-90 days		91-183 days		184-365 days		366-455 days		456+ days			
	Total Number of Episodes	Total Number of Episodes Censored due to Evidence of Death ¹	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Bydureon</i>	1,321	*****	*****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Mounjaro</i>	18,842	*****	*****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Ozempic</i>	117,008	32	*****	68.8%	*****	15.6%	*****	6.3%	*****	9.4%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Rybelsus</i>	34,058	*****	*****	66.7%	*****	33.3%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Saxenda</i>	386	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Trulicity</i>	66,978	49	32	65.3%	*****	16.3%	*****	8.2%	*****	8.2%	*****	2.0%	0	0.0%	0	0.0%	0	0.0%
<i>Victoza</i>	5,354	*****	*****	75.0%	*****	25.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Wegovy</i>	828	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Xultophy</i>	364	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

¹Represents episodes censored due to evidence of death. Death data source and completeness varies by Data Partner.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

*NaN: Not a number

Table 14. Summary of Time to End of At-Risk Period due to Evidence of Death for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 (Continued)

	Total Number of Episodes Censored due to Evidence of Death ¹		Distribution of At-Risk Time in Days, by Episode						
	Total Number of Episodes		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Bydureon</i>	1,321	*****	7	7	7	7	7	7.0	NaN
<i>Mounjaro</i>	18,842	*****	7	7	11	15	15	11.0	5.7
<i>Ozempic</i>	117,008	32	3	14	21	36	165	32.9	35.2
<i>Rybelsus</i>	34,058	*****	18	18	23	49	52	30.5	15.7
<i>Saxenda</i>	386	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Trulicity</i>	66,978	49	1	9	17	57	192	35.8	42.5
<i>Victoza</i>	5,354	*****	3	3	12	30	39	16.5	17.2
<i>Wegovy</i>	828	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Xultophy</i>	364	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

¹Represents episodes censored due to evidence of death. Death data source and completeness varies by Data Partner.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

*NaN: Not a number

Table 15. Summary of Time to End of At-Risk Period due to Disenrollment for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

			Number of Episodes Censored due to Disenrollment by Episode Length													
			0-30 days		31-60 days		61-90 days		91-183 days		184-365 days		366-455 days		456+ days	
	Total Number of Episodes	Total Number of Episodes Censored due to Disenrollment ¹	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Bydureon</i>	1,321	191	98	51.3%	33	17.3%	21	11.0%	*****	15.2%	*****	5.2%	0	0.0%	0	0.0%
<i>Mounjaro</i>	18,842	1,574	952	60.5%	360	22.9%	158	10.0%	*****	6.5%	*****	0.1%	0	0.0%	0	0.0%
<i>Ozempic</i>	117,008	12,066	5,410	44.8%	2,900	0.23	1,708	14.2%	1,703	14.1%	*****	2.9%	*****	0.0%	0	0.0%
<i>Rybelsus</i>	34,058	4,385	1,997	45.5%	913	20.8%	615	14.0%	696	15.9%	164	3.7%	0	0.0%	0	0.0%
<i>Saxenda</i>	386	*****	*****	75.0%	*****	12.5%	0	0.0%	*****	12.5%	0	0.0%	0	0.0%	0	0.0%
<i>Trulicity</i>	66,978	9,721	3,987	41.0%	2,280	23.5%	1,410	14.5%	1,646	16.9%	398	4.1%	0	0.0%	0	0.0%
<i>Victoza</i>	5,354	721	319	44.2%	184	25.5%	88	12.2%	99	13.7%	31	4.3%	0	0.0%	0	0.0%
<i>Wegovy</i>	828	*****	*****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Xultophy</i>	364	44	12	27.3%	11	25.0%	*****	15.9%	*****	20.5%	*****	11.4%	0	0.0%	0	0.0%

¹Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 15. Summary of Time to End of At-Risk Period due to Disenrollment for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 (Continued)

	Total Number of Episodes Censored due to Disenrollment ¹		Distribution of At-Risk Time in Days, by Episode						
			Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Bydureon</i>	1,321	191	1	13	30	76	232	53.5	54.4
<i>Mounjaro</i>	18,842	1,574	1	15	25	47	189	35.1	31.1
<i>Ozempic</i>	117,008	12,066	1	18	38	71	383	52.1	47.9
<i>Rybelsus</i>	34,058	4,385	1	18	38	78	262	55.1	51.0
<i>Saxenda</i>	386	*****	8	15	26	32	127	34.9	38.2
<i>Trulicity</i>	66,978	9,721	1	18	43	80	291	57.6	51.8
<i>Victoza</i>	5,354	721	1	17	38	72	238	54.8	52.6
<i>Wegovy</i>	828	*****	1	1	11	21	23	11.7	8.9
<i>Xultophy</i>	364	44	2	28	59	119	227	76.0	64.2

¹Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 16. Summary of Time to End of At-Risk Period due to End of Data for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

			Number of Episodes Censored due to End of Data by Episode Length													
			0-30 days		31-60 days		61-90 days		91-183 days		184-365 days		366-455 days		456+ days	
	Total Number of Episodes	Total Number of Episodes Censored due to End of Data ¹	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Bydureon</i>	1,321	285	147	51.6%	51	17.9%	28	9.8%	45	15.8%	14	4.9%	0	0.0%	0	0.0%
<i>Mounjaro</i>	18,842	5,680	3,071	54.1%	1,428	25.1%	675	11.9%	439	7.7%	67	1.2%	0	0.0%	0	0.0%
<i>Ozempic</i>	117,008	31,994	15,252	47.7%	8,120	25.4%	4,183	13.1%	3,458	10.8%	970	3.0%	11	0.0%	0	0.0%
<i>Rybelsus</i>	34,058	8,350	3,822	45.8%	1,758	21.1%	1,214	14.5%	1,175	14.1%	*****	4.5%	*****	0.1%	0	0.0%
<i>Saxenda</i>	386	29	12	41.4%	*****	10.3%	*****	17.2%	*****	23.10%	*****	6.9%	0	0.0%	0	0.0%
<i>Trulicity</i>	66,978	16,261	6,412	39.4%	3,888	23.9%	2,497	15.4%	2,566	15.8%	886	5.4%	12	0.1%	0	0.0%
<i>Victoza</i>	5,354	1,187	510	43.0%	288	23.30%	179	15.1%	153	12.9%	*****	4.7%	*****	0.1%	0	0.0%
<i>Wegovy</i>	828	398	262	65.8%	88	22.1%	*****	10.1%	*****	2.0%	0	0.0%	0	0.0%	0	0.0%
<i>Xultophy</i>	364	122	45	36.9%	23	18.9%	25	20.5%	*****	19.7%	*****	4.1%	0	0.0%	0	0.0%

¹Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 16. Summary of Time to End of At-Risk Period due to End of Data for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 (Continued)

	Total Number of Episodes Censored due to End of Data ¹		Distribution of At-Risk Time in Days, by Episode						
	Total Number of Episodes		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Bydureon</i>	1,321	285	1	15	30	77	319	53.8	56.4
<i>Mounjaro</i>	18,842	5,680	1	15	28	53	309	40.3	38.3
<i>Ozempic</i>	117,008	31,994	1	16	33	64	383	48.9	49.8
<i>Rybelsus</i>	34,058	8,350	1	17	37	77	380	56.0	56.3
<i>Saxenda</i>	386	29	2	14	58	96	277	70.3	71.6
<i>Trulicity</i>	66,978	16,261	1	19	44	80	383	61.2	59.0
<i>Victoza</i>	5,354	1,187	1	17	39	75	369	56.7	56.8
<i>Wegovy</i>	828	398	1	10	22	43	118	28.9	23.1
<i>Xultophy</i>	364	122	1	21	51	89	301	62.6	54.2

¹Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 17. Summary of Time to End of At-Risk Period due to End of Study Period for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

			Number of Episodes Censored due to End of Study Period by Episode Length													
			0-30 days		31-60 days		61-90 days		91-183 days		184-365 days		366-455 days		456+ days	
	Total Number of Episodes	Number of Episodes Censored due to End of Study Period ¹	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Bydureon</i>	1,321	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Mounjaro</i>	18,842	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Ozempic</i>	117,008	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Rybelsus</i>	34,058	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Saxenda</i>	386	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Trulicity</i>	66,978	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Victoza</i>	5,354	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Wegovy</i>	828	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Xultophy</i>	364	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

¹Represents episodes censored due to user-specified study end date.

*NaN: Not a number

Table 17. Summary of Time to End of At-Risk Period due to End of Study Period for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 (Continued)

			Distribution of At-Risk Time in Days, by Episode						
	Total Number of Episodes Censored due to End of Study Period ¹		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Bydureon</i>	1,321	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Mounjaro</i>	18,842	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Ozempic</i>	117,008	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Rybelsus</i>	34,058	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Saxenda</i>	386	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Trulicity</i>	66,978	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Victoza</i>	5,354	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Wegovy</i>	828	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Xultophy</i>	364	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

¹Represents episodes censored due to user-specified study end date.

*NaN: Not a number

Table 18. Summary of Time to End of Observable Data for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023¹

	Total Number of	Number of Episodes by Observable Time													
		0-30 days		31-60 days		61-90 days		91-183 days		184-365 days		366-455 days		456+ days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Bydureon</i>	1,321	167	12.6%	137	10.4%	131	9.9%	454	34.4%	414	31.3%	18	1.4%	0	0.0%
<i>Mounjaro</i>	18,842	3,410	18.1%	3,499	18.6%	2,949	15.7%	6,095	32.3%	2,889	15.3%	0	0.0%	0	0.0%
<i>Ozempic</i>	117,008	16,529	14.1%	16,599	14.2%	15,068	12.9%	34,089	29.1%	33,825	28.9%	898	0.8%	0	0.0%
<i>Rybelsus</i>	34,058	4,148	12.2%	4,312	12.7%	4,162	12.2%	10,803	31.7%	10,373	30.5%	260	0.8%	0	0.0%
<i>Saxenda</i>	386	18	4.7%	22	5.7%	22	5.7%	125	32.4%	*****	51.0%	*****	0.5%	0	0.0%
<i>Trulicity</i>	66,978	7,299	10.9%	8,134	12.1%	8,189	12.2%	21,727	32.4%	21,023	31.4%	606	0.9%	0	0.0%
<i>Victoza</i>	5,354	577	10.8%	683	12.8%	642	12.0%	1,730	32.3%	1,662	31.0%	60	1.1%	0	0.0%
<i>Wegovy</i>	828	275	33.2%	230	29.0%	192	23.2%	81	9.8%	40	4.8%	0	0.0%	0	0.0%
<i>Xultophy</i>	364	45	12.4%	39	10.7%	61	16.8%	125	34.3%	*****	23.70%	*****	1.1%	0	0.0%

¹Time to end of observable data is for characterization purposes only. It does not necessarily represent at-risk time, and does not consider episode end, outcome occurrence, blackout period, or delay risk period start.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 18. Summary of Time to End of Observable Data for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023¹ (Continued)

		Distribution of Observable Time in Days, by Episode						
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Bydureon</i>	1,321	2	66	137	206	384	143.3	92.2
<i>Mounjaro</i>	18,842	2	42	86	147	359	101.7	73.8
<i>Ozempic</i>	117,008	2	53	114	199	410	132.1	93.0
<i>Rybelsus</i>	34,058	2	61	125	201	384	137.9	91.6
<i>Saxenda</i>	386	3	115	187	256	372	184.7	87.0
<i>Trulicity</i>	66,978	2	66	130	205	389	141.1	91.2
<i>Victoza</i>	5,354	2	65	130	205	412	141.3	92.3
<i>Wegovy</i>	828	2	23	50	75	363	60.6	61.2
<i>Xultophy</i>	364	2	65	112	190	381	131.7	91.6

¹Time to end of observable data is for characterization purposes only. It does not necessarily represent at-risk time, and does not consider episode end, outcome occurrence, blackout period, or delay risk period start.

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 19. Summary of Time to End of Observable Data due to Evidence of Death for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023¹

			Number of Episodes Censored due to Evidence of Death by Observable Time															
			0-30 days		31-60 days		61-90 days		91-183 days		184-365 days		366-455 days		456+ days			
	Total Number of Episodes	Total Number of Episodes Censored due to Evidence of Death ²	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Bydureon</i>	1,321	*****	*****	25.0%	*****	12.5%	*****	12.5%	*****	37.5%	*****	12.5%	0	0.0%	0	0.0%	0	0.0%
<i>Mounjaro</i>	18,842	16	*****	25.0%	*****	43.8%	*****	12.5%	*****	12.5%	*****	6.3%	0	0.0%	0	0.0%	0	0.0%
<i>Ozempic</i>	117,008	290	49	16.9%	40	13.8%	47	16.2%	113	39.0%	41	14.1%	0	0.0%	0	0.0%	0	0.0%
<i>Rybelsus</i>	34,058	104	11	10.6%	20	19.2%	17	16.3%	*****	45.2%	*****	8.7%	0	0.0%	0	0.0%	0	0.0%
<i>Saxenda</i>	386	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Trulicity</i>	66,978	363	63	17.4%	60	16.5%	70	19.3%	127	35.0%	43	11.8%	0	0.0%	0	0.0%	0	0.0%
<i>Victoza</i>	5,354	26	*****	19.2%	*****	38.5%	*****	7.7%	*****	26.9%	*****	7.7%	0	0.0%	0	0.0%	0	0.0%
<i>Wegovy</i>	828	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Xultophy</i>	364	*****	0	0.0%	0	0.0%	*****	50.0%	*****	50.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

¹Time to end of observable data is for characterization purposes only. It does not necessarily represent at-risk time, and does not consider episode end, outcome occurrence, blackout period, or delay risk period start.

²Represents episodes censored due to evidence of death. Death data source and completeness varies by Data Partner.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

*NaN: Not a number

Table 19. Summary of Time to End of Observable Data due to Evidence of Death for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023¹ (Continued)

	Total Number of Episodes Censored due to Evidence of Death ²		Distribution of Observable Time in Days, by Episode						
			Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Bydureon</i>	1,321	*****	8	43	88	156	360	117.6	112.7
<i>Mounjaro</i>	18,842	16	8	29	42	76	235	66.6	65.1
<i>Ozempic</i>	117,008	290	4	48	94	155	363	106.9	73.9
<i>Rybelsus</i>	34,058	104	8	51	97	128	260	98.2	57.2
<i>Saxenda</i>	386	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Trulicity</i>	66,978	363	2	46	86	143	345	99.5	68.6
<i>Victoza</i>	5,354	26	4	40	60	129	220	79.0	57.5
<i>Wegovy</i>	828	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Xultophy</i>	364	*****	84	84	131	178	178	131.0	66.5

¹Time to end of observable data is for characterization purposes only. It does not necessarily represent at-risk time, and does not consider episode end, outcome occurrence, blackout period, or delay risk period start.

²Represents episodes censored due to evidence of death. Death data source and completeness varies by Data Partner.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

*NaN: Not a number

Table 20. Summary of Time to End of Observable Data due to Disenrollment for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023¹

			Number of Episodes Censored due to Disenrollment by Observable Time															
			0-30 days		31-60 days		61-90 days		91-183 days		184-365 days		366-455 days		456+ days			
	Total Number of Episodes	Total Number of Episodes Censored due to Disenrollment ²	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Bydureon</i>	1,321	741	101	13.6%	82	11.1%	82	11.1%	296	39.9%	180	23.30%	0	0.0%	0	0.0%	0	0.0%
<i>Mounjaro</i>	18,842	3,984	987	23.80%	982	23.60%	808	20.3%	1,090	27.4%	117	2.9%	0	0.0%	0	0.0%	0	0.0%
<i>Ozempic</i>	117,008	44,596	5,571	12.5%	5,699	12.8%	6,671	15.0%	16,795	37.7%	9,790	22.0%	70	0.2%	0	0.0%	0	0.0%
<i>Rybelsus</i>	34,058	14,702	2,007	13.7%	1,996	13.6%	2,014	13.7%	5,425	36.9%	*****	22.2%	*****	0.0%	0	0.0%	0	0.0%
<i>Saxenda</i>	386	29	*****	20.7%	*****	17.2%	*****	3.4%	*****	31.0%	*****	27.6%	0	0.0%	0	0.0%	0	0.0%
<i>Trulicity</i>	66,978	33,533	4,149	12.4%	4,573	13.6%	4,525	13.5%	12,749	38.0%	*****	22.5%	*****	0.0%	0	0.0%	0	0.0%
<i>Victoza</i>	5,354	2,647	325	12.3%	379	14.3%	326	12.3%	1,007	38.0%	*****	22.9%	*****	0.2%	0	0.0%	0	0.0%
<i>Wegovy</i>	828	15	*****	46.7%	*****	20.0%	*****	26.7%	*****	6.7%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Xultophy</i>	364	127	12	9.4%	20	15.7%	23	18.9%	47	37.0%	23	18.9%	0	0.0%	0	0.0%	0	0.0%

¹Time to end of observable data is for characterization purposes only. It does not necessarily represent at-risk time, and does not consider episode end, outcome occurrence, blackout period, or delay risk period start.

²Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 20. Summary of Time to End of Observable Data due to Disenrollment for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023¹ (Continued)

	Total Number of Episodes Censored due to Disenrollment ²		Distribution of Observable Time in Days, by Episode						
	Total Number of Episodes		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Bydureon</i>	1,321	741	2	61	130	180	360	122.5	70.3
<i>Mounjaro</i>	18,842	3,984	2	31	61	102	328	71.7	50.8
<i>Ozempic</i>	117,008	44,596	2	60	112	174	410	117.3	69.0
<i>Rybelsus</i>	34,058	14,702	2	55	111	174	372	115.5	68.6
<i>Saxenda</i>	386	29	9	39	113	213	318	123.9	96.5
<i>Trulicity</i>	66,978	33,533	2	59	115	175	389	117.3	68.1
<i>Victoza</i>	5,354	2,647	2	58	117	174	412	119.0	70.1
<i>Wegovy</i>	828	15	2	12	31	75	94	40.7	31.6
<i>Xultophy</i>	364	127	3	60	104	169	233	113.4	65.7

¹Time to end of observable data is for characterization purposes only. It does not necessarily represent at-risk time, and does not consider episode end, outcome occurrence, blackout period, or delay risk period start.

²Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 21. Summary of Time to End of Observable Data due to End of Data for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023¹

			Number of Episodes Censored due to End of Data by Observable Time															
			0-30 days		31-60 days		61-90 days		91-183 days		184-365 days		366-455 days		456+ days			
	Total Number of Episodes	Total Number of Episodes Censored due to End of Data ²	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Bydureon</i>	1,321	1,238	152	12.2%	126	10.1%	120	9.6%	430	34.5%	402	32.2%	18	1.4%	0	0.0%		
<i>Mounjaro</i>	18,842	18,010	3,199	17.8%	3,309	18.4%	2,796	15.5%	5,856	32.5%	2,850	15.8%	0	0.0%	0	0.0%		
<i>Ozempic</i>	117,008	110,821	15,535	14.0%	15,635	14.1%	14,113	12.7%	31,962	28.8%	32,678	29.5%	898	0.8%	0	0.0%		
<i>Rybelsus</i>	34,058	32,166	3,823	11.9%	4,017	12.5%	3,889	12.1%	10,159	31.6%	10,017	31.1%	260	0.8%	0	0.0%		
<i>Saxenda</i>	386	362	12	3.3%	17	4.7%	21	5.8%	116	32.0%	*****	53.6%	*****	0.6%	0	0.0%		
<i>Trulicity</i>	66,978	62,950	6,621	10.5%	7,483	11.9%	7,610	12.1%	20,340	32.3%	20,290	32.2%	606	1.0%	0	0.0%		
<i>Victoza</i>	5,354	5,028	519	10.3%	623	12.4%	598	11.9%	1,618	32.2%	1,610	32.0%	60	1.2%	0	0.0%		
<i>Wegovy</i>	828	820	271	33.0%	238	29.0%	190	23.2%	81	9.9%	40	4.9%	0	0.0%	0	0.0%		
<i>Xultophy</i>	364	351	45	12.8%	38	10.8%	58	16.5%	119	33.9%	*****	23.80%	*****	1.1%	0	0.0%		

¹Time to end of observable data is for characterization purposes only. It does not necessarily represent at-risk time, and does not consider episode end, outcome occurrence, blackout period, or delay risk period start.

²Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 21. Summary of Time to End of Observable Data due to End of Data for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023¹ (Continued)

	Total Number of Episodes Censored due to End of Data ²		Distribution of Observable Time in Days, by Episode						
	Total Number of Episodes		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Bydureon</i>	1,321	1,238	2	68	139	207	384	145.5	92.7
<i>Mounjaro</i>	18,842	18,010	2	42	87	149	359	103.0	74.3
<i>Ozempic</i>	117,008	110,821	2	54	115	200	410	133.4	93.8
<i>Rybelsus</i>	34,058	32,166	2	62	128	204	384	139.7	92.3
<i>Saxenda</i>	386	362	3	123	194	261	372	190.7	84.4
<i>Trulicity</i>	66,978	62,950	2	67	132	207	389	143.3	91.8
<i>Victoza</i>	5,354	5,028	2	66	132	208	412	143.8	92.9
<i>Wegovy</i>	828	820	2	23	50	75	363	60.8	61.4
<i>Xultophy</i>	364	351	2	65	111	191	381	131.3	92.5

¹Time to end of observable data is for characterization purposes only. It does not necessarily represent at-risk time, and does not consider episode end, outcome occurrence, blackout period, or delay risk period start.

²Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 22. Summary of Time to End of Observable Data due to End of Study Period for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023¹

			Number of Episodes Censored due to End of Study Period by Observable Time													
			0-30 days		31-60 days		61-90 days		91-183 days		184-365 days		366-455 days		456+ days	
			Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
	Total Number of Episodes	Number of Episodes Censored due to End of Study Period ²														
<i>Bydureon</i>	1,321	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Mounjaro</i>	18,842	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Ozempic</i>	117,008	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Rybelsus</i>	34,058	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Saxenda</i>	386	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Trulicity</i>	66,978	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Victoza</i>	5,354	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Wegovy</i>	828	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
<i>Xultophy</i>	364	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

¹ Time to end of observable data is for characterization purposes only. It does not necessarily represent at-risk time, and does not consider episode end, outcome occurrence, lackout period, or delay risk period start.

² Represents episodes censored due to user-specified study end date.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Table 22. Summary of Time to End of Observable Data due to End of Study Period for Exposures of Interest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023¹ (Continued)

	Total Number of Episodes Censored due to End of Study Period ²		Distribution of Observable Time in Days, by Episode						
	Total Number of Episodes		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Bydureon</i>	1,321	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Mounjaro</i>	18,842	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Ozempic</i>	117,008	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Rybelsus</i>	34,058	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Saxenda</i>	386	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Trulicity</i>	66,978	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Victoza</i>	5,354	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Wegovy</i>	828	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>Xultophy</i>	364	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

¹Time to end of observable data is for characterization purposes only. It does not necessarily represent at-risk time, and does not consider episode end, outcome occurrence, blackout period, or delay risk period start.

²Represents episodes censored due to user-specified study end date.

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

*NaN: Not a number

Table 23a. Full Code Distribution of Bydureon, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	*****	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23b. Total Code Counts of Bydureon, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	93
Inpatientencounter	Inpatient Encounter	RX	N/A	27
Ozempic	Ozempic	RX	N/A	*****
Trulicity	Trulicity	RX	N/A	*****
Mounjaro	Mounjaro	RX	N/A	*****
Victoza	Victoza	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23c. Full Code Distribution of Mounjaro, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	877	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	37	N/A
Rybelsus	Rybelsus	RX	N/A	20	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****	AV
Ozempic	Ozempic	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23d. Total Code Counts of Mounjaro, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	976
Inpatientencounter	Inpatient Encounter	RX	N/A	235
Ozempic	Ozempic	RX	N/A	81
Trulicity	Trulicity	RX	N/A	37
Rybelsus	Rybelsus	RX	N/A	20
Victoza	Victoza	RX	N/A	*****
Bydureonbcise	Bydureon Bcise	RX	N/A	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23e. Full Code Distribution of Ozempic, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	6,840	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	508	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Mounjaro	Mounjaro	RX	N/A	277	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	62	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	17	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Saxenda	Saxenda	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	IP
Z33.2	Encounter For Elective Termination Of Pregnancy	DX	10	*****	AV
S0199		PX	HC		AV
S0190	Medically Induced Abortion By Oral Ingestion Of Medication Including All Associated Services And Supplies (E.G., Patient Counseling, Office Visits, Confirmation Of Pregnancy By Hcg, Ultrasound To Conf Mifepristone, Oral, 200 Mg)	PX	HC		AV
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****	AV
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	ED
O00.201	Right Ovarian Pregnancy Without Intrauterine Pregnancy	DX	10		ED
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	ED
O99.211	Obesity Complicating Pregnancy, First Trimester	DX	10	*****	AV
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10		AV
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23f. Total Code Counts of Ozempic, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	7,340
Inpatientencounter	Inpatient Encounter	RX	N/A	2,078
Trulicity	Trulicity	RX	N/A	508
Mounjaro	Mounjaro	RX	N/A	277
Rybelsus	Rybelsus	RX	N/A	191
Victoza	Victoza	RX	N/A	62
Bydureonbcise	Bydureon Bcise	RX	N/A	17
Wegovy	Wegovy	RX	N/A	*****
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
Saxenda	Saxenda	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Z33.2	Encounter For Elective Termination Of Pregnancy	DX	10	*****
S0199	Medically Induced Abortion By Oral Ingestion Of Medication Including All Associated Services And Supplies (E.G., Patient Counseling, Office Visits, Confirmation Of Pregnancy By Hcg, Ultrasound To Conf	PX	HC	*****
S0190	Mifepristone, Oral, 200 Mg	PX	HC	*****
O99.211	Obesity Complicating Pregnancy, First Trimester	DX	10	*****
O00.201	Right Ovarian Pregnancy Without Intrauterine Pregnancy	DX	10	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23g. Full Code Distribution of Rybelsus, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,632	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	83	N/A
Mounjaro	Mounjaro	RX	N/A	51	N/A
Victoza	Victoza	RX	N/A	12	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
002.1	Missed Abortion	DX	10	*****	OA

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.
N/A: Not applicable

Table 23h. Total Code Counts of Rybelsus, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,746
Inpatientencounter	Inpatient Encounter	RX	N/A	531
Ozempic	Ozempic	RX	N/A	265
Trulicity	Trulicity	RX	N/A	83
Mounjaro	Mounjaro	RX	N/A	52
Victoza	Victoza	RX	N/A	12
Wegovy	Wegovy	RX	N/A	*****
Bydureonbcise	Bydureon Bcise	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
002.1	Missed Abortion	DX	10	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23i. Full Code Distribution of Saxenda, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23j. Total Code Counts of Saxenda, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code	Code	Overall
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Ozempic	Ozempic	RX	N/A	*****
Trulicity	Trulicity	RX	N/A	*****
Wegovy	Wegovy	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****
Victoza	Victoza	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23k. Full Code Distribution of Trulicity, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,512	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	380	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Mounjaro	Mounjaro	RX	N/A	114	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	11	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Wegovy	Wegovy	RX	N/A	*****	N/A
O23.011	Pre-Existing Type 1 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	AV
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	ED
O23.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10	*****	OA
O23.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10		AV
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Victoza	Victoza	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Saxenda	Saxenda	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23I. Total Code Counts of Trulicity, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,823
Inpatientencounter	Inpatient Encounter	RX	N/A	1,606
Ozempic	Ozempic	RX	N/A	380
Mounjaro	Mounjaro	RX	N/A	114
Rybelsus	Rybelsus	RX	N/A	87
Victoza	Victoza	RX	N/A	33
Bydureonbcise	Bydureon Bcise	RX	N/A	11
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
O23.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10	*****
Wegovy	Wegovy	RX	N/A	*****
O23.011	Pre-Existing Type 1 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
Saxenda	Saxenda	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23m. Full Code Distribution of Victoza, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	440	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	92	N/A
Ozempic	Ozempic	RX	N/A	90	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	36	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	26	N/A
Rybelsus	Rybelsus	RX	N/A	14	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	13	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****	ED
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10		OA
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10		AV
Saxenda	Saxenda	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.
N/A: Not applicable

Table 23n. Total Code Counts of Victoza, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	476
Inpatientencounter	Inpatient Encounter	RX	N/A	128
Ozempic	Ozempic	RX	N/A	90
Trulicity	Trulicity	RX	N/A	26
Rybelsus	Rybelsus	RX	N/A	14
Bydureonbcise	Bydureon Bcise	RX	N/A	13
Mounjaro	Mounjaro	RX	N/A	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Wegovy	Wegovy	RX	N/A	*****
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
Saxenda	Saxenda	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23o. Full Code Distribution of Wegovy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23p. Total Code Counts of Wegovy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****
Ozempic	Ozempic	RX	N/A	*****
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Mounjaro	Mounjaro	RX	N/A	*****
Trulicity	Trulicity	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23q. Full Code Distribution of Xultophy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23r. Total Code Counts of Xultophy, Hospitalized Tachyarrhythmia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Ozempic	Ozempic	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23s. Full Code Distribution of Mounjaro, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	877	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	37	N/A
Rybelsus	Rybelsus	RX	N/A	20	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****	AV
Ozempic	Ozempic	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23t. Total Code Counts of Mounjaro, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	976
Inpatientencounter	Inpatient Encounter	RX	N/A	235
Ozempic	Ozempic	RX	N/A	81
Trulicity	Trulicity	RX	N/A	37
Rybelsus	Rybelsus	RX	N/A	20
Victoza	Victoza	RX	N/A	*****
Bydureonbcise	Bydureon Bcise	RX	N/A	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23u. Full Code Distribution of Bydureon, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	*****	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.
N/A: Not applicable

Table 23v. Total Code Counts of Bydureon, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	93
Inpatientencounter	Inpatient Encounter	RX	N/A	27
Ozempic	Ozempic	RX	N/A	*****
Trulicity	Trulicity	RX	N/A	*****
Mounjaro	Mounjaro	RX	N/A	*****
Victoza	Victoza	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23w. Full Code Distribution of Ozempic, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	6,840	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	508	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Mounjaro	Mounjaro	RX	N/A	277	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	62	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	17	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Saxenda	Saxenda	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	IP
Z33.2	Encounter For Elective Termination Of	DX	10	*****	AV
S0199	Pregnancy	PX	HC		AV
S0190	Medically Induced Abortion By Oral Ingestion Of Medication Including All Associated Services And Supplies (E.G., Patient Counseling, Office Visits, Confirmation Of Pregnancy By Hcg, Ultrasound To Conf	PX	HC		AV
O03.9	Mifepristone Oral 200 Mg Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****	AV
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10	*****	ED
O00.201	Pregnancy, First Trimester	DX	10		ED
O23.111	Right Ovarian Pregnancy Without Intrauterine Pregnancy				
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10	*****	ED
O99.211	Pregnancy, First Trimester				
O99.211	Obesity Complicating Pregnancy, First	DX	10	*****	AV
O23.111	Trimester	DX	10		AV
	Pre-Existing Type 2 Diabetes Mellitus, In				
	Pregnancy, First Trimester				
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23x. Total Code Counts of Ozempic, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	7,340
Inpatientencounter	Inpatient Encounter	RX	N/A	2,078
Trulicity	Trulicity	RX	N/A	508
Mounjaro	Mounjaro	RX	N/A	277
Rybelsus	Rybelsus	RX	N/A	191
Victoza	Victoza	RX	N/A	62
Bydureonbcise	Bydureon Bcise	RX	N/A	17
Wegovy	Wegovy	RX	N/A	*****
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
Saxenda	Saxenda	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Z33.2	Encounter For Elective Termination Of Pregnancy	DX	10	*****
S0199	Medically Induced Abortion By Oral Ingestion Of Medication Including All Associated Services And Supplies (E.G., Patient Counseling, Office Visits, Confirmation Of Pregnancy By Hcg, Ultrasound To Conf	PX	HC	*****
S0190	Mifepristone, Oral, 200 Mg	PX	HC	*****
O99.211	Obesity Complicating Pregnancy, First Trimester	DX	10	*****
O00.201	Right Ovarian Pregnancy Without Intrauterine Pregnancy	DX	10	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.
N/A: Not applicable

Table 23y. Full Code Distribution of Rybelsus, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,633	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	83	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	12	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
002.1	Missed Abortion	DX	10	*****	OA

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23z. Total Code Counts of Rybelsus, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,746
Inpatientencounter	Inpatient Encounter	RX	N/A	531
Ozempic	Ozempic	RX	N/A	265
Trulicity	Trulicity	RX	N/A	83
Mounjaro	Mounjaro	RX	N/A	52
Victoza	Victoza	RX	N/A	12
Wegovy	Wegovy	RX	N/A	*****
Bydureonbcise	Bydureon Bcise	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
O02.1	Missed Abortion	DX	10	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.
N/A: Not applicable

Table 23aa. Full Code Distribution of Wegovy, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23ab. Total Code Counts of Wegovy, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****
Ozempic	Ozempic	RX	N/A	*****
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Mounjaro	Mounjaro	RX	N/A	*****
Trulicity	Trulicity	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.
N/A: Not applicable

Table 23ac. Full Code Distribution of Saxenda, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23ad. Total Code Counts of Saxenda, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Ozempic	Ozempic	RX	N/A	*****
Trulicity	Trulicity	RX	N/A	*****
Wegovy	Wegovy	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****
Victoza	Victoza	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23ae. Full Code Distribution of Victoza, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	440	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	92	N/A
Ozempic	Ozempic	RX	N/A	90	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	36	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	26	N/A
Rybelsus	Rybelsus	RX	N/A	14	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	13	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****	OA
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10		AV
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10		ED
Saxenda	Saxenda	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23af. Total Code Counts of Victoza, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	476
Inpatientencounter	Inpatient Encounter	RX	N/A	128
Ozempic	Ozempic	RX	N/A	90
Trulicity	Trulicity	RX	N/A	26
Rybelsus	Rybelsus	RX	N/A	14
Bydureonbcise	Bydureon Bcise	RX	N/A	13
Mounjaro	Mounjaro	RX	N/A	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Wegovy	Wegovy	RX	N/A	*****
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
Saxenda	Saxenda	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23ag. Full Code Distribution of Trulicity, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,512	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	380	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Mounjaro	Mounjaro	RX	N/A	114	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	11	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Wegovy	Wegovy	RX	N/A	*****	N/A
O23.011	Pre-Existing Type 1 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	AV
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	ED
O23.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10	*****	OA
O23.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10		AV
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Victoza	Victoza	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Saxenda	Saxenda	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.
N/A: Not applicable

Table 23ah. Total Code Counts of Trulicity, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,823
Inpatientencounter	Inpatient Encounter	RX	N/A	1,606
Ozempic	Ozempic	RX	N/A	380
Mounjaro	Mounjaro	RX	N/A	114
Rybelsus	Rybelsus	RX	N/A	87
Victoza	Victoza	RX	N/A	33
Bydureonbcise	Bydureon Bcise	RX	N/A	11
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
O23.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10	*****
Wegovy	Wegovy	RX	N/A	*****
O23.011	Pre-Existing Type 1 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
Saxenda	Saxenda	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23ai. Full Code Distribution of Xultophy, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23aj. Total Code Counts of Xultophy, Atrial Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Ozempic	Ozempic	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23ak. Full Code Distribution of Mounjaro, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	877	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	37	N/A
Rybelsus	Rybelsus	RX	N/A	20	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****	AV
Ozempic	Ozempic	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23a. Total Code Counts of Mounjaro, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	976
Inpatientencounter	Inpatient Encounter	RX	N/A	235
Ozempic	Ozempic	RX	N/A	81
Trulicity	Trulicity	RX	N/A	37
Rybelsus	Rybelsus	RX	N/A	20
Victoza	Victoza	RX	N/A	*****
Bydureonbcise	Bydureon Bcise	RX	N/A	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23am. Full Code Distribution of Bydureon, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	*****	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Victoza	Victoza	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23an. Total Code Counts of Bydureon, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	93
Inpatientencounter	Inpatient Encounter	RX	N/A	27
Ozempic	Ozempic	RX	N/A	*****
Trulicity	Trulicity	RX	N/A	*****
Mounjaro	Mounjaro	RX	N/A	*****
Victoza	Victoza	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23ao. Full Code Distribution of Ozempic, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	6,840	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	508	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Mounjaro	Mounjaro	RX	N/A	277	N/A
Rybelsus	Rybelsus	RX	N/A	190	N/A
Victoza	Victoza	RX	N/A	62	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	17	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Saxenda	Saxenda	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	IP
Z33.2	Encounter For Elective Termination Of	DX	10	*****	AV
S0199	Pregnancy	PX	HC		AV
S0190	Medically Induced Abortion By Oral Ingestion Of Medication Including All Associated Services And Supplies (E.G., Patient Counseling, Office Visits, Confirmation Of Pregnancy By Hcg, Ultrasound To Conf Mifepristone, Oral, 200 Mg	PX	HC		AV
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****	AV
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10	*****	ED
O00.201	Pregnancy, First Trimester	DX	10		ED
	Right Ovarian Pregnancy Without Intrauterine Pregnancy				
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10	*****	ED
	Pregnancy, First Trimester				
O99.211	Obesity Complicating Pregnancy, First	DX	10	*****	AV
O23.111	Trimester	DX	10		AV
	Pre-Existing Type 2 Diabetes Mellitus, In				
	Pregnancy, First Trimester				
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23ap. Total Code Counts of Ozempic, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	7,340
Inpatientencounter	Inpatient Encounter	RX	N/A	2,078
Trulicity	Trulicity	RX	N/A	508
Mounjaro	Mounjaro	RX	N/A	277
Rybelsus	Rybelsus	RX	N/A	191
Victoza	Victoza	RX	N/A	62
Bydureonbcise	Bydureon Bcise	RX	N/A	17
Wegovy	Wegovy	RX	N/A	*****
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
Saxenda	Saxenda	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Z33.2	Encounter For Elective Termination Of Pregnancy	DX	10	*****
S0199	Medically Induced Abortion By Oral Ingestion Of Medication Including All Associated Services And Supplies (E.G., Patient Counseling, Office Visits, Confirmation Of Pregnancy By Hcg, Ultrasound To Conf	PX	HC	*****
S0190	Mifepristone, Oral, 200 Mg	PX	HC	*****
O99.211	Obesity Complicating Pregnancy, First Trimester	DX	10	*****
O00.201	Right Ovarian Pregnancy Without Intrauterine Pregnancy	DX	10	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23aq. Full Code Distribution of Rybelsus, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,633	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	83	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	12	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
002.1	Missed Abortion	DX	10	*****	OA

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23ar. Total Code Counts of Rybelsus, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,746
Inpatientencounter	Inpatient Encounter	RX	N/A	531
Ozempic	Ozempic	RX	N/A	265
Trulicity	Trulicity	RX	N/A	83
Mounjaro	Mounjaro	RX	N/A	52
Victoza	Victoza	RX	N/A	12
Wegovy	Wegovy	RX	N/A	*****
Bydureonbcise	Bydureon Bcise	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
002.1	Missed Abortion	DX	10	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23as. Full Code Distribution of Wegovy, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23at. Total Code Counts of Wegovy, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****
Ozempic	Ozempic	RX	N/A	*****
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Mounjaro	Mounjaro	RX	N/A	*****
Trulicity	Trulicity	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23au. Full Code Distribution of Saxenda, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23av. Total Code Counts of Saxenda, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Ozempic	Ozempic	RX	N/A	*****
Trulicity	Trulicity	RX	N/A	*****
Wegovy	Wegovy	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****
Victoza	Victoza	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23aw. Full Code Distribution of Victoza, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	440	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	92	N/A
Ozempic	Ozempic	RX	N/A	90	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	36	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	26	N/A
Rybelsus	Rybelsus	RX	N/A	14	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	13	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****	AV
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10		OA
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10		ED
Saxenda	Saxenda	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23ax. Total Code Counts of Victoza, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	476
Inpatientencounter	Inpatient Encounter	RX	N/A	128
Ozempic	Ozempic	RX	N/A	90
Trulicity	Trulicity	RX	N/A	26
Rybelsus	Rybelsus	RX	N/A	14
Bydureonbcise	Bydureon Bcise	RX	N/A	13
Mounjaro	Mounjaro	RX	N/A	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Wegovy	Wegovy	RX	N/A	*****
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
Saxenda	Saxenda	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23ay. Full Code Distribution of Trulicity, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,512	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	380	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Mounjaro	Mounjaro	RX	N/A	114	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	11	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
O23.011	Pre-Existing Type 1 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	AV
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	ED
O23.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10	*****	OA
O23.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10		AV
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Victoza	Victoza	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Saxenda	Saxenda	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23az. Total Code Counts of Trulicity, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,823
Inpatientencounter	Inpatient Encounter	RX	N/A	1,606
Ozempic	Ozempic	RX	N/A	380
Mounjaro	Mounjaro	RX	N/A	114
Rybelsus	Rybelsus	RX	N/A	87
Victoza	Victoza	RX	N/A	33
Bydureonbcise	Bydureon Bcise	RX	N/A	11
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
O23.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10	*****
Wegovy	Wegovy	RX	N/A	*****
O23.011	Pre-Existing Type 1 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
Saxenda	Saxenda	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23ba. Full Code Distribution of Xultophy, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23bb. Total Code Counts of Xultophy, Sinus Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	39
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Ozempic	Ozempic	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23bc. Full Code Distribution of Mounjaro, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	877	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	37	N/A
Rybelsus	Rybelsus	RX	N/A	20	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****	AV
Ozempic	Ozempic	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23bd. Total Code Counts of Mounjaro, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	976
Inpatientencounter	Inpatient Encounter	RX	N/A	235
Ozempic	Ozempic	RX	N/A	81
Trulicity	Trulicity	RX	N/A	37
Rybelsus	Rybelsus	RX	N/A	20
Victoza	Victoza	RX	N/A	*****
Bydureonbcise	Bydureon Bcise	RX	N/A	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23be. Full Code Distribution of Bydureon, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	*****	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23bf. Total Code Counts of Bydureon, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	93
Inpatientencounter	Inpatient Encounter	RX	N/A	27
Ozempic	Ozempic	RX	N/A	15
Trulicity	Trulicity	RX	N/A	*****
Mounjaro	Mounjaro	RX	N/A	*****
Victoza	Victoza	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23bg. Full Code Distribution of Ozempic, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	6,840	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	508	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Mounjaro	Mounjaro	RX	N/A	277	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	62	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	17	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Saxenda	Saxenda	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	IP
Z33.2	Encounter For Elective Termination Of Pregnancy	DX	10	*****	AV
S0199		PX	HC		AV
S0190	Medically Induced Abortion By Oral Ingestion Of Medication Including All Associated Services And Supplies (E.G., Patient Counseling, Office Visits, Confirmation Of Pregnancy By Hcg, Ultrasound To Conf	PX	HC		AV
O03.9	Mifepristone. Oral. 200 Mg Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****	AV
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10	*****	ED
O00.201	Pregnancy, First Trimester Right Ovarian Pregnancy Without Intrauterine Pregnancy	DX	10		ED

Table 23bg. Full Code Distribution of Ozempic, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	ED
O99.211	Obesity Complicating Pregnancy, First Trimester	DX	10	*****	AV
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	AV
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23bh. Total Code Counts of Ozempic, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	7,340
Inpatientencounter	Inpatient Encounter	RX	N/A	2,078
Trulicity	Trulicity	RX	N/A	508
Mounjaro	Mounjaro	RX	N/A	277
Rybelsus	Rybelsus	RX	N/A	191
Victoza	Victoza	RX	N/A	62
Bydureonbcise	Bydureon Bcise	RX	N/A	17
Wegovy	Wegovy	RX	N/A	*****
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
Saxenda	Saxenda	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Z33.2	Encounter For Elective Termination Of Pregnancy	DX	10	*****
S0199	Medically Induced Abortion By Oral Ingestion Of Medication Including All Associated Services And Supplies (E.G., Patient Counseling, Office Visits, Confirmation Of Pregnancy By Hcg, Ultrasound To Conf	PX	HC	*****
S0190	Mifepristone, Oral, 200 Mg	PX	HC	*****
O99.211	Obesity Complicating Pregnancy, First Trimester	DX	10	*****
O00.201	Right Ovarian Pregnancy Without Intrauterine Pregnancy	DX	10	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23bi. Full Code Distribution of Rybelsus, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,633	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	83	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	12	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
002.1	Missed Abortion	DX	10	*****	OA

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23bj. Total Code Counts of Rybelsus, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,746
Inpatientencounter	Inpatient Encounter	RX	N/A	531
Ozempic	Ozempic	RX	N/A	265
Trulicity	Trulicity	RX	N/A	83
Mounjaro	Mounjaro	RX	N/A	52
Victoza	Victoza	RX	N/A	12
Wegovy	Wegovy	RX	N/A	*****
Bydureonbcise	Bydureon Bcise	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
002.1	Missed Abortion	DX	10	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23bk. Full Code Distribution of Wegovy, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23bl. Total Code Counts of Wegovy, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	25
Ozempic	Ozempic	RX	N/A	*****
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Mounjaro	Mounjaro	RX	N/A	*****
Trulicity	Trulicity	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23bm. Full Code Distribution of Saxenda, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23bn. Total Code Counts of Saxenda, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Ozempic	Ozempic	RX	N/A	*****
Trulicity	Trulicity	RX	N/A	*****
Wegovy	Wegovy	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****
Victoza	Victoza	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23bo. Full Code Distribution of Victoza, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	440	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	92	N/A
Ozempic	Ozempic	RX	N/A	90	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	36	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	26	N/A
Rybelsus	Rybelsus	RX	N/A	14	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	13	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****	ED
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10		AV
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10		OA
Saxenda	Saxenda	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23bp. Total Code Counts of Victoza, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	476
Inpatientencounter	Inpatient Encounter	RX	N/A	128
Ozempic	Ozempic	RX	N/A	90
Trulicity	Trulicity	RX	N/A	26
Rybelsus	Rybelsus	RX	N/A	14
Bydureonbcise	Bydureon Bcise	RX	N/A	13
Mounjaro	Mounjaro	RX	N/A	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Wegovy	Wegovy	RX	N/A	*****
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
Saxenda	Saxenda	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23bq. Full Code Distribution of Trulicity, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,512	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	380	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Mounjaro	Mounjaro	RX	N/A	114	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	11	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
O23.011	Pre-Existing Type 1 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	AV
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	ED
O23.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10	*****	OA
O23.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10		AV
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Victoza	Victoza	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Saxenda	Saxenda	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23br. Total Code Counts of Trulicity, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,823
Inpatientencounter	Inpatient Encounter	RX	N/A	1,606
Ozempic	Ozempic	RX	N/A	380
Mounjaro	Mounjaro	RX	N/A	114
Rybelsus	Rybelsus	RX	N/A	87
Victoza	Victoza	RX	N/A	33
Bydureonbcise	Bydureon Bcise	RX	N/A	11
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
O23.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10	*****
Wegovy	Wegovy	RX	N/A	*****
O23.011	Pre-Existing Type 1 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
Saxenda	Saxenda	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23bs. Full Code Distribution of Xultophy, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23bt. Total Code Counts of Xultophy, Supraventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Ozempic	Ozempic	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23bu. Full Code Distribution of Mounjaro, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	877	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	37	N/A
Rybelsus	Rybelsus	RX	N/A	20	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****	AV
Ozempic	Ozempic	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23bv. Total Code Counts of Mounjaro, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	976
Inpatientencounter	Inpatient Encounter	RX	N/A	235
Ozempic	Ozempic	RX	N/A	81
Trulicity	Trulicity	RX	N/A	37
Rybelsus	Rybelsus	RX	N/A	20
Victoza	Victoza	RX	N/A	*****
Bydureonbcise	Bydureon Bcise	RX	N/A	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23bw. Full Code Distribution of Bydureon, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	*****	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Victoza	Victoza	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23bx. Total Code Counts of Bydureon, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	93
Inpatientencounter	Inpatient Encounter	RX	N/A	27
Ozempic	Ozempic	RX	N/A	15
Trulicity	Trulicity	RX	N/A	*****
Mounjaro	Mounjaro	RX	N/A	*****
Victoza	Victoza	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23by. Full Code Distribution of Ozempic, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	6,840	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	508	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Mounjaro	Mounjaro	RX	N/A	277	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	62	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	17	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Saxenda	Saxenda	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	IP
Z33.2	Encounter For Elective Termination Of Pregnancy	DX	10	*****	AV
S0199		PX	HC		AV
S0190	Medically Induced Abortion By Oral Ingestion Of Medication Including All Associated Services And Supplies (E.G., Patient Counseling, Office Visits, Confirmation Of Pregnancy By Hcg, Ultrasound To Conf	PX	HC		AV
O03.9	Mifepristone. Oral. 200 Mg Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****	AV
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	ED
O00.201	Right Ovarian Pregnancy Without Intrauterine Pregnancy	DX	10		ED
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	ED
O99.211	Obesity Complicating Pregnancy, First Trimester	DX	10	*****	AV
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10		AV
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23bz. Total Code Counts of Ozempic, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	7,340
Inpatientencounter	Inpatient Encounter	RX	N/A	2,078
Trulicity	Trulicity	RX	N/A	508
Mounjaro	Mounjaro	RX	N/A	277
Rybelsus	Rybelsus	RX	N/A	191
Victoza	Victoza	RX	N/A	62
Bydureonbcise	Bydureon Bcise	RX	N/A	17
Wegovy	Wegovy	RX	N/A	*****
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
Saxenda	Saxenda	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Z33.2	Encounter For Elective Termination Of Pregnancy	DX	10	*****
S0199	Medically Induced Abortion By Oral Ingestion Of Medication Including All Associated Services And Supplies (E.G., Patient Counseling, Office Visits, Confirmation Of Pregnancy By Hcg, Ultrasound To Conf	PX	HC	*****
S0190	Mifepristone, Oral, 200 Mg	PX	HC	*****
O99.211	Obesity Complicating Pregnancy, First Trimester	DX	10	*****
O00.201	Right Ovarian Pregnancy Without Intrauterine Pregnancy	DX	10	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23ca. Full Code Distribution of Rybelsus, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,633	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	83	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	12	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
O02.1	Missed Abortion	DX	10	*****	OA

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23cb. Total Code Counts of Rybelsus, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,746
Inpatientencounter	Inpatient Encounter	RX	N/A	531
Ozempic	Ozempic	RX	N/A	265
Trulicity	Trulicity	RX	N/A	83
Mounjaro	Mounjaro	RX	N/A	52
Victoza	Victoza	RX	N/A	12
Wegovy	Wegovy	RX	N/A	*****
Bydureonbcise	Bydureon Bcise	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
58661	Laparoscopy, Surgical; With Removal Of PX Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)		C4	*****
002.1	Missed Abortion	DX	10	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23cc. Full Code Distribution of Wegovy, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23cd. Total Code Counts of Wegovy, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****
Ozempic	Ozempic	RX	N/A	*****
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Mounjaro	Mounjaro	RX	N/A	*****
Trulicity	Trulicity	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23ce. Full Code Distribution of Saxenda, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23cf. Total Code Counts of Saxenda, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Ozempic	Ozempic	RX	N/A	*****
Trulicity	Trulicity	RX	N/A	*****
Wegovy	Wegovy	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****
Victoza	Victoza	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23cg. Full Code Distribution of Victoza, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	440	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	92	N/A
Ozempic	Ozempic	RX	N/A	90	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	36	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	26	N/A
Rybelsus	Rybelsus	RX	N/A	14	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	13	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****	ED
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10		OA
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10		AV
Saxenda	Saxenda	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23ch. Total Code Counts of Victoza, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	476
Inpatientencounter	Inpatient Encounter	RX	N/A	128
Ozempic	Ozempic	RX	N/A	90
Trulicity	Trulicity	RX	N/A	26
Rybelsus	Rybelsus	RX	N/A	14
Bydureonbcise	Bydureon Bcise	RX	N/A	13
Mounjaro	Mounjaro	RX	N/A	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Wegovy	Wegovy	RX	N/A	*****
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
Saxenda	Saxenda	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23cj. Total Code Counts of Trulicity, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,823
Inpatientencounter	Inpatient Encounter	RX	N/A	1,606
Ozempic	Ozempic	RX	N/A	380
Mounjaro	Mounjaro	RX	N/A	114
Rybelsus	Rybelsus	RX	N/A	87
Victoza	Victoza	RX	N/A	33
Bydureonbcise	Bydureon Bcise	RX	N/A	11
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
O23.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10	*****
Wegovy	Wegovy	RX	N/A	*****
O23.011	Pre-Existing Type 1 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
Saxenda	Saxenda	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23ci. Full Code Distribution of Trulicity, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

		Encounter			
Code	Code Description	Code Category	Code Type	Overall Counts	Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,508	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	1,295	N/A
Ozempic	Ozempic	RX	N/A	380	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Mounjaro	Mounjaro	RX	N/A	114	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	11	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
O23.011	Pre-Existing Type 1 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	AV
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	ED
O23.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10	*****	OA
O23.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10		AV
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Victoza	Victoza	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Saxenda	Saxenda	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23ck. Full Code Distribution of Xultophy, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23cl. Total Code Counts of Xultophy, Other Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Ozempic	Ozempic	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23cm. Full Code Distribution of Mounjaro, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	877	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	37	N/A
Rybelsus	Rybelsus	RX	N/A	20	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****	AV
Ozempic	Ozempic	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23cn. Total Code Counts of Mounjaro, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	976
Inpatientencounter	Inpatient Encounter	RX	N/A	235
Ozempic	Ozempic	RX	N/A	81
Trulicity	Trulicity	RX	N/A	37
Rybelsus	Rybelsus	RX	N/A	20
Victoza	Victoza	RX	N/A	*****
Bydureonbcise	Bydureon Bcise	RX	N/A	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23co. Full Code Distribution of Bydureon, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	15	N/A
Trulicity	Trulicity	RX	N/A	*****	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23cp. Total Code Counts of Bydureon, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	93
Inpatientencounter	Inpatient Encounter	RX	N/A	27
Ozempic	Ozempic	RX	N/A	15
Trulicity	Trulicity	RX	N/A	*****
Mounjaro	Mounjaro	RX	N/A	*****
Victoza	Victoza	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23cq. Full Code Distribution of Ozempic, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	6,834	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	508	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Mounjaro	Mounjaro	RX	N/A	277	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	62	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	17	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Saxenda	Saxenda	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	IP
Z33.2	Encounter For Elective Termination Of Pregnancy	DX	10	*****	AV
S0199	Pregnancy	PX	HC		AV
S0190	Medically Induced Abortion By Oral Ingestion Of Medication Including All Associated Services And Supplies (E.G., Patient Counseling, Office Visits, Confirmation Of Pregnancy By Hcg, Ultrasound To Conf	PX	HC		AV
O03.9	Mifepristone. Oral. 200 Mg Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****	AV
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	ED
O00.201	Right Ovarian Pregnancy Without Intrauterine Pregnancy	DX	10		ED
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	ED
O99.211	Obesity Complicating Pregnancy, First Trimester	DX	10	*****	AV
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10		AV
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23cr. Total Code Counts of Ozempic, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	7,340
Inpatientencounter	Inpatient Encounter	RX	N/A	2,078
Trulicity	Trulicity	RX	N/A	508
Mounjaro	Mounjaro	RX	N/A	277
Rybelsus	Rybelsus	RX	N/A	191
Victoza	Victoza	RX	N/A	62
Bydureonbcise	Bydureon Bcise	RX	N/A	17
Wegovy	Wegovy	RX	N/A	*****
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
Saxenda	Saxenda	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Z33.2	Encounter For Elective Termination Of Pregnancy	DX	10	*****
S0199	Medically Induced Abortion By Oral Ingestion Of Medication Including All Associated Services And Supplies (E.G., Patient Counseling, Office Visits, Confirmation Of Pregnancy By Hcg, Ultrasound To Conf	PX	HC	*****
S0190	Mifepristone, Oral, 200 Mg	PX	HC	*****
O99.211	Obesity Complicating Pregnancy, First Trimester	DX	10	*****
O00.201	Right Ovarian Pregnancy Without Intrauterine Pregnancy	DX	10	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23cs. Full Code Distribution of Rybelsus, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,633	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	83	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	12	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
002.1	Missed Abortion	DX	10	*****	OA

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23ct. Total Code Counts of Rybelsus, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,746
Inpatientencounter	Inpatient Encounter	RX	N/A	531
Ozempic	Ozempic	RX	N/A	265
Trulicity	Trulicity	RX	N/A	83
Mounjaro	Mounjaro	RX	N/A	52
Victoza	Victoza	RX	N/A	12
Wegovy	Wegovy	RX	N/A	*****
Bydureonbcise	Bydureon Bcise	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
58661	Laparoscopy, Surgical; With Removal Of PX		C4	*****
	Adnexal Structures (Partial Or Total			
	Oophorectomy And/Or Salpingectomy)			
002.1	Missed Abortion	DX	10	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23cu. Full Code Distribution of Wegovy, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23cv. Total Code Counts of Wegovy, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****
Ozempic	Ozempic	RX	N/A	*****
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Mounjaro	Mounjaro	RX	N/A	*****
Trulicity	Trulicity	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23cw. Full Code Distribution of Saxenda, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23cx. Total Code Counts of Saxenda, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Ozempic	Ozempic	RX	N/A	*****
Trulicity	Trulicity	RX	N/A	*****
Wegovy	Wegovy	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****
Victoza	Victoza	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23cy. Full Code Distribution of Victoza, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	440	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	92	N/A
Ozempic	Ozempic	RX	N/A	90	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	36	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	26	N/A
Rybelsus	Rybelsus	RX	N/A	14	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	13	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****	ED
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10		OA
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10		AV
Saxenda	Saxenda	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23cz. Total Code Counts of Victoza, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	476
Inpatientencounter	Inpatient Encounter	RX	N/A	128
Ozempic	Ozempic	RX	N/A	90
Trulicity	Trulicity	RX	N/A	26
Rybelsus	Rybelsus	RX	N/A	14
Bydureonbcise	Bydureon Bcise	RX	N/A	13
Mounjaro	Mounjaro	RX	N/A	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Wegovy	Wegovy	RX	N/A	*****
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
Saxenda	Saxenda	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23da. Full Code Distribution of Trulicity, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,508	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	380	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Mounjaro	Mounjaro	RX	N/A	114	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	11	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
O23.011	Pre-Existing Type 1 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	AV
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	ED
O23.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10	*****	OA
O23.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10		AV
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Victoza	Victoza	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Saxenda	Saxenda	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23db. Total Code Counts of Trulicity, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,823
Inpatientencounter	Inpatient Encounter	RX	N/A	1,606
Ozempic	Ozempic	RX	N/A	380
Mounjaro	Mounjaro	RX	N/A	114
Rybelsus	Rybelsus	RX	N/A	87
Victoza	Victoza	RX	N/A	33
Bydureonbcise	Bydureon Bcise	RX	N/A	11
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
O23.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10	*****
Wegovy	Wegovy	RX	N/A	*****
O23.011	Pre-Existing Type 1 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
Saxenda	Saxenda	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23dc. Full Code Distribution of Xultophy, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23dd. Total Code Counts of Xultophy, Cardiac Arrest in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Ozempic	Ozempic	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23de. Full Code Distribution of Mounjaro, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	877	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	37	N/A
Rybelsus	Rybelsus	RX	N/A	20	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****	AV
Ozempic	Ozempic	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23df. Total Code Counts of Mounjaro, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	976
Inpatientencounter	Inpatient Encounter	RX	N/A	235
Ozempic	Ozempic	RX	N/A	81
Trulicity	Trulicity	RX	N/A	37
Rybelsus	Rybelsus	RX	N/A	20
Victoza	Victoza	RX	N/A	*****
Bydureonbcise	Bydureon Bcise	RX	N/A	*****
O03.9	Complete Or Unspecified Spontaneous	DX	10	*****
	Abortion Without Complication			
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23dg. Full Code Distribution of Bydureon, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	*****	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23dh. Total Code Counts of Bydureon, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Ozempic	Ozempic	RX	N/A	*****
Trulicity	Trulicity	RX	N/A	*****
Mounjaro	Mounjaro	RX	N/A	*****
Victoza	Victoza	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23di. Full Code Distribution of Ozempic, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	6,840	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	508	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Mounjaro	Mounjaro	RX	N/A	277	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	62	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	17	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Saxenda	Saxenda	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	IP
Z33.2	Encounter For Elective Termination Of	DX	10	*****	AV
S0199	Pregnancy	PX	HC		AV
S0190	Medically Induced Abortion By Oral Ingestion Of Medication Including All Associated Services And Supplies (E.G., Patient Counseling, Office Visits, Confirmation Of Pregnancy By Hcg, Ultrasound To Conf Mifepristone, Oral, 200 Mg	PX	HC		AV
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****	AV
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10	*****	ED
O00.201	Pregnancy, First Trimester	DX	10		ED
	Right Ovarian Pregnancy Without Intrauterine Pregnancy				
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In	DX	10	*****	ED
	Pregnancy, First Trimester				
O99.211	Obesity Complicating Pregnancy, First	DX	10	*****	AV
O23.111	Trimester	DX	10		AV
	Pre-Existing Type 2 Diabetes Mellitus, In				
	Pregnancy, First Trimester				
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23dj. Total Code Counts of Ozempic, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	7,340
Inpatientencounter	Inpatient Encounter	RX	N/A	2,078
Trulicity	Trulicity	RX	N/A	508
Mounjaro	Mounjaro	RX	N/A	277
Rybelsus	Rybelsus	RX	N/A	191
Victoza	Victoza	RX	N/A	62
Bydureonbcise	Bydureon Bcise	RX	N/A	17
Wegovy	Wegovy	RX	N/A	*****
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
Saxenda	Saxenda	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Z33.2	Encounter For Elective Termination Of Pregnancy	DX	10	*****
S0199	Medically Induced Abortion By Oral Ingestion Of Medication Including All Associated Services And Supplies (E.G., Patient Counseling, Office Visits, Confirmation Of Pregnancy By Hcg, Ultrasound To Conf	PX	HC	*****
S0190	Mifepristone, Oral, 200 Mg	PX	HC	*****
O99.211	Obesity Complicating Pregnancy, First Trimester	DX	10	*****
O00.201	Right Ovarian Pregnancy Without Intrauterine Pregnancy	DX	10	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23dk. Full Code Distribution of Rybelsus, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,633	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	83	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	12	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
002.1	Missed Abortion	DX	10	*****	OA

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23dI. Total Code Counts of Rybelsus, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,746
Inpatientencounter	Inpatient Encounter	RX	N/A	531
Ozempic	Ozempic	RX	N/A	265
Trulicity	Trulicity	RX	N/A	83
Mounjaro	Mounjaro	RX	N/A	*****
Victoza	Victoza	RX	N/A	12
Wegovy	Wegovy	RX	N/A	*****
Bydureonbcise	Bydureon Bcise	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
002.1	Missed Abortion	DX	10	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23dm. Full Code Distribution of Wegovy, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code		Overall Counts	Encounter Care Setting
		Category	Code Type		
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23dn. Total Code Counts of Wegovy, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****
Ozempic	Ozempic	RX	N/A	*****
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Mounjaro	Mounjaro	RX	N/A	*****
Trulicity	Trulicity	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23do. Full Code Distribution of Saxenda, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23dp. Total Code Counts of Saxenda, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Ozempic	Ozempic	RX	N/A	*****
Trulicity	Trulicity	RX	N/A	*****
Wegovy	Wegovy	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****
Victoza	Victoza	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23dq. Full Code Distribution of Victoza, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	440	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	92	N/A
Ozempic	Ozempic	RX	N/A	90	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	36	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	26	N/A
Rybelsus	Rybelsus	RX	N/A	14	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	13	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****	ED
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10		OA
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10		AV
Saxenda	Saxenda	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23dr. Total Code Counts of Victoza, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	476
Inpatientencounter	Inpatient Encounter	RX	N/A	128
Ozempic	Ozempic	RX	N/A	90
Trulicity	Trulicity	RX	N/A	26
Rybelsus	Rybelsus	RX	N/A	14
Bydureonbcise	Bydureon Bcise	RX	N/A	13
Mounjaro	Mounjaro	RX	N/A	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Wegovy	Wegovy	RX	N/A	*****
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
Saxenda	Saxenda	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23ds. Full Code Distribution of Trulicity, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,512	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	380	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Mounjaro	Mounjaro	RX	N/A	114	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	11	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
O23.011	Pre-Existing Type 1 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	AV
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	ED
O23.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10	*****	OA
O23.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10		AV
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Victoza	Victoza	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Saxenda	Saxenda	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23dt. Total Code Counts of Trulicity, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,823
Inpatientencounter	Inpatient Encounter	RX	N/A	1,606
Ozempic	Ozempic	RX	N/A	380
Mounjaro	Mounjaro	RX	N/A	114
Rybelsus	Rybelsus	RX	N/A	87
Victoza	Victoza	RX	N/A	33
Bydureonbcise	Bydureon Bcise	RX	N/A	11
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
O23.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10	*****
Wegovy	Wegovy	RX	N/A	*****
O23.011	Pre-Existing Type 1 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
Saxenda	Saxenda	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23du. Full Code Distribution of Xultophy, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23dv. Total Code Counts of Xultophy, Ventricular Tachycardia in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Ozempic	Ozempic	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23dw. Full Code Distribution of Mounjaro, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	877	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	37	N/A
Rybelsus	Rybelsus	RX	N/A	20	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
O03.9	Complete Or Unspecified Spontaneous	DX	10	*****	AV
	Abortion Without Complication				
Ozempic	Ozempic	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23dx. Total Code Counts of Mounjaro, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	976
Inpatientencounter	Inpatient Encounter	RX	N/A	235
Ozempic	Ozempic	RX	N/A	81
Trulicity	Trulicity	RX	N/A	37
Rybelsus	Rybelsus	RX	N/A	20
Victoza	Victoza	RX	N/A	*****
Bydureonbcise	Bydureon Bcise	RX	N/A	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23dy. Full Code Distribution of Bydureon, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	*****	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23dz. Total Code Counts of Bydureon, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	93
Inpatientencounter	Inpatient Encounter	RX	N/A	27
Ozempic	Ozempic	RX	N/A	*****
Trulicity	Trulicity	RX	N/A	*****
Mounjaro	Mounjaro	RX	N/A	*****
Victoza	Victoza	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23ea. Full Code Distribution of Ozempic, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	6,834	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	508	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Mounjaro	Mounjaro	RX	N/A	277	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	62	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	17	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Saxenda	Saxenda	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	IP
Z33.2	Encounter For Elective Termination Of Pregnancy	DX	10	*****	AV
S0199		PX	HC		AV
S0190	Medically Induced Abortion By Oral Ingestion Of Medication Including All Associated Services And Supplies (E.G., Patient Counseling, Office Visits, Confirmation Of Pregnancy By Hcg, Ultrasound To Conf	PX	HC		AV
O03.9	Mifepristone, Oral, 200 Mg Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****	AV
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	ED
O00.201	Right Ovarian Pregnancy Without Intrauterine Pregnancy	DX	10		ED
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	ED
O99.211	Obesity Complicating Pregnancy, First Trimester	DX	10	*****	AV
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10		AV
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23eb. Total Code Counts of Ozempic, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	7,340
Inpatientencounter	Inpatient Encounter	RX	N/A	2,078
Trulicity	Trulicity	RX	N/A	508
Mounjaro	Mounjaro	RX	N/A	277
Rybelsus	Rybelsus	RX	N/A	191
Victoza	Victoza	RX	N/A	62
Bydureonbcise	Bydureon Bcise	RX	N/A	17
Wegovy	Wegovy	RX	N/A	*****
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
Saxenda	Saxenda	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Z33.2	Encounter For Elective Termination Of Pregnancy	DX	10	*****
S0199	Medically Induced Abortion By Oral Ingestion Of Medication Including All Associated Services And Supplies (E.G., Patient Counseling, Office Visits, Confirmation Of Pregnancy By Hcg, Ultrasound To Conf	PX	HC	*****
S0190	Mifepristone, Oral, 200 Mg	PX	HC	*****
O99.211	Obesity Complicating Pregnancy, First Trimester	DX	10	*****
O00.201	Right Ovarian Pregnancy Without Intrauterine Pregnancy	DX	10	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23ec. Full Code Distribution of Rybelsus, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,632	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	83	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	12	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
002.1	Missed Abortion	DX	10	*****	OA

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23ed. Total Code Counts of Rybelsus, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	1,746
Inpatientencounter	Inpatient Encounter	RX	N/A	531
Ozempic	Ozempic	RX	N/A	265
Trulicity	Trulicity	RX	N/A	83
Mounjaro	Mounjaro	RX	N/A	52
Victoza	Victoza	RX	N/A	12
Wegovy	Wegovy	RX	N/A	*****
Bydureonbcise	Bydureon Bcise	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
002.1	Missed Abortion	DX	10	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23ee. Full Code Distribution of Wegovy, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23ef. Total Code Counts of Wegovy, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****
Ozempic	Ozempic	RX	N/A	*****
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Mounjaro	Mounjaro	RX	N/A	*****
Trulicity	Trulicity	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23eg. Full Code Distribution of Saxenda, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
Trulicity	Trulicity	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23eh. Total Code Counts of Saxenda, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Ozempic	Ozempic	RX	N/A	*****
Trulicity	Trulicity	RX	N/A	*****
Wegovy	Wegovy	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****
Victoza	Victoza	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23ei. Full Code Distribution of Victoza, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	440	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	92	N/A
Ozempic	Ozempic	RX	N/A	90	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	36	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Trulicity	Trulicity	RX	N/A	26	N/A
Rybelsus	Rybelsus	RX	N/A	14	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	13	N/A
Mounjaro	Mounjaro	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****	ED
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10		OA
003.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10		AV
Saxenda	Saxenda	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23ej. Total Code Counts of Victoza, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	476
Inpatientencounter	Inpatient Encounter	RX	N/A	128
Ozempic	Ozempic	RX	N/A	90
Trulicity	Trulicity	RX	N/A	26
Rybelsus	Rybelsus	RX	N/A	14
Bydureonbcise	Bydureon Bcise	RX	N/A	13
Mounjaro	Mounjaro	RX	N/A	*****
O03.9	Complete Or Unspecified Spontaneous Abortion Without Complication	DX	10	*****
Wegovy	Wegovy	RX	N/A	*****
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
Saxenda	Saxenda	RX	N/A	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23ek. Full Code Distribution of Trulicity, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,512	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	380	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Mounjaro	Mounjaro	RX	N/A	114	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Victoza	Victoza	RX	N/A	*****	N/A
Bydureonbcise	Bydureon Bcise	RX	N/A	11	N/A
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****	AV
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****	N/A
Wegovy	Wegovy	RX	N/A	*****	N/A
O23.011	Pre-Existing Type 1 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	AV
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****	ED
O23.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10	*****	OA
O23.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10		AV
Rybelsus	Rybelsus	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Victoza	Victoza	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A		N/A
Saxenda	Saxenda	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23el. Total Code Counts of Trulicity, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	4,823
Inpatientencounter	Inpatient Encounter	RX	N/A	1,606
Ozempic	Ozempic	RX	N/A	380
Mounjaro	Mounjaro	RX	N/A	114
Rybelsus	Rybelsus	RX	N/A	87
Victoza	Victoza	RX	N/A	33
Bydureonbcise	Bydureon Bcise	RX	N/A	11
58661	Laparoscopy, Surgical; With Removal Of Adnexal Structures (Partial Or Total Oophorectomy And/Or Salpingectomy)	PX	C4	*****
Xultophy10036	Xultophy 100/3.6	RX	N/A	*****
O23.311	Unspecified Pre-Existing Diabetes Mellitus In Pregnancy, First Trimester	DX	10	*****
Wegovy	Wegovy	RX	N/A	*****
O23.011	Pre-Existing Type 1 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
O23.111	Pre-Existing Type 2 Diabetes Mellitus, In Pregnancy, First Trimester	DX	10	*****
Saxenda	Saxenda	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23em. Full Code Distribution of Xultophy, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts	Encounter Care Setting
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Inpatientencounter	Inpatient Encounter	RX	N/A	*****	N/A
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****	N/A
Ozempic	Ozempic	RX	N/A	*****	N/A
Rybelsus	Rybelsus	RX	N/A	*****	N/A

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 23en. Total Code Counts of Xultophy, Ventricular Fibrillation and Flutter in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 for Episode Truncation

Code	Code Description	Code Category	Code Type	Overall Counts
Emergencydepartmentencounter	Emergency Department Encounter	RX	N/A	*****
Inpatientencounter	Inpatient Encounter	RX	N/A	*****
Ozempic	Ozempic	RX	N/A	*****
Rybelsus	Rybelsus	RX	N/A	*****

*****Data are not presented in these cells due to a small sample size or to ensure a small cell count cannot be recalculated through the cells presented.

The same code can appear in multiple rows to account for multiple occurrences of the code on the same day.

N/A: Not applicable

Table 24. Summary of Patient-Level Cohort Attrition in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Bydureon		Mounjaro		Ozempic		Rybelsus		Saxenda	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements										
Enrolled at any point during the query period	102,111,871	N/A	102,111,871	N/A	102,111,871	N/A	102,111,871	N/A	102,111,871	N/A
Had required coverage type (medical and/or drug coverage)	64,062,688	38,049,183	64,062,688	38,049,183	64,062,688	38,049,183	64,062,688	38,049,183	64,062,688	38,049,183
Enrolled during specified age range	64,062,253	435	64,062,253	435	64,062,253	435	64,062,253	435	64,062,253	435
Had requestable medical charts	64,062,253	0	64,062,253	0	64,062,253	0	64,062,253	0	64,062,253	0
Met demographic requirements (sex, race, and Hispanic origin)	64,023,825	38,428	64,023,825	38,428	64,023,825	38,428	64,023,825	38,428	64,023,825	38,428
Members with a valid index event										
Had any cohort-defining claim during the query period	28,331	63,995,494	111,549	63,912,276	759,923	63,263,902	144,832	63,878,993	35,314	63,988,511
Claim recorded during specified age range	28,331	0	111,549	0	759,923	0	144,832	0	35,314	0
Episode defining index claim recorded during the query period	25,705	2,626	111,549	0	732,176	27,747	138,261	6,571	34,747	567
Members with required pre-index history										
Had sufficient pre-index continuous enrollment	21,407	4,298	85,913	25,636	577,425	154,751	109,675	28,586	29,118	5,629
Met inclusion and exclusion criteria ¹	*****	*****	18,996	66,917	117,721	459,704	34,260	75,415	386	28,732
Evidence of gestational diabetes	N/A	*****	N/A	115	N/A	701	N/A	52	N/A	100
Evidence of insulin with no evidence of any anti-diabetic drug	N/A	1,656	N/A	4,483	N/A	39,740	N/A	3,364	N/A	182
Evidence of other secondary diabetes illness	N/A	1,751	N/A	3,897	N/A	34,029	N/A	5,946	N/A	108
Evidence of pregnancy	N/A	35	N/A	532	N/A	2,621	N/A	214	N/A	542
Evidence of short-acting GLP-1 receptor agonist	N/A	104	N/A	562	N/A	2,155	N/A	314	N/A	*****
Evidence of type 1 diabetes	N/A	1,236	N/A	3,308	N/A	26,508	N/A	3,138	N/A	188
Evidence of washout	N/A	19,689	N/A	54,323	N/A	398,929	N/A	66,865	N/A	21,063
No evidence of inclusion criteria	N/A	3,737	N/A	36,260	N/A	207,285	N/A	23601	N/A	27,984
Met event incidence criteria	*****	0	18,996	0	117,721	0	34,260	0	386	0
Members with required post-index follow-up										
Had sufficient post-index continuous enrollment	*****	0	18,996	0	117,721	0	34,260	0	386	0
Had minimum days' supply on index date	*****	0	18,996	0	117,721	0	34,260	0	386	0

Table 24. Summary of Patient-Level Cohort Attrition in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023

	Bydureon		Mounjaro		Ozempic		Rybelsus		Saxenda	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Had index episode of at least required length	*****	0	18,996	0	117,721	0	34,260	0	386	0
Had index episode longer than blackout period	1,321	*****	18,842	154	117,008	713	34,058	202	386	0
Did not have an event during blackout period	1,321	0	18,842	0	117,008	0	34,058	0	386	0
Final cohort										
Number of members	1,321	N/A	18,842	N/A	117,008	N/A	34,058	N/A	386	N/A
Number of episodes	1,321	N/A	18,842	N/A	117,008	N/A	34,058	N/A	386	N/A

¹Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 24. Summary of Patient-Level Cohort Attrition in the Rapid Sentinel Distributed Database and Sentinel Distributed Database from May 13, 2022 to June 30, 2023 (Continued)

	Trulicity		Victoza		Wegovy		Xultophy	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	102,111,871	N/A	102,111,871	N/A	102,111,871	N/A	102,111,871	N/A
Had required coverage type (medical and/or drug coverage)	64,062,688	38,049,183	64,062,688	38,049,183	64,062,688	38,049,183	64,062,688	38,049,183
Enrolled during specified age range	64,062,253	435	64,062,253	435	64,062,253	435	64,062,253	435
Had requestable medical charts	64,062,253	0	64,062,253	0	64,062,253	0	64,062,253	0
Met demographic requirements (sex, race, and Hispanic origin)	64,023,825	38,428	64,023,825	38,428	64,023,825	38,428	64,023,825	38,428
Members with a valid index event								
Had any cohort-defining claim during the query period	600,556	63,423,269	130,989	63,892,836	75,900	63,947,925	7,954	64,015,871
Claim recorded during specified age range	600,556	0	130,989	0	75,900	0	7,954	0
Episode defining index claim recorded during the query period	563,759	36,797	119,663	11,326	75,220	680	7,348	606
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	439,194	123,565	96,267	23,396	63,144	12,076	6,067	1,281
Met inclusion and exclusion criteria ¹	67,310	371,884	5,398	90,869	842	62,302	*****	*****
Evidence of gestational diabetes	N/A	159	N/A	28	N/A	216	N/A	0
Evidence of insulin with no evidence of any anti-diabetic drug	N/A	41,097	N/A	11,935	N/A	365	N/A	491
Evidence of other secondary diabetes illness	N/A	35,989	N/A	7,729	N/A	175	N/A	531
Evidence of pregnancy	N/A	732	N/A	187	N/A	1,168	N/A	*****
Evidence of short-acting GLP-1 receptor agonist	N/A	1,446	N/A	235	N/A	*****	N/A	101
Evidence of type 1 diabetes	N/A	25,028	N/A	6,049	N/A	419	N/A	476
Evidence of washout	N/A	354,726	N/A	87,843	N/A	34,794	N/A	5,590
No evidence of inclusion criteria	N/A	92,962	N/A	26,549	N/A	60,678	N/A	1,376
Met event incidence criteria	67,310	0	5,398	0	842	0	*****	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	67,310	0	5,398	0	842	0	*****	0
Had minimum days' supply on index date	67,310	0	5,398	0	842	0	*****	0
Had index episode of at least required length	67,310	0	5,398	0	842	0	*****	0
Had index episode longer than blackout period	66,978	332	5,354	44	828	14	364	*****
Did not have an event during blackout period	66,978	0	5,354	0	828	0	364	0
Final cohort								
Number of members	66,978	N/A	5,354	N/A	828	N/A	364	N/A
Number of episodes	66,978	N/A	5,354	N/A	828	N/A	364	N/A

¹Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Appendix A. Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (September 28, 2023)

Masked DP ID ¹	DP Start Date	DP End Date ¹
DP01	07/01/2017	05/31/2023
DP02	07/01/2017	05/31/2023
DP03	01/01/2000	10/31/2022
DP04	01/01/2017	03/31/2023
DP05	01/01/2010	12/31/2022
DP06	01/01/2017	04/30/2023
DP07	07/01/2017	06/30/2023

¹End Date represents the earliest of: (1) query end date, or (2) last day of the most recent month for which all of a Data Partner's data tables (enrollment, dispensing, etc.) have at least 80% of the record count relative to the prior month.

Appendix B. Generic and Brand Names of Medical Products Used to Define Exposures or Exposure Washout in this Request

Generic Name	Brand Name
Mounjaro (tirzepatide)	
tirzepatide	Mounjaro
Bydureon, Bydureon BCISE (exenatide synthetic)	
exenatide microspheres	Bydureon
exenatide microspheres	Bydureon BCise
Ozempic (semaglutide)	
semaglutide	Ozempic
Rybelsus (semaglutide)	
semaglutide	Rybelsus
Wegovy (semaglutide)	
semaglutide	Wegovy
Saxenda (liraglutide)	
liraglutide	Saxenda
Victoza (liraglutide)	
liraglutide	Victoza 2-Pak
liraglutide	Victoza 3-Pak
Trulicity (dulaglutide)	
dulaglutide	Trulicity
Xultophy (insulin degludec/liraglutide)	
insulin degludec/liraglutide	Xultophy 100/3.6

Appendix C. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Tachyarrhythmia in this Request

Code	Description	Code Category	Code Type
Atrial Fibrillation and Flutter			
I48	Atrial fibrillation and flutter	Diagnosis	ICD-10-CM
I48.0	Paroxysmal atrial fibrillation	Diagnosis	ICD-10-CM
I48.1	Persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.11	Longstanding persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.19	Other persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.2	Chronic atrial fibrillation	Diagnosis	ICD-10-CM
I48.20	Chronic atrial fibrillation, unspecified	Diagnosis	ICD-10-CM
I48.21	Permanent atrial fibrillation	Diagnosis	ICD-10-CM
I48.3	Typical atrial flutter	Diagnosis	ICD-10-CM
I48.4	Atypical atrial flutter	Diagnosis	ICD-10-CM
I48.9	Unspecified atrial fibrillation and atrial flutter	Diagnosis	ICD-10-CM
I48.91	Unspecified atrial fibrillation	Diagnosis	ICD-10-CM
I48.92	Unspecified atrial flutter	Diagnosis	ICD-10-CM
Sinus Tachycardia			
R00.0	Tachycardia, unspecified	Diagnosis	ICD-10-CM
Supraventricular Tachycardia			
I47.1	Supraventricular tachycardia	Diagnosis	ICD-10-CM
I47.9	Paroxysmal tachycardia, unspecified	Diagnosis	ICD-10-CM
I49.1	Atrial premature depolarization	Diagnosis	ICD-10-CM
I49.2	Junctional premature depolarization	Diagnosis	ICD-10-CM
I49.9	Cardiac arrhythmia, unspecified	Diagnosis	ICD-10-CM
Other Tachycardia			
I47	Paroxysmal tachycardia	Diagnosis	ICD-10-CM
I49	Other cardiac arrhythmias	Diagnosis	ICD-10-CM
I49.3	Ventricular premature depolarization	Diagnosis	ICD-10-CM
I49.4	Other and unspecified premature depolarization	Diagnosis	ICD-10-CM
I49.40	Unspecified premature depolarization	Diagnosis	ICD-10-CM
I49.49	Other premature depolarization	Diagnosis	ICD-10-CM
I49.8	Other specified cardiac arrhythmias	Diagnosis	ICD-10-CM
Cardiac Arrest			
I46	Cardiac arrest	Diagnosis	ICD-10-CM
I46.2	Cardiac arrest due to underlying cardiac condition	Diagnosis	ICD-10-CM
I46.8	Cardiac arrest due to other underlying condition	Diagnosis	ICD-10-CM
I46.9	Cardiac arrest, cause unspecified	Diagnosis	ICD-10-CM
Ventricular Fibrillation and Flutter			
I49.0	Ventricular fibrillation and flutter	Diagnosis	ICD-10-CM
I49.01	Ventricular fibrillation	Diagnosis	ICD-10-CM
I49.02	Ventricular flutter	Diagnosis	ICD-10-CM
Ventricular Tachycardia			
I47.0	Re-entry ventricular arrhythmia	Diagnosis	ICD-10-CM
I47.2	Ventricular tachycardia	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
Type 2 Diabetes Mellitus			
E11	Type 2 diabetes mellitus	Diagnosis	ICD-10-CM
E11.0	Type 2 diabetes mellitus with hyperosmolarity	Diagnosis	ICD-10-CM
E11.00	Type 2 diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E11.01	Type 2 diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E11.1	Type 2 diabetes mellitus with ketoacidosis	Diagnosis	ICD-10-CM
E11.10	Type 2 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E11.11	Type 2 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E11.2	Type 2 diabetes mellitus with kidney complications	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.3	Type 2 diabetes mellitus with ophthalmic complications	Diagnosis	ICD-10-CM
E11.31	Type 2 diabetes mellitus with unspecified diabetic retinopathy	Diagnosis	ICD-10-CM
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.32	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E11.321	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3211	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3219	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.329	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3291	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3292	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3299	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.33	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E11.331	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3319	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.339	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3391	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3392	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3399	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.34	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E11.341	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3411	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3412	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3419	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.349	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3491	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3492	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3499	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.35	Type 2 diabetes mellitus with proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E11.351	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
E11.3519	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.352	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula	Diagnosis	ICD-10-CM
E11.3521	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3522	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3523	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3529	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.353	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula	Diagnosis	ICD-10-CM
E11.3531	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3532	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3533	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3539	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.354	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment	Diagnosis	ICD-10-CM
E11.3541	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E11.3542	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E11.3543	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E11.3549	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E11.355	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E11.3551	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E11.3552	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E11.3559	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E11.359	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3591	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3592	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
E11.3599	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.36	Type 2 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E11.37	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment	Diagnosis	ICD-10-CM
E11.37X1	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E11.37X2	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E11.37X3	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E11.37X9	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E11.39	Type 2 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E11.4	Type 2 diabetes mellitus with neurological complications	Diagnosis	ICD-10-CM
E11.40	Type 2 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E11.41	Type 2 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E11.42	Type 2 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E11.43	Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E11.44	Type 2 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E11.49	Type 2 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E11.5	Type 2 diabetes mellitus with circulatory complications	Diagnosis	ICD-10-CM
E11.51	Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E11.52	Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E11.59	Type 2 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E11.6	Type 2 diabetes mellitus with other specified complications	Diagnosis	ICD-10-CM
E11.61	Type 2 diabetes mellitus with diabetic arthropathy	Diagnosis	ICD-10-CM
E11.610	Type 2 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E11.618	Type 2 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E11.62	Type 2 diabetes mellitus with skin complications	Diagnosis	ICD-10-CM
E11.620	Type 2 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E11.621	Type 2 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E11.622	Type 2 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E11.628	Type 2 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E11.63	Type 2 diabetes mellitus with oral complications	Diagnosis	ICD-10-CM
E11.630	Type 2 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E11.638	Type 2 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E11.64	Type 2 diabetes mellitus with hypoglycemia	Diagnosis	ICD-10-CM
E11.641	Type 2 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E11.649	Type 2 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E11.65	Type 2 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E11.69	Type 2 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E11.8	Type 2 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E11.9	Type 2 diabetes mellitus without complications	Diagnosis	ICD-10-CM
Type 1 Diabetes Mellitus			
E10	Type 1 diabetes mellitus	Diagnosis	ICD-10-CM
E10.1	Type 1 diabetes mellitus with ketoacidosis	Diagnosis	ICD-10-CM
E10.10	Type 1 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E10.11	Type 1 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E10.2	Type 1 diabetes mellitus with kidney complications	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code	
		Category	Code Type
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10.3	Type 1 diabetes mellitus with ophthalmic complications	Diagnosis	ICD-10-CM
E10.31	Type 1 diabetes mellitus with unspecified diabetic retinopathy	Diagnosis	ICD-10-CM
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.319	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.32	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E10.321	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3219	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.329	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3291	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3292	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3299	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.33	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E10.331	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3311	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3319	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.339	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3391	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
E10.3392	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3399	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.34	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E10.341	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3411	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3412	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3419	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.349	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3491	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3492	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3499	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.35	Type 1 diabetes mellitus with proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E10.351	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3519	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.352	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula	Diagnosis	ICD-10-CM
E10.3521	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3522	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
E10.3523	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3529	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.353	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula	Diagnosis	ICD-10-CM
E10.3531	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3532	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3533	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3539	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.354	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment	Diagnosis	ICD-10-CM
E10.3541	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E10.3542	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E10.3543	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E10.3549	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E10.355	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E10.3551	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E10.3552	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E10.3553	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E10.3559	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E10.359	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3591	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3592	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3593	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3599	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.36	Type 1 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E10.37	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment	Diagnosis	ICD-10-CM
E10.37X1	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E10.37X2	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code	
		Category	Code Type
E10.37X3	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E10.37X9	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E10.39	Type 1 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E10.4	Type 1 diabetes mellitus with neurological complications	Diagnosis	ICD-10-CM
E10.40	Type 1 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E10.41	Type 1 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E10.42	Type 1 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E10.43	Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E10.44	Type 1 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E10.49	Type 1 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E10.5	Type 1 diabetes mellitus with circulatory complications	Diagnosis	ICD-10-CM
E10.51	Type 1 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E10.52	Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E10.59	Type 1 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E10.6	Type 1 diabetes mellitus with other specified complications	Diagnosis	ICD-10-CM
E10.61	Type 1 diabetes mellitus with diabetic arthropathy	Diagnosis	ICD-10-CM
E10.610	Type 1 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E10.618	Type 1 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E10.62	Type 1 diabetes mellitus with skin complications	Diagnosis	ICD-10-CM
E10.620	Type 1 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E10.621	Type 1 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E10.622	Type 1 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E10.628	Type 1 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E10.63	Type 1 diabetes mellitus with oral complications	Diagnosis	ICD-10-CM
E10.630	Type 1 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E10.638	Type 1 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E10.64	Type 1 diabetes mellitus with hypoglycemia	Diagnosis	ICD-10-CM
E10.641	Type 1 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E10.649	Type 1 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E10.65	Type 1 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E10.69	Type 1 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E10.8	Type 1 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E10.9	Type 1 diabetes mellitus without complications	Diagnosis	ICD-10-CM
Gestational Diabetes			
O24.4	Gestational diabetes mellitus	Diagnosis	ICD-10-CM
O24.41	Gestational diabetes mellitus in pregnancy	Diagnosis	ICD-10-CM
O24.410	Gestational diabetes mellitus in pregnancy, diet controlled	Diagnosis	ICD-10-CM
O24.414	Gestational diabetes mellitus in pregnancy, insulin controlled	Diagnosis	ICD-10-CM
O24.415	Gestational diabetes mellitus in pregnancy, controlled by oral hypoglycemic drugs	Diagnosis	ICD-10-CM
O24.419	Gestational diabetes mellitus in pregnancy, unspecified control	Diagnosis	ICD-10-CM
O24.42	Gestational diabetes mellitus in childbirth	Diagnosis	ICD-10-CM
O24.420	Gestational diabetes mellitus in childbirth, diet controlled	Diagnosis	ICD-10-CM
O24.424	Gestational diabetes mellitus in childbirth, insulin controlled	Diagnosis	ICD-10-CM
O24.425	Gestational diabetes mellitus in childbirth, controlled by oral hypoglycemic drugs	Diagnosis	ICD-10-CM
O24.429	Gestational diabetes mellitus in childbirth, unspecified control	Diagnosis	ICD-10-CM
O24.43	Gestational diabetes mellitus in the puerperium	Diagnosis	ICD-10-CM
O24.430	Gestational diabetes mellitus in the puerperium, diet controlled	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code	
		Category	Code Type
O24.434	Gestational diabetes mellitus in the puerperium, insulin controlled	Diagnosis	ICD-10-CM
O24.435	Gestational diabetes mellitus in puerperium, controlled by oral hypoglycemic drugs	Diagnosis	ICD-10-CM
O24.439	Gestational diabetes mellitus in the puerperium, unspecified control	Diagnosis	ICD-10-CM
Other Secondary Diabetes Illnesses			
E08	Diabetes mellitus due to underlying condition	Diagnosis	ICD-10-CM
E08.0	Diabetes mellitus due to underlying condition with hyperosmolarity	Diagnosis	ICD-10-CM
E08.00	Diabetes mellitus due to underlying condition with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E08.01	Diabetes mellitus due to underlying condition with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E08.1	Diabetes mellitus due to underlying condition with ketoacidosis	Diagnosis	ICD-10-CM
E08.10	Diabetes mellitus due to underlying condition with ketoacidosis without coma	Diagnosis	ICD-10-CM
E08.11	Diabetes mellitus due to underlying condition with ketoacidosis with coma	Diagnosis	ICD-10-CM
E08.2	Diabetes mellitus due to underlying condition with kidney complications	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E08.3	Diabetes mellitus due to underlying condition with ophthalmic complications	Diagnosis	ICD-10-CM
E08.31	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy	Diagnosis	ICD-10-CM
E08.311	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.319	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.32	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E08.321	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3211	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3212	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3219	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.329	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3291	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3292	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3293	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3299	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
E08.33	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E08.331	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3311	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3312	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3319	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.339	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3391	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3392	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3393	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3399	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.34	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E08.341	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3411	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3412	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3419	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.349	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3491	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3492	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3493	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
E08.3499	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.35	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E08.351	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3511	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3512	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3519	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.352	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula	Diagnosis	ICD-10-CM
E08.3521	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3522	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3523	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3529	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.353	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula	Diagnosis	ICD-10-CM
E08.3531	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3532	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3533	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3539	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.354	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment	Diagnosis	ICD-10-CM
E08.3541	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E08.3542	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E08.3543	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
E08.3549	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E08.355	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E08.3551	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E08.3552	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E08.3553	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E08.3559	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E08.359	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3591	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3592	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3593	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3599	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.36	Diabetes mellitus due to underlying condition with diabetic cataract	Diagnosis	ICD-10-CM
E08.37	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment	Diagnosis	ICD-10-CM
E08.37X1	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E08.37X2	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E08.37X3	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E08.37X9	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E08.39	Diabetes mellitus due to underlying condition with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E08.4	Diabetes mellitus due to underlying condition with neurological complications	Diagnosis	ICD-10-CM
E08.40	Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E08.41	Diabetes mellitus due to underlying condition with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E08.42	Diabetes mellitus due to underlying condition with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E08.43	Diabetes mellitus due to underlying condition with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E08.44	Diabetes mellitus due to underlying condition with diabetic amyotrophy	Diagnosis	ICD-10-CM
E08.49	Diabetes mellitus due to underlying condition with other diabetic neurological complication	Diagnosis	ICD-10-CM
E08.5	Diabetes mellitus due to underlying condition with circulatory complications	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
E08.51	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E08.52	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E08.59	Diabetes mellitus due to underlying condition with other circulatory complications	Diagnosis	ICD-10-CM
E08.6	Diabetes mellitus due to underlying condition with other specified complications	Diagnosis	ICD-10-CM
E08.61	Diabetes mellitus due to underlying condition with diabetic arthropathy	Diagnosis	ICD-10-CM
E08.610	Diabetes mellitus due to underlying condition with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E08.618	Diabetes mellitus due to underlying condition with other diabetic arthropathy	Diagnosis	ICD-10-CM
E08.62	Diabetes mellitus due to underlying condition with skin complications	Diagnosis	ICD-10-CM
E08.620	Diabetes mellitus due to underlying condition with diabetic dermatitis	Diagnosis	ICD-10-CM
E08.621	Diabetes mellitus due to underlying condition with foot ulcer	Diagnosis	ICD-10-CM
E08.622	Diabetes mellitus due to underlying condition with other skin ulcer	Diagnosis	ICD-10-CM
E08.628	Diabetes mellitus due to underlying condition with other skin complications	Diagnosis	ICD-10-CM
E08.63	Diabetes mellitus due to underlying condition with oral complications	Diagnosis	ICD-10-CM
E08.630	Diabetes mellitus due to underlying condition with periodontal disease	Diagnosis	ICD-10-CM
E08.638	Diabetes mellitus due to underlying condition with other oral complications	Diagnosis	ICD-10-CM
E08.64	Diabetes mellitus due to underlying condition with hypoglycemia	Diagnosis	ICD-10-CM
E08.641	Diabetes mellitus due to underlying condition with hypoglycemia with coma	Diagnosis	ICD-10-CM
E08.649	Diabetes mellitus due to underlying condition with hypoglycemia without coma	Diagnosis	ICD-10-CM
E08.65	Diabetes mellitus due to underlying condition with hyperglycemia	Diagnosis	ICD-10-CM
E08.69	Diabetes mellitus due to underlying condition with other specified complication	Diagnosis	ICD-10-CM
E08.8	Diabetes mellitus due to underlying condition with unspecified complications	Diagnosis	ICD-10-CM
E08.9	Diabetes mellitus due to underlying condition without complications	Diagnosis	ICD-10-CM
E13	Other specified diabetes mellitus	Diagnosis	ICD-10-CM
E13.0	Other specified diabetes mellitus with hyperosmolarity	Diagnosis	ICD-10-CM
E13.00	Other specified diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E13.01	Other specified diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E13.1	Other specified diabetes mellitus with ketoacidosis	Diagnosis	ICD-10-CM
E13.10	Other specified diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E13.11	Other specified diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E13.2	Other specified diabetes mellitus with kidney complications	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.3	Other specified diabetes mellitus with ophthalmic complications	Diagnosis	ICD-10-CM
E13.31	Other specified diabetes mellitus with unspecified diabetic retinopathy	Diagnosis	ICD-10-CM
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.319	Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.32	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E13.321	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3211	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
E13.3212	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3219	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.329	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3291	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3292	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3293	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3299	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.33	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E13.331	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3311	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3312	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3319	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.339	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3391	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3392	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3393	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3399	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.34	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E13.341	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3411	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3412	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3419	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.349	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3491	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3492	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3493	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3499	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.35	Other specified diabetes mellitus with proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E13.351	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3511	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3512	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3519	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.352	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula	Diagnosis	ICD-10-CM
E13.3521	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3522	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3523	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3529	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.353	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula	Diagnosis	ICD-10-CM
E13.3531	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3532	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3533	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
E13.3539	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.354	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment	Diagnosis	ICD-10-CM
E13.3541	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E13.3542	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E13.3543	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E13.3549	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E13.355	Other specified diabetes mellitus with stable proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E13.3551	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E13.3552	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E13.3553	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E13.3559	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E13.359	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3591	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3592	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3593	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3599	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.36	Other specified diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E13.37	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment	Diagnosis	ICD-10-CM
E13.37X1	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E13.37X2	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E13.37X3	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E13.37X9	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E13.39	Other specified diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E13.4	Other specified diabetes mellitus with neurological complications	Diagnosis	ICD-10-CM
E13.40	Other specified diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E13.41	Other specified diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E13.42	Other specified diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E13.43	Other specified diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code	
		Category	Code Type
E13.44	Other specified diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E13.49	Other specified diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E13.5	Other specified diabetes mellitus with circulatory complications	Diagnosis	ICD-10-CM
E13.51	Other specified diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E13.52	Other specified diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E13.59	Other specified diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E13.6	Other specified diabetes mellitus with other specified complications	Diagnosis	ICD-10-CM
E13.61	Other specified diabetes mellitus with diabetic arthropathy	Diagnosis	ICD-10-CM
E13.610	Other specified diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E13.618	Other specified diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E13.62	Other specified diabetes mellitus with skin complications	Diagnosis	ICD-10-CM
E13.620	Other specified diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E13.621	Other specified diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E13.622	Other specified diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E13.628	Other specified diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E13.63	Other specified diabetes mellitus with oral complications	Diagnosis	ICD-10-CM
E13.630	Other specified diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E13.638	Other specified diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E13.64	Other specified diabetes mellitus with hypoglycemia	Diagnosis	ICD-10-CM
E13.641	Other specified diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E13.649	Other specified diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E13.65	Other specified diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E13.69	Other specified diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E13.8	Other specified diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E13.9	Other specified diabetes mellitus without complications	Diagnosis	ICD-10-CM
Pregnancy			
O00	Ectopic pregnancy	Diagnosis	ICD-10-CM
O0000	Abdominal pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
O0001	Abdominal pregnancy with intrauterine pregnancy	Diagnosis	ICD-10-CM
O00101	Right tubal pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
O00102	Left tubal pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
O00109	Unspecified tubal pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
O00111	Right tubal pregnancy with intrauterine pregnancy	Diagnosis	ICD-10-CM
O00112	Left tubal pregnancy with intrauterine pregnancy	Diagnosis	ICD-10-CM
O00119	Unspecified tubal pregnancy with intrauterine pregnancy	Diagnosis	ICD-10-CM
O00201	Right ovarian pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
O00202	Left ovarian pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
O00209	Unspecified ovarian pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
O00211	Right ovarian pregnancy with intrauterine pregnancy	Diagnosis	ICD-10-CM
O00212	Left ovarian pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
O00219	Unspecified ovarian pregnancy with intrauterine pregnancy	Diagnosis	ICD-10-CM
O008	Other ectopic pregnancy	Diagnosis	ICD-10-CM
O0080	Other ectopic pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
O0081	Other ectopic pregnancy with intrauterine pregnancy	Diagnosis	ICD-10-CM
O009	Ectopic pregnancy, unspecified	Diagnosis	ICD-10-CM
O0090	Unspecified ectopic pregnancy without intrauterine pregnancy	Diagnosis	ICD-10-CM
O0091	Unspecified ectopic pregnancy with intrauterine pregnancy	Diagnosis	ICD-10-CM
O01	Hydatidiform mole	Diagnosis	ICD-10-CM
O01.0	Classical hydatidiform mole	Diagnosis	ICD-10-CM
O01.1	Incomplete and partial hydatidiform mole	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code	
		Category	Code Type
001.9	Hydatidiform mole, unspecified	Diagnosis	ICD-10-CM
002.0	Blighted ovum and nonhydatidiform mole	Diagnosis	ICD-10-CM
002.1	Missed abortion	Diagnosis	ICD-10-CM
00289	Other abnormal products of conception	Diagnosis	ICD-10-CM
0029	Abnormal products of conception, unspecified	Diagnosis	ICD-10-CM
003	Spontaneous abortion	Diagnosis	ICD-10-CM
003.0	Genital tract and pelvic infection following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.1	Delayed or excessive hemorrhage following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.2	Embolism following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.3	Other and unspecified complications following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.30	Unspecified complication following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.31	Shock following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.32	Renal failure following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.33	Metabolic disorder following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.34	Damage to pelvic organs following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.35	Other venous complications following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.36	Cardiac arrest following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.37	Sepsis following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.38	Urinary tract infection following incomplete spontaneous abortion	Diagnosis	ICD-10-CM
003.39	Incomplete spontaneous abortion with other complications	Diagnosis	ICD-10-CM
003.4	Incomplete spontaneous abortion without complication	Diagnosis	ICD-10-CM
003.5	Genital tract and pelvic infection following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
003.6	Delayed or excessive hemorrhage following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
003.7	Embolism following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
003.8	Other and unspecified complications following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
003.80	Unspecified complication following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
003.81	Shock following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
003.82	Renal failure following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
003.83	Metabolic disorder following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
003.84	Damage to pelvic organs following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
003.85	Other venous complications following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
003.86	Cardiac arrest following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
003.87	Sepsis following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
003.88	Urinary tract infection following complete or unspecified spontaneous abortion	Diagnosis	ICD-10-CM
003.89	Complete or unspecified spontaneous abortion with other complications	Diagnosis	ICD-10-CM
003.9	Complete or unspecified spontaneous abortion without complication	Diagnosis	ICD-10-CM
004.5	Genital tract and pelvic infection following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
004.6	Delayed or excessive hemorrhage following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
004.7	Embolism following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
004.80	(Induced) termination of pregnancy with unspecified complications	Diagnosis	ICD-10-CM
004.81	Shock following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
004.82	Renal failure following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
004.83	Metabolic disorder following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
004.84	Damage to pelvic organs following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
004.85	Other venous complications following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
004.86	Cardiac arrest following (induced) termination of pregnancy	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code	
		Category	Code Type
004.87	Sepsis following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
004.88	Urinary tract infection following (induced) termination of pregnancy	Diagnosis	ICD-10-CM
004.89	(Induced) termination of pregnancy with other complications	Diagnosis	ICD-10-CM
007.30	Failed attempted termination of pregnancy with unspecified complications	Diagnosis	ICD-10-CM
007.35	Other venous complications following failed attempted termination of pregnancy	Diagnosis	ICD-10-CM
007.36	Cardiac arrest following failed attempted termination of pregnancy	Diagnosis	ICD-10-CM
007.38	Urinary tract infection following failed attempted termination of pregnancy	Diagnosis	ICD-10-CM
007.39	Failed attempted termination of pregnancy with other complications	Diagnosis	ICD-10-CM
0080	Genitl trct and pelvic infct fol ectopic and molar pregnancy	Diagnosis	ICD-10-CM
0081	Delayed or excess hemor fol ectopic and molar pregnancy	Diagnosis	ICD-10-CM
0082	Embolism following ectopic and molar pregnancy	Diagnosis	ICD-10-CM
0083	Shock following ectopic and molar pregnancy	Diagnosis	ICD-10-CM
0084	Renal failure following ectopic and molar pregnancy	Diagnosis	ICD-10-CM
0085	Metabolic disorders following an ectopic and molar pregnancy	Diagnosis	ICD-10-CM
0086	Damage to pelvic organs and tiss fol an ect and molar preg	Diagnosis	ICD-10-CM
0087	Oth venous comp following an ectopic and molar pregnancy	Diagnosis	ICD-10-CM
00881	Cardiac arrest following an ectopic and molar pregnancy	Diagnosis	ICD-10-CM
00882	Sepsis following ectopic and molar pregnancy	Diagnosis	ICD-10-CM
00883	Urinary tract infection fol an ectopic and molar pregnancy	Diagnosis	ICD-10-CM
00889	Other complications following an ectopic and molar pregnancy	Diagnosis	ICD-10-CM
0089	Unsp complication following an ectopic and molar pregnancy	Diagnosis	ICD-10-CM
010.02	Pre-existing essential hypertension complicating childbirth	Diagnosis	ICD-10-CM
010.12	Pre-existing hypertensive heart disease complicating childbirth	Diagnosis	ICD-10-CM
010.22	Pre-existing hypertensive chronic kidney disease complicating childbirth	Diagnosis	ICD-10-CM
010.32	Pre-existing hypertensive heart and chronic kidney disease complicating childbirth	Diagnosis	ICD-10-CM
010.42	Pre-existing secondary hypertension complicating childbirth	Diagnosis	ICD-10-CM
010.92	Unspecified pre-existing hypertension complicating childbirth	Diagnosis	ICD-10-CM
011.4	Pre-existing hypertension with pre-eclampsia, complicating childbirth	Diagnosis	ICD-10-CM
012.04	Gestational edema, complicating childbirth	Diagnosis	ICD-10-CM
012.14	Gestational proteinuria, complicating childbirth	Diagnosis	ICD-10-CM
012.24	Gestational edema with proteinuria, complicating childbirth	Diagnosis	ICD-10-CM
013.4	Gestational [pregnancy-induced] hypertension without significant proteinuria, complicating childbirth	Diagnosis	ICD-10-CM
014.04	Mild to moderate pre-eclampsia, complicating childbirth	Diagnosis	ICD-10-CM
014.14	Severe pre-eclampsia complicating childbirth	Diagnosis	ICD-10-CM
014.24	HELLP syndrome, complicating childbirth	Diagnosis	ICD-10-CM
014.94	Unspecified pre-eclampsia, complicating childbirth	Diagnosis	ICD-10-CM
016.4	Unspecified maternal hypertension, complicating childbirth	Diagnosis	ICD-10-CM
024	Diabetes mellitus in pregnancy, childbirth, and the puerperium	Diagnosis	ICD-10-CM
024.0	Pre-existing type 1 diabetes mellitus, in pregnancy, childbirth and the puerperium	Diagnosis	ICD-10-CM
024.01	Pre-existing type 1 diabetes mellitus, in pregnancy	Diagnosis	ICD-10-CM
024.011	Pre-existing type 1 diabetes mellitus, in pregnancy, first trimester	Diagnosis	ICD-10-CM
024.012	Pre-existing type 1 diabetes mellitus, in pregnancy, second trimester	Diagnosis	ICD-10-CM
024.013	Pre-existing type 1 diabetes mellitus, in pregnancy, third trimester	Diagnosis	ICD-10-CM
024.019	Pre-existing type 1 diabetes mellitus, in pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
024.02	Pre-existing type 1 diabetes mellitus, in childbirth	Diagnosis	ICD-10-CM
024.03	Pre-existing type 1 diabetes mellitus, in the puerperium	Diagnosis	ICD-10-CM
024.1	Pre-existing type 2 diabetes mellitus, in pregnancy, childbirth and the puerperium	Diagnosis	ICD-10-CM
024.11	Pre-existing type 2 diabetes mellitus, in pregnancy	Diagnosis	ICD-10-CM
024.111	Pre-existing type 2 diabetes mellitus, in pregnancy, first trimester	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code	
		Category	Code Type
O24.112	Pre-existing type 2 diabetes mellitus, in pregnancy, second trimester	Diagnosis	ICD-10-CM
O24.113	Pre-existing type 2 diabetes mellitus, in pregnancy, third trimester	Diagnosis	ICD-10-CM
O24.119	Pre-existing type 2 diabetes mellitus, in pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O24.12	Pre-existing type 2 diabetes mellitus, in childbirth	Diagnosis	ICD-10-CM
O24.13	Pre-existing type 2 diabetes mellitus, in the puerperium	Diagnosis	ICD-10-CM
O24.3	Unspecified pre-existing diabetes mellitus in pregnancy, childbirth and the puerperium	Diagnosis	ICD-10-CM
O24.31	Unspecified pre-existing diabetes mellitus in pregnancy	Diagnosis	ICD-10-CM
O24.311	Unspecified pre-existing diabetes mellitus in pregnancy, first trimester	Diagnosis	ICD-10-CM
O24.312	Unspecified pre-existing diabetes mellitus in pregnancy, second trimester	Diagnosis	ICD-10-CM
O24.313	Unspecified pre-existing diabetes mellitus in pregnancy, third trimester	Diagnosis	ICD-10-CM
O24.319	Unspecified pre-existing diabetes mellitus in pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O24.32	Unspecified pre-existing diabetes mellitus in childbirth	Diagnosis	ICD-10-CM
O24.33	Unspecified pre-existing diabetes mellitus in the puerperium	Diagnosis	ICD-10-CM
O24.420	Gestational diabetes mellitus in childbirth, diet controlled	Diagnosis	ICD-10-CM
O24.424	Gestational diabetes mellitus in childbirth, insulin controlled	Diagnosis	ICD-10-CM
O24.425	Gestational diabetes mellitus in childbirth, controlled by oral hypoglycemic drugs	Diagnosis	ICD-10-CM
O24.429	Gestational diabetes mellitus in childbirth, unspecified control	Diagnosis	ICD-10-CM
O24.8	Other pre-existing diabetes mellitus in pregnancy, childbirth, and the puerperium	Diagnosis	ICD-10-CM
O24.81	Other pre-existing diabetes mellitus in pregnancy	Diagnosis	ICD-10-CM
O24.811	Other pre-existing diabetes mellitus in pregnancy, first trimester	Diagnosis	ICD-10-CM
O24.812	Other pre-existing diabetes mellitus in pregnancy, second trimester	Diagnosis	ICD-10-CM
O24.813	Other pre-existing diabetes mellitus in pregnancy, third trimester	Diagnosis	ICD-10-CM
O24.819	Other pre-existing diabetes mellitus in pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O24.82	Other pre-existing diabetes mellitus in childbirth	Diagnosis	ICD-10-CM
O24.83	Other pre-existing diabetes mellitus in the puerperium	Diagnosis	ICD-10-CM
O24.9	Unspecified diabetes mellitus in pregnancy, childbirth and the puerperium	Diagnosis	ICD-10-CM
O24.91	Unspecified diabetes mellitus in pregnancy	Diagnosis	ICD-10-CM
O24.911	Unspecified diabetes mellitus in pregnancy, first trimester	Diagnosis	ICD-10-CM
O24.912	Unspecified diabetes mellitus in pregnancy, second trimester	Diagnosis	ICD-10-CM
O24.913	Unspecified diabetes mellitus in pregnancy, third trimester	Diagnosis	ICD-10-CM
O24.919	Unspecified diabetes mellitus in pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O24.92	Unspecified diabetes mellitus in childbirth	Diagnosis	ICD-10-CM
O24.93	Unspecified diabetes mellitus in the puerperium	Diagnosis	ICD-10-CM
O25.2	Malnutrition in childbirth	Diagnosis	ICD-10-CM
O26.62	Liver and biliary tract disorders in childbirth	Diagnosis	ICD-10-CM
O26.72	Subluxation of symphysis (pubis) in childbirth	Diagnosis	ICD-10-CM
O31.00X0	Papryaceous fetus, unspecified trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O31.00X1	Papryaceous fetus, unspecified trimester, fetus 1	Diagnosis	ICD-10-CM
O31.00X2	Papryaceous fetus, unspecified trimester, fetus 2	Diagnosis	ICD-10-CM
O31.00X3	Papryaceous fetus, unspecified trimester, fetus 3	Diagnosis	ICD-10-CM
O31.00X4	Papryaceous fetus, unspecified trimester, fetus 4	Diagnosis	ICD-10-CM
O31.00X5	Papryaceous fetus, unspecified trimester, fetus 5	Diagnosis	ICD-10-CM
O31.00X9	Papryaceous fetus, unspecified trimester, other fetus	Diagnosis	ICD-10-CM
O31.02X0	Papryaceous fetus, second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O31.02X1	Papryaceous fetus, second trimester, fetus 1	Diagnosis	ICD-10-CM
O31.02X2	Papryaceous fetus, second trimester, fetus 2	Diagnosis	ICD-10-CM
O31.02X3	Papryaceous fetus, second trimester, fetus 3	Diagnosis	ICD-10-CM
O31.02X4	Papryaceous fetus, second trimester, fetus 4	Diagnosis	ICD-10-CM
O31.02X5	Papryaceous fetus, second trimester, fetus 5	Diagnosis	ICD-10-CM
O31.02X9	Papryaceous fetus, second trimester, other fetus	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code	
		Category	Code Type
O31.03X0	Papyraceous fetus, third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O31.03X1	Papyraceous fetus, third trimester, fetus 1	Diagnosis	ICD-10-CM
O31.03X2	Papyraceous fetus, third trimester, fetus 2	Diagnosis	ICD-10-CM
O31.03X3	Papyraceous fetus, third trimester, fetus 3	Diagnosis	ICD-10-CM
O31.03X4	Papyraceous fetus, third trimester, fetus 4	Diagnosis	ICD-10-CM
O31.03X5	Papyraceous fetus, third trimester, fetus 5	Diagnosis	ICD-10-CM
O31.03X9	Papyraceous fetus, third trimester, other fetus	Diagnosis	ICD-10-CM
O31.1	Continuing pregnancy after spontaneous abortion of one fetus or more	Diagnosis	ICD-10-CM
O31.10	Continuing pregnancy after spontaneous abortion of one fetus or more, unspecified trimester	Diagnosis	ICD-10-CM
O31.10X0	Continuing pregnancy after spontaneous abortion of one fetus or more, unspecified trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O31.10X1	Continuing pregnancy after spontaneous abortion of one fetus or more, unspecified trimester, fetus 1	Diagnosis	ICD-10-CM
O31.10X2	Continuing pregnancy after spontaneous abortion of one fetus or more, unspecified trimester, fetus 2	Diagnosis	ICD-10-CM
O31.10X3	Continuing pregnancy after spontaneous abortion of one fetus or more, unspecified trimester, fetus 3	Diagnosis	ICD-10-CM
O31.10X4	Continuing pregnancy after spontaneous abortion of one fetus or more, unspecified trimester, fetus 4	Diagnosis	ICD-10-CM
O31.10X5	Continuing pregnancy after spontaneous abortion of one fetus or more, unspecified trimester, fetus 5	Diagnosis	ICD-10-CM
O31.10X9	Continuing pregnancy after spontaneous abortion of one fetus or more, unspecified trimester, other fetus	Diagnosis	ICD-10-CM
O31.11	Continuing pregnancy after spontaneous abortion of one fetus or more, first trimester	Diagnosis	ICD-10-CM
O31.11X0	Continuing pregnancy after spontaneous abortion of one fetus or more, first trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O31.11X1	Continuing pregnancy after spontaneous abortion of one fetus or more, first trimester, fetus 1	Diagnosis	ICD-10-CM
O31.11X2	Continuing pregnancy after spontaneous abortion of one fetus or more, first trimester, fetus 2	Diagnosis	ICD-10-CM
O31.11X3	Continuing pregnancy after spontaneous abortion of one fetus or more, first trimester, fetus 3	Diagnosis	ICD-10-CM
O31.11X4	Continuing pregnancy after spontaneous abortion of one fetus or more, first trimester, fetus 4	Diagnosis	ICD-10-CM
O31.11X5	Continuing pregnancy after spontaneous abortion of one fetus or more, first trimester, fetus 5	Diagnosis	ICD-10-CM
O31.11X9	Continuing pregnancy after spontaneous abortion of one fetus or more, first trimester, other fetus	Diagnosis	ICD-10-CM
O31.12	Continuing pregnancy after spontaneous abortion of one fetus or more, second trimester	Diagnosis	ICD-10-CM
O31.12X0	Continuing pregnancy after spontaneous abortion of one fetus or more, second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O31.12X1	Continuing pregnancy after spontaneous abortion of one fetus or more, second trimester, fetus 1	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
O31.12X2	Continuing pregnancy after spontaneous abortion of one fetus or more, second trimester, fetus 2	Diagnosis	ICD-10-CM
O31.12X3	Continuing pregnancy after spontaneous abortion of one fetus or more, second trimester, fetus 3	Diagnosis	ICD-10-CM
O31.12X4	Continuing pregnancy after spontaneous abortion of one fetus or more, second trimester, fetus 4	Diagnosis	ICD-10-CM
O31.12X5	Continuing pregnancy after spontaneous abortion of one fetus or more, second trimester, fetus 5	Diagnosis	ICD-10-CM
O31.12X9	Continuing pregnancy after spontaneous abortion of one fetus or more, second trimester, other fetus	Diagnosis	ICD-10-CM
O31.13	Continuing pregnancy after spontaneous abortion of one fetus or more, third trimester	Diagnosis	ICD-10-CM
O31.13X0	Continuing pregnancy after spontaneous abortion of one fetus or more, third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O31.13X1	Continuing pregnancy after spontaneous abortion of one fetus or more, third trimester, fetus 1	Diagnosis	ICD-10-CM
O31.13X2	Continuing pregnancy after spontaneous abortion of one fetus or more, third trimester, fetus 2	Diagnosis	ICD-10-CM
O31.13X3	Continuing pregnancy after spontaneous abortion of one fetus or more, third trimester, fetus 3	Diagnosis	ICD-10-CM
O31.13X4	Continuing pregnancy after spontaneous abortion of one fetus or more, third trimester, fetus 4	Diagnosis	ICD-10-CM
O31.13X5	Continuing pregnancy after spontaneous abortion of one fetus or more, third trimester, fetus 5	Diagnosis	ICD-10-CM
O31.13X9	Continuing pregnancy after spontaneous abortion of one fetus or more, third trimester, other fetus	Diagnosis	ICD-10-CM
O31.2	Continuing pregnancy after intrauterine death of one fetus or more	Diagnosis	ICD-10-CM
O31.20	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester	Diagnosis	ICD-10-CM
O31.20X0	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O31.20X1	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester, fetus 1	Diagnosis	ICD-10-CM
O31.20X2	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester, fetus 2	Diagnosis	ICD-10-CM
O31.20X3	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester, fetus 3	Diagnosis	ICD-10-CM
O31.20X4	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester, fetus 4	Diagnosis	ICD-10-CM
O31.20X5	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester, fetus 5	Diagnosis	ICD-10-CM
O31.20X9	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester, other fetus	Diagnosis	ICD-10-CM
O31.22	Continuing pregnancy after intrauterine death of one fetus or more, second trimester	Diagnosis	ICD-10-CM
O31.22X0	Continuing pregnancy after intrauterine death of one fetus or more, second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
O31.22X1	Continuing pregnancy after intrauterine death of one fetus or more, second trimester, fetus 1	Diagnosis	ICD-10-CM
O31.22X2	Continuing pregnancy after intrauterine death of one fetus or more, second trimester, fetus 2	Diagnosis	ICD-10-CM
O31.22X3	Continuing pregnancy after intrauterine death of one fetus or more, second trimester, fetus 3	Diagnosis	ICD-10-CM
O31.22X4	Continuing pregnancy after intrauterine death of one fetus or more, second trimester, fetus 4	Diagnosis	ICD-10-CM
O31.22X5	Continuing pregnancy after intrauterine death of one fetus or more, second trimester, fetus 5	Diagnosis	ICD-10-CM
O31.22X9	Continuing pregnancy after intrauterine death of one fetus or more, second trimester, other fetus	Diagnosis	ICD-10-CM
O31.23	Continuing pregnancy after intrauterine death of one fetus or more, third trimester	Diagnosis	ICD-10-CM
O31.23X0	Continuing pregnancy after intrauterine death of one fetus or more, third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O31.23X1	Continuing pregnancy after intrauterine death of one fetus or more, third trimester, fetus 1	Diagnosis	ICD-10-CM
O31.23X2	Continuing pregnancy after intrauterine death of one fetus or more, third trimester, fetus 2	Diagnosis	ICD-10-CM
O31.23X3	Continuing pregnancy after intrauterine death of one fetus or more, third trimester, fetus 3	Diagnosis	ICD-10-CM
O31.23X4	Continuing pregnancy after intrauterine death of one fetus or more, third trimester, fetus 4	Diagnosis	ICD-10-CM
O31.23X5	Continuing pregnancy after intrauterine death of one fetus or more, third trimester, fetus 5	Diagnosis	ICD-10-CM
O31.23X9	Continuing pregnancy after intrauterine death of one fetus or more, third trimester, other fetus	Diagnosis	ICD-10-CM
O36.4	Maternal care for intrauterine death	Diagnosis	ICD-10-CM
O36.4XX0	Maternal care for intrauterine death, not applicable or unspecified	Diagnosis	ICD-10-CM
O36.4XX1	Maternal care for intrauterine death, fetus 1	Diagnosis	ICD-10-CM
O36.4XX2	Maternal care for intrauterine death, fetus 2	Diagnosis	ICD-10-CM
O36.4XX3	Maternal care for intrauterine death, fetus 3	Diagnosis	ICD-10-CM
O36.4XX4	Maternal care for intrauterine death, fetus 4	Diagnosis	ICD-10-CM
O36.4XX5	Maternal care for intrauterine death, fetus 5	Diagnosis	ICD-10-CM
O36.4XX9	Maternal care for intrauterine death, other fetus	Diagnosis	ICD-10-CM
O48.0	Post-term pregnancy	Diagnosis	ICD-10-CM
O48.1	Prolonged pregnancy	Diagnosis	ICD-10-CM
O60.12X0	Preterm labor second trimester with preterm delivery second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O60.12X1	Preterm labor second trimester with preterm delivery second trimester, fetus 1	Diagnosis	ICD-10-CM
O60.12X2	Preterm labor second trimester with preterm delivery second trimester, fetus 2	Diagnosis	ICD-10-CM
O60.12X3	Preterm labor second trimester with preterm delivery second trimester, fetus 3	Diagnosis	ICD-10-CM
O60.12X4	Preterm labor second trimester with preterm delivery second trimester, fetus 4	Diagnosis	ICD-10-CM
O60.12X5	Preterm labor second trimester with preterm delivery second trimester, fetus 5	Diagnosis	ICD-10-CM
O60.12X9	Preterm labor second trimester with preterm delivery second trimester, other fetus	Diagnosis	ICD-10-CM
O60.13X0	Preterm labor second trimester with preterm delivery third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O60.13X1	Preterm labor second trimester with preterm delivery third trimester, fetus 1	Diagnosis	ICD-10-CM
O60.13X2	Preterm labor second trimester with preterm delivery third trimester, fetus 2	Diagnosis	ICD-10-CM
O60.13X3	Preterm labor second trimester with preterm delivery third trimester, fetus 3	Diagnosis	ICD-10-CM
O60.13X4	Preterm labor second trimester with preterm delivery third trimester, fetus 4	Diagnosis	ICD-10-CM
O60.13X5	Preterm labor second trimester with preterm delivery third trimester, fetus 5	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
O60.13X9	Preterm labor second trimester with preterm delivery third trimester, other fetus	Diagnosis	ICD-10-CM
O60.14X0	Preterm labor third trimester with preterm delivery third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O60.14X1	Preterm labor third trimester with preterm delivery third trimester, fetus 1	Diagnosis	ICD-10-CM
O60.14X2	Preterm labor third trimester with preterm delivery third trimester, fetus 2	Diagnosis	ICD-10-CM
O60.14X3	Preterm labor third trimester with preterm delivery third trimester, fetus 3	Diagnosis	ICD-10-CM
O60.14X4	Preterm labor third trimester with preterm delivery third trimester, fetus 4	Diagnosis	ICD-10-CM
O60.14X5	Preterm labor third trimester with preterm delivery third trimester, fetus 5	Diagnosis	ICD-10-CM
O60.14X9	Preterm labor third trimester with preterm delivery third trimester, other fetus	Diagnosis	ICD-10-CM
O60.22X0	Term delivery with preterm labor, second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O60.22X1	Term delivery with preterm labor, second trimester, fetus 1	Diagnosis	ICD-10-CM
O60.22X2	Term delivery with preterm labor, second trimester, fetus 2	Diagnosis	ICD-10-CM
O60.22X3	Term delivery with preterm labor, second trimester, fetus 3	Diagnosis	ICD-10-CM
O60.22X4	Term delivery with preterm labor, second trimester, fetus 4	Diagnosis	ICD-10-CM
O60.22X5	Term delivery with preterm labor, second trimester, fetus 5	Diagnosis	ICD-10-CM
O60.22X9	Term delivery with preterm labor, second trimester, other fetus	Diagnosis	ICD-10-CM
O60.23X0	Term delivery with preterm labor, third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O60.23X1	Term delivery with preterm labor, third trimester, fetus 1	Diagnosis	ICD-10-CM
O60.23X2	Term delivery with preterm labor, third trimester, fetus 2	Diagnosis	ICD-10-CM
O60.23X3	Term delivery with preterm labor, third trimester, fetus 3	Diagnosis	ICD-10-CM
O60.23X4	Term delivery with preterm labor, third trimester, fetus 4	Diagnosis	ICD-10-CM
O60.23X5	Term delivery with preterm labor, third trimester, fetus 5	Diagnosis	ICD-10-CM
O60.23X9	Term delivery with preterm labor, third trimester, other fetus	Diagnosis	ICD-10-CM
O63.2	Delayed delivery of second twin, triplet, etc.	Diagnosis	ICD-10-CM
O67.0	Intrapartum hemorrhage with coagulation defect	Diagnosis	ICD-10-CM
O67.8	Other intrapartum hemorrhage	Diagnosis	ICD-10-CM
O67.9	Intrapartum hemorrhage, unspecified	Diagnosis	ICD-10-CM
O68	Labor and delivery complicated by abnormality of fetal acid-base balance	Diagnosis	ICD-10-CM
O69.0XX0	Labor and delivery complicated by prolapse of cord, not applicable or unspecified	Diagnosis	ICD-10-CM
O69.0XX1	Labor and delivery complicated by prolapse of cord, fetus 1	Diagnosis	ICD-10-CM
O69.0XX2	Labor and delivery complicated by prolapse of cord, fetus 2	Diagnosis	ICD-10-CM
O69.0XX3	Labor and delivery complicated by prolapse of cord, fetus 3	Diagnosis	ICD-10-CM
O69.0XX4	Labor and delivery complicated by prolapse of cord, fetus 4	Diagnosis	ICD-10-CM
O69.0XX5	Labor and delivery complicated by prolapse of cord, fetus 5	Diagnosis	ICD-10-CM
O69.0XX9	Labor and delivery complicated by prolapse of cord, other fetus	Diagnosis	ICD-10-CM
O69.1XX0	Labor and delivery complicated by cord around neck, with compression, not applicable or unspecified	Diagnosis	ICD-10-CM
O69.1XX1	Labor and delivery complicated by cord around neck, with compression, fetus 1	Diagnosis	ICD-10-CM
O69.1XX2	Labor and delivery complicated by cord around neck, with compression, fetus 2	Diagnosis	ICD-10-CM
O69.1XX3	Labor and delivery complicated by cord around neck, with compression, fetus 3	Diagnosis	ICD-10-CM
O69.1XX4	Labor and delivery complicated by cord around neck, with compression, fetus 4	Diagnosis	ICD-10-CM
O69.1XX5	Labor and delivery complicated by cord around neck, with compression, fetus 5	Diagnosis	ICD-10-CM
O69.1XX9	Labor and delivery complicated by cord around neck, with compression, other fetus	Diagnosis	ICD-10-CM
O69.2XX0	Labor and delivery complicated by other cord entanglement, with compression, not applicable or unspecified	Diagnosis	ICD-10-CM
O69.2XX1	Labor and delivery complicated by other cord entanglement, with compression, fetus 1	Diagnosis	ICD-10-CM
O69.2XX2	Labor and delivery complicated by other cord entanglement, with compression, fetus 2	Diagnosis	ICD-10-CM
O69.2XX3	Labor and delivery complicated by other cord entanglement, with compression, fetus 3	Diagnosis	ICD-10-CM
O69.2XX4	Labor and delivery complicated by other cord entanglement, with compression, fetus 4	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
O69.2XX5	Labor and delivery complicated by other cord entanglement, with compression, fetus 5	Diagnosis	ICD-10-CM
O69.2XX9	Labor and delivery complicated by other cord entanglement, with compression, other	Diagnosis	ICD-10-CM
O69.3XX0	Labor and delivery complicated by short cord, not applicable or unspecified	Diagnosis	ICD-10-CM
O69.3XX1	Labor and delivery complicated by short cord, fetus 1	Diagnosis	ICD-10-CM
O69.3XX2	Labor and delivery complicated by short cord, fetus 2	Diagnosis	ICD-10-CM
O69.3XX3	Labor and delivery complicated by short cord, fetus 3	Diagnosis	ICD-10-CM
O69.3XX4	Labor and delivery complicated by short cord, fetus 4	Diagnosis	ICD-10-CM
O69.3XX5	Labor and delivery complicated by short cord, fetus 5	Diagnosis	ICD-10-CM
O69.3XX9	Labor and delivery complicated by short cord, other fetus	Diagnosis	ICD-10-CM
O69.4XX0	Labor and delivery complicated by vasa previa, not applicable or unspecified	Diagnosis	ICD-10-CM
O69.4XX1	Labor and delivery complicated by vasa previa, fetus 1	Diagnosis	ICD-10-CM
O69.4XX2	Labor and delivery complicated by vasa previa, fetus 2	Diagnosis	ICD-10-CM
O69.4XX3	Labor and delivery complicated by vasa previa, fetus 3	Diagnosis	ICD-10-CM
O69.4XX4	Labor and delivery complicated by vasa previa, fetus 4	Diagnosis	ICD-10-CM
O69.4XX5	Labor and delivery complicated by vasa previa, fetus 5	Diagnosis	ICD-10-CM
O69.4XX9	Labor and delivery complicated by vasa previa, other fetus	Diagnosis	ICD-10-CM
O69.5XX0	Labor and delivery complicated by vascular lesion of cord, not applicable or unspecified	Diagnosis	ICD-10-CM
O69.5XX1	Labor and delivery complicated by vascular lesion of cord, fetus 1	Diagnosis	ICD-10-CM
O69.5XX2	Labor and delivery complicated by vascular lesion of cord, fetus 2	Diagnosis	ICD-10-CM
O69.5XX3	Labor and delivery complicated by vascular lesion of cord, fetus 3	Diagnosis	ICD-10-CM
O69.5XX4	Labor and delivery complicated by vascular lesion of cord, fetus 4	Diagnosis	ICD-10-CM
O69.5XX5	Labor and delivery complicated by vascular lesion of cord, fetus 5	Diagnosis	ICD-10-CM
O69.5XX9	Labor and delivery complicated by vascular lesion of cord, other fetus	Diagnosis	ICD-10-CM
O69.81X0	Labor and delivery complicated by cord around neck, without compression, not applicable or unspecified	Diagnosis	ICD-10-CM
O69.81X1	Labor and delivery complicated by cord around neck, without compression, fetus 1	Diagnosis	ICD-10-CM
O69.81X2	Labor and delivery complicated by cord around neck, without compression, fetus 2	Diagnosis	ICD-10-CM
O69.81X3	Labor and delivery complicated by cord around neck, without compression, fetus 3	Diagnosis	ICD-10-CM
O69.81X4	Labor and delivery complicated by cord around neck, without compression, fetus 4	Diagnosis	ICD-10-CM
O69.81X5	Labor and delivery complicated by cord around neck, without compression, fetus 5	Diagnosis	ICD-10-CM
O69.81X9	Labor and delivery complicated by cord around neck, without compression, other fetus	Diagnosis	ICD-10-CM
O69.82X0	Labor and delivery complicated by other cord entanglement, without compression, not applicable or unspecified	Diagnosis	ICD-10-CM
O69.82X1	Labor and delivery complicated by other cord entanglement, without compression, fetus 1	Diagnosis	ICD-10-CM
O69.82X2	Labor and delivery complicated by other cord entanglement, without compression, fetus 2	Diagnosis	ICD-10-CM
O69.82X3	Labor and delivery complicated by other cord entanglement, without compression, fetus 3	Diagnosis	ICD-10-CM
O69.82X4	Labor and delivery complicated by other cord entanglement, without compression, fetus 4	Diagnosis	ICD-10-CM
O69.82X5	Labor and delivery complicated by other cord entanglement, without compression, fetus 5	Diagnosis	ICD-10-CM
O69.82X9	Labor and delivery complicated by other cord entanglement, without compression, other fetus	Diagnosis	ICD-10-CM
O69.89X0	Labor and delivery complicated by other cord complications, not applicable or unspecified	Diagnosis	ICD-10-CM
O69.89X1	Labor and delivery complicated by other cord complications, fetus 1	Diagnosis	ICD-10-CM
O69.89X2	Labor and delivery complicated by other cord complications, fetus 2	Diagnosis	ICD-10-CM
O69.89X3	Labor and delivery complicated by other cord complications, fetus 3	Diagnosis	ICD-10-CM
O69.89X4	Labor and delivery complicated by other cord complications, fetus 4	Diagnosis	ICD-10-CM
O69.89X5	Labor and delivery complicated by other cord complications, fetus 5	Diagnosis	ICD-10-CM
O69.89X9	Labor and delivery complicated by other cord complications, other fetus	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code	
		Category	Code Type
O69.9XX0	Labor and delivery complicated by cord complication, unspecified, not applicable or unspecified	Diagnosis	ICD-10-CM
O69.9XX1	Labor and delivery complicated by cord complication, unspecified, fetus 1	Diagnosis	ICD-10-CM
O69.9XX2	Labor and delivery complicated by cord complication, unspecified, fetus 2	Diagnosis	ICD-10-CM
O69.9XX3	Labor and delivery complicated by cord complication, unspecified, fetus 3	Diagnosis	ICD-10-CM
O69.9XX4	Labor and delivery complicated by cord complication, unspecified, fetus 4	Diagnosis	ICD-10-CM
O69.9XX5	Labor and delivery complicated by cord complication, unspecified, fetus 5	Diagnosis	ICD-10-CM
O69.9XX9	Labor and delivery complicated by cord complication, unspecified, other fetus	Diagnosis	ICD-10-CM
O70.0	First degree perineal laceration during delivery	Diagnosis	ICD-10-CM
O70.1	Second degree perineal laceration during delivery	Diagnosis	ICD-10-CM
O70.20	Third degree perineal laceration during delivery, unspecified	Diagnosis	ICD-10-CM
O70.21	Third degree perineal laceration during delivery, IIIa	Diagnosis	ICD-10-CM
O70.22	Third degree perineal laceration during delivery, IIIb	Diagnosis	ICD-10-CM
O70.23	Third degree perineal laceration during delivery, IIIc	Diagnosis	ICD-10-CM
O70.3	Fourth degree perineal laceration during delivery	Diagnosis	ICD-10-CM
O70.4	Anal sphincter tear complicating delivery, not associated with third degree laceration	Diagnosis	ICD-10-CM
O70.9	Perineal laceration during delivery, unspecified	Diagnosis	ICD-10-CM
O74.0	Aspiration pneumonitis due to anesthesia during labor and delivery	Diagnosis	ICD-10-CM
O74.1	Other pulmonary complications of anesthesia during labor and delivery	Diagnosis	ICD-10-CM
O74.2	Cardiac complications of anesthesia during labor and delivery	Diagnosis	ICD-10-CM
O74.3	Central nervous system complications of anesthesia during labor and delivery	Diagnosis	ICD-10-CM
O74.4	Toxic reaction to local anesthesia during labor and delivery	Diagnosis	ICD-10-CM
O74.5	Spinal and epidural anesthesia-induced headache during labor and delivery	Diagnosis	ICD-10-CM
O74.6	Other complications of spinal and epidural anesthesia during labor and delivery	Diagnosis	ICD-10-CM
O74.7	Failed or difficult intubation for anesthesia during labor and delivery	Diagnosis	ICD-10-CM
O74.8	Other complications of anesthesia during labor and delivery	Diagnosis	ICD-10-CM
O74.9	Complication of anesthesia during labor and delivery, unspecified	Diagnosis	ICD-10-CM
O75.0	Maternal distress during labor and delivery	Diagnosis	ICD-10-CM
O75.1	Shock during or following labor and delivery	Diagnosis	ICD-10-CM
O75.5	Delayed delivery after artificial rupture of membranes	Diagnosis	ICD-10-CM
O75.81	Maternal exhaustion complicating labor and delivery	Diagnosis	ICD-10-CM
O75.82	Onset (spontaneous) of labor after 37 completed weeks of gestation but before 39 completed weeks gestation, with delivery by (planned) cesarean section	Diagnosis	ICD-10-CM
O75.89	Other specified complications of labor and delivery	Diagnosis	ICD-10-CM
O75.9	Complication of labor and delivery, unspecified	Diagnosis	ICD-10-CM
O76	Abnormality in fetal heart rate and rhythm complicating labor and delivery	Diagnosis	ICD-10-CM
O77.0	Labor and delivery complicated by meconium in amniotic fluid	Diagnosis	ICD-10-CM
O77.8	Labor and delivery complicated by other evidence of fetal stress	Diagnosis	ICD-10-CM
O77.9	Labor and delivery complicated by fetal stress, unspecified	Diagnosis	ICD-10-CM
O80	Encounter for full-term uncomplicated delivery	Diagnosis	ICD-10-CM
O82	Encounter for cesarean delivery without indication	Diagnosis	ICD-10-CM
O88.02	Air embolism in childbirth	Diagnosis	ICD-10-CM
O88.12	Amniotic fluid embolism in childbirth	Diagnosis	ICD-10-CM
O88.22	Thromboembolism in childbirth	Diagnosis	ICD-10-CM
O88.32	Pyemic and septic embolism in childbirth	Diagnosis	ICD-10-CM
O88.82	Other embolism in childbirth	Diagnosis	ICD-10-CM
O98.02	Tuberculosis complicating childbirth	Diagnosis	ICD-10-CM
O98.12	Syphilis complicating childbirth	Diagnosis	ICD-10-CM
O98.22	Gonorrhea complicating childbirth	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
O98.32	Other infections with a predominantly sexual mode of transmission complicating childbirth	Diagnosis	ICD-10-CM
O98.42	Viral hepatitis complicating childbirth	Diagnosis	ICD-10-CM
O98.52	Other viral diseases complicating childbirth	Diagnosis	ICD-10-CM
O98.62	Protozoal diseases complicating childbirth	Diagnosis	ICD-10-CM
O98.72	Human immunodeficiency virus [HIV] disease complicating childbirth	Diagnosis	ICD-10-CM
O98.82	Other maternal infectious and parasitic diseases complicating childbirth	Diagnosis	ICD-10-CM
O98.92	Unspecified maternal infectious and parasitic disease complicating childbirth	Diagnosis	ICD-10-CM
O99.02	Anemia complicating childbirth	Diagnosis	ICD-10-CM
O99.12	Other diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism complicating childbirth	Diagnosis	ICD-10-CM
O99.210	Obesity complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.211	Obesity complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.212	Obesity complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.213	Obesity complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.214	Obesity complicating childbirth	Diagnosis	ICD-10-CM
O99.215	Obesity complicating the puerperium	Diagnosis	ICD-10-CM
O99.284	Endocrine, nutritional and metabolic diseases complicating childbirth	Diagnosis	ICD-10-CM
O99.314	Alcohol use complicating childbirth	Diagnosis	ICD-10-CM
O99.324	Drug use complicating childbirth	Diagnosis	ICD-10-CM
O99.334	Smoking (tobacco) complicating childbirth	Diagnosis	ICD-10-CM
O99.344	Other mental disorders complicating childbirth	Diagnosis	ICD-10-CM
O99.354	Diseases of the nervous system complicating childbirth	Diagnosis	ICD-10-CM
O99.42	Diseases of the circulatory system complicating childbirth	Diagnosis	ICD-10-CM
O99.52	Diseases of the respiratory system complicating childbirth	Diagnosis	ICD-10-CM
O99.62	Diseases of the digestive system complicating childbirth	Diagnosis	ICD-10-CM
O99.72	Diseases of the skin and subcutaneous tissue complicating childbirth	Diagnosis	ICD-10-CM
O99.814	Abnormal glucose complicating childbirth	Diagnosis	ICD-10-CM
O99.824	Streptococcus B carrier state complicating childbirth	Diagnosis	ICD-10-CM
O99.834	Other infection carrier state complicating childbirth	Diagnosis	ICD-10-CM
O99.844	Bariatric surgery status complicating childbirth	Diagnosis	ICD-10-CM
O9A.12	Malignant neoplasm complicating childbirth	Diagnosis	ICD-10-CM
O9A.22	Injury, poisoning and certain other consequences of external causes complicating childbirth	Diagnosis	ICD-10-CM
O9A.32	Physical abuse complicating childbirth	Diagnosis	ICD-10-CM
O9A.42	Sexual abuse complicating childbirth	Diagnosis	ICD-10-CM
O9A.52	Psychological abuse complicating childbirth	Diagnosis	ICD-10-CM
P03.0	Newborn affected by breech delivery and extraction	Diagnosis	ICD-10-CM
P03.2	Newborn affected by forceps delivery	Diagnosis	ICD-10-CM
P03.3	Newborn affected by delivery by vacuum extractor [ventouse]	Diagnosis	ICD-10-CM
P03.4	Newborn affected by Cesarean delivery	Diagnosis	ICD-10-CM
P03.5	Newborn affected by precipitate delivery	Diagnosis	ICD-10-CM
P07.00	Extremely low birth weight newborn, unspecified weight	Diagnosis	ICD-10-CM
P07.01	Extremely low birth weight newborn, less than 500 grams	Diagnosis	ICD-10-CM
P07.02	Extremely low birth weight newborn, 500-749 grams	Diagnosis	ICD-10-CM
P07.03	Extremely low birth weight newborn, 750-999 grams	Diagnosis	ICD-10-CM
P07.10	Other low birth weight newborn, unspecified weight	Diagnosis	ICD-10-CM
P07.14	Other low birth weight newborn, 1000-1249 grams	Diagnosis	ICD-10-CM
P07.15	Other low birth weight newborn, 1250-1499 grams	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code	
		Category	Code Type
P07.16	Other low birth weight newborn, 1500-1749 grams	Diagnosis	ICD-10-CM
P07.17	Other low birth weight newborn, 1750-1999 grams	Diagnosis	ICD-10-CM
P07.18	Other low birth weight newborn, 2000-2499 grams	Diagnosis	ICD-10-CM
P07.20	Extreme immaturity of newborn, unspecified weeks of gestation	Diagnosis	ICD-10-CM
P07.21	Extreme immaturity of newborn, gestational age less than 23 completed weeks	Diagnosis	ICD-10-CM
P07.22	Extreme immaturity of newborn, gestational age 23 completed weeks	Diagnosis	ICD-10-CM
P07.23	Extreme immaturity of newborn, gestational age 24 completed weeks	Diagnosis	ICD-10-CM
P07.24	Extreme immaturity of newborn, gestational age 25 completed weeks	Diagnosis	ICD-10-CM
P07.25	Extreme immaturity of newborn, gestational age 26 completed weeks	Diagnosis	ICD-10-CM
P07.26	Extreme immaturity of newborn, gestational age 27 completed weeks	Diagnosis	ICD-10-CM
P07.30	Preterm newborn, unspecified weeks of gestation	Diagnosis	ICD-10-CM
P07.31	Preterm newborn, gestational age 28 completed weeks	Diagnosis	ICD-10-CM
P07.32	Preterm newborn, gestational age 29 completed weeks	Diagnosis	ICD-10-CM
P07.33	Preterm newborn, gestational age 30 completed weeks	Diagnosis	ICD-10-CM
P07.34	Preterm newborn, gestational age 31 completed weeks	Diagnosis	ICD-10-CM
P07.35	Preterm newborn, gestational age 32 completed weeks	Diagnosis	ICD-10-CM
P07.36	Preterm newborn, gestational age 33 completed weeks	Diagnosis	ICD-10-CM
P07.37	Preterm newborn, gestational age 34 completed weeks	Diagnosis	ICD-10-CM
P07.38	Preterm newborn, gestational age 35 completed weeks	Diagnosis	ICD-10-CM
P07.39	Preterm newborn, gestational age 36 completed weeks	Diagnosis	ICD-10-CM
P08.21	Post-term newborn	Diagnosis	ICD-10-CM
P08.22	Prolonged gestation of newborn	Diagnosis	ICD-10-CM
P95	Stillbirth	Diagnosis	ICD-10-CM
Z33.2	Encounter for elective termination of pregnancy	Diagnosis	ICD-10-CM
Z37.0	Single live birth	Diagnosis	ICD-10-CM
Z37.1	Single stillbirth	Diagnosis	ICD-10-CM
Z37.2	Twins, both liveborn	Diagnosis	ICD-10-CM
Z37.3	Twins, one liveborn and one stillborn	Diagnosis	ICD-10-CM
Z37.3	Twins, one liveborn and one stillborn	Diagnosis	ICD-10-CM
Z37.4	Twins, both stillborn	Diagnosis	ICD-10-CM
Z37.50	Multiple births, unspecified, all liveborn	Diagnosis	ICD-10-CM
Z37.51	Triplets, all liveborn	Diagnosis	ICD-10-CM
Z37.52	Quadruplets, all liveborn	Diagnosis	ICD-10-CM
Z37.53	Quintuplets, all liveborn	Diagnosis	ICD-10-CM
Z37.54	Sextuplets, all liveborn	Diagnosis	ICD-10-CM
Z37.59	Other multiple births, all liveborn	Diagnosis	ICD-10-CM
Z37.6	Other multiple births, some liveborn	Diagnosis	ICD-10-CM
Z37.60	Multiple births, unspecified, some liveborn	Diagnosis	ICD-10-CM
Z37.60	Multiple births, unspecified, some liveborn	Diagnosis	ICD-10-CM
Z37.61	Triplets, some liveborn	Diagnosis	ICD-10-CM
Z37.61	Triplets, some liveborn	Diagnosis	ICD-10-CM
Z37.62	Quadruplets, some liveborn	Diagnosis	ICD-10-CM
Z37.62	Quadruplets, some liveborn	Diagnosis	ICD-10-CM
Z37.63	Quintuplets, some liveborn	Diagnosis	ICD-10-CM
Z37.63	Quintuplets, some liveborn	Diagnosis	ICD-10-CM
Z37.64	Sextuplets, some liveborn	Diagnosis	ICD-10-CM
Z37.64	Sextuplets, some liveborn	Diagnosis	ICD-10-CM
Z37.69	Other multiple births, some liveborn	Diagnosis	ICD-10-CM
Z37.69	Other multiple births, some liveborn	Diagnosis	ICD-10-CM
Z37.7	Other multiple births, all stillborn	Diagnosis	ICD-10-CM

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code	
		Category	Code Type
Z37.9	Outcome of delivery, unspecified	Diagnosis	ICD-10-CM
Z38.00	Single liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z38.01	Single liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z38.1	Single liveborn infant, born outside hospital	Diagnosis	ICD-10-CM
Z38.2	Single liveborn infant, unspecified as to place of birth	Diagnosis	ICD-10-CM
Z38.30	Twin liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z38.31	Twin liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z38.4	Twin liveborn infant, born outside hospital	Diagnosis	ICD-10-CM
Z38.5	Twin liveborn infant, unspecified as to place of birth	Diagnosis	ICD-10-CM
Z38.61	Triplet liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z38.62	Triplet liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z38.63	Quadruplet liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z38.64	Quadruplet liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z38.65	Quintuplet liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z38.66	Quintuplet liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z38.68	Other multiple liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z38.69	Other multiple liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z38.7	Other multiple liveborn infant, born outside hospital	Diagnosis	ICD-10-CM
Z38.8	Other multiple liveborn infant, unspecified as to place of birth	Diagnosis	ICD-10-CM
Z3A.20	20 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.21	21 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.22	22 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.23	23 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.24	24 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.25	25 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.26	26 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.27	27 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.28	28 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.29	29 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.30	30 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.31	31 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.32	32 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.33	33 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.34	34 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.35	35 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.36	36 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.37	37 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.38	38 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.39	39 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.40	40 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.41	41 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.42	42 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
Z3A.49	Greater than 42 weeks gestation of pregnancy	Diagnosis	ICD-10-CM
0W8NXZZ	Division of Female Perineum, External Approach	Procedure	ICD-10-PCS
10900ZC	Drainage of Amniotic Fluid, Therapeutic from Products of Conception, Open Approach	Procedure	ICD-10-PCS
10903ZC	Drainage of Amniotic Fluid, Therapeutic from Products of Conception, Percutaneous Approach	Procedure	ICD-10-PCS
10904ZC	Drainage of Amniotic Fluid, Therapeutic from Products of Conception, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
10907ZC	Drainage of Amniotic Fluid, Therapeutic from Products of Conception, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10908ZC	Drainage of Amniotic Fluid, Therapeutic from Products of Conception, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
10A00ZZ	Abortion of Products of Conception, Open Approach	Procedure	ICD-10-PCS
10A03ZZ	Abortion of Products of Conception, Percutaneous Approach	Procedure	ICD-10-PCS
10A04ZZ	Abortion of Products of Conception, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
10A07Z6	Abortion of Products of Conception, Vacuum, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10A07ZW	Abortion of Products of Conception, Laminaria, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10A07ZX	Abortion of Products of Conception, Abortifacient, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10A07ZZ	Abortion of Products of Conception, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10A08ZZ	Abortion of Products of Conception, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
10D00Z0	Extraction of Products of Conception, High, Open Approach	Procedure	ICD-10-PCS
10D00Z1	Extraction of Products of Conception, Low, Open Approach	Procedure	ICD-10-PCS
10D00Z2	Extraction of Products of Conception, Extraperitoneal, Open Approach	Procedure	ICD-10-PCS
10D07Z3	Extraction of Products of Conception, Low Forceps, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10D07Z4	Extraction of Products of Conception, Mid Forceps, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10D07Z5	Extraction of Products of Conception, High Forceps, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10D07Z6	Extraction of Products of Conception, Vacuum, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10D07Z7	Extraction of Products of Conception, Internal Version, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10D07Z8	Extraction of Products of Conception, Other, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10D17Z9	Manual Extraction of Products of Conception, Retained, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10D18Z9	Manual Extraction of Products of Conception, Retained, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
10D27ZZ	Extraction of products of conception, ectopic, via natural or artificial opening	Procedure	ICD-10-PCS
10D28ZZ	Extraction of products of conception, ectopic, via natural or artificial opening endoscopic	Procedure	ICD-10-PCS
10E0XZZ	Delivery of Products of Conception, External Approach	Procedure	ICD-10-PCS
10S07ZZ	Reposition Products of Conception, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
10T20ZZ	Resection of products of conception, ectopic, open approach	Procedure	ICD-10-PCS
10T23ZZ	Resection of products of conception, ectopic, percutaneous approach	Procedure	ICD-10-PCS
10T24ZZ	Resection of products of conception, ectopic, percutaneous endoscopic approach	Procedure	ICD-10-PCS
10T27ZZ	Resection of products of conception, ectopic, via natural or artificial opening	Procedure	ICD-10-PCS
10T28ZZ	Resection of products of conception, ectopic, via natural or artificial opening endoscopic	Procedure	ICD-10-PCS
58661	Laparoscopy, surgical; with removal of adnexal structures (partial or total oophorectomy and/or salpingectomy)	Procedure	CPT-4
58673	Laparoscopy, surgical; with salpingostomy (salpingoneostomy)	Procedure	CPT-4
58700	Salpingectomy, complete or partial, unilateral or bilateral (separate procedure)	Procedure	CPT-4
58770	Salpingostomy (salpingoneostomy)	Procedure	CPT-4
59100	Surgical treatment of ectopic pregnancy: tubal or ovarian, requiring salpingectomy and/or oophorectomy, abdominal or vaginal approach	Procedure	CPT-4
59830	TREATMENT OF SEPTIC ABORTION, COMPLETED SURGICALLY	Procedure	CPT-4
59840	INDUCED ABORTION, BY DILATION AND CURETTAGE	Procedure	CPT-4
59841	INDUCED ABORTION, BY DILATION AND EVACUATION	Procedure	CPT-4
59850	INDUCED ABORTION, BY ONE OR MORE INTRAAMNIOTIC INJECTIONS	Procedure	CPT-4
59851	INDUCED ABORTION, BY ONE OR MORE INTRAAMNIOTIC INJECTIONS, WITH DILATION AND CURETTAGE AND/OR EVACUATION	Procedure	CPT-4
59852	INDUCED ABORTION, BY ONE OR MORE INTRAAMNIOTIC INJECTIONS, WITH	Procedure	CPT-4

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code	
		Category	Code Type
59855	INDUCED ABORTION, BY ONE OR MORE VAGINAL SUPPOSITORIES	Procedure	CPT-4
59856	INDUCED ABORTION, BY ONE OR MORE VAGINAL SUPPOSITORIES, WITH DILATION AND CURETTAGE AND/OR EVACUATION	Procedure	CPT-4
59857	INDUCED ABORTION, BY ONE OR MORE VAGINAL SUPPOSITORIES, WITH HYSTEROTOMY	Procedure	CPT-4
59870	Evacuation and curettage of uterus for hydatidiform mole	Procedure	CPT-4
01964	ANESTHESIA FOR ABORTION PROCEDURES	Procedure	CPT-4
01965	Anesthesia for incomplete or missed abortion procedures	Procedure	CPT-4
01966	Anesthesia for induced abortion procedures	Procedure	CPT-4
59120	Surgical treatment of ectopic pregnancy; tubal or ovarian, requiring salpingectomy and/or oophorectomy, abdominal or vaginal approach	Procedure	CPT-4
59121	Surgical treatment of ectopic pregnancy; tubal or ovarian, without salpingectomy and/or oophorectomy	Procedure	CPT-4
59125	Surgical Treatment Of Ectopic Pregnancy	Procedure	CPT-4
59126	Surgical Treatment Of Ectopic Pregnancy	Procedure	CPT-4
59130	Surgical treatment of ectopic pregnancy; abdominal pregnancy	Procedure	CPT-4
59135	Surgical treatment of ectopic pregnancy; interstitial, uterine pregnancy requiring total hysterectomy	Procedure	CPT-4
59136	Surgical treatment of ectopic pregnancy; interstitial, uterine pregnancy with partial resection of uterus	Procedure	CPT-4
59140	Surgical treatment of ectopic pregnancy; cervical, with evacuation	Procedure	CPT-4
59150	Laparoscopic treatment of ectopic pregnancy; without salpingectomy and/or oophorectomy	Procedure	CPT-4
59151	Laparoscopic treatment of ectopic pregnancy; with salpingectomy and/or oophorectomy	Procedure	CPT-4
59400	Routine obstetric care including antepartum care, vaginal delivery (with or without episiotomy, and/or forceps) and postpartum care	Procedure	CPT-4
59409	Vaginal delivery only (with or without episiotomy and/or forceps);	Procedure	CPT-4
59410	Vaginal delivery only (with or without episiotomy and/or forceps); including postpartum care	Procedure	CPT-4
59510	Routine obstetric care including antepartum care, cesarean delivery, and postpartum care	Procedure	CPT-4
59514	Cesarean delivery only;	Procedure	CPT-4
59515	Cesarean delivery only; including postpartum care	Procedure	CPT-4
59610	Routine obstetric care including antepartum care, vaginal delivery (with or without episiotomy, and/or forceps) and postpartum care, after previous cesarean delivery	Procedure	CPT-4
59612	Vaginal delivery only, after previous cesarean delivery (with or without episiotomy and/or forceps);	Procedure	CPT-4
59614	Vaginal delivery only, after previous cesarean delivery (with or without episiotomy and/or forceps); including postpartum care	Procedure	CPT-4
59618	Routine obstetric care including antepartum care, cesarean delivery, and postpartum care, following attempted vaginal delivery after previous cesarean delivery	Procedure	CPT-4
59620	Cesarean delivery only, following attempted vaginal delivery after previous cesarean delivery;	Procedure	CPT-4
59622	Cesarean delivery only, following attempted vaginal delivery after previous cesarean delivery; including postpartum care	Procedure	CPT-4
59812	Treatment of incomplete abortion, any trimester, completed surgically	Procedure	CPT-4

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I Procedure Codes Used to Define Inclusion or Exclusion Criteria in this Request

Code	Description	Code	
		Category	Code Type
59820	Treatment of missed abortion, completed surgically; first trimester	Procedure	CPT-4
59821	Treatment of missed abortion, completed surgically; second trimester	Procedure	CPT-4
S0190	Mifepristone, oral, 200 mg	Procedure	HCPCS
S0191	Misoprostol, oral, 200 mcg	Procedure	HCPCS
S0199	Medically induced abortion by oral ingestion of medication including all associated services and supplies (e.g., patient counseling, office visits, confirmation of pregnancy by HCG, ultrasound to confirm duration of pregnancy, ultrasound to confirm completion of abortion) except drugs	Procedure	HCPCS
S2260	Induced abortion, 17 to 24 weeks	Procedure	HCPCS
S2265	Induced abortion, 25 to 28 weeks	Procedure	HCPCS
S2266	Induced abortion, 29 to 31 weeks	Procedure	HCPCS
S2267	Induced abortion, 32 weeks or greater	Procedure	HCPCS

Appendix E. Generic and Brand Names of Medical Products Used to Define Inclusion or Exclusion Criteria in this Request

Generic Name	Brand Name
Short-Acting Glucagon-Like Peptide-1 Receptor Agonists (SA GLP-1 RAs)	
exenatide	Byetta
lixisenatide	Adlyxin
insulin glargine,human recombinant analog/lixisenatide	Soliqua 100/33
Insulin	
insulin aspart	insulin aspart U-100
insulin aspart	Novolog FlexPen U-100 Insulin
insulin aspart	Novolog PenFill U-100 Insulin
insulin aspart	Novolog U-100 Insulin aspart
insulin aspart (niacinamide)	Fiasp FlexTouch U-100 Insulin
insulin aspart (niacinamide)	Fiasp Penfill U-100 Insulin
insulin aspart (niacinamide)	Fiasp U-100 Insulin
insulin aspart protamine human/insulin aspart	insulin asp prt-insulin aspart
insulin aspart protamine human/insulin aspart	Novolog Mix 70-30 U-100 Insulin
insulin aspart protamine human/insulin aspart	Novolog Mix 70-30FlexPen U-100
insulin degludec	insulin degludec
insulin degludec	Tresiba FlexTouch U-100
insulin degludec	Tresiba FlexTouch U-200
insulin degludec	Tresiba U-100 Insulin
insulin detemir	Levemir FlexPen
insulin detemir	Levemir FlexTouch U-100 Insulin
insulin detemir	Levemir U-100 Insulin
insulin glargine,human recombinant analog	Basaglar KwikPen U-100 Insulin
insulin glargine,human recombinant analog	Basaglar Tempo Pen(U-100)Insulin
insulin glargine,human recombinant analog	insulin glargine
insulin glargine,human recombinant analog	Lantus Solostar U-100 Insulin
insulin glargine,human recombinant analog	Lantus U-100 Insulin
insulin glargine,human recombinant analog	Semglee Pen U-100 Insulin
insulin glargine,human recombinant analog	Semglee U-100 Insulin
insulin glargine,human recombinant analog	Toujeo Max U-300 SoloStar
insulin glargine,human recombinant analog	Toujeo SoloStar U-300 Insulin
insulin glargine-yfgn	insulin glargine-yfgn
insulin glargine-yfgn	Semglee(insulin glargine-yfgn)
insulin glargine-yfgn	Semglee(insulin glarg-yfgn)Pen
insulin glulisine	Apidra SoloStar U-100 Insulin
insulin glulisine	Apidra U-100 Insulin
insulin lispro	Admelog SoloStar U-100 Insulin
insulin lispro	Admelog U-100 Insulin lispro
insulin lispro	Humalog Junior KwikPen U-100
insulin lispro	Humalog KwikPen Insulin
insulin lispro	Humalog Tempo Pen(U-100)Insulin
insulin lispro	Humalog U-100 Insulin
insulin lispro	insulin lispro
insulin lispro protamine and insulin lispro	Humalog Mix 50-50 Insulin U-100
insulin lispro protamine and insulin lispro	Humalog Mix 50-50 KwikPen
insulin lispro protamine and insulin lispro	Humalog Mix 75-25 KwikPen
insulin lispro protamine and insulin lispro	Humalog Mix 75-25(U-100)Insulin
insulin lispro protamine and insulin lispro	insulin lispro protamin-lispro
insulin lispro-aabc	Lyumjev KwikPen U-100 Insulin
insulin lispro-aabc	Lyumjev KwikPen U-200 Insulin
insulin lispro-aabc	Lyumjev Tempo Pen(U-100)Insulin
insulin lispro-aabc	Lyumjev U-100 Insulin
insulin NPH human isophane	Humulin N NPH Insulin KwikPen
insulin NPH human isophane	Humulin N NPH U-100 Insulin

Appendix E. Generic and Brand Names of Medical Products Used to Define Inclusion or Exclusion Criteria in this Request

Generic Name	Brand Name
insulin NPH human isophane	Novolin N FlexPen
insulin NPH human isophane	Novolin N NPH U-100 Insulin
insulin NPH human isophane/insulin regular, human	Humulin 70/30 U-100 Insulin
insulin NPH human isophane/insulin regular, human	Humulin 70/30 U-100 KwikPen
insulin NPH human isophane/insulin regular, human	Novolin 70/30 U-100 Insulin
insulin NPH human isophane/insulin regular, human	Novolin 70-30 FlexPen U-100
insulin regular, human	Afrezza
insulin regular, human	Humulin R Regular U-100 Insulin
insulin regular, human	Humulin R U-500 (Conc) Insulin
insulin regular, human	Humulin R U-500 (Conc) Kwikpen
insulin regular, human	Novolin R FlexPen
insulin regular, human	Novolin R Regular U-100 Insulin
insulin regular, human in 0.9 % sodium chloride	Myxredlin
Oral Antidiabetics	
acarbose	acarbose
acarbose	Precose
alogliptin benzoate	alogliptin
alogliptin benzoate	Nesina
alogliptin benzoate/metformin HCl	alogliptin-metformin
alogliptin benzoate/metformin HCl	Kazano
alogliptin benzoate/pioglitazone HCl	alogliptin-pioglitazone
alogliptin benzoate/pioglitazone HCl	Oseni
bromocriptine mesylate	Cycloset
canagliflozin	Invokana
canagliflozin/metformin HCl	Invokamet
canagliflozin/metformin HCl	Invokamet XR
dapagliflozin propanediol	Farxiga
dapagliflozin propanediol/metformin HCl	Xigduo XR
dapagliflozin propanediol/saxagliptin HCl	Qtern
empagliflozin	Jardiance
empagliflozin/linagliptin	Glyxambi
empagliflozin/linagliptin/metformin HCl	Trijardy XR
empagliflozin/metformin HCl	Synjardy
empagliflozin/metformin HCl	Synjardy XR
ertugliflozin pidolate	Steglatro
ertugliflozin pidolate/metformin HCl	Segluromet
ertugliflozin pidolate/sitagliptin phosphate	Steglujan
glimepiride	Amaryl
glimepiride	glimepiride
glipizide	glipizide
glipizide	Glucotrol
glipizide	Glucotrol XL
glipizide/metformin HCl	glipizide-metformin
glyburide	glyburide
glyburide,micronized	glyburide micronized
glyburide,micronized	Glynase
glyburide/metformin HCl	glyburide-metformin
linagliptin	Tradjenta
linagliptin/metformin HCl	Jentadueto
linagliptin/metformin HCl	Jentadueto XR
metformin HCl	Fortamet
metformin HCl	Glumetza
metformin HCl	metformin
metformin HCl	Riomet

Appendix E. Generic and Brand Names of Medical Products Used to Define Inclusion or Exclusion Criteria in this Request

Generic Name	Brand Name
metformin HCl	Riomet ER
mifepristone	Korlym
miglitol	miglitol
nateglinide	nateglinide
pioglitazone HCl	Actos
pioglitazone HCl	pioglitazone
pioglitazone HCl/glimepiride	DUETACT
pioglitazone HCl/glimepiride	pioglitazone-glimepiride
pioglitazone HCl/metformin HCl	Actoplus MET
pioglitazone HCl/metformin HCl	pioglitazone-metformin
repaglinide	repaglinide
repaglinide/metformin HCl	repaglinide-metformin
saxagliptin HCl	Onglyza
saxagliptin HCl/metformin HCl	Kombiglyze XR
sitagliptin phosphate	Januvia
sitagliptin phosphate/metformin HCl	Janumet
sitagliptin phosphate/metformin HCl	Janumet XR
Non-Oral Antidiabetics	
pramlintide acetate	SymlinPen 60
pramlintide acetate	SymlinPen 120

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

		Code	
Code	Description	Category	Code Type
Alcohol Use or Abuse			
F10	Alcohol related disorders	Diagnosis	ICD-10-CM
F10.1	Alcohol abuse	Diagnosis	ICD-10-CM
F10.10	Alcohol abuse, uncomplicated	Diagnosis	ICD-10-CM
F10.11	Alcohol abuse, in remission	Diagnosis	ICD-10-CM
F10.12	Alcohol abuse with intoxication	Diagnosis	ICD-10-CM
F10.120	Alcohol abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.121	Alcohol abuse with intoxication delirium	Diagnosis	ICD-10-CM
F10.129	Alcohol abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.14	Alcohol abuse with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.15	Alcohol abuse with alcohol-induced psychotic disorder	Diagnosis	ICD-10-CM
F10.150	Alcohol abuse with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.151	Alcohol abuse with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.159	Alcohol abuse with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.18	Alcohol abuse with other alcohol-induced disorders	Diagnosis	ICD-10-CM
F10.180	Alcohol abuse with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.181	Alcohol abuse with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.182	Alcohol abuse with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.188	Alcohol abuse with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.19	Alcohol abuse with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.2	Alcohol dependence	Diagnosis	ICD-10-CM
F10.20	Alcohol dependence, uncomplicated	Diagnosis	ICD-10-CM
F10.21	Alcohol dependence, in remission	Diagnosis	ICD-10-CM
F10.22	Alcohol dependence with intoxication	Diagnosis	ICD-10-CM
F10.220	Alcohol dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.221	Alcohol dependence with intoxication delirium	Diagnosis	ICD-10-CM
F10.229	Alcohol dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.23	Alcohol dependence with withdrawal	Diagnosis	ICD-10-CM
F10.230	Alcohol dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.231	Alcohol dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F10.232	Alcohol dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.239	Alcohol dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.24	Alcohol dependence with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.25	Alcohol dependence with alcohol-induced psychotic disorder	Diagnosis	ICD-10-CM
F10.250	Alcohol dependence with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.251	Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.259	Alcohol dependence with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.26	Alcohol dependence with alcohol-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F10.27	Alcohol dependence with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.28	Alcohol dependence with other alcohol-induced disorders	Diagnosis	ICD-10-CM
F10.280	Alcohol dependence with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.281	Alcohol dependence with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
F10.282	Alcohol dependence with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.288	Alcohol dependence with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.29	Alcohol dependence with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.9	Alcohol use, unspecified	Diagnosis	ICD-10-CM
F10.92	Alcohol use, unspecified with intoxication	Diagnosis	ICD-10-CM
F10.920	Alcohol use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.921	Alcohol use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F10.929	Alcohol use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.94	Alcohol use, unspecified with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.95	Alcohol use, unspecified with alcohol-induced psychotic disorder	Diagnosis	ICD-10-CM
F10.950	Alcohol use, unspecified with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.951	Alcohol use, unspecified with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.959	Alcohol use, unspecified with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.96	Alcohol use, unspecified with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.97	Alcohol use, unspecified with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.98	Alcohol use, unspecified with other alcohol-induced disorders	Diagnosis	ICD-10-CM
F10.980	Alcohol use, unspecified with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.981	Alcohol use, unspecified with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.982	Alcohol use, unspecified with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.988	Alcohol use, unspecified with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.99	Alcohol use, unspecified with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
G62.1	Alcoholic polyneuropathy	Diagnosis	ICD-10-CM
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
K29.2	Alcoholic gastritis	Diagnosis	ICD-10-CM
K29.20	Alcoholic gastritis without bleeding	Diagnosis	ICD-10-CM
K29.21	Alcoholic gastritis with bleeding	Diagnosis	ICD-10-CM
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.3	Alcoholic cirrhosis of liver	Diagnosis	ICD-10-CM
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM
R78.0	Finding of alcohol in blood	Diagnosis	ICD-10-CM
T51	Toxic effect of alcohol	Diagnosis	ICD-10-CM
T51.0	Toxic effect of ethanol	Diagnosis	ICD-10-CM
T51.0X	Toxic effect of ethanol	Diagnosis	ICD-10-CM
T51.0X1	Toxic effect of ethanol, accidental (unintentional)	Diagnosis	ICD-10-CM
T51.0X1A	Toxic effect of ethanol, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
T51.0X1D	Toxic effect of ethanol, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T51.0X1S	Toxic effect of ethanol, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T51.0X2	Toxic effect of ethanol, intentional self-harm	Diagnosis	ICD-10-CM
T51.0X2A	Toxic effect of ethanol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T51.0X2D	Toxic effect of ethanol, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T51.0X2S	Toxic effect of ethanol, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T51.0X3	Toxic effect of ethanol, assault	Diagnosis	ICD-10-CM
T51.0X3A	Toxic effect of ethanol, assault, initial encounter	Diagnosis	ICD-10-CM
T51.0X3D	Toxic effect of ethanol, assault, subsequent encounter	Diagnosis	ICD-10-CM
T51.0X3S	Toxic effect of ethanol, assault, sequela	Diagnosis	ICD-10-CM
T51.0X4	Toxic effect of ethanol, undetermined	Diagnosis	ICD-10-CM
T51.0X4A	Toxic effect of ethanol, undetermined, initial encounter	Diagnosis	ICD-10-CM
T51.0X4D	Toxic effect of ethanol, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T51.0X4S	Toxic effect of ethanol, undetermined, sequela	Diagnosis	ICD-10-CM
T51.8	Toxic effect of other alcohols	Diagnosis	ICD-10-CM
T51.8X	Toxic effect of other alcohols	Diagnosis	ICD-10-CM
T51.8X1	Toxic effect of other alcohols, accidental (unintentional)	Diagnosis	ICD-10-CM
T51.8X1A	Toxic effect of other alcohols, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T51.8X1D	Toxic effect of other alcohols, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T51.8X1S	Toxic effect of other alcohols, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T51.8X2	Toxic effect of other alcohols, intentional self-harm	Diagnosis	ICD-10-CM
T51.8X2A	Toxic effect of other alcohols, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T51.8X2D	Toxic effect of other alcohols, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T51.8X2S	Toxic effect of other alcohols, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T51.8X3	Toxic effect of other alcohols, assault	Diagnosis	ICD-10-CM
T51.8X3A	Toxic effect of other alcohols, assault, initial encounter	Diagnosis	ICD-10-CM
T51.8X3D	Toxic effect of other alcohols, assault, subsequent encounter	Diagnosis	ICD-10-CM
T51.8X3S	Toxic effect of other alcohols, assault, sequela	Diagnosis	ICD-10-CM
T51.8X4	Toxic effect of other alcohols, undetermined	Diagnosis	ICD-10-CM
T51.8X4A	Toxic effect of other alcohols, undetermined, initial encounter	Diagnosis	ICD-10-CM
T51.8X4D	Toxic effect of other alcohols, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T51.8X4S	Toxic effect of other alcohols, undetermined, sequela	Diagnosis	ICD-10-CM
T51.9	Toxic effect of unspecified alcohol	Diagnosis	ICD-10-CM
T51.91	Toxic effect of unspecified alcohol, accidental (unintentional)	Diagnosis	ICD-10-CM
T51.91XA	Toxic effect of unspecified alcohol, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T51.91XD	Toxic effect of unspecified alcohol, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T51.91XS	Toxic effect of unspecified alcohol, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T51.92	Toxic effect of unspecified alcohol, intentional self-harm	Diagnosis	ICD-10-CM
T51.92XA	Toxic effect of unspecified alcohol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T51.92XD	Toxic effect of unspecified alcohol, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T51.92XS	Toxic effect of unspecified alcohol, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T51.93	Toxic effect of unspecified alcohol, assault	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
T51.93XA	Toxic effect of unspecified alcohol, assault, initial encounter	Diagnosis	ICD-10-CM
T51.93XD	Toxic effect of unspecified alcohol, assault, subsequent encounter	Diagnosis	ICD-10-CM
T51.93XS	Toxic effect of unspecified alcohol, assault, sequela	Diagnosis	ICD-10-CM
T51.94	Toxic effect of unspecified alcohol, undetermined	Diagnosis	ICD-10-CM
T51.94XA	Toxic effect of unspecified alcohol, undetermined, initial encounter	Diagnosis	ICD-10-CM
T51.94XD	Toxic effect of unspecified alcohol, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T51.94XS	Toxic effect of unspecified alcohol, undetermined, sequela	Diagnosis	ICD-10-CM
Z71.4	Alcohol abuse counseling and surveillance	Diagnosis	ICD-10-CM
Obesity			
Z68.3	Body mass index [BMI] 30-39, adult	Diagnosis	ICD-10-CM
Z68.4	Body mass index [BMI] 40 or greater, adult	Diagnosis	ICD-10-CM
E66.01	Morbid (severe) obesity due to excess calories	Diagnosis	ICD-10-CM
E66.09	Other obesity due to excess calories	Diagnosis	ICD-10-CM
E66.1	Drug-induced obesity	Diagnosis	ICD-10-CM
E66.2	Morbid (severe) obesity with alveolar hypoventilation	Diagnosis	ICD-10-CM
E66.8	Other obesity	Diagnosis	ICD-10-CM
E66.9	Obesity, unspecified	Diagnosis	ICD-10-CM
K95.01	Infection due to gastric band procedure	Diagnosis	ICD-10-CM
K95.09	Other complications of gastric band procedure	Diagnosis	ICD-10-CM
K95.81	Infection due to other bariatric procedure	Diagnosis	ICD-10-CM
K95.89	Other complications of other bariatric procedure	Diagnosis	ICD-10-CM
O99.840	Bariatric surgery status complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.841	Bariatric surgery status complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.842	Bariatric surgery status complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.843	Bariatric surgery status complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.844	Bariatric surgery status complicating childbirth	Diagnosis	ICD-10-CM
O99.845	Bariatric surgery status complicating the puerperium	Diagnosis	ICD-10-CM
Z68.30	Body mass index [BMI] 30.0-30.9, adult	Diagnosis	ICD-10-CM
Z68.31	Body mass index [BMI] 31.0-31.9, adult	Diagnosis	ICD-10-CM
Z68.32	Body mass index [BMI] 32.0-32.9, adult	Diagnosis	ICD-10-CM
Z68.33	Body mass index [BMI] 33.0-33.9, adult	Diagnosis	ICD-10-CM
Z68.34	Body mass index [BMI] 34.0-34.9, adult	Diagnosis	ICD-10-CM
Z68.35	Body mass index [BMI] 35.0-35.9, adult	Diagnosis	ICD-10-CM
Z68.36	Body mass index [BMI] 36.0-36.9, adult	Diagnosis	ICD-10-CM
Z68.37	Body mass index [BMI] 37.0-37.9, adult	Diagnosis	ICD-10-CM
Z68.38	Body mass index [BMI] 38.0-38.9, adult	Diagnosis	ICD-10-CM
Z68.39	Body mass index [BMI] 39.0-39.9, adult	Diagnosis	ICD-10-CM
Z68.41	Body mass index [BMI] 40.0-44.9, adult	Diagnosis	ICD-10-CM
Z68.42	Body mass index [BMI] 45.0-49.9, adult	Diagnosis	ICD-10-CM
Z68.43	Body mass index [BMI] 50.0-59.9, adult	Diagnosis	ICD-10-CM
Z68.44	Body mass index [BMI] 60.0-69.9, adult	Diagnosis	ICD-10-CM
Z68.45	Body mass index [BMI] 70 or greater, adult	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
Z98.84	Bariatric surgery status	Diagnosis	ICD-10-CM
0D16079	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160J9	Bypass Stomach to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JA	Bypass Stomach to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JB	Bypass Stomach to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160Z9	Bypass Stomach to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D160ZA	Bypass Stomach to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D160ZB	Bypass Stomach to Ileum, Open Approach	Procedure	ICD-10-PCS
0D160ZL	Bypass Stomach to Transverse Colon, Open Approach	Procedure	ICD-10-PCS
0D16479	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164J9	Bypass Stomach to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JA	Bypass Stomach to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JB	Bypass Stomach to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164Z9	Bypass Stomach to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZA	Bypass Stomach to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZB	Bypass Stomach to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
0D164ZL	Bypass Stomach to Transverse Colon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D16879	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168J9	Bypass Stomach to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JA	Bypass Stomach to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JB	Bypass Stomach to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168Z9	Bypass Stomach to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZA	Bypass Stomach to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZB	Bypass Stomach to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZL	Bypass Stomach to Transverse Colon, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D19079	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190JB	Bypass Duodenum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190Z9	Bypass Duodenum to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D190ZA	Bypass Duodenum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D190ZB	Bypass Duodenum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D19479	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
0D1947A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1947B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194JB	Bypass Duodenum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194Z9	Bypass Duodenum to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194ZA	Bypass Duodenum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194ZB	Bypass Duodenum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D19879	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1987A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1987B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198JB	Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198Z9	Bypass Duodenum to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198ZA	Bypass Duodenum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198ZB	Bypass Duodenum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A07A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A07B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0JB	Bypass Jejunum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
0D1A0KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0ZA	Bypass Jejunum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D1A0ZB	Bypass Jejunum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1A47A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A47B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4JB	Bypass Jejunum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZA	Bypass Jejunum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZB	Bypass Jejunum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A87A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A87B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8JB	Bypass Jejunum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZA	Bypass Jejunum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZB	Bypass Jejunum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B07B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0JB	Bypass Ileum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0ZB	Bypass Ileum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1B47B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4JB	Bypass Ileum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4ZB	Bypass Ileum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B87B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
0D1B8JB	Bypass Ileum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8ZB	Bypass Ileum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8ZH	Bypass Ileum to Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DB60Z3	Excision of Stomach, Open Approach, Vertical	Procedure	ICD-10-PCS
0DB60ZZ	Excision of Stomach, Open Approach	Procedure	ICD-10-PCS
0DB63Z3	Excision of Stomach, Percutaneous Approach, Vertical	Procedure	ICD-10-PCS
0DB63ZZ	Excision of Stomach, Percutaneous Approach	Procedure	ICD-10-PCS
0DB67Z3	Excision of Stomach, Via Natural or Artificial Opening, Vertical	Procedure	ICD-10-PCS
0DB67ZZ	Excision of Stomach, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DB68Z3	Excision of Stomach, Via Natural or Artificial Opening Endoscopic, Vertical	Procedure	ICD-10-PCS
0DB80ZZ	Excision of Small Intestine, Open Approach	Procedure	ICD-10-PCS
0DBB0ZZ	Excision of Ileum, Open Approach	Procedure	ICD-10-PCS
0DV64CZ	Restriction of Stomach with Extraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0F190Z3	Bypass Common Bile Duct to Duodenum, Open Approach	Procedure	ICD-10-PCS
0TRB07Z	Replacement of Bladder with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
43644	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (roux limb 150 cm or less)	Procedure	CPT-4
43645	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption	Procedure	CPT-4
43770	Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (eg, gastric band and subcutaneous port components)	Procedure	CPT-4
43842	Gastric restrictive procedure, without gastric bypass, for morbid obesity; vertical-banded gastroplasty	Procedure	CPT-4
43843	Gastric restrictive procedure, without gastric bypass, for morbid obesity; other than vertical-banded gastroplasty	Procedure	CPT-4
43845	Gastric restrictive procedure with partial gastrectomy, pylorus-preserving duodenoileostomy and ileoileostomy (50 to 100 cm common channel) to limit absorption (biliopancreatic diversion with duodenal switch)	Procedure	CPT-4
43846	Gastric restrictive procedure, with gastric bypass for morbid obesity; with short limb (150 cm or less) Roux-en-Y gastroenterostomy	Procedure	CPT-4
43847	Gastric restrictive procedure, with gastric bypass for morbid obesity; with small intestine reconstruction to limit absorption	Procedure	CPT-4
Tobacco Use			
F17.200	Nicotine dependence, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F17.201	Nicotine dependence, unspecified, in remission	Diagnosis	ICD-10-CM
F17.203	Nicotine dependence unspecified, with withdrawal	Diagnosis	ICD-10-CM
F17.208	Nicotine dependence, unspecified, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.209	Nicotine dependence, unspecified, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.21	Nicotine dependence, cigarettes	Diagnosis	ICD-10-CM
F17.210	Nicotine dependence, cigarettes, uncomplicated	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
F17.211	Nicotine dependence, cigarettes, in remission	Diagnosis	ICD-10-CM
F17.213	Nicotine dependence, cigarettes, with withdrawal	Diagnosis	ICD-10-CM
F17.218	Nicotine dependence, cigarettes, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.219	Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.22	Nicotine dependence, chewing tobacco	Diagnosis	ICD-10-CM
F17.220	Nicotine dependence, chewing tobacco, uncomplicated	Diagnosis	ICD-10-CM
F17.221	Nicotine dependence, chewing tobacco, in remission	Diagnosis	ICD-10-CM
F17.223	Nicotine dependence, chewing tobacco, with withdrawal	Diagnosis	ICD-10-CM
F17.228	Nicotine dependence, chewing tobacco, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.229	Nicotine dependence, chewing tobacco, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.29	Nicotine dependence, other tobacco product	Diagnosis	ICD-10-CM
F17.290	Nicotine dependence, other tobacco product, uncomplicated	Diagnosis	ICD-10-CM
F17.291	Nicotine dependence, other tobacco product, in remission	Diagnosis	ICD-10-CM
F17.293	Nicotine dependence, other tobacco product, with withdrawal	Diagnosis	ICD-10-CM
F17.298	Nicotine dependence, other tobacco product, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.299	Nicotine dependence, other tobacco product, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
T65.21	Toxic effect of chewing tobacco	Diagnosis	ICD-10-CM
T65.211	Toxic effect of chewing tobacco, accidental (unintentional)	Diagnosis	ICD-10-CM
T65.211A	Toxic effect of chewing tobacco, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.211D	Toxic effect of chewing tobacco, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T65.211S	Toxic effect of chewing tobacco, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T65.212	Toxic effect of chewing tobacco, intentional self-harm	Diagnosis	ICD-10-CM
T65.212A	Toxic effect of chewing tobacco, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.212D	Toxic effect of chewing tobacco, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.212S	Toxic effect of chewing tobacco, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.213	Toxic effect of chewing tobacco, assault	Diagnosis	ICD-10-CM
T65.213A	Toxic effect of chewing tobacco, assault, initial encounter	Diagnosis	ICD-10-CM
T65.213D	Toxic effect of chewing tobacco, assault, subsequent encounter	Diagnosis	ICD-10-CM
T65.213S	Toxic effect of chewing tobacco, assault, sequela	Diagnosis	ICD-10-CM
T65.214	Toxic effect of chewing tobacco, undetermined	Diagnosis	ICD-10-CM
T65.214A	Toxic effect of chewing tobacco, undetermined, initial encounter	Diagnosis	ICD-10-CM
T65.214D	Toxic effect of chewing tobacco, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T65.214S	Toxic effect of chewing tobacco, undetermined, sequela	Diagnosis	ICD-10-CM
T65.221A	Toxic effect of tobacco cigarettes, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.221D	Toxic effect of tobacco cigarettes, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T65.221S	Toxic effect of tobacco cigarettes, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T65.222A	Toxic effect of tobacco cigarettes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.222D	Toxic effect of tobacco cigarettes, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.222S	Toxic effect of tobacco cigarettes, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.223A	Toxic effect of tobacco cigarettes, assault, initial encounter	Diagnosis	ICD-10-CM
T65.223D	Toxic effect of tobacco cigarettes, assault, subsequent encounter	Diagnosis	ICD-10-CM
T65.223S	Toxic effect of tobacco cigarettes, assault, sequela	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
T65.224A	Toxic effect of tobacco cigarettes, undetermined, initial encounter	Diagnosis	ICD-10-CM
T65.224D	Toxic effect of tobacco cigarettes, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T65.224S	Toxic effect of tobacco cigarettes, undetermined, sequela	Diagnosis	ICD-10-CM
T65.291A	Toxic effect of other tobacco and nicotine, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.291D	Toxic effect of other tobacco and nicotine, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T65.291S	Toxic effect of other tobacco and nicotine, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T65.292A	Toxic effect of other tobacco and nicotine, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.292D	Toxic effect of other tobacco and nicotine, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T65.292S	Toxic effect of other tobacco and nicotine, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T65.293A	Toxic effect of other tobacco and nicotine, assault, initial encounter	Diagnosis	ICD-10-CM
T65.293D	Toxic effect of other tobacco and nicotine, assault, subsequent encounter	Diagnosis	ICD-10-CM
T65.293S	Toxic effect of other tobacco and nicotine, assault, sequela	Diagnosis	ICD-10-CM
T65.294A	Toxic effect of other tobacco and nicotine, undetermined, initial encounter	Diagnosis	ICD-10-CM
T65.294D	Toxic effect of other tobacco and nicotine, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T65.294S	Toxic effect of other tobacco and nicotine, undetermined, sequela	Diagnosis	ICD-10-CM
Z71.6	Tobacco abuse counseling	Diagnosis	ICD-10-CM
Z72.0	Tobacco use	Diagnosis	ICD-10-CM
Z87.891	Personal history of nicotine dependence	Diagnosis	ICD-10-CM
S9453	Smoking cessation classes, nonphysician provider, per session	Procedure	HCPCS
1032F	Current tobacco smoker or currently exposed to secondhand smoke (asthma)	Procedure	HCPCS
1034F	Current tobacco smoker (cad, cap, copd, pv) (dm)	Procedure	HCPCS
1035F	Current smokeless tobacco user (eg, chew, snuff) (pv)	Procedure	HCPCS
4000F	Tobacco use cessation intervention, counseling (copd, cap, cad, asthma) (dm) (pv)	Procedure	HCPCS
4001F	Tobacco use cessation intervention, pharmacologic therapy (copd, cad, cap, pv, asthma) (dm) (pv)	Procedure	HCPCS
4004F	Patient screened for tobacco use and received tobacco cessation intervention (counseling, pharmacotherapy, or both), if identified as a tobacco user (pv, cad)	Procedure	HCPCS
99406	Smoking and tobacco use intermediate counseling, greater than 3 minutes up to 10 minutes	Procedure	HCPCS
99407	Smoking and tobacco use intensive counseling, greater than 10 minutes	Procedure	HCPCS
C9801	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intermediate, greater than 3 minutes, up to 10 minutes	Procedure	HCPCS
C9802	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intensive, greater than 10 minutes	Procedure	HCPCS
D1320	Tobacco counseling for the control and prevention of oral disease	Procedure	HCPCS
G0375	SMOKING AND TOBACCO USE CESSATION COUNSELING VISIT; INTERMEDIATE, GREATER THAN 3 MINUTES UP TO 10 MINUTES	Procedure	HCPCS
G0376	SMOKING AND TOBACCO USE CESSATION COUNSELING VISIT; INTENSIVE, GREATER THAN 10 MINUTES	Procedure	HCPCS
G0436	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intermediate, greater than 3 minutes, up to 10 minutes	Procedure	HCPCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
G0437	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intensive, greater than 10 minutes	Procedure	HCPCS
G8093	Newly diagnosed chronic obstructive pulmonary disease (copd) patient documented to have received smoking cessation intervention, within 3 months of diagnosis	Procedure	HCPCS
G8094	Newly diagnosed chronic obstructive pulmonary disease (copd) patient not documented to have received smoking cessation intervention, within 3 months of diagnosis	Procedure	HCPCS
G8402	Tobacco (smoke) use cessation intervention, counseling	Procedure	HCPCS
G8403	Tobacco (smoke) use cessation intervention not counseled	Procedure	HCPCS
G8453	Tobacco use cessation intervention, counseling	Procedure	HCPCS
G8454	Tobacco use cessation intervention not counseled, reason not specified	Procedure	HCPCS
G8455	Current tobacco smoker	Procedure	HCPCS
G8456	Current smokeless tobacco user	Procedure	HCPCS
G8686	Currently a tobacco smoker or current exposure to secondhand smoke	Procedure	HCPCS
G8688	Currently a smokeless tobacco user (eg, chew, snuff) and no exposure to secondhand smoke	Procedure	HCPCS
G8690	Current tobacco smoker or current exposure to secondhand smoke	Procedure	HCPCS
G8692	Current smokeless tobacco user (eg, chew, snuff) and no exposure to secondhand smoke	Procedure	HCPCS
G9016	Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) âdemo project code only	Procedure	HCPCS
G9276	Documentation that patient is a current tobacco user	Procedure	HCPCS
G9458	Patient documented as tobacco user and received tobacco cessation intervention (must include at least one of the following: advice given to quit smoking or tobacco use, counseling on the benefits of q	Procedure	HCPCS
G9645	Patients who did not abstain from smoking prior to anesthesia on the day of surgery or procedure	Procedure	HCPCS
G9792	Most recent tobacco status is not tobacco free	Procedure	HCPCS
G9902	Patient screened for tobacco use and identified as a tobacco user	Procedure	HCPCS
G9906	Patient identified as a tobacco user received tobacco cessation intervention (counseling and/or pharmacotherapy)	Procedure	HCPCS
G9908	Patient identified as tobacco user did not receive tobacco cessation intervention (counseling and/or pharmacotherapy), reason not given	Procedure	HCPCS
G9909	Documentation of medical reason(s) for not providing tobacco cessation intervention if identified as a tobacco user (eg, limited life expectancy, other medical reason)	Procedure	HCPCS
S4990	Nicotine patches, legend	Procedure	HCPCS
S4991	Nicotine patches, non-legend	Procedure	HCPCS
S4995	Smoking cessation gum	Procedure	HCPCS
S9075	Smoking cessation treatment	Procedure	HCPCS
Arrhythmia			
I44	Atrioventricular and left bundle-branch block	Diagnosis	ICD-10-CM
I44.0	Atrioventricular block, first degree	Diagnosis	ICD-10-CM
I44.1	Atrioventricular block, second degree	Diagnosis	ICD-10-CM
I44.2	Atrioventricular block, complete	Diagnosis	ICD-10-CM
I44.3	Other and unspecified atrioventricular block	Diagnosis	ICD-10-CM
I44.30	Unspecified atrioventricular block	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I44.39	Other atrioventricular block	Diagnosis	ICD-10-CM
I44.4	Left anterior fascicular block	Diagnosis	ICD-10-CM
I44.5	Left posterior fascicular block	Diagnosis	ICD-10-CM
I44.6	Other and unspecified fascicular block	Diagnosis	ICD-10-CM
I44.60	Unspecified fascicular block	Diagnosis	ICD-10-CM
I44.69	Other fascicular block	Diagnosis	ICD-10-CM
I44.7	Left bundle-branch block, unspecified	Diagnosis	ICD-10-CM
I45	Other conduction disorders	Diagnosis	ICD-10-CM
I45.0	Right fascicular block	Diagnosis	ICD-10-CM
I45.1	Other and unspecified right bundle-branch block	Diagnosis	ICD-10-CM
I45.10	Unspecified right bundle-branch block	Diagnosis	ICD-10-CM
I45.19	Other right bundle-branch block	Diagnosis	ICD-10-CM
I45.2	Bifascicular block	Diagnosis	ICD-10-CM
I45.3	Trifascicular block	Diagnosis	ICD-10-CM
I45.4	Nonspecific intraventricular block	Diagnosis	ICD-10-CM
I45.5	Other specified heart block	Diagnosis	ICD-10-CM
I45.6	Pre-excitation syndrome	Diagnosis	ICD-10-CM
I45.8	Other specified conduction disorders	Diagnosis	ICD-10-CM
I45.89	Other specified conduction disorders	Diagnosis	ICD-10-CM
I45.9	Conduction disorder, unspecified	Diagnosis	ICD-10-CM
I46	Cardiac arrest	Diagnosis	ICD-10-CM
I46.2	Cardiac arrest due to underlying cardiac condition	Diagnosis	ICD-10-CM
I46.8	Cardiac arrest due to other underlying condition	Diagnosis	ICD-10-CM
I46.9	Cardiac arrest, cause unspecified	Diagnosis	ICD-10-CM
I47	Paroxysmal tachycardia	Diagnosis	ICD-10-CM
I47.0	Re-entry ventricular arrhythmia	Diagnosis	ICD-10-CM
I47.1	Supraventricular tachycardia	Diagnosis	ICD-10-CM
I47.2	Ventricular tachycardia	Diagnosis	ICD-10-CM
I47.9	Paroxysmal tachycardia, unspecified	Diagnosis	ICD-10-CM
I48	Atrial fibrillation and flutter	Diagnosis	ICD-10-CM
I48.0	Paroxysmal atrial fibrillation	Diagnosis	ICD-10-CM
I48.1	Persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.11	Longstanding persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.19	Other persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.2	Chronic atrial fibrillation	Diagnosis	ICD-10-CM
I48.20	Chronic atrial fibrillation, unspecified	Diagnosis	ICD-10-CM
I48.21	Permanent atrial fibrillation	Diagnosis	ICD-10-CM
I48.3	Typical atrial flutter	Diagnosis	ICD-10-CM
I48.4	Atypical atrial flutter	Diagnosis	ICD-10-CM
I48.9	Unspecified atrial fibrillation and atrial flutter	Diagnosis	ICD-10-CM
I48.91	Unspecified atrial fibrillation	Diagnosis	ICD-10-CM
I48.92	Unspecified atrial flutter	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I49	Other cardiac arrhythmias	Diagnosis	ICD-10-CM
I49.0	Ventricular fibrillation and flutter	Diagnosis	ICD-10-CM
I49.01	Ventricular fibrillation	Diagnosis	ICD-10-CM
I49.02	Ventricular flutter	Diagnosis	ICD-10-CM
I49.1	Atrial premature depolarization	Diagnosis	ICD-10-CM
I49.2	Junctional premature depolarization	Diagnosis	ICD-10-CM
I49.3	Ventricular premature depolarization	Diagnosis	ICD-10-CM
I49.4	Other and unspecified premature depolarization	Diagnosis	ICD-10-CM
I49.40	Unspecified premature depolarization	Diagnosis	ICD-10-CM
I49.49	Other premature depolarization	Diagnosis	ICD-10-CM
I49.5	Sick sinus syndrome	Diagnosis	ICD-10-CM
I49.8	Other specified cardiac arrhythmias	Diagnosis	ICD-10-CM
I49.9	Cardiac arrhythmia, unspecified	Diagnosis	ICD-10-CM
R00	Abnormalities of heart beat	Diagnosis	ICD-10-CM
R00.0	Tachycardia, unspecified	Diagnosis	ICD-10-CM
R00.1	Bradycardia, unspecified	Diagnosis	ICD-10-CM
R00.2	Palpitations	Diagnosis	ICD-10-CM
R00.8	Other abnormalities of heart beat	Diagnosis	ICD-10-CM
R00.9	Unspecified abnormalities of heart beat	Diagnosis	ICD-10-CM
Cerebrovascular Disease/Stroke/Transient Ischemic Attack			
G43.5	Persistent migraine aura without cerebral infarction	Diagnosis	ICD-10-CM
G43.50	Persistent migraine aura without cerebral infarction, not intractable	Diagnosis	ICD-10-CM
G43.501	Persistent migraine aura without cerebral infarction, not intractable, with status migrainosus	Diagnosis	ICD-10-CM
G43.509	Persistent migraine aura without cerebral infarction, not intractable, without status migrainosus	Diagnosis	ICD-10-CM
G43.51	Persistent migraine aura without cerebral infarction, intractable	Diagnosis	ICD-10-CM
G43.511	Persistent migraine aura without cerebral infarction, intractable, with status migrainosus	Diagnosis	ICD-10-CM
G43.519	Persistent migraine aura without cerebral infarction, intractable, without status migrainosus	Diagnosis	ICD-10-CM
G43.6	Persistent migraine aura with cerebral infarction	Diagnosis	ICD-10-CM
G43.60	Persistent migraine aura with cerebral infarction, not intractable	Diagnosis	ICD-10-CM
G43.601	Persistent migraine aura with cerebral infarction, not intractable, with status migrainosus	Diagnosis	ICD-10-CM
G43.609	Persistent migraine aura with cerebral infarction, not intractable, without status migrainosus	Diagnosis	ICD-10-CM
G43.61	Persistent migraine aura with cerebral infarction, intractable	Diagnosis	ICD-10-CM
G43.611	Persistent migraine aura with cerebral infarction, intractable, with status migrainosus	Diagnosis	ICD-10-CM
G43.619	Persistent migraine aura with cerebral infarction, intractable, without status migrainosus	Diagnosis	ICD-10-CM
G45	Transient cerebral ischemic attacks and related syndromes	Diagnosis	ICD-10-CM
G45.0	Vertebro-basilar artery syndrome	Diagnosis	ICD-10-CM
G45.1	Carotid artery syndrome (hemispheric)	Diagnosis	ICD-10-CM
G45.2	Multiple and bilateral precerebral artery syndromes	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
G45.3	Amaurosis fugax	Diagnosis	ICD-10-CM
G45.4	Transient global amnesia	Diagnosis	ICD-10-CM
G45.8	Other transient cerebral ischemic attacks and related syndromes	Diagnosis	ICD-10-CM
G45.9	Transient cerebral ischemic attack, unspecified	Diagnosis	ICD-10-CM
G46.0	Middle cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.1	Anterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.2	Posterior cerebral artery syndrome	Diagnosis	ICD-10-CM
I60	Nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I60.0	Nontraumatic subarachnoid hemorrhage from carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.00	Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.01	Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.02	Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.1	Nontraumatic subarachnoid hemorrhage from middle cerebral artery	Diagnosis	ICD-10-CM
I60.10	Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I60.11	Nontraumatic subarachnoid hemorrhage from right middle cerebral artery	Diagnosis	ICD-10-CM
I60.12	Nontraumatic subarachnoid hemorrhage from left middle cerebral artery	Diagnosis	ICD-10-CM
I60.2	Nontraumatic subarachnoid hemorrhage from anterior communicating artery	Diagnosis	ICD-10-CM
I60.20	Nontraumatic subarachnoid hemorrhage from unspecified anterior communicating artery	Diagnosis	ICD-10-CM
I60.21	Nontraumatic subarachnoid hemorrhage from right anterior communicating artery	Diagnosis	ICD-10-CM
I60.22	Nontraumatic subarachnoid hemorrhage from left anterior communicating artery	Diagnosis	ICD-10-CM
I60.3	Nontraumatic subarachnoid hemorrhage from posterior communicating artery	Diagnosis	ICD-10-CM
I60.30	Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating artery	Diagnosis	ICD-10-CM
I60.31	Nontraumatic subarachnoid hemorrhage from right posterior communicating artery	Diagnosis	ICD-10-CM
I60.32	Nontraumatic subarachnoid hemorrhage from left posterior communicating artery	Diagnosis	ICD-10-CM
I60.4	Nontraumatic subarachnoid hemorrhage from basilar artery	Diagnosis	ICD-10-CM
I60.5	Nontraumatic subarachnoid hemorrhage from vertebral artery	Diagnosis	ICD-10-CM
I60.50	Nontraumatic subarachnoid hemorrhage from unspecified vertebral artery	Diagnosis	ICD-10-CM
I60.51	Nontraumatic subarachnoid hemorrhage from right vertebral artery	Diagnosis	ICD-10-CM
I60.52	Nontraumatic subarachnoid hemorrhage from left vertebral artery	Diagnosis	ICD-10-CM
I60.6	Nontraumatic subarachnoid hemorrhage from other intracranial arteries	Diagnosis	ICD-10-CM
I60.7	Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery	Diagnosis	ICD-10-CM
I60.8	Other nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I60.9	Nontraumatic subarachnoid hemorrhage, unspecified	Diagnosis	ICD-10-CM
I61	Nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I61.0	Nontraumatic intracerebral hemorrhage in hemisphere, subcortical	Diagnosis	ICD-10-CM
I61.1	Nontraumatic intracerebral hemorrhage in hemisphere, cortical	Diagnosis	ICD-10-CM
I61.2	Nontraumatic intracerebral hemorrhage in hemisphere, unspecified	Diagnosis	ICD-10-CM
I61.3	Nontraumatic intracerebral hemorrhage in brain stem	Diagnosis	ICD-10-CM
I61.4	Nontraumatic intracerebral hemorrhage in cerebellum	Diagnosis	ICD-10-CM
I61.5	Nontraumatic intracerebral hemorrhage, intraventricular	Diagnosis	ICD-10-CM
I61.6	Nontraumatic intracerebral hemorrhage, multiple localized	Diagnosis	ICD-10-CM
I61.8	Other nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I61.9	Nontraumatic intracerebral hemorrhage, unspecified	Diagnosis	ICD-10-CM
I62	Other and unspecified nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I62.0	Nontraumatic subdural hemorrhage	Diagnosis	ICD-10-CM
I62.00	Nontraumatic subdural hemorrhage, unspecified	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I62.01	Nontraumatic acute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.02	Nontraumatic subacute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.03	Nontraumatic chronic subdural hemorrhage	Diagnosis	ICD-10-CM
I62.1	Nontraumatic extradural hemorrhage	Diagnosis	ICD-10-CM
I62.9	Nontraumatic intracranial hemorrhage, unspecified	Diagnosis	ICD-10-CM
I63	Cerebral infarction	Diagnosis	ICD-10-CM
I63.0	Cerebral infarction due to thrombosis of precerebral arteries	Diagnosis	ICD-10-CM
I63.00	Cerebral infarction due to thrombosis of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.01	Cerebral infarction due to thrombosis of vertebral artery	Diagnosis	ICD-10-CM
I63.011	Cerebral infarction due to thrombosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.012	Cerebral infarction due to thrombosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.013	Cerebral infarction due to thrombosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.019	Cerebral infarction due to thrombosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.02	Cerebral infarction due to thrombosis of basilar artery	Diagnosis	ICD-10-CM
I63.03	Cerebral infarction due to thrombosis of carotid artery	Diagnosis	ICD-10-CM
I63.031	Cerebral infarction due to thrombosis of right carotid artery	Diagnosis	ICD-10-CM
I63.032	Cerebral infarction due to thrombosis of left carotid artery	Diagnosis	ICD-10-CM
I63.033	Cerebral infarction due to thrombosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.039	Cerebral infarction due to thrombosis of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.09	Cerebral infarction due to thrombosis of other precerebral artery	Diagnosis	ICD-10-CM
I63.1	Cerebral infarction due to embolism of precerebral arteries	Diagnosis	ICD-10-CM
I63.10	Cerebral infarction due to embolism of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.11	Cerebral infarction due to embolism of vertebral artery	Diagnosis	ICD-10-CM
I63.111	Cerebral infarction due to embolism of right vertebral artery	Diagnosis	ICD-10-CM
I63.112	Cerebral infarction due to embolism of left vertebral artery	Diagnosis	ICD-10-CM
I63.113	Cerebral infarction due to embolism of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.119	Cerebral infarction due to embolism of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.12	Cerebral infarction due to embolism of basilar artery	Diagnosis	ICD-10-CM
I63.13	Cerebral infarction due to embolism of carotid artery	Diagnosis	ICD-10-CM
I63.131	Cerebral infarction due to embolism of right carotid artery	Diagnosis	ICD-10-CM
I63.132	Cerebral infarction due to embolism of left carotid artery	Diagnosis	ICD-10-CM
I63.133	Cerebral infarction due to embolism of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.139	Cerebral infarction due to embolism of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.19	Cerebral infarction due to embolism of other precerebral artery	Diagnosis	ICD-10-CM
I63.2	Cerebral infarction due to unspecified occlusion or stenosis of precerebral arteries	Diagnosis	ICD-10-CM
I63.20	Cerebral infarction due to unspecified occlusion or stenosis of unspecified precerebral arteries	Diagnosis	ICD-10-CM
I63.21	Cerebral infarction due to unspecified occlusion or stenosis of vertebral arteries	Diagnosis	ICD-10-CM
I63.211	Cerebral infarction due to unspecified occlusion or stenosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.212	Cerebral infarction due to unspecified occlusion or stenosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.213	Cerebral infarction due to unspecified occlusion or stenosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.219	Cerebral infarction due to unspecified occlusion or stenosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.22	Cerebral infarction due to unspecified occlusion or stenosis of basilar artery	Diagnosis	ICD-10-CM
I63.23	Cerebral infarction due to unspecified occlusion or stenosis of carotid arteries	Diagnosis	ICD-10-CM
I63.231	Cerebral infarction due to unspecified occlusion or stenosis of right carotid arteries	Diagnosis	ICD-10-CM
I63.232	Cerebral infarction due to unspecified occlusion or stenosis of left carotid arteries	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I63.233	Cerebral infarction due to unspecified occlusion or stenosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.239	Cerebral infarction due to unspecified occlusion or stenosis of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.29	Cerebral infarction due to unspecified occlusion or stenosis of other precerebral arteries	Diagnosis	ICD-10-CM
I63.3	Cerebral infarction due to thrombosis of cerebral arteries	Diagnosis	ICD-10-CM
I63.30	Cerebral infarction due to thrombosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.31	Cerebral infarction due to thrombosis of middle cerebral artery	Diagnosis	ICD-10-CM
I63.311	Cerebral infarction due to thrombosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.312	Cerebral infarction due to thrombosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.313	Cerebral infarction due to thrombosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.319	Cerebral infarction due to thrombosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.32	Cerebral infarction due to thrombosis of anterior cerebral artery	Diagnosis	ICD-10-CM
I63.321	Cerebral infarction due to thrombosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.322	Cerebral infarction due to thrombosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.323	Cerebral infarction due to thrombosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.329	Cerebral infarction due to thrombosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.33	Cerebral infarction due to thrombosis of posterior cerebral artery	Diagnosis	ICD-10-CM
I63.331	Cerebral infarction due to thrombosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.332	Cerebral infarction due to thrombosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.333	Cerebral infarction due to thrombosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.339	Cerebral infarction due to thrombosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.34	Cerebral infarction due to thrombosis of cerebellar artery	Diagnosis	ICD-10-CM
I63.341	Cerebral infarction due to thrombosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.342	Cerebral infarction due to thrombosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.343	Cerebral infarction due to thrombosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.349	Cerebral infarction due to thrombosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.39	Cerebral infarction due to thrombosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.4	Cerebral infarction due to embolism of cerebral arteries	Diagnosis	ICD-10-CM
I63.40	Cerebral infarction due to embolism of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.41	Cerebral infarction due to embolism of middle cerebral artery	Diagnosis	ICD-10-CM
I63.411	Cerebral infarction due to embolism of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.412	Cerebral infarction due to embolism of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.413	Cerebral infarction due to embolism of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.419	Cerebral infarction due to embolism of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.42	Cerebral infarction due to embolism of anterior cerebral artery	Diagnosis	ICD-10-CM
I63.421	Cerebral infarction due to embolism of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.422	Cerebral infarction due to embolism of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.423	Cerebral infarction due to embolism of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.429	Cerebral infarction due to embolism of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.43	Cerebral infarction due to embolism of posterior cerebral artery	Diagnosis	ICD-10-CM
I63.431	Cerebral infarction due to embolism of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.432	Cerebral infarction due to embolism of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.433	Cerebral infarction due to embolism of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.439	Cerebral infarction due to embolism of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.44	Cerebral infarction due to embolism of cerebellar artery	Diagnosis	ICD-10-CM
I63.441	Cerebral infarction due to embolism of right cerebellar artery	Diagnosis	ICD-10-CM
I63.442	Cerebral infarction due to embolism of left cerebellar artery	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I63.443	Cerebral infarction due to embolism of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.449	Cerebral infarction due to embolism of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.49	Cerebral infarction due to embolism of other cerebral artery	Diagnosis	ICD-10-CM
I63.5	Cerebral infarction due to unspecified occlusion or stenosis of cerebral arteries	Diagnosis	ICD-10-CM
I63.50	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.51	Cerebral infarction due to unspecified occlusion or stenosis of middle cerebral artery	Diagnosis	ICD-10-CM
I63.511	Cerebral infarction due to unspecified occlusion or stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.512	Cerebral infarction due to unspecified occlusion or stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.513	Cerebral infarction due to unspecified occlusion or stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.519	Cerebral infarction due to unspecified occlusion or stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.52	Cerebral infarction due to unspecified occlusion or stenosis of anterior cerebral artery	Diagnosis	ICD-10-CM
I63.521	Cerebral infarction due to unspecified occlusion or stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.522	Cerebral infarction due to unspecified occlusion or stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.523	Cerebral infarction due to unspecified occlusion or stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.529	Cerebral infarction due to unspecified occlusion or stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.53	Cerebral infarction due to unspecified occlusion or stenosis of posterior cerebral artery	Diagnosis	ICD-10-CM
I63.531	Cerebral infarction due to unspecified occlusion or stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.532	Cerebral infarction due to unspecified occlusion or stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.533	Cerebral infarction due to unspecified occlusion or stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.539	Cerebral infarction due to unspecified occlusion or stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.54	Cerebral infarction due to unspecified occlusion or stenosis of cerebellar artery	Diagnosis	ICD-10-CM
I63.541	Cerebral infarction due to unspecified occlusion or stenosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.542	Cerebral infarction due to unspecified occlusion or stenosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.543	Cerebral infarction due to unspecified occlusion or stenosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.549	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.59	Cerebral infarction due to unspecified occlusion or stenosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.6	Cerebral infarction due to cerebral venous thrombosis, nonpyogenic	Diagnosis	ICD-10-CM
I63.8	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.81	Other cerebral infarction due to occlusion or stenosis of small artery	Diagnosis	ICD-10-CM
I63.89	Other cerebral infarction	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I63.9	Cerebral infarction, unspecified	Diagnosis	ICD-10-CM
I65	Occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction	Diagnosis	ICD-10-CM
I65.0	Occlusion and stenosis of vertebral artery	Diagnosis	ICD-10-CM
I65.01	Occlusion and stenosis of right vertebral artery	Diagnosis	ICD-10-CM
I65.02	Occlusion and stenosis of left vertebral artery	Diagnosis	ICD-10-CM
I65.03	Occlusion and stenosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I65.09	Occlusion and stenosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
I65.1	Occlusion and stenosis of basilar artery	Diagnosis	ICD-10-CM
I65.2	Occlusion and stenosis of carotid artery	Diagnosis	ICD-10-CM
I65.21	Occlusion and stenosis of right carotid artery	Diagnosis	ICD-10-CM
I65.22	Occlusion and stenosis of left carotid artery	Diagnosis	ICD-10-CM
I65.23	Occlusion and stenosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I65.29	Occlusion and stenosis of unspecified carotid artery	Diagnosis	ICD-10-CM
I65.8	Occlusion and stenosis of other precerebral arteries	Diagnosis	ICD-10-CM
I65.9	Occlusion and stenosis of unspecified precerebral artery	Diagnosis	ICD-10-CM
I66	Occlusion and stenosis of cerebral arteries, not resulting in cerebral infarction	Diagnosis	ICD-10-CM
I66.0	Occlusion and stenosis of middle cerebral artery	Diagnosis	ICD-10-CM
I66.01	Occlusion and stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I66.02	Occlusion and stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I66.03	Occlusion and stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I66.09	Occlusion and stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I66.1	Occlusion and stenosis of anterior cerebral artery	Diagnosis	ICD-10-CM
I66.11	Occlusion and stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I66.12	Occlusion and stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I66.13	Occlusion and stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I66.19	Occlusion and stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I66.2	Occlusion and stenosis of posterior cerebral artery	Diagnosis	ICD-10-CM
I66.21	Occlusion and stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I66.22	Occlusion and stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I66.23	Occlusion and stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I66.29	Occlusion and stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I66.3	Occlusion and stenosis of cerebellar arteries	Diagnosis	ICD-10-CM
I66.8	Occlusion and stenosis of other cerebral arteries	Diagnosis	ICD-10-CM
I66.9	Occlusion and stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I67	Other cerebrovascular diseases	Diagnosis	ICD-10-CM
I67.0	Dissection of cerebral arteries, nonruptured	Diagnosis	ICD-10-CM
I67.1	Cerebral aneurysm, nonruptured	Diagnosis	ICD-10-CM
I67.2	Cerebral atherosclerosis	Diagnosis	ICD-10-CM
I67.3	Progressive vascular leukoencephalopathy	Diagnosis	ICD-10-CM
I67.4	Hypertensive encephalopathy	Diagnosis	ICD-10-CM
I67.5	Moyamoya disease	Diagnosis	ICD-10-CM
I67.7	Cerebral arteritis, not elsewhere classified	Diagnosis	ICD-10-CM
I67.8	Other specified cerebrovascular diseases	Diagnosis	ICD-10-CM
I67.81	Acute cerebrovascular insufficiency	Diagnosis	ICD-10-CM
I67.82	Cerebral ischemia	Diagnosis	ICD-10-CM
I67.83	Posterior reversible encephalopathy syndrome	Diagnosis	ICD-10-CM
I67.84	Cerebral vasospasm and vasoconstriction	Diagnosis	ICD-10-CM
I67.841	Reversible cerebrovascular vasoconstriction syndrome	Diagnosis	ICD-10-CM
I67.848	Other cerebrovascular vasospasm and vasoconstriction	Diagnosis	ICD-10-CM
I67.85	Hereditary cerebrovascular diseases	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I67.850	Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy	Diagnosis	ICD-10-CM
I67.858	Other hereditary cerebrovascular disease	Diagnosis	ICD-10-CM
I67.89	Other cerebrovascular disease	Diagnosis	ICD-10-CM
I67.9	Cerebrovascular disease, unspecified	Diagnosis	ICD-10-CM
I68	Cerebrovascular disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
I68.0	Cerebral amyloid angiopathy	Diagnosis	ICD-10-CM
I68.2	Cerebral arteritis in other diseases classified elsewhere	Diagnosis	ICD-10-CM
I68.8	Other cerebrovascular disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
I69	Sequelae of cerebrovascular disease	Diagnosis	ICD-10-CM
I69.0	Sequelae of nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.00	Unspecified sequelae of nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.01	Cognitive deficits following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.010	Attention and concentration deficit following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.011	Memory deficit following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.012	Visuospatial deficit and spatial neglect following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.013	Psychomotor deficit following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.014	Frontal lobe and executive function deficit following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.015	Cognitive social or emotional deficit following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.018	Other symptoms and signs involving cognitive functions following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.019	Unspecified symptoms and signs involving cognitive functions following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.02	Speech and language deficits following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.020	Aphasia following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.021	Dysphasia following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.022	Dysarthria following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.023	Fluency disorder following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.028	Other speech and language deficits following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.03	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.031	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM
I69.032	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
I69.033	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.034	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.039	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
I69.04	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.041	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I69.042	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
I69.043	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.044	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.049	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
I69.05	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.051	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM
I69.052	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
I69.053	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.054	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.059	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
I69.06	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.061	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM
I69.062	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
I69.063	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.064	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.065	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage, bilateral	Diagnosis	ICD-10-CM
I69.069	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
I69.09	Other sequelae of nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.090	Apraxia following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.091	Dysphagia following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.092	Facial weakness following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.093	Ataxia following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.098	Other sequelae following nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I69.1	Sequelae of nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.10	Unspecified sequelae of nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.11	Cognitive deficits following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.110	Attention and concentration deficit following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.111	Memory deficit following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.112	Visuospatial deficit and spatial neglect following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.113	Psychomotor deficit following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I69.114	Frontal lobe and executive function deficit following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.115	Cognitive social or emotional deficit following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.118	Other symptoms and signs involving cognitive functions following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.119	Unspecified symptoms and signs involving cognitive functions following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.12	Speech and language deficits following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.120	Aphasia following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.121	Dysphasia following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.122	Dysarthria following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.123	Fluency disorder following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.128	Other speech and language deficits following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.13	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.131	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM
I69.132	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
I69.133	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.134	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.139	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
I69.14	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.141	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM
I69.142	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
I69.143	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.144	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.149	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
I69.15	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.151	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM
I69.152	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
I69.153	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I69.154	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.159	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
I69.16	Other paralytic syndrome following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.161	Other paralytic syndrome following nontraumatic intracerebral hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM
I69.162	Other paralytic syndrome following nontraumatic intracerebral hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
I69.163	Other paralytic syndrome following nontraumatic intracerebral hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.164	Other paralytic syndrome following nontraumatic intracerebral hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.165	Other paralytic syndrome following nontraumatic intracerebral hemorrhage, bilateral	Diagnosis	ICD-10-CM
I69.169	Other paralytic syndrome following nontraumatic intracerebral hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
I69.19	Other sequelae of nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.190	Apraxia following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.191	Dysphagia following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.192	Facial weakness following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.193	Ataxia following nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.198	Other sequelae of nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I69.2	Sequelae of other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.20	Unspecified sequelae of other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.21	Cognitive deficits following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.210	Attention and concentration deficit following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.211	Memory deficit following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.212	Visuospatial deficit and spatial neglect following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.213	Psychomotor deficit following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.214	Frontal lobe and executive function deficit following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.215	Cognitive social or emotional deficit following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.218	Other symptoms and signs involving cognitive functions following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.219	Unspecified symptoms and signs involving cognitive functions following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.22	Speech and language deficits following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.220	Aphasia following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.221	Dysphasia following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.222	Dysarthria following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.223	Fluency disorder following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I69.228	Other speech and language deficits following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.23	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.231	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM
I69.232	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
I69.233	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.234	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.239	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
I69.24	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.241	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM
I69.242	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
I69.243	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.244	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.249	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
I69.25	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.251	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM
I69.252	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
I69.253	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.254	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.259	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
I69.26	Other paralytic syndrome following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.261	Other paralytic syndrome following other nontraumatic intracranial hemorrhage affecting right dominant side	Diagnosis	ICD-10-CM
I69.262	Other paralytic syndrome following other nontraumatic intracranial hemorrhage affecting left dominant side	Diagnosis	ICD-10-CM
I69.263	Other paralytic syndrome following other nontraumatic intracranial hemorrhage affecting right non-dominant side	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I69.264	Other paralytic syndrome following other nontraumatic intracranial hemorrhage affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.265	Other paralytic syndrome following other nontraumatic intracranial hemorrhage, bilateral	Diagnosis	ICD-10-CM
I69.269	Other paralytic syndrome following other nontraumatic intracranial hemorrhage affecting unspecified side	Diagnosis	ICD-10-CM
I69.29	Other sequelae of other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.290	Apraxia following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.291	Dysphagia following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.292	Facial weakness following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.293	Ataxia following other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.298	Other sequelae of other nontraumatic intracranial hemorrhage	Diagnosis	ICD-10-CM
I69.3	Sequelae of cerebral infarction	Diagnosis	ICD-10-CM
I69.30	Unspecified sequelae of cerebral infarction	Diagnosis	ICD-10-CM
I69.31	Cognitive deficits following cerebral infarction	Diagnosis	ICD-10-CM
I69.310	Attention and concentration deficit following cerebral infarction	Diagnosis	ICD-10-CM
I69.311	Memory deficit following cerebral infarction	Diagnosis	ICD-10-CM
I69.312	Visuospatial deficit and spatial neglect following cerebral infarction	Diagnosis	ICD-10-CM
I69.313	Psychomotor deficit following cerebral infarction	Diagnosis	ICD-10-CM
I69.314	Frontal lobe and executive function deficit following cerebral infarction	Diagnosis	ICD-10-CM
I69.315	Cognitive social or emotional deficit following cerebral infarction	Diagnosis	ICD-10-CM
I69.318	Other symptoms and signs involving cognitive functions following cerebral infarction	Diagnosis	ICD-10-CM
I69.319	Unspecified symptoms and signs involving cognitive functions following cerebral infarction	Diagnosis	ICD-10-CM
I69.32	Speech and language deficits following cerebral infarction	Diagnosis	ICD-10-CM
I69.320	Aphasia following cerebral infarction	Diagnosis	ICD-10-CM
I69.321	Dysphasia following cerebral infarction	Diagnosis	ICD-10-CM
I69.322	Dysarthria following cerebral infarction	Diagnosis	ICD-10-CM
I69.323	Fluency disorder following cerebral infarction	Diagnosis	ICD-10-CM
I69.328	Other speech and language deficits following cerebral infarction	Diagnosis	ICD-10-CM
I69.33	Monoplegia of upper limb following cerebral infarction	Diagnosis	ICD-10-CM
I69.331	Monoplegia of upper limb following cerebral infarction affecting right dominant side	Diagnosis	ICD-10-CM
I69.332	Monoplegia of upper limb following cerebral infarction affecting left dominant side	Diagnosis	ICD-10-CM
I69.333	Monoplegia of upper limb following cerebral infarction affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.334	Monoplegia of upper limb following cerebral infarction affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.339	Monoplegia of upper limb following cerebral infarction affecting unspecified side	Diagnosis	ICD-10-CM
I69.34	Monoplegia of lower limb following cerebral infarction	Diagnosis	ICD-10-CM
I69.341	Monoplegia of lower limb following cerebral infarction affecting right dominant side	Diagnosis	ICD-10-CM
I69.342	Monoplegia of lower limb following cerebral infarction affecting left dominant side	Diagnosis	ICD-10-CM
I69.343	Monoplegia of lower limb following cerebral infarction affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.344	Monoplegia of lower limb following cerebral infarction affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.349	Monoplegia of lower limb following cerebral infarction affecting unspecified side	Diagnosis	ICD-10-CM
I69.35	Hemiplegia and hemiparesis following cerebral infarction	Diagnosis	ICD-10-CM
I69.351	Hemiplegia and hemiparesis following cerebral infarction affecting right dominant side	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I69.352	Hemiplegia and hemiparesis following cerebral infarction affecting left dominant side	Diagnosis	ICD-10-CM
I69.353	Hemiplegia and hemiparesis following cerebral infarction affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.354	Hemiplegia and hemiparesis following cerebral infarction affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.359	Hemiplegia and hemiparesis following cerebral infarction affecting unspecified side	Diagnosis	ICD-10-CM
I69.36	Other paralytic syndrome following cerebral infarction	Diagnosis	ICD-10-CM
I69.361	Other paralytic syndrome following cerebral infarction affecting right dominant side	Diagnosis	ICD-10-CM
I69.362	Other paralytic syndrome following cerebral infarction affecting left dominant side	Diagnosis	ICD-10-CM
I69.363	Other paralytic syndrome following cerebral infarction affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.364	Other paralytic syndrome following cerebral infarction affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.365	Other paralytic syndrome following cerebral infarction, bilateral	Diagnosis	ICD-10-CM
I69.369	Other paralytic syndrome following cerebral infarction affecting unspecified side	Diagnosis	ICD-10-CM
I69.39	Other sequelae of cerebral infarction	Diagnosis	ICD-10-CM
I69.390	Apraxia following cerebral infarction	Diagnosis	ICD-10-CM
I69.391	Dysphagia following cerebral infarction	Diagnosis	ICD-10-CM
I69.392	Facial weakness following cerebral infarction	Diagnosis	ICD-10-CM
I69.393	Ataxia following cerebral infarction	Diagnosis	ICD-10-CM
I69.398	Other sequelae of cerebral infarction	Diagnosis	ICD-10-CM
I69.8	Sequelae of other cerebrovascular diseases	Diagnosis	ICD-10-CM
I69.80	Unspecified sequelae of other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.81	Cognitive deficits following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.810	Attention and concentration deficit following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.811	Memory deficit following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.812	Visuospatial deficit and spatial neglect following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.813	Psychomotor deficit following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.814	Frontal lobe and executive function deficit following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.815	Cognitive social or emotional deficit following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.818	Other symptoms and signs involving cognitive functions following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.819	Unspecified symptoms and signs involving cognitive functions following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.82	Speech and language deficits following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.820	Aphasia following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.821	Dysphasia following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.822	Dysarthria following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.823	Fluency disorder following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.828	Other speech and language deficits following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.83	Monoplegia of upper limb following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.831	Monoplegia of upper limb following other cerebrovascular disease affecting right dominant side	Diagnosis	ICD-10-CM
I69.832	Monoplegia of upper limb following other cerebrovascular disease affecting left dominant side	Diagnosis	ICD-10-CM
I69.833	Monoplegia of upper limb following other cerebrovascular disease affecting right non-dominant side	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I69.834	Monoplegia of upper limb following other cerebrovascular disease affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.839	Monoplegia of upper limb following other cerebrovascular disease affecting unspecified side	Diagnosis	ICD-10-CM
I69.84	Monoplegia of lower limb following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.841	Monoplegia of lower limb following other cerebrovascular disease affecting right dominant side	Diagnosis	ICD-10-CM
I69.842	Monoplegia of lower limb following other cerebrovascular disease affecting left dominant side	Diagnosis	ICD-10-CM
I69.843	Monoplegia of lower limb following other cerebrovascular disease affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.844	Monoplegia of lower limb following other cerebrovascular disease affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.849	Monoplegia of lower limb following other cerebrovascular disease affecting unspecified side	Diagnosis	ICD-10-CM
I69.85	Hemiplegia and hemiparesis following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.851	Hemiplegia and hemiparesis following other cerebrovascular disease affecting right dominant side	Diagnosis	ICD-10-CM
I69.852	Hemiplegia and hemiparesis following other cerebrovascular disease affecting left dominant side	Diagnosis	ICD-10-CM
I69.853	Hemiplegia and hemiparesis following other cerebrovascular disease affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.854	Hemiplegia and hemiparesis following other cerebrovascular disease affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.859	Hemiplegia and hemiparesis following other cerebrovascular disease affecting unspecified side	Diagnosis	ICD-10-CM
I69.86	Other paralytic syndrome following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.861	Other paralytic syndrome following other cerebrovascular disease affecting right dominant side	Diagnosis	ICD-10-CM
I69.862	Other paralytic syndrome following other cerebrovascular disease affecting left dominant side	Diagnosis	ICD-10-CM
I69.863	Other paralytic syndrome following other cerebrovascular disease affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.864	Other paralytic syndrome following other cerebrovascular disease affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.865	Other paralytic syndrome following other cerebrovascular disease, bilateral	Diagnosis	ICD-10-CM
I69.869	Other paralytic syndrome following other cerebrovascular disease affecting unspecified side	Diagnosis	ICD-10-CM
I69.89	Other sequelae of other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.890	Apraxia following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.891	Dysphagia following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.892	Facial weakness following other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.893	Ataxia following other cerebrovascular disease	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I69.898	Other sequelae of other cerebrovascular disease	Diagnosis	ICD-10-CM
I69.9	Sequelae of unspecified cerebrovascular diseases	Diagnosis	ICD-10-CM
I69.90	Unspecified sequelae of unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.91	Cognitive deficits following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.910	Attention and concentration deficit following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.911	Memory deficit following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.912	Visuospatial deficit and spatial neglect following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.913	Psychomotor deficit following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.914	Frontal lobe and executive function deficit following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.915	Cognitive social or emotional deficit following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.918	Other symptoms and signs involving cognitive functions following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.919	Unspecified symptoms and signs involving cognitive functions following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.92	Speech and language deficits following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.920	Aphasia following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.921	Dysphasia following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.922	Dysarthria following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.923	Fluency disorder following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.928	Other speech and language deficits following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.93	Monoplegia of upper limb following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.931	Monoplegia of upper limb following unspecified cerebrovascular disease affecting right dominant side	Diagnosis	ICD-10-CM
I69.932	Monoplegia of upper limb following unspecified cerebrovascular disease affecting left dominant side	Diagnosis	ICD-10-CM
I69.933	Monoplegia of upper limb following unspecified cerebrovascular disease affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.934	Monoplegia of upper limb following unspecified cerebrovascular disease affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.939	Monoplegia of upper limb following unspecified cerebrovascular disease affecting unspecified side	Diagnosis	ICD-10-CM
I69.94	Monoplegia of lower limb following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.941	Monoplegia of lower limb following unspecified cerebrovascular disease affecting right dominant side	Diagnosis	ICD-10-CM
I69.942	Monoplegia of lower limb following unspecified cerebrovascular disease affecting left dominant side	Diagnosis	ICD-10-CM
I69.943	Monoplegia of lower limb following unspecified cerebrovascular disease affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.944	Monoplegia of lower limb following unspecified cerebrovascular disease affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.949	Monoplegia of lower limb following unspecified cerebrovascular disease affecting unspecified side	Diagnosis	ICD-10-CM
I69.95	Hemiplegia and hemiparesis following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.951	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting right dominant side	Diagnosis	ICD-10-CM
I69.952	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting left dominant side	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I69.953	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.954	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.959	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting unspecified side	Diagnosis	ICD-10-CM
I69.96	Other paralytic syndrome following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.961	Other paralytic syndrome following unspecified cerebrovascular disease affecting right dominant side	Diagnosis	ICD-10-CM
I69.962	Other paralytic syndrome following unspecified cerebrovascular disease affecting left dominant side	Diagnosis	ICD-10-CM
I69.963	Other paralytic syndrome following unspecified cerebrovascular disease affecting right non-dominant side	Diagnosis	ICD-10-CM
I69.964	Other paralytic syndrome following unspecified cerebrovascular disease affecting left non-dominant side	Diagnosis	ICD-10-CM
I69.965	Other paralytic syndrome following unspecified cerebrovascular disease, bilateral	Diagnosis	ICD-10-CM
I69.969	Other paralytic syndrome following unspecified cerebrovascular disease affecting unspecified side	Diagnosis	ICD-10-CM
I69.99	Other sequelae of unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.990	Apraxia following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.991	Dysphagia following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.992	Facial weakness following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.993	Ataxia following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
I69.998	Other sequelae following unspecified cerebrovascular disease	Diagnosis	ICD-10-CM
P91.82	Neonatal cerebral infarction	Diagnosis	ICD-10-CM
P91.821	Neonatal cerebral infarction, right side of brain	Diagnosis	ICD-10-CM
P91.822	Neonatal cerebral infarction, left side of brain	Diagnosis	ICD-10-CM
P91.823	Neonatal cerebral infarction, bilateral	Diagnosis	ICD-10-CM
P91.829	Neonatal cerebral infarction, unspecified side	Diagnosis	ICD-10-CM
Q28.0	Arteriovenous malformation of precerebral vessels	Diagnosis	ICD-10-CM
Q28.2	Arteriovenous malformation of cerebral vessels	Diagnosis	ICD-10-CM
Z86.73	Personal history of transient ischemic attack (TIA), and cerebral infarction without residual deficits	Diagnosis	ICD-10-CM
61630	Balloon angioplasty, intracranial (eg, atherosclerotic stenosis), percutaneous	Procedure	CPT-4
61635	Transcatheter placement of intravascular stent(s), intracranial (eg, atherosclerotic stenosis), including balloon angioplasty, if performed	Procedure	CPT-4
Chronic Kidney Disease			
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.1	Hypertensive heart and chronic kidney disease without heart failure	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
N18.1	Chronic kidney disease, stage 1	Diagnosis	ICD-10-CM
N18.2	Chronic kidney disease, stage 2 (mild)	Diagnosis	ICD-10-CM
N18.3	Chronic kidney disease, stage 3 (moderate)	Diagnosis	ICD-10-CM
N18.4	Chronic kidney disease, stage 4 (severe)	Diagnosis	ICD-10-CM
N18.5	Chronic kidney disease, stage 5	Diagnosis	ICD-10-CM
N18.9	Chronic kidney disease, unspecified	Diagnosis	ICD-10-CM
N19	Unspecified kidney failure	Diagnosis	ICD-10-CM
N99.0	Postprocedural (acute) (chronic) kidney failure	Diagnosis	ICD-10-CM
R34	Anuria and oliguria	Diagnosis	ICD-10-CM
Z49.01	Encounter for fitting and adjustment of extracorporeal dialysis catheter	Diagnosis	ICD-10-CM
Z49.02	Encounter for fitting and adjustment of peritoneal dialysis catheter	Diagnosis	ICD-10-CM
Z49.31	Encounter for adequacy testing for hemodialysis	Diagnosis	ICD-10-CM
Z49.32	Encounter for adequacy testing for peritoneal dialysis	Diagnosis	ICD-10-CM
Z99.2	Dependence on renal dialysis	Diagnosis	ICD-10-CM
36147	Introduction of needle and/or catheter, arteriovenous shunt created for dialysis (graft/fistula); initial access with complete radiological evaluation of dialysis access, including fluoroscopy, image documentation and report (includes access of shunt, injection[s] of contrast, and all necessary imaging from the arterial anastomosis and adjacent artery through entire venous outflow including the inferior or superior vena cava)	Procedure	CPT-4
36148	Introduction of needle and/or catheter, arteriovenous shunt created for dialysis (graft/fistula); additional access for therapeutic intervention (List separately in addition to code for primary procedure)	Procedure	CPT-4
36818	Arteriovenous anastomosis, open; by upper arm cephalic vein transposition	Procedure	CPT-4
36819	Arteriovenous anastomosis, open; by upper arm basilic vein transposition	Procedure	CPT-4
36820	Arteriovenous anastomosis, open; by forearm vein transposition	Procedure	CPT-4
36821	Arteriovenous anastomosis, open; direct, any site (eg, Cimino type) (separate procedure)	Procedure	CPT-4
36825	Creation of arteriovenous fistula by other than direct arteriovenous anastomosis (separate procedure); autogenous graft	Procedure	CPT-4
36830	Creation of arteriovenous fistula by other than direct arteriovenous anastomosis (separate procedure); nonautogenous graft (eg, biological collagen, thermoplastic graft)	Procedure	CPT-4
36831	Thrombectomy, open, arteriovenous fistula without revision, autogenous or nonautogenous dialysis graft (separate procedure)	Procedure	CPT-4
36832	Revision, open, arteriovenous fistula; without thrombectomy, autogenous or nonautogenous dialysis graft (separate procedure)	Procedure	CPT-4
36833	Revision, open, arteriovenous fistula; with thrombectomy, autogenous or nonautogenous dialysis graft (separate procedure)	Procedure	CPT-4
36870	Thrombectomy, percutaneous, arteriovenous fistula, autogenous or nonautogenous graft (includes mechanical thrombus extraction and intra-graft thrombolysis)	Procedure	CPT-4
50360	Renal allotransplantation, implantation of graft; without recipient nephrectomy	Procedure	CPT-4
50365	Renal allotransplantation, implantation of graft; with recipient nephrectomy	Procedure	CPT-4

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
75791	Angiography, arteriovenous shunt (eg, dialysis patient fistula/graft), complete evaluation of dialysis access, including fluoroscopy, image documentation and report (includes injections of contrast and all necessary imaging from the arterial anastomosis and adjacent artery through entire venous outflow including the inferior or superior vena cava), radiological supervision and interpretation	Procedure	CPT-4
90935	Hemodialysis procedure with single evaluation by a physician or other qualified health care professional	Procedure	CPT-4
90937	Hemodialysis procedure requiring repeated evaluation(s) with or without substantial revision of dialysis prescription	Procedure	CPT-4
90945	Dialysis procedure other than hemodialysis (eg, peritoneal dialysis, hemofiltration, or other continuous renal replacement therapies), with single evaluation by a physician or other qualified health care professional	Procedure	CPT-4
90947	Dialysis procedure other than hemodialysis (eg, peritoneal dialysis, hemofiltration, or other continuous renal replacement therapies) requiring repeated evaluations by a physician or other qualified health care professional, with or without substantial revision of dialysis prescription	Procedure	CPT-4
90951	End-stage renal disease (ESRD) related services monthly, for patients younger than 2 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 4 or more face-to-face visits by a physician or other qualified health care professional per month	Procedure	CPT-4
90952	End-stage renal disease (ESRD) related services monthly, for patients younger than 2 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 2-3 face-to-face visits by a physician or other qualified health care professional per month	Procedure	CPT-4
90953	End-stage renal disease (ESRD) related services monthly, for patients younger than 2 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 1 face-to-face visit by a physician or other qualified health care professional per month	Procedure	CPT-4
90954	End-stage renal disease (ESRD) related services monthly, for patients 2-11 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 4 or more face-to-face visits by a physician or other qualified health care professional per month	Procedure	CPT-4
90955	End-stage renal disease (ESRD) related services monthly, for patients 2-11 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 2-3 face-to-face visits by a physician or other qualified health care professional per month	Procedure	CPT-4
90956	End-stage renal disease (ESRD) related services monthly, for patients 2-11 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 1 face-to-face visit by a physician or other qualified health care professional per month	Procedure	CPT-4

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
90957	End-stage renal disease (ESRD) related services monthly, for patients 12-19 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 4 or more face-to-face visits by a physician or other qualified health care professional per month	Procedure	CPT-4
90958	End-stage renal disease (ESRD) related services monthly, for patients 12-19 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 2-3 face-to-face visits by a physician or other qualified health care professional per month	Procedure	CPT-4
90959	End-stage renal disease (ESRD) related services monthly, for patients 12-19 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 1 face-to-face visit by a physician or other qualified health care professional per month	Procedure	CPT-4
90960	End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month	Procedure	CPT-4
90961	End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 2-3 face-to-face visits by a physician or other qualified health care professional per month	Procedure	CPT-4
90962	End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 1 face-to-face visit by a physician or other qualified health care professional per month	Procedure	CPT-4
90963	End-stage renal disease (ESRD) related services for home dialysis per full month, for patients younger than 2 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents	Procedure	CPT-4
90964	End-stage renal disease (ESRD) related services for home dialysis per full month, for patients 2-11 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents	Procedure	CPT-4
90965	End-stage renal disease (ESRD) related services for home dialysis per full month, for patients 12-19 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents	Procedure	CPT-4
90966	End-stage renal disease (ESRD) related services for home dialysis per full month, for patients 20 years of age and older	Procedure	CPT-4
90967	End-stage renal disease (ESRD) related services for dialysis less than a full month of service, per day; for patients younger than 2 years of age	Procedure	CPT-4
90968	End-stage renal disease (ESRD) related services for dialysis less than a full month of service, per day; for patients 2-11 years of age	Procedure	CPT-4
90969	End-stage renal disease (ESRD) related services for dialysis less than a full month of service, per day; for patients 12-19 years of age	Procedure	CPT-4
90970	End-stage renal disease (ESRD) related services for dialysis less than a full month of service, per day; for patients 20 years of age and older	Procedure	CPT-4
Chronic Obstructive Pulmonary Disease			
J44.0	Chronic obstructive pulmonary disease with (acute) lower respiratory infection	Diagnosis	ICD-10-CM
J44.1	Chronic obstructive pulmonary disease with (acute) exacerbation	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
J44.9	Chronic obstructive pulmonary disease, unspecified	Diagnosis	ICD-10-CM
Congenital Heart Disease			
I97.13	Postprocedural heart failure	Diagnosis	ICD-10-CM
I97.130	Postprocedural heart failure following cardiac surgery	Diagnosis	ICD-10-CM
I97.131	Postprocedural heart failure following other surgery	Diagnosis	ICD-10-CM
P29.3	Persistent fetal circulation	Diagnosis	ICD-10-CM
P29.38	Other persistent fetal circulation	Diagnosis	ICD-10-CM
P29.8	Other cardiovascular disorders originating in the perinatal period	Diagnosis	ICD-10-CM
Q20	Congenital malformations of cardiac chambers and connections	Diagnosis	ICD-10-CM
Q20.0	Common arterial trunk	Diagnosis	ICD-10-CM
Q20.1	Double outlet right ventricle	Diagnosis	ICD-10-CM
Q20.2	Double outlet left ventricle	Diagnosis	ICD-10-CM
Q20.3	Discordant ventriculoarterial connection	Diagnosis	ICD-10-CM
Q20.4	Double inlet ventricle	Diagnosis	ICD-10-CM
Q20.5	Discordant atrioventricular connection	Diagnosis	ICD-10-CM
Q20.6	Isomerism of atrial appendages	Diagnosis	ICD-10-CM
Q20.8	Other congenital malformations of cardiac chambers and connections	Diagnosis	ICD-10-CM
Q20.9	Congenital malformation of cardiac chambers and connections, unspecified	Diagnosis	ICD-10-CM
Q21	Congenital malformations of cardiac septa	Diagnosis	ICD-10-CM
Q21.0	Ventricular septal defect	Diagnosis	ICD-10-CM
Q21.1	Atrial septal defect	Diagnosis	ICD-10-CM
Q21.2	Atrioventricular septal defect	Diagnosis	ICD-10-CM
Q21.3	Tetralogy of Fallot	Diagnosis	ICD-10-CM
Q21.4	Aortopulmonary septal defect	Diagnosis	ICD-10-CM
Q21.8	Other congenital malformations of cardiac septa	Diagnosis	ICD-10-CM
Q21.9	Congenital malformation of cardiac septum, unspecified	Diagnosis	ICD-10-CM
Q22	Congenital malformations of pulmonary and tricuspid valves	Diagnosis	ICD-10-CM
Q22.0	Pulmonary valve atresia	Diagnosis	ICD-10-CM
Q22.1	Congenital pulmonary valve stenosis	Diagnosis	ICD-10-CM
Q22.2	Congenital pulmonary valve insufficiency	Diagnosis	ICD-10-CM
Q22.3	Other congenital malformations of pulmonary valve	Diagnosis	ICD-10-CM
Q22.4	Congenital tricuspid stenosis	Diagnosis	ICD-10-CM
Q22.5	Ebstein's anomaly	Diagnosis	ICD-10-CM
Q22.6	Hypoplastic right heart syndrome	Diagnosis	ICD-10-CM
Q22.8	Other congenital malformations of tricuspid valve	Diagnosis	ICD-10-CM
Q22.9	Congenital malformation of tricuspid valve, unspecified	Diagnosis	ICD-10-CM
Q23	Congenital malformations of aortic and mitral valves	Diagnosis	ICD-10-CM
Q23.0	Congenital stenosis of aortic valve	Diagnosis	ICD-10-CM
Q23.1	Congenital insufficiency of aortic valve	Diagnosis	ICD-10-CM
Q23.2	Congenital mitral stenosis	Diagnosis	ICD-10-CM
Q23.3	Congenital mitral insufficiency	Diagnosis	ICD-10-CM
Q23.4	Hypoplastic left heart syndrome	Diagnosis	ICD-10-CM
Q23.8	Other congenital malformations of aortic and mitral valves	Diagnosis	ICD-10-CM
Q23.9	Congenital malformation of aortic and mitral valves, unspecified	Diagnosis	ICD-10-CM
Q24	Other congenital malformations of heart	Diagnosis	ICD-10-CM
Q24.0	Dextrocardia	Diagnosis	ICD-10-CM
Q24.1	Levocardia	Diagnosis	ICD-10-CM
Q24.2	Cor triatriatum	Diagnosis	ICD-10-CM
Q24.3	Pulmonary infundibular stenosis	Diagnosis	ICD-10-CM
Q24.4	Congenital subaortic stenosis	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
Q24.5	Malformation of coronary vessels	Diagnosis	ICD-10-CM
Q24.6	Congenital heart block	Diagnosis	ICD-10-CM
Q24.8	Other specified congenital malformations of heart	Diagnosis	ICD-10-CM
Q24.9	Congenital malformation of heart, unspecified	Diagnosis	ICD-10-CM
Q25.0	Patent ductus arteriosus	Diagnosis	ICD-10-CM
Q25.1	Coarctation of aorta	Diagnosis	ICD-10-CM
Q25.21	Interruption of aortic arch	Diagnosis	ICD-10-CM
Q25.29	Other atresia of aorta	Diagnosis	ICD-10-CM
Q25.3	Supravalvular aortic stenosis	Diagnosis	ICD-10-CM
Q25.40	Congenital malformation of aorta unspecified	Diagnosis	ICD-10-CM
Q25.41	Absence and aplasia of aorta	Diagnosis	ICD-10-CM
Q25.42	Hypoplasia of aorta	Diagnosis	ICD-10-CM
Q25.43	Congenital aneurysm of aorta	Diagnosis	ICD-10-CM
Q25.44	Congenital dilation of aorta	Diagnosis	ICD-10-CM
Q25.45	Double aortic arch	Diagnosis	ICD-10-CM
Q25.46	Tortuous aortic arch	Diagnosis	ICD-10-CM
Q25.47	Right aortic arch	Diagnosis	ICD-10-CM
Q25.48	Anomalous origin of subclavian artery	Diagnosis	ICD-10-CM
Q25.49	Other congenital malformations of aorta	Diagnosis	ICD-10-CM
Q25.5	Atresia of pulmonary artery	Diagnosis	ICD-10-CM
Q25.6	Stenosis of pulmonary artery	Diagnosis	ICD-10-CM
Q25.71	Coarctation of pulmonary artery	Diagnosis	ICD-10-CM
Q25.72	Congenital pulmonary arteriovenous malformation	Diagnosis	ICD-10-CM
Q25.79	Other congenital malformations of pulmonary artery	Diagnosis	ICD-10-CM
Q25.8	Other congenital malformations of other great arteries	Diagnosis	ICD-10-CM
Q25.9	Congenital malformation of great arteries, unspecified	Diagnosis	ICD-10-CM
Q26.0	Congenital stenosis of vena cava	Diagnosis	ICD-10-CM
Q26.1	Persistent left superior vena cava	Diagnosis	ICD-10-CM
Q26.2	Total anomalous pulmonary venous connection	Diagnosis	ICD-10-CM
Q26.3	Partial anomalous pulmonary venous connection	Diagnosis	ICD-10-CM
Q26.4	Anomalous pulmonary venous connection, unspecified	Diagnosis	ICD-10-CM
Q87.40	Marfan's syndrome, unspecified	Diagnosis	ICD-10-CM
Q87.41	Marfan's syndrome with cardiovascular manifestations	Diagnosis	ICD-10-CM
Q87.410	Marfan's syndrome with aortic dilation	Diagnosis	ICD-10-CM
Q87.418	Marfan's syndrome with other cardiovascular manifestations	Diagnosis	ICD-10-CM
Q87.82	Arterial tortuosity syndrome	Diagnosis	ICD-10-CM
Q90.0	Trisomy 21, nonmosaicism (meiotic nondisjunction)	Diagnosis	ICD-10-CM
Q90.1	Trisomy 21, mosaicism (mitotic nondisjunction)	Diagnosis	ICD-10-CM
Q90.2	Trisomy 21, translocation	Diagnosis	ICD-10-CM
Q90.9	Down syndrome, unspecified	Diagnosis	ICD-10-CM
Q91.0	Trisomy 18, nonmosaicism (meiotic nondisjunction)	Diagnosis	ICD-10-CM
Q91.1	Trisomy 18, mosaicism (mitotic nondisjunction)	Diagnosis	ICD-10-CM
Q91.2	Trisomy 18, translocation	Diagnosis	ICD-10-CM
Q91.3	Trisomy 18, unspecified	Diagnosis	ICD-10-CM
Q91.4	Trisomy 13, nonmosaicism (meiotic nondisjunction)	Diagnosis	ICD-10-CM
Q91.5	Trisomy 13, mosaicism (mitotic nondisjunction)	Diagnosis	ICD-10-CM
Q91.6	Trisomy 13, translocation	Diagnosis	ICD-10-CM
Q91.7	Trisomy 13, unspecified	Diagnosis	ICD-10-CM
Q93.81	Velo-cardio-facial syndrome	Diagnosis	ICD-10-CM
Q93.82	Williams syndrome	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
02Q50ZZ	Repair Atrial Septum, Open Approach	Procedure	ICD-10-PCS
02QM0ZZ	Repair Ventricular Septum, Open Approach	Procedure	ICD-10-PCS
02U507Z	Supplement Atrial Septum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02U50JZ	Supplement Atrial Septum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02U53JZ	Supplement Atrial Septum with Synthetic Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
02UM07Z	Supplement Ventricular Septum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02UM0JZ	Supplement Ventricular Septum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02UM3JZ	Supplement Ventricular Septum with Synthetic Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
33647	Repair of atrial septal defect and ventricular septal defect, with direct or patch closure	Procedure	CPT-4
33720	Repair sinus of Valsalva aneurysm, with cardiopulmonary bypass	Procedure	CPT-4
33741	Transcatheter atrial septostomy (TAS) for congenital cardiac anomalies to create effective atrial flow, including all imaging guidance by the proceduralist, when performed, any method (eg, Rashkind, Sang-Park, balloon, cutting balloon, blade)	Procedure	CPT-4
33745	Transcatheter intracardiac shunt (TIS) creation by stent placement for congenital cardiac anomalies to establish effective intracardiac flow, including all imaging guidance by the proceduralist, when performed, left and right heart diagnostic cardiac catheterization for congenital cardiac anomalies, and target zone angioplasty, when performed (eg, atrial septum, Fontan fenestration, right ventricular outflow tract, Mustard/Senning/Warden baffles); initial intracardiac shunt	Procedure	CPT-4
33746	Transcatheter intracardiac shunt (TIS) creation by stent placement for congenital cardiac anomalies to establish effective intracardiac flow, including all imaging guidance by the proceduralist, when performed, left and right heart diagnostic cardiac catheterization for congenital cardiac anomalies, and target zone angioplasty, when performed (eg, atrial septum, Fontan fenestration, right ventricular outflow tract, Mustard/Senning/Warden baffles); each additional intracardiac shunt location (List separately in addition to code for primary procedure)	Procedure	CPT-4
33924	Ligation and takedown of a systemic-to-pulmonary artery shunt, performed in conjunction with a congenital heart procedure (List separately in addition to code for primary procedure)	Procedure	CPT-4
75572	Computed tomography, heart, with contrast material, for evaluation of cardiac structure and morphology (including 3D image postprocessing, assessment of cardiac function, and evaluation of venous structures, if performed)	Procedure	CPT-4
75573	Computed tomography, heart, with contrast material, for evaluation of cardiac structure and morphology in the setting of congenital heart disease (including 3D image postprocessing, assessment of LV cardiac function, RV structure and function and evaluation of venous structures, if performed)	Procedure	CPT-4
93303	Transthoracic echocardiography for congenital cardiac anomalies; complete	Procedure	CPT-4
93304	Transthoracic echocardiography for congenital cardiac anomalies; follow-up or limited study	Procedure	CPT-4
93315	Transesophageal echocardiography for congenital cardiac anomalies; including probe placement. image acquisition. interpretation and report	Procedure	CPT-4
93316	Transesophageal echocardiography for congenital cardiac anomalies; placement of transesophageal probe only	Procedure	CPT-4

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
93317	Transesophageal echocardiography for congenital cardiac anomalies; image acquisition, interpretation and report only	Procedure	CPT-4
93530	Right heart catheterization, for congenital cardiac anomalies	Procedure	CPT-4
93531	Combined right heart catheterization and retrograde left heart catheterization, for congenital cardiac anomalies	Procedure	CPT-4
93532	Combined right heart catheterization and transseptal left heart catheterization through intact septum with or without retrograde left heart catheterization, for congenital cardiac anomalies	Procedure	CPT-4
93533	Combined right heart catheterization and transseptal left heart catheterization through existing septal opening, with or without retrograde left heart catheterization, for congenital cardiac anomalies	Procedure	CPT-4
93563	Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for selective coronary angiography during congenital heart catheterization (List separately in addition to code for primary procedure)	Procedure	CPT-4
93564	Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for selective opacification of aortocoronary venous or arterial bypass graft(s) (eg, aortocoronary saphenous vein, free radial artery, or free mammary artery graft) to one or more coronary arteries and in situ arterial conduits (eg, internal mammary), whether native or used for bypass to one or more coronary arteries during congenital heart catheterization, when performed (List separately in addition to code for primary procedure)	Procedure	CPT-4
93580	Percutaneous transcatheter closure of congenital interatrial communication (ie, Fontan fenestration, atrial septal defect) with implant	Procedure	CPT-4
93581	Percutaneous transcatheter closure of a congenital ventricular septal defect with implant	Procedure	CPT-4
Heart Failure			
I09.81	Rheumatic heart failure	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease. or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease. or end stage renal disease	Diagnosis	ICD-10-CM
I50	Heart failure	Diagnosis	ICD-10-CM
I50.1	Left ventricular failure, unspecified	Diagnosis	ICD-10-CM
I50.2	Systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.20	Unspecified systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.21	Acute systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.22	Chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.23	Acute on chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.3	Diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.30	Unspecified diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.31	Acute diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.32	Chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.33	Acute on chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.4	Combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.40	Unspecified combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I50.41	Acute combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.42	Chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.43	Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.8	Other heart failure	Diagnosis	ICD-10-CM
I50.81	Right heart failure	Diagnosis	ICD-10-CM
I50.810	Right heart failure, unspecified	Diagnosis	ICD-10-CM
I50.811	Acute right heart failure	Diagnosis	ICD-10-CM
I50.812	Chronic right heart failure	Diagnosis	ICD-10-CM
I50.813	Acute on chronic right heart failure	Diagnosis	ICD-10-CM
I50.814	Right heart failure due to left heart failure	Diagnosis	ICD-10-CM
I50.82	Biventricular heart failure	Diagnosis	ICD-10-CM
I50.83	High output heart failure	Diagnosis	ICD-10-CM
I50.84	End stage heart failure	Diagnosis	ICD-10-CM
I50.89	Other heart failure	Diagnosis	ICD-10-CM
I50.9	Heart failure, unspecified	Diagnosis	ICD-10-CM
I97.13	Postprocedural heart failure	Diagnosis	ICD-10-CM
I97.130	Postprocedural heart failure following cardiac surgery	Diagnosis	ICD-10-CM
I97.131	Postprocedural heart failure following other surgery	Diagnosis	ICD-10-CM
Hyperlipidemia			
E78.00	Pure hypercholesterolemia, unspecified	Diagnosis	ICD-10-CM
E78.01	Familial hypercholesterolemia	Diagnosis	ICD-10-CM
E78.1	Pure hyperglyceridemia	Diagnosis	ICD-10-CM
E78.2	Mixed hyperlipidemia	Diagnosis	ICD-10-CM
E78.4	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.5	Hyperlipidemia, unspecified	Diagnosis	ICD-10-CM
Hypertensive Disease			
H35.031	Hypertensive retinopathy, right eye	Diagnosis	ICD-10-CM
H35.032	Hypertensive retinopathy, left eye	Diagnosis	ICD-10-CM
H35.033	Hypertensive retinopathy, bilateral	Diagnosis	ICD-10-CM
H35.039	Hypertensive retinopathy, unspecified eye	Diagnosis	ICD-10-CM
I10	Essential (primary) hypertension	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I11.9	Hypertensive heart disease without heart failure	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.1	Hypertensive heart and chronic kidney disease without heart failure	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I15.0	Renovascular hypertension	Diagnosis	ICD-10-CM
I15.1	Hypertension secondary to other renal disorders	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I15.2	Hypertension secondary to endocrine disorders	Diagnosis	ICD-10-CM
I15.8	Other secondary hypertension	Diagnosis	ICD-10-CM
I15.9	Secondary hypertension, unspecified	Diagnosis	ICD-10-CM
I16.0	Hypertensive urgency	Diagnosis	ICD-10-CM
I16.1	Hypertensive emergency	Diagnosis	ICD-10-CM
I16.9	Hypertensive crisis, unspecified	Diagnosis	ICD-10-CM
I67.4	Hypertensive encephalopathy	Diagnosis	ICD-10-CM
N26.2	Page kidney	Diagnosis	ICD-10-CM
Thyroid Disease			
E00.0	Congenital iodine-deficiency syndrome, neurological type	Diagnosis	ICD-10-CM
E00.1	Congenital iodine-deficiency syndrome, myxedematous type	Diagnosis	ICD-10-CM
E00.2	Congenital iodine-deficiency syndrome, mixed type	Diagnosis	ICD-10-CM
E00.9	Congenital iodine-deficiency syndrome, unspecified	Diagnosis	ICD-10-CM
E01.8	Other iodine-deficiency related thyroid disorders and allied conditions	Diagnosis	ICD-10-CM
E02	Subclinical iodine-deficiency hypothyroidism	Diagnosis	ICD-10-CM
E03.0	Congenital hypothyroidism with diffuse goiter	Diagnosis	ICD-10-CM
E03.1	Congenital hypothyroidism without goiter	Diagnosis	ICD-10-CM
E03.2	Hypothyroidism due to medicaments and other exogenous substances	Diagnosis	ICD-10-CM
E03.3	Postinfectious hypothyroidism	Diagnosis	ICD-10-CM
E03.4	Atrophy of thyroid (acquired)	Diagnosis	ICD-10-CM
E03.8	Other specified hypothyroidism	Diagnosis	ICD-10-CM
E03.9	Hypothyroidism, unspecified	Diagnosis	ICD-10-CM
E89.0	Postprocedural hypothyroidism	Diagnosis	ICD-10-CM
Ischemic Heart Disease/Coronary Artery Disease/Myocardial Infarction			
I20	Angina pectoris	Diagnosis	ICD-10-CM
I20.0	Unstable angina	Diagnosis	ICD-10-CM
I20.1	Angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I20.8	Other forms of angina pectoris	Diagnosis	ICD-10-CM
I20.9	Angina pectoris, unspecified	Diagnosis	ICD-10-CM
I21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
I21.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery	Diagnosis	ICD-10-CM
I21.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis	ICD-10-CM
I21.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM
I21.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall	Diagnosis	ICD-10-CM
I21.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM
I21.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM
I21.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I21.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I21.9	Acute myocardial infarction, unspecified	Diagnosis	ICD-10-CM
I21.A1	Myocardial infarction type 2	Diagnosis	ICD-10-CM
I21.A9	Other myocardial infarction type	Diagnosis	ICD-10-CM
I22.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM
I22.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
I22.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I22.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I22.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I23.0	Hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.1	Atrial septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.2	Ventricular septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.7	Postinfarction angina	Diagnosis	ICD-10-CM
I23.8	Other current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I24	Other acute ischemic heart diseases	Diagnosis	ICD-10-CM
I24.0	Acute coronary thrombosis not resulting in myocardial infarction	Diagnosis	ICD-10-CM
I24.1	Dressler's syndrome	Diagnosis	ICD-10-CM
I24.8	Other forms of acute ischemic heart disease	Diagnosis	ICD-10-CM
I24.9	Acute ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
I25.10	Atherosclerotic heart disease of native coronary artery without angina pectoris	Diagnosis	ICD-10-CM
I25.11	Atherosclerotic heart disease of native coronary artery with angina pectoris	Diagnosis	ICD-10-CM
I25.110	Atherosclerotic heart disease of native coronary artery with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.111	Atherosclerotic heart disease of native coronary artery with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.118	Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.119	Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.3	Aneurysm of heart	Diagnosis	ICD-10-CM
I25.41	Coronary artery aneurysm	Diagnosis	ICD-10-CM
I25.42	Coronary artery dissection	Diagnosis	ICD-10-CM
I25.5	Ischemic cardiomyopathy	Diagnosis	ICD-10-CM
I25.6	Silent myocardial ischemia	Diagnosis	ICD-10-CM
I25.7	Atherosclerosis of coronary artery bypass graft(s) and coronary artery of transplanted heart with angina pectoris	Diagnosis	ICD-10-CM
I25.70	Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris	Diagnosis	ICD-10-CM
I25.700	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.701	Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.708	Atherosclerosis of coronary artery bypass graft(s), unspecified, with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.709	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.71	Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris	Diagnosis	ICD-10-CM
I25.710	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I25.711	Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.718	Atherosclerosis of autologous vein coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.719	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.72	Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris	Diagnosis	ICD-10-CM
I25.720	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.721	Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.728	Atherosclerosis of autologous artery coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.729	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.73	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris	Diagnosis	ICD-10-CM
I25.730	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.731	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.738	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.739	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.75	Atherosclerosis of native coronary artery of transplanted heart with angina pectoris	Diagnosis	ICD-10-CM
I25.750	Atherosclerosis of native coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.751	Atherosclerosis of native coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.758	Atherosclerosis of native coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.759	Atherosclerosis of native coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.76	Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris	Diagnosis	ICD-10-CM
I25.760	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.761	Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.768	Atherosclerosis of bypass graft of coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I25.769	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.79	Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris	Diagnosis	ICD-10-CM
I25.790	Atherosclerosis of other coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.791	Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.798	Atherosclerosis of other coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.799	Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.810	Atherosclerosis of coronary artery bypass graft(s) without angina pectoris	Diagnosis	ICD-10-CM
I25.811	Atherosclerosis of native coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.812	Atherosclerosis of bypass graft of coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.82	Chronic total occlusion of coronary artery	Diagnosis	ICD-10-CM
I25.83	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-10-CM
I25.84	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-10-CM
I25.89	Other forms of chronic ischemic heart disease	Diagnosis	ICD-10-CM
I25.9	Chronic ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
I46.2	Cardiac arrest due to underlying cardiac condition	Diagnosis	ICD-10-CM
I46.8	Cardiac arrest due to other underlying condition	Diagnosis	ICD-10-CM
I46.9	Cardiac arrest, cause unspecified	Diagnosis	ICD-10-CM
I47.0	Re-entry ventricular arrhythmia	Diagnosis	ICD-10-CM
I47.2	Ventricular tachycardia	Diagnosis	ICD-10-CM
Z95.1	Presence of aortocoronary bypass graft	Diagnosis	ICD-10-CM
Z95.5	Presence of coronary angioplasty implant and graft	Diagnosis	ICD-10-CM
0210083	Bypass Coronary Artery, One Artery from Coronary Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
0210088	Bypass Coronary Artery, One Artery from Right Internal Mammary with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
0210089	Bypass Coronary Artery, One Artery from Left Internal Mammary with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
0210093	Bypass Coronary Artery, One Artery from Coronary Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0210098	Bypass Coronary Artery, One Artery from Right Internal Mammary with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0210099	Bypass Coronary Artery, One Artery from Left Internal Mammary with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0210483	Bypass Coronary Artery, One Artery from Coronary Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0210488	Bypass Coronary Artery, One Artery from Right Internal Mammary with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
0210489	Bypass Coronary Artery, One Artery from Left Internal Mammary with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0210493	Bypass Coronary Artery, One Artery from Coronary Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0210498	Bypass Coronary Artery, One Artery from Right Internal Mammary with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0210499	Bypass Coronary Artery, One Artery from Left Internal Mammary with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0211083	Bypass Coronary Artery, Two Arteries from Coronary Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
0211088	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
0211089	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
0211093	Bypass Coronary Artery, Two Arteries from Coronary Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0211098	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0211099	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0211483	Bypass Coronary Artery, Two Arteries from Coronary Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0211488	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0211489	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0211493	Bypass Coronary Artery, Two Arteries from Coronary Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0211498	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0211499	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0212083	Bypass Coronary Artery, Three Arteries from Coronary Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
0212088	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
0212089	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
0212093	Bypass Coronary Artery, Three Arteries from Coronary Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0212098	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0212099	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
0212483	Bypass Coronary Artery, Three Arteries from Coronary Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0212488	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0212489	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0212493	Bypass Coronary Artery, Three Arteries from Coronary Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0212498	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0212499	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0213083	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
0213088	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
0213089	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
0213093	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0213098	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0213099	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0213483	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0213488	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0213489	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0213493	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0213498	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0213499	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0270046	Dilation of Coronary Artery, One Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
0270056	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0270066	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0270076	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
0270346	Dilation of Coronary Artery, One Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0270356	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0270366	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0270376	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0270446	Dilation of Coronary Artery, One Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0270456	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0270466	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0270476	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0271046	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
0271056	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0271066	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0271076	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0271346	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0271356	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0271366	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0271376	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0271446	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0271456	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0271466	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0271476	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0272046	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
0272056	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
0272066	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0272076	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0272346	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0272356	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0272366	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0272376	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0272446	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0272456	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0272466	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0272476	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0273046	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
0273056	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0273066	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0273076	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0273346	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0273356	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0273366	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0273376	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0273446	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0273456	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0273466	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0273476	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
02700E6	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02703E6	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02704E6	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02710E6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02713E6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02714E6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02720E6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02723E6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02724E6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02730E6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02733E6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02734E6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021008C	Bypass Coronary Artery, One Artery from Thoracic Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021008F	Bypass Coronary Artery, One Artery from Abdominal Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021008W	Bypass Coronary Artery, One Artery from Aorta with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021009C	Bypass Coronary Artery, One Artery from Thoracic Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021009F	Bypass Coronary Artery, One Artery from Abdominal Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021009W	Bypass Coronary Artery, One Artery from Aorta with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
02100A3	Bypass Coronary Artery, One Artery from Coronary Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02100A8	Bypass Coronary Artery, One Artery from Right Internal Mammary with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02100A9	Bypass Coronary Artery, One Artery from Left Internal Mammary with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02100AC	Bypass Coronary Artery, One Artery from Thoracic Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
02100AF	Bypass Coronary Artery, One Artery from Abdominal Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02100AW	Bypass Coronary Artery, One Artery from Aorta with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02100J3	Bypass Coronary Artery, One Artery from Coronary Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02100J8	Bypass Coronary Artery, One Artery from Right Internal Mammary with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02100J9	Bypass Coronary Artery, One Artery from Left Internal Mammary with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02100JC	Bypass Coronary Artery, One Artery from Thoracic Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02100JF	Bypass Coronary Artery, One Artery from Abdominal Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02100JW	Bypass Coronary Artery, One Artery from Aorta with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02100K3	Bypass Coronary Artery, One Artery from Coronary Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02100K8	Bypass Coronary Artery, One Artery from Right Internal Mammary with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02100K9	Bypass Coronary Artery, One Artery from Left Internal Mammary with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02100KC	Bypass Coronary Artery, One Artery from Thoracic Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02100KF	Bypass Coronary Artery, One Artery from Abdominal Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02100KW	Bypass Coronary Artery, One Artery from Aorta with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02100Z3	Bypass Coronary Artery, One Artery from Coronary Artery, Open Approach	Procedure	ICD-10-PCS
02100Z8	Bypass Coronary Artery, One Artery from Right Internal Mammary, Open Approach	Procedure	ICD-10-PCS
02100Z9	Bypass Coronary Artery, One Artery from Left Internal Mammary, Open Approach	Procedure	ICD-10-PCS
02100ZC	Bypass Coronary Artery, One Artery from Thoracic Artery, Open Approach	Procedure	ICD-10-PCS
02100ZF	Bypass Coronary Artery, One Artery from Abdominal Artery, Open Approach	Procedure	ICD-10-PCS
021048C	Bypass Coronary Artery, One Artery from Thoracic Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021048F	Bypass Coronary Artery, One Artery from Abdominal Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021048W	Bypass Coronary Artery, One Artery from Aorta with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021049C	Bypass Coronary Artery, One Artery from Thoracic Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021049F	Bypass Coronary Artery, One Artery from Abdominal Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
021049W	Bypass Coronary Artery, One Artery from Aorta with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104A3	Bypass Coronary Artery, One Artery from Coronary Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104A8	Bypass Coronary Artery, One Artery from Right Internal Mammary with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104A9	Bypass Coronary Artery, One Artery from Left Internal Mammary with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104AC	Bypass Coronary Artery, One Artery from Thoracic Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104AF	Bypass Coronary Artery, One Artery from Abdominal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104AW	Bypass Coronary Artery, One Artery from Aorta with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104J3	Bypass Coronary Artery, One Artery from Coronary Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104J8	Bypass Coronary Artery, One Artery from Right Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104J9	Bypass Coronary Artery, One Artery from Left Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104JC	Bypass Coronary Artery, One Artery from Thoracic Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104JF	Bypass Coronary Artery, One Artery from Abdominal Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104JW	Bypass Coronary Artery, One Artery from Aorta with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104K3	Bypass Coronary Artery, One Artery from Coronary Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104K8	Bypass Coronary Artery, One Artery from Right Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104K9	Bypass Coronary Artery, One Artery from Left Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104KC	Bypass Coronary Artery, One Artery from Thoracic Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104KF	Bypass Coronary Artery, One Artery from Abdominal Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104KW	Bypass Coronary Artery, One Artery from Aorta with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104Z3	Bypass Coronary Artery, One Artery from Coronary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104Z8	Bypass Coronary Artery, One Artery from Right Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104Z9	Bypass Coronary Artery, One Artery from Left Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
02104ZC	Bypass Coronary Artery, One Artery from Thoracic Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02104ZF	Bypass Coronary Artery, One Artery from Abdominal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021108C	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021108F	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021108W	Bypass Coronary Artery, Two Arteries from Aorta with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021109C	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021109F	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021109W	Bypass Coronary Artery, Two Arteries from Aorta with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
02110A3	Bypass Coronary Artery, Two Arteries from Coronary Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02110A8	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02110A9	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02110AC	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02110AF	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02110AW	Bypass Coronary Artery, Two Arteries from Aorta with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02110J3	Bypass Coronary Artery, Two Arteries from Coronary Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02110J8	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02110J9	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02110JC	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02110JF	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02110JW	Bypass Coronary Artery, Two Arteries from Aorta with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02110K3	Bypass Coronary Artery, Two Arteries from Coronary Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02110K8	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
02110K9	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02110KC	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02110KF	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02110KW	Bypass Coronary Artery, Two Arteries from Aorta with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02110Z3	Bypass Coronary Artery, Two Arteries from Coronary Artery, Open Approach	Procedure	ICD-10-PCS
02110Z8	Bypass Coronary Artery, Two Arteries from Right Internal Mammary, Open Approach	Procedure	ICD-10-PCS
02110Z9	Bypass Coronary Artery, Two Arteries from Left Internal Mammary, Open Approach	Procedure	ICD-10-PCS
02110ZC	Bypass Coronary Artery, Two Arteries from Thoracic Artery, Open Approach	Procedure	ICD-10-PCS
02110ZF	Bypass Coronary Artery, Two Arteries from Abdominal Artery, Open Approach	Procedure	ICD-10-PCS
021148C	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021148F	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021148W	Bypass Coronary Artery, Two Arteries from Aorta with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021149C	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021149F	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021149W	Bypass Coronary Artery, Two Arteries from Aorta with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114A3	Bypass Coronary Artery, Two Arteries from Coronary Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114A8	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114A9	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114AC	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114AF	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114AW	Bypass Coronary Artery, Two Arteries from Aorta with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114J3	Bypass Coronary Artery, Two Arteries from Coronary Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114J8	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114J9	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
02114JC	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114JF	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114JW	Bypass Coronary Artery, Two Arteries from Aorta with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114K3	Bypass Coronary Artery, Two Arteries from Coronary Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114K8	Bypass Coronary Artery, Two Arteries from Right Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114K9	Bypass Coronary Artery, Two Arteries from Left Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114KC	Bypass Coronary Artery, Two Arteries from Thoracic Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114KF	Bypass Coronary Artery, Two Arteries from Abdominal Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114KW	Bypass Coronary Artery, Two Arteries from Aorta with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114Z3	Bypass Coronary Artery, Two Arteries from Coronary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114Z8	Bypass Coronary Artery, Two Arteries from Right Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114Z9	Bypass Coronary Artery, Two Arteries from Left Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114ZC	Bypass Coronary Artery, Two Arteries from Thoracic Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114ZF	Bypass Coronary Artery, Two Arteries from Abdominal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021208C	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021208F	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021208W	Bypass Coronary Artery, Three Arteries from Aorta with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021209C	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021209F	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021209W	Bypass Coronary Artery, Three Arteries from Aorta with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
02120A3	Bypass Coronary Artery, Three Arteries from Coronary Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02120A8	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
02120A9	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02120AC	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02120AF	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02120AW	Bypass Coronary Artery, Three Arteries from Aorta with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02120J3	Bypass Coronary Artery, Three Arteries from Coronary Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02120J8	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02120J9	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02120JC	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02120JF	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02120JW	Bypass Coronary Artery, Three Arteries from Aorta with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02120K3	Bypass Coronary Artery, Three Arteries from Coronary Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02120K8	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02120K9	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02120KC	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02120KF	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02120KW	Bypass Coronary Artery, Three Arteries from Aorta with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02120Z3	Bypass Coronary Artery, Three Arteries from Coronary Artery, Open Approach	Procedure	ICD-10-PCS
02120Z8	Bypass Coronary Artery, Three Arteries from Right Internal Mammary, Open Approach	Procedure	ICD-10-PCS
02120Z9	Bypass Coronary Artery, Three Arteries from Left Internal Mammary, Open Approach	Procedure	ICD-10-PCS
02120ZC	Bypass Coronary Artery, Three Arteries from Thoracic Artery, Open Approach	Procedure	ICD-10-PCS
02120ZF	Bypass Coronary Artery, Three Arteries from Abdominal Artery, Open Approach	Procedure	ICD-10-PCS
021248C	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021248F	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021248W	Bypass Coronary Artery, Three Arteries from Aorta with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
021249C	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021249F	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021249W	Bypass Coronary Artery, Three Arteries from Aorta with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124A3	Bypass Coronary Artery, Three Arteries from Coronary Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124A8	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124A9	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124AC	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124AF	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124AW	Bypass Coronary Artery, Three Arteries from Aorta with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124J3	Bypass Coronary Artery, Three Arteries from Coronary Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124J8	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124J9	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124JC	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124JF	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124JW	Bypass Coronary Artery, Three Arteries from Aorta with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124K3	Bypass Coronary Artery, Three Arteries from Coronary Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124K8	Bypass Coronary Artery, Three Arteries from Right Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124K9	Bypass Coronary Artery, Three Arteries from Left Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124KC	Bypass Coronary Artery, Three Arteries from Thoracic Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124KF	Bypass Coronary Artery, Three Arteries from Abdominal Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124KW	Bypass Coronary Artery, Three Arteries from Aorta with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124Z3	Bypass Coronary Artery, Three Arteries from Coronary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
02124Z8	Bypass Coronary Artery, Three Arteries from Right Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124Z9	Bypass Coronary Artery, Three Arteries from Left Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124ZC	Bypass Coronary Artery, Three Arteries from Thoracic Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124ZF	Bypass Coronary Artery, Three Arteries from Abdominal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021308C	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021308F	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021308W	Bypass Coronary Artery, Four or More Arteries from Aorta with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021309C	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021309F	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021309W	Bypass Coronary Artery, Four or More Arteries from Aorta with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
02130A3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02130A8	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02130A9	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02130AC	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02130AF	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02130AW	Bypass Coronary Artery, Four or More Arteries from Aorta with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
02130J3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02130J8	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02130J9	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02130JC	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02130JF	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02130JW	Bypass Coronary Artery, Four or More Arteries from Aorta with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
02130K3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02130K8	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02130K9	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02130KC	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02130KF	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02130KW	Bypass Coronary Artery, Four or More Arteries from Aorta with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02130Z3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery, Open Approach	Procedure	ICD-10-PCS
02130Z8	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary, Open Approach	Procedure	ICD-10-PCS
02130Z9	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary, Open Approach	Procedure	ICD-10-PCS
02130ZC	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery, Open Approach	Procedure	ICD-10-PCS
02130ZF	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery, Open Approach	Procedure	ICD-10-PCS
021348C	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021348F	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021348W	Bypass Coronary Artery, Four or More Arteries from Aorta with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021349C	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021349F	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021349W	Bypass Coronary Artery, Four or More Arteries from Aorta with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134A3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134A8	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134A9	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134AC	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134AF	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134AW	Bypass Coronary Artery, Four or More Arteries from Aorta with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
02134J3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134J8	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134J9	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134JC	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134JF	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134JW	Bypass Coronary Artery, Four or More Arteries from Aorta with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134K3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134K8	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134K9	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134KC	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134KF	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134KW	Bypass Coronary Artery, Four or More Arteries from Aorta with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134Z3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134Z8	Bypass Coronary Artery, Four or More Arteries from Right Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134Z9	Bypass Coronary Artery, Four or More Arteries from Left Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134ZC	Bypass Coronary Artery, Four or More Arteries from Thoracic Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134ZF	Bypass Coronary Artery, Four or More Arteries from Abdominal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021K0Z8	Bypass Right Ventricle to Right Internal Mammary, Open Approach	Procedure	ICD-10-PCS
021K0Z9	Bypass Right Ventricle to Left Internal Mammary, Open Approach	Procedure	ICD-10-PCS
021K0ZC	Bypass Right Ventricle to Thoracic Artery, Open Approach	Procedure	ICD-10-PCS
021K0ZF	Bypass Right Ventricle to Abdominal Artery, Open Approach	Procedure	ICD-10-PCS
021K0ZW	Bypass Right Ventricle to Aorta, Open Approach	Procedure	ICD-10-PCS
021K4Z8	Bypass Right Ventricle to Right Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021K4Z9	Bypass Right Ventricle to Left Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021K4ZC	Bypass Right Ventricle to Thoracic Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021K4ZF	Bypass Right Ventricle to Abdominal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
021K4ZW	Bypass Right Ventricle to Aorta, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L08P	Bypass Left Ventricle to Pulmonary Trunk with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021L08Q	Bypass Left Ventricle to Right Pulmonary Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021L08R	Bypass Left Ventricle to Left Pulmonary Artery with Zooplastic Tissue, Open Approach	Procedure	ICD-10-PCS
021L09P	Bypass Left Ventricle to Pulmonary Trunk with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021L09Q	Bypass Left Ventricle to Right Pulmonary Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021L09R	Bypass Left Ventricle to Left Pulmonary Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
021L0AP	Bypass Left Ventricle to Pulmonary Trunk with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
021L0AQ	Bypass Left Ventricle to Right Pulmonary Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
021L0AR	Bypass Left Ventricle to Left Pulmonary Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
021L0JP	Bypass Left Ventricle to Pulmonary Trunk with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
021L0JQ	Bypass Left Ventricle to Right Pulmonary Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
021L0JR	Bypass Left Ventricle to Left Pulmonary Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
021L0KP	Bypass Left Ventricle to Pulmonary Trunk with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
021L0KQ	Bypass Left Ventricle to Right Pulmonary Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
021L0KR	Bypass Left Ventricle to Left Pulmonary Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
021L0Z8	Bypass Left Ventricle to Right Internal Mammary, Open Approach	Procedure	ICD-10-PCS
021L0Z9	Bypass Left Ventricle to Left Internal Mammary, Open Approach	Procedure	ICD-10-PCS
021L0ZC	Bypass Left Ventricle to Thoracic Artery, Open Approach	Procedure	ICD-10-PCS
021L0ZF	Bypass Left Ventricle to Abdominal Artery, Open Approach	Procedure	ICD-10-PCS
021L0ZP	Bypass Left Ventricle to Pulmonary Trunk, Open Approach	Procedure	ICD-10-PCS
021L0ZQ	Bypass Left Ventricle to Right Pulmonary Artery, Open Approach	Procedure	ICD-10-PCS
021L0ZR	Bypass Left Ventricle to Left Pulmonary Artery, Open Approach	Procedure	ICD-10-PCS
021L48P	Bypass Left Ventricle to Pulmonary Trunk with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L48Q	Bypass Left Ventricle to Right Pulmonary Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L48R	Bypass Left Ventricle to Left Pulmonary Artery with Zooplastic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L49P	Bypass Left Ventricle to Pulmonary Trunk with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
021L49Q	Bypass Left Ventricle to Right Pulmonary Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L49R	Bypass Left Ventricle to Left Pulmonary Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4AP	Bypass Left Ventricle to Pulmonary Trunk with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4AQ	Bypass Left Ventricle to Right Pulmonary Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4AR	Bypass Left Ventricle to Left Pulmonary Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4JP	Bypass Left Ventricle to Pulmonary Trunk with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4JQ	Bypass Left Ventricle to Right Pulmonary Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4JR	Bypass Left Ventricle to Left Pulmonary Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4KP	Bypass Left Ventricle to Pulmonary Trunk with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4KQ	Bypass Left Ventricle to Right Pulmonary Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4KR	Bypass Left Ventricle to Left Pulmonary Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4Z8	Bypass Left Ventricle to Right Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4Z9	Bypass Left Ventricle to Left Internal Mammary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4ZC	Bypass Left Ventricle to Thoracic Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4ZF	Bypass Left Ventricle to Abdominal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4ZP	Bypass Left Ventricle to Pulmonary Trunk, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4ZQ	Bypass Left Ventricle to Right Pulmonary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
021L4ZR	Bypass Left Ventricle to Left Pulmonary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027004Z	Dilation of Coronary Artery, One Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027005Z	Dilation of Coronary Artery, One Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
027006Z	Dilation of Coronary Artery, One Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
027007Z	Dilation of Coronary Artery, One Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02700D6	Dilation of Coronary Artery, One Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02700DZ	Dilation of Coronary Artery, One Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02700EZ	Dilation of Coronary Artery, One Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02700F6	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
02700FZ	Dilation of Coronary Artery, One Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02700G6	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02700GZ	Dilation of Coronary Artery, One Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02700T6	Dilation of Coronary Artery, One Artery, Bifurcation, with Radioactive Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02700TZ	Dilation of Coronary Artery, One Artery with Radioactive Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02700Z6	Dilation of Coronary Artery, One Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
02700ZZ	Dilation of Coronary Artery, One Artery, Open Approach	Procedure	ICD-10-PCS
027034Z	Dilation of Coronary Artery, One Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
027035Z	Dilation of Coronary Artery, One Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027036Z	Dilation of Coronary Artery, One Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027037Z	Dilation of Coronary Artery, One Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703D6	Dilation of Coronary Artery, One Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02703DZ	Dilation of Coronary Artery, One Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02703EZ	Dilation of Coronary Artery, One Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703F6	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703FZ	Dilation of Coronary Artery, One Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703G6	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703GZ	Dilation of Coronary Artery, One Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703T6	Dilation of Coronary Artery, One Artery, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02703TZ	Dilation of Coronary Artery, One Artery with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
027044Z	Dilation of Coronary Artery, One Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027045Z	Dilation of Coronary Artery, One Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027046Z	Dilation of Coronary Artery, One Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
027047Z	Dilation of Coronary Artery, One Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704D6	Dilation of Coronary Artery, One Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704DZ	Dilation of Coronary Artery, One Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704EZ	Dilation of Coronary Artery, One Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704F6	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704FZ	Dilation of Coronary Artery, One Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704G6	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704GZ	Dilation of Coronary Artery, One Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704T6	Dilation of Coronary Artery, One Artery, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704TZ	Dilation of Coronary Artery, One Artery with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027104Z	Dilation of Coronary Artery, Two Arteries with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027105Z	Dilation of Coronary Artery, Two Arteries with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
027106Z	Dilation of Coronary Artery, Two Arteries with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
027107Z	Dilation of Coronary Artery, Two Arteries with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02710D6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02710DZ	Dilation of Coronary Artery, Two Arteries with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02710EZ	Dilation of Coronary Artery, Two Arteries with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02710F6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02710FZ	Dilation of Coronary Artery, Two Arteries with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02710G6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02710GZ	Dilation of Coronary Artery, Two Arteries with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02710T6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Radioactive Intraluminal Device, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
02710TZ	Dilation of Coronary Artery, Two Arteries with Radioactive Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02710Z6	Dilation of Coronary Artery, Two Arteries, Bifurcation, Open Approach	Procedure	ICD-10-PCS
02710ZZ	Dilation of Coronary Artery, Two Arteries, Open Approach	Procedure	ICD-10-PCS
027134Z	Dilation of Coronary Artery, Two Arteries with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
027135Z	Dilation of Coronary Artery, Two Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027136Z	Dilation of Coronary Artery, Two Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027137Z	Dilation of Coronary Artery, Two Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713D6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02713DZ	Dilation of Coronary Artery, Two Arteries with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02713EZ	Dilation of Coronary Artery, Two Arteries with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713F6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713FZ	Dilation of Coronary Artery, Two Arteries with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713G6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713GZ	Dilation of Coronary Artery, Two Arteries with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713T6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02713TZ	Dilation of Coronary Artery, Two Arteries with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
027144Z	Dilation of Coronary Artery, Two Arteries with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027145Z	Dilation of Coronary Artery, Two Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027146Z	Dilation of Coronary Artery, Two Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027147Z	Dilation of Coronary Artery, Two Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714D6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714DZ	Dilation of Coronary Artery, Two Arteries with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714EZ	Dilation of Coronary Artery, Two Arteries with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
02714F6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714FZ	Dilation of Coronary Artery, Two Arteries with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714G6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714GZ	Dilation of Coronary Artery, Two Arteries with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714T6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714TZ	Dilation of Coronary Artery, Two Arteries with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027204Z	Dilation of Coronary Artery, Three Arteries with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027205Z	Dilation of Coronary Artery, Three Arteries with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
027206Z	Dilation of Coronary Artery, Three Arteries with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
027207Z	Dilation of Coronary Artery, Three Arteries with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02720D6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02720DZ	Dilation of Coronary Artery, Three Arteries with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02720EZ	Dilation of Coronary Artery, Three Arteries with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02720F6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02720FZ	Dilation of Coronary Artery, Three Arteries with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02720G6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02720GZ	Dilation of Coronary Artery, Three Arteries with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02720T6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Radioactive Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02720TZ	Dilation of Coronary Artery, Three Arteries with Radioactive Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02720Z6	Dilation of Coronary Artery, Three Arteries, Bifurcation, Open Approach	Procedure	ICD-10-PCS
02720ZZ	Dilation of Coronary Artery, Three Arteries, Open Approach	Procedure	ICD-10-PCS
027234Z	Dilation of Coronary Artery, Three Arteries with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
027235Z	Dilation of Coronary Artery, Three Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
027236Z	Dilation of Coronary Artery, Three Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027237Z	Dilation of Coronary Artery, Three Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723D6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02723DZ	Dilation of Coronary Artery, Three Arteries with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02723EZ	Dilation of Coronary Artery, Three Arteries with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723F6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723FZ	Dilation of Coronary Artery, Three Arteries with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723G6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723GZ	Dilation of Coronary Artery, Three Arteries with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723T6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02723TZ	Dilation of Coronary Artery, Three Arteries with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
027244Z	Dilation of Coronary Artery, Three Arteries with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027245Z	Dilation of Coronary Artery, Three Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027246Z	Dilation of Coronary Artery, Three Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027247Z	Dilation of Coronary Artery, Three Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724D6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724DZ	Dilation of Coronary Artery, Three Arteries with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724EZ	Dilation of Coronary Artery, Three Arteries with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724F6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724FZ	Dilation of Coronary Artery, Three Arteries with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724G6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724GZ	Dilation of Coronary Artery, Three Arteries with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
02724T6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724TZ	Dilation of Coronary Artery, Three Arteries with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027304Z	Dilation of Coronary Artery, Four or More Arteries with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027305Z	Dilation of Coronary Artery, Four or More Arteries with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
027306Z	Dilation of Coronary Artery, Four or More Arteries with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
027307Z	Dilation of Coronary Artery, Four or More Arteries with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02730D6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02730DZ	Dilation of Coronary Artery, Four or More Arteries with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02730EZ	Dilation of Coronary Artery, Four or More Arteries with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02730F6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02730FZ	Dilation of Coronary Artery, Four or More Arteries with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02730G6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02730GZ	Dilation of Coronary Artery, Four or More Arteries with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
02730T6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Radioactive Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02730TZ	Dilation of Coronary Artery, Four or More Arteries with Radioactive Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
02730Z6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, Open Approach	Procedure	ICD-10-PCS
02730ZZ	Dilation of Coronary Artery, Four or More Arteries, Open Approach	Procedure	ICD-10-PCS
027334Z	Dilation of Coronary Artery, Four or More Arteries with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
027335Z	Dilation of Coronary Artery, Four or More Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027336Z	Dilation of Coronary Artery, Four or More Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027337Z	Dilation of Coronary Artery, Four or More Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733D6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02733DZ	Dilation of Coronary Artery, Four or More Arteries with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
02733EZ	Dilation of Coronary Artery, Four or More Arteries with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733F6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733FZ	Dilation of Coronary Artery, Four or More Arteries with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733G6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733GZ	Dilation of Coronary Artery, Four or More Arteries with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733T6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02733TZ	Dilation of Coronary Artery, Four or More Arteries with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
027344Z	Dilation of Coronary Artery, Four or More Arteries with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027345Z	Dilation of Coronary Artery, Four or More Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027346Z	Dilation of Coronary Artery, Four or More Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027347Z	Dilation of Coronary Artery, Four or More Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734D6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734DZ	Dilation of Coronary Artery, Four or More Arteries with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734EZ	Dilation of Coronary Artery, Four or More Arteries with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734F6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734FZ	Dilation of Coronary Artery, Four or More Arteries with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734G6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734GZ	Dilation of Coronary Artery, Four or More Arteries with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734T6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734TZ	Dilation of Coronary Artery, Four or More Arteries with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02C00Z6	Extirpation of Matter from Coronary Artery, One Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
02C00ZZ	Extirpation of Matter from Coronary Artery, One Artery, Open Approach	Procedure	ICD-10-PCS
02C03Z6	Extirpation of Matter from Coronary Artery, One Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
02C03ZZ	Extirpation of Matter from Coronary Artery, One Artery, Percutaneous Approach	Procedure	ICD-10-PCS
02C04Z6	Extirpation of Matter from Coronary Artery, One Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02C04ZZ	Extirpation of Matter from Coronary Artery, One Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02C10Z6	Extirpation of Matter from Coronary Artery, Two Arteries, Bifurcation, Open Approach	Procedure	ICD-10-PCS
02C10ZZ	Extirpation of Matter from Coronary Artery, Two Arteries, Open Approach	Procedure	ICD-10-PCS
02C13Z6	Extirpation of Matter from Coronary Artery, Two Arteries, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
02C13ZZ	Extirpation of Matter from Coronary Artery, Two Arteries, Percutaneous Approach	Procedure	ICD-10-PCS
02C14Z6	Extirpation of Matter from Coronary Artery, Two Arteries, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02C14ZZ	Extirpation of Matter from Coronary Artery, Two Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02C20Z6	Extirpation of Matter from Coronary Artery, Three Arteries, Bifurcation, Open Approach	Procedure	ICD-10-PCS
02C20ZZ	Extirpation of Matter from Coronary Artery, Three Arteries, Open Approach	Procedure	ICD-10-PCS
02C23Z6	Extirpation of Matter from Coronary Artery, Three Arteries, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
02C23ZZ	Extirpation of Matter from Coronary Artery, Three Arteries, Percutaneous Approach	Procedure	ICD-10-PCS
02C24Z6	Extirpation of Matter from Coronary Artery, Three Arteries, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02C24ZZ	Extirpation of Matter from Coronary Artery, Three Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02C30Z6	Extirpation of Matter from Coronary Artery, Four or More Arteries, Bifurcation, Open Approach	Procedure	ICD-10-PCS
02C30ZZ	Extirpation of Matter from Coronary Artery, Four or More Arteries, Open Approach	Procedure	ICD-10-PCS
02C33Z6	Extirpation of Matter from Coronary Artery, Four or More Arteries, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
02C33ZZ	Extirpation of Matter from Coronary Artery, Four or More Arteries, Percutaneous Approach	Procedure	ICD-10-PCS
02C34Z6	Extirpation of Matter from Coronary Artery, Four or More Arteries, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02C34ZZ	Extirpation of Matter from Coronary Artery, Four or More Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
3E07017	Introduction of Other Thrombolytic into Coronary Artery, Open Approach	Procedure	ICD-10-PCS
3E070PZ	Introduction of Platelet Inhibitor into Coronary Artery, Open Approach	Procedure	ICD-10-PCS
3E07317	Introduction of Other Thrombolytic into Coronary Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E073PZ	Introduction of Platelet Inhibitor into Coronary Artery, Percutaneous Approach	Procedure	ICD-10-PCS
X2C0361	Extirpation of Matter from Coronary Artery, One Artery using Orbital Atherectomy Technology, Percutaneous Approach, New Technology Group 1	Procedure	ICD-10-PCS
X2C1361	Extirpation of Matter from Coronary Artery, Two Arteries using Orbital Atherectomy Technology, Percutaneous Approach, New Technology Group 1	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
X2C2361	Extirpation of Matter from Coronary Artery, Three Arteries using Orbital Atherectomy Technology, Percutaneous Approach, New Technology Group 1	Procedure	ICD-10-PCS
X2C3361	Extirpation of Matter from Coronary Artery, Four or More Arteries using Orbital Atherectomy Technology, Percutaneous Approach, New Technology Group 1	Procedure	ICD-10-PCS
33510	Coronary artery bypass, vein only; single coronary venous graft	Procedure	CPT-4
33511	Coronary artery bypass, vein only; 2 coronary venous grafts	Procedure	CPT-4
33512	Coronary artery bypass, vein only; 3 coronary venous grafts	Procedure	CPT-4
33513	Coronary artery bypass, vein only; 4 coronary venous grafts	Procedure	CPT-4
33514	Coronary artery bypass, vein only; 5 coronary venous grafts	Procedure	CPT-4
33516	Coronary artery bypass, vein only; 6 or more coronary venous grafts	Procedure	CPT-4
33517	Coronary artery bypass, using venous graft(s) and arterial graft(s); single vein graft (List separately in addition to code for primary procedure)	Procedure	CPT-4
33518	Coronary artery bypass, using venous graft(s) and arterial graft(s); 2 venous grafts (List separately in addition to code for primary procedure)	Procedure	CPT-4
33519	Coronary artery bypass, using venous graft(s) and arterial graft(s); 3 venous grafts (List separately in addition to code for primary procedure)	Procedure	CPT-4
33520	Coronary Artery Bypass, Nonautogenous Graft (eg, Synthetic Or Cadaver); Single Graft	Procedure	CPT-4
33521	Coronary artery bypass, using venous graft(s) and arterial graft(s); 4 venous grafts (List separately in addition to code for primary procedure)	Procedure	CPT-4
33522	Coronary artery bypass, using venous graft(s) and arterial graft(s); 5 venous grafts (List separately in addition to code for primary procedure)	Procedure	CPT-4
33523	Coronary artery bypass, using venous graft(s) and arterial graft(s); 6 or more venous grafts (List separately in addition to code for primary procedure)	Procedure	CPT-4
33525	Coronary Artery Bypass, Nonautogenous Graft (eg, Synthetic Or Cadaver); Two Coronary Grafts	Procedure	CPT-4
33528	Coronary Artery Bypass, Nonautogenous Graft (eg, Synthetic Or Cadaver); Three Or More Coronary Grafts	Procedure	CPT-4
33530	Reoperation, coronary artery bypass procedure or valve procedure, more than 1 month after original operation (List separately in addition to code for primary procedure)	Procedure	CPT-4
33533	Coronary artery bypass, using arterial graft(s); single arterial graft	Procedure	CPT-4
33534	Coronary artery bypass, using arterial graft(s); 2 coronary arterial grafts	Procedure	CPT-4
33535	Coronary artery bypass, using arterial graft(s); 3 coronary arterial grafts	Procedure	CPT-4
33536	Coronary artery bypass, using arterial graft(s); 4 or more coronary arterial grafts	Procedure	CPT-4
33560	Myocardial Operation Combined With Coronary Bypass Procedure	Procedure	CPT-4
33570	CORONARY ANGIOPLASTY W/BYPASS	Procedure	CPT-4
33572	Coronary endarterectomy, open, any method, of left anterior descending, circumflex, or right coronary artery performed in conjunction with coronary artery bypass graft procedure, each vessel (List separately in addition to primary procedure)	Procedure	CPT-4
33575	CORON ANGIOPLSTY W/BYPASS; COMBO W/VASCULARIZAT	Procedure	CPT-4
35600	Harvest of upper extremity artery, 1 segment, for coronary artery bypass procedure (List separately in addition to code for primary procedure)	Procedure	CPT-4

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
92920	Percutaneous transluminal coronary angioplasty; single major coronary artery or branch	Procedure	CPT-4
92921	Percutaneous transluminal coronary angioplasty; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)	Procedure	CPT-4
92924	Percutaneous transluminal coronary atherectomy, with coronary angioplasty when performed; single major coronary artery or branch	Procedure	CPT-4
92925	Percutaneous transluminal coronary atherectomy, with coronary angioplasty when performed; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)	Procedure	CPT-4
92928	Percutaneous transcatheter placement of intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch	Procedure	CPT-4
92929	Percutaneous transcatheter placement of intracoronary stent(s), with coronary angioplasty when performed; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)	Procedure	CPT-4
92933	Percutaneous transluminal coronary atherectomy, with intracoronary stent, with coronary angioplasty when performed; single major coronary artery or branch	Procedure	CPT-4
92934	Percutaneous transluminal coronary atherectomy, with intracoronary stent, with coronary angioplasty when performed; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)	Procedure	CPT-4
92937	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of intracoronary stent, atherectomy and angioplasty, including distal protection when performed; single vessel	Procedure	CPT-4
92938	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of intracoronary stent, atherectomy and angioplasty, including distal protection when performed; each additional branch subtended by the bypass graft (List separately in addition to code for primary procedure)	Procedure	CPT-4
92941	Percutaneous transluminal revascularization of acute total/subtotal occlusion during acute myocardial infarction, coronary artery or coronary artery bypass graft, any combination of intracoronary stent, atherectomy and angioplasty, including aspiration thrombectomy when performed, single vessel	Procedure	CPT-4
92943	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of intracoronary stent, atherectomy and angioplasty; single vessel	Procedure	CPT-4
92944	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of intracoronary stent, atherectomy and angioplasty; each additional coronary artery, coronary artery branch, or bypass graft (List separately in addition to code for primary procedure)	Procedure	CPT-4
92973	Percutaneous transluminal coronary thrombectomy mechanical (List separately in addition to code for primary procedure)	Procedure	CPT-4

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
92974	Transcatheter placement of radiation delivery device for subsequent coronary intravascular brachytherapy (List separately in addition to code for primary procedure)	Procedure	CPT-4
92977	Thrombolysis, coronary; by intravenous infusion	Procedure	CPT-4
92980	Transcatheter placement of an intracoronary stent(s), percutaneous, with or without other therapeutic intervention, any method; single vessel	Procedure	CPT-4
92981	Transcatheter placement of an intracoronary stent(s), percutaneous, with or without other therapeutic intervention, any method; each additional vessel (List separately in addition to code for primary procedure)	Procedure	CPT-4
92982	Percutaneous transluminal coronary balloon angioplasty; single vessel	Procedure	CPT-4
92984	Percutaneous transluminal coronary balloon angioplasty; each additional vessel (List separately in addition to code for primary procedure)	Procedure	CPT-4
92995	Percutaneous transluminal coronary atherectomy, by mechanical or other method, with or without balloon angioplasty; single vessel	Procedure	CPT-4
92996	Percutaneous transluminal coronary atherectomy, by mechanical or other method, with or without balloon angioplasty; each additional vessel (List separately in addition to code for primary procedure)	Procedure	CPT-4
C1034	Catheter, coronary angioplasty, surpass superfusion catheter, long 30 surpass superfusion catheter	Procedure	HCPCS
C1100	Guide wire, percutaneous transluminal coronary angioplasty, medtronic ave gt1 guide wire, medtronic ave gt2 fusion guide wire, interventional technologies trackwire, interventional technologies trackwire support, interventional technologies trackwire extra support	Procedure	HCPCS
C1101	Catheter, percutaneous transluminal coronary angioplasty guide, medtronic ave 5f, 6f, 7f, 8f, 9f zuma guide catheter, medtronic ave z2 5f, 6f, 7f, 8f, 9f zuma guide catheter, medtronic ave vector guide catheter, medtronic ave vector x guide catheter. note: only the medtronic ave z2 zuma guide catheters are effective october 1, 2000. the medtronic ave zuma guide catheters were effective august 1, 2000.	Procedure	HCPCS
C1366	Guide wire, percutaneous transluminal coronary angioplasty, hi-torque iron man, hi-torque balance middleweight, hi-torque all star, hi-torque balance heavyweight, hi-torque balance trek	Procedure	HCPCS
C1367	Guide wire, percutaneous transluminal coronary angioplasty, hi-torque cross it, hi-torque cross-it 100xt, hi-torque cross-it 200xt, hi-torque cross-it 300xt, hi-torque wiggle	Procedure	HCPCS
C1500	Atherectomy system, peripheral, rotablator rotational angioplasty system with rotalink exchangeable catheter, advancer, and guide wire	Procedure	HCPCS
C1725	Catheter, transluminal angioplasty, nonlaser (may include guidance, infusion/perfusion capability)	Procedure	HCPCS
C1885	Catheter, transluminal angioplasty, laser	Procedure	HCPCS
C1930	Catheter, percutaneous transluminal coronary angioplasty, coyote dilatation catheter 20mm/30mm/40mm	Procedure	HCPCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
C1933	Catheter, opti-plast centurion 5.5f pta catheter (shaft length 50 cm to 120 cm), opti-plast xl 5.5f pta catheter (shaft length 75 cm to 120 cm), opti-plast pta catheter (5.5 fr), tru trac 5fr percutaneous transluminal angioplasty balloon dilatation catheter, optiplast xt 5 fr percutaneous transluminal angioplasty catheter (various sizes)	Procedure	HCPCS
C1948	Catheter, pursuit balloon angioplasty catheter, cook accent balloon angioplasty catheter	Procedure	HCPCS
C1981	Catheter ,coronary angioplasty balloon, adante, bonnie, bonnie 15mm, bonnie monorail 30mm or 40mm, bonnie sliding rail, bypass speedy, chubby, chubby sliding rail, coyote 20mm, coyote 9/15/25mm, maxxum, nc ranger, nc ranger 9mm, ranger 20mm, long ranger 30mm or 40mm, nc ranger 16/18mm, nc ranger 22/25/30mm, nc big ranger, quantum ranger, quantum ranger 1/4 sizes, quantum ranger 9/16/18mm, quantum ranger 22/30mm, quantum ranger 25mm, ranger lp 20/30/40, viva/long viva, ace - 1cm, ace - 2cm, ace graft, long ace, pivot cobra (10, 14, 18, 30, 40mm in lengths) note: only the bonnie monorail 30mm or 40mm, long ranger 30mm or 40mm, and ranger 20mm are effective 01/01/01. the other catheters were effective 08/01/00.	Procedure	HCPCS
C2605	Catheter, spectranetics extreme laser catheter, spectranetics extreme 0.9mm coronary angioplasty catheter (model 110-001)	Procedure	HCPCS
C2623	Catheter, transluminal angioplasty, drug-coated, nonlaser	Procedure	HCPCS
C3551	Guide wire, percutaneous transluminal coronary angioplasty, choice, luge, patriot, pt graphix intermediate, trooper, mailman 182/300 cm, glidewire gold guidewire, platinum plus guidewire, platinum plus guidewire with glidex hydrophilic coating, jagwire single-use high performance guide wire, merit medical systems extender guidewire, merit medical systems tomcat ptca guidewire, platinum plus guidewire (0.014 and 0.018 in diameters)	Procedure	HCPCS
C8526	Optiplast xt 5f percutaneous transluminal angioplasty catheter (various sizes)	Procedure	HCPCS
C9600	Percutaneous transcatheter placement of drug eluting intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch	Procedure	HCPCS
C9601	Percutaneous transcatheter placement of drug-eluting intracoronary stent(s), with coronary angioplasty when performed; each additional branch of a major coronary artery (list separately in addition to code for primary procedure)	Procedure	HCPCS
C9602	Percutaneous transluminal coronary atherectomy, with drug eluting intracoronary stent, with coronary angioplasty when performed; single major coronary artery or branch	Procedure	HCPCS
C9603	Percutaneous transluminal coronary atherectomy, with drug-eluting intracoronary stent, with coronary angioplasty when performed; each additional branch of a major coronary artery (list separately in addition to code for primary procedure)	Procedure	HCPCS
C9604	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, including distal protection when performed; single vessel	Procedure	HCPCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
C9605	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, including distal protection when performed; each additional branch subtended by the bypass graft (list separately in addition to code for primary procedure)	Procedure	HCPCS
C9606	Percutaneous transluminal revascularization of acute total/subtotal occlusion during acute myocardial infarction, coronary artery or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, including aspiration thrombectomy when performed, single vessel	Procedure	HCPCS
C9607	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty; single vessel	Procedure	HCPCS
C9608	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty; each additional coronary artery, coronary artery branch, or bypass graft (list separately in addition to code for primary procedure)	Procedure	HCPCS
G0290	Transcatheter placement of a drug eluting intracoronary stent(s), percutaneous, with or without other therapeutic intervention, any method; single vessel	Procedure	HCPCS
G0291	Transcatheter placement of a drug eluting intracoronary stent(s), percutaneous, with or without other therapeutic intervention, any method; each additional vessel	Procedure	HCPCS
S2205	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using arterial graft(s), single coronary arterial graft	Procedure	HCPCS
S2206	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using arterial graft(s), 2 coronary arterial grafts	Procedure	HCPCS
S2207	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using venous graft only, single coronary venous graft	Procedure	HCPCS
S2208	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using single arterial and venous graft(s), single venous graft	Procedure	HCPCS
S2209	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using 2 arterial grafts and single venous graft	Procedure	HCPCS
Left Ventricular Hypertrophy			
I42.1	Obstructive hypertrophic cardiomyopathy	Diagnosis	ICD-10-CM
I42.2	Other hypertrophic cardiomyopathy	Diagnosis	ICD-10-CM
I51.7	Cardiomegaly	Diagnosis	ICD-10-CM
Peripheral Artery Disease			
I70.1	Atherosclerosis of renal artery	Diagnosis	ICD-10-CM
I70.201	Unspecified atherosclerosis of native arteries of extremities, right leg	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I70.202	Unspecified atherosclerosis of native arteries of extremities, left leg	Diagnosis	ICD-10-CM
I70.203	Unspecified atherosclerosis of native arteries of extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.208	Unspecified atherosclerosis of native arteries of extremities, other extremity	Diagnosis	ICD-10-CM
I70.209	Unspecified atherosclerosis of native arteries of extremities, unspecified extremity	Diagnosis	ICD-10-CM
I70.211	Atherosclerosis of native arteries of extremities with intermittent claudication, right leg	Diagnosis	ICD-10-CM
I70.212	Atherosclerosis of native arteries of extremities with intermittent claudication, left leg	Diagnosis	ICD-10-CM
I70.213	Atherosclerosis of native arteries of extremities with intermittent claudication, bilateral legs	Diagnosis	ICD-10-CM
I70.218	Atherosclerosis of native arteries of extremities with intermittent claudication, other extremity	Diagnosis	ICD-10-CM
I70.219	Atherosclerosis of native arteries of extremities with intermittent claudication, unspecified extremity	Diagnosis	ICD-10-CM
I70.221	Atherosclerosis of native arteries of extremities with rest pain, right leg	Diagnosis	ICD-10-CM
I70.222	Atherosclerosis of native arteries of extremities with rest pain, left leg	Diagnosis	ICD-10-CM
I70.223	Atherosclerosis of native arteries of extremities with rest pain, bilateral legs	Diagnosis	ICD-10-CM
I70.228	Atherosclerosis of native arteries of extremities with rest pain, other extremity	Diagnosis	ICD-10-CM
I70.229	Atherosclerosis of native arteries of extremities with rest pain, unspecified extremity	Diagnosis	ICD-10-CM
I70.231	Atherosclerosis of native arteries of right leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.232	Atherosclerosis of native arteries of right leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.233	Atherosclerosis of native arteries of right leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.234	Atherosclerosis of native arteries of right leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.235	Atherosclerosis of native arteries of right leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.238	Atherosclerosis of native arteries of right leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
I70.239	Atherosclerosis of native arteries of right leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.241	Atherosclerosis of native arteries of left leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.242	Atherosclerosis of native arteries of left leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.243	Atherosclerosis of native arteries of left leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.244	Atherosclerosis of native arteries of left leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.245	Atherosclerosis of native arteries of left leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.248	Atherosclerosis of native arteries of left leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
I70.249	Atherosclerosis of native arteries of left leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.25	Atherosclerosis of native arteries of other extremities with ulceration	Diagnosis	ICD-10-CM
I70.261	Atherosclerosis of native arteries of extremities with gangrene, right leg	Diagnosis	ICD-10-CM
I70.262	Atherosclerosis of native arteries of extremities with gangrene, left leg	Diagnosis	ICD-10-CM
I70.263	Atherosclerosis of native arteries of extremities with gangrene, bilateral legs	Diagnosis	ICD-10-CM
I70.268	Atherosclerosis of native arteries of extremities with gangrene, other extremity	Diagnosis	ICD-10-CM
I70.269	Atherosclerosis of native arteries of extremities with gangrene, unspecified extremity	Diagnosis	ICD-10-CM
I70.291	Other atherosclerosis of native arteries of extremities, right leg	Diagnosis	ICD-10-CM
I70.292	Other atherosclerosis of native arteries of extremities, left leg	Diagnosis	ICD-10-CM
I70.293	Other atherosclerosis of native arteries of extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.298	Other atherosclerosis of native arteries of extremities, other extremity	Diagnosis	ICD-10-CM
I70.299	Other atherosclerosis of native arteries of extremities, unspecified extremity	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I70.301	Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
I70.302	Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
I70.303	Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.308	Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
I70.309	Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
I70.311	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, right leg	Diagnosis	ICD-10-CM
I70.312	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, left leg	Diagnosis	ICD-10-CM
I70.313	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, bilateral legs	Diagnosis	ICD-10-CM
I70.318	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, other extremity	Diagnosis	ICD-10-CM
I70.319	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, unspecified extremity	Diagnosis	ICD-10-CM
I70.321	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, right leg	Diagnosis	ICD-10-CM
I70.322	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, left leg	Diagnosis	ICD-10-CM
I70.323	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, bilateral legs	Diagnosis	ICD-10-CM
I70.328	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, other extremity	Diagnosis	ICD-10-CM
I70.329	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, unspecified extremity	Diagnosis	ICD-10-CM
I70.331	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.332	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.333	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.334	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.335	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.338	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I70.339	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.341	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.342	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.343	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.344	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.345	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.348	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
I70.349	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.35	Atherosclerosis of unspecified type of bypass graft(s) of other extremity with ulceration	Diagnosis	ICD-10-CM
I70.361	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, right leg	Diagnosis	ICD-10-CM
I70.362	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, left leg	Diagnosis	ICD-10-CM
I70.363	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, bilateral legs	Diagnosis	ICD-10-CM
I70.368	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, other extremity	Diagnosis	ICD-10-CM
I70.369	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, unspecified extremity	Diagnosis	ICD-10-CM
I70.391	Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
I70.392	Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
I70.393	Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.398	Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
I70.399	Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
I70.501	Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
I70.502	Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I70.503	Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.508	Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
I70.509	Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
I70.511	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, right leg	Diagnosis	ICD-10-CM
I70.512	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, left leg	Diagnosis	ICD-10-CM
I70.513	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, bilateral legs	Diagnosis	ICD-10-CM
I70.518	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, other extremity	Diagnosis	ICD-10-CM
I70.519	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, unspecified extremity	Diagnosis	ICD-10-CM
I70.521	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, right leg	Diagnosis	ICD-10-CM
I70.522	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, left leg	Diagnosis	ICD-10-CM
I70.523	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, bilateral legs	Diagnosis	ICD-10-CM
I70.528	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, other extremity	Diagnosis	ICD-10-CM
I70.529	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, unspecified extremity	Diagnosis	ICD-10-CM
I70.531	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.532	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.533	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.534	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.535	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.538	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
I70.539	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.541	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of thigh	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I70.542	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.543	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.544	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.545	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.548	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
I70.549	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.55	Atherosclerosis of nonautologous biological bypass graft(s) of other extremity with ulceration	Diagnosis	ICD-10-CM
I70.561	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, right leg	Diagnosis	ICD-10-CM
I70.562	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, left leg	Diagnosis	ICD-10-CM
I70.563	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, bilateral legs	Diagnosis	ICD-10-CM
I70.568	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, other extremity	Diagnosis	ICD-10-CM
I70.569	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, unspecified extremity	Diagnosis	ICD-10-CM
I70.591	Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
I70.592	Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
I70.593	Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.598	Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
I70.599	Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
I70.601	Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
I70.602	Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
I70.603	Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.608	Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I70.609	Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
I70.611	Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, right leg	Diagnosis	ICD-10-CM
I70.612	Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, left leg	Diagnosis	ICD-10-CM
I70.613	Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, bilateral legs	Diagnosis	ICD-10-CM
I70.618	Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, other extremity	Diagnosis	ICD-10-CM
I70.619	Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, unspecified extremity	Diagnosis	ICD-10-CM
I70.621	Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, right leg	Diagnosis	ICD-10-CM
I70.622	Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, left leg	Diagnosis	ICD-10-CM
I70.623	Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, bilateral legs	Diagnosis	ICD-10-CM
I70.628	Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, other extremity	Diagnosis	ICD-10-CM
I70.629	Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, unspecified extremity	Diagnosis	ICD-10-CM
I70.631	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.632	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.633	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.634	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.635	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.638	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
I70.639	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.641	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.642	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.643	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of ankle	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I70.644	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.645	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.648	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
I70.649	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.65	Atherosclerosis of nonbiological bypass graft(s) of other extremity with ulceration	Diagnosis	ICD-10-CM
I70.661	Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, right leg	Diagnosis	ICD-10-CM
I70.662	Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, left leg	Diagnosis	ICD-10-CM
I70.663	Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, bilateral legs	Diagnosis	ICD-10-CM
I70.668	Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, other extremity	Diagnosis	ICD-10-CM
I70.669	Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, unspecified extremity	Diagnosis	ICD-10-CM
I70.691	Other atherosclerosis of nonbiological bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
I70.692	Other atherosclerosis of nonbiological bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
I70.693	Other atherosclerosis of nonbiological bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.698	Other atherosclerosis of nonbiological bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
I70.699	Other atherosclerosis of nonbiological bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
I70.701	Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
I70.702	Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
I70.703	Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.708	Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
I70.709	Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
I70.711	Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, right leg	Diagnosis	ICD-10-CM
I70.712	Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, left leg	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I70.713	Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, bilateral legs	Diagnosis	ICD-10-CM
I70.718	Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, other extremity	Diagnosis	ICD-10-CM
I70.719	Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, unspecified extremity	Diagnosis	ICD-10-CM
I70.721	Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, right leg	Diagnosis	ICD-10-CM
I70.722	Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, left leg	Diagnosis	ICD-10-CM
I70.723	Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, bilateral legs	Diagnosis	ICD-10-CM
I70.728	Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, other extremity	Diagnosis	ICD-10-CM
I70.729	Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, unspecified extremity	Diagnosis	ICD-10-CM
I70.731	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.732	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.733	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.734	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.735	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.738	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
I70.739	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.741	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.742	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.743	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.744	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.745	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.748	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
I70.749	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.75	Atherosclerosis of other type of bypass graft(s) of other extremity with ulceration	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I70.761	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, right leg	Diagnosis	ICD-10-CM
I70.762	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, left leg	Diagnosis	ICD-10-CM
I70.763	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, bilateral legs	Diagnosis	ICD-10-CM
I70.768	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, other extremity	Diagnosis	ICD-10-CM
I70.769	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, unspecified extremity	Diagnosis	ICD-10-CM
I70.791	Other atherosclerosis of other type of bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
I70.792	Other atherosclerosis of other type of bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
I70.793	Other atherosclerosis of other type of bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.798	Other atherosclerosis of other type of bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
I70.799	Other atherosclerosis of other type of bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
I70.8	Atherosclerosis of other arteries	Diagnosis	ICD-10-CM
I70.90	Unspecified atherosclerosis	Diagnosis	ICD-10-CM
I70.91	Generalized atherosclerosis	Diagnosis	ICD-10-CM
I70.92	Chronic total occlusion of artery of the extremities	Diagnosis	ICD-10-CM
I72.0	Aneurysm of carotid artery	Diagnosis	ICD-10-CM
I72.1	Aneurysm of artery of upper extremity	Diagnosis	ICD-10-CM
I72.2	Aneurysm of renal artery	Diagnosis	ICD-10-CM
I72.3	Aneurysm of iliac artery	Diagnosis	ICD-10-CM
I72.4	Aneurysm of artery of lower extremity	Diagnosis	ICD-10-CM
I72.8	Aneurysm of other specified arteries	Diagnosis	ICD-10-CM
I72.9	Aneurysm of unspecified site	Diagnosis	ICD-10-CM
I73.89	Other specified peripheral vascular diseases	Diagnosis	ICD-10-CM
I73.9	Peripheral vascular disease, unspecified	Diagnosis	ICD-10-CM
I77.71	Dissection of carotid artery	Diagnosis	ICD-10-CM
I77.72	Dissection of iliac artery	Diagnosis	ICD-10-CM
I77.73	Dissection of renal artery	Diagnosis	ICD-10-CM
I77.74	Dissection of vertebral artery	Diagnosis	ICD-10-CM
I77.79	Dissection of other specified artery	Diagnosis	ICD-10-CM
I79.8	Other disorders of arteries, arterioles and capillaries in diseases classified elsewhere	Diagnosis	ICD-10-CM
Z95.820	Peripheral vascular angioplasty status with implants and grafts	Diagnosis	ICD-10-CM
Z95.828	Presence of other vascular implants and grafts	Diagnosis	ICD-10-CM
0312090	Bypass Innominate Artery to Right Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0312091	Bypass Innominate Artery to Left Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
0312092	Bypass Innominate Artery to Bilateral Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0312093	Bypass Innominate Artery to Right Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0312094	Bypass Innominate Artery to Left Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0312095	Bypass Innominate Artery to Bilateral Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0312096	Bypass Innominate Artery to Right Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0312097	Bypass Innominate Artery to Left Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0312098	Bypass Innominate Artery to Bilateral Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0312099	Bypass Innominate Artery to Right Lower Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0313090	Bypass Right Subclavian Artery to Right Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0313091	Bypass Right Subclavian Artery to Left Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0313092	Bypass Right Subclavian Artery to Bilateral Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0313093	Bypass Right Subclavian Artery to Right Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0313094	Bypass Right Subclavian Artery to Left Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0313095	Bypass Right Subclavian Artery to Bilateral Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0313096	Bypass Right Subclavian Artery to Right Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0313097	Bypass Right Subclavian Artery to Left Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0313098	Bypass Right Subclavian Artery to Bilateral Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0313099	Bypass Right Subclavian Artery to Right Lower Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0314090	Bypass Left Subclavian Artery to Right Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0314091	Bypass Left Subclavian Artery to Left Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0314092	Bypass Left Subclavian Artery to Bilateral Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
0314093	Bypass Left Subclavian Artery to Right Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0314094	Bypass Left Subclavian Artery to Left Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0314095	Bypass Left Subclavian Artery to Bilateral Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0314096	Bypass Left Subclavian Artery to Right Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0314097	Bypass Left Subclavian Artery to Left Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0314098	Bypass Left Subclavian Artery to Bilateral Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0314099	Bypass Left Subclavian Artery to Right Lower Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0315090	Bypass Right Axillary Artery to Right Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0315091	Bypass Right Axillary Artery to Left Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0315092	Bypass Right Axillary Artery to Bilateral Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0315093	Bypass Right Axillary Artery to Right Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0315094	Bypass Right Axillary Artery to Left Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0315095	Bypass Right Axillary Artery to Bilateral Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0315096	Bypass Right Axillary Artery to Right Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0315097	Bypass Right Axillary Artery to Left Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0315098	Bypass Right Axillary Artery to Bilateral Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0315099	Bypass Right Axillary Artery to Right Lower Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0316090	Bypass Left Axillary Artery to Right Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0316091	Bypass Left Axillary Artery to Left Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0316092	Bypass Left Axillary Artery to Bilateral Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0316093	Bypass Left Axillary Artery to Right Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
0316094	Bypass Left Axillary Artery to Left Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0316095	Bypass Left Axillary Artery to Bilateral Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0316096	Bypass Left Axillary Artery to Right Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0316097	Bypass Left Axillary Artery to Left Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0316098	Bypass Left Axillary Artery to Bilateral Upper Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0316099	Bypass Left Axillary Artery to Right Lower Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0317090	Bypass Right Brachial Artery to Right Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0317093	Bypass Right Brachial Artery to Right Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0318091	Bypass Left Brachial Artery to Left Upper Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0318094	Bypass Left Brachial Artery to Left Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0319093	Bypass Right Ulnar Artery to Right Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0373046	Dilation of Right Subclavian Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
0373056	Dilation of Right Subclavian Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0373066	Dilation of Right Subclavian Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0373076	Dilation of Right Subclavian Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0373346	Dilation of Right Subclavian Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0373356	Dilation of Right Subclavian Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0373366	Dilation of Right Subclavian Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0373376	Dilation of Right Subclavian Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0373446	Dilation of Right Subclavian Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0373456	Dilation of Right Subclavian Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
0373466	Dilation of Right Subclavian Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0373476	Dilation of Right Subclavian Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0374046	Dilation of Left Subclavian Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
0374056	Dilation of Left Subclavian Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0374066	Dilation of Left Subclavian Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0374076	Dilation of Left Subclavian Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0374346	Dilation of Left Subclavian Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0374356	Dilation of Left Subclavian Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0374366	Dilation of Left Subclavian Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0374376	Dilation of Left Subclavian Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0374446	Dilation of Left Subclavian Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0374456	Dilation of Left Subclavian Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0374466	Dilation of Left Subclavian Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0374476	Dilation of Left Subclavian Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0375046	Dilation of Right Axillary Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
0375056	Dilation of Right Axillary Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0375066	Dilation of Right Axillary Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0375076	Dilation of Right Axillary Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0375346	Dilation of Right Axillary Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0375356	Dilation of Right Axillary Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0375366	Dilation of Right Axillary Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
0375376	Dilation of Right Axillary Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0375446	Dilation of Right Axillary Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0375456	Dilation of Right Axillary Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0375466	Dilation of Right Axillary Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0375476	Dilation of Right Axillary Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0376046	Dilation of Left Axillary Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
0376056	Dilation of Left Axillary Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0376066	Dilation of Left Axillary Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0376076	Dilation of Left Axillary Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0376346	Dilation of Left Axillary Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0376356	Dilation of Left Axillary Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0376366	Dilation of Left Axillary Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0376376	Dilation of Left Axillary Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0376446	Dilation of Left Axillary Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0376456	Dilation of Left Axillary Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0376466	Dilation of Left Axillary Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0376476	Dilation of Left Axillary Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0377046	Dilation of Right Brachial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
0377056	Dilation of Right Brachial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0377066	Dilation of Right Brachial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0377076	Dilation of Right Brachial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
0377346	Dilation of Right Brachial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0377356	Dilation of Right Brachial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0377366	Dilation of Right Brachial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0377376	Dilation of Right Brachial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0377446	Dilation of Right Brachial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0377456	Dilation of Right Brachial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0377466	Dilation of Right Brachial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0377476	Dilation of Right Brachial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0378046	Dilation of Left Brachial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
0378056	Dilation of Left Brachial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0378066	Dilation of Left Brachial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0378076	Dilation of Left Brachial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0378346	Dilation of Left Brachial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0378356	Dilation of Left Brachial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0378366	Dilation of Left Brachial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0378376	Dilation of Left Brachial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0378446	Dilation of Left Brachial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0378456	Dilation of Left Brachial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0378466	Dilation of Left Brachial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0378476	Dilation of Left Brachial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0379046	Dilation of Right Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
0379056	Dilation of Right Ulnar Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0379066	Dilation of Right Ulnar Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0379076	Dilation of Right Ulnar Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0379346	Dilation of Right Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0379356	Dilation of Right Ulnar Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0379366	Dilation of Right Ulnar Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0379376	Dilation of Right Ulnar Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0379446	Dilation of Right Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0379456	Dilation of Right Ulnar Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0379466	Dilation of Right Ulnar Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0379476	Dilation of Right Ulnar Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0410096	Bypass Abdominal Aorta to Right Common Iliac Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0410097	Bypass Abdominal Aorta to Left Common Iliac Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0410098	Bypass Abdominal Aorta to Bilateral Common Iliac Arteries with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0410099	Bypass Abdominal Aorta to Right Internal Iliac Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
0410496	Bypass Abdominal Aorta to Right Common Iliac Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0410497	Bypass Abdominal Aorta to Left Common Iliac Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0410498	Bypass Abdominal Aorta to Bilateral Common Iliac Arteries with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0410499	Bypass Abdominal Aorta to Right Internal Iliac Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0470046	Dilation of Abdominal Aorta, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
0470056	Dilation of Abdominal Aorta, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
0470066	Dilation of Abdominal Aorta, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0470076	Dilation of Abdominal Aorta, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
0470346	Dilation of Abdominal Aorta, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0470356	Dilation of Abdominal Aorta, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0470366	Dilation of Abdominal Aorta, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0470376	Dilation of Abdominal Aorta, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0470446	Dilation of Abdominal Aorta, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0470456	Dilation of Abdominal Aorta, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0470466	Dilation of Abdominal Aorta, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0470476	Dilation of Abdominal Aorta, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03730E6	Dilation of Right Subclavian Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03733E6	Dilation of Right Subclavian Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03734E6	Dilation of Right Subclavian Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03740E6	Dilation of Left Subclavian Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03743E6	Dilation of Left Subclavian Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03744E6	Dilation of Left Subclavian Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03750E6	Dilation of Right Axillary Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03753E6	Dilation of Right Axillary Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03754E6	Dilation of Right Axillary Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03760E6	Dilation of Left Axillary Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03763E6	Dilation of Left Axillary Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
03764E6	Dilation of Left Axillary Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03770E6	Dilation of Right Brachial Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03773E6	Dilation of Right Brachial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03774E6	Dilation of Right Brachial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03780E6	Dilation of Left Brachial Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03783E6	Dilation of Left Brachial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03784E6	Dilation of Left Brachial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03790E6	Dilation of Right Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03793E6	Dilation of Right Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03794E6	Dilation of Right Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04700E6	Dilation of Abdominal Aorta, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
04703E6	Dilation of Abdominal Aorta, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
04704E6	Dilation of Abdominal Aorta, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E041	Dilation of Right Internal Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047E046	Dilation of Right Internal Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047E056	Dilation of Right Internal Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047E066	Dilation of Right Internal Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047E076	Dilation of Right Internal Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
031209B	Bypass Innominate Artery to Left Lower Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
031209C	Bypass Innominate Artery to Bilateral Lower Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
03120A0	Bypass Innominate Artery to Right Upper Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
03120A1	Bypass Innominate Artery to Left Upper Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120A2	Bypass Innominate Artery to Bilateral Upper Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120A3	Bypass Innominate Artery to Right Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120A4	Bypass Innominate Artery to Left Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120A5	Bypass Innominate Artery to Bilateral Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120A6	Bypass Innominate Artery to Right Upper Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120A7	Bypass Innominate Artery to Left Upper Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120A8	Bypass Innominate Artery to Bilateral Upper Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120A9	Bypass Innominate Artery to Right Lower Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120AB	Bypass Innominate Artery to Left Lower Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120AC	Bypass Innominate Artery to Bilateral Lower Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03120J0	Bypass Innominate Artery to Right Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03120J1	Bypass Innominate Artery to Left Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03120J2	Bypass Innominate Artery to Bilateral Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03120J3	Bypass Innominate Artery to Right Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03120J4	Bypass Innominate Artery to Left Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03120J5	Bypass Innominate Artery to Bilateral Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03120J6	Bypass Innominate Artery to Right Upper Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03120J7	Bypass Innominate Artery to Left Upper Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03120J8	Bypass Innominate Artery to Bilateral Upper Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03120J9	Bypass Innominate Artery to Right Lower Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
03120JB	Bypass Innominate Artery to Left Lower Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03120JC	Bypass Innominate Artery to Bilateral Lower Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03120K0	Bypass Innominate Artery to Right Upper Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03120K1	Bypass Innominate Artery to Left Upper Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03120K2	Bypass Innominate Artery to Bilateral Upper Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03120K3	Bypass Innominate Artery to Right Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03120K4	Bypass Innominate Artery to Left Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03120K5	Bypass Innominate Artery to Bilateral Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03120K6	Bypass Innominate Artery to Right Upper Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03120K7	Bypass Innominate Artery to Left Upper Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03120K8	Bypass Innominate Artery to Bilateral Upper Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03120K9	Bypass Innominate Artery to Right Lower Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03120KB	Bypass Innominate Artery to Left Lower Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03120KC	Bypass Innominate Artery to Bilateral Lower Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03120Z0	Bypass Innominate Artery to Right Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03120Z1	Bypass Innominate Artery to Left Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03120Z2	Bypass Innominate Artery to Bilateral Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03120Z3	Bypass Innominate Artery to Right Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03120Z4	Bypass Innominate Artery to Left Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03120Z5	Bypass Innominate Artery to Bilateral Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03120Z6	Bypass Innominate Artery to Right Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03120Z7	Bypass Innominate Artery to Left Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03120Z8	Bypass Innominate Artery to Bilateral Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03120Z9	Bypass Innominate Artery to Right Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
03120ZB	Bypass Innominate Artery to Left Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
03120ZC	Bypass Innominate Artery to Bilateral Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
031309B	Bypass Right Subclavian Artery to Left Lower Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
031309C	Bypass Right Subclavian Artery to Bilateral Lower Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
03130A0	Bypass Right Subclavian Artery to Right Upper Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03130A1	Bypass Right Subclavian Artery to Left Upper Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03130A2	Bypass Right Subclavian Artery to Bilateral Upper Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03130A3	Bypass Right Subclavian Artery to Right Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03130A4	Bypass Right Subclavian Artery to Left Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03130A5	Bypass Right Subclavian Artery to Bilateral Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03130A6	Bypass Right Subclavian Artery to Right Upper Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03130A7	Bypass Right Subclavian Artery to Left Upper Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03130A8	Bypass Right Subclavian Artery to Bilateral Upper Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03130A9	Bypass Right Subclavian Artery to Right Lower Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03130AB	Bypass Right Subclavian Artery to Left Lower Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03130AC	Bypass Right Subclavian Artery to Bilateral Lower Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03130J0	Bypass Right Subclavian Artery to Right Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03130J1	Bypass Right Subclavian Artery to Left Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03130J2	Bypass Right Subclavian Artery to Bilateral Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03130J3	Bypass Right Subclavian Artery to Right Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03130J4	Bypass Right Subclavian Artery to Left Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03130J5	Bypass Right Subclavian Artery to Bilateral Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03130J6	Bypass Right Subclavian Artery to Right Upper Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03130J7	Bypass Right Subclavian Artery to Left Upper Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03130J8	Bypass Right Subclavian Artery to Bilateral Upper Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03130J9	Bypass Right Subclavian Artery to Right Lower Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
03130JB	Bypass Right Subclavian Artery to Left Lower Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03130JC	Bypass Right Subclavian Artery to Bilateral Lower Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03130K0	Bypass Right Subclavian Artery to Right Upper Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03130K1	Bypass Right Subclavian Artery to Left Upper Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03130K2	Bypass Right Subclavian Artery to Bilateral Upper Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03130K3	Bypass Right Subclavian Artery to Right Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03130K4	Bypass Right Subclavian Artery to Left Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03130K5	Bypass Right Subclavian Artery to Bilateral Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03130K6	Bypass Right Subclavian Artery to Right Upper Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03130K7	Bypass Right Subclavian Artery to Left Upper Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03130K8	Bypass Right Subclavian Artery to Bilateral Upper Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03130K9	Bypass Right Subclavian Artery to Right Lower Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03130KB	Bypass Right Subclavian Artery to Left Lower Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03130KC	Bypass Right Subclavian Artery to Bilateral Lower Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03130Z0	Bypass Right Subclavian Artery to Right Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03130Z1	Bypass Right Subclavian Artery to Left Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03130Z2	Bypass Right Subclavian Artery to Bilateral Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03130Z3	Bypass Right Subclavian Artery to Right Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03130Z4	Bypass Right Subclavian Artery to Left Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03130Z5	Bypass Right Subclavian Artery to Bilateral Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03130Z6	Bypass Right Subclavian Artery to Right Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03130Z7	Bypass Right Subclavian Artery to Left Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03130Z8	Bypass Right Subclavian Artery to Bilateral Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03130Z9	Bypass Right Subclavian Artery to Right Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
03130ZB	Bypass Right Subclavian Artery to Left Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
03130ZC	Bypass Right Subclavian Artery to Bilateral Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
031409B	Bypass Left Subclavian Artery to Left Lower Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
031409C	Bypass Left Subclavian Artery to Bilateral Lower Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
03140A0	Bypass Left Subclavian Artery to Right Upper Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03140A1	Bypass Left Subclavian Artery to Left Upper Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03140A2	Bypass Left Subclavian Artery to Bilateral Upper Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03140A3	Bypass Left Subclavian Artery to Right Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03140A4	Bypass Left Subclavian Artery to Left Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03140A5	Bypass Left Subclavian Artery to Bilateral Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03140A6	Bypass Left Subclavian Artery to Right Upper Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03140A7	Bypass Left Subclavian Artery to Left Upper Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03140A8	Bypass Left Subclavian Artery to Bilateral Upper Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03140A9	Bypass Left Subclavian Artery to Right Lower Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03140AB	Bypass Left Subclavian Artery to Left Lower Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03140AC	Bypass Left Subclavian Artery to Bilateral Lower Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03140J0	Bypass Left Subclavian Artery to Right Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03140J1	Bypass Left Subclavian Artery to Left Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03140J2	Bypass Left Subclavian Artery to Bilateral Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03140J3	Bypass Left Subclavian Artery to Right Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03140J4	Bypass Left Subclavian Artery to Left Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03140J5	Bypass Left Subclavian Artery to Bilateral Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03140J6	Bypass Left Subclavian Artery to Right Upper Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03140J7	Bypass Left Subclavian Artery to Left Upper Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03140J8	Bypass Left Subclavian Artery to Bilateral Upper Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03140J9	Bypass Left Subclavian Artery to Right Lower Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
03140JB	Bypass Left Subclavian Artery to Left Lower Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03140JC	Bypass Left Subclavian Artery to Bilateral Lower Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03140K0	Bypass Left Subclavian Artery to Right Upper Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03140K1	Bypass Left Subclavian Artery to Left Upper Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03140K2	Bypass Left Subclavian Artery to Bilateral Upper Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03140K3	Bypass Left Subclavian Artery to Right Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03140K4	Bypass Left Subclavian Artery to Left Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03140K5	Bypass Left Subclavian Artery to Bilateral Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03140K6	Bypass Left Subclavian Artery to Right Upper Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03140K7	Bypass Left Subclavian Artery to Left Upper Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03140K8	Bypass Left Subclavian Artery to Bilateral Upper Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03140K9	Bypass Left Subclavian Artery to Right Lower Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03140KB	Bypass Left Subclavian Artery to Left Lower Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03140KC	Bypass Left Subclavian Artery to Bilateral Lower Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03140Z0	Bypass Left Subclavian Artery to Right Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03140Z1	Bypass Left Subclavian Artery to Left Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03140Z2	Bypass Left Subclavian Artery to Bilateral Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03140Z3	Bypass Left Subclavian Artery to Right Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03140Z4	Bypass Left Subclavian Artery to Left Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03140Z5	Bypass Left Subclavian Artery to Bilateral Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03140Z6	Bypass Left Subclavian Artery to Right Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03140Z7	Bypass Left Subclavian Artery to Left Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03140Z8	Bypass Left Subclavian Artery to Bilateral Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03140Z9	Bypass Left Subclavian Artery to Right Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
03140ZB	Bypass Left Subclavian Artery to Left Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
03140ZC	Bypass Left Subclavian Artery to Bilateral Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
031509B	Bypass Right Axillary Artery to Left Lower Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
031509C	Bypass Right Axillary Artery to Bilateral Lower Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
03150A0	Bypass Right Axillary Artery to Right Upper Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03150A1	Bypass Right Axillary Artery to Left Upper Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03150A2	Bypass Right Axillary Artery to Bilateral Upper Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03150A3	Bypass Right Axillary Artery to Right Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03150A4	Bypass Right Axillary Artery to Left Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03150A5	Bypass Right Axillary Artery to Bilateral Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03150A6	Bypass Right Axillary Artery to Right Upper Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03150A7	Bypass Right Axillary Artery to Left Upper Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03150A8	Bypass Right Axillary Artery to Bilateral Upper Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03150A9	Bypass Right Axillary Artery to Right Lower Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03150AB	Bypass Right Axillary Artery to Left Lower Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03150AC	Bypass Right Axillary Artery to Bilateral Lower Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03150J0	Bypass Right Axillary Artery to Right Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03150J1	Bypass Right Axillary Artery to Left Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03150J2	Bypass Right Axillary Artery to Bilateral Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03150J3	Bypass Right Axillary Artery to Right Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03150J4	Bypass Right Axillary Artery to Left Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03150J5	Bypass Right Axillary Artery to Bilateral Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03150J6	Bypass Right Axillary Artery to Right Upper Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03150J7	Bypass Right Axillary Artery to Left Upper Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03150J8	Bypass Right Axillary Artery to Bilateral Upper Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03150J9	Bypass Right Axillary Artery to Right Lower Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
03150JB	Bypass Right Axillary Artery to Left Lower Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03150JC	Bypass Right Axillary Artery to Bilateral Lower Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03150K0	Bypass Right Axillary Artery to Right Upper Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03150K1	Bypass Right Axillary Artery to Left Upper Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03150K2	Bypass Right Axillary Artery to Bilateral Upper Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03150K3	Bypass Right Axillary Artery to Right Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03150K4	Bypass Right Axillary Artery to Left Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03150K5	Bypass Right Axillary Artery to Bilateral Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03150K6	Bypass Right Axillary Artery to Right Upper Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03150K7	Bypass Right Axillary Artery to Left Upper Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03150K8	Bypass Right Axillary Artery to Bilateral Upper Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03150K9	Bypass Right Axillary Artery to Right Lower Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03150KB	Bypass Right Axillary Artery to Left Lower Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03150KC	Bypass Right Axillary Artery to Bilateral Lower Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03150Z0	Bypass Right Axillary Artery to Right Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03150Z1	Bypass Right Axillary Artery to Left Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03150Z2	Bypass Right Axillary Artery to Bilateral Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03150Z3	Bypass Right Axillary Artery to Right Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03150Z4	Bypass Right Axillary Artery to Left Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03150Z5	Bypass Right Axillary Artery to Bilateral Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03150Z6	Bypass Right Axillary Artery to Right Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03150Z7	Bypass Right Axillary Artery to Left Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03150Z8	Bypass Right Axillary Artery to Bilateral Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03150Z9	Bypass Right Axillary Artery to Right Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
03150ZB	Bypass Right Axillary Artery to Left Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
03150ZC	Bypass Right Axillary Artery to Bilateral Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
031609B	Bypass Left Axillary Artery to Left Lower Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
031609C	Bypass Left Axillary Artery to Bilateral Lower Leg Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
03160A0	Bypass Left Axillary Artery to Right Upper Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03160A1	Bypass Left Axillary Artery to Left Upper Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03160A2	Bypass Left Axillary Artery to Bilateral Upper Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03160A3	Bypass Left Axillary Artery to Right Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03160A4	Bypass Left Axillary Artery to Left Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03160A5	Bypass Left Axillary Artery to Bilateral Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03160A6	Bypass Left Axillary Artery to Right Upper Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03160A7	Bypass Left Axillary Artery to Left Upper Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03160A8	Bypass Left Axillary Artery to Bilateral Upper Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03160A9	Bypass Left Axillary Artery to Right Lower Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03160AB	Bypass Left Axillary Artery to Left Lower Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03160AC	Bypass Left Axillary Artery to Bilateral Lower Leg Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03160J0	Bypass Left Axillary Artery to Right Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03160J1	Bypass Left Axillary Artery to Left Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03160J2	Bypass Left Axillary Artery to Bilateral Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03160J3	Bypass Left Axillary Artery to Right Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03160J4	Bypass Left Axillary Artery to Left Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03160J5	Bypass Left Axillary Artery to Bilateral Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03160J6	Bypass Left Axillary Artery to Right Upper Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03160J7	Bypass Left Axillary Artery to Left Upper Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03160J8	Bypass Left Axillary Artery to Bilateral Upper Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03160J9	Bypass Left Axillary Artery to Right Lower Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
03160JB	Bypass Left Axillary Artery to Left Lower Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03160JC	Bypass Left Axillary Artery to Bilateral Lower Leg Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03160K0	Bypass Left Axillary Artery to Right Upper Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03160K1	Bypass Left Axillary Artery to Left Upper Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03160K2	Bypass Left Axillary Artery to Bilateral Upper Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03160K3	Bypass Left Axillary Artery to Right Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03160K4	Bypass Left Axillary Artery to Left Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03160K5	Bypass Left Axillary Artery to Bilateral Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03160K6	Bypass Left Axillary Artery to Right Upper Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03160K7	Bypass Left Axillary Artery to Left Upper Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03160K8	Bypass Left Axillary Artery to Bilateral Upper Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03160K9	Bypass Left Axillary Artery to Right Lower Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03160KB	Bypass Left Axillary Artery to Left Lower Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03160KC	Bypass Left Axillary Artery to Bilateral Lower Leg Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03160Z0	Bypass Left Axillary Artery to Right Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03160Z1	Bypass Left Axillary Artery to Left Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03160Z2	Bypass Left Axillary Artery to Bilateral Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03160Z3	Bypass Left Axillary Artery to Right Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03160Z4	Bypass Left Axillary Artery to Left Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03160Z5	Bypass Left Axillary Artery to Bilateral Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03160Z6	Bypass Left Axillary Artery to Right Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03160Z7	Bypass Left Axillary Artery to Left Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03160Z8	Bypass Left Axillary Artery to Bilateral Upper Leg Artery, Open Approach	Procedure	ICD-10-PCS
03160Z9	Bypass Left Axillary Artery to Right Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
03160ZB	Bypass Left Axillary Artery to Left Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
03160ZC	Bypass Left Axillary Artery to Bilateral Lower Leg Artery, Open Approach	Procedure	ICD-10-PCS
03170A0	Bypass Right Brachial Artery to Right Upper Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03170A3	Bypass Right Brachial Artery to Right Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
03170J0	Bypass Right Brachial Artery to Right Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03170J3	Bypass Right Brachial Artery to Right Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03170K0	Bypass Right Brachial Artery to Right Upper Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03170K3	Bypass Right Brachial Artery to Right Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03170Z0	Bypass Right Brachial Artery to Right Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03170Z3	Bypass Right Brachial Artery to Right Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03180A1	Bypass Left Brachial Artery to Left Upper Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03180A4	Bypass Left Brachial Artery to Left Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03180J1	Bypass Left Brachial Artery to Left Upper Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03180J4	Bypass Left Brachial Artery to Left Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03180K1	Bypass Left Brachial Artery to Left Upper Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03180K4	Bypass Left Brachial Artery to Left Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03180Z1	Bypass Left Brachial Artery to Left Upper Arm Artery, Open Approach	Procedure	ICD-10-PCS
03180Z4	Bypass Left Brachial Artery to Left Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
03190A3	Bypass Right Ulnar Artery to Right Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
03190J3	Bypass Right Ulnar Artery to Right Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
03190K3	Bypass Right Ulnar Artery to Right Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
03190Z3	Bypass Right Ulnar Artery to Right Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
031A094	Bypass Left Ulnar Artery to Left Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
031A0A4	Bypass Left Ulnar Artery to Left Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
031A0J4	Bypass Left Ulnar Artery to Left Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
031A0K4	Bypass Left Ulnar Artery to Left Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
031A0Z4	Bypass Left Ulnar Artery to Left Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
031B093	Bypass Right Radial Artery to Right Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
031B0A3	Bypass Right Radial Artery to Right Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
031B0J3	Bypass Right Radial Artery to Right Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
031B0K3	Bypass Right Radial Artery to Right Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
031B0Z3	Bypass Right Radial Artery to Right Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
031C094	Bypass Left Radial Artery to Left Lower Arm Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
031C0A4	Bypass Left Radial Artery to Left Lower Arm Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
031C0J4	Bypass Left Radial Artery to Left Lower Arm Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
031C0K4	Bypass Left Radial Artery to Left Lower Arm Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
031C0Z4	Bypass Left Radial Artery to Left Lower Arm Artery, Open Approach	Procedure	ICD-10-PCS
037304Z	Dilation of Right Subclavian Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037305Z	Dilation of Right Subclavian Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037306Z	Dilation of Right Subclavian Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037307Z	Dilation of Right Subclavian Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03730D6	Dilation of Right Subclavian Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03730DZ	Dilation of Right Subclavian Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03730EZ	Dilation of Right Subclavian Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03730F6	Dilation of Right Subclavian Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03730FZ	Dilation of Right Subclavian Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03730G6	Dilation of Right Subclavian Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03730GZ	Dilation of Right Subclavian Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03730Z6	Dilation of Right Subclavian Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
03730ZZ	Dilation of Right Subclavian Artery, Open Approach	Procedure	ICD-10-PCS
037334Z	Dilation of Right Subclavian Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037335Z	Dilation of Right Subclavian Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037336Z	Dilation of Right Subclavian Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037337Z	Dilation of Right Subclavian Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
03733D6	Dilation of Right Subclavian Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03733DZ	Dilation of Right Subclavian Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03733EZ	Dilation of Right Subclavian Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03733F6	Dilation of Right Subclavian Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03733FZ	Dilation of Right Subclavian Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03733G6	Dilation of Right Subclavian Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03733GZ	Dilation of Right Subclavian Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03733Z6	Dilation of Right Subclavian Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03733ZZ	Dilation of Right Subclavian Artery, Percutaneous Approach	Procedure	ICD-10-PCS
037344Z	Dilation of Right Subclavian Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037345Z	Dilation of Right Subclavian Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037346Z	Dilation of Right Subclavian Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037347Z	Dilation of Right Subclavian Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03734D6	Dilation of Right Subclavian Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03734DZ	Dilation of Right Subclavian Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03734EZ	Dilation of Right Subclavian Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03734F6	Dilation of Right Subclavian Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03734FZ	Dilation of Right Subclavian Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03734G6	Dilation of Right Subclavian Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03734GZ	Dilation of Right Subclavian Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03734Z6	Dilation of Right Subclavian Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03734ZZ	Dilation of Right Subclavian Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037404Z	Dilation of Left Subclavian Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
037405Z	Dilation of Left Subclavian Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037406Z	Dilation of Left Subclavian Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037407Z	Dilation of Left Subclavian Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03740D6	Dilation of Left Subclavian Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03740DZ	Dilation of Left Subclavian Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03740EZ	Dilation of Left Subclavian Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03740F6	Dilation of Left Subclavian Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03740FZ	Dilation of Left Subclavian Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03740G6	Dilation of Left Subclavian Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03740GZ	Dilation of Left Subclavian Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03740Z6	Dilation of Left Subclavian Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
03740ZZ	Dilation of Left Subclavian Artery, Open Approach	Procedure	ICD-10-PCS
037434Z	Dilation of Left Subclavian Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037435Z	Dilation of Left Subclavian Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037436Z	Dilation of Left Subclavian Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037437Z	Dilation of Left Subclavian Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03743D6	Dilation of Left Subclavian Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03743DZ	Dilation of Left Subclavian Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03743EZ	Dilation of Left Subclavian Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03743F6	Dilation of Left Subclavian Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03743FZ	Dilation of Left Subclavian Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03743G6	Dilation of Left Subclavian Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03743GZ	Dilation of Left Subclavian Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03743Z6	Dilation of Left Subclavian Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03743ZZ	Dilation of Left Subclavian Artery, Percutaneous Approach	Procedure	ICD-10-PCS
037444Z	Dilation of Left Subclavian Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
037445Z	Dilation of Left Subclavian Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037446Z	Dilation of Left Subclavian Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037447Z	Dilation of Left Subclavian Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03744D6	Dilation of Left Subclavian Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03744DZ	Dilation of Left Subclavian Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03744EZ	Dilation of Left Subclavian Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03744F6	Dilation of Left Subclavian Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03744FZ	Dilation of Left Subclavian Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03744G6	Dilation of Left Subclavian Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03744GZ	Dilation of Left Subclavian Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03744Z6	Dilation of Left Subclavian Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03744ZZ	Dilation of Left Subclavian Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037504Z	Dilation of Right Axillary Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037505Z	Dilation of Right Axillary Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037506Z	Dilation of Right Axillary Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037507Z	Dilation of Right Axillary Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03750D6	Dilation of Right Axillary Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03750DZ	Dilation of Right Axillary Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03750EZ	Dilation of Right Axillary Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03750F6	Dilation of Right Axillary Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03750FZ	Dilation of Right Axillary Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03750G6	Dilation of Right Axillary Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03750GZ	Dilation of Right Axillary Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03750Z6	Dilation of Right Axillary Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
03750ZZ	Dilation of Right Axillary Artery, Open Approach	Procedure	ICD-10-PCS
037534Z	Dilation of Right Axillary Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
037535Z	Dilation of Right Axillary Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037536Z	Dilation of Right Axillary Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037537Z	Dilation of Right Axillary Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03753D6	Dilation of Right Axillary Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03753DZ	Dilation of Right Axillary Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03753EZ	Dilation of Right Axillary Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03753F6	Dilation of Right Axillary Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03753FZ	Dilation of Right Axillary Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03753G6	Dilation of Right Axillary Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03753GZ	Dilation of Right Axillary Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03753Z6	Dilation of Right Axillary Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03753ZZ	Dilation of Right Axillary Artery, Percutaneous Approach	Procedure	ICD-10-PCS
037544Z	Dilation of Right Axillary Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037545Z	Dilation of Right Axillary Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037546Z	Dilation of Right Axillary Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037547Z	Dilation of Right Axillary Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03754D6	Dilation of Right Axillary Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03754DZ	Dilation of Right Axillary Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03754EZ	Dilation of Right Axillary Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03754F6	Dilation of Right Axillary Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03754FZ	Dilation of Right Axillary Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03754G6	Dilation of Right Axillary Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03754GZ	Dilation of Right Axillary Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03754Z6	Dilation of Right Axillary Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
03754ZZ	Dilation of Right Axillary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037604Z	Dilation of Left Axillary Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037605Z	Dilation of Left Axillary Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037606Z	Dilation of Left Axillary Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037607Z	Dilation of Left Axillary Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03760D6	Dilation of Left Axillary Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03760DZ	Dilation of Left Axillary Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03760EZ	Dilation of Left Axillary Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03760F6	Dilation of Left Axillary Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03760FZ	Dilation of Left Axillary Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03760G6	Dilation of Left Axillary Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03760GZ	Dilation of Left Axillary Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03760Z6	Dilation of Left Axillary Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
03760ZZ	Dilation of Left Axillary Artery, Open Approach	Procedure	ICD-10-PCS
037634Z	Dilation of Left Axillary Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037635Z	Dilation of Left Axillary Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037636Z	Dilation of Left Axillary Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037637Z	Dilation of Left Axillary Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03763D6	Dilation of Left Axillary Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03763DZ	Dilation of Left Axillary Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03763EZ	Dilation of Left Axillary Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03763F6	Dilation of Left Axillary Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03763FZ	Dilation of Left Axillary Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03763G6	Dilation of Left Axillary Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03763GZ	Dilation of Left Axillary Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03763Z6	Dilation of Left Axillary Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03763ZZ	Dilation of Left Axillary Artery, Percutaneous Approach	Procedure	ICD-10-PCS
037644Z	Dilation of Left Axillary Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
037645Z	Dilation of Left Axillary Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037646Z	Dilation of Left Axillary Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037647Z	Dilation of Left Axillary Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03764D6	Dilation of Left Axillary Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03764DZ	Dilation of Left Axillary Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03764EZ	Dilation of Left Axillary Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03764F6	Dilation of Left Axillary Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03764FZ	Dilation of Left Axillary Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03764G6	Dilation of Left Axillary Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03764GZ	Dilation of Left Axillary Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03764Z6	Dilation of Left Axillary Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03764ZZ	Dilation of Left Axillary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037704Z	Dilation of Right Brachial Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037705Z	Dilation of Right Brachial Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037706Z	Dilation of Right Brachial Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037707Z	Dilation of Right Brachial Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03770D6	Dilation of Right Brachial Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03770DZ	Dilation of Right Brachial Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03770EZ	Dilation of Right Brachial Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03770F6	Dilation of Right Brachial Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03770FZ	Dilation of Right Brachial Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03770G6	Dilation of Right Brachial Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03770GZ	Dilation of Right Brachial Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03770Z6	Dilation of Right Brachial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
03770ZZ	Dilation of Right Brachial Artery, Open Approach	Procedure	ICD-10-PCS
037734Z	Dilation of Right Brachial Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
037735Z	Dilation of Right Brachial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037736Z	Dilation of Right Brachial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037737Z	Dilation of Right Brachial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03773D6	Dilation of Right Brachial Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03773DZ	Dilation of Right Brachial Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03773EZ	Dilation of Right Brachial Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03773F6	Dilation of Right Brachial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03773FZ	Dilation of Right Brachial Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03773G6	Dilation of Right Brachial Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03773GZ	Dilation of Right Brachial Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03773Z6	Dilation of Right Brachial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03773ZZ	Dilation of Right Brachial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
037744Z	Dilation of Right Brachial Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037745Z	Dilation of Right Brachial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037746Z	Dilation of Right Brachial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037747Z	Dilation of Right Brachial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03774D6	Dilation of Right Brachial Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03774DZ	Dilation of Right Brachial Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03774EZ	Dilation of Right Brachial Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03774F6	Dilation of Right Brachial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03774FZ	Dilation of Right Brachial Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03774G6	Dilation of Right Brachial Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03774GZ	Dilation of Right Brachial Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03774Z6	Dilation of Right Brachial Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
03774ZZ	Dilation of Right Brachial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037804Z	Dilation of Left Brachial Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037805Z	Dilation of Left Brachial Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037806Z	Dilation of Left Brachial Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037807Z	Dilation of Left Brachial Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03780D6	Dilation of Left Brachial Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03780DZ	Dilation of Left Brachial Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03780EZ	Dilation of Left Brachial Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03780F6	Dilation of Left Brachial Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03780FZ	Dilation of Left Brachial Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03780G6	Dilation of Left Brachial Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03780GZ	Dilation of Left Brachial Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03780Z6	Dilation of Left Brachial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
03780ZZ	Dilation of Left Brachial Artery, Open Approach	Procedure	ICD-10-PCS
037834Z	Dilation of Left Brachial Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037835Z	Dilation of Left Brachial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037836Z	Dilation of Left Brachial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037837Z	Dilation of Left Brachial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03783D6	Dilation of Left Brachial Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03783DZ	Dilation of Left Brachial Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03783EZ	Dilation of Left Brachial Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03783F6	Dilation of Left Brachial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03783FZ	Dilation of Left Brachial Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03783G6	Dilation of Left Brachial Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03783GZ	Dilation of Left Brachial Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03783Z6	Dilation of Left Brachial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03783ZZ	Dilation of Left Brachial Artery, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
037844Z	Dilation of Left Brachial Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037845Z	Dilation of Left Brachial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037846Z	Dilation of Left Brachial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037847Z	Dilation of Left Brachial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03784D6	Dilation of Left Brachial Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03784DZ	Dilation of Left Brachial Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03784EZ	Dilation of Left Brachial Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03784F6	Dilation of Left Brachial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03784FZ	Dilation of Left Brachial Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03784G6	Dilation of Left Brachial Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03784GZ	Dilation of Left Brachial Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03784Z6	Dilation of Left Brachial Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03784ZZ	Dilation of Left Brachial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037904Z	Dilation of Right Ulnar Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037905Z	Dilation of Right Ulnar Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037906Z	Dilation of Right Ulnar Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037907Z	Dilation of Right Ulnar Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03790D6	Dilation of Right Ulnar Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03790DZ	Dilation of Right Ulnar Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
03790EZ	Dilation of Right Ulnar Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03790F6	Dilation of Right Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03790FZ	Dilation of Right Ulnar Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03790G6	Dilation of Right Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03790GZ	Dilation of Right Ulnar Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
03790Z6	Dilation of Right Ulnar Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
03790ZZ	Dilation of Right Ulnar Artery, Open Approach	Procedure	ICD-10-PCS
037934Z	Dilation of Right Ulnar Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
037935Z	Dilation of Right Ulnar Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037936Z	Dilation of Right Ulnar Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037937Z	Dilation of Right Ulnar Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03793D6	Dilation of Right Ulnar Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03793DZ	Dilation of Right Ulnar Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
03793EZ	Dilation of Right Ulnar Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03793F6	Dilation of Right Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03793FZ	Dilation of Right Ulnar Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03793G6	Dilation of Right Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03793GZ	Dilation of Right Ulnar Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
03793Z6	Dilation of Right Ulnar Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03793ZZ	Dilation of Right Ulnar Artery, Percutaneous Approach	Procedure	ICD-10-PCS
037944Z	Dilation of Right Ulnar Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037945Z	Dilation of Right Ulnar Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037946Z	Dilation of Right Ulnar Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037947Z	Dilation of Right Ulnar Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03794D6	Dilation of Right Ulnar Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03794DZ	Dilation of Right Ulnar Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03794EZ	Dilation of Right Ulnar Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03794F6	Dilation of Right Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03794FZ	Dilation of Right Ulnar Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03794G6	Dilation of Right Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03794GZ	Dilation of Right Ulnar Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03794Z6	Dilation of Right Ulnar Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
03794ZZ	Dilation of Right Ulnar Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037A046	Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037A04Z	Dilation of Left Ulnar Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037A056	Dilation of Left Ulnar Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037A05Z	Dilation of Left Ulnar Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037A066	Dilation of Left Ulnar Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037A06Z	Dilation of Left Ulnar Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037A076	Dilation of Left Ulnar Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037A07Z	Dilation of Left Ulnar Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037A0D6	Dilation of Left Ulnar Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037A0DZ	Dilation of Left Ulnar Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037A0E6	Dilation of Left Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037A0EZ	Dilation of Left Ulnar Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037A0F6	Dilation of Left Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037A0FZ	Dilation of Left Ulnar Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037A0G6	Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037A0GZ	Dilation of Left Ulnar Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037A0Z6	Dilation of Left Ulnar Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
037A0ZZ	Dilation of Left Ulnar Artery, Open Approach	Procedure	ICD-10-PCS
037A346	Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037A34Z	Dilation of Left Ulnar Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037A356	Dilation of Left Ulnar Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037A35Z	Dilation of Left Ulnar Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037A366	Dilation of Left Ulnar Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037A36Z	Dilation of Left Ulnar Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037A376	Dilation of Left Ulnar Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037A37Z	Dilation of Left Ulnar Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
037A3D6	Dilation of Left Ulnar Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037A3DZ	Dilation of Left Ulnar Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037A3E6	Dilation of Left Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037A3EZ	Dilation of Left Ulnar Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037A3F6	Dilation of Left Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037A3FZ	Dilation of Left Ulnar Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037A3G6	Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037A3GZ	Dilation of Left Ulnar Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037A3Z6	Dilation of Left Ulnar Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
037A3ZZ	Dilation of Left Ulnar Artery, Percutaneous Approach	Procedure	ICD-10-PCS
037A446	Dilation of Left Ulnar Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037A44Z	Dilation of Left Ulnar Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037A456	Dilation of Left Ulnar Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037A45Z	Dilation of Left Ulnar Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037A466	Dilation of Left Ulnar Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037A46Z	Dilation of Left Ulnar Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037A476	Dilation of Left Ulnar Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037A47Z	Dilation of Left Ulnar Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037A4D6	Dilation of Left Ulnar Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037A4DZ	Dilation of Left Ulnar Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037A4E6	Dilation of Left Ulnar Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037A4EZ	Dilation of Left Ulnar Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037A4F6	Dilation of Left Ulnar Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037A4FZ	Dilation of Left Ulnar Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
037A4G6	Dilation of Left Ulnar Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037A4GZ	Dilation of Left Ulnar Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037A4Z6	Dilation of Left Ulnar Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037A4ZZ	Dilation of Left Ulnar Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B046	Dilation of Right Radial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037B04Z	Dilation of Right Radial Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037B056	Dilation of Right Radial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037B05Z	Dilation of Right Radial Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037B066	Dilation of Right Radial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037B06Z	Dilation of Right Radial Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037B076	Dilation of Right Radial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037B07Z	Dilation of Right Radial Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037B0D6	Dilation of Right Radial Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037B0DZ	Dilation of Right Radial Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037B0E6	Dilation of Right Radial Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037B0EZ	Dilation of Right Radial Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037B0F6	Dilation of Right Radial Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037B0FZ	Dilation of Right Radial Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037B0G6	Dilation of Right Radial Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037B0GZ	Dilation of Right Radial Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037B0Z6	Dilation of Right Radial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
037B0ZZ	Dilation of Right Radial Artery, Open Approach	Procedure	ICD-10-PCS
037B346	Dilation of Right Radial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037B34Z	Dilation of Right Radial Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037B356	Dilation of Right Radial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037B35Z	Dilation of Right Radial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
037B366	Dilation of Right Radial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037B36Z	Dilation of Right Radial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037B376	Dilation of Right Radial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037B37Z	Dilation of Right Radial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037B3D6	Dilation of Right Radial Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037B3DZ	Dilation of Right Radial Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037B3E6	Dilation of Right Radial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037B3EZ	Dilation of Right Radial Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037B3F6	Dilation of Right Radial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037B3FZ	Dilation of Right Radial Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037B3G6	Dilation of Right Radial Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037B3GZ	Dilation of Right Radial Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037B3Z6	Dilation of Right Radial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
037B3ZZ	Dilation of Right Radial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
037B446	Dilation of Right Radial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B44Z	Dilation of Right Radial Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B456	Dilation of Right Radial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B45Z	Dilation of Right Radial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B466	Dilation of Right Radial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B46Z	Dilation of Right Radial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B476	Dilation of Right Radial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B47Z	Dilation of Right Radial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B4D6	Dilation of Right Radial Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
037B4DZ	Dilation of Right Radial Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B4E6	Dilation of Right Radial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B4EZ	Dilation of Right Radial Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B4F6	Dilation of Right Radial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B4FZ	Dilation of Right Radial Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B4G6	Dilation of Right Radial Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B4GZ	Dilation of Right Radial Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B4Z6	Dilation of Right Radial Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037B4ZZ	Dilation of Right Radial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037C046	Dilation of Left Radial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037C04Z	Dilation of Left Radial Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037C056	Dilation of Left Radial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C05Z	Dilation of Left Radial Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C066	Dilation of Left Radial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C06Z	Dilation of Left Radial Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C076	Dilation of Left Radial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C07Z	Dilation of Left Radial Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C0D6	Dilation of Left Radial Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037C0DZ	Dilation of Left Radial Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037C0E6	Dilation of Left Radial Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C0EZ	Dilation of Left Radial Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C0F6	Dilation of Left Radial Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C0FZ	Dilation of Left Radial Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C0G6	Dilation of Left Radial Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C0GZ	Dilation of Left Radial Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037C0Z6	Dilation of Left Radial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
037C0ZZ	Dilation of Left Radial Artery, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
037C346	Dilation of Left Radial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037C34Z	Dilation of Left Radial Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037C356	Dilation of Left Radial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037C35Z	Dilation of Left Radial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037C366	Dilation of Left Radial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037C36Z	Dilation of Left Radial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037C376	Dilation of Left Radial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037C37Z	Dilation of Left Radial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037C3D6	Dilation of Left Radial Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037C3DZ	Dilation of Left Radial Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037C3E6	Dilation of Left Radial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037C3EZ	Dilation of Left Radial Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037C3F6	Dilation of Left Radial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037C3FZ	Dilation of Left Radial Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037C3G6	Dilation of Left Radial Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037C3GZ	Dilation of Left Radial Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037C3Z6	Dilation of Left Radial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
037C3ZZ	Dilation of Left Radial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
037C446	Dilation of Left Radial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037C44Z	Dilation of Left Radial Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037C456	Dilation of Left Radial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037C45Z	Dilation of Left Radial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037C466	Dilation of Left Radial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037C46Z	Dilation of Left Radial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
037C476	Dilation of Left Radial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037C47Z	Dilation of Left Radial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037C4D6	Dilation of Left Radial Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037C4DZ	Dilation of Left Radial Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037C4E6	Dilation of Left Radial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037C4EZ	Dilation of Left Radial Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037C4F6	Dilation of Left Radial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037C4FZ	Dilation of Left Radial Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037C4G6	Dilation of Left Radial Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037C4GZ	Dilation of Left Radial Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037C4Z6	Dilation of Left Radial Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037C4ZZ	Dilation of Left Radial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D046	Dilation of Right Hand Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037D04Z	Dilation of Right Hand Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037D056	Dilation of Right Hand Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037D05Z	Dilation of Right Hand Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037D066	Dilation of Right Hand Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037D06Z	Dilation of Right Hand Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037D076	Dilation of Right Hand Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037D07Z	Dilation of Right Hand Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037D0D6	Dilation of Right Hand Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037D0DZ	Dilation of Right Hand Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037D0E6	Dilation of Right Hand Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037D0EZ	Dilation of Right Hand Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037D0F6	Dilation of Right Hand Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
037D0FZ	Dilation of Right Hand Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037D0G6	Dilation of Right Hand Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037D0GZ	Dilation of Right Hand Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037D0Z6	Dilation of Right Hand Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
037D0ZZ	Dilation of Right Hand Artery, Open Approach	Procedure	ICD-10-PCS
037D346	Dilation of Right Hand Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037D34Z	Dilation of Right Hand Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037D356	Dilation of Right Hand Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037D35Z	Dilation of Right Hand Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037D366	Dilation of Right Hand Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037D36Z	Dilation of Right Hand Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037D376	Dilation of Right Hand Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037D37Z	Dilation of Right Hand Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037D3D6	Dilation of Right Hand Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037D3DZ	Dilation of Right Hand Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037D3E6	Dilation of Right Hand Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037D3EZ	Dilation of Right Hand Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037D3F6	Dilation of Right Hand Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037D3FZ	Dilation of Right Hand Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037D3G6	Dilation of Right Hand Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037D3GZ	Dilation of Right Hand Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037D3Z6	Dilation of Right Hand Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
037D3ZZ	Dilation of Right Hand Artery, Percutaneous Approach	Procedure	ICD-10-PCS
037D446	Dilation of Right Hand Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D44Z	Dilation of Right Hand Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
037D456	Dilation of Right Hand Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D45Z	Dilation of Right Hand Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D466	Dilation of Right Hand Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D46Z	Dilation of Right Hand Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D476	Dilation of Right Hand Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D47Z	Dilation of Right Hand Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D4D6	Dilation of Right Hand Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D4DZ	Dilation of Right Hand Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D4E6	Dilation of Right Hand Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D4EZ	Dilation of Right Hand Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D4F6	Dilation of Right Hand Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D4FZ	Dilation of Right Hand Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D4G6	Dilation of Right Hand Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D4GZ	Dilation of Right Hand Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D4Z6	Dilation of Right Hand Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037D4ZZ	Dilation of Right Hand Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F046	Dilation of Left Hand Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037F04Z	Dilation of Left Hand Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037F056	Dilation of Left Hand Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037F05Z	Dilation of Left Hand Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037F066	Dilation of Left Hand Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037F06Z	Dilation of Left Hand Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
037F076	Dilation of Left Hand Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037F07Z	Dilation of Left Hand Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037F0D6	Dilation of Left Hand Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037F0DZ	Dilation of Left Hand Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
037F0E6	Dilation of Left Hand Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037F0EZ	Dilation of Left Hand Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037F0F6	Dilation of Left Hand Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037F0FZ	Dilation of Left Hand Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037F0G6	Dilation of Left Hand Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037F0GZ	Dilation of Left Hand Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
037F0Z6	Dilation of Left Hand Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
037F0ZZ	Dilation of Left Hand Artery, Open Approach	Procedure	ICD-10-PCS
037F346	Dilation of Left Hand Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037F34Z	Dilation of Left Hand Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037F356	Dilation of Left Hand Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037F35Z	Dilation of Left Hand Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037F366	Dilation of Left Hand Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037F36Z	Dilation of Left Hand Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037F376	Dilation of Left Hand Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037F37Z	Dilation of Left Hand Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037F3D6	Dilation of Left Hand Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037F3DZ	Dilation of Left Hand Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
037F3E6	Dilation of Left Hand Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037F3EZ	Dilation of Left Hand Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037F3F6	Dilation of Left Hand Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037F3FZ	Dilation of Left Hand Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037F3G6	Dilation of Left Hand Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
037F3GZ	Dilation of Left Hand Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
037F3Z6	Dilation of Left Hand Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
037F3ZZ	Dilation of Left Hand Artery, Percutaneous Approach	Procedure	ICD-10-PCS
037F446	Dilation of Left Hand Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F44Z	Dilation of Left Hand Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F456	Dilation of Left Hand Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F45Z	Dilation of Left Hand Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F466	Dilation of Left Hand Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F46Z	Dilation of Left Hand Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F476	Dilation of Left Hand Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F47Z	Dilation of Left Hand Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F4D6	Dilation of Left Hand Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F4DZ	Dilation of Left Hand Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F4E6	Dilation of Left Hand Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F4EZ	Dilation of Left Hand Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F4F6	Dilation of Left Hand Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F4FZ	Dilation of Left Hand Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F4G6	Dilation of Left Hand Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F4GZ	Dilation of Left Hand Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F4Z6	Dilation of Left Hand Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
037F4ZZ	Dilation of Left Hand Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
03C33Z6	Extirpation of Matter from Right Subclavian Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03C33ZZ	Extirpation of Matter from Right Subclavian Artery, Percutaneous Approach	Procedure	ICD-10-PCS
03C43Z6	Extirpation of Matter from Left Subclavian Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03C43ZZ	Extirpation of Matter from Left Subclavian Artery, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
03C53Z6	Extirpation of Matter from Right Axillary Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03C53ZZ	Extirpation of Matter from Right Axillary Artery, Percutaneous Approach	Procedure	ICD-10-PCS
03C63Z6	Extirpation of Matter from Left Axillary Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03C63ZZ	Extirpation of Matter from Left Axillary Artery, Percutaneous Approach	Procedure	ICD-10-PCS
03C73Z6	Extirpation of Matter from Right Brachial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03C73ZZ	Extirpation of Matter from Right Brachial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
03C83Z6	Extirpation of Matter from Left Brachial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03C83ZZ	Extirpation of Matter from Left Brachial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
03C93Z6	Extirpation of Matter from Right Ulnar Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03C93ZZ	Extirpation of Matter from Right Ulnar Artery, Percutaneous Approach	Procedure	ICD-10-PCS
03CA3Z6	Extirpation of Matter from Left Ulnar Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03CA3ZZ	Extirpation of Matter from Left Ulnar Artery, Percutaneous Approach	Procedure	ICD-10-PCS
03CB3Z6	Extirpation of Matter from Right Radial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03CB3ZZ	Extirpation of Matter from Right Radial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
03CC3Z6	Extirpation of Matter from Left Radial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03CC3ZZ	Extirpation of Matter from Left Radial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
03CD3Z6	Extirpation of Matter from Right Hand Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03CD3ZZ	Extirpation of Matter from Right Hand Artery, Percutaneous Approach	Procedure	ICD-10-PCS
03CF3Z6	Extirpation of Matter from Left Hand Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
03CF3ZZ	Extirpation of Matter from Left Hand Artery, Percutaneous Approach	Procedure	ICD-10-PCS
041009B	Bypass Abdominal Aorta to Left Internal Iliac Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041009C	Bypass Abdominal Aorta to Bilateral Internal Iliac Arteries with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041009D	Bypass Abdominal Aorta to Right External Iliac Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041009F	Bypass Abdominal Aorta to Left External Iliac Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041009G	Bypass Abdominal Aorta to Bilateral External Iliac Arteries with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041009H	Bypass Abdominal Aorta to Right Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041009J	Bypass Abdominal Aorta to Left Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041009K	Bypass Abdominal Aorta to Bilateral Femoral Arteries with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041009Q	Bypass Abdominal Aorta to Lower Extremity Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
04100A6	Bypass Abdominal Aorta to Right Common Iliac Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
04100A7	Bypass Abdominal Aorta to Left Common Iliac Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
04100A8	Bypass Abdominal Aorta to Bilateral Common Iliac Arteries with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
04100A9	Bypass Abdominal Aorta to Right Internal Iliac Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
04100AB	Bypass Abdominal Aorta to Left Internal Iliac Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
04100AC	Bypass Abdominal Aorta to Bilateral Internal Iliac Arteries with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
04100AD	Bypass Abdominal Aorta to Right External Iliac Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
04100AF	Bypass Abdominal Aorta to Left External Iliac Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
04100AG	Bypass Abdominal Aorta to Bilateral External Iliac Arteries with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
04100AH	Bypass Abdominal Aorta to Right Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
04100AJ	Bypass Abdominal Aorta to Left Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
04100AK	Bypass Abdominal Aorta to Bilateral Femoral Arteries with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
04100AQ	Bypass Abdominal Aorta to Lower Extremity Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
04100AR	Bypass Abdominal Aorta to Lower Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
04100J6	Bypass Abdominal Aorta to Right Common Iliac Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
04100J7	Bypass Abdominal Aorta to Left Common Iliac Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
04100J8	Bypass Abdominal Aorta to Bilateral Common Iliac Arteries with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
04100J9	Bypass Abdominal Aorta to Right Internal Iliac Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
04100JB	Bypass Abdominal Aorta to Left Internal Iliac Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
04100JC	Bypass Abdominal Aorta to Bilateral Internal Iliac Arteries with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
04100JD	Bypass Abdominal Aorta to Right External Iliac Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
04100JF	Bypass Abdominal Aorta to Left External Iliac Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
04100JG	Bypass Abdominal Aorta to Bilateral External Iliac Arteries with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
04100JH	Bypass Abdominal Aorta to Right Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
04100JJ	Bypass Abdominal Aorta to Left Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
04100JK	Bypass Abdominal Aorta to Bilateral Femoral Arteries with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
04100JQ	Bypass Abdominal Aorta to Lower Extremity Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
04100K6	Bypass Abdominal Aorta to Right Common Iliac Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
04100K7	Bypass Abdominal Aorta to Left Common Iliac Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
04100K8	Bypass Abdominal Aorta to Bilateral Common Iliac Arteries with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
04100K9	Bypass Abdominal Aorta to Right Internal Iliac Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
04100KB	Bypass Abdominal Aorta to Left Internal Iliac Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
04100KC	Bypass Abdominal Aorta to Bilateral Internal Iliac Arteries with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
04100KD	Bypass Abdominal Aorta to Right External Iliac Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
04100KF	Bypass Abdominal Aorta to Left External Iliac Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
04100KG	Bypass Abdominal Aorta to Bilateral External Iliac Arteries with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
04100KH	Bypass Abdominal Aorta to Right Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
04100KJ	Bypass Abdominal Aorta to Left Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
04100KK	Bypass Abdominal Aorta to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
04100KQ	Bypass Abdominal Aorta to Lower Extremity Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
04100KR	Bypass Abdominal Aorta to Lower Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
04100Z6	Bypass Abdominal Aorta to Right Common Iliac Artery, Open Approach	Procedure	ICD-10-PCS
04100Z7	Bypass Abdominal Aorta to Left Common Iliac Artery, Open Approach	Procedure	ICD-10-PCS
04100Z8	Bypass Abdominal Aorta to Bilateral Common Iliac Arteries, Open Approach	Procedure	ICD-10-PCS
04100Z9	Bypass Abdominal Aorta to Right Internal Iliac Artery, Open Approach	Procedure	ICD-10-PCS
04100ZB	Bypass Abdominal Aorta to Left Internal Iliac Artery, Open Approach	Procedure	ICD-10-PCS
04100ZC	Bypass Abdominal Aorta to Bilateral Internal Iliac Arteries, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
04100ZD	Bypass Abdominal Aorta to Right External Iliac Artery, Open Approach	Procedure	ICD-10-PCS
04100ZF	Bypass Abdominal Aorta to Left External Iliac Artery, Open Approach	Procedure	ICD-10-PCS
04100ZG	Bypass Abdominal Aorta to Bilateral External Iliac Arteries, Open Approach	Procedure	ICD-10-PCS
04100ZH	Bypass Abdominal Aorta to Right Femoral Artery, Open Approach	Procedure	ICD-10-PCS
04100ZJ	Bypass Abdominal Aorta to Left Femoral Artery, Open Approach	Procedure	ICD-10-PCS
04100ZK	Bypass Abdominal Aorta to Bilateral Femoral Arteries, Open Approach	Procedure	ICD-10-PCS
04100ZQ	Bypass Abdominal Aorta to Lower Extremity Artery, Open Approach	Procedure	ICD-10-PCS
041049B	Bypass Abdominal Aorta to Left Internal Iliac Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041049C	Bypass Abdominal Aorta to Bilateral Internal Iliac Arteries with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041049D	Bypass Abdominal Aorta to Right External Iliac Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041049F	Bypass Abdominal Aorta to Left External Iliac Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041049G	Bypass Abdominal Aorta to Bilateral External Iliac Arteries with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041049H	Bypass Abdominal Aorta to Right Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041049J	Bypass Abdominal Aorta to Left Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041049K	Bypass Abdominal Aorta to Bilateral Femoral Arteries with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041049Q	Bypass Abdominal Aorta to Lower Extremity Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104A6	Bypass Abdominal Aorta to Right Common Iliac Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104A7	Bypass Abdominal Aorta to Left Common Iliac Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104A8	Bypass Abdominal Aorta to Bilateral Common Iliac Arteries with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104A9	Bypass Abdominal Aorta to Right Internal Iliac Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104AB	Bypass Abdominal Aorta to Left Internal Iliac Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104AC	Bypass Abdominal Aorta to Bilateral Internal Iliac Arteries with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
04104AD	Bypass Abdominal Aorta to Right External Iliac Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104AF	Bypass Abdominal Aorta to Left External Iliac Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104AG	Bypass Abdominal Aorta to Bilateral External Iliac Arteries with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104AH	Bypass Abdominal Aorta to Right Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104AJ	Bypass Abdominal Aorta to Left Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104AK	Bypass Abdominal Aorta to Bilateral Femoral Arteries with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104AQ	Bypass Abdominal Aorta to Lower Extremity Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104J6	Bypass Abdominal Aorta to Right Common Iliac Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104J7	Bypass Abdominal Aorta to Left Common Iliac Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104J8	Bypass Abdominal Aorta to Bilateral Common Iliac Arteries with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104J9	Bypass Abdominal Aorta to Right Internal Iliac Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104JB	Bypass Abdominal Aorta to Left Internal Iliac Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104JC	Bypass Abdominal Aorta to Bilateral Internal Iliac Arteries with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104JD	Bypass Abdominal Aorta to Right External Iliac Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104JF	Bypass Abdominal Aorta to Left External Iliac Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104JG	Bypass Abdominal Aorta to Bilateral External Iliac Arteries with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104JH	Bypass Abdominal Aorta to Right Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104JJ	Bypass Abdominal Aorta to Left Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104JK	Bypass Abdominal Aorta to Bilateral Femoral Arteries with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104JQ	Bypass Abdominal Aorta to Lower Extremity Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104K6	Bypass Abdominal Aorta to Right Common Iliac Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104K7	Bypass Abdominal Aorta to Left Common Iliac Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
04104K8	Bypass Abdominal Aorta to Bilateral Common Iliac Arteries with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104K9	Bypass Abdominal Aorta to Right Internal Iliac Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104KB	Bypass Abdominal Aorta to Left Internal Iliac Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104KC	Bypass Abdominal Aorta to Bilateral Internal Iliac Arteries with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104KD	Bypass Abdominal Aorta to Right External Iliac Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104KF	Bypass Abdominal Aorta to Left External Iliac Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104KG	Bypass Abdominal Aorta to Bilateral External Iliac Arteries with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104KH	Bypass Abdominal Aorta to Right Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104KJ	Bypass Abdominal Aorta to Left Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104KK	Bypass Abdominal Aorta to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104KQ	Bypass Abdominal Aorta to Lower Extremity Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104Z6	Bypass Abdominal Aorta to Right Common Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104Z7	Bypass Abdominal Aorta to Left Common Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104Z8	Bypass Abdominal Aorta to Bilateral Common Iliac Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104Z9	Bypass Abdominal Aorta to Right Internal Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104ZB	Bypass Abdominal Aorta to Left Internal Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104ZC	Bypass Abdominal Aorta to Bilateral Internal Iliac Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104ZD	Bypass Abdominal Aorta to Right External Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104ZF	Bypass Abdominal Aorta to Left External Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104ZG	Bypass Abdominal Aorta to Bilateral External Iliac Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104ZH	Bypass Abdominal Aorta to Right Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104ZJ	Bypass Abdominal Aorta to Left Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
04104ZK	Bypass Abdominal Aorta to Bilateral Femoral Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04104ZQ	Bypass Abdominal Aorta to Lower Extremity Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C09H	Bypass Right Common Iliac Artery to Right Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041C09J	Bypass Right Common Iliac Artery to Left Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041C09K	Bypass Right Common Iliac Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041C0AH	Bypass Right Common Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041C0AJ	Bypass Right Common Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041C0AK	Bypass Right Common Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041C0JH	Bypass Right Common Iliac Artery to Right Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041C0JJ	Bypass Right Common Iliac Artery to Left Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041C0JK	Bypass Right Common Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041C0KH	Bypass Right Common Iliac Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041C0KJ	Bypass Right Common Iliac Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041C0KK	Bypass Right Common Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041C0ZH	Bypass Right Common Iliac Artery to Right Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041C0ZJ	Bypass Right Common Iliac Artery to Left Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041C0ZK	Bypass Right Common Iliac Artery to Bilateral Femoral Arteries, Open Approach	Procedure	ICD-10-PCS
041C49H	Bypass Right Common Iliac Artery to Right Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C49J	Bypass Right Common Iliac Artery to Left Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C49K	Bypass Right Common Iliac Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C4AH	Bypass Right Common Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C4AJ	Bypass Right Common Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C4AK	Bypass Right Common Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
041C4JH	Bypass Right Common Iliac Artery to Right Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C4JJ	Bypass Right Common Iliac Artery to Left Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C4JK	Bypass Right Common Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C4KH	Bypass Right Common Iliac Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C4KJ	Bypass Right Common Iliac Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C4KK	Bypass Right Common Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C4ZH	Bypass Right Common Iliac Artery to Right Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C4ZJ	Bypass Right Common Iliac Artery to Left Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041C4ZK	Bypass Right Common Iliac Artery to Bilateral Femoral Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041D09H	Bypass Left Common Iliac Artery to Right Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041D09J	Bypass Left Common Iliac Artery to Left Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041D09K	Bypass Left Common Iliac Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041D0AH	Bypass Left Common Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041D0AJ	Bypass Left Common Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041D0AK	Bypass Left Common Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041D0JH	Bypass Left Common Iliac Artery to Right Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041D0JJ	Bypass Left Common Iliac Artery to Left Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041D0JK	Bypass Left Common Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041D0KH	Bypass Left Common Iliac Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041D0KJ	Bypass Left Common Iliac Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041D0KK	Bypass Left Common Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041D0ZH	Bypass Left Common Iliac Artery to Right Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041D0ZJ	Bypass Left Common Iliac Artery to Left Femoral Artery, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
041D0ZK	Bypass Left Common Iliac Artery to Bilateral Femoral Arteries, Open Approach	Procedure	ICD-10-PCS
041D49H	Bypass Left Common Iliac Artery to Right Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041D49J	Bypass Left Common Iliac Artery to Left Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041D49K	Bypass Left Common Iliac Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041D4AH	Bypass Left Common Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041D4AJ	Bypass Left Common Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041D4AK	Bypass Left Common Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041D4JH	Bypass Left Common Iliac Artery to Right Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041D4JJ	Bypass Left Common Iliac Artery to Left Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041D4JK	Bypass Left Common Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041D4KH	Bypass Left Common Iliac Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041D4KJ	Bypass Left Common Iliac Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041D4KK	Bypass Left Common Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041D4ZH	Bypass Left Common Iliac Artery to Right Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041D4ZJ	Bypass Left Common Iliac Artery to Left Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041D4ZK	Bypass Left Common Iliac Artery to Bilateral Femoral Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041E09H	Bypass Right Internal Iliac Artery to Right Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041E09J	Bypass Right Internal Iliac Artery to Left Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041E09K	Bypass Right Internal Iliac Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041E0AH	Bypass Right Internal Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041E0AJ	Bypass Right Internal Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041E0AK	Bypass Right Internal Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
041E0JH	Bypass Right Internal Iliac Artery to Right Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041E0JJ	Bypass Right Internal Iliac Artery to Left Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041E0JK	Bypass Right Internal Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041E0KH	Bypass Right Internal Iliac Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041E0KJ	Bypass Right Internal Iliac Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041E0KK	Bypass Right Internal Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041E0ZH	Bypass Right Internal Iliac Artery to Right Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041E0ZJ	Bypass Right Internal Iliac Artery to Left Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041E0ZK	Bypass Right Internal Iliac Artery to Bilateral Femoral Arteries, Open Approach	Procedure	ICD-10-PCS
041E49H	Bypass Right Internal Iliac Artery to Right Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041E49J	Bypass Right Internal Iliac Artery to Left Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041E49K	Bypass Right Internal Iliac Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041E4AH	Bypass Right Internal Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041E4AJ	Bypass Right Internal Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041E4AK	Bypass Right Internal Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041E4JH	Bypass Right Internal Iliac Artery to Right Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041E4JJ	Bypass Right Internal Iliac Artery to Left Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041E4JK	Bypass Right Internal Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041E4KH	Bypass Right Internal Iliac Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041E4KJ	Bypass Right Internal Iliac Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041E4KK	Bypass Right Internal Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041E4ZH	Bypass Right Internal Iliac Artery to Right Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041E4ZJ	Bypass Right Internal Iliac Artery to Left Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
041E4ZK	Bypass Right Internal Iliac Artery to Bilateral Femoral Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041F09H	Bypass Left Internal Iliac Artery to Right Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041F09J	Bypass Left Internal Iliac Artery to Left Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041F09K	Bypass Left Internal Iliac Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041F0AH	Bypass Left Internal Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041F0AJ	Bypass Left Internal Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041F0AK	Bypass Left Internal Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041F0JH	Bypass Left Internal Iliac Artery to Right Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041F0JJ	Bypass Left Internal Iliac Artery to Left Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041F0JK	Bypass Left Internal Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041F0KH	Bypass Left Internal Iliac Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041F0KJ	Bypass Left Internal Iliac Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041F0KK	Bypass Left Internal Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041F0ZH	Bypass Left Internal Iliac Artery to Right Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041F0ZJ	Bypass Left Internal Iliac Artery to Left Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041F0ZK	Bypass Left Internal Iliac Artery to Bilateral Femoral Arteries, Open Approach	Procedure	ICD-10-PCS
041F49H	Bypass Left Internal Iliac Artery to Right Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041F49J	Bypass Left Internal Iliac Artery to Left Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041F49K	Bypass Left Internal Iliac Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041F4AH	Bypass Left Internal Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041F4AJ	Bypass Left Internal Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041F4AK	Bypass Left Internal Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041F4JH	Bypass Left Internal Iliac Artery to Right Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
041F4JJ	Bypass Left Internal Iliac Artery to Left Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041F4JK	Bypass Left Internal Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041F4KH	Bypass Left Internal Iliac Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041F4KJ	Bypass Left Internal Iliac Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041F4KK	Bypass Left Internal Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041F4ZH	Bypass Left Internal Iliac Artery to Right Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041F4ZJ	Bypass Left Internal Iliac Artery to Left Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041F4ZK	Bypass Left Internal Iliac Artery to Bilateral Femoral Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H09H	Bypass Right External Iliac Artery to Right Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041H09J	Bypass Right External Iliac Artery to Left Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041H09K	Bypass Right External Iliac Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041H0AH	Bypass Right External Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041H0AJ	Bypass Right External Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041H0AK	Bypass Right External Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041H0JH	Bypass Right External Iliac Artery to Right Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041H0JJ	Bypass Right External Iliac Artery to Left Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041H0JK	Bypass Right External Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041H0KH	Bypass Right External Iliac Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041H0KJ	Bypass Right External Iliac Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041H0KK	Bypass Right External Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041H0ZH	Bypass Right External Iliac Artery to Right Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041H0ZJ	Bypass Right External Iliac Artery to Left Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041H0ZK	Bypass Right External Iliac Artery to Bilateral Femoral Arteries, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
041H49H	Bypass Right External Iliac Artery to Right Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H49J	Bypass Right External Iliac Artery to Left Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H49K	Bypass Right External Iliac Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H4AH	Bypass Right External Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H4AJ	Bypass Right External Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H4AK	Bypass Right External Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H4JH	Bypass Right External Iliac Artery to Right Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H4JJ	Bypass Right External Iliac Artery to Left Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H4JK	Bypass Right External Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H4KH	Bypass Right External Iliac Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H4KJ	Bypass Right External Iliac Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H4KK	Bypass Right External Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H4ZH	Bypass Right External Iliac Artery to Right Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H4ZJ	Bypass Right External Iliac Artery to Left Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041H4ZK	Bypass Right External Iliac Artery to Bilateral Femoral Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041J09H	Bypass Left External Iliac Artery to Right Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041J09J	Bypass Left External Iliac Artery to Left Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041J09K	Bypass Left External Iliac Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041J0AH	Bypass Left External Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041J0AJ	Bypass Left External Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041J0AK	Bypass Left External Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
041J0JH	Bypass Left External Iliac Artery to Right Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041J0JJ	Bypass Left External Iliac Artery to Left Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041J0JK	Bypass Left External Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041J0KH	Bypass Left External Iliac Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041J0KJ	Bypass Left External Iliac Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041J0KK	Bypass Left External Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041J0ZH	Bypass Left External Iliac Artery to Right Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041J0ZJ	Bypass Left External Iliac Artery to Left Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041J0ZK	Bypass Left External Iliac Artery to Bilateral Femoral Arteries, Open Approach	Procedure	ICD-10-PCS
041J49H	Bypass Left External Iliac Artery to Right Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041J49J	Bypass Left External Iliac Artery to Left Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041J49K	Bypass Left External Iliac Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041J4AH	Bypass Left External Iliac Artery to Right Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041J4AJ	Bypass Left External Iliac Artery to Left Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041J4AK	Bypass Left External Iliac Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041J4JH	Bypass Left External Iliac Artery to Right Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041J4JJ	Bypass Left External Iliac Artery to Left Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041J4JK	Bypass Left External Iliac Artery to Bilateral Femoral Arteries with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041J4KH	Bypass Left External Iliac Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041J4KJ	Bypass Left External Iliac Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041J4KK	Bypass Left External Iliac Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041J4ZH	Bypass Left External Iliac Artery to Right Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041J4ZJ	Bypass Left External Iliac Artery to Left Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
041J4ZK	Bypass Left External Iliac Artery to Bilateral Femoral Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K09H	Bypass Right Femoral Artery to Right Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041K09J	Bypass Right Femoral Artery to Left Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041K09K	Bypass Right Femoral Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041K09L	Bypass Right Femoral Artery to Popliteal Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041K09M	Bypass Right Femoral Artery to Peroneal Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041K09N	Bypass Right Femoral Artery to Posterior Tibial Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041K09P	Bypass Right Femoral Artery to Foot Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041K09Q	Bypass Right Femoral Artery to Lower Extremity Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041K09S	Bypass Right Femoral Artery to Lower Extremity Vein with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041K0AH	Bypass Right Femoral Artery to Right Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041K0AJ	Bypass Right Femoral Artery to Left Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041K0AK	Bypass Right Femoral Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041K0AL	Bypass Right Femoral Artery to Popliteal Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041K0AM	Bypass Right Femoral Artery to Peroneal Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041K0AN	Bypass Right Femoral Artery to Posterior Tibial Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041K0AP	Bypass Right Femoral Artery to Foot Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041K0AQ	Bypass Right Femoral Artery to Lower Extremity Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041K0AS	Bypass Right Femoral Artery to Lower Extremity Vein with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041K0JH	Bypass Right Femoral Artery to Right Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041K0JJ	Bypass Right Femoral Artery to Left Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
041K0JK	Bypass Right Femoral Artery to Bilateral Femoral Arteries with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041K0JL	Bypass Right Femoral Artery to Popliteal Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041K0JM	Bypass Right Femoral Artery to Peroneal Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041K0JN	Bypass Right Femoral Artery to Posterior Tibial Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041K0JP	Bypass Right Femoral Artery to Foot Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041K0JQ	Bypass Right Femoral Artery to Lower Extremity Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041K0JS	Bypass Right Femoral Artery to Lower Extremity Vein with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041K0KH	Bypass Right Femoral Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041K0KJ	Bypass Right Femoral Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041K0KK	Bypass Right Femoral Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041K0KL	Bypass Right Femoral Artery to Popliteal Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041K0KM	Bypass Right Femoral Artery to Peroneal Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041K0KN	Bypass Right Femoral Artery to Posterior Tibial Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041K0KP	Bypass Right Femoral Artery to Foot Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041K0KQ	Bypass Right Femoral Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041K0KS	Bypass Right Femoral Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041K0ZH	Bypass Right Femoral Artery to Right Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041K0ZJ	Bypass Right Femoral Artery to Left Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041K0ZK	Bypass Right Femoral Artery to Bilateral Femoral Arteries, Open Approach	Procedure	ICD-10-PCS
041K0ZL	Bypass Right Femoral Artery to Popliteal Artery, Open Approach	Procedure	ICD-10-PCS
041K0ZM	Bypass Right Femoral Artery to Peroneal Artery, Open Approach	Procedure	ICD-10-PCS
041K0ZN	Bypass Right Femoral Artery to Posterior Tibial Artery, Open Approach	Procedure	ICD-10-PCS
041K0ZP	Bypass Right Femoral Artery to Foot Artery, Open Approach	Procedure	ICD-10-PCS
041K0ZQ	Bypass Right Femoral Artery to Lower Extremity Artery, Open Approach	Procedure	ICD-10-PCS
041K0ZS	Bypass Right Femoral Artery to Lower Extremity Vein, Open Approach	Procedure	ICD-10-PCS
041K49H	Bypass Right Femoral Artery to Right Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K49J	Bypass Right Femoral Artery to Left Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
041K49K	Bypass Right Femoral Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K49L	Bypass Right Femoral Artery to Popliteal Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K49M	Bypass Right Femoral Artery to Peroneal Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K49N	Bypass Right Femoral Artery to Posterior Tibial Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K49P	Bypass Right Femoral Artery to Foot Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K49Q	Bypass Right Femoral Artery to Lower Extremity Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K49S	Bypass Right Femoral Artery to Lower Extremity Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4AH	Bypass Right Femoral Artery to Right Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4AJ	Bypass Right Femoral Artery to Left Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4AK	Bypass Right Femoral Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4AL	Bypass Right Femoral Artery to Popliteal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4AM	Bypass Right Femoral Artery to Peroneal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4AN	Bypass Right Femoral Artery to Posterior Tibial Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4AP	Bypass Right Femoral Artery to Foot Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4AQ	Bypass Right Femoral Artery to Lower Extremity Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4AS	Bypass Right Femoral Artery to Lower Extremity Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4JH	Bypass Right Femoral Artery to Right Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4JJ	Bypass Right Femoral Artery to Left Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4JK	Bypass Right Femoral Artery to Bilateral Femoral Arteries with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4JL	Bypass Right Femoral Artery to Popliteal Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4JM	Bypass Right Femoral Artery to Peroneal Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
041K4JN	Bypass Right Femoral Artery to Posterior Tibial Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4JP	Bypass Right Femoral Artery to Foot Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4JQ	Bypass Right Femoral Artery to Lower Extremity Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4JS	Bypass Right Femoral Artery to Lower Extremity Vein with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4KH	Bypass Right Femoral Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4KJ	Bypass Right Femoral Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4KK	Bypass Right Femoral Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4KL	Bypass Right Femoral Artery to Popliteal Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4KM	Bypass Right Femoral Artery to Peroneal Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4KN	Bypass Right Femoral Artery to Posterior Tibial Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4KP	Bypass Right Femoral Artery to Foot Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4KQ	Bypass Right Femoral Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4KS	Bypass Right Femoral Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4ZH	Bypass Right Femoral Artery to Right Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4ZJ	Bypass Right Femoral Artery to Left Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4ZK	Bypass Right Femoral Artery to Bilateral Femoral Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4ZL	Bypass Right Femoral Artery to Popliteal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4ZM	Bypass Right Femoral Artery to Peroneal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4ZN	Bypass Right Femoral Artery to Posterior Tibial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4ZP	Bypass Right Femoral Artery to Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4ZQ	Bypass Right Femoral Artery to Lower Extremity Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041K4ZS	Bypass Right Femoral Artery to Lower Extremity Vein, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
041L09H	Bypass Left Femoral Artery to Right Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041L09J	Bypass Left Femoral Artery to Left Femoral Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041L09K	Bypass Left Femoral Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041L09L	Bypass Left Femoral Artery to Popliteal Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041L09M	Bypass Left Femoral Artery to Peroneal Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041L09N	Bypass Left Femoral Artery to Posterior Tibial Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041L09P	Bypass Left Femoral Artery to Foot Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041L09Q	Bypass Left Femoral Artery to Lower Extremity Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041L09S	Bypass Left Femoral Artery to Lower Extremity Vein with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041L0AH	Bypass Left Femoral Artery to Right Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041L0AJ	Bypass Left Femoral Artery to Left Femoral Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041L0AK	Bypass Left Femoral Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041L0AL	Bypass Left Femoral Artery to Popliteal Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041L0AM	Bypass Left Femoral Artery to Peroneal Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041L0AN	Bypass Left Femoral Artery to Posterior Tibial Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041L0AP	Bypass Left Femoral Artery to Foot Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041L0AQ	Bypass Left Femoral Artery to Lower Extremity Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041L0AS	Bypass Left Femoral Artery to Lower Extremity Vein with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041L0JH	Bypass Left Femoral Artery to Right Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041L0JJ	Bypass Left Femoral Artery to Left Femoral Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041L0JK	Bypass Left Femoral Artery to Bilateral Femoral Arteries with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
041L0JL	Bypass Left Femoral Artery to Popliteal Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041L0JM	Bypass Left Femoral Artery to Peroneal Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041L0JN	Bypass Left Femoral Artery to Posterior Tibial Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041L0JP	Bypass Left Femoral Artery to Foot Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041L0JQ	Bypass Left Femoral Artery to Lower Extremity Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041L0JS	Bypass Left Femoral Artery to Lower Extremity Vein with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041L0KH	Bypass Left Femoral Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041L0KJ	Bypass Left Femoral Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041L0KK	Bypass Left Femoral Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041L0KL	Bypass Left Femoral Artery to Popliteal Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041L0KM	Bypass Left Femoral Artery to Peroneal Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041L0KN	Bypass Left Femoral Artery to Posterior Tibial Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041L0KP	Bypass Left Femoral Artery to Foot Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041L0KQ	Bypass Left Femoral Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041L0KS	Bypass Left Femoral Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041L0ZH	Bypass Left Femoral Artery to Right Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041L0ZJ	Bypass Left Femoral Artery to Left Femoral Artery, Open Approach	Procedure	ICD-10-PCS
041L0ZK	Bypass Left Femoral Artery to Bilateral Femoral Arteries, Open Approach	Procedure	ICD-10-PCS
041L0ZL	Bypass Left Femoral Artery to Popliteal Artery, Open Approach	Procedure	ICD-10-PCS
041L0ZM	Bypass Left Femoral Artery to Peroneal Artery, Open Approach	Procedure	ICD-10-PCS
041L0ZN	Bypass Left Femoral Artery to Posterior Tibial Artery, Open Approach	Procedure	ICD-10-PCS
041L0ZP	Bypass Left Femoral Artery to Foot Artery, Open Approach	Procedure	ICD-10-PCS
041L0ZQ	Bypass Left Femoral Artery to Lower Extremity Artery, Open Approach	Procedure	ICD-10-PCS
041L0ZS	Bypass Left Femoral Artery to Lower Extremity Vein, Open Approach	Procedure	ICD-10-PCS
041L49H	Bypass Left Femoral Artery to Right Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L49J	Bypass Left Femoral Artery to Left Femoral Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L49K	Bypass Left Femoral Artery to Bilateral Femoral Arteries with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
041L49L	Bypass Left Femoral Artery to Popliteal Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L49M	Bypass Left Femoral Artery to Peroneal Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L49N	Bypass Left Femoral Artery to Posterior Tibial Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L49P	Bypass Left Femoral Artery to Foot Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L49Q	Bypass Left Femoral Artery to Lower Extremity Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L49S	Bypass Left Femoral Artery to Lower Extremity Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4AH	Bypass Left Femoral Artery to Right Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4AJ	Bypass Left Femoral Artery to Left Femoral Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4AK	Bypass Left Femoral Artery to Bilateral Femoral Arteries with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4AL	Bypass Left Femoral Artery to Popliteal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4AM	Bypass Left Femoral Artery to Peroneal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4AN	Bypass Left Femoral Artery to Posterior Tibial Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4AP	Bypass Left Femoral Artery to Foot Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4AQ	Bypass Left Femoral Artery to Lower Extremity Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4AS	Bypass Left Femoral Artery to Lower Extremity Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4JH	Bypass Left Femoral Artery to Right Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4JJ	Bypass Left Femoral Artery to Left Femoral Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4JK	Bypass Left Femoral Artery to Bilateral Femoral Arteries with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4JL	Bypass Left Femoral Artery to Popliteal Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4JM	Bypass Left Femoral Artery to Peroneal Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4JN	Bypass Left Femoral Artery to Posterior Tibial Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4JP	Bypass Left Femoral Artery to Foot Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
041L4JQ	Bypass Left Femoral Artery to Lower Extremity Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4JS	Bypass Left Femoral Artery to Lower Extremity Vein with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4KH	Bypass Left Femoral Artery to Right Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4KJ	Bypass Left Femoral Artery to Left Femoral Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4KK	Bypass Left Femoral Artery to Bilateral Femoral Arteries with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4KL	Bypass Left Femoral Artery to Popliteal Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4KM	Bypass Left Femoral Artery to Peroneal Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4KN	Bypass Left Femoral Artery to Posterior Tibial Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4KP	Bypass Left Femoral Artery to Foot Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4KQ	Bypass Left Femoral Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4KS	Bypass Left Femoral Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4ZH	Bypass Left Femoral Artery to Right Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4ZJ	Bypass Left Femoral Artery to Left Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4ZK	Bypass Left Femoral Artery to Bilateral Femoral Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4ZL	Bypass Left Femoral Artery to Popliteal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4ZM	Bypass Left Femoral Artery to Peroneal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4ZN	Bypass Left Femoral Artery to Posterior Tibial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4ZP	Bypass Left Femoral Artery to Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4ZQ	Bypass Left Femoral Artery to Lower Extremity Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041L4ZS	Bypass Left Femoral Artery to Lower Extremity Vein, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M09L	Bypass Right Popliteal Artery to Popliteal Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041M09M	Bypass Right Popliteal Artery to Peroneal Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041M09P	Bypass Right Popliteal Artery to Foot Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
041M09Q	Bypass Right Popliteal Artery to Lower Extremity Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041M09S	Bypass Right Popliteal Artery to Lower Extremity Vein with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041M0AL	Bypass Right Popliteal Artery to Popliteal Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041M0AM	Bypass Right Popliteal Artery to Peroneal Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041M0AP	Bypass Right Popliteal Artery to Foot Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041M0AQ	Bypass Right Popliteal Artery to Lower Extremity Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041M0AS	Bypass Right Popliteal Artery to Lower Extremity Vein with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041M0JL	Bypass Right Popliteal Artery to Popliteal Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041M0JM	Bypass Right Popliteal Artery to Peroneal Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041M0JP	Bypass Right Popliteal Artery to Foot Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041M0JQ	Bypass Right Popliteal Artery to Lower Extremity Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041M0JS	Bypass Right Popliteal Artery to Lower Extremity Vein with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041M0KL	Bypass Right Popliteal Artery to Popliteal Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041M0KM	Bypass Right Popliteal Artery to Peroneal Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041M0KP	Bypass Right Popliteal Artery to Foot Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041M0KQ	Bypass Right Popliteal Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041M0KS	Bypass Right Popliteal Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041M0ZL	Bypass Right Popliteal Artery to Popliteal Artery, Open Approach	Procedure	ICD-10-PCS
041M0ZM	Bypass Right Popliteal Artery to Peroneal Artery, Open Approach	Procedure	ICD-10-PCS
041M0ZP	Bypass Right Popliteal Artery to Foot Artery, Open Approach	Procedure	ICD-10-PCS
041M0ZQ	Bypass Right Popliteal Artery to Lower Extremity Artery, Open Approach	Procedure	ICD-10-PCS
041M0ZS	Bypass Right Popliteal Artery to Lower Extremity Vein, Open Approach	Procedure	ICD-10-PCS
041M49L	Bypass Right Popliteal Artery to Popliteal Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M49M	Bypass Right Popliteal Artery to Peroneal Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
041M49P	Bypass Right Popliteal Artery to Foot Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M49Q	Bypass Right Popliteal Artery to Lower Extremity Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M49S	Bypass Right Popliteal Artery to Lower Extremity Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4AL	Bypass Right Popliteal Artery to Popliteal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4AM	Bypass Right Popliteal Artery to Peroneal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4AP	Bypass Right Popliteal Artery to Foot Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4AQ	Bypass Right Popliteal Artery to Lower Extremity Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4AS	Bypass Right Popliteal Artery to Lower Extremity Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4JL	Bypass Right Popliteal Artery to Popliteal Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4JM	Bypass Right Popliteal Artery to Peroneal Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4JP	Bypass Right Popliteal Artery to Foot Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4JQ	Bypass Right Popliteal Artery to Lower Extremity Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4JS	Bypass Right Popliteal Artery to Lower Extremity Vein with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4KL	Bypass Right Popliteal Artery to Popliteal Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4KM	Bypass Right Popliteal Artery to Peroneal Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4KP	Bypass Right Popliteal Artery to Foot Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4KQ	Bypass Right Popliteal Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4KS	Bypass Right Popliteal Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4ZL	Bypass Right Popliteal Artery to Popliteal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4ZM	Bypass Right Popliteal Artery to Peroneal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4ZP	Bypass Right Popliteal Artery to Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4ZQ	Bypass Right Popliteal Artery to Lower Extremity Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041M4ZS	Bypass Right Popliteal Artery to Lower Extremity Vein, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
041N09L	Bypass Left Popliteal Artery to Popliteal Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041N09M	Bypass Left Popliteal Artery to Peroneal Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041N09P	Bypass Left Popliteal Artery to Foot Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041N09Q	Bypass Left Popliteal Artery to Lower Extremity Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041N09S	Bypass Left Popliteal Artery to Lower Extremity Vein with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041N0AL	Bypass Left Popliteal Artery to Popliteal Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041N0AM	Bypass Left Popliteal Artery to Peroneal Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041N0AP	Bypass Left Popliteal Artery to Foot Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041N0AQ	Bypass Left Popliteal Artery to Lower Extremity Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041N0AS	Bypass Left Popliteal Artery to Lower Extremity Vein with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041N0JL	Bypass Left Popliteal Artery to Popliteal Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041N0JM	Bypass Left Popliteal Artery to Peroneal Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041N0JP	Bypass Left Popliteal Artery to Foot Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041N0JQ	Bypass Left Popliteal Artery to Lower Extremity Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041N0JS	Bypass Left Popliteal Artery to Lower Extremity Vein with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041N0KL	Bypass Left Popliteal Artery to Popliteal Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041N0KM	Bypass Left Popliteal Artery to Peroneal Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041N0KP	Bypass Left Popliteal Artery to Foot Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041N0KQ	Bypass Left Popliteal Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041N0KS	Bypass Left Popliteal Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041N0ZL	Bypass Left Popliteal Artery to Popliteal Artery, Open Approach	Procedure	ICD-10-PCS
041N0ZM	Bypass Left Popliteal Artery to Peroneal Artery, Open Approach	Procedure	ICD-10-PCS
041N0ZP	Bypass Left Popliteal Artery to Foot Artery, Open Approach	Procedure	ICD-10-PCS
041N0ZQ	Bypass Left Popliteal Artery to Lower Extremity Artery, Open Approach	Procedure	ICD-10-PCS
041N0ZS	Bypass Left Popliteal Artery to Lower Extremity Vein, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
041N49L	Bypass Left Popliteal Artery to Popliteal Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N49M	Bypass Left Popliteal Artery to Peroneal Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N49P	Bypass Left Popliteal Artery to Foot Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N49Q	Bypass Left Popliteal Artery to Lower Extremity Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N49S	Bypass Left Popliteal Artery to Lower Extremity Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4AL	Bypass Left Popliteal Artery to Popliteal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4AM	Bypass Left Popliteal Artery to Peroneal Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4AP	Bypass Left Popliteal Artery to Foot Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4AQ	Bypass Left Popliteal Artery to Lower Extremity Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4AS	Bypass Left Popliteal Artery to Lower Extremity Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4JL	Bypass Left Popliteal Artery to Popliteal Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4JM	Bypass Left Popliteal Artery to Peroneal Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4JP	Bypass Left Popliteal Artery to Foot Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4JQ	Bypass Left Popliteal Artery to Lower Extremity Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4JS	Bypass Left Popliteal Artery to Lower Extremity Vein with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4KL	Bypass Left Popliteal Artery to Popliteal Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4KM	Bypass Left Popliteal Artery to Peroneal Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4KP	Bypass Left Popliteal Artery to Foot Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4KQ	Bypass Left Popliteal Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4KS	Bypass Left Popliteal Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4ZL	Bypass Left Popliteal Artery to Popliteal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4ZM	Bypass Left Popliteal Artery to Peroneal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4ZP	Bypass Left Popliteal Artery to Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
041N4ZQ	Bypass Left Popliteal Artery to Lower Extremity Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041N4ZS	Bypass Left Popliteal Artery to Lower Extremity Vein, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T09P	Bypass Right Peroneal Artery to Foot Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041T09Q	Bypass Right Peroneal Artery to Lower Extremity Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041T09S	Bypass Right Peroneal Artery to Lower Extremity Vein with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041T0AP	Bypass Right Peroneal Artery to Foot Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041T0AQ	Bypass Right Peroneal Artery to Lower Extremity Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041T0AS	Bypass Right Peroneal Artery to Lower Extremity Vein with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041T0JP	Bypass Right Peroneal Artery to Foot Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041T0JQ	Bypass Right Peroneal Artery to Lower Extremity Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041T0JS	Bypass Right Peroneal Artery to Lower Extremity Vein with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041T0KP	Bypass Right Peroneal Artery to Foot Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041T0KQ	Bypass Right Peroneal Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041T0KS	Bypass Right Peroneal Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041T0ZP	Bypass Right Peroneal Artery to Foot Artery, Open Approach	Procedure	ICD-10-PCS
041T0ZQ	Bypass Right Peroneal Artery to Lower Extremity Artery, Open Approach	Procedure	ICD-10-PCS
041T0ZS	Bypass Right Peroneal Artery to Lower Extremity Vein, Open Approach	Procedure	ICD-10-PCS
041T49P	Bypass Right Peroneal Artery to Foot Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T49Q	Bypass Right Peroneal Artery to Lower Extremity Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T49S	Bypass Right Peroneal Artery to Lower Extremity Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T4AP	Bypass Right Peroneal Artery to Foot Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T4AQ	Bypass Right Peroneal Artery to Lower Extremity Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T4AS	Bypass Right Peroneal Artery to Lower Extremity Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T4JP	Bypass Right Peroneal Artery to Foot Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
041T4JQ	Bypass Right Peroneal Artery to Lower Extremity Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T4JS	Bypass Right Peroneal Artery to Lower Extremity Vein with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T4KP	Bypass Right Peroneal Artery to Foot Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T4KQ	Bypass Right Peroneal Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T4KS	Bypass Right Peroneal Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T4ZP	Bypass Right Peroneal Artery to Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T4ZQ	Bypass Right Peroneal Artery to Lower Extremity Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041T4ZS	Bypass Right Peroneal Artery to Lower Extremity Vein, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041U09P	Bypass Left Peroneal Artery to Foot Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041U09Q	Bypass Left Peroneal Artery to Lower Extremity Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041U09S	Bypass Left Peroneal Artery to Lower Extremity Vein with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041U0AP	Bypass Left Peroneal Artery to Foot Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041U0AQ	Bypass Left Peroneal Artery to Lower Extremity Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041U0AS	Bypass Left Peroneal Artery to Lower Extremity Vein with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041U0JP	Bypass Left Peroneal Artery to Foot Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041U0JQ	Bypass Left Peroneal Artery to Lower Extremity Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041U0JS	Bypass Left Peroneal Artery to Lower Extremity Vein with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041U0KP	Bypass Left Peroneal Artery to Foot Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041U0KQ	Bypass Left Peroneal Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041U0KS	Bypass Left Peroneal Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041U0ZP	Bypass Left Peroneal Artery to Foot Artery, Open Approach	Procedure	ICD-10-PCS
041U0ZQ	Bypass Left Peroneal Artery to Lower Extremity Artery, Open Approach	Procedure	ICD-10-PCS
041U0ZS	Bypass Left Peroneal Artery to Lower Extremity Vein, Open Approach	Procedure	ICD-10-PCS
041U49P	Bypass Left Peroneal Artery to Foot Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
041U49Q	Bypass Left Peroneal Artery to Lower Extremity Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041U49S	Bypass Left Peroneal Artery to Lower Extremity Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041U4AP	Bypass Left Peroneal Artery to Foot Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041U4AQ	Bypass Left Peroneal Artery to Lower Extremity Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041U4AS	Bypass Left Peroneal Artery to Lower Extremity Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041U4JP	Bypass Left Peroneal Artery to Foot Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041U4JQ	Bypass Left Peroneal Artery to Lower Extremity Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041U4JS	Bypass Left Peroneal Artery to Lower Extremity Vein with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041U4KP	Bypass Left Peroneal Artery to Foot Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041U4KQ	Bypass Left Peroneal Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041U4KS	Bypass Left Peroneal Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041U4ZP	Bypass Left Peroneal Artery to Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041U4ZQ	Bypass Left Peroneal Artery to Lower Extremity Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041U4ZS	Bypass Left Peroneal Artery to Lower Extremity Vein, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V09P	Bypass Right Foot Artery to Foot Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041V09Q	Bypass Right Foot Artery to Lower Extremity Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041V09S	Bypass Right Foot Artery to Lower Extremity Vein with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041V0AP	Bypass Right Foot Artery to Foot Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041V0AQ	Bypass Right Foot Artery to Lower Extremity Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041V0AS	Bypass Right Foot Artery to Lower Extremity Vein with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041V0JP	Bypass Right Foot Artery to Foot Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041V0JQ	Bypass Right Foot Artery to Lower Extremity Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041V0JS	Bypass Right Foot Artery to Lower Extremity Vein with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
041V0KP	Bypass Right Foot Artery to Foot Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041V0KQ	Bypass Right Foot Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041V0KS	Bypass Right Foot Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041V0ZP	Bypass Right Foot Artery to Foot Artery, Open Approach	Procedure	ICD-10-PCS
041V0ZQ	Bypass Right Foot Artery to Lower Extremity Artery, Open Approach	Procedure	ICD-10-PCS
041V0ZS	Bypass Right Foot Artery to Lower Extremity Vein, Open Approach	Procedure	ICD-10-PCS
041V49P	Bypass Right Foot Artery to Foot Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V49Q	Bypass Right Foot Artery to Lower Extremity Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V49S	Bypass Right Foot Artery to Lower Extremity Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4AP	Bypass Right Foot Artery to Foot Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4AQ	Bypass Right Foot Artery to Lower Extremity Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4AS	Bypass Right Foot Artery to Lower Extremity Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4JP	Bypass Right Foot Artery to Foot Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4JQ	Bypass Right Foot Artery to Lower Extremity Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4JS	Bypass Right Foot Artery to Lower Extremity Vein with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4KP	Bypass Right Foot Artery to Foot Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4KQ	Bypass Right Foot Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4KS	Bypass Right Foot Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4ZP	Bypass Right Foot Artery to Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4ZQ	Bypass Right Foot Artery to Lower Extremity Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041V4ZS	Bypass Right Foot Artery to Lower Extremity Vein, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W09P	Bypass Left Foot Artery to Foot Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041W09Q	Bypass Left Foot Artery to Lower Extremity Artery with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
041W09S	Bypass Left Foot Artery to Lower Extremity Vein with Autologous Venous Tissue, Open Approach	Procedure	ICD-10-PCS
041W0AP	Bypass Left Foot Artery to Foot Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041W0AQ	Bypass Left Foot Artery to Lower Extremity Artery with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041W0AS	Bypass Left Foot Artery to Lower Extremity Vein with Autologous Arterial Tissue, Open Approach	Procedure	ICD-10-PCS
041W0JP	Bypass Left Foot Artery to Foot Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041W0JQ	Bypass Left Foot Artery to Lower Extremity Artery with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041W0JS	Bypass Left Foot Artery to Lower Extremity Vein with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
041W0KP	Bypass Left Foot Artery to Foot Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041W0KQ	Bypass Left Foot Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041W0KS	Bypass Left Foot Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
041W0ZP	Bypass Left Foot Artery to Foot Artery, Open Approach	Procedure	ICD-10-PCS
041W0ZQ	Bypass Left Foot Artery to Lower Extremity Artery, Open Approach	Procedure	ICD-10-PCS
041W0ZS	Bypass Left Foot Artery to Lower Extremity Vein, Open Approach	Procedure	ICD-10-PCS
041W49P	Bypass Left Foot Artery to Foot Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W49Q	Bypass Left Foot Artery to Lower Extremity Artery with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W49S	Bypass Left Foot Artery to Lower Extremity Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W4AP	Bypass Left Foot Artery to Foot Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W4AQ	Bypass Left Foot Artery to Lower Extremity Artery with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W4AS	Bypass Left Foot Artery to Lower Extremity Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W4JP	Bypass Left Foot Artery to Foot Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W4JQ	Bypass Left Foot Artery to Lower Extremity Artery with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W4JS	Bypass Left Foot Artery to Lower Extremity Vein with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W4KP	Bypass Left Foot Artery to Foot Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
041W4KQ	Bypass Left Foot Artery to Lower Extremity Artery with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W4KS	Bypass Left Foot Artery to Lower Extremity Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W4ZP	Bypass Left Foot Artery to Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W4ZQ	Bypass Left Foot Artery to Lower Extremity Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
041W4ZS	Bypass Left Foot Artery to Lower Extremity Vein, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04700D6	Dilation of Abdominal Aorta, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
04700F6	Dilation of Abdominal Aorta, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
04700G6	Dilation of Abdominal Aorta, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
04700Z6	Dilation of Abdominal Aorta, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04703D6	Dilation of Abdominal Aorta, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
04703F6	Dilation of Abdominal Aorta, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
04703G6	Dilation of Abdominal Aorta, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
04703Z6	Dilation of Abdominal Aorta, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04704D6	Dilation of Abdominal Aorta, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04704F6	Dilation of Abdominal Aorta, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04704G6	Dilation of Abdominal Aorta, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04704Z6	Dilation of Abdominal Aorta, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C041	Dilation of Right Common Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047C046	Dilation of Right Common Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047C04Z	Dilation of Right Common Iliac Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047C056	Dilation of Right Common Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047C05Z	Dilation of Right Common Iliac Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047C066	Dilation of Right Common Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047C06Z	Dilation of Right Common Iliac Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
047C076	Dilation of Right Common Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047C07Z	Dilation of Right Common Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047C0D1	Dilation of Right Common Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047C0D6	Dilation of Right Common Iliac Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047C0DZ	Dilation of Right Common Iliac Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047C0E6	Dilation of Right Common Iliac Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047C0EZ	Dilation of Right Common Iliac Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047C0F6	Dilation of Right Common Iliac Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047C0FZ	Dilation of Right Common Iliac Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047C0G6	Dilation of Right Common Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047C0GZ	Dilation of Right Common Iliac Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047C0Z1	Dilation of Right Common Iliac Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047C0Z6	Dilation of Right Common Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047C0ZZ	Dilation of Right Common Iliac Artery, Open Approach	Procedure	ICD-10-PCS
047C341	Dilation of Right Common Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047C346	Dilation of Right Common Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047C34Z	Dilation of Right Common Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047C356	Dilation of Right Common Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047C35Z	Dilation of Right Common Iliac Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047C366	Dilation of Right Common Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047C36Z	Dilation of Right Common Iliac Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047C376	Dilation of Right Common Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047C37Z	Dilation of Right Common Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
047C3D1	Dilation of Right Common Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047C3D6	Dilation of Right Common Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047C3DZ	Dilation of Right Common Iliac Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047C3E6	Dilation of Right Common Iliac Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047C3EZ	Dilation of Right Common Iliac Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047C3F6	Dilation of Right Common Iliac Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047C3FZ	Dilation of Right Common Iliac Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047C3G6	Dilation of Right Common Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047C3GZ	Dilation of Right Common Iliac Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047C3Z1	Dilation of Right Common Iliac Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047C3Z6	Dilation of Right Common Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047C3ZZ	Dilation of Right Common Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047C441	Dilation of Right Common Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C446	Dilation of Right Common Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C44Z	Dilation of Right Common Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C456	Dilation of Right Common Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C45Z	Dilation of Right Common Iliac Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C466	Dilation of Right Common Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C46Z	Dilation of Right Common Iliac Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C476	Dilation of Right Common Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C47Z	Dilation of Right Common Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4D1	Dilation of Right Common Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047C4D6	Dilation of Right Common Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4DZ	Dilation of Right Common Iliac Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4E6	Dilation of Right Common Iliac Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4EZ	Dilation of Right Common Iliac Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4F6	Dilation of Right Common Iliac Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4FZ	Dilation of Right Common Iliac Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4G6	Dilation of Right Common Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4GZ	Dilation of Right Common Iliac Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4Z1	Dilation of Right Common Iliac Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4Z6	Dilation of Right Common Iliac Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047C4ZZ	Dilation of Right Common Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D041	Dilation of Left Common Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047D046	Dilation of Left Common Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047D04Z	Dilation of Left Common Iliac Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047D056	Dilation of Left Common Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D05Z	Dilation of Left Common Iliac Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D066	Dilation of Left Common Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D06Z	Dilation of Left Common Iliac Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D076	Dilation of Left Common Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D07Z	Dilation of Left Common Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D0D1	Dilation of Left Common Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
047D0D6	Dilation of Left Common Iliac Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047D0DZ	Dilation of Left Common Iliac Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047D0E6	Dilation of Left Common Iliac Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D0EZ	Dilation of Left Common Iliac Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D0F6	Dilation of Left Common Iliac Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D0FZ	Dilation of Left Common Iliac Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D0G6	Dilation of Left Common Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D0GZ	Dilation of Left Common Iliac Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047D0Z1	Dilation of Left Common Iliac Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047D0Z6	Dilation of Left Common Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047D0ZZ	Dilation of Left Common Iliac Artery, Open Approach	Procedure	ICD-10-PCS
047D341	Dilation of Left Common Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047D346	Dilation of Left Common Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047D34Z	Dilation of Left Common Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047D356	Dilation of Left Common Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D35Z	Dilation of Left Common Iliac Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D366	Dilation of Left Common Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D36Z	Dilation of Left Common Iliac Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D376	Dilation of Left Common Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D37Z	Dilation of Left Common Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D3D1	Dilation of Left Common Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047D3D6	Dilation of Left Common Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047D3DZ	Dilation of Left Common Iliac Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047D3E6	Dilation of Left Common Iliac Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047D3EZ	Dilation of Left Common Iliac Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D3F6	Dilation of Left Common Iliac Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D3FZ	Dilation of Left Common Iliac Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D3G6	Dilation of Left Common Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D3GZ	Dilation of Left Common Iliac Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047D3Z1	Dilation of Left Common Iliac Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047D3Z6	Dilation of Left Common Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047D3ZZ	Dilation of Left Common Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047D441	Dilation of Left Common Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D446	Dilation of Left Common Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D44Z	Dilation of Left Common Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D456	Dilation of Left Common Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D45Z	Dilation of Left Common Iliac Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D466	Dilation of Left Common Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D46Z	Dilation of Left Common Iliac Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D476	Dilation of Left Common Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D47Z	Dilation of Left Common Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4D1	Dilation of Left Common Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4D6	Dilation of Left Common Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4DZ	Dilation of Left Common Iliac Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4E6	Dilation of Left Common Iliac Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4EZ	Dilation of Left Common Iliac Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047D4F6	Dilation of Left Common Iliac Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4FZ	Dilation of Left Common Iliac Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4G6	Dilation of Left Common Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4GZ	Dilation of Left Common Iliac Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4Z1	Dilation of Left Common Iliac Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4Z6	Dilation of Left Common Iliac Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047D4ZZ	Dilation of Left Common Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E04Z	Dilation of Right Internal Iliac Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047E05Z	Dilation of Right Internal Iliac Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047E06Z	Dilation of Right Internal Iliac Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047E07Z	Dilation of Right Internal Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047E0D1	Dilation of Right Internal Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047E0D6	Dilation of Right Internal Iliac Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047E0DZ	Dilation of Right Internal Iliac Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047E0E6	Dilation of Right Internal Iliac Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047E0EZ	Dilation of Right Internal Iliac Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047E0F6	Dilation of Right Internal Iliac Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047E0FZ	Dilation of Right Internal Iliac Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047E0G6	Dilation of Right Internal Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047E0GZ	Dilation of Right Internal Iliac Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047E0Z1	Dilation of Right Internal Iliac Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047E0Z6	Dilation of Right Internal Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047E0ZZ	Dilation of Right Internal Iliac Artery, Open Approach	Procedure	ICD-10-PCS
047E341	Dilation of Right Internal Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047E346	Dilation of Right Internal Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047E34Z	Dilation of Right Internal Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047E356	Dilation of Right Internal Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E35Z	Dilation of Right Internal Iliac Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E366	Dilation of Right Internal Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E36Z	Dilation of Right Internal Iliac Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E376	Dilation of Right Internal Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E37Z	Dilation of Right Internal Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E3D1	Dilation of Right Internal Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047E3D6	Dilation of Right Internal Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047E3DZ	Dilation of Right Internal Iliac Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047E3E6	Dilation of Right Internal Iliac Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E3EZ	Dilation of Right Internal Iliac Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E3F6	Dilation of Right Internal Iliac Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E3FZ	Dilation of Right Internal Iliac Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E3G6	Dilation of Right Internal Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E3GZ	Dilation of Right Internal Iliac Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047E3Z1	Dilation of Right Internal Iliac Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047E3Z6	Dilation of Right Internal Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047E3ZZ	Dilation of Right Internal Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047E441	Dilation of Right Internal Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E446	Dilation of Right Internal Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047E44Z	Dilation of Right Internal Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E456	Dilation of Right Internal Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E45Z	Dilation of Right Internal Iliac Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E466	Dilation of Right Internal Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E46Z	Dilation of Right Internal Iliac Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E476	Dilation of Right Internal Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E47Z	Dilation of Right Internal Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E4D1	Dilation of Right Internal Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E4D6	Dilation of Right Internal Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E4DZ	Dilation of Right Internal Iliac Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E4E6	Dilation of Right Internal Iliac Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E4EZ	Dilation of Right Internal Iliac Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E4F6	Dilation of Right Internal Iliac Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E4FZ	Dilation of Right Internal Iliac Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E4G6	Dilation of Right Internal Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E4GZ	Dilation of Right Internal Iliac Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E4Z1	Dilation of Right Internal Iliac Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E4Z6	Dilation of Right Internal Iliac Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047E4ZZ	Dilation of Right Internal Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F041	Dilation of Left Internal Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047F046	Dilation of Left Internal Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047F04Z	Dilation of Left Internal Iliac Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
047F056	Dilation of Left Internal Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047F05Z	Dilation of Left Internal Iliac Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047F066	Dilation of Left Internal Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047F06Z	Dilation of Left Internal Iliac Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047F076	Dilation of Left Internal Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047F07Z	Dilation of Left Internal Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047F0D1	Dilation of Left Internal Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047F0D6	Dilation of Left Internal Iliac Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047F0DZ	Dilation of Left Internal Iliac Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047F0E6	Dilation of Left Internal Iliac Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047F0EZ	Dilation of Left Internal Iliac Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047F0F6	Dilation of Left Internal Iliac Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047F0FZ	Dilation of Left Internal Iliac Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047F0G6	Dilation of Left Internal Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047F0GZ	Dilation of Left Internal Iliac Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047F0Z1	Dilation of Left Internal Iliac Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047F0Z6	Dilation of Left Internal Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047F0ZZ	Dilation of Left Internal Iliac Artery, Open Approach	Procedure	ICD-10-PCS
047F341	Dilation of Left Internal Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047F346	Dilation of Left Internal Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047F34Z	Dilation of Left Internal Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047F356	Dilation of Left Internal Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047F35Z	Dilation of Left Internal Iliac Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047F366	Dilation of Left Internal Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047F36Z	Dilation of Left Internal Iliac Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047F376	Dilation of Left Internal Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047F37Z	Dilation of Left Internal Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047F3D1	Dilation of Left Internal Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047F3D6	Dilation of Left Internal Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047F3DZ	Dilation of Left Internal Iliac Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047F3E6	Dilation of Left Internal Iliac Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047F3EZ	Dilation of Left Internal Iliac Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047F3F6	Dilation of Left Internal Iliac Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047F3FZ	Dilation of Left Internal Iliac Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047F3G6	Dilation of Left Internal Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047F3GZ	Dilation of Left Internal Iliac Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047F3Z1	Dilation of Left Internal Iliac Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047F3Z6	Dilation of Left Internal Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047F3ZZ	Dilation of Left Internal Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047F441	Dilation of Left Internal Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F446	Dilation of Left Internal Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F44Z	Dilation of Left Internal Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F456	Dilation of Left Internal Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F45Z	Dilation of Left Internal Iliac Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F466	Dilation of Left Internal Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F46Z	Dilation of Left Internal Iliac Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F476	Dilation of Left Internal Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047F47Z	Dilation of Left Internal Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F4D1	Dilation of Left Internal Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F4D6	Dilation of Left Internal Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F4DZ	Dilation of Left Internal Iliac Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F4E6	Dilation of Left Internal Iliac Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F4EZ	Dilation of Left Internal Iliac Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F4F6	Dilation of Left Internal Iliac Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F4FZ	Dilation of Left Internal Iliac Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F4G6	Dilation of Left Internal Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F4GZ	Dilation of Left Internal Iliac Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F4Z1	Dilation of Left Internal Iliac Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F4Z6	Dilation of Left Internal Iliac Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047F4ZZ	Dilation of Left Internal Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H041	Dilation of Right External Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047H046	Dilation of Right External Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047H04Z	Dilation of Right External Iliac Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047H056	Dilation of Right External Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047H05Z	Dilation of Right External Iliac Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047H066	Dilation of Right External Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047H06Z	Dilation of Right External Iliac Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047H076	Dilation of Right External Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047H07Z	Dilation of Right External Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047H0D1	Dilation of Right External Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047H0D6	Dilation of Right External Iliac Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047H0DZ	Dilation of Right External Iliac Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047H0E6	Dilation of Right External Iliac Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047H0EZ	Dilation of Right External Iliac Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047H0F6	Dilation of Right External Iliac Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047H0FZ	Dilation of Right External Iliac Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047H0G6	Dilation of Right External Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047H0GZ	Dilation of Right External Iliac Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047H0Z1	Dilation of Right External Iliac Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047H0Z6	Dilation of Right External Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047H0ZZ	Dilation of Right External Iliac Artery, Open Approach	Procedure	ICD-10-PCS
047H341	Dilation of Right External Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047H346	Dilation of Right External Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047H34Z	Dilation of Right External Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047H356	Dilation of Right External Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047H35Z	Dilation of Right External Iliac Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047H366	Dilation of Right External Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047H36Z	Dilation of Right External Iliac Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047H376	Dilation of Right External Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047H37Z	Dilation of Right External Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047H3D1	Dilation of Right External Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047H3D6	Dilation of Right External Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047H3DZ	Dilation of Right External Iliac Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
047H3E6	Dilation of Right External Iliac Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047H3EZ	Dilation of Right External Iliac Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047H3F6	Dilation of Right External Iliac Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047H3FZ	Dilation of Right External Iliac Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047H3G6	Dilation of Right External Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047H3GZ	Dilation of Right External Iliac Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047H3Z1	Dilation of Right External Iliac Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047H3Z6	Dilation of Right External Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047H3ZZ	Dilation of Right External Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047H441	Dilation of Right External Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H446	Dilation of Right External Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H44Z	Dilation of Right External Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H456	Dilation of Right External Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H45Z	Dilation of Right External Iliac Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H466	Dilation of Right External Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H46Z	Dilation of Right External Iliac Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H476	Dilation of Right External Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H47Z	Dilation of Right External Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H4D1	Dilation of Right External Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H4D6	Dilation of Right External Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H4DZ	Dilation of Right External Iliac Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H4E6	Dilation of Right External Iliac Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047H4EZ	Dilation of Right External Iliac Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H4F6	Dilation of Right External Iliac Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H4FZ	Dilation of Right External Iliac Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H4G6	Dilation of Right External Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H4GZ	Dilation of Right External Iliac Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H4Z1	Dilation of Right External Iliac Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H4Z6	Dilation of Right External Iliac Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047H4ZZ	Dilation of Right External Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J041	Dilation of Left External Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047J046	Dilation of Left External Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047J04Z	Dilation of Left External Iliac Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047J056	Dilation of Left External Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047J05Z	Dilation of Left External Iliac Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047J066	Dilation of Left External Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047J06Z	Dilation of Left External Iliac Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047J076	Dilation of Left External Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047J07Z	Dilation of Left External Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047J0D1	Dilation of Left External Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047J0D6	Dilation of Left External Iliac Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047J0DZ	Dilation of Left External Iliac Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047J0E6	Dilation of Left External Iliac Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047J0EZ	Dilation of Left External Iliac Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047J0F6	Dilation of Left External Iliac Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
047J0FZ	Dilation of Left External Iliac Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047J0G6	Dilation of Left External Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047J0GZ	Dilation of Left External Iliac Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047J0Z1	Dilation of Left External Iliac Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047J0Z6	Dilation of Left External Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047J0ZZ	Dilation of Left External Iliac Artery, Open Approach	Procedure	ICD-10-PCS
047J341	Dilation of Left External Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047J346	Dilation of Left External Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047J34Z	Dilation of Left External Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047J356	Dilation of Left External Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047J35Z	Dilation of Left External Iliac Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047J366	Dilation of Left External Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047J36Z	Dilation of Left External Iliac Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047J376	Dilation of Left External Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047J37Z	Dilation of Left External Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047J3D1	Dilation of Left External Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047J3D6	Dilation of Left External Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047J3DZ	Dilation of Left External Iliac Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047J3E6	Dilation of Left External Iliac Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047J3EZ	Dilation of Left External Iliac Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047J3F6	Dilation of Left External Iliac Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047J3FZ	Dilation of Left External Iliac Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047J3G6	Dilation of Left External Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047J3GZ	Dilation of Left External Iliac Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047J3Z1	Dilation of Left External Iliac Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047J3Z6	Dilation of Left External Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047J3ZZ	Dilation of Left External Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047J441	Dilation of Left External Iliac Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J446	Dilation of Left External Iliac Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J44Z	Dilation of Left External Iliac Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J456	Dilation of Left External Iliac Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J45Z	Dilation of Left External Iliac Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J466	Dilation of Left External Iliac Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J46Z	Dilation of Left External Iliac Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J476	Dilation of Left External Iliac Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J47Z	Dilation of Left External Iliac Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4D1	Dilation of Left External Iliac Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4D6	Dilation of Left External Iliac Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4DZ	Dilation of Left External Iliac Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4E6	Dilation of Left External Iliac Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4EZ	Dilation of Left External Iliac Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4F6	Dilation of Left External Iliac Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4FZ	Dilation of Left External Iliac Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4G6	Dilation of Left External Iliac Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4GZ	Dilation of Left External Iliac Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047J4Z1	Dilation of Left External Iliac Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4Z6	Dilation of Left External Iliac Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047J4ZZ	Dilation of Left External Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K041	Dilation of Right Femoral Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047K046	Dilation of Right Femoral Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047K04Z	Dilation of Right Femoral Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047K056	Dilation of Right Femoral Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K05Z	Dilation of Right Femoral Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K066	Dilation of Right Femoral Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K06Z	Dilation of Right Femoral Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K076	Dilation of Right Femoral Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K07Z	Dilation of Right Femoral Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K0D1	Dilation of Right Femoral Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047K0D6	Dilation of Right Femoral Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047K0DZ	Dilation of Right Femoral Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047K0E6	Dilation of Right Femoral Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K0EZ	Dilation of Right Femoral Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K0F6	Dilation of Right Femoral Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K0FZ	Dilation of Right Femoral Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K0G6	Dilation of Right Femoral Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K0GZ	Dilation of Right Femoral Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047K0Z1	Dilation of Right Femoral Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047K0Z6	Dilation of Right Femoral Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047K0ZZ	Dilation of Right Femoral Artery, Open Approach	Procedure	ICD-10-PCS
047K341	Dilation of Right Femoral Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
047K346	Dilation of Right Femoral Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047K34Z	Dilation of Right Femoral Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047K356	Dilation of Right Femoral Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047K35Z	Dilation of Right Femoral Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047K366	Dilation of Right Femoral Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047K36Z	Dilation of Right Femoral Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047K376	Dilation of Right Femoral Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047K37Z	Dilation of Right Femoral Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047K3D1	Dilation of Right Femoral Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047K3D6	Dilation of Right Femoral Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047K3DZ	Dilation of Right Femoral Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047K3E6	Dilation of Right Femoral Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047K3EZ	Dilation of Right Femoral Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047K3F6	Dilation of Right Femoral Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047K3FZ	Dilation of Right Femoral Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047K3G6	Dilation of Right Femoral Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047K3GZ	Dilation of Right Femoral Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047K3Z1	Dilation of Right Femoral Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047K3Z6	Dilation of Right Femoral Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047K3ZZ	Dilation of Right Femoral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047K441	Dilation of Right Femoral Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K446	Dilation of Right Femoral Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K44Z	Dilation of Right Femoral Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047K456	Dilation of Right Femoral Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K45Z	Dilation of Right Femoral Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K466	Dilation of Right Femoral Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K46Z	Dilation of Right Femoral Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K476	Dilation of Right Femoral Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K47Z	Dilation of Right Femoral Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K4D1	Dilation of Right Femoral Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K4D6	Dilation of Right Femoral Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K4DZ	Dilation of Right Femoral Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K4E6	Dilation of Right Femoral Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K4EZ	Dilation of Right Femoral Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K4F6	Dilation of Right Femoral Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K4FZ	Dilation of Right Femoral Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K4G6	Dilation of Right Femoral Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K4GZ	Dilation of Right Femoral Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K4Z1	Dilation of Right Femoral Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K4Z6	Dilation of Right Femoral Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047K4ZZ	Dilation of Right Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L041	Dilation of Left Femoral Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047L046	Dilation of Left Femoral Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047L04Z	Dilation of Left Femoral Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047L056	Dilation of Left Femoral Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047L05Z	Dilation of Left Femoral Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047L066	Dilation of Left Femoral Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047L06Z	Dilation of Left Femoral Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047L076	Dilation of Left Femoral Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047L07Z	Dilation of Left Femoral Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047L0D1	Dilation of Left Femoral Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047L0D6	Dilation of Left Femoral Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047L0DZ	Dilation of Left Femoral Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047L0E6	Dilation of Left Femoral Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047L0EZ	Dilation of Left Femoral Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047L0F6	Dilation of Left Femoral Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047L0FZ	Dilation of Left Femoral Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047L0G6	Dilation of Left Femoral Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047L0GZ	Dilation of Left Femoral Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047L0Z1	Dilation of Left Femoral Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047L0Z6	Dilation of Left Femoral Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047L0ZZ	Dilation of Left Femoral Artery, Open Approach	Procedure	ICD-10-PCS
047L341	Dilation of Left Femoral Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047L346	Dilation of Left Femoral Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047L34Z	Dilation of Left Femoral Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047L356	Dilation of Left Femoral Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047L35Z	Dilation of Left Femoral Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047L366	Dilation of Left Femoral Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047L36Z	Dilation of Left Femoral Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
047L376	Dilation of Left Femoral Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047L37Z	Dilation of Left Femoral Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047L3D1	Dilation of Left Femoral Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047L3D6	Dilation of Left Femoral Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047L3DZ	Dilation of Left Femoral Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047L3E6	Dilation of Left Femoral Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047L3EZ	Dilation of Left Femoral Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047L3F6	Dilation of Left Femoral Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047L3FZ	Dilation of Left Femoral Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047L3G6	Dilation of Left Femoral Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047L3GZ	Dilation of Left Femoral Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047L3Z1	Dilation of Left Femoral Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047L3Z6	Dilation of Left Femoral Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047L3ZZ	Dilation of Left Femoral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047L441	Dilation of Left Femoral Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L446	Dilation of Left Femoral Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L44Z	Dilation of Left Femoral Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L456	Dilation of Left Femoral Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L45Z	Dilation of Left Femoral Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L466	Dilation of Left Femoral Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L46Z	Dilation of Left Femoral Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L476	Dilation of Left Femoral Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L47Z	Dilation of Left Femoral Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
047L4D1	Dilation of Left Femoral Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4D6	Dilation of Left Femoral Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4DZ	Dilation of Left Femoral Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4E6	Dilation of Left Femoral Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4EZ	Dilation of Left Femoral Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4F6	Dilation of Left Femoral Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4FZ	Dilation of Left Femoral Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4G6	Dilation of Left Femoral Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4GZ	Dilation of Left Femoral Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4Z1	Dilation of Left Femoral Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4Z6	Dilation of Left Femoral Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047L4ZZ	Dilation of Left Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M041	Dilation of Right Popliteal Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047M046	Dilation of Right Popliteal Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047M04Z	Dilation of Right Popliteal Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047M056	Dilation of Right Popliteal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047M05Z	Dilation of Right Popliteal Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047M066	Dilation of Right Popliteal Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047M06Z	Dilation of Right Popliteal Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047M076	Dilation of Right Popliteal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047M07Z	Dilation of Right Popliteal Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047M0D1	Dilation of Right Popliteal Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
047M0D6	Dilation of Right Popliteal Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047M0DZ	Dilation of Right Popliteal Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047M0E6	Dilation of Right Popliteal Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047M0EZ	Dilation of Right Popliteal Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047M0F6	Dilation of Right Popliteal Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047M0FZ	Dilation of Right Popliteal Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047M0G6	Dilation of Right Popliteal Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047M0GZ	Dilation of Right Popliteal Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047M0Z1	Dilation of Right Popliteal Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047M0Z6	Dilation of Right Popliteal Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047M0ZZ	Dilation of Right Popliteal Artery, Open Approach	Procedure	ICD-10-PCS
047M341	Dilation of Right Popliteal Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047M346	Dilation of Right Popliteal Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047M34Z	Dilation of Right Popliteal Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047M356	Dilation of Right Popliteal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047M35Z	Dilation of Right Popliteal Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047M366	Dilation of Right Popliteal Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047M36Z	Dilation of Right Popliteal Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047M376	Dilation of Right Popliteal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047M37Z	Dilation of Right Popliteal Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047M3D1	Dilation of Right Popliteal Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047M3D6	Dilation of Right Popliteal Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047M3DZ	Dilation of Right Popliteal Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047M3E6	Dilation of Right Popliteal Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047M3EZ	Dilation of Right Popliteal Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047M3F6	Dilation of Right Popliteal Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047M3FZ	Dilation of Right Popliteal Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047M3G6	Dilation of Right Popliteal Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047M3GZ	Dilation of Right Popliteal Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047M3Z1	Dilation of Right Popliteal Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047M3Z6	Dilation of Right Popliteal Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047M3ZZ	Dilation of Right Popliteal Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047M441	Dilation of Right Popliteal Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M446	Dilation of Right Popliteal Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M44Z	Dilation of Right Popliteal Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M456	Dilation of Right Popliteal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M45Z	Dilation of Right Popliteal Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M466	Dilation of Right Popliteal Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M46Z	Dilation of Right Popliteal Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M476	Dilation of Right Popliteal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M47Z	Dilation of Right Popliteal Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M4D1	Dilation of Right Popliteal Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M4D6	Dilation of Right Popliteal Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M4DZ	Dilation of Right Popliteal Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M4E6	Dilation of Right Popliteal Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M4EZ	Dilation of Right Popliteal Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M4F6	Dilation of Right Popliteal Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047M4FZ	Dilation of Right Popliteal Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M4G6	Dilation of Right Popliteal Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M4GZ	Dilation of Right Popliteal Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M4Z1	Dilation of Right Popliteal Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M4Z6	Dilation of Right Popliteal Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047M4ZZ	Dilation of Right Popliteal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N041	Dilation of Left Popliteal Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047N046	Dilation of Left Popliteal Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047N04Z	Dilation of Left Popliteal Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047N056	Dilation of Left Popliteal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047N05Z	Dilation of Left Popliteal Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047N066	Dilation of Left Popliteal Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047N06Z	Dilation of Left Popliteal Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047N076	Dilation of Left Popliteal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047N07Z	Dilation of Left Popliteal Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047N0D1	Dilation of Left Popliteal Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047N0D6	Dilation of Left Popliteal Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047N0DZ	Dilation of Left Popliteal Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047N0E6	Dilation of Left Popliteal Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047N0EZ	Dilation of Left Popliteal Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047N0F6	Dilation of Left Popliteal Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047N0FZ	Dilation of Left Popliteal Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047N0G6	Dilation of Left Popliteal Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047N0GZ	Dilation of Left Popliteal Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
047N0Z1	Dilation of Left Popliteal Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047N0Z6	Dilation of Left Popliteal Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047N0ZZ	Dilation of Left Popliteal Artery, Open Approach	Procedure	ICD-10-PCS
047N341	Dilation of Left Popliteal Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047N346	Dilation of Left Popliteal Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047N34Z	Dilation of Left Popliteal Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047N356	Dilation of Left Popliteal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047N35Z	Dilation of Left Popliteal Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047N366	Dilation of Left Popliteal Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047N36Z	Dilation of Left Popliteal Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047N376	Dilation of Left Popliteal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047N37Z	Dilation of Left Popliteal Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047N3D1	Dilation of Left Popliteal Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047N3D6	Dilation of Left Popliteal Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047N3DZ	Dilation of Left Popliteal Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047N3E6	Dilation of Left Popliteal Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047N3EZ	Dilation of Left Popliteal Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047N3F6	Dilation of Left Popliteal Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047N3FZ	Dilation of Left Popliteal Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047N3G6	Dilation of Left Popliteal Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047N3GZ	Dilation of Left Popliteal Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047N3Z1	Dilation of Left Popliteal Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047N3Z6	Dilation of Left Popliteal Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047N3ZZ	Dilation of Left Popliteal Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047N441	Dilation of Left Popliteal Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047N446	Dilation of Left Popliteal Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N44Z	Dilation of Left Popliteal Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N456	Dilation of Left Popliteal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N45Z	Dilation of Left Popliteal Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N466	Dilation of Left Popliteal Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N46Z	Dilation of Left Popliteal Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N476	Dilation of Left Popliteal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N47Z	Dilation of Left Popliteal Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4D1	Dilation of Left Popliteal Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4D6	Dilation of Left Popliteal Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4DZ	Dilation of Left Popliteal Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4E6	Dilation of Left Popliteal Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4EZ	Dilation of Left Popliteal Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4F6	Dilation of Left Popliteal Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4FZ	Dilation of Left Popliteal Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4G6	Dilation of Left Popliteal Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4GZ	Dilation of Left Popliteal Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4Z1	Dilation of Left Popliteal Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4Z6	Dilation of Left Popliteal Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047N4ZZ	Dilation of Left Popliteal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P041	Dilation of Right Anterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047P046	Dilation of Right Anterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047P04Z	Dilation of Right Anterior Tibial Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047P056	Dilation of Right Anterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047P05Z	Dilation of Right Anterior Tibial Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047P066	Dilation of Right Anterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047P06Z	Dilation of Right Anterior Tibial Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047P076	Dilation of Right Anterior Tibial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047P07Z	Dilation of Right Anterior Tibial Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047P0D1	Dilation of Right Anterior Tibial Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047P0D6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047P0DZ	Dilation of Right Anterior Tibial Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047P0E6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047P0EZ	Dilation of Right Anterior Tibial Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047P0F6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047P0FZ	Dilation of Right Anterior Tibial Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047P0G6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047P0GZ	Dilation of Right Anterior Tibial Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047P0Z1	Dilation of Right Anterior Tibial Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047P0Z6	Dilation of Right Anterior Tibial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047P0ZZ	Dilation of Right Anterior Tibial Artery, Open Approach	Procedure	ICD-10-PCS
047P341	Dilation of Right Anterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047P346	Dilation of Right Anterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047P34Z	Dilation of Right Anterior Tibial Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047P356	Dilation of Right Anterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047P35Z	Dilation of Right Anterior Tibial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047P366	Dilation of Right Anterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047P36Z	Dilation of Right Anterior Tibial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047P376	Dilation of Right Anterior Tibial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047P37Z	Dilation of Right Anterior Tibial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047P3D1	Dilation of Right Anterior Tibial Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047P3D6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047P3DZ	Dilation of Right Anterior Tibial Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047P3E6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047P3EZ	Dilation of Right Anterior Tibial Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047P3F6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047P3FZ	Dilation of Right Anterior Tibial Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047P3G6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047P3GZ	Dilation of Right Anterior Tibial Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047P3Z1	Dilation of Right Anterior Tibial Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047P3Z6	Dilation of Right Anterior Tibial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047P3ZZ	Dilation of Right Anterior Tibial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047P441	Dilation of Right Anterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P446	Dilation of Right Anterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P44Z	Dilation of Right Anterior Tibial Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P456	Dilation of Right Anterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
047P45Z	Dilation of Right Anterior Tibial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P466	Dilation of Right Anterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P46Z	Dilation of Right Anterior Tibial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P476	Dilation of Right Anterior Tibial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P47Z	Dilation of Right Anterior Tibial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P4D1	Dilation of Right Anterior Tibial Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P4D6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P4DZ	Dilation of Right Anterior Tibial Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P4E6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P4EZ	Dilation of Right Anterior Tibial Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P4F6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P4FZ	Dilation of Right Anterior Tibial Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P4G6	Dilation of Right Anterior Tibial Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P4GZ	Dilation of Right Anterior Tibial Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P4Z1	Dilation of Right Anterior Tibial Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P4Z6	Dilation of Right Anterior Tibial Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047P4ZZ	Dilation of Right Anterior Tibial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q041	Dilation of Left Anterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047Q046	Dilation of Left Anterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047Q04Z	Dilation of Left Anterior Tibial Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047Q056	Dilation of Left Anterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047Q05Z	Dilation of Left Anterior Tibial Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
047Q066	Dilation of Left Anterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047Q06Z	Dilation of Left Anterior Tibial Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047Q076	Dilation of Left Anterior Tibial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047Q07Z	Dilation of Left Anterior Tibial Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047Q0D1	Dilation of Left Anterior Tibial Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047Q0D6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047Q0DZ	Dilation of Left Anterior Tibial Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047Q0E6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047Q0EZ	Dilation of Left Anterior Tibial Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047Q0F6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047Q0FZ	Dilation of Left Anterior Tibial Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047Q0G6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047Q0GZ	Dilation of Left Anterior Tibial Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047Q0Z1	Dilation of Left Anterior Tibial Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047Q0Z6	Dilation of Left Anterior Tibial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047Q0ZZ	Dilation of Left Anterior Tibial Artery, Open Approach	Procedure	ICD-10-PCS
047Q341	Dilation of Left Anterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047Q346	Dilation of Left Anterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047Q34Z	Dilation of Left Anterior Tibial Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047Q356	Dilation of Left Anterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047Q35Z	Dilation of Left Anterior Tibial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047Q366	Dilation of Left Anterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047Q36Z	Dilation of Left Anterior Tibial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047Q376	Dilation of Left Anterior Tibial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047Q37Z	Dilation of Left Anterior Tibial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047Q3D1	Dilation of Left Anterior Tibial Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047Q3D6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047Q3DZ	Dilation of Left Anterior Tibial Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047Q3E6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047Q3EZ	Dilation of Left Anterior Tibial Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047Q3F6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047Q3FZ	Dilation of Left Anterior Tibial Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047Q3G6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047Q3GZ	Dilation of Left Anterior Tibial Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047Q3Z1	Dilation of Left Anterior Tibial Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047Q3Z6	Dilation of Left Anterior Tibial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047Q3ZZ	Dilation of Left Anterior Tibial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047Q441	Dilation of Left Anterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q446	Dilation of Left Anterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q44Z	Dilation of Left Anterior Tibial Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q456	Dilation of Left Anterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q45Z	Dilation of Left Anterior Tibial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q466	Dilation of Left Anterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q46Z	Dilation of Left Anterior Tibial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q476	Dilation of Left Anterior Tibial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q47Z	Dilation of Left Anterior Tibial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q4D1	Dilation of Left Anterior Tibial Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047Q4D6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q4DZ	Dilation of Left Anterior Tibial Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q4E6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q4EZ	Dilation of Left Anterior Tibial Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q4F6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q4FZ	Dilation of Left Anterior Tibial Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q4G6	Dilation of Left Anterior Tibial Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q4GZ	Dilation of Left Anterior Tibial Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q4Z1	Dilation of Left Anterior Tibial Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q4Z6	Dilation of Left Anterior Tibial Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047Q4ZZ	Dilation of Left Anterior Tibial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R041	Dilation of Right Posterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047R046	Dilation of Right Posterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047R04Z	Dilation of Right Posterior Tibial Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047R056	Dilation of Right Posterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047R05Z	Dilation of Right Posterior Tibial Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047R066	Dilation of Right Posterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047R06Z	Dilation of Right Posterior Tibial Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047R076	Dilation of Right Posterior Tibial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047R07Z	Dilation of Right Posterior Tibial Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047R0D1	Dilation of Right Posterior Tibial Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047R0D6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047R0DZ	Dilation of Right Posterior Tibial Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047R0E6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047R0EZ	Dilation of Right Posterior Tibial Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047R0F6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047R0FZ	Dilation of Right Posterior Tibial Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047R0G6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047R0GZ	Dilation of Right Posterior Tibial Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047R0Z1	Dilation of Right Posterior Tibial Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047R0Z6	Dilation of Right Posterior Tibial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047R0ZZ	Dilation of Right Posterior Tibial Artery, Open Approach	Procedure	ICD-10-PCS
047R341	Dilation of Right Posterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047R346	Dilation of Right Posterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047R34Z	Dilation of Right Posterior Tibial Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047R356	Dilation of Right Posterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047R35Z	Dilation of Right Posterior Tibial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047R366	Dilation of Right Posterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047R36Z	Dilation of Right Posterior Tibial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047R376	Dilation of Right Posterior Tibial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047R37Z	Dilation of Right Posterior Tibial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047R3D1	Dilation of Right Posterior Tibial Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047R3D6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047R3DZ	Dilation of Right Posterior Tibial Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047R3E6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047R3EZ	Dilation of Right Posterior Tibial Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
047R3F6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047R3FZ	Dilation of Right Posterior Tibial Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047R3G6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047R3GZ	Dilation of Right Posterior Tibial Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047R3Z1	Dilation of Right Posterior Tibial Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047R3Z6	Dilation of Right Posterior Tibial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047R3ZZ	Dilation of Right Posterior Tibial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047R441	Dilation of Right Posterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R446	Dilation of Right Posterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R44Z	Dilation of Right Posterior Tibial Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R456	Dilation of Right Posterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R45Z	Dilation of Right Posterior Tibial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R466	Dilation of Right Posterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R46Z	Dilation of Right Posterior Tibial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R476	Dilation of Right Posterior Tibial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R47Z	Dilation of Right Posterior Tibial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R4D1	Dilation of Right Posterior Tibial Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R4D6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R4DZ	Dilation of Right Posterior Tibial Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R4E6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R4EZ	Dilation of Right Posterior Tibial Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R4F6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R4FZ	Dilation of Right Posterior Tibial Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
047R4G6	Dilation of Right Posterior Tibial Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R4GZ	Dilation of Right Posterior Tibial Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R4Z1	Dilation of Right Posterior Tibial Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R4Z6	Dilation of Right Posterior Tibial Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047R4ZZ	Dilation of Right Posterior Tibial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S041	Dilation of Left Posterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047S046	Dilation of Left Posterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047S04Z	Dilation of Left Posterior Tibial Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047S056	Dilation of Left Posterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047S05Z	Dilation of Left Posterior Tibial Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047S066	Dilation of Left Posterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047S06Z	Dilation of Left Posterior Tibial Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047S076	Dilation of Left Posterior Tibial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047S07Z	Dilation of Left Posterior Tibial Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047S0D1	Dilation of Left Posterior Tibial Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047S0D6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047S0DZ	Dilation of Left Posterior Tibial Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047S0E6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047S0EZ	Dilation of Left Posterior Tibial Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047S0F6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047S0FZ	Dilation of Left Posterior Tibial Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047S0G6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047S0GZ	Dilation of Left Posterior Tibial Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
047S0Z1	Dilation of Left Posterior Tibial Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047S0Z6	Dilation of Left Posterior Tibial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047S0ZZ	Dilation of Left Posterior Tibial Artery, Open Approach	Procedure	ICD-10-PCS
047S341	Dilation of Left Posterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047S346	Dilation of Left Posterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047S34Z	Dilation of Left Posterior Tibial Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047S356	Dilation of Left Posterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S35Z	Dilation of Left Posterior Tibial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S366	Dilation of Left Posterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S36Z	Dilation of Left Posterior Tibial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S376	Dilation of Left Posterior Tibial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S37Z	Dilation of Left Posterior Tibial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S3D1	Dilation of Left Posterior Tibial Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047S3D6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047S3DZ	Dilation of Left Posterior Tibial Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047S3E6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S3EZ	Dilation of Left Posterior Tibial Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S3F6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S3FZ	Dilation of Left Posterior Tibial Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S3G6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S3GZ	Dilation of Left Posterior Tibial Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047S3Z1	Dilation of Left Posterior Tibial Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047S3Z6	Dilation of Left Posterior Tibial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047S3ZZ	Dilation of Left Posterior Tibial Artery, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047S441	Dilation of Left Posterior Tibial Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S446	Dilation of Left Posterior Tibial Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S44Z	Dilation of Left Posterior Tibial Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S456	Dilation of Left Posterior Tibial Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S45Z	Dilation of Left Posterior Tibial Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S466	Dilation of Left Posterior Tibial Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S46Z	Dilation of Left Posterior Tibial Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S476	Dilation of Left Posterior Tibial Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S47Z	Dilation of Left Posterior Tibial Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S4D1	Dilation of Left Posterior Tibial Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S4D6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S4DZ	Dilation of Left Posterior Tibial Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S4E6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S4EZ	Dilation of Left Posterior Tibial Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S4F6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S4FZ	Dilation of Left Posterior Tibial Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S4G6	Dilation of Left Posterior Tibial Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S4GZ	Dilation of Left Posterior Tibial Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S4Z1	Dilation of Left Posterior Tibial Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S4Z6	Dilation of Left Posterior Tibial Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047S4ZZ	Dilation of Left Posterior Tibial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T041	Dilation of Right Peroneal Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047T046	Dilation of Right Peroneal Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047T04Z	Dilation of Right Peroneal Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047T056	Dilation of Right Peroneal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047T05Z	Dilation of Right Peroneal Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047T066	Dilation of Right Peroneal Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047T06Z	Dilation of Right Peroneal Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047T076	Dilation of Right Peroneal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047T07Z	Dilation of Right Peroneal Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047T0D1	Dilation of Right Peroneal Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047T0D6	Dilation of Right Peroneal Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047T0DZ	Dilation of Right Peroneal Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047T0E6	Dilation of Right Peroneal Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047T0EZ	Dilation of Right Peroneal Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047T0F6	Dilation of Right Peroneal Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047T0FZ	Dilation of Right Peroneal Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047T0G6	Dilation of Right Peroneal Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047T0GZ	Dilation of Right Peroneal Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047T0Z1	Dilation of Right Peroneal Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047T0Z6	Dilation of Right Peroneal Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047T0ZZ	Dilation of Right Peroneal Artery, Open Approach	Procedure	ICD-10-PCS
047T341	Dilation of Right Peroneal Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047T346	Dilation of Right Peroneal Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047T34Z	Dilation of Right Peroneal Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047T356	Dilation of Right Peroneal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047T35Z	Dilation of Right Peroneal Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
047T366	Dilation of Right Peroneal Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047T36Z	Dilation of Right Peroneal Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047T376	Dilation of Right Peroneal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047T37Z	Dilation of Right Peroneal Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047T3D1	Dilation of Right Peroneal Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047T3D6	Dilation of Right Peroneal Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047T3DZ	Dilation of Right Peroneal Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047T3E6	Dilation of Right Peroneal Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047T3EZ	Dilation of Right Peroneal Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047T3F6	Dilation of Right Peroneal Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047T3FZ	Dilation of Right Peroneal Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047T3G6	Dilation of Right Peroneal Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047T3GZ	Dilation of Right Peroneal Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047T3Z1	Dilation of Right Peroneal Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047T3Z6	Dilation of Right Peroneal Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047T3ZZ	Dilation of Right Peroneal Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047T441	Dilation of Right Peroneal Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T446	Dilation of Right Peroneal Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T44Z	Dilation of Right Peroneal Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T456	Dilation of Right Peroneal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T45Z	Dilation of Right Peroneal Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T466	Dilation of Right Peroneal Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T46Z	Dilation of Right Peroneal Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047T476	Dilation of Right Peroneal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T47Z	Dilation of Right Peroneal Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T4D1	Dilation of Right Peroneal Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T4D6	Dilation of Right Peroneal Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T4DZ	Dilation of Right Peroneal Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T4E6	Dilation of Right Peroneal Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T4EZ	Dilation of Right Peroneal Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T4F6	Dilation of Right Peroneal Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T4FZ	Dilation of Right Peroneal Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T4G6	Dilation of Right Peroneal Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T4GZ	Dilation of Right Peroneal Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T4Z1	Dilation of Right Peroneal Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T4Z6	Dilation of Right Peroneal Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047T4ZZ	Dilation of Right Peroneal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U041	Dilation of Left Peroneal Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047U046	Dilation of Left Peroneal Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047U04Z	Dilation of Left Peroneal Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047U056	Dilation of Left Peroneal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047U05Z	Dilation of Left Peroneal Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047U066	Dilation of Left Peroneal Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047U06Z	Dilation of Left Peroneal Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047U076	Dilation of Left Peroneal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047U07Z	Dilation of Left Peroneal Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
047U0D1	Dilation of Left Peroneal Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047U0D6	Dilation of Left Peroneal Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047U0DZ	Dilation of Left Peroneal Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047U0E6	Dilation of Left Peroneal Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047U0EZ	Dilation of Left Peroneal Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047U0F6	Dilation of Left Peroneal Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047U0FZ	Dilation of Left Peroneal Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047U0G6	Dilation of Left Peroneal Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047U0GZ	Dilation of Left Peroneal Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047U0Z1	Dilation of Left Peroneal Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047U0Z6	Dilation of Left Peroneal Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047U0ZZ	Dilation of Left Peroneal Artery, Open Approach	Procedure	ICD-10-PCS
047U341	Dilation of Left Peroneal Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047U346	Dilation of Left Peroneal Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047U34Z	Dilation of Left Peroneal Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047U356	Dilation of Left Peroneal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047U35Z	Dilation of Left Peroneal Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047U366	Dilation of Left Peroneal Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047U36Z	Dilation of Left Peroneal Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047U376	Dilation of Left Peroneal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047U37Z	Dilation of Left Peroneal Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047U3D1	Dilation of Left Peroneal Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047U3D6	Dilation of Left Peroneal Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047U3DZ	Dilation of Left Peroneal Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047U3E6	Dilation of Left Peroneal Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047U3EZ	Dilation of Left Peroneal Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047U3F6	Dilation of Left Peroneal Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047U3FZ	Dilation of Left Peroneal Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047U3G6	Dilation of Left Peroneal Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047U3GZ	Dilation of Left Peroneal Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047U3Z1	Dilation of Left Peroneal Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047U3Z6	Dilation of Left Peroneal Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047U3ZZ	Dilation of Left Peroneal Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047U441	Dilation of Left Peroneal Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U446	Dilation of Left Peroneal Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U44Z	Dilation of Left Peroneal Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U456	Dilation of Left Peroneal Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U45Z	Dilation of Left Peroneal Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U466	Dilation of Left Peroneal Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U46Z	Dilation of Left Peroneal Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U476	Dilation of Left Peroneal Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U47Z	Dilation of Left Peroneal Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U4D1	Dilation of Left Peroneal Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U4D6	Dilation of Left Peroneal Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U4DZ	Dilation of Left Peroneal Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U4E6	Dilation of Left Peroneal Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U4EZ	Dilation of Left Peroneal Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U4F6	Dilation of Left Peroneal Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U4FZ	Dilation of Left Peroneal Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
047U4G6	Dilation of Left Peroneal Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U4GZ	Dilation of Left Peroneal Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U4Z1	Dilation of Left Peroneal Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U4Z6	Dilation of Left Peroneal Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047U4ZZ	Dilation of Left Peroneal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V041	Dilation of Right Foot Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047V046	Dilation of Right Foot Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047V04Z	Dilation of Right Foot Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047V056	Dilation of Right Foot Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047V05Z	Dilation of Right Foot Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047V066	Dilation of Right Foot Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047V06Z	Dilation of Right Foot Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047V076	Dilation of Right Foot Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047V07Z	Dilation of Right Foot Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047V0D1	Dilation of Right Foot Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047V0D6	Dilation of Right Foot Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047V0DZ	Dilation of Right Foot Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047V0E6	Dilation of Right Foot Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047V0EZ	Dilation of Right Foot Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047V0F6	Dilation of Right Foot Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047V0FZ	Dilation of Right Foot Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047V0G6	Dilation of Right Foot Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047V0GZ	Dilation of Right Foot Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047V0Z1	Dilation of Right Foot Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047V0Z6	Dilation of Right Foot Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047V0ZZ	Dilation of Right Foot Artery, Open Approach	Procedure	ICD-10-PCS
047V341	Dilation of Right Foot Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047V346	Dilation of Right Foot Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047V34Z	Dilation of Right Foot Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047V356	Dilation of Right Foot Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047V35Z	Dilation of Right Foot Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047V366	Dilation of Right Foot Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047V36Z	Dilation of Right Foot Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047V376	Dilation of Right Foot Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047V37Z	Dilation of Right Foot Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047V3D1	Dilation of Right Foot Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047V3D6	Dilation of Right Foot Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047V3DZ	Dilation of Right Foot Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047V3E6	Dilation of Right Foot Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047V3EZ	Dilation of Right Foot Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047V3F6	Dilation of Right Foot Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047V3FZ	Dilation of Right Foot Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047V3G6	Dilation of Right Foot Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047V3GZ	Dilation of Right Foot Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047V3Z1	Dilation of Right Foot Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047V3Z6	Dilation of Right Foot Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047V3ZZ	Dilation of Right Foot Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047V441	Dilation of Right Foot Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V446	Dilation of Right Foot Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V44Z	Dilation of Right Foot Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V456	Dilation of Right Foot Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V45Z	Dilation of Right Foot Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
047V466	Dilation of Right Foot Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V46Z	Dilation of Right Foot Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V476	Dilation of Right Foot Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V47Z	Dilation of Right Foot Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V4D1	Dilation of Right Foot Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V4D6	Dilation of Right Foot Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V4DZ	Dilation of Right Foot Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V4E6	Dilation of Right Foot Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V4EZ	Dilation of Right Foot Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V4F6	Dilation of Right Foot Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V4FZ	Dilation of Right Foot Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V4G6	Dilation of Right Foot Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V4GZ	Dilation of Right Foot Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V4Z1	Dilation of Right Foot Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V4Z6	Dilation of Right Foot Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047V4ZZ	Dilation of Right Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W041	Dilation of Left Foot Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047W046	Dilation of Left Foot Artery, Bifurcation, with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047W04Z	Dilation of Left Foot Artery with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047W056	Dilation of Left Foot Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047W05Z	Dilation of Left Foot Artery with Two Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047W066	Dilation of Left Foot Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047W06Z	Dilation of Left Foot Artery with Three Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
047W076	Dilation of Left Foot Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047W07Z	Dilation of Left Foot Artery with Four or More Drug-eluting Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047W0D1	Dilation of Left Foot Artery with Intraluminal Device, using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047W0D6	Dilation of Left Foot Artery, Bifurcation, with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047W0DZ	Dilation of Left Foot Artery with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
047W0E6	Dilation of Left Foot Artery, Bifurcation, with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047W0EZ	Dilation of Left Foot Artery with Two Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047W0F6	Dilation of Left Foot Artery, Bifurcation, with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047W0FZ	Dilation of Left Foot Artery with Three Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047W0G6	Dilation of Left Foot Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047W0GZ	Dilation of Left Foot Artery with Four or More Intraluminal Devices, Open Approach	Procedure	ICD-10-PCS
047W0Z1	Dilation of Left Foot Artery using Drug-Coated Balloon, Open Approach	Procedure	ICD-10-PCS
047W0Z6	Dilation of Left Foot Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
047W0ZZ	Dilation of Left Foot Artery, Open Approach	Procedure	ICD-10-PCS
047W341	Dilation of Left Foot Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047W346	Dilation of Left Foot Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047W34Z	Dilation of Left Foot Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047W356	Dilation of Left Foot Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047W35Z	Dilation of Left Foot Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047W366	Dilation of Left Foot Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047W36Z	Dilation of Left Foot Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047W376	Dilation of Left Foot Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047W37Z	Dilation of Left Foot Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047W3D1	Dilation of Left Foot Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047W3D6	Dilation of Left Foot Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047W3DZ	Dilation of Left Foot Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
047W3E6	Dilation of Left Foot Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
047W3EZ	Dilation of Left Foot Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047W3F6	Dilation of Left Foot Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047W3FZ	Dilation of Left Foot Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047W3G6	Dilation of Left Foot Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047W3GZ	Dilation of Left Foot Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
047W3Z1	Dilation of Left Foot Artery using Drug-Coated Balloon, Percutaneous Approach	Procedure	ICD-10-PCS
047W3Z6	Dilation of Left Foot Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
047W3ZZ	Dilation of Left Foot Artery, Percutaneous Approach	Procedure	ICD-10-PCS
047W441	Dilation of Left Foot Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W446	Dilation of Left Foot Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W44Z	Dilation of Left Foot Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W456	Dilation of Left Foot Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W45Z	Dilation of Left Foot Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W466	Dilation of Left Foot Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W46Z	Dilation of Left Foot Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W476	Dilation of Left Foot Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W47Z	Dilation of Left Foot Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W4D1	Dilation of Left Foot Artery with Intraluminal Device, using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W4D6	Dilation of Left Foot Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W4DZ	Dilation of Left Foot Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W4E6	Dilation of Left Foot Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W4EZ	Dilation of Left Foot Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W4F6	Dilation of Left Foot Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W4FZ	Dilation of Left Foot Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
047W4G6	Dilation of Left Foot Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W4GZ	Dilation of Left Foot Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W4Z1	Dilation of Left Foot Artery using Drug-Coated Balloon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W4Z6	Dilation of Left Foot Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
047W4ZZ	Dilation of Left Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04C00Z6	Extirpation of Matter from Abdominal Aorta, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04C03Z6	Extirpation of Matter from Abdominal Aorta, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04C04Z6	Extirpation of Matter from Abdominal Aorta, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CC0Z6	Extirpation of Matter from Right Common Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CC0ZZ	Extirpation of Matter from Right Common Iliac Artery, Open Approach	Procedure	ICD-10-PCS
04CC3Z6	Extirpation of Matter from Right Common Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CC3ZZ	Extirpation of Matter from Right Common Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CC4Z6	Extirpation of Matter from Right Common Iliac Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CC4ZZ	Extirpation of Matter from Right Common Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CD0Z6	Extirpation of Matter from Left Common Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CD0ZZ	Extirpation of Matter from Left Common Iliac Artery, Open Approach	Procedure	ICD-10-PCS
04CD3Z6	Extirpation of Matter from Left Common Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CD3ZZ	Extirpation of Matter from Left Common Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CD4Z6	Extirpation of Matter from Left Common Iliac Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CD4ZZ	Extirpation of Matter from Left Common Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CE0Z6	Extirpation of Matter from Right Internal Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CE0ZZ	Extirpation of Matter from Right Internal Iliac Artery, Open Approach	Procedure	ICD-10-PCS
04CE3Z6	Extirpation of Matter from Right Internal Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CE3ZZ	Extirpation of Matter from Right Internal Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CE4Z6	Extirpation of Matter from Right Internal Iliac Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CE4ZZ	Extirpation of Matter from Right Internal Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CF0Z6	Extirpation of Matter from Left Internal Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CF0ZZ	Extirpation of Matter from Left Internal Iliac Artery, Open Approach	Procedure	ICD-10-PCS
04CF3Z6	Extirpation of Matter from Left Internal Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CF3ZZ	Extirpation of Matter from Left Internal Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CF4Z6	Extirpation of Matter from Left Internal Iliac Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
04CF4ZZ	Extirpation of Matter from Left Internal Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CH0Z6	Extirpation of Matter from Right External Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CH0ZZ	Extirpation of Matter from Right External Iliac Artery, Open Approach	Procedure	ICD-10-PCS
04CH3Z6	Extirpation of Matter from Right External Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CH3ZZ	Extirpation of Matter from Right External Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CH4Z6	Extirpation of Matter from Right External Iliac Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CH4ZZ	Extirpation of Matter from Right External Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CJ0Z6	Extirpation of Matter from Left External Iliac Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CJ0ZZ	Extirpation of Matter from Left External Iliac Artery, Open Approach	Procedure	ICD-10-PCS
04CJ3Z6	Extirpation of Matter from Left External Iliac Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CJ3ZZ	Extirpation of Matter from Left External Iliac Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CJ4Z6	Extirpation of Matter from Left External Iliac Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CJ4ZZ	Extirpation of Matter from Left External Iliac Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CK0Z6	Extirpation of Matter from Right Femoral Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CK0ZZ	Extirpation of Matter from Right Femoral Artery, Open Approach	Procedure	ICD-10-PCS
04CK3Z6	Extirpation of Matter from Right Femoral Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CK3ZZ	Extirpation of Matter from Right Femoral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CK4Z6	Extirpation of Matter from Right Femoral Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CK4ZZ	Extirpation of Matter from Right Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CL0Z6	Extirpation of Matter from Left Femoral Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CL0ZZ	Extirpation of Matter from Left Femoral Artery, Open Approach	Procedure	ICD-10-PCS
04CL3Z6	Extirpation of Matter from Left Femoral Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CL3ZZ	Extirpation of Matter from Left Femoral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CL4Z6	Extirpation of Matter from Left Femoral Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CL4ZZ	Extirpation of Matter from Left Femoral Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CM0Z6	Extirpation of Matter from Right Popliteal Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CM0ZZ	Extirpation of Matter from Right Popliteal Artery, Open Approach	Procedure	ICD-10-PCS
04CM3Z6	Extirpation of Matter from Right Popliteal Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CM3ZZ	Extirpation of Matter from Right Popliteal Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CM4Z6	Extirpation of Matter from Right Popliteal Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CM4ZZ	Extirpation of Matter from Right Popliteal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CN0Z6	Extirpation of Matter from Left Popliteal Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CN0ZZ	Extirpation of Matter from Left Popliteal Artery, Open Approach	Procedure	ICD-10-PCS
04CN3Z6	Extirpation of Matter from Left Popliteal Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
04CN3ZZ	Extirpation of Matter from Left Popliteal Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CN4Z6	Extirpation of Matter from Left Popliteal Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CN4ZZ	Extirpation of Matter from Left Popliteal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CP0Z6	Extirpation of Matter from Right Anterior Tibial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CP0ZZ	Extirpation of Matter from Right Anterior Tibial Artery, Open Approach	Procedure	ICD-10-PCS
04CP3Z6	Extirpation of Matter from Right Anterior Tibial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CP3ZZ	Extirpation of Matter from Right Anterior Tibial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CP4Z6	Extirpation of Matter from Right Anterior Tibial Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CP4ZZ	Extirpation of Matter from Right Anterior Tibial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CQ0Z6	Extirpation of Matter from Left Anterior Tibial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CQ0ZZ	Extirpation of Matter from Left Anterior Tibial Artery, Open Approach	Procedure	ICD-10-PCS
04CQ3Z6	Extirpation of Matter from Left Anterior Tibial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CQ3ZZ	Extirpation of Matter from Left Anterior Tibial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CQ4Z6	Extirpation of Matter from Left Anterior Tibial Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CQ4ZZ	Extirpation of Matter from Left Anterior Tibial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CR0Z6	Extirpation of Matter from Right Posterior Tibial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CR0ZZ	Extirpation of Matter from Right Posterior Tibial Artery, Open Approach	Procedure	ICD-10-PCS
04CR3Z6	Extirpation of Matter from Right Posterior Tibial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CR3ZZ	Extirpation of Matter from Right Posterior Tibial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CR4Z6	Extirpation of Matter from Right Posterior Tibial Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CR4ZZ	Extirpation of Matter from Right Posterior Tibial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CS0Z6	Extirpation of Matter from Left Posterior Tibial Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CS0ZZ	Extirpation of Matter from Left Posterior Tibial Artery, Open Approach	Procedure	ICD-10-PCS
04CS3Z6	Extirpation of Matter from Left Posterior Tibial Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CS3ZZ	Extirpation of Matter from Left Posterior Tibial Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CS4Z6	Extirpation of Matter from Left Posterior Tibial Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CS4ZZ	Extirpation of Matter from Left Posterior Tibial Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CT0Z6	Extirpation of Matter from Right Peroneal Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CT0ZZ	Extirpation of Matter from Right Peroneal Artery, Open Approach	Procedure	ICD-10-PCS
04CT3Z6	Extirpation of Matter from Right Peroneal Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CT3ZZ	Extirpation of Matter from Right Peroneal Artery, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
04CT4Z6	Extirpation of Matter from Right Peroneal Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CT4ZZ	Extirpation of Matter from Right Peroneal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CU0Z6	Extirpation of Matter from Left Peroneal Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CU0ZZ	Extirpation of Matter from Left Peroneal Artery, Open Approach	Procedure	ICD-10-PCS
04CU3Z6	Extirpation of Matter from Left Peroneal Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CU3ZZ	Extirpation of Matter from Left Peroneal Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CU4Z6	Extirpation of Matter from Left Peroneal Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CU4ZZ	Extirpation of Matter from Left Peroneal Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CV0Z6	Extirpation of Matter from Right Foot Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CV0ZZ	Extirpation of Matter from Right Foot Artery, Open Approach	Procedure	ICD-10-PCS
04CV3Z6	Extirpation of Matter from Right Foot Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CV3ZZ	Extirpation of Matter from Right Foot Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CV4Z6	Extirpation of Matter from Right Foot Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CV4ZZ	Extirpation of Matter from Right Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CW0Z6	Extirpation of Matter from Left Foot Artery, Bifurcation, Open Approach	Procedure	ICD-10-PCS
04CW0ZZ	Extirpation of Matter from Left Foot Artery, Open Approach	Procedure	ICD-10-PCS
04CW3Z6	Extirpation of Matter from Left Foot Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
04CW3ZZ	Extirpation of Matter from Left Foot Artery, Percutaneous Approach	Procedure	ICD-10-PCS
04CW4Z6	Extirpation of Matter from Left Foot Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
04CW4ZZ	Extirpation of Matter from Left Foot Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0Y6C0Z1	Detachment at Right Upper Leg, High, Open Approach	Procedure	ICD-10-PCS
0Y6C0Z2	Detachment at Right Upper Leg, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6C0Z3	Detachment at Right Upper Leg, Low, Open Approach	Procedure	ICD-10-PCS
0Y6D0Z1	Detachment at Left Upper Leg, High, Open Approach	Procedure	ICD-10-PCS
0Y6D0Z2	Detachment at Left Upper Leg, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6D0Z3	Detachment at Left Upper Leg, Low, Open Approach	Procedure	ICD-10-PCS
0Y6F0ZZ	Detachment at Right Knee Region, Open Approach	Procedure	ICD-10-PCS
0Y6G0ZZ	Detachment at Left Knee Region, Open Approach	Procedure	ICD-10-PCS
0Y6H0Z1	Detachment at Right Lower Leg, High, Open Approach	Procedure	ICD-10-PCS
0Y6H0Z2	Detachment at Right Lower Leg, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6H0Z3	Detachment at Right Lower Leg, Low, Open Approach	Procedure	ICD-10-PCS
0Y6J0Z1	Detachment at Left Lower Leg, High, Open Approach	Procedure	ICD-10-PCS
0Y6J0Z2	Detachment at Left Lower Leg, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6J0Z3	Detachment at Left Lower Leg, Low, Open Approach	Procedure	ICD-10-PCS
0Y6M0Z0	Detachment at Right Foot, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6M0Z4	Detachment at Right Foot, Complete 1st Ray, Open Approach	Procedure	ICD-10-PCS
0Y6M0Z5	Detachment at Right Foot, Complete 2nd Ray, Open Approach	Procedure	ICD-10-PCS
0Y6M0Z6	Detachment at Right Foot, Complete 3rd Ray, Open Approach	Procedure	ICD-10-PCS
0Y6M0Z7	Detachment at Right Foot, Complete 4th Ray, Open Approach	Procedure	ICD-10-PCS
0Y6M0Z8	Detachment at Right Foot, Complete 5th Ray, Open Approach	Procedure	ICD-10-PCS
0Y6M0Z9	Detachment at Right Foot, Partial 1st Ray, Open Approach	Procedure	ICD-10-PCS
0Y6M0ZB	Detachment at Right Foot, Partial 2nd Ray, Open Approach	Procedure	ICD-10-PCS
0Y6M0ZC	Detachment at Right Foot, Partial 3rd Ray, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
0Y6M0ZD	Detachment at Right Foot, Partial 4th Ray, Open Approach	Procedure	ICD-10-PCS
0Y6M0ZF	Detachment at Right Foot, Partial 5th Ray, Open Approach	Procedure	ICD-10-PCS
0Y6N0Z0	Detachment at Left Foot, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6N0Z4	Detachment at Left Foot, Complete 1st Ray, Open Approach	Procedure	ICD-10-PCS
0Y6N0Z5	Detachment at Left Foot, Complete 2nd Ray, Open Approach	Procedure	ICD-10-PCS
0Y6N0Z6	Detachment at Left Foot, Complete 3rd Ray, Open Approach	Procedure	ICD-10-PCS
0Y6N0Z7	Detachment at Left Foot, Complete 4th Ray, Open Approach	Procedure	ICD-10-PCS
0Y6N0Z8	Detachment at Left Foot, Complete 5th Ray, Open Approach	Procedure	ICD-10-PCS
0Y6N0Z9	Detachment at Left Foot, Partial 1st Ray, Open Approach	Procedure	ICD-10-PCS
0Y6N0ZB	Detachment at Left Foot, Partial 2nd Ray, Open Approach	Procedure	ICD-10-PCS
0Y6N0ZC	Detachment at Left Foot, Partial 3rd Ray, Open Approach	Procedure	ICD-10-PCS
0Y6N0ZD	Detachment at Left Foot, Partial 4th Ray, Open Approach	Procedure	ICD-10-PCS
0Y6N0ZF	Detachment at Left Foot, Partial 5th Ray, Open Approach	Procedure	ICD-10-PCS
0Y6P0Z0	Detachment at Right 1st Toe, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6P0Z1	Detachment at Right 1st Toe, High, Open Approach	Procedure	ICD-10-PCS
0Y6P0Z2	Detachment at Right 1st Toe, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6P0Z3	Detachment at Right 1st Toe, Low, Open Approach	Procedure	ICD-10-PCS
0Y6Q0Z0	Detachment at Left 1st Toe, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6Q0Z1	Detachment at Left 1st Toe, High, Open Approach	Procedure	ICD-10-PCS
0Y6Q0Z2	Detachment at Left 1st Toe, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6Q0Z3	Detachment at Left 1st Toe, Low, Open Approach	Procedure	ICD-10-PCS
0Y6R0Z0	Detachment at Right 2nd Toe, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6R0Z1	Detachment at Right 2nd Toe, High, Open Approach	Procedure	ICD-10-PCS
0Y6R0Z2	Detachment at Right 2nd Toe, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6R0Z3	Detachment at Right 2nd Toe, Low, Open Approach	Procedure	ICD-10-PCS
0Y6S0Z0	Detachment at Left 2nd Toe, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6S0Z1	Detachment at Left 2nd Toe, High, Open Approach	Procedure	ICD-10-PCS
0Y6S0Z2	Detachment at Left 2nd Toe, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6S0Z3	Detachment at Left 2nd Toe, Low, Open Approach	Procedure	ICD-10-PCS
0Y6T0Z0	Detachment at Right 3rd Toe, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6T0Z1	Detachment at Right 3rd Toe, High, Open Approach	Procedure	ICD-10-PCS
0Y6T0Z2	Detachment at Right 3rd Toe, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6T0Z3	Detachment at Right 3rd Toe, Low, Open Approach	Procedure	ICD-10-PCS
0Y6U0Z0	Detachment at Left 3rd Toe, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6U0Z1	Detachment at Left 3rd Toe, High, Open Approach	Procedure	ICD-10-PCS
0Y6U0Z2	Detachment at Left 3rd Toe, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6U0Z3	Detachment at Left 3rd Toe, Low, Open Approach	Procedure	ICD-10-PCS
0Y6V0Z0	Detachment at Right 4th Toe, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6V0Z1	Detachment at Right 4th Toe, High, Open Approach	Procedure	ICD-10-PCS
0Y6V0Z2	Detachment at Right 4th Toe, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6V0Z3	Detachment at Right 4th Toe, Low, Open Approach	Procedure	ICD-10-PCS
0Y6W0Z0	Detachment at Left 4th Toe, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6W0Z1	Detachment at Left 4th Toe, High, Open Approach	Procedure	ICD-10-PCS
0Y6W0Z2	Detachment at Left 4th Toe, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6W0Z3	Detachment at Left 4th Toe, Low, Open Approach	Procedure	ICD-10-PCS
0Y6X0Z0	Detachment at Right 5th Toe, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6X0Z1	Detachment at Right 5th Toe, High, Open Approach	Procedure	ICD-10-PCS
0Y6X0Z2	Detachment at Right 5th Toe, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6X0Z3	Detachment at Right 5th Toe, Low, Open Approach	Procedure	ICD-10-PCS
0Y6Y0Z0	Detachment at Left 5th Toe, Complete, Open Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
0Y6Y0Z1	Detachment at Left 5th Toe, High, Open Approach	Procedure	ICD-10-PCS
0Y6Y0Z2	Detachment at Left 5th Toe, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6Y0Z3	Detachment at Left 5th Toe, Low, Open Approach	Procedure	ICD-10-PCS
33877	Repair of thoracoabdominal aortic aneurysm with graft, with or without cardiopulmonary bypass	Procedure	CPT-4
34151	Embolectomy or thrombectomy, with or without catheter; renal, celiac, mesentery, aortoiliac artery, by abdominal incision	Procedure	CPT-4
34201	Embolectomy or thrombectomy, with or without catheter; femoropopliteal, aortoiliac artery, by leg incision	Procedure	CPT-4
34808	Endovascular placement of iliac artery occlusion device (List separately in addition to code for primary procedure)	Procedure	CPT-4
34820	Open iliac artery exposure for delivery of endovascular prosthesis or iliac occlusion during endovascular therapy, by abdominal or retroperitoneal incision, unilateral (List separately in addition to code for primary procedure)	Procedure	CPT-4
34825	Placement of proximal or distal extension prosthesis for endovascular repair of infrarenal abdominal aortic or iliac aneurysm, false aneurysm, or dissection; initial vessel	Procedure	CPT-4
34826	Placement of proximal or distal extension prosthesis for endovascular repair of infrarenal abdominal aortic or iliac aneurysm, false aneurysm, or dissection; each additional vessel (List separately in addition to code for primary procedure)	Procedure	CPT-4
35081	Direct repair of aneurysm, pseudoaneurysm, or excision (partial or total) and graft insertion, with or without patch graft; for aneurysm, pseudoaneurysm, and associated occlusive disease, abdominal aorta	Procedure	CPT-4
35102	Direct repair of aneurysm, pseudoaneurysm, or excision (partial or total) and graft insertion, with or without patch graft; for aneurysm, pseudoaneurysm, and associated occlusive disease, abdominal aorta involving iliac vessels (common, hypogastric, external)	Procedure	CPT-4
35131	Direct repair of aneurysm, pseudoaneurysm, or excision (partial or total) and graft insertion, with or without patch graft; for aneurysm, pseudoaneurysm, and associated occlusive disease, iliac artery (common, hypogastric, external)	Procedure	CPT-4
35132	Direct repair of aneurysm, pseudoaneurysm, or excision (partial or total) and graft insertion, with or without patch graft; for ruptured aneurysm, iliac artery (common, hypogastric, external)	Procedure	CPT-4
35141	Direct repair of aneurysm, pseudoaneurysm, or excision (partial or total) and graft insertion, with or without patch graft; for aneurysm, pseudoaneurysm, and associated occlusive disease, common femoral artery (profunda femoris, superficial femoral)	Procedure	CPT-4
35142	Direct repair of aneurysm, pseudoaneurysm, or excision (partial or total) and graft insertion, with or without patch graft; for ruptured aneurysm, common femoral artery (profunda femoris, superficial femoral)	Procedure	CPT-4
35450	Transluminal balloon angioplasty, open; renal or other visceral artery	Procedure	CPT-4
35452	Transluminal balloon angioplasty, open; aortic	Procedure	CPT-4
35454	Transluminal balloon angioplasty, open; iliac	Procedure	CPT-4

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
35471	Transluminal balloon angioplasty, percutaneous; renal or visceral artery	Procedure	CPT-4
35472	Transluminal balloon angioplasty, percutaneous; aortic	Procedure	CPT-4
35473	Transluminal balloon angioplasty, percutaneous; iliac	Procedure	CPT-4
35480	Transluminal peripheral atherectomy, open; renal or other visceral artery	Procedure	CPT-4
35490	Transluminal peripheral atherectomy, percutaneous; renal or other visceral artery	Procedure	CPT-4
35537	Bypass graft, with vein; aortoiliac	Procedure	CPT-4
35538	Bypass graft, with vein; aortobi-iliac	Procedure	CPT-4
35540	Bypass graft, with vein; aortobifemoral	Procedure	CPT-4
35548	Bypass graft, with vein; aortoiliofemoral, unilateral	Procedure	CPT-4
35549	Bypass graft, with vein; aortoiliofemoral, bilateral	Procedure	CPT-4
35563	Bypass graft, with vein; ilioiliac	Procedure	CPT-4
35566	Bypass graft, with vein; femoral-anterior tibial, posterior tibial, peroneal artery or other distal vessels	Procedure	CPT-4
35621	Bypass graft, with other than vein; axillary-femoral	Procedure	CPT-4
35637	Bypass graft, with other than vein; aortoiliac	Procedure	CPT-4
35638	Bypass graft, with other than vein; aortobi-iliac	Procedure	CPT-4
35646	Bypass graft, with other than vein; aortobifemoral	Procedure	CPT-4
35647	Bypass graft, with other than vein; aortofemoral	Procedure	CPT-4
35651	Bypass graft, with other than vein; aortofemoral-popliteal	Procedure	CPT-4
35654	Bypass graft, with other than vein; axillary-femoral-femoral	Procedure	CPT-4
35656	Bypass graft, with other than vein; femoral-popliteal	Procedure	CPT-4
35661	Bypass graft, with other than vein; femoral-femoral	Procedure	CPT-4
35663	Bypass graft, with other than vein; ilioiliac	Procedure	CPT-4
35665	Bypass graft, with other than vein; iliofemoral	Procedure	CPT-4
35666	Bypass graft, with other than vein; femoral-anterior tibial, posterior tibial, or peroneal artery	Procedure	CPT-4
Valvular/Mitral Valve Disease			
I05.0	Rheumatic mitral stenosis	Diagnosis	ICD-10-CM
I05.1	Rheumatic mitral insufficiency	Diagnosis	ICD-10-CM
I05.2	Rheumatic mitral stenosis with insufficiency	Diagnosis	ICD-10-CM
I05.8	Other rheumatic mitral valve diseases	Diagnosis	ICD-10-CM
I05.9	Rheumatic mitral valve disease, unspecified	Diagnosis	ICD-10-CM
I06.0	Rheumatic aortic stenosis	Diagnosis	ICD-10-CM
I06.1	Rheumatic aortic insufficiency	Diagnosis	ICD-10-CM
I06.2	Rheumatic aortic stenosis with insufficiency	Diagnosis	ICD-10-CM
I06.8	Other rheumatic aortic valve diseases	Diagnosis	ICD-10-CM
I06.9	Rheumatic aortic valve disease, unspecified	Diagnosis	ICD-10-CM
I07.0	Rheumatic tricuspid stenosis	Diagnosis	ICD-10-CM
I07.1	Rheumatic tricuspid insufficiency	Diagnosis	ICD-10-CM
I07.2	Rheumatic tricuspid stenosis and insufficiency	Diagnosis	ICD-10-CM
I07.8	Other rheumatic tricuspid valve diseases	Diagnosis	ICD-10-CM
I07.9	Rheumatic tricuspid valve disease, unspecified	Diagnosis	ICD-10-CM
I08.0	Rheumatic disorders of both mitral and aortic valves	Diagnosis	ICD-10-CM
I08.1	Rheumatic disorders of both mitral and tricuspid valves	Diagnosis	ICD-10-CM
I08.2	Rheumatic disorders of both aortic and tricuspid valves	Diagnosis	ICD-10-CM
I08.3	Combined rheumatic disorders of mitral, aortic and tricuspid valves	Diagnosis	ICD-10-CM
I08.8	Other rheumatic multiple valve diseases	Diagnosis	ICD-10-CM
I08.9	Rheumatic multiple valve disease, unspecified	Diagnosis	ICD-10-CM
I09.1	Rheumatic diseases of endocardium, valve unspecified	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I09.81	Rheumatic heart failure	Diagnosis	ICD-10-CM
I09.89	Other specified rheumatic heart diseases	Diagnosis	ICD-10-CM
I09.9	Rheumatic heart disease, unspecified	Diagnosis	ICD-10-CM
Z95.2	Presence of prosthetic heart valve	Diagnosis	ICD-10-CM
Z95.3	Presence of xenogenic heart valve	Diagnosis	ICD-10-CM
Z95.4	Presence of other heart-valve replacement	Diagnosis	ICD-10-CM
027F04Z	Dilation of Aortic Valve with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027F0DZ	Dilation of Aortic Valve with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027F0ZZ	Dilation of Aortic Valve, Open Approach	Procedure	ICD-10-PCS
027G04Z	Dilation of Mitral Valve with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027G0DZ	Dilation of Mitral Valve with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027G0ZZ	Dilation of Mitral Valve, Open Approach	Procedure	ICD-10-PCS
027H04Z	Dilation of Pulmonary Valve with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027H0DZ	Dilation of Pulmonary Valve with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027H0ZZ	Dilation of Pulmonary Valve, Open Approach	Procedure	ICD-10-PCS
027J04Z	Dilation of Tricuspid Valve with Drug-eluting Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027J0DZ	Dilation of Tricuspid Valve with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
027J0ZZ	Dilation of Tricuspid Valve, Open Approach	Procedure	ICD-10-PCS
02NF0ZZ	Release Aortic Valve, Open Approach	Procedure	ICD-10-PCS
02NG0ZZ	Release Mitral Valve, Open Approach	Procedure	ICD-10-PCS
02NH0ZZ	Release Pulmonary Valve, Open Approach	Procedure	ICD-10-PCS
02NJ0ZZ	Release Tricuspid Valve, Open Approach	Procedure	ICD-10-PCS
02QF0ZZ	Repair Aortic Valve, Open Approach	Procedure	ICD-10-PCS
02QG0ZZ	Repair Mitral Valve, Open Approach	Procedure	ICD-10-PCS
02QH0ZZ	Repair Pulmonary Valve, Open Approach	Procedure	ICD-10-PCS
02QJ0ZZ	Repair Tricuspid Valve, Open Approach	Procedure	ICD-10-PCS
02RF07Z	Replacement of Aortic Valve with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02RF08Z	Replacement of Aortic Valve with Zooplasic Tissue, Open Approach	Procedure	ICD-10-PCS
02RF0JZ	Replacement of Aortic Valve with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02RF0KZ	Replacement of Aortic Valve with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02RF47Z	Replacement of Aortic Valve with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RF48Z	Replacement of Aortic Valve with Zooplasic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RF4JZ	Replacement of Aortic Valve with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RF4KZ	Replacement of Aortic Valve with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RG07Z	Replacement of Mitral Valve with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02RG08Z	Replacement of Mitral Valve with Zooplasic Tissue, Open Approach	Procedure	ICD-10-PCS
02RG0JZ	Replacement of Mitral Valve with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02RG0KZ	Replacement of Mitral Valve with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02RG37Z	Replacement of Mitral Valve with Autologous Tissue Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
02RG38Z	Replacement of Mitral Valve with Zooplasic Tissue, Percutaneous Approach	Procedure	ICD-10-PCS
02RG3JZ	Replacement of Mitral Valve with Synthetic Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
02RG3KZ	Replacement of Mitral Valve with Nonautologous Tissue Substitute, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
02RG47Z	Replacement of Mitral Valve with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RG48Z	Replacement of Mitral Valve with Zooplasic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RG4JZ	Replacement of Mitral Valve with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RG4KZ	Replacement of Mitral Valve with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RH07Z	Replacement of Pulmonary Valve with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02RH08Z	Replacement of Pulmonary Valve with Zooplasic Tissue, Open Approach	Procedure	ICD-10-PCS
02RH0JZ	Replacement of Pulmonary Valve with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02RH0KZ	Replacement of Pulmonary Valve with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02RH47Z	Replacement of Pulmonary Valve with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RH48Z	Replacement of Pulmonary Valve with Zooplasic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RH4JZ	Replacement of Pulmonary Valve with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RH4KZ	Replacement of Pulmonary Valve with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RJ07Z	Replacement of Tricuspid Valve with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02RJ08Z	Replacement of Tricuspid Valve with Zooplasic Tissue, Open Approach	Procedure	ICD-10-PCS
02RJ0JZ	Replacement of Tricuspid Valve with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02RJ0KZ	Replacement of Tricuspid Valve with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02RJ37Z	Replacement of Tricuspid Valve with Autologous Tissue Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
02RJ38Z	Replacement of Tricuspid Valve with Zooplasic Tissue, Percutaneous Approach	Procedure	ICD-10-PCS
02RJ3JZ	Replacement of Tricuspid Valve with Synthetic Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
02RJ3KZ	Replacement of Tricuspid Valve with Nonautologous Tissue Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
02RJ47Z	Replacement of Tricuspid Valve with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RJ48Z	Replacement of Tricuspid Valve with Zooplasic Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RJ4JZ	Replacement of Tricuspid Valve with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02RJ4KZ	Replacement of Tricuspid Valve with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02VG0ZZ	Restriction of Mitral Valve, Open Approach	Procedure	ICD-10-PCS
X2RF03Z	Replacement of Aortic Valve using Zooplasic Tissue, Rapid Deployment Technique, Open Approach, New Technology Group 2	Procedure	ICD-10-PCS
X2RF43Z	Replacement of Aortic Valve using Zooplasic Tissue, Rapid Deployment Technique, Percutaneous Endoscopic Approach, New Technology Group 2	Procedure	ICD-10-PCS

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
0257T	Implantation of catheter-delivered prosthetic aortic heart valve; open thoracic approach (eg, transapical, transventricular)	Procedure	CPT-4, Category III
0258T	Transthoracic cardiac exposure (eg, sternotomy, thoracotomy, subxiphoid) for catheter-delivered aortic valve replacement; without cardiopulmonary bypass	Procedure	CPT-4, Category III
0259T	Transthoracic cardiac exposure (eg, sternotomy, thoracotomy, subxiphoid) for catheter-delivered aortic valve replacement; with cardiopulmonary bypass	Procedure	CPT-4, Category III
0262T	Implantation of catheter-delivered prosthetic pulmonary valve, endovascular approach	Procedure	CPT-4, Category III
33400	Valvuloplasty, aortic valve; open, with cardiopulmonary bypass	Procedure	CPT-4
33401	Valvuloplasty, aortic valve; open, with inflow occlusion	Procedure	CPT-4
33403	Valvuloplasty, aortic valve; using transventricular dilation, with cardiopulmonary bypass	Procedure	CPT-4
33420	Valvotomy, mitral valve; closed heart	Procedure	CPT-4
33422	Valvotomy, mitral valve; open heart, with cardiopulmonary bypass	Procedure	CPT-4
33425	Valvuloplasty, mitral valve, with cardiopulmonary bypass;	Procedure	CPT-4
33426	Valvuloplasty, mitral valve, with cardiopulmonary bypass; with prosthetic ring	Procedure	CPT-4
33427	Valvuloplasty, mitral valve, with cardiopulmonary bypass; radical reconstruction, with or without ring	Procedure	CPT-4
33430	Replacement, mitral valve, with cardiopulmonary bypass	Procedure	CPT-4
33460	Valvectomy, tricuspid valve, with cardiopulmonary bypass	Procedure	CPT-4
33463	Valvuloplasty, tricuspid valve; without ring insertion	Procedure	CPT-4
33464	Valvuloplasty, tricuspid valve; with ring insertion	Procedure	CPT-4
33465	Replacement, tricuspid valve, with cardiopulmonary bypass	Procedure	CPT-4
33468	Tricuspid valve repositioning and plication for Ebstein anomaly	Procedure	CPT-4
33475	Replacement, pulmonary valve	Procedure	CPT-4
33496	Repair of non-structural prosthetic valve dysfunction with cardiopulmonary bypass (separate procedure)	Procedure	CPT-4
33660	Repair of incomplete or partial atrioventricular canal (ostium primum atrial septal defect), with or without atrioventricular valve repair	Procedure	CPT-4
33665	Repair of intermediate or transitional atrioventricular canal, with or without atrioventricular valve repair	Procedure	CPT-4
Diseases of Veins and Lymphatics and Other Diseases of the Circulatory System			
I80	Phlebitis and thrombophlebitis	Diagnosis	ICD-10-CM
I80.0	Phlebitis and thrombophlebitis of superficial vessels of lower extremities	Diagnosis	ICD-10-CM
I80.00	Phlebitis and thrombophlebitis of superficial vessels of unspecified lower extremity	Diagnosis	ICD-10-CM
I80.01	Phlebitis and thrombophlebitis of superficial vessels of right lower extremity	Diagnosis	ICD-10-CM
I80.02	Phlebitis and thrombophlebitis of superficial vessels of left lower extremity	Diagnosis	ICD-10-CM
I80.03	Phlebitis and thrombophlebitis of superficial vessels of lower extremities, bilateral	Diagnosis	ICD-10-CM
I80.1	Phlebitis and thrombophlebitis of femoral vein	Diagnosis	ICD-10-CM
I80.10	Phlebitis and thrombophlebitis of unspecified femoral vein	Diagnosis	ICD-10-CM
I80.11	Phlebitis and thrombophlebitis of right femoral vein	Diagnosis	ICD-10-CM
I80.12	Phlebitis and thrombophlebitis of left femoral vein	Diagnosis	ICD-10-CM
I80.13	Phlebitis and thrombophlebitis of femoral vein, bilateral	Diagnosis	ICD-10-CM
I80.2	Phlebitis and thrombophlebitis of other and unspecified deep vessels of lower extremities	Diagnosis	ICD-10-CM
I80.20	Phlebitis and thrombophlebitis of unspecified deep vessels of lower extremities	Diagnosis	ICD-10-CM
I80.201	Phlebitis and thrombophlebitis of unspecified deep vessels of right lower extremity	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I80.202	Phlebitis and thrombophlebitis of unspecified deep vessels of left lower extremity	Diagnosis	ICD-10-CM
I80.203	Phlebitis and thrombophlebitis of unspecified deep vessels of lower extremities, bilateral	Diagnosis	ICD-10-CM
I80.209	Phlebitis and thrombophlebitis of unspecified deep vessels of unspecified lower extremity	Diagnosis	ICD-10-CM
I80.21	Phlebitis and thrombophlebitis of iliac vein	Diagnosis	ICD-10-CM
I80.211	Phlebitis and thrombophlebitis of right iliac vein	Diagnosis	ICD-10-CM
I80.212	Phlebitis and thrombophlebitis of left iliac vein	Diagnosis	ICD-10-CM
I80.213	Phlebitis and thrombophlebitis of iliac vein, bilateral	Diagnosis	ICD-10-CM
I80.219	Phlebitis and thrombophlebitis of unspecified iliac vein	Diagnosis	ICD-10-CM
I80.22	Phlebitis and thrombophlebitis of popliteal vein	Diagnosis	ICD-10-CM
I80.221	Phlebitis and thrombophlebitis of right popliteal vein	Diagnosis	ICD-10-CM
I80.222	Phlebitis and thrombophlebitis of left popliteal vein	Diagnosis	ICD-10-CM
I80.223	Phlebitis and thrombophlebitis of popliteal vein, bilateral	Diagnosis	ICD-10-CM
I80.229	Phlebitis and thrombophlebitis of unspecified popliteal vein	Diagnosis	ICD-10-CM
I80.23	Phlebitis and thrombophlebitis of tibial vein	Diagnosis	ICD-10-CM
I80.231	Phlebitis and thrombophlebitis of right tibial vein	Diagnosis	ICD-10-CM
I80.232	Phlebitis and thrombophlebitis of left tibial vein	Diagnosis	ICD-10-CM
I80.233	Phlebitis and thrombophlebitis of tibial vein, bilateral	Diagnosis	ICD-10-CM
I80.239	Phlebitis and thrombophlebitis of unspecified tibial vein	Diagnosis	ICD-10-CM
I80.24	Phlebitis and thrombophlebitis of peroneal vein	Diagnosis	ICD-10-CM
I80.241	Phlebitis and thrombophlebitis of right peroneal vein	Diagnosis	ICD-10-CM
I80.242	Phlebitis and thrombophlebitis of left peroneal vein	Diagnosis	ICD-10-CM
I80.243	Phlebitis and thrombophlebitis of peroneal vein, bilateral	Diagnosis	ICD-10-CM
I80.249	Phlebitis and thrombophlebitis of unspecified peroneal vein	Diagnosis	ICD-10-CM
I80.25	Phlebitis and thrombophlebitis of calf muscular vein	Diagnosis	ICD-10-CM
I80.251	Phlebitis and thrombophlebitis of right calf muscular vein	Diagnosis	ICD-10-CM
I80.252	Phlebitis and thrombophlebitis of left calf muscular vein	Diagnosis	ICD-10-CM
I80.253	Phlebitis and thrombophlebitis of calf muscular vein, bilateral	Diagnosis	ICD-10-CM
I80.259	Phlebitis and thrombophlebitis of unspecified calf muscular vein	Diagnosis	ICD-10-CM
I80.29	Phlebitis and thrombophlebitis of other deep vessels of lower extremities	Diagnosis	ICD-10-CM
I80.291	Phlebitis and thrombophlebitis of other deep vessels of right lower extremity	Diagnosis	ICD-10-CM
I80.292	Phlebitis and thrombophlebitis of other deep vessels of left lower extremity	Diagnosis	ICD-10-CM
I80.293	Phlebitis and thrombophlebitis of other deep vessels of lower extremity, bilateral	Diagnosis	ICD-10-CM
I80.299	Phlebitis and thrombophlebitis of other deep vessels of unspecified lower extremity	Diagnosis	ICD-10-CM
I80.3	Phlebitis and thrombophlebitis of lower extremities, unspecified	Diagnosis	ICD-10-CM
I80.8	Phlebitis and thrombophlebitis of other sites	Diagnosis	ICD-10-CM
I80.9	Phlebitis and thrombophlebitis of unspecified site	Diagnosis	ICD-10-CM
I81	Portal vein thrombosis	Diagnosis	ICD-10-CM
I82	Other venous embolism and thrombosis	Diagnosis	ICD-10-CM
I82.0	Budd-Chiari syndrome	Diagnosis	ICD-10-CM
I82.1	Thrombophlebitis migrans	Diagnosis	ICD-10-CM
I82.2	Embolism and thrombosis of vena cava and other thoracic veins	Diagnosis	ICD-10-CM
I82.21	Embolism and thrombosis of superior vena cava	Diagnosis	ICD-10-CM
I82.210	Acute embolism and thrombosis of superior vena cava	Diagnosis	ICD-10-CM
I82.211	Chronic embolism and thrombosis of superior vena cava	Diagnosis	ICD-10-CM
I82.22	Embolism and thrombosis of inferior vena cava	Diagnosis	ICD-10-CM
I82.220	Acute embolism and thrombosis of inferior vena cava	Diagnosis	ICD-10-CM
I82.221	Chronic embolism and thrombosis of inferior vena cava	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I82.29	Embolism and thrombosis of other thoracic veins	Diagnosis	ICD-10-CM
I82.290	Acute embolism and thrombosis of other thoracic veins	Diagnosis	ICD-10-CM
I82.291	Chronic embolism and thrombosis of other thoracic veins	Diagnosis	ICD-10-CM
I82.3	Embolism and thrombosis of renal vein	Diagnosis	ICD-10-CM
I82.4	Acute embolism and thrombosis of deep veins of lower extremity	Diagnosis	ICD-10-CM
I82.40	Acute embolism and thrombosis of unspecified deep veins of lower extremity	Diagnosis	ICD-10-CM
I82.401	Acute embolism and thrombosis of unspecified deep veins of right lower extremity	Diagnosis	ICD-10-CM
I82.402	Acute embolism and thrombosis of unspecified deep veins of left lower extremity	Diagnosis	ICD-10-CM
I82.403	Acute embolism and thrombosis of unspecified deep veins of lower extremity, bilateral	Diagnosis	ICD-10-CM
I82.409	Acute embolism and thrombosis of unspecified deep veins of unspecified lower extremity	Diagnosis	ICD-10-CM
I82.41	Acute embolism and thrombosis of femoral vein	Diagnosis	ICD-10-CM
I82.411	Acute embolism and thrombosis of right femoral vein	Diagnosis	ICD-10-CM
I82.412	Acute embolism and thrombosis of left femoral vein	Diagnosis	ICD-10-CM
I82.413	Acute embolism and thrombosis of femoral vein, bilateral	Diagnosis	ICD-10-CM
I82.419	Acute embolism and thrombosis of unspecified femoral vein	Diagnosis	ICD-10-CM
I82.42	Acute embolism and thrombosis of iliac vein	Diagnosis	ICD-10-CM
I82.421	Acute embolism and thrombosis of right iliac vein	Diagnosis	ICD-10-CM
I82.422	Acute embolism and thrombosis of left iliac vein	Diagnosis	ICD-10-CM
I82.423	Acute embolism and thrombosis of iliac vein, bilateral	Diagnosis	ICD-10-CM
I82.429	Acute embolism and thrombosis of unspecified iliac vein	Diagnosis	ICD-10-CM
I82.43	Acute embolism and thrombosis of popliteal vein	Diagnosis	ICD-10-CM
I82.431	Acute embolism and thrombosis of right popliteal vein	Diagnosis	ICD-10-CM
I82.432	Acute embolism and thrombosis of left popliteal vein	Diagnosis	ICD-10-CM
I82.433	Acute embolism and thrombosis of popliteal vein, bilateral	Diagnosis	ICD-10-CM
I82.439	Acute embolism and thrombosis of unspecified popliteal vein	Diagnosis	ICD-10-CM
I82.44	Acute embolism and thrombosis of tibial vein	Diagnosis	ICD-10-CM
I82.441	Acute embolism and thrombosis of right tibial vein	Diagnosis	ICD-10-CM
I82.442	Acute embolism and thrombosis of left tibial vein	Diagnosis	ICD-10-CM
I82.443	Acute embolism and thrombosis of tibial vein, bilateral	Diagnosis	ICD-10-CM
I82.449	Acute embolism and thrombosis of unspecified tibial vein	Diagnosis	ICD-10-CM
I82.45	Acute embolism and thrombosis of peroneal vein	Diagnosis	ICD-10-CM
I82.451	Acute embolism and thrombosis of right peroneal vein	Diagnosis	ICD-10-CM
I82.452	Acute embolism and thrombosis of left peroneal vein	Diagnosis	ICD-10-CM
I82.453	Acute embolism and thrombosis of peroneal vein, bilateral	Diagnosis	ICD-10-CM
I82.459	Acute embolism and thrombosis of unspecified peroneal vein	Diagnosis	ICD-10-CM
I82.46	Acute embolism and thrombosis of calf muscular vein	Diagnosis	ICD-10-CM
I82.461	Acute embolism and thrombosis of right calf muscular vein	Diagnosis	ICD-10-CM
I82.462	Acute embolism and thrombosis of left calf muscular vein	Diagnosis	ICD-10-CM
I82.463	Acute embolism and thrombosis of calf muscular vein, bilateral	Diagnosis	ICD-10-CM
I82.469	Acute embolism and thrombosis of unspecified calf muscular vein	Diagnosis	ICD-10-CM
I82.49	Acute embolism and thrombosis of other specified deep vein of lower extremity	Diagnosis	ICD-10-CM
I82.491	Acute embolism and thrombosis of other specified deep vein of right lower extremity	Diagnosis	ICD-10-CM
I82.492	Acute embolism and thrombosis of other specified deep vein of left lower extremity	Diagnosis	ICD-10-CM
I82.493	Acute embolism and thrombosis of other specified deep vein of lower extremity, bilateral	Diagnosis	ICD-10-CM
I82.499	Acute embolism and thrombosis of other specified deep vein of unspecified lower extremity	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I82.4Y	Acute embolism and thrombosis of unspecified deep veins of proximal lower extremity	Diagnosis	ICD-10-CM
I82.4Y1	Acute embolism and thrombosis of unspecified deep veins of right proximal lower extremity	Diagnosis	ICD-10-CM
I82.4Y2	Acute embolism and thrombosis of unspecified deep veins of left proximal lower extremity	Diagnosis	ICD-10-CM
I82.4Y3	Acute embolism and thrombosis of unspecified deep veins of proximal lower extremity, bilateral	Diagnosis	ICD-10-CM
I82.4Y9	Acute embolism and thrombosis of unspecified deep veins of unspecified proximal lower extremity	Diagnosis	ICD-10-CM
I82.4Z	Acute embolism and thrombosis of unspecified deep veins of distal lower extremity	Diagnosis	ICD-10-CM
I82.4Z1	Acute embolism and thrombosis of unspecified deep veins of right distal lower extremity	Diagnosis	ICD-10-CM
I82.4Z2	Acute embolism and thrombosis of unspecified deep veins of left distal lower extremity	Diagnosis	ICD-10-CM
I82.4Z3	Acute embolism and thrombosis of unspecified deep veins of distal lower extremity, bilateral	Diagnosis	ICD-10-CM
I82.4Z9	Acute embolism and thrombosis of unspecified deep veins of unspecified distal lower extremity	Diagnosis	ICD-10-CM
I82.5	Chronic embolism and thrombosis of deep veins of lower extremity	Diagnosis	ICD-10-CM
I82.50	Chronic embolism and thrombosis of unspecified deep veins of lower extremity	Diagnosis	ICD-10-CM
I82.501	Chronic embolism and thrombosis of unspecified deep veins of right lower extremity	Diagnosis	ICD-10-CM
I82.502	Chronic embolism and thrombosis of unspecified deep veins of left lower extremity	Diagnosis	ICD-10-CM
I82.503	Chronic embolism and thrombosis of unspecified deep veins of lower extremity, bilateral	Diagnosis	ICD-10-CM
I82.509	Chronic embolism and thrombosis of unspecified deep veins of unspecified lower extremity	Diagnosis	ICD-10-CM
I82.51	Chronic embolism and thrombosis of femoral vein	Diagnosis	ICD-10-CM
I82.511	Chronic embolism and thrombosis of right femoral vein	Diagnosis	ICD-10-CM
I82.512	Chronic embolism and thrombosis of left femoral vein	Diagnosis	ICD-10-CM
I82.513	Chronic embolism and thrombosis of femoral vein, bilateral	Diagnosis	ICD-10-CM
I82.519	Chronic embolism and thrombosis of unspecified femoral vein	Diagnosis	ICD-10-CM
I82.52	Chronic embolism and thrombosis of iliac vein	Diagnosis	ICD-10-CM
I82.521	Chronic embolism and thrombosis of right iliac vein	Diagnosis	ICD-10-CM
I82.522	Chronic embolism and thrombosis of left iliac vein	Diagnosis	ICD-10-CM
I82.523	Chronic embolism and thrombosis of iliac vein, bilateral	Diagnosis	ICD-10-CM
I82.529	Chronic embolism and thrombosis of unspecified iliac vein	Diagnosis	ICD-10-CM
I82.53	Chronic embolism and thrombosis of popliteal vein	Diagnosis	ICD-10-CM
I82.531	Chronic embolism and thrombosis of right popliteal vein	Diagnosis	ICD-10-CM
I82.532	Chronic embolism and thrombosis of left popliteal vein	Diagnosis	ICD-10-CM
I82.533	Chronic embolism and thrombosis of popliteal vein, bilateral	Diagnosis	ICD-10-CM
I82.539	Chronic embolism and thrombosis of unspecified popliteal vein	Diagnosis	ICD-10-CM
I82.54	Chronic embolism and thrombosis of tibial vein	Diagnosis	ICD-10-CM
I82.541	Chronic embolism and thrombosis of right tibial vein	Diagnosis	ICD-10-CM
I82.542	Chronic embolism and thrombosis of left tibial vein	Diagnosis	ICD-10-CM
I82.543	Chronic embolism and thrombosis of tibial vein, bilateral	Diagnosis	ICD-10-CM
I82.549	Chronic embolism and thrombosis of unspecified tibial vein	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I82.55	Chronic embolism and thrombosis of peroneal vein	Diagnosis	ICD-10-CM
I82.551	Chronic embolism and thrombosis of right peroneal vein	Diagnosis	ICD-10-CM
I82.552	Chronic embolism and thrombosis of left peroneal vein	Diagnosis	ICD-10-CM
I82.553	Chronic embolism and thrombosis of peroneal vein, bilateral	Diagnosis	ICD-10-CM
I82.559	Chronic embolism and thrombosis of unspecified peroneal vein	Diagnosis	ICD-10-CM
I82.56	Chronic embolism and thrombosis of calf muscular vein	Diagnosis	ICD-10-CM
I82.561	Chronic embolism and thrombosis of right calf muscular vein	Diagnosis	ICD-10-CM
I82.562	Chronic embolism and thrombosis of left calf muscular vein	Diagnosis	ICD-10-CM
I82.563	Chronic embolism and thrombosis of calf muscular vein, bilateral	Diagnosis	ICD-10-CM
I82.569	Chronic embolism and thrombosis of unspecified calf muscular vein	Diagnosis	ICD-10-CM
I82.59	Chronic embolism and thrombosis of other specified deep vein of lower extremity	Diagnosis	ICD-10-CM
I82.591	Chronic embolism and thrombosis of other specified deep vein of right lower extremity	Diagnosis	ICD-10-CM
I82.592	Chronic embolism and thrombosis of other specified deep vein of left lower extremity	Diagnosis	ICD-10-CM
I82.593	Chronic embolism and thrombosis of other specified deep vein of lower extremity, bilateral	Diagnosis	ICD-10-CM
I82.599	Chronic embolism and thrombosis of other specified deep vein of unspecified lower extremity	Diagnosis	ICD-10-CM
I82.5Y	Chronic embolism and thrombosis of unspecified deep veins of proximal lower extremity	Diagnosis	ICD-10-CM
I82.5Y1	Chronic embolism and thrombosis of unspecified deep veins of right proximal lower extremity	Diagnosis	ICD-10-CM
I82.5Y2	Chronic embolism and thrombosis of unspecified deep veins of left proximal lower extremity	Diagnosis	ICD-10-CM
I82.5Y3	Chronic embolism and thrombosis of unspecified deep veins of proximal lower extremity, bilateral	Diagnosis	ICD-10-CM
I82.5Y9	Chronic embolism and thrombosis of unspecified deep veins of unspecified proximal lower extremity	Diagnosis	ICD-10-CM
I82.5Z	Chronic embolism and thrombosis of unspecified deep veins of distal lower extremity	Diagnosis	ICD-10-CM
I82.5Z1	Chronic embolism and thrombosis of unspecified deep veins of right distal lower extremity	Diagnosis	ICD-10-CM
I82.5Z2	Chronic embolism and thrombosis of unspecified deep veins of left distal lower extremity	Diagnosis	ICD-10-CM
I82.5Z3	Chronic embolism and thrombosis of unspecified deep veins of distal lower extremity, bilateral	Diagnosis	ICD-10-CM
I82.5Z9	Chronic embolism and thrombosis of unspecified deep veins of unspecified distal lower extremity	Diagnosis	ICD-10-CM
I82.6	Acute embolism and thrombosis of veins of upper extremity	Diagnosis	ICD-10-CM
I82.60	Acute embolism and thrombosis of unspecified veins of upper extremity	Diagnosis	ICD-10-CM
I82.601	Acute embolism and thrombosis of unspecified veins of right upper extremity	Diagnosis	ICD-10-CM
I82.602	Acute embolism and thrombosis of unspecified veins of left upper extremity	Diagnosis	ICD-10-CM
I82.603	Acute embolism and thrombosis of unspecified veins of upper extremity, bilateral	Diagnosis	ICD-10-CM
I82.609	Acute embolism and thrombosis of unspecified veins of unspecified upper extremity	Diagnosis	ICD-10-CM
I82.61	Acute embolism and thrombosis of superficial veins of upper extremity	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I82.611	Acute embolism and thrombosis of superficial veins of right upper extremity	Diagnosis	ICD-10-CM
I82.612	Acute embolism and thrombosis of superficial veins of left upper extremity	Diagnosis	ICD-10-CM
I82.613	Acute embolism and thrombosis of superficial veins of upper extremity, bilateral	Diagnosis	ICD-10-CM
I82.619	Acute embolism and thrombosis of superficial veins of unspecified upper extremity	Diagnosis	ICD-10-CM
I82.62	Acute embolism and thrombosis of deep veins of upper extremity	Diagnosis	ICD-10-CM
I82.621	Acute embolism and thrombosis of deep veins of right upper extremity	Diagnosis	ICD-10-CM
I82.622	Acute embolism and thrombosis of deep veins of left upper extremity	Diagnosis	ICD-10-CM
I82.623	Acute embolism and thrombosis of deep veins of upper extremity, bilateral	Diagnosis	ICD-10-CM
I82.629	Acute embolism and thrombosis of deep veins of unspecified upper extremity	Diagnosis	ICD-10-CM
I82.7	Chronic embolism and thrombosis of veins of upper extremity	Diagnosis	ICD-10-CM
I82.70	Chronic embolism and thrombosis of unspecified veins of upper extremity	Diagnosis	ICD-10-CM
I82.701	Chronic embolism and thrombosis of unspecified veins of right upper extremity	Diagnosis	ICD-10-CM
I82.702	Chronic embolism and thrombosis of unspecified veins of left upper extremity	Diagnosis	ICD-10-CM
I82.703	Chronic embolism and thrombosis of unspecified veins of upper extremity, bilateral	Diagnosis	ICD-10-CM
I82.709	Chronic embolism and thrombosis of unspecified veins of unspecified upper extremity	Diagnosis	ICD-10-CM
I82.71	Chronic embolism and thrombosis of superficial veins of upper extremity	Diagnosis	ICD-10-CM
I82.711	Chronic embolism and thrombosis of superficial veins of right upper extremity	Diagnosis	ICD-10-CM
I82.712	Chronic embolism and thrombosis of superficial veins of left upper extremity	Diagnosis	ICD-10-CM
I82.713	Chronic embolism and thrombosis of superficial veins of upper extremity, bilateral	Diagnosis	ICD-10-CM
I82.719	Chronic embolism and thrombosis of superficial veins of unspecified upper extremity	Diagnosis	ICD-10-CM
I82.72	Chronic embolism and thrombosis of deep veins of upper extremity	Diagnosis	ICD-10-CM
I82.721	Chronic embolism and thrombosis of deep veins of right upper extremity	Diagnosis	ICD-10-CM
I82.722	Chronic embolism and thrombosis of deep veins of left upper extremity	Diagnosis	ICD-10-CM
I82.723	Chronic embolism and thrombosis of deep veins of upper extremity, bilateral	Diagnosis	ICD-10-CM
I82.729	Chronic embolism and thrombosis of deep veins of unspecified upper extremity	Diagnosis	ICD-10-CM
I82.8	Embolism and thrombosis of other specified veins	Diagnosis	ICD-10-CM
I82.81	Embolism and thrombosis of superficial veins of lower extremities	Diagnosis	ICD-10-CM
I82.811	Embolism and thrombosis of superficial veins of right lower extremity	Diagnosis	ICD-10-CM
I82.812	Embolism and thrombosis of superficial veins of left lower extremity	Diagnosis	ICD-10-CM
I82.813	Embolism and thrombosis of superficial veins of lower extremities, bilateral	Diagnosis	ICD-10-CM
I82.819	Embolism and thrombosis of superficial veins of unspecified lower extremity	Diagnosis	ICD-10-CM
I82.89	Embolism and thrombosis of other specified veins	Diagnosis	ICD-10-CM
I82.890	Acute embolism and thrombosis of other specified veins	Diagnosis	ICD-10-CM
I82.891	Chronic embolism and thrombosis of other specified veins	Diagnosis	ICD-10-CM
I82.9	Embolism and thrombosis of unspecified vein	Diagnosis	ICD-10-CM
I82.90	Acute embolism and thrombosis of unspecified vein	Diagnosis	ICD-10-CM
I82.91	Chronic embolism and thrombosis of unspecified vein	Diagnosis	ICD-10-CM
I82.A	Embolism and thrombosis of axillary vein	Diagnosis	ICD-10-CM
I82.A1	Acute embolism and thrombosis of axillary vein	Diagnosis	ICD-10-CM
I82.A11	Acute embolism and thrombosis of right axillary vein	Diagnosis	ICD-10-CM
I82.A12	Acute embolism and thrombosis of left axillary vein	Diagnosis	ICD-10-CM
I82.A13	Acute embolism and thrombosis of axillary vein, bilateral	Diagnosis	ICD-10-CM
I82.A19	Acute embolism and thrombosis of unspecified axillary vein	Diagnosis	ICD-10-CM
I82.A2	Chronic embolism and thrombosis of axillary vein	Diagnosis	ICD-10-CM
I82.A21	Chronic embolism and thrombosis of right axillary vein	Diagnosis	ICD-10-CM
I82.A22	Chronic embolism and thrombosis of left axillary vein	Diagnosis	ICD-10-CM
I82.A23	Chronic embolism and thrombosis of axillary vein, bilateral	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I82.A29	Chronic embolism and thrombosis of unspecified axillary vein	Diagnosis	ICD-10-CM
I82.B	Embolism and thrombosis of subclavian vein	Diagnosis	ICD-10-CM
I82.B1	Acute embolism and thrombosis of subclavian vein	Diagnosis	ICD-10-CM
I82.B11	Acute embolism and thrombosis of right subclavian vein	Diagnosis	ICD-10-CM
I82.B12	Acute embolism and thrombosis of left subclavian vein	Diagnosis	ICD-10-CM
I82.B13	Acute embolism and thrombosis of subclavian vein, bilateral	Diagnosis	ICD-10-CM
I82.B19	Acute embolism and thrombosis of unspecified subclavian vein	Diagnosis	ICD-10-CM
I82.B2	Chronic embolism and thrombosis of subclavian vein	Diagnosis	ICD-10-CM
I82.B21	Chronic embolism and thrombosis of right subclavian vein	Diagnosis	ICD-10-CM
I82.B22	Chronic embolism and thrombosis of left subclavian vein	Diagnosis	ICD-10-CM
I82.B23	Chronic embolism and thrombosis of subclavian vein, bilateral	Diagnosis	ICD-10-CM
I82.B29	Chronic embolism and thrombosis of unspecified subclavian vein	Diagnosis	ICD-10-CM
I82.C	Embolism and thrombosis of internal jugular vein	Diagnosis	ICD-10-CM
I82.C1	Acute embolism and thrombosis of internal jugular vein	Diagnosis	ICD-10-CM
I82.C11	Acute embolism and thrombosis of right internal jugular vein	Diagnosis	ICD-10-CM
I82.C12	Acute embolism and thrombosis of left internal jugular vein	Diagnosis	ICD-10-CM
I82.C13	Acute embolism and thrombosis of internal jugular vein, bilateral	Diagnosis	ICD-10-CM
I82.C19	Acute embolism and thrombosis of unspecified internal jugular vein	Diagnosis	ICD-10-CM
I82.C2	Chronic embolism and thrombosis of internal jugular vein	Diagnosis	ICD-10-CM
I82.C21	Chronic embolism and thrombosis of right internal jugular vein	Diagnosis	ICD-10-CM
I82.C22	Chronic embolism and thrombosis of left internal jugular vein	Diagnosis	ICD-10-CM
I82.C23	Chronic embolism and thrombosis of internal jugular vein, bilateral	Diagnosis	ICD-10-CM
I82.C29	Chronic embolism and thrombosis of unspecified internal jugular vein	Diagnosis	ICD-10-CM
I83	Varicose veins of lower extremities	Diagnosis	ICD-10-CM
I83.0	Varicose veins of lower extremities with ulcer	Diagnosis	ICD-10-CM
I83.00	Varicose veins of unspecified lower extremity with ulcer	Diagnosis	ICD-10-CM
I83.001	Varicose veins of unspecified lower extremity with ulcer of thigh	Diagnosis	ICD-10-CM
I83.002	Varicose veins of unspecified lower extremity with ulcer of calf	Diagnosis	ICD-10-CM
I83.003	Varicose veins of unspecified lower extremity with ulcer of ankle	Diagnosis	ICD-10-CM
I83.004	Varicose veins of unspecified lower extremity with ulcer of heel and midfoot	Diagnosis	ICD-10-CM
I83.005	Varicose veins of unspecified lower extremity with ulcer other part of foot	Diagnosis	ICD-10-CM
I83.008	Varicose veins of unspecified lower extremity with ulcer other part of lower leg	Diagnosis	ICD-10-CM
I83.009	Varicose veins of unspecified lower extremity with ulcer of unspecified site	Diagnosis	ICD-10-CM
I83.01	Varicose veins of right lower extremity with ulcer	Diagnosis	ICD-10-CM
I83.011	Varicose veins of right lower extremity with ulcer of thigh	Diagnosis	ICD-10-CM
I83.012	Varicose veins of right lower extremity with ulcer of calf	Diagnosis	ICD-10-CM
I83.013	Varicose veins of right lower extremity with ulcer of ankle	Diagnosis	ICD-10-CM
I83.014	Varicose veins of right lower extremity with ulcer of heel and midfoot	Diagnosis	ICD-10-CM
I83.015	Varicose veins of right lower extremity with ulcer other part of foot	Diagnosis	ICD-10-CM
I83.018	Varicose veins of right lower extremity with ulcer other part of lower leg	Diagnosis	ICD-10-CM
I83.019	Varicose veins of right lower extremity with ulcer of unspecified site	Diagnosis	ICD-10-CM
I83.02	Varicose veins of left lower extremity with ulcer	Diagnosis	ICD-10-CM
I83.021	Varicose veins of left lower extremity with ulcer of thigh	Diagnosis	ICD-10-CM
I83.022	Varicose veins of left lower extremity with ulcer of calf	Diagnosis	ICD-10-CM
I83.023	Varicose veins of left lower extremity with ulcer of ankle	Diagnosis	ICD-10-CM
I83.024	Varicose veins of left lower extremity with ulcer of heel and midfoot	Diagnosis	ICD-10-CM
I83.025	Varicose veins of left lower extremity with ulcer other part of foot	Diagnosis	ICD-10-CM
I83.028	Varicose veins of left lower extremity with ulcer other part of lower leg	Diagnosis	ICD-10-CM
I83.029	Varicose veins of left lower extremity with ulcer of unspecified site	Diagnosis	ICD-10-CM
I83.1	Varicose veins of lower extremities with inflammation	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I83.10	Varicose veins of unspecified lower extremity with inflammation	Diagnosis	ICD-10-CM
I83.11	Varicose veins of right lower extremity with inflammation	Diagnosis	ICD-10-CM
I83.12	Varicose veins of left lower extremity with inflammation	Diagnosis	ICD-10-CM
I83.2	Varicose veins of lower extremities with both ulcer and inflammation	Diagnosis	ICD-10-CM
I83.20	Varicose veins of unspecified lower extremity with both ulcer and inflammation	Diagnosis	ICD-10-CM
I83.201	Varicose veins of unspecified lower extremity with both ulcer of thigh and inflammation	Diagnosis	ICD-10-CM
I83.202	Varicose veins of unspecified lower extremity with both ulcer of calf and inflammation	Diagnosis	ICD-10-CM
I83.203	Varicose veins of unspecified lower extremity with both ulcer of ankle and inflammation	Diagnosis	ICD-10-CM
I83.204	Varicose veins of unspecified lower extremity with both ulcer of heel and midfoot and inflammation	Diagnosis	ICD-10-CM
I83.205	Varicose veins of unspecified lower extremity with both ulcer other part of foot and inflammation	Diagnosis	ICD-10-CM
I83.208	Varicose veins of unspecified lower extremity with both ulcer of other part of lower extremity and inflammation	Diagnosis	ICD-10-CM
I83.209	Varicose veins of unspecified lower extremity with both ulcer of unspecified site and inflammation	Diagnosis	ICD-10-CM
I83.21	Varicose veins of right lower extremity with both ulcer and inflammation	Diagnosis	ICD-10-CM
I83.211	Varicose veins of right lower extremity with both ulcer of thigh and inflammation	Diagnosis	ICD-10-CM
I83.212	Varicose veins of right lower extremity with both ulcer of calf and inflammation	Diagnosis	ICD-10-CM
I83.213	Varicose veins of right lower extremity with both ulcer of ankle and inflammation	Diagnosis	ICD-10-CM
I83.214	Varicose veins of right lower extremity with both ulcer of heel and midfoot and inflammation	Diagnosis	ICD-10-CM
I83.215	Varicose veins of right lower extremity with both ulcer other part of foot and inflammation	Diagnosis	ICD-10-CM
I83.218	Varicose veins of right lower extremity with both ulcer of other part of lower extremity and inflammation	Diagnosis	ICD-10-CM
I83.219	Varicose veins of right lower extremity with both ulcer of unspecified site and inflammation	Diagnosis	ICD-10-CM
I83.22	Varicose veins of left lower extremity with both ulcer and inflammation	Diagnosis	ICD-10-CM
I83.221	Varicose veins of left lower extremity with both ulcer of thigh and inflammation	Diagnosis	ICD-10-CM
I83.222	Varicose veins of left lower extremity with both ulcer of calf and inflammation	Diagnosis	ICD-10-CM
I83.223	Varicose veins of left lower extremity with both ulcer of ankle and inflammation	Diagnosis	ICD-10-CM
I83.224	Varicose veins of left lower extremity with both ulcer of heel and midfoot and inflammation	Diagnosis	ICD-10-CM
I83.225	Varicose veins of left lower extremity with both ulcer other part of foot and inflammation	Diagnosis	ICD-10-CM
I83.228	Varicose veins of left lower extremity with both ulcer of other part of lower extremity and inflammation	Diagnosis	ICD-10-CM
I83.229	Varicose veins of left lower extremity with both ulcer of unspecified site and inflammation	Diagnosis	ICD-10-CM
I83.8	Varicose veins of lower extremities with other complications	Diagnosis	ICD-10-CM
I83.81	Varicose veins of lower extremities with pain	Diagnosis	ICD-10-CM
I83.811	Varicose veins of right lower extremity with pain	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I83.812	Varicose veins of left lower extremity with pain	Diagnosis	ICD-10-CM
I83.813	Varicose veins of bilateral lower extremities with pain	Diagnosis	ICD-10-CM
I83.819	Varicose veins of unspecified lower extremity with pain	Diagnosis	ICD-10-CM
I83.89	Varicose veins of lower extremities with other complications	Diagnosis	ICD-10-CM
I83.891	Varicose veins of right lower extremity with other complications	Diagnosis	ICD-10-CM
I83.892	Varicose veins of left lower extremity with other complications	Diagnosis	ICD-10-CM
I83.893	Varicose veins of bilateral lower extremities with other complications	Diagnosis	ICD-10-CM
I83.899	Varicose veins of unspecified lower extremity with other complications	Diagnosis	ICD-10-CM
I83.9	Asymptomatic varicose veins of lower extremities	Diagnosis	ICD-10-CM
I83.90	Asymptomatic varicose veins of unspecified lower extremity	Diagnosis	ICD-10-CM
I83.91	Asymptomatic varicose veins of right lower extremity	Diagnosis	ICD-10-CM
I83.92	Asymptomatic varicose veins of left lower extremity	Diagnosis	ICD-10-CM
I83.93	Asymptomatic varicose veins of bilateral lower extremities	Diagnosis	ICD-10-CM
I85	Esophageal varices	Diagnosis	ICD-10-CM
I85.0	Esophageal varices	Diagnosis	ICD-10-CM
I85.00	Esophageal varices without bleeding	Diagnosis	ICD-10-CM
I85.01	Esophageal varices with bleeding	Diagnosis	ICD-10-CM
I85.1	Secondary esophageal varices	Diagnosis	ICD-10-CM
I85.10	Secondary esophageal varices without bleeding	Diagnosis	ICD-10-CM
I85.11	Secondary esophageal varices with bleeding	Diagnosis	ICD-10-CM
I86	Varicose veins of other sites	Diagnosis	ICD-10-CM
I86.0	Sublingual varices	Diagnosis	ICD-10-CM
I86.1	Scrotal varices	Diagnosis	ICD-10-CM
I86.2	Pelvic varices	Diagnosis	ICD-10-CM
I86.3	Vulval varices	Diagnosis	ICD-10-CM
I86.4	Gastric varices	Diagnosis	ICD-10-CM
I86.8	Varicose veins of other specified sites	Diagnosis	ICD-10-CM
I87	Other disorders of veins	Diagnosis	ICD-10-CM
I87.0	Postthrombotic syndrome	Diagnosis	ICD-10-CM
I87.00	Postthrombotic syndrome without complications	Diagnosis	ICD-10-CM
I87.001	Postthrombotic syndrome without complications of right lower extremity	Diagnosis	ICD-10-CM
I87.002	Postthrombotic syndrome without complications of left lower extremity	Diagnosis	ICD-10-CM
I87.003	Postthrombotic syndrome without complications of bilateral lower extremity	Diagnosis	ICD-10-CM
I87.009	Postthrombotic syndrome without complications of unspecified extremity	Diagnosis	ICD-10-CM
I87.01	Postthrombotic syndrome with ulcer	Diagnosis	ICD-10-CM
I87.011	Postthrombotic syndrome with ulcer of right lower extremity	Diagnosis	ICD-10-CM
I87.012	Postthrombotic syndrome with ulcer of left lower extremity	Diagnosis	ICD-10-CM
I87.013	Postthrombotic syndrome with ulcer of bilateral lower extremity	Diagnosis	ICD-10-CM
I87.019	Postthrombotic syndrome with ulcer of unspecified lower extremity	Diagnosis	ICD-10-CM
I87.02	Postthrombotic syndrome with inflammation	Diagnosis	ICD-10-CM
I87.021	Postthrombotic syndrome with inflammation of right lower extremity	Diagnosis	ICD-10-CM
I87.022	Postthrombotic syndrome with inflammation of left lower extremity	Diagnosis	ICD-10-CM
I87.023	Postthrombotic syndrome with inflammation of bilateral lower extremity	Diagnosis	ICD-10-CM
I87.029	Postthrombotic syndrome with inflammation of unspecified lower extremity	Diagnosis	ICD-10-CM
I87.03	Postthrombotic syndrome with ulcer and inflammation	Diagnosis	ICD-10-CM
I87.031	Postthrombotic syndrome with ulcer and inflammation of right lower extremity	Diagnosis	ICD-10-CM
I87.032	Postthrombotic syndrome with ulcer and inflammation of left lower extremity	Diagnosis	ICD-10-CM
I87.033	Postthrombotic syndrome with ulcer and inflammation of bilateral lower extremity	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I87.039	Postthrombotic syndrome with ulcer and inflammation of unspecified lower extremity	Diagnosis	ICD-10-CM
I87.09	Postthrombotic syndrome with other complications	Diagnosis	ICD-10-CM
I87.091	Postthrombotic syndrome with other complications of right lower extremity	Diagnosis	ICD-10-CM
I87.092	Postthrombotic syndrome with other complications of left lower extremity	Diagnosis	ICD-10-CM
I87.093	Postthrombotic syndrome with other complications of bilateral lower extremity	Diagnosis	ICD-10-CM
I87.099	Postthrombotic syndrome with other complications of unspecified lower extremity	Diagnosis	ICD-10-CM
I87.1	Compression of vein	Diagnosis	ICD-10-CM
I87.2	Venous insufficiency (chronic) (peripheral)	Diagnosis	ICD-10-CM
I87.3	Chronic venous hypertension (idiopathic)	Diagnosis	ICD-10-CM
I87.30	Chronic venous hypertension (idiopathic) without complications	Diagnosis	ICD-10-CM
I87.301	Chronic venous hypertension (idiopathic) without complications of right lower extremity	Diagnosis	ICD-10-CM
I87.302	Chronic venous hypertension (idiopathic) without complications of left lower extremity	Diagnosis	ICD-10-CM
I87.303	Chronic venous hypertension (idiopathic) without complications of bilateral lower extremity	Diagnosis	ICD-10-CM
I87.309	Chronic venous hypertension (idiopathic) without complications of unspecified lower extremity	Diagnosis	ICD-10-CM
I87.31	Chronic venous hypertension (idiopathic) with ulcer	Diagnosis	ICD-10-CM
I87.311	Chronic venous hypertension (idiopathic) with ulcer of right lower extremity	Diagnosis	ICD-10-CM
I87.312	Chronic venous hypertension (idiopathic) with ulcer of left lower extremity	Diagnosis	ICD-10-CM
I87.313	Chronic venous hypertension (idiopathic) with ulcer of bilateral lower extremity	Diagnosis	ICD-10-CM
I87.319	Chronic venous hypertension (idiopathic) with ulcer of unspecified lower extremity	Diagnosis	ICD-10-CM
I87.32	Chronic venous hypertension (idiopathic) with inflammation	Diagnosis	ICD-10-CM
I87.321	Chronic venous hypertension (idiopathic) with inflammation of right lower extremity	Diagnosis	ICD-10-CM
I87.322	Chronic venous hypertension (idiopathic) with inflammation of left lower extremity	Diagnosis	ICD-10-CM
I87.323	Chronic venous hypertension (idiopathic) with inflammation of bilateral lower extremity	Diagnosis	ICD-10-CM
I87.329	Chronic venous hypertension (idiopathic) with inflammation of unspecified lower extremity	Diagnosis	ICD-10-CM
I87.33	Chronic venous hypertension (idiopathic) with ulcer and inflammation	Diagnosis	ICD-10-CM
I87.331	Chronic venous hypertension (idiopathic) with ulcer and inflammation of right lower extremity	Diagnosis	ICD-10-CM
I87.332	Chronic venous hypertension (idiopathic) with ulcer and inflammation of left lower extremity	Diagnosis	ICD-10-CM
I87.333	Chronic venous hypertension (idiopathic) with ulcer and inflammation of bilateral lower extremity	Diagnosis	ICD-10-CM
I87.339	Chronic venous hypertension (idiopathic) with ulcer and inflammation of unspecified lower extremity	Diagnosis	ICD-10-CM
I87.39	Chronic venous hypertension (idiopathic) with other complications	Diagnosis	ICD-10-CM
I87.391	Chronic venous hypertension (idiopathic) with other complications of right lower extremity	Diagnosis	ICD-10-CM
I87.392	Chronic venous hypertension (idiopathic) with other complications of left lower extremity	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I87.393	Chronic venous hypertension (idiopathic) with other complications of bilateral lower extremity	Diagnosis	ICD-10-CM
I87.399	Chronic venous hypertension (idiopathic) with other complications of unspecified lower extremity	Diagnosis	ICD-10-CM
I87.8	Other specified disorders of veins	Diagnosis	ICD-10-CM
I87.9	Disorder of vein, unspecified	Diagnosis	ICD-10-CM
I88	Nonspecific lymphadenitis	Diagnosis	ICD-10-CM
I88.0	Nonspecific mesenteric lymphadenitis	Diagnosis	ICD-10-CM
I88.1	Chronic lymphadenitis, except mesenteric	Diagnosis	ICD-10-CM
I88.8	Other nonspecific lymphadenitis	Diagnosis	ICD-10-CM
I88.9	Nonspecific lymphadenitis, unspecified	Diagnosis	ICD-10-CM
I89	Other noninfective disorders of lymphatic vessels and lymph nodes	Diagnosis	ICD-10-CM
I89.0	Lymphedema, not elsewhere classified	Diagnosis	ICD-10-CM
I89.1	Lymphangitis	Diagnosis	ICD-10-CM
I89.8	Other specified noninfective disorders of lymphatic vessels and lymph nodes	Diagnosis	ICD-10-CM
I89.9	Noninfective disorder of lymphatic vessels and lymph nodes, unspecified	Diagnosis	ICD-10-CM
I95	Hypotension	Diagnosis	ICD-10-CM
I95.0	Idiopathic hypotension	Diagnosis	ICD-10-CM
I95.1	Orthostatic hypotension	Diagnosis	ICD-10-CM
I95.2	Hypotension due to drugs	Diagnosis	ICD-10-CM
I95.3	Hypotension of hemodialysis	Diagnosis	ICD-10-CM
I95.8	Other hypotension	Diagnosis	ICD-10-CM
I95.81	Postprocedural hypotension	Diagnosis	ICD-10-CM
I95.89	Other hypotension	Diagnosis	ICD-10-CM
I95.9	Hypotension, unspecified	Diagnosis	ICD-10-CM
I96	Gangrene, not elsewhere classified	Diagnosis	ICD-10-CM
I97	Intraoperative and postprocedural complications and disorders of circulatory system, not elsewhere classified	Diagnosis	ICD-10-CM
I97.0	Postcardiotomy syndrome	Diagnosis	ICD-10-CM
I97.1	Other postprocedural cardiac functional disturbances	Diagnosis	ICD-10-CM
I97.11	Postprocedural cardiac insufficiency	Diagnosis	ICD-10-CM
I97.110	Postprocedural cardiac insufficiency following cardiac surgery	Diagnosis	ICD-10-CM
I97.111	Postprocedural cardiac insufficiency following other surgery	Diagnosis	ICD-10-CM
I97.12	Postprocedural cardiac arrest	Diagnosis	ICD-10-CM
I97.120	Postprocedural cardiac arrest following cardiac surgery	Diagnosis	ICD-10-CM
I97.121	Postprocedural cardiac arrest following other surgery	Diagnosis	ICD-10-CM
I97.13	Postprocedural heart failure	Diagnosis	ICD-10-CM
I97.130	Postprocedural heart failure following cardiac surgery	Diagnosis	ICD-10-CM
I97.131	Postprocedural heart failure following other surgery	Diagnosis	ICD-10-CM
I97.19	Other postprocedural cardiac functional disturbances	Diagnosis	ICD-10-CM
I97.190	Other postprocedural cardiac functional disturbances following cardiac surgery	Diagnosis	ICD-10-CM
I97.191	Other postprocedural cardiac functional disturbances following other surgery	Diagnosis	ICD-10-CM
I97.2	Postmastectomy lymphedema syndrome	Diagnosis	ICD-10-CM
I97.3	Postprocedural hypertension	Diagnosis	ICD-10-CM
I97.4	Intraoperative hemorrhage and hematoma of a circulatory system organ or structure complicating a procedure	Diagnosis	ICD-10-CM
I97.41	Intraoperative hemorrhage and hematoma of a circulatory system organ or structure complicating a circulatory system procedure	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I97.410	Intraoperative hemorrhage and hematoma of a circulatory system organ or structure complicating a cardiac catheterization	Diagnosis	ICD-10-CM
I97.411	Intraoperative hemorrhage and hematoma of a circulatory system organ or structure complicating a cardiac bypass	Diagnosis	ICD-10-CM
I97.418	Intraoperative hemorrhage and hematoma of a circulatory system organ or structure complicating other circulatory system procedure	Diagnosis	ICD-10-CM
I97.42	Intraoperative hemorrhage and hematoma of a circulatory system organ or structure complicating other procedure	Diagnosis	ICD-10-CM
I97.5	Accidental puncture and laceration of a circulatory system organ or structure during a procedure	Diagnosis	ICD-10-CM
I97.51	Accidental puncture and laceration of a circulatory system organ or structure during a circulatory system procedure	Diagnosis	ICD-10-CM
I97.52	Accidental puncture and laceration of a circulatory system organ or structure during other procedure	Diagnosis	ICD-10-CM
I97.6	Postprocedural hemorrhage, hematoma and seroma of a circulatory system organ or structure following a procedure	Diagnosis	ICD-10-CM
I97.61	Postprocedural hemorrhage of a circulatory system organ or structure following a circulatory system procedure	Diagnosis	ICD-10-CM
I97.610	Postprocedural hemorrhage of a circulatory system organ or structure following a cardiac catheterization	Diagnosis	ICD-10-CM
I97.611	Postprocedural hemorrhage of a circulatory system organ or structure following cardiac bypass	Diagnosis	ICD-10-CM
I97.618	Postprocedural hemorrhage of a circulatory system organ or structure following other circulatory system procedure	Diagnosis	ICD-10-CM
I97.62	Postprocedural hemorrhage, hematoma and seroma of a circulatory system organ or structure following other procedure	Diagnosis	ICD-10-CM
I97.620	Postprocedural hemorrhage of a circulatory system organ or structure following other procedure	Diagnosis	ICD-10-CM
I97.621	Postprocedural hematoma of a circulatory system organ or structure following other procedure	Diagnosis	ICD-10-CM
I97.622	Postprocedural seroma of a circulatory system organ or structure following other procedure	Diagnosis	ICD-10-CM
I97.63	Postprocedural hematoma of a circulatory system organ or structure following a circulatory system procedure	Diagnosis	ICD-10-CM
I97.630	Postprocedural hematoma of a circulatory system organ or structure following a cardiac catheterization	Diagnosis	ICD-10-CM
I97.631	Postprocedural hematoma of a circulatory system organ or structure following cardiac bypass	Diagnosis	ICD-10-CM
I97.638	Postprocedural hematoma of a circulatory system organ or structure following other circulatory system procedure	Diagnosis	ICD-10-CM
I97.64	Postprocedural seroma of a circulatory system organ or structure following a circulatory system procedure	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I97.640	Postprocedural seroma of a circulatory system organ or structure following a cardiac catheterization	Diagnosis	ICD-10-CM
I97.641	Postprocedural seroma of a circulatory system organ or structure following cardiac bypass	Diagnosis	ICD-10-CM
I97.648	Postprocedural seroma of a circulatory system organ or structure following other circulatory system procedure	Diagnosis	ICD-10-CM
I97.7	Intraoperative cardiac functional disturbances	Diagnosis	ICD-10-CM
I97.71	Intraoperative cardiac arrest	Diagnosis	ICD-10-CM
I97.710	Intraoperative cardiac arrest during cardiac surgery	Diagnosis	ICD-10-CM
I97.711	Intraoperative cardiac arrest during other surgery	Diagnosis	ICD-10-CM
I97.79	Other intraoperative cardiac functional disturbances	Diagnosis	ICD-10-CM
I97.790	Other intraoperative cardiac functional disturbances during cardiac surgery	Diagnosis	ICD-10-CM
I97.791	Other intraoperative cardiac functional disturbances during other surgery	Diagnosis	ICD-10-CM
I97.8	Other intraoperative and postprocedural complications and disorders of the circulatory system, not elsewhere classified	Diagnosis	ICD-10-CM
I97.81	Intraoperative cerebrovascular infarction	Diagnosis	ICD-10-CM
I97.810	Intraoperative cerebrovascular infarction during cardiac surgery	Diagnosis	ICD-10-CM
I97.811	Intraoperative cerebrovascular infarction during other surgery	Diagnosis	ICD-10-CM
I97.82	Postprocedural cerebrovascular infarction	Diagnosis	ICD-10-CM
I97.820	Postprocedural cerebrovascular infarction following cardiac surgery	Diagnosis	ICD-10-CM
I97.821	Postprocedural cerebrovascular infarction following other surgery	Diagnosis	ICD-10-CM
I97.88	Other intraoperative complications of the circulatory system, not elsewhere classified	Diagnosis	ICD-10-CM
I97.89	Other postprocedural complications and disorders of the circulatory system, not elsewhere classified	Diagnosis	ICD-10-CM
I99	Other and unspecified disorders of circulatory system	Diagnosis	ICD-10-CM
I99.8	Other disorder of circulatory system	Diagnosis	ICD-10-CM
I99.9	Unspecified disorder of circulatory system	Diagnosis	ICD-10-CM
Obstructive Sleep Apnea			
G47.3	Sleep apnea	Diagnosis	ICD-10-CM
G47.30	Sleep apnea, unspecified	Diagnosis	ICD-10-CM
G47.31	Primary central sleep apnea	Diagnosis	ICD-10-CM
G47.33	Obstructive sleep apnea (adult) (pediatric)	Diagnosis	ICD-10-CM
G47.37	Central sleep apnea in conditions classified elsewhere	Diagnosis	ICD-10-CM
G47.39	Other sleep apnea	Diagnosis	ICD-10-CM
R06.81	Apnea, not elsewhere classified	Diagnosis	ICD-10-CM
Hypertrophic Cardiomyopathy			
I42.1	Obstructive hypertrophic cardiomyopathy	Diagnosis	ICD-10-CM
I42.2	Other hypertrophic cardiomyopathy	Diagnosis	ICD-10-CM
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
I42.7	Cardiomyopathy due to drug and external agent	Diagnosis	ICD-10-CM
I42.8	Other cardiomyopathies	Diagnosis	ICD-10-CM
I42.9	Cardiomyopathy, unspecified	Diagnosis	ICD-10-CM
I43	Cardiomyopathy in diseases classified elsewhere	Diagnosis	ICD-10-CM
O90.3	Peripartum cardiomyopathy	Diagnosis	ICD-10-CM
I42	Cardiomyopathy	Diagnosis	ICD-10-CM
I42.0	Dilated cardiomyopathy	Diagnosis	ICD-10-CM
A36.81	Diphtheritic cardiomyopathy	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I25.5	Ischemic cardiomyopathy	Diagnosis	ICD-10-CM
I42.5	Other restrictive cardiomyopathy	Diagnosis	ICD-10-CM
B33.24	Viral cardiomyopathy	Diagnosis	ICD-10-CM
I42.3	Endomyocardial (eosinophilic) disease	Diagnosis	ICD-10-CM
I42.4	Endocardial fibroelastosis	Diagnosis	ICD-10-CM
Tachyarrhythmia			
I46	Cardiac arrest	Diagnosis	ICD-10-CM
I46.2	Cardiac arrest due to underlying cardiac condition	Diagnosis	ICD-10-CM
I46.8	Cardiac arrest due to other underlying condition	Diagnosis	ICD-10-CM
I46.9	Cardiac arrest, cause unspecified	Diagnosis	ICD-10-CM
I47	Paroxysmal tachycardia	Diagnosis	ICD-10-CM
I47.0	Re-entry ventricular arrhythmia	Diagnosis	ICD-10-CM
I47.1	Supraventricular tachycardia	Diagnosis	ICD-10-CM
I47.2	Ventricular tachycardia	Diagnosis	ICD-10-CM
I47.9	Paroxysmal tachycardia, unspecified	Diagnosis	ICD-10-CM
I48	Atrial fibrillation and flutter	Diagnosis	ICD-10-CM
I48.0	Paroxysmal atrial fibrillation	Diagnosis	ICD-10-CM
I48.1	Persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.11	Longstanding persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.19	Other persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.2	Chronic atrial fibrillation	Diagnosis	ICD-10-CM
I48.20	Chronic atrial fibrillation, unspecified	Diagnosis	ICD-10-CM
I48.21	Permanent atrial fibrillation	Diagnosis	ICD-10-CM
I48.3	Typical atrial flutter	Diagnosis	ICD-10-CM
I48.4	Atypical atrial flutter	Diagnosis	ICD-10-CM
I48.9	Unspecified atrial fibrillation and atrial flutter	Diagnosis	ICD-10-CM
I48.91	Unspecified atrial fibrillation	Diagnosis	ICD-10-CM
I48.92	Unspecified atrial flutter	Diagnosis	ICD-10-CM
I49	Other cardiac arrhythmias	Diagnosis	ICD-10-CM
I49.0	Ventricular fibrillation and flutter	Diagnosis	ICD-10-CM
I49.01	Ventricular fibrillation	Diagnosis	ICD-10-CM
I49.02	Ventricular flutter	Diagnosis	ICD-10-CM
I49.1	Atrial premature depolarization	Diagnosis	ICD-10-CM
I49.2	Junctional premature depolarization	Diagnosis	ICD-10-CM
I49.3	Ventricular premature depolarization	Diagnosis	ICD-10-CM
I49.4	Other and unspecified premature depolarization	Diagnosis	ICD-10-CM
I49.40	Unspecified premature depolarization	Diagnosis	ICD-10-CM
I49.49	Other premature depolarization	Diagnosis	ICD-10-CM
I49.8	Other specified cardiac arrhythmias	Diagnosis	ICD-10-CM
I49.9	Cardiac arrhythmia, unspecified	Diagnosis	ICD-10-CM
R00.0	Tachycardia, unspecified	Diagnosis	ICD-10-CM
History of Serious Hypoglycemia			
E08.64	Diabetes mellitus due to underlying condition with hypoglycemia	Diagnosis	ICD-10-CM
E08.641	Diabetes mellitus due to underlying condition with hypoglycemia with coma	Diagnosis	ICD-10-CM
E08.649	Diabetes mellitus due to underlying condition with hypoglycemia without coma	Diagnosis	ICD-10-CM
E09.64	Drug or chemical induced diabetes mellitus with hypoglycemia	Diagnosis	ICD-10-CM
E09.641	Drug or chemical induced diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E09.649	Drug or chemical induced diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E11.64	Type 2 diabetes mellitus with hypoglycemia	Diagnosis	ICD-10-CM
E11.641	Type 2 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM

Appendix F. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), Level II, and Current Procedural Terminology, Fourth Edition (CPT-4), Category I and Category III Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
E11.649	Type 2 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E13.64	Other specified diabetes mellitus with hypoglycemia	Diagnosis	ICD-10-CM
E13.641	Other specified diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E13.649	Other specified diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E16.0	Drug-induced hypoglycemia without coma	Diagnosis	ICD-10-CM
E16.1	Other hypoglycemia	Diagnosis	ICD-10-CM
E16.2	Hypoglycemia, unspecified	Diagnosis	ICD-10-CM
P70.3	Iatrogenic neonatal hypoglycemia	Diagnosis	ICD-10-CM
P70.4	Other neonatal hypoglycemia	Diagnosis	ICD-10-CM

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
Alpha-Glucosidase Inhibitor	
acarbose	acarbose
acarbose	Precose
miglitol	miglitol
Amylin Analogs	
pramlintide acetate	SymlinPen 60
pramlintide acetate	SymlinPen 120
Dipeptidyl Peptidase 4 (DPP-4) Inhibitors	
alogliptin benzoate	alogliptin
alogliptin benzoate	Nesina
dapagliflozin propanediol/saxagliptin HCl	Qtern
empagliflozin/linagliptin	Glyxambi
ertugliflozin pidolate/sitagliptin phosphate	Steglujan
linagliptin	Tradjenta
saxagliptin HCl	Onglyza
sitagliptin phosphate	Januvia
Incretin Mimetics	
dulaglutide	Trulicity
exenatide	Byetta
exenatide microspheres	Bydureon
exenatide microspheres	Bydureon BCise
insulin degludec/liraglutide	Xultophy 100/3.6
insulin glargine,human recombinant analog/lixisenatide	Soliqua 100/33
liraglutide	Saxenda
liraglutide	Victoza 2-Pak
liraglutide	Victoza 3-Pak
lixisenatide	Adlyxin
semaglutide	Ozempic
semaglutide	Rybelsus
semaglutide	Wegovy
tirzepatide	Mounjaro
Meglitinides	
nateglinide	nateglinide
repaglinide	repaglinide
repaglinide/metformin HCl	repaglinide-metformin
Insulin	
insulin aspart	insulin aspart U-100
insulin aspart	Novolog FlexPen U-100 Insulin
insulin aspart	Novolog PenFill U-100 Insulin
insulin aspart	Novolog U-100 Insulin aspart
insulin aspart (niacinamide)	Fiasp FlexTouch U-100 Insulin
insulin aspart (niacinamide)	Fiasp Penfill U-100 Insulin
insulin aspart (niacinamide)	Fiasp U-100 Insulin
insulin aspart protamine human/insulin aspart	insulin asp prt-insulin aspart
insulin aspart protamine human/insulin aspart	Novolog Mix 70-30 U-100 Insulin
insulin aspart protamine human/insulin aspart	Novolog Mix 70-30FlexPen U-100
insulin degludec	insulin degludec
insulin degludec	Tresiba FlexTouch U-100
insulin degludec	Tresiba FlexTouch U-200
insulin degludec	Tresiba U-100 Insulin
insulin detemir	Levemir FlexPen
insulin detemir	Levemir FlexTouch U-100 Insulin
insulin detemir	Levemir U-100 Insulin
insulin glargine,human recombinant analog	Basaglar KwikPen U-100 Insulin

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
insulin glargine,human recombinant analog	Basaglar Tempo Pen(U-100)Insln
insulin glargine,human recombinant analog	insulin glargine
insulin glargine,human recombinant analog	Lantus Solostar U-100 Insulin
insulin glargine,human recombinant analog	Lantus U-100 Insulin
insulin glargine,human recombinant analog	Semglee Pen U-100 Insulin
insulin glargine,human recombinant analog	Semglee U-100 Insulin
insulin glargine,human recombinant analog	Toujeo Max U-300 SoloStar
insulin glargine,human recombinant analog	Toujeo SoloStar U-300 Insulin
insulin glargine-yfgn	insulin glargine-yfgn
insulin glargine-yfgn	Semglee(insulin glargine-yfgn)
insulin glargine-yfgn	Semglee(insulin glarg-yfgn)Pen
insulin glulisine	Apidra SoloStar U-100 Insulin
insulin glulisine	Apidra U-100 Insulin
insulin lispro	Admelog SoloStar U-100 Insulin
insulin lispro	Admelog U-100 Insulin lispro
insulin lispro	Humalog Junior KwikPen U-100
insulin lispro	Humalog KwikPen Insulin
insulin lispro	Humalog Tempo Pen(U-100)Insuln
insulin lispro	Humalog U-100 Insulin
insulin lispro	insulin lispro
insulin lispro protamine and insulin lispro	Humalog Mix 50-50 Insuln U-100
insulin lispro protamine and insulin lispro	Humalog Mix 50-50 KwikPen
insulin lispro protamine and insulin lispro	Humalog Mix 75-25 KwikPen
insulin lispro protamine and insulin lispro	Humalog Mix 75-25(U-100)Insuln
insulin lispro protamine and insulin lispro	insulin lispro protamin-lispro
insulin lispro-aabc	Lyumjev KwikPen U-100 Insulin
insulin lispro-aabc	Lyumjev KwikPen U-200 Insulin
insulin lispro-aabc	Lyumjev Tempo Pen(U-100)Insuln
insulin lispro-aabc	Lyumjev U-100 Insulin
insulin NPH human isophane	Humulin N NPH Insulin KwikPen
insulin NPH human isophane	Humulin N NPH U-100 Insulin
insulin NPH human isophane	Novolin N FlexPen
insulin NPH human isophane	Novolin N NPH U-100 Insulin
insulin NPH human isophane/insulin regular, human	Humulin 70/30 U-100 Insulin
insulin NPH human isophane/insulin regular, human	Humulin 70/30 U-100 KwikPen
insulin NPH human isophane/insulin regular, human	Novolin 70/30 U-100 Insulin
insulin NPH human isophane/insulin regular, human	Novolin 70-30 FlexPen U-100
insulin regular, human	Afrezza
insulin regular, human	Humulin R Regular U-100 Insuln
insulin regular, human	Humulin R U-500 (Conc) Insulin
insulin regular, human	Humulin R U-500 (Conc) Kwikpen
insulin regular, human	Novolin R FlexPen
insulin regular, human	Novolin R Regular U-100 Insulin
insulin regular, human in 0.9 % sodium chloride	Myxredlin
Biguanides	
alogliptin benzoate/metformin HCl	alogliptin-metformin
alogliptin benzoate/metformin HCl	Kazano
canagliflozin/metformin HCl	Invokamet
canagliflozin/metformin HCl	Invokamet XR
dapagliflozin propanediol/metformin HCl	Xigduo XR
empagliflozin/linagliptin/metformin HCl	Trijardy XR
empagliflozin/metformin HCl	Synjardy
empagliflozin/metformin HCl	Synjardy XR
ertugliflozin pidolate/metformin HCl	Segluromet

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
glipizide/metformin HCl	glipizide-metformin
glyburide/metformin HCl	glyburide-metformin
linagliptin/metformin HCl	Jentadueto
linagliptin/metformin HCl	Jentadueto XR
metformin HCl	Fortamet
metformin HCl	Glumetza
metformin HCl	metformin
metformin HCl	Riomet
metformin HCl	Riomet ER
pioglitazone HCl/metformin HCl	Actoplus MET
pioglitazone HCl/metformin HCl	pioglitazone-metformin
repaglinide/metformin HCl	repaglinide-metformin
saxagliptin HCl/metformin HCl	Kombiglyze XR
sitagliptin phosphate/metformin HCl	Janumet
sitagliptin phosphate/metformin HCl	Janumet XR
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors	
canagliflozin	Invokana
dapagliflozin propanediol	Farxiga
dapagliflozin propanediol/saxagliptin HCl	Qtern
empagliflozin	Jardiance
empagliflozin/linagliptin	Glyxambi
ertugliflozin pidolate	Steglatro
ertugliflozin pidolate/sitagliptin phosphate	Steglujan
Sulfonylurea	
glimepiride	Amaryl
glimepiride	glimepiride
glipizide	glipizide
glipizide	Glucotrol
glipizide	Glucotrol XL
glipizide/metformin HCl	glipizide-metformin
glyburide	glyburide
glyburide,micronized	glyburide micronized
glyburide,micronized	Glynase
glyburide/metformin HCl	glyburide-metformin
pioglitazone HCl/glimepiride	DUETACT
pioglitazone HCl/glimepiride	pioglitazone-glimepiride
Thiazolidinedione	
alogliptin benzoate/pioglitazone HCl	alogliptin-pioglitazone
alogliptin benzoate/pioglitazone HCl	Oseni
pioglitazone HCl	Actos
pioglitazone HCl	pioglitazone
pioglitazone HCl/glimepiride	DUETACT
pioglitazone HCl/glimepiride	pioglitazone-glimepiride
pioglitazone HCl/metformin HCl	Actoplus MET
pioglitazone HCl/metformin HCl	pioglitazone-metformin
Other Antidiabetic Drugs (Bromocriptine, Mifepristone)	
bromocriptine mesylate	Cycloset
mifepristone	Korlym
Sodium Channel Blocker	
disopyramide phosphate	disopyramide phosphate
disopyramide phosphate	Norpace
disopyramide phosphate	Norpace CR
flecainide acetate	flecainide
lidocaine HCl in dextrose 5% in water/PF	lidocaine in 5 % dextrose (PF)

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
lidocaine HCl in sodium chloride, iso-osmotic/PF	lidocaine in NaCl,iso-osmo(PF)
lidocaine HCl/PF	lidocaine (PF)
lidocaine HCl/PF	Xylocaine (Cardiac) (PF)
mexiletine HCl	mexiletine
phenytoin sodium	phenytoin sodium
procainamide HCl	procainamide
propafenone HCl	propafenone
propafenone HCl	Rythmol SR
quinidine gluconate	quinidine gluconate
quinidine sulfate	quinidine sulfate
Beta Blocker	
acebutolol HCl	acebutolol
atenolol	atenolol
atenolol	Tenormin
atenolol/chlorthalidone	atenolol-chlorthalidone
atenolol/chlorthalidone	Tenoretic 100
atenolol/chlorthalidone	Tenoretic 50
betaxolol HCl	betaxolol
bisoprolol fumarate	bisoprolol fumarate
bisoprolol fumarate/hydrochlorothiazide	bisoprolol-hydrochlorothiazide
bisoprolol fumarate/hydrochlorothiazide	Ziac
canakinumab/PF	Ilaris (PF)
carvedilol	carvedilol
carvedilol	Coreg
carvedilol phosphate	carvedilol phosphate
carvedilol phosphate	Coreg CR
esmolol HCl	Brevibloc
esmolol HCl	esmolol
esmolol HCl in sodium chloride, iso-osmotic	Brevibloc in NaCl (iso-osm)
esmolol HCl in sodium chloride, iso-osmotic	esmolol in NaCl (iso-osm)
esmolol HCl in sterile water	esmolol in sterile water
labetalol HCl	labetalol
labetalol HCl in dextrose, iso-osmotic	labetalol in dextrose,iso-osm
labetalol HCl in sodium chloride, iso-osmotic	labetalol in NaCl (iso-osmot)
metoprolol succinate	Kaspargo Sprinkle
metoprolol succinate	metoprolol succinate
metoprolol succinate	Toprol XL
metoprolol succinate/hydrochlorothiazide	Dutoprol
metoprolol tartrate	Lopressor
metoprolol tartrate	metoprolol tartrate
metoprolol tartrate/hydrochlorothiazide	metoprolol ta-hydrochlorothiaz
nadolol	Corgard
nadolol	nadolol
nebivolol HCl	Bystolic
nebivolol HCl	nebivolol
pindolol	pindolol
propranolol HCl	Hemangeol
propranolol HCl	Inderal LA
propranolol HCl	Inderal XL
propranolol HCl	InnoPran XL
propranolol HCl	propranolol
propranolol HCl/hydrochlorothiazide	propranolol-hydrochlorothiazid
sotalol HCl	Betapace
sotalol HCl	Betapace AF

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
sotalol HCl	Sorine
sotalol HCl	sotalol
sotalol HCl	Sotalol AF
sotalol HCl	Sotylize
timolol maleate	timolol maleate
Potassium Channel Blocker/Openers	
amiodarone HCl	amiodarone
amiodarone HCl	Pacerone
amiodarone HCl/dextrose 5 % in water	amiodarone in dextrose 5 %
amiodarone in dextrose, iso-osmotic	Nexterone
bretylum tosylate	bretylum tosylate
dofetilide	dofetilide
dofetilide	Tikosyn
dronedarone HCl	Multaq
ibutilide fumarate	Corvert
ibutilide fumarate	ibutilide fumarate
Non-Dihydropyridine Calcium Channel Blockers	
diltiazem HCl	diltiazem HCl
verapamil HCl	verapamil
Digoxin	
digoxin	Digitek
digoxin	Digox
digoxin	digoxin
digoxin	Lanoxin
digoxin	Lanoxin Pediatric
Other Antiarrhythmic Agents	
adenosine	adenosine
Angiotensin-Converting-Enzyme (ACE) Inhibitors	
amlodipine besylate/benazepril HCl	amlodipine-benazepril
amlodipine besylate/benazepril HCl	Lotrel
benazepril HCl	benazepril
benazepril HCl	Lotensin
benazepril HCl/hydrochlorothiazide	benazepril-hydrochlorothiazide
benazepril HCl/hydrochlorothiazide	Lotensin HCT
captopril	captopril
captopril/hydrochlorothiazide	captopril-hydrochlorothiazide
enalapril maleate	enalapril maleate
enalapril maleate	Epaned
enalapril maleate	Vasotec
enalapril maleate/hydrochlorothiazide	enalapril-hydrochlorothiazide
enalapril maleate/hydrochlorothiazide	Vaseretic
enalaprilat dihydrate	enalaprilat
fosinopril sodium	fosinopril
fosinopril sodium/hydrochlorothiazide	fosinopril-hydrochlorothiazide
lisinopril	lisinopril
lisinopril	Prinivil
lisinopril	Qbrelis
lisinopril	Zestril
lisinopril/hydrochlorothiazide	lisinopril-hydrochlorothiazide
lisinopril/hydrochlorothiazide	Zestoretic
moexipril HCl	moexipril
perindopril arginine/amlodipine besylate	Prestalia
perindopril erbumine	perindopril erbumine
quinapril HCl	Accupril

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
quinapril HCl	quinapril
quinapril HCl/hydrochlorothiazide	Accuretic
quinapril HCl/hydrochlorothiazide	quinapril-hydrochlorothiazide
ramipril	Altace
ramipril	ramipril
trandolapril	trandolapril
trandolapril/verapamil HCl	Tarka
trandolapril/verapamil HCl	trandolapril-verapamil
Angiotensin II Receptor Blockers (ARBs)	
amlodipine besylate/olmesartan medoxomil	amlodipine-olmesartan
amlodipine besylate/olmesartan medoxomil	Azor
amlodipine besylate/valsartan	amlodipine-valsartan
amlodipine besylate/valsartan	Exforge
amlodipine besylate/valsartan/hydrochlorothiazide	amlodipine-valsartan-hcthiazid
amlodipine besylate/valsartan/hydrochlorothiazide	Exforge HCT
azilsartan medoxomil	Edarbi
azilsartan medoxomil/chlorthalidone	Edarbyclor
candesartan cilexetil	Atacand
candesartan cilexetil	candesartan
candesartan cilexetil/hydrochlorothiazide	Atacand HCT
candesartan cilexetil/hydrochlorothiazide	candesartan-hydrochlorothiazid
eprosartan mesylate	eprosartan
irbesartan	Avapro
irbesartan	irbesartan
irbesartan/hydrochlorothiazide	Avalide
irbesartan/hydrochlorothiazide	irbesartan-hydrochlorothiazide
losartan potassium	Cozaar
losartan potassium	losartan
losartan potassium/hydrochlorothiazide	Hyzaar
losartan potassium/hydrochlorothiazide	losartan-hydrochlorothiazide
olmesartan medoxomil	Benicar
olmesartan medoxomil	olmesartan
olmesartan medoxomil/amlodipine	
besylate/hydrochlorothiazide	olmesartan-amlodipin-hcthiazid
olmesartan medoxomil/amlodipine	
besylate/hydrochlorothiazide	Tribenzor
olmesartan medoxomil/hydrochlorothiazide	Benicar HCT
olmesartan medoxomil/hydrochlorothiazide	olmesartan-hydrochlorothiazide
sacubitril/valsartan	Entresto
telmisartan	Micardis
telmisartan	telmisartan
telmisartan/amlodipine besylate	telmisartan-amlodipine
telmisartan/amlodipine besylate	Twynsta
telmisartan/hydrochlorothiazide	Micardis HCT
telmisartan/hydrochlorothiazide	telmisartan-hydrochlorothiazid
valsartan	Diovan
valsartan	valsartan
valsartan/hydrochlorothiazide	Diovan HCT
valsartan/hydrochlorothiazide	valsartan-hydrochlorothiazide
Dihydropyridines	
amlodipine benzoate	Katerzia
amlodipine besylate	amlodipine
amlodipine besylate	Norliqva
amlodipine besylate	Norvasc

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
amlodipine besylate/celecoxib	Consensi
clevipidine butyrate	Cleviprex
felodipine	felodipine
isradipine	isradipine
levamlodipine maleate	Conjupri
levamlodipine maleate	levamlodipine
nicardipine HCl	Cardene IV
nicardipine HCl	nicardipine
nicardipine HCl in 0.9 % sodium chloride	nicardipine in 0.9 % sod chlor
nicardipine in dextrose, iso-osmotic	Cardene IV in dextrose
nicardipine in sodium chloride, iso-osmotic	Cardene IV in sodium chloride
nicardipine in sodium chloride, iso-osmotic	nicardipine in NaCl (iso-os)
nifedipine	nifedipine
nifedipine	Procardia
nifedipine	Procardia XL
nimodipine	nimodipine
nimodipine	Nymalize
nisoldipine	nisoldipine
nisoldipine	Sular
Diuretics	
acetazolamide	acetazolamide
acetazolamide sodium	acetazolamide sodium
amiloride HCl	amiloride
amiloride HCl/hydrochlorothiazide	amiloride-hydrochlorothiazide
bumetanide	bumetanide
chlorothiazide	Diuril
chlorothiazide sodium	chlorothiazide sodium
chlorothiazide sodium	Diuril IV
chlorthalidone	chlorthalidone
chlorthalidone	Thalitone
conivaptan HCl/dextrose 5 % in water	Vaprisol in 5 % dextrose
eplerenone	eplerenone
eplerenone	Inspra
ethacrynate sodium	ethacrynate sodium
ethacrynate sodium	Sodium Edecrin
ethacrynic acid	Edecrin
ethacrynic acid	ethacrynic acid
furosemide	Furoscix
furosemide	furosemide
furosemide	Lasix
furosemide in 0.9 % sodium chloride	furosemide in 0.9 % NaCl
hydrochlorothiazide	hydrochlorothiazide
indapamide	indapamide
methazolamide	methazolamide
metolazone	metolazone
spironolactone	Aldactone
spironolactone	CaroSpir
spironolactone	spironolactone
spironolactone/hydrochlorothiazide	Aldactazide
spironolactone/hydrochlorothiazide	spironolacton-hydrochlorothiaz
tolvaptan	Samsca
tolvaptan	tolvaptan
torsemide	Soanz
torsemide	torsemide

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
triamterene	Dyrenium
triamterene	triamterene
triamterene/hydrochlorothiazide	Maxzide
triamterene/hydrochlorothiazide	Maxzide-25mg
triamterene/hydrochlorothiazide	triamterene-hydrochlorothiazid
Other Antihypertensives	
aliskiren hemifumarate	aliskiren
aliskiren hemifumarate	Tekturna
aliskiren hemifumarate/hydrochlorothiazide	Tekturna HCT
atenolol/chlorthalidone	atenolol-chlorthalidone
atenolol/chlorthalidone	Tenoretic 100
atenolol/chlorthalidone	Tenoretic 50
bisoprolol fumarate/hydrochlorothiazide	bisoprolol-hydrochlorothiazide
bisoprolol fumarate/hydrochlorothiazide	Ziac
clonidine	Catapres-TTS-1
clonidine	Catapres-TTS-2
clonidine	Catapres-TTS-3
clonidine	clonidine
clonidine HCl	clonidine HCl
clonidine HCl	Nexiclon XR
doxazosin mesylate	Cardura
doxazosin mesylate	Cardura XL
doxazosin mesylate	doxazosin
fenoldopam mesylate	Corlopam
finerenone	Kerendia
guanfacine HCl	guanfacine
hydralazine HCl	hydralazine
isosorbide dinitrate/hydralazine HCl	BiDil
isosorbide dinitrate/hydralazine HCl	isosorbide-hydralazine
isoxsuprine HCl	isoxsuprine
mecamylamine HCl	Vecamyl
methyl dopa	methyl dopa
methyl dopa/hydrochlorothiazide	methyl dopa-hydrochlorothiazide
methyl dopate HCl	methyl dopate
metoprolol succinate/hydrochlorothiazide	Dutoprol
metoprolol tartrate/hydrochlorothiazide	metoprolol ta-hydrochlorothiaz
metirosine	Demser
metirosine	metirosine
minoxidil	minoxidil
nitroprusside sodium	Nitropress
nitroprusside sodium	sodium nitroprusside
nitroprusside sodium in 0.9 % sodium chloride	Nipride RTU
papaverine HCl	papaverine
phenoxybenzamine HCl	Dibenzylamine
phenoxybenzamine HCl	phenoxybenzamine
phentolamine mesylate	phentolamine
prazosin HCl	Minipress
prazosin HCl	prazosin
propranolol HCl/hydrochlorothiazide	propranolol-hydrochlorothiazid
terazosin HCl	terazosin
Oral Anticoagulants	
apixaban	Eliquis
apixaban	Eliquis DVT-PE Treat 30D Start
dabigatran etexilate mesylate	dabigatran etexilate

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
dabigatran etexilate mesylate	Pradaxa
edoxaban tosylate	Savaysa
rivaroxaban	Xarelto
rivaroxaban	Xarelto DVT-PE Treat 30d Start
Vitamin K Antagonists	
warfarin sodium	Jantoven
warfarin sodium	warfarin
Other Cardiac Medications (Not Including Oral Anticoagulants or Vitamin K Antagonists)	
ambrisentan	ambrisentan
ambrisentan	Letairis
amyl nitrite	amyl nitrite
bosentan	bosentan
bosentan	Tracleer
epoprostenol sodium	epoprostenol
epoprostenol sodium	Veletri
epoprostenol sodium (glycine)	epoprostenol (glycine)
epoprostenol sodium (glycine)	Flolan
iloprost tromethamine	Ventavis
isosorbide dinitrate	Dilatrate-SR
isosorbide dinitrate	Isordil
isosorbide dinitrate	Isordil Titradose
isosorbide dinitrate	isosorbide dinitrate
isosorbide mononitrate	isosorbide mononitrate
ivabradine HCl	Corlanor
macitentan	Opsumit
nitroglycerin	GoNitro
nitroglycerin	Minitran
nitroglycerin	Nitro-Bid
nitroglycerin	Nitro-Dur
nitroglycerin	nitroglycerin
nitroglycerin	Nitrolingual
nitroglycerin	Nitromist
nitroglycerin	Nitrostat
nitroglycerin	Nitro-Time
nitroglycerin in 5 % dextrose in water	nitroglycerin in 5 % dextrose
ranolazine	Aspruzo Sprinkle
ranolazine	Ranexa
ranolazine	ranolazine
riociguat	Adempas
selexipag	Upravi
sildenafil citrate	Revatio
sildenafil citrate	sildenafil (pulm.hypertension)
tadalafil	Adcirca
tadalafil	Alyq
tadalafil	tadalafil (pulm. hypertension)
tadalafil	Tadliq
treprostinil	Tyvaso
treprostinil	Tyvaso DPI
treprostinil diolamine	Orenitram
treprostinil sodium	Remodulin
treprostinil sodium	treprostinil sodium
treprostinil/nebulizer accessories	Tyvaso Refill Kit
treprostinil/nebulizer and accessories	Tyvaso Institutional Start Kit
treprostinil/nebulizer and accessories	Tyvaso Starter Kit

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
vericiguat	Verquvo
Lipid Lowering Therapy	
alirocumab	Praluent Pen
amlodipine besylate/atorvastatin calcium	amlodipine-atorvastatin
amlodipine besylate/atorvastatin calcium	Caduet
atorvastatin calcium	atorvastatin
atorvastatin calcium	Lipitor
bempedoic acid	Nexletol
bempedoic acid/ezetimibe	Nexlizet
cholestyramine (with sugar)	cholestyramine (with sugar)
cholestyramine (with sugar)	Questran
cholestyramine/aspartame	Cholestyramine Light
cholestyramine/aspartame	cholestyramine-aspartame
cholestyramine/aspartame	Prevalite
cholestyramine/aspartame	Questran Light
colesevelam HCl	colesevelam
colesevelam HCl	WelChol
colestipol HCl	Colestid
colestipol HCl	Colestid Flavored
colestipol HCl	colestipol
evinacumab-dgnb	Evkeeza
evolocumab	Repatha Pushtronex
evolocumab	Repatha SureClick
evolocumab	Repatha Syringe
ezetimibe	ezetimibe
ezetimibe	Zetia
ezetimibe/atorvastatin calcium	ezetimibe-atorvastatin
ezetimibe/rosuvastatin calcium	ezetimibe-rosuvastatin
ezetimibe/rosuvastatin calcium	Roszet
ezetimibe/simvastatin	ezetimibe-simvastatin
ezetimibe/simvastatin	Vytorin 10-10
ezetimibe/simvastatin	Vytorin 10-20
ezetimibe/simvastatin	Vytorin 10-40
ezetimibe/simvastatin	Vytorin 10-80
fenofibrate	fenofibrate
fenofibrate	Fenoglide
fenofibrate	Lipofen
fenofibrate nanocrystallized	fenofibrate nanocrystallized
fenofibrate nanocrystallized	Tricor
fenofibrate,micronized	Antara
fenofibrate,micronized	fenofibrate micronized
fenofibric acid	fenofibric acid
fenofibric acid	Fibricor
fenofibric acid (choline)	fenofibric acid (choline)
fenofibric acid (choline)	Trilipix
fluvastatin sodium	fluvastatin
fluvastatin sodium	Lescol XL
gemfibrozil	gemfibrozil
gemfibrozil	Lopid
icosapent ethyl	icosapent ethyl
icosapent ethyl	Vascepa
inclisiran sodium	Leqvio
lomitapide mesylate	Juxtapid
lovastatin	Altoprev

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
lovastatin	lovastatin
niacin	niacin
niacin	Niacor
niacin	Niaspan Extended-Release
omega-3 acid ethyl esters	Lovaza
omega-3 acid ethyl esters	omega-3 acid ethyl esters
pitavastatin calcium	Livalo
pitavastatin magnesium	Zypitamag
pravastatin sodium	pravastatin
rosuvastatin calcium	Crestor
rosuvastatin calcium	Ezallor Sprinkle
rosuvastatin calcium	rosuvastatin
simvastatin	FloLipid
simvastatin	simvastatin
simvastatin	Zocor
Drugs with a Known Risk of Prolonged QT and Torsades de Pointes	
amiodarone HCl	amiodarone
amiodarone HCl	Pacerone
amiodarone HCl/dextrose 5 % in water	amiodarone in dextrose 5 %
amiodarone in dextrose, iso-osmotic	Nexterone
anagrelide HCl	Agrylin
anagrelide HCl	anagrelide
arsenic trioxide	arsenic trioxide
arsenic trioxide	Trisenox
azithromycin	AzaSite
azithromycin	azithromycin
azithromycin	Zithromax
azithromycin	Zithromax TRI-PAK
azithromycin	Zithromax Z-Pak
azithromycin/chondroitin sulfate A sodium/PF	Klarity-A (azithro-chondr)(PF)
chloroquine phosphate	chloroquine phosphate
chlorpromazine HCl	chlorpromazine
cilostazol	cilostazol
ciprofloxacin	Cipro
ciprofloxacin	ciprofloxacin
ciprofloxacin	Otiprio
ciprofloxacin HCl	Cetraxal
ciprofloxacin HCl	Ciloxan
ciprofloxacin HCl	Cipro
ciprofloxacin HCl	ciprofloxacin HCl
ciprofloxacin HCl/dexamethasone	Ciprodex
ciprofloxacin HCl/dexamethasone	ciprofloxacin-dexamethasone
ciprofloxacin HCl/fluocinolone acetonide	ciprofloxacin-fluocinolone
ciprofloxacin HCl/fluocinolone acetonide	Otovel
ciprofloxacin HCl/hydrocortisone	Cipro HC
ciprofloxacin lactate/dextrose 5 % in water	ciprofloxacin in 5 % dextrose
citalopram hydrobromide	Celexa
citalopram hydrobromide	citalopram
clarithromycin	clarithromycin
cocaine HCl	cocaine
cocaine HCl	Goprelto
cocaine HCl	Numbrino
dexamethasone sod ph/moxifloxacin HCl in NaCl,iso-osmotic/PF	dexameth-moxiflox(PF)-NaCl,iso

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
dexamethasone sod ph/moxifloxacin HCl/ketorolac/sod chlor/PF	dexamet-moxifl-ketoro-NaCl(PF)
dextromethorphan Hbr/quinidine sulfate	Nuedexta
disopyramide phosphate	disopyramide phosphate
disopyramide phosphate	Norpace
disopyramide phosphate	Norpace CR
dofetilide	dofetilide
dofetilide	Tikosyn
donepezil HCl	Adlarity
donepezil HCl	Aricept
donepezil HCl	donepezil
dronedarone HCl	Multaq
droperidol	droperidol
erythromycin base	Ery-Tab
erythromycin base	erythromycin
erythromycin ethylsuccinate	E.E.S. 400
erythromycin ethylsuccinate	E.E.S. Granules
erythromycin ethylsuccinate	EryPed 200
erythromycin ethylsuccinate	EryPed 400
erythromycin ethylsuccinate	erythromycin ethylsuccinate
erythromycin lactobionate	Erythrocin
erythromycin lactobionate	erythromycin lactobionate
erythromycin stearate	Erythrocin (as stearate)
erythromycin stearate	erythromycin stearate
escitalopram oxalate	escitalopram oxalate
escitalopram oxalate	Lexapro
flecainide acetate	flecainide
fluconazole	Diflucan
fluconazole	fluconazole
fluconazole in sodium chloride, iso-osmotic	fluconazole in NaCl (iso-osm)
gatifloxacin	gatifloxacin
gatifloxacin	Zymaxid
haloperidol	haloperidol
haloperidol decanoate	Haldol Decanoate
haloperidol decanoate	haloperidol decanoate
haloperidol lactate	Haldol
haloperidol lactate	haloperidol lactate
hydroxychloroquine sulfate	hydroxychloroquine
hydroxychloroquine sulfate	Plaquenil
ibutilide fumarate	Corvert
ibutilide fumarate	ibutilide fumarate
lansoprazole/amoxicillin trihydrate/clarithromycin	amoxicil-clarithromy-lansopraz
levofloxacin	levofloxacin
levofloxacin/dextrose 5 % in water	levofloxacin in D5W
memantine HCl/donepezil HCl	Namzaric
methadone HCl	Diskets
methadone HCl	methadone
methadone HCl	Methadone Intensol
methadone HCl	Methadose
methadone hydrochloride in 0.9 % sodium chloride	methadone in 0.9 % sod.chlorid
midazolam/ketamine HCl/ondansetron HCl	MKO (Midazolam-Ketamine-Ondan)
mobocertinib succinate	Exkivity
moxifloxacin HCl	Moxeza
moxifloxacin HCl	moxifloxacin

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
moxifloxacin HCl	Vigamox
moxifloxacin HCl in balanced salt solution no.2/PF	moxifloxacin (PF)-BSS
moxifloxacin HCl in sodium acetate and sulfate,water,iso-osm	moxifloxacin-sod.ace,sul-water
moxifloxacin HCl in sodium chloride, iso-osmotic	Avelox in NaCl (iso-osmotic)
moxifloxacin HCl in sodium chloride, iso-osmotic	moxifloxacin-sod.chloride(iso)
moxifloxacin HCl in sodium chloride,iso-osmotic/PF	moxifloxacin-sod chlor,iso(PF)
omeprazole/clarithromycin/amoxicillin trihydrate	Omeclamox-Pak
ondansetron	ondansetron
ondansetron	Zuplenz
ondansetron HCl	ondansetron HCl
ondansetron HCl	Zofran
ondansetron HCl in 0.9 % sodium chloride	ondansetron in 0.9 % sod chlor
ondansetron HCl/PF	ondansetron HCl (PF)
oxaliplatin	oxaliplatin
papaverine HCl	papaverine
papaverine HCl/phentolamine mesylate in water	IFE-BiMix 30/1
papaverine HCl/phentolamine mesylate/alprostadi	Tri-Mix (papavrn-phntlmn-PGE1)
pentamidine isethionate	Nebupent
pentamidine isethionate	Pentam
pentamidine isethionate	pentamidine
pimozide	pimozide
prednisolone acetate/gatifloxacin	prednisolone acet-gatifloxacin
prednisolone acetate/gatifloxacin/bromfenac sodium	prednisol ace-gatiflox-bromfen
prednisolone acetate/moxifloxacin HCl	prednisolone-moxifloxacin HCl
prednisolone acetate/moxifloxacin HCl/bromfenac sodium	prednisolone-moxiflox-bromfen
prednisolone acetate/moxifloxacin HCl/nepafenac	prednisolone-moxiflo-nepafenac
prednisolone sodium phosphate/gatifloxacin/bromfenac sodium	prednisoln sp-gatiflox-bromfen
prednisolone sodium phosphate/moxifloxacin HCl	prednisolone sod ph-moxiflox
prednisolone sodium phosphate/moxifloxacin HCl/bromfenac sod	prednisoln sp-moxiflox-bromfen
procainamide HCl	procainamide
propofol	Anesthesia S/I-40 (propofol)
propofol	Anesthesia S/I-40A (propofol)
propofol	Anesthesia S/I-40H (propofol)
propofol	Anesthesia S/I-40S (propofol)
propofol	Anesthesia S/I-60 (propofol)
propofol	Diprivan
propofol	propofol
propofol in lipid emulsion MCT/LCT (1:1)/PF	Propofol-Lipuro (PF)
propofol in lipid emulsion MCT/LCT (1:1)/PF	Propoven (EUA) (PF)
quinidine gluconate	quinidine gluconate
quinidine sulfate	quinidine sulfate
sevoflurane	sevoflurane
sevoflurane	Ultane
sotalol HCl	Betapace
sotalol HCl	Betapace AF
sotalol HCl	Sorine
sotalol HCl	sotalol
sotalol HCl	Sotalol AF
sotalol HCl	Sotylize
terlipressin acetate	Terlivaz
thioridazine HCl	thioridazine
triamcinolone acetonide/moxifloxacin HCl/water/PF	triamcinolon-moxiflox-watr(PF)

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
vandetanib	Caprelsa
vonoprazan fumarate/amoxicillin trihydrate/clarithromycin	Voquezna Triple Pak
Drugs with a Known/Possible/Conditional Risk of Prolonged QT and Torsades de Pointes	
abiraterone acetate	abiraterone
abiraterone acetate	Zytiga
abiraterone acetate, submicronized	Yonsa
acetaminophen/diphenhydramine citrate	Goody's PM
acetaminophen/diphenhydramine citrate	Headache Relief PM
acetaminophen/diphenhydramine citrate	Midol PM
acetaminophen/diphenhydramine HCl	Acetadryl
acetaminophen/diphenhydramine HCl	Acetaminophen PM
acetaminophen/diphenhydramine HCl	Acetaminophen PM Extra Str
acetaminophen/diphenhydramine HCl	EaZZZe The Pain
acetaminophen/diphenhydramine HCl	Headache PM
acetaminophen/diphenhydramine HCl	Night Time Pain Medicine
acetaminophen/diphenhydramine HCl	Non-Aspirin PM
acetaminophen/diphenhydramine HCl	Pain and Sleep
acetaminophen/diphenhydramine HCl	Pain Relief PM
acetaminophen/diphenhydramine HCl	Pain Relief PM Rapid Release
acetaminophen/diphenhydramine HCl	Pain Reliever PM Ex-Strength
acetaminophen/diphenhydramine HCl	Percogesic
acetaminophen/diphenhydramine HCl	Percogesic Extra Strength
acetaminophen/diphenhydramine HCl	Severe Allergy
acetaminophen/diphenhydramine HCl	Tylenol PM Extra Strength
acetaminophen/diphenhydramine HCl	Unisom PM Pain
acetaminophen/diphenhydramine HCl	Wal-Nadol PM
adagrasib	Krazati
alfuzosin HCl	alfuzosin
alfuzosin HCl	Uroxatral
aliskiren hemifumarate/hydrochlorothiazide	Tektura HCT
amantadine HCl	amantadine HCl
amantadine HCl	Gocovri
amantadine HCl	Osmolex ER
amiloride HCl/hydrochlorothiazide	amiloride-hydrochlorothiazide
amiodarone HCl	amiodarone
amiodarone HCl	Pacerone
amiodarone HCl/dextrose 5 % in water	amiodarone in dextrose 5 %
amiodarone in dextrose, iso-osmotic	Nexterone
amisulpride	Barhemsys
amitriptyline HCl	amitriptyline
amitriptyline HCl/chlordiazepoxide	amitriptyline-chlordiazepoxide
amlodipine besylate/valsartan/hydrochlorothiazide	amlodipine-valsartan-hcthiiazid
amlodipine besylate/valsartan/hydrochlorothiazide	Exforge HCT
amphetamine	Adzenys ER
amphetamine	Adzenys XR-ODT
amphetamine	amphetamine
amphetamine	Dyanavel XR
amphetamine sulfate	amphetamine sulfate
amphetamine sulfate	Evekeo
amphetamine sulfate	Evekeo ODT
amphotericin B	amphotericin B
amphotericin B lipid complex	Abelcet
amphotericin B liposome	AmBisome
amphotericin B liposome	amphotericin B liposome

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
anagrelide HCl	Agrylin
anagrelide HCl	anagrelide
apalutamide	Erleada
apomorphine HCl	APOKYN
apomorphine HCl	apomorphine
apomorphine HCl	Kynmobi
aripiprazole	Abilify
aripiprazole	Abilify Maintena
aripiprazole	Abilify MyCite
aripiprazole	Abilify MyCite Maintenance Kit
aripiprazole	Abilify MyCite Starter Kit
aripiprazole	aripiprazole
aripiprazole lauroxil	Aristada
aripiprazole lauroxil, submicronized	Aristada Initio
arsenic trioxide	arsenic trioxide
arsenic trioxide	Trisenox
artemether/lumefantrine	Coartem
asenapine	Secuado
asenapine maleate	asenapine maleate
asenapine maleate	Saphris
aspirin/acetaminophen/diphenhydramine citrate	Pain Relief PM (w-aspirin)
aspirin/diphenhydramine citrate	Bayer PM
aspirin/omeprazole	aspirin-omeprazole
aspirin/omeprazole	Yosprala
atazanavir sulfate	atazanavir
atazanavir sulfate	Reyataz
atazanavir sulfate/cobicistat	Evotaz
atomoxetine HCl	atomoxetine
atomoxetine HCl	Strattera
azithromycin	AzaSite
azithromycin	azithromycin
azithromycin	Zithromax
azithromycin	Zithromax TRI-PAK
azithromycin	Zithromax Z-Pak
azithromycin/chondroitin sulfate A sodium/PF	Klarity-A (azithro-chondr)(PF)
bedaquiline fumarate	Sirturo
benazepril HCl/hydrochlorothiazide	benazepril-hydrochlorothiazide
benazepril HCl/hydrochlorothiazide	Lotensin HCT
bendamustine HCl	Belrapzo
bendamustine HCl	bendamustine
bendamustine HCl	Bendeka
bendamustine HCl	Treanda
bendamustine HCl	Vivimusta
benzhydrocodone HCl/acetaminophen	Apadaz
benzhydrocodone HCl/acetaminophen	benzhydrocodone-acetaminophen
bicalutamide	bicalutamide
bicalutamide	Casodex
bismuth subsalicylate/metronidazole/tetracycline HCl	Helidac
bisoprolol fumarate/hydrochlorothiazide	bisoprolol-hydrochlorothiazide
bisoprolol fumarate/hydrochlorothiazide	Ziac
bortezomib	bortezomib
bortezomib	Velcade
bosutinib	Bosulif
buprenorphine	buprenorphine

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
buprenorphine	Butrans
buprenorphine	Sublocade
buprenorphine HCl	Belbuca
buprenorphine HCl	Buprenex
buprenorphine HCl	buprenorphine HCl
buprenorphine HCl	Probuphine
buprenorphine HCl/naloxone HCl	Bunavail
buprenorphine HCl/naloxone HCl	buprenorphine-naloxone
buprenorphine HCl/naloxone HCl	Suboxone
buprenorphine HCl/naloxone HCl	Zubsolv
cabotegravir/rilpivirine	Cabenuva
cabozantinib s-malate	Cabometyx
cabozantinib s-malate	Cometriq
candesartan cilexetil/hydrochlorothiazide	Atacand HCT
candesartan cilexetil/hydrochlorothiazide	candesartan-hydrochlorothiazid
capecitabine	capecitabine
capecitabine	Xeloda
captopril/hydrochlorothiazide	captopril-hydrochlorothiazide
ceritinib	Zykadia
chloroquine phosphate	chloroquine phosphate
chlorpromazine HCl	chlorpromazine
cilostazol	cilostazol
cimetidine	Acid Reducer (cimetidine)
cimetidine	cimetidine
cimetidine	Heartburn Relief (cimetidine)
cimetidine	Tagamet HB
cimetidine HCl	cimetidine HCl
ciprofloxacin	Cipro
ciprofloxacin	ciprofloxacin
ciprofloxacin	Otiprio
ciprofloxacin HCl	Cetraxal
ciprofloxacin HCl	Ciloxan
ciprofloxacin HCl	Cipro
ciprofloxacin HCl	ciprofloxacin HCl
ciprofloxacin HCl/dexamethasone	Ciprodex
ciprofloxacin HCl/dexamethasone	ciprofloxacin-dexamethasone
ciprofloxacin HCl/fluocinolone acetonide	ciprofloxacin-fluocinolone
ciprofloxacin HCl/fluocinolone acetonide	Otovel
ciprofloxacin HCl/hydrocortisone	Cipro HC
ciprofloxacin lactate/dextrose 5 % in water	ciprofloxacin in 5 % dextrose
citalopram hydrobromide	Celexa
citalopram hydrobromide	citalopram
clarithromycin	clarithromycin
clomipramine HCl	Anafranil
clomipramine HCl	clomipramine
clozapine	clozapine
clozapine	Clozaril
clozapine	Versacloz
cobimetinib fumarate	Cotellic
cocaine HCl	cocaine
cocaine HCl	Goprelto
cocaine HCl	Numbrino
colloidal bismuth subcitrate/metronidazole/tetracycline HCl	Pylera
crizotinib	Xalkori

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
dabrafenib mesylate	Tafinlar
dasatinib	Sprycel
degarelix acetate	Firmagon
degarelix acetate	Firmagon kit w diluent syringe
desipramine HCl	desipramine
desipramine HCl	Norpramin
desvenlafaxine	desvenlafaxine
desvenlafaxine succinate	desvenlafaxine succinate
desvenlafaxine succinate	Pristiq
deutetrabenazine	Austedo
deutetrabenazine	Austedo 12mg Start Titr(Wk1-4)
deutetrabenazine	Austedo TD Titratn Pk (Wk 1-2)
dexamethasone sod ph/moxifloxacin HCl in NaCl,iso-osmotic/PF	dexameth-moxiflox(PF)-NaCl,iso
dexamethasone sod ph/moxifloxacin HCl/ketorolac/sod chlor/PF	dexamet-moxifl-ketoro-NaCl(PF)
dexlansoprazole	Dexilant
dexlansoprazole	dexlansoprazole
dexmedetomidine HCl	dexmedetomidine
dexmedetomidine HCl	Igalmi
dexmedetomidine HCl	Precedex
dexmedetomidine HCl in 0.9 % sodium chloride	dexmedetomidine in 0.9 % NaCl
dexmedetomidine HCl in 0.9 % sodium chloride	Precedex in 0.9 % sodium chlor
dexmedetomidine in 5 % dextrose in water	dexmedetomidine in dextrose 5%
dextroamphetamine	Xelstryl
dextroamphetamine sulfate	Dexedrine Spansule
dextroamphetamine sulfate	dextroamphetamine sulfate
dextroamphetamine sulfate	ProCentra
dextroamphetamine sulfate	Zenzedi
dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Adderall
dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Adderall XR
dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	dextroamphetamine-amphetamine
dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Mydayis
dextromethorphan HBr/acetaminophen/diphenhydramine HCl	Diabetic Tussin Night Time
dextromethorphan HBr/quinidine sulfate	Nuedexta
dextromethorphan/phenylephrine/acetaminophen/diphenhydramine	Day-Night Severe Cold-Flu
dextromethorphan/phenylephrine/acetaminophen/diphenhydramine	HerbioMed Deep Cold-Flu Night
dextromethorphan/phenylephrine/acetaminophen/diphenhydramine	Multi-Symptom Severe Cold-Nt
dextromethorphan/phenylephrine/acetaminophen/diphenhydramine	Wal-Flu Day-Night Cold-Cough
diltiazem HCl	Cardizem
diltiazem HCl	Cardizem CD
diltiazem HCl	Cardizem LA
diltiazem HCl	Cartia XT
diltiazem HCl	diltiazem HCl
diltiazem HCl	DILT-XR
diltiazem HCl	Matzim LA
diltiazem HCl	Taztia XT

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
diltiazem HCl	Tiadyt ER
diltiazem HCl	Tiazac
diltiazem HCl in 0.9 % sodium chloride	diltiazem HCl in 0.9% NaCl
diltiazem HCl/dextrose 5 % in water	diltiazem in dextrose 5 %
diluent for lefamulin(10mM citrate buffered 0.9 % sod chlor)	Diluent for lefamulin(Xenleta)
diluent for leuprolide (polyglactin)	Diluent for Eligard
diluent for romidepsin (propylene glycol)	Diluent For Istodax
diluent for romidepsin (propylene glycol)	diluent, romidepsin (prop gly)
diphenhydramine HCl	Aler-Cap
diphenhydramine HCl	Alka-Seltzer Plus Allergy
diphenhydramine HCl	Aller-G-Time
diphenhydramine HCl	Allergy
diphenhydramine HCl	Allergy (diphenhydramine)
diphenhydramine HCl	Allergy Medication
diphenhydramine HCl	Allergy Medicine
diphenhydramine HCl	Allergy Relief(diphenhydramin)
diphenhydramine HCl	Banophen
diphenhydramine HCl	Benadryl
diphenhydramine HCl	Benadryl Allergy
diphenhydramine HCl	Child Allergy Relief (diphen)
diphenhydramine HCl	Children's Allergy (diphenhyd)
diphenhydramine HCl	Children's Benadryl Allergy
diphenhydramine HCl	Children's Diphenhydramine
diphenhydramine HCl	Children's Wal-Dryl Allergy
diphenhydramine HCl	Complete Allergy
diphenhydramine HCl	Complete Allergy Medicine
DIPHENHYDRAMINE HCL	Dicopanor
diphenhydramine HCl	Diphedryl
diphenhydramine HCl	Diphedryl Allergy
diphenhydramine HCl	Diphen
diphenhydramine HCl	Diphenhist
diphenhydramine HCl	diphenhydramine HCl
diphenhydramine HCl	EZ Nite Sleep
diphenhydramine HCl	Geri-Dryl
diphenhydramine HCl	M-Dryl
diphenhydramine HCl	Naramin
diphenhydramine HCl	Nighttime Sleep
diphenhydramine HCl	Nighttime Allergy Relief
diphenhydramine HCl	NightTime Sleep Aid (diphen)
diphenhydramine HCl	Nytol
diphenhydramine HCl	PediaClear Cough
diphenhydramine HCl	Pharbedryl
diphenhydramine HCl	Siladryl SA
diphenhydramine HCl	Simply Sleep
diphenhydramine HCl	Sleep Aid (diphenhydramine)
diphenhydramine HCl	Sleep Aid Max Str (diphenhydr)
diphenhydramine HCl	Sleep II
diphenhydramine HCl	Sleep Tablet (diphenhydramine)
diphenhydramine HCl	Sleep Time
diphenhydramine HCl	Sleeping
diphenhydramine HCl	Sleep-Tabs
diphenhydramine HCl	Sominex
diphenhydramine HCl	Sominex Maximum Strength
diphenhydramine HCl	Total Allergy Medicine

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
diphenhydramine HCl	Unisom (diphenhydramine)
diphenhydramine HCl	Unisom SleepGels
diphenhydramine HCl	Unisom SleepMelts
diphenhydramine HCl	Unisom SleepMinis
diphenhydramine HCl	Wal-Dryl Allergy
diphenhydramine HCl	Wal-Sleep Z
diphenhydramine HCl	Wal-Som (diphenhydramine)
diphenhydramine HCl	Z-Sleep
diphenhydramine HCl	ZzzQuil
diphenhydramine HCl in 0.9 % sodium chloride	diphenhydramine-0.9 % sod.chlr
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Allergy Sinus Headache (PE)
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Child Delsym Cough-Cold
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Child Mucinex M-S Cold Night
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Children Dimetapp M-S Cold-Flu
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Children's Mucinex Night Time
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Cold and Flu Relief(diphen-pe)
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Cough and Severe Cold
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Delsym Cough-Cold NightTime
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Flu Severe Cold-Night(diph-pe)
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Flu-Severe Cold-Cough Night
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Herbiomed Allergy Cold-Sinus
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Mucinex Fast-Max Nite Cold-Flu
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Mucinex Sinus-Max Nite Congest
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Robitussin Cold-Flu Night (PE)
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Severe Allergy-Sinus Headache
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Severe Cold Cough-Flu
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Severe Cold PE
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Theraflu ExpressMax Cold Night
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Theraflu Night Severe Cold-Cgh
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Theraflu Nighttime PowerPod
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Wal-Dryl Severe Allergy-Sinus
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Wal-Flu Night Severe Cold
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Wal-Flu Severe Cold and Cough
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Wal-Phed PE Nighttime Cold
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Wal-phed PE Severe Cold
diphenhydramine HCl/phenylephrine HCl/dextromethorphan	Child Cold-Cough Day-Night
diphenhydramine	
HCl/phenylephrine/acetaminophen/guaifenesin	Mucinex Sinus-Max D-N (diphen)
diphenhydramine	
HCl/phenylephrine/acetaminophen/guaifenesin	Sinus Relief Max Str Day-Night
diphenhydramine/brompheniramine/phenyleph/dextromethorphan	
han	Children's Dimetapp Day Night
diphenhydramine/phenylephrin/dextromethorphan/acetaminophen/GG	Child Delsym Cough Plus Dy-Nt
diphenhydramine/phenylephrin/dextromethorphan/acetaminophen/GG	Child Mucinex M-S Cold Day-Nte
diphenhydramine/phenylephrin/dextromethorphan/acetaminophen/GG	Children's M-S Cold Day-Night
diphenhydramine/phenylephrin/dextromethorphan/acetaminophen/GG	Daytime-Cold Nighttime-Cld-Flu
diphenhydramine/phenylephrin/dextromethorphan/acetaminophen/GG	Delsym Cough Plus Day-Night
diphenhydramine/phenylephrin/dextromethorphan/acetaminophen/GG	Mucinex Fast-Max Day-Nite Cold

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
diphenhydramine/phenylephrin/dextromethorph/acetaminophe n/GG	Mucinex Fast-Max Day-Nite Cong
diphenhydramine/phenylephrin/dextromethorph/acetaminophe n/GG	Mucinex Fst-Mx Dy-Nt Cold(dph)
diphenhydramine/phenylephrin/dextromethorph/acetaminophe n/GG	Wal-Phed PE Day-Night
disopyramide phosphate	disopyramide phosphate
disopyramide phosphate	Norpace
disopyramide phosphate	Norpace CR
dofetilide	dofetilide
dofetilide	Tikosyn
dolasetron mesylate	Anzemet
dolutegravir sodium/rilpivirine HCl	Juluca
donepezil HCl	Adlarity
donepezil HCl	Aricept
donepezil HCl	donepezil
doxepin HCl	doxepin
doxepin HCl	Silenor
dronedarone HCl	Multaq
droperidol	droperidol
efavirenz	efavirenz
efavirenz	Sustiva
efavirenz/emtricitabine/tenofovir disoproxil fumarate	Atripla
efavirenz/emtricitabine/tenofovir disoproxil fumarate	efavirenz-emtricitabin-tenofov
efavirenz/lamivudine/tenofovir disoproxil fumarate	efavirenz-lamivu-tenofov disop
efavirenz/lamivudine/tenofovir disoproxil fumarate	Symfi
efavirenz/lamivudine/tenofovir disoproxil fumarate	Symfi Lo
eliglustat tartrate	Cerdelga
emtricitabine/rilpivirine HCl/tenofovir alafenamide fumarate	Odefsey
emtricitabine/rilpivirine HCl/tenofovir disoproxil fumarate	Complera
enalapril maleate/hydrochlorothiazide	enalapril-hydrochlorothiazide
enalapril maleate/hydrochlorothiazide	Vaseretic
encorafenib	Braftovi
entrectinib	Rozlytrek
epirubicin HCl	Ellence
epirubicin HCl	epirubicin
eribulin mesylate	Halaven
erythromycin base	Ery-Tab
erythromycin base	erythromycin
erythromycin ethylsuccinate	E.E.S. 400
erythromycin ethylsuccinate	E.E.S. Granules
erythromycin ethylsuccinate	EryPed 200
erythromycin ethylsuccinate	EryPed 400
erythromycin ethylsuccinate	erythromycin ethylsuccinate
erythromycin lactobionate	Erythrocin
erythromycin lactobionate	erythromycin lactobionate
erythromycin stearate	Erythrocin (as stearate)
erythromycin stearate	erythromycin stearate
escitalopram oxalate	escitalopram oxalate
escitalopram oxalate	Lexapro
esomeprazole magnesium	esomeprazole magnesium
esomeprazole magnesium	Nexium
esomeprazole magnesium	Nexium 24HR
esomeprazole magnesium	Nexium Packet

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
esomeprazole magnesium/glycerin	Esomep-EZS
esomeprazole sodium	esomeprazole sodium
esomeprazole sodium	Nexium IV
esomeprazole strontium	esomeprazole strontium
famotidine	Acid Controller
famotidine	Acid Reducer (famotidine)
famotidine	Acid-Pep
famotidine	famotidine
famotidine	Heartburn Prevention
famotidine	Heartburn Relief (famotidine)
famotidine	Pepcid
famotidine	Pepcid AC
famotidine	Pepcid AC Maximum Strength
famotidine	Zantac-360 (famotidine)
famotidine in sodium chloride, iso-osmotic/PF	famotidine (PF)-NaCl (iso-os)
famotidine/calcium carbonate/magnesium hydroxide	Acid Controller Complete
famotidine/calcium carbonate/magnesium hydroxide	Acid Reducer Complete (famot)
famotidine/calcium carbonate/magnesium hydroxide	Complete
famotidine/calcium carbonate/magnesium hydroxide	Dual Action Complete
famotidine/calcium carbonate/magnesium hydroxide	Pepcid Complete
famotidine/calcium carbonate/magnesium hydroxide	Tums Dual Action (famotidine)
famotidine/PF	famotidine (PF)
felbamate	felbamate
felbamate	Felbatol
fingolimod HCl	fingolimod
fingolimod HCl	Gilenya
fingolimod lauryl sulfate	Tascenso ODT
flecainide acetate	flecainide
fluconazole	Diflucan
fluconazole	fluconazole
fluconazole in sodium chloride, iso-osmotic	fluconazole in NaCl (iso-osm)
fluorouracil	Adrucil
fluorouracil	fluorouracil
fluoxetine HCl	fluoxetine
fluoxetine HCl	Prozac
fluvoxamine maleate	fluvoxamine
fosinopril sodium/hydrochlorothiazide	fosinopril-hydrochlorothiazide
fosnetupitant chloride HCl/palonosetron HCl	Akynzeo (fosnetupitant)
furosemide	Furoscix
furosemide	furosemide
furosemide	Lasix
furosemide in 0.9 % sodium chloride	furosemide in 0.9 % NaCl
galantamine HBr	galantamine
galantamine HBr	Razadyne ER
gatifloxacin	gatifloxacin
gatifloxacin	Zymaxid
gemifloxacin mesylate	Factive
gilteritinib fumarate	Xospata
glasdegib maleate	Daurismo
granisetron	Sancuso
granisetron	Sustol
granisetron HCl	granisetron HCl
granisetron HCl/PF	granisetron (PF)
haloperidol	haloperidol

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
haloperidol decanoate	Haldol Decanoate
haloperidol decanoate	haloperidol decanoate
haloperidol lactate	Haldol
haloperidol lactate	haloperidol lactate
hydrochlorothiazide	hydrochlorothiazide
hydrocodone bitartrate	hydrocodone bitartrate
hydrocodone bitartrate	Hysingla ER
hydrocodone bitartrate	Zohydro ER
hydrocodone bitartrate/acetaminophen	hydrocodone-acetaminophen
hydrocodone bitartrate/acetaminophen	Lortab Elixir
hydrocodone bitartrate/guaifenesin	Obredon
hydrocodone bitartrate/homatropine methylbromide	Hycodan
hydrocodone bitartrate/homatropine methylbromide	Hycodan (with homatropine)
hydrocodone bitartrate/homatropine methylbromide	Hydrocodone Compound
hydrocodone bitartrate/homatropine methylbromide	hydrocodone-homatropine
hydrocodone bitartrate/homatropine methylbromide	Hydromet
hydrocodone polistirex/chlorpheniramine polistirex	hydrocodone-chlorpheniramine
hydrocodone polistirex/chlorpheniramine polistirex	TussiCaps
hydrocodone/ibuprofen	hydrocodone-ibuprofen
hydroxyamphetamine hbr/tropicamide	Paremyd
hydroxychloroquine sulfate	hydroxychloroquine
hydroxychloroquine sulfate	Plaquenil
hydroxyzine HCl	hydroxyzine HCl
hydroxyzine pamoate	hydroxyzine pamoate
hydroxyzine pamoate	Vistaril
ibuprofen/diphenhydramine citrate	Advil PM
ibuprofen/diphenhydramine citrate	Ibuprofen PM
ibuprofen/diphenhydramine citrate	Motrin PM
ibuprofen/diphenhydramine HCl	Advil PM Liqui-Gels
ibuprofen/diphenhydramine HCl	Ibuprofen PM
ibuprofen/famotidine	Duexis
ibuprofen/famotidine	ibuprofen-famotidine
ibutilide fumarate	Corvert
ibutilide fumarate	ibutilide fumarate
iloperidone	Fanapt
imatinib mesylate	Gleevec
imatinib mesylate	imatinib
imipramine HCl	imipramine HCl
imipramine pamoate	imipramine pamoate
indapamide	indapamide
inotuzumab ozogamicin	Besponsa
irbesartan/hydrochlorothiazide	Avalide
irbesartan/hydrochlorothiazide	irbesartan-hydrochlorothiazide
isradipine	isradipine
itraconazole	itraconazole
itraconazole	Sporanox
itraconazole	Sporanox Pulsepak
itraconazole	Tolsura
ivabradine HCl	Corlanor
ivosidenib	Tibsovo
ketoconazole	ketoconazole
LANSOPRAZOLE	FIRST-Lansoprazole
lansoprazole	lansoprazole
lansoprazole	Prevacid

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
lansoprazole	Prevacid 24Hr
lansoprazole	Prevacid SoluTab
lansoprazole/amoxicillin trihydrate/clarithromycin	amoxicil-clarithromy-lansopraz
lapatinib ditosylate	lapatinib
lapatinib ditosylate	Tykerb
lefamulin acetate	Xenleta
lenvatinib mesylate	Lenvima
leuprolide acetate	Eligard
leuprolide acetate	Eligard (3 month)
leuprolide acetate	Eligard (4 month)
leuprolide acetate	Eligard (6 month)
leuprolide acetate	Fensolvi
leuprolide acetate	leuprolide
leuprolide acetate	leuprolide (3 month)
leuprolide acetate	Lupron Depot
leuprolide acetate	Lupron Depot (3 month)
leuprolide acetate	Lupron Depot (4 month)
leuprolide acetate	Lupron Depot (6 Month)
leuprolide acetate	Lupron Depot-Ped
leuprolide acetate	Lupron Depot-Ped (3 month)
leuprolide acetate/norethindrone acetate	Lupaneta Pack (1 month)
leuprolide acetate/norethindrone acetate	Lupaneta Pack (3 month)
leuprolide mesylate	Camcevi (6 month)
levetiracetam	Elepsia XR
levetiracetam	Keppra
levetiracetam	Keppra XR
levetiracetam	levetiracetam
levetiracetam	Roweepra
levetiracetam	Roweepra XR
levetiracetam	Spritam
levetiracetam in sodium chloride, iso-osmotic	levetiracetam in NaCl (iso-os)
levofloxacin	levofloxacin
levofloxacin/dextrose 5 % in water	levofloxacin in D5W
levoketoconazole	Recorlev
lisinopril/hydrochlorothiazide	lisinopril-hydrochlorothiazide
lisinopril/hydrochlorothiazide	Zestoretic
lithium aspartate	Lithate
lithium carbonate	lithium carbonate
lithium carbonate	Lithobid
lofexidine HCl	Lucemyra
loperamide HCl	Anti-Diarrheal (loperamide)
loperamide HCl	Diamode
loperamide HCl	Imodium A-D
loperamide HCl	loperamide
loperamide HCl	Ultra A-D
loperamide HCl/simethicone	Anti-Diarrheal (lope)-Anti-Gas
loperamide HCl/simethicone	Imodium Multi-Symptom Relief
loperamide HCl/simethicone	loperamide-simethicone
lopinavir/ritonavir	Kaletra
lopinavir/ritonavir	lopinavir-ritonavir
losartan potassium/hydrochlorothiazide	Hyzaar
losartan potassium/hydrochlorothiazide	losartan-hydrochlorothiazide
lumateperone tosylate	Caplyta
lurasidone HCl	Latuda

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
macimorelin acetate	Macrilen
MAG HYDROXIDE/AL	
HYDROXIDE/SIMETH/DIPHENHYDRAMINE/LIDOCAINE	FIRST-Mouthwash BLM
memantine HCl/donepezil HCl	Namzaric
methadone HCl	Diskets
methadone HCl	methadone
methadone HCl	Methadone Intenso
methadone HCl	Methadose
methadone hydrochloride in 0.9 % sodium chloride	methadone in 0.9 % sod.chlorid
methamphetamine HCl	Desoxyn
methamphetamine HCl	methamphetamine
methyldopa/hydrochlorothiazide	methyldopa-hydrochlorothiazide
metoclopramide HCl	Gimoti
metoclopramide HCl	metoclopramide HCl
metoclopramide HCl	Reglan
metolazone	metolazone
metoprolol succinate/hydrochlorothiazide	Dutoprol
metoprolol tartrate/hydrochlorothiazide	metoprolol ta-hydrochlorothiaz
metronidazole	Flagyl
metronidazole	Metrogel Vaginal
metronidazole	metronidazole
metronidazole	Nuessa
metronidazole	Vandazole
metronidazole in sodium chloride	Metro I.V.
metronidazole in sodium chloride	metronidazole in NaCl (iso-os)
midazolam/ketamine HCl/ondansetron HCl	MKO (Midazolam-Ketamine-Ondan)
midostaurin	Rydapt
mifepristone	Korlym
mifepristone	Mifeprex
mifepristone	mifepristone
mirabegron	Myrbetriq
mirtazapine	mirtazapine
mirtazapine	Remeron
mirtazapine	Remeron SolTab
mobocertinib succinate	Exkivity
moxifloxacin HCl	Moxeza
moxifloxacin HCl	moxifloxacin
moxifloxacin HCl	Vigamox
moxifloxacin HCl in balanced salt solution no.2/PF	moxifloxacin (PF)-BSS
moxifloxacin HCl in sodium acetate and sulfate,water,iso-osm	moxifloxacin-sod.ace,sul-water
moxifloxacin HCl in sodium chloride, iso-osmotic	Avelox in NaCl (iso-osmotic)
moxifloxacin HCl in sodium chloride, iso-osmotic	moxifloxacin-sod.chloride(iso)
moxifloxacin HCl in sodium chloride,iso-osmotic/PF	moxifloxacin-sod chlor,iso(PF)
naproxen sodium/diphenhydramine HCl	Aleve PM
naproxen/esomeprazole magnesium	naproxen-esomeprazole
naproxen/esomeprazole magnesium	Vimovo
necitumumab	Portrazza
nelfinavir mesylate	Viracept
netupitant/palonosetron HCl	Akynzeo (netupitant)
nicardipine HCl	Cardene IV
nicardipine HCl	nicardipine
nicardipine HCl in 0.9 % sodium chloride	nicardipine in 0.9 % sod chlor
nicardipine in dextrose, iso-osmotic	Cardene IV in dextrose
nicardipine in sodium chloride, iso-osmotic	Cardene IV in sodium chloride

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
nicardipine in sodium chloride, iso-osmotic	nicardipine in NaCl (iso-os)
nilotinib HCl	Tasigna
nortriptyline HCl	nortriptyline
nortriptyline HCl	Pamelor
nusinersen sodium/PF	Spinraza (PF)
NYSTATIN/HYDROCORTISONE/DIPHENHYDRAMINE HCL	FIRST-Duke's
NYSTATIN/LIDOCAINE HCL/DIPHENHYDRAMINE HCL	First-BXN
NYSTATIN/TETRACYCLINE	
HCL/HYDROCORTISONE/DIPHENHYDRAMINE HCL	FIRST-Mary's Mouthwash
ofloxacin	Ocuflox
ofloxacin	ofloxacin
olanzapine	olanzapine
olanzapine	Zyprexa
olanzapine	Zyprexa Zydis
olanzapine pamoate	Zyprexa Relprevv
olanzapine/fluoxetine HCl	olanzapine-fluoxetine
olanzapine/fluoxetine HCl	Symbyax
olanzapine/samidorphan malate	Lybalvi
oliceridine fumarate	Olinvyk
olmesartan medoxomil/amlodipine	
besylate/hydrochlorothiazide	olmesartan-amlodipin-hcthiazid
olmesartan medoxomil/amlodipine	
besylate/hydrochlorothiazide	Tribenzor
olmesartan medoxomil/hydrochlorothiazide	Benicar HCT
olmesartan medoxomil/hydrochlorothiazide	olmesartan-hydrochlorothiazide
OMEPRAZOLE	FIRST-Omeprazole
omeprazole	omeprazole
OMEPRAZOLE	Omeprazole+SyrSpend SF Alka
omeprazole magnesium	Acid Reducer (omeprazole)
omeprazole magnesium	omeprazole magnesium
omeprazole magnesium	Prilosec
omeprazole magnesium	Prilosec OTC
omeprazole magnesium/amoxicillin trihydrate/rifabutin	Talicia
omeprazole/clarithromycin/amoxicillin trihydrate	Omeclamox-Pak
omeprazole/sodium bicarbonate	omeprazole-sodium bicarbonate
omeprazole/sodium bicarbonate	Zegerid
omeprazole/sodium bicarbonate	Zegerid OTC
ondansetron	ondansetron
ondansetron	Zuplenz
ondansetron HCl	ondansetron HCl
ondansetron HCl	Zofran
ondansetron HCl in 0.9 % sodium chloride	ondansetron in 0.9 % sod chlor
ondansetron HCl/PF	ondansetron HCl (PF)
osilodrostat phosphate	Isturisa
osimertinib mesylate	Tagrisso
oxaliplatin	oxaliplatin
oxytocin	oxytocin
oxytocin	Pitocin
oxytocin in 0.9 % sodium chloride	oxytocin in 0.9 % sod chloride
oxytocin in dextrose 5 %-lactated ringers	oxytocin in dextrose 5 % in LR
oxytocin/Ringer's solution,lactated	oxytocin in lactated ringers
ozanimod hydrochloride	Zeposia
ozanimod hydrochloride	Zeposia Starter Kit
ozanimod hydrochloride	Zeposia Starter Pack

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
paliperidone	Invega
paliperidone	paliperidone
paliperidone palmitate	Invega Hafyera
paliperidone palmitate	Invega Sustenna
paliperidone palmitate	Invega Trinza
palonosetron HCl	palonosetron
panobinostat lactate	Farydak
pantoprazole sodium	pantoprazole
pantoprazole sodium	Protonix
papaverine HCl	papaverine
papaverine HCl/phentolamine mesylate in water	IFE-BiMix 30/1
papaverine HCl/phentolamine mesylate/alprostadil	Tri-Mix (papavrn-phntlmn-PGE1)
paroxetine HCl	paroxetine HCl
paroxetine HCl	Paxil
paroxetine HCl	Paxil CR
paroxetine mesylate	Brisdelle
paroxetine mesylate	paroxetine mesylate(menop.sym)
paroxetine mesylate	Pexeva
pasireotide diaspargate	Signifor
pasireotide pamoate	Signifor LAR
pazopanib HCl	Votrient
pentamidine isethionate	Nebupent
pentamidine isethionate	Pentam
pentamidine isethionate	pentamidine
perphenazine	perphenazine
perphenazine/amitriptyline HCl	perphenazine-amitriptyline
phenylephrine HCl/diphenhydramine HCl	Allergy and Sinus Relief
phenylephrine HCl/diphenhydramine HCl	Benadryl Allergy Plus Congest
phenylephrine HCl/diphenhydramine HCl	Child Allergy Plus Congestion
phenylephrine HCl/diphenhydramine HCl	Child Benadryl Plus Congestion
phenylephrine HCl/diphenhydramine HCl	Children Night Time Cold-Cough
phenylephrine HCl/diphenhydramine HCl	Childs Triacting Cold-Cough
phenylephrine HCl/diphenhydramine HCl	Dimetapp Cold-Congestion
phenylephrine HCl/diphenhydramine HCl	Dr Manzanilla Cough-Cold
phenylephrine HCl/diphenhydramine HCl	KinderMed Kid Night Cold-Cough
phenylephrine HCl/diphenhydramine HCl	Sudafed PE Day and Night
phenylephrine HCl/diphenhydramine HCl	Triaminic Cold and CoughNT(PE)
phenylephrine HCl/diphenhydramine HCl	Wal-Dryl-D Allergy and Sinus
phenylephrine HCl/promethazine HCl	Promethazine VC
phenylephrine HCl/promethazine HCl	promethazine-phenylephrine
pimavanserin tartrate	Nuplazid
pimozide	pimozide
piperacillin and tazobactam in dextrose, iso-osmotic	Zosyn in dextrose (iso-osm)
piperacillin sodium/tazobactam sodium	piperacillin-tazobactam
pitolisant HCl	Wakix
ponesimod	Ponvory
ponesimod	Ponvory 14-Day Starter Pack
posaconazole	Noxafil
posaconazole	posaconazole
pralsetinib	Gavreto
prednisolone acetate/gatifloxacin	prednisolone acet-gatifloxacin
prednisolone acetate/gatifloxacin/bromfenac sodium	prednisol ace-gatiflox-bromfen
prednisolone acetate/moxifloxacin HCl	prednisolone-moxifloxacin HCl
prednisolone acetate/moxifloxacin HCl/bromfenac sodium	prednisolone-moxiflox-bromfen

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
prednisolone acetate/moxifloxacin HCl/nepafenac	prednisolone-moxiflo-nepafenac
prednisolone sodium phosphate/gatifloxacin/bromfenac sodium	prednisoln sp-gatiflox-bromfen
prednisolone sodium phosphate/moxifloxacin HCl	prednisolone sod ph-moxiflox
prednisolone sodium phosphate/moxifloxacin HCl/bromfenac sod	prednisoln sp-moxiflox-bromfen
pretomanid	pretomanid
primaquine phosphate	primaquine
procainamide HCl	procainamide
promethazine HCl	Phenergan
promethazine HCl	promethazine
promethazine HCl	Promethegan
promethazine HCl in 0.9 % sodium chloride	promethazine in 0.9 % NaCl
promethazine HCl/codeine	promethazine-codeine
promethazine HCl/dextromethorphan HBr	promethazine-DM
promethazine/phenylephrine HCl/codeine	Promethazine VC-Codeine
promethazine/phenylephrine HCl/codeine	promethazine-phenyleph-codeine
propafenone HCl	propafenone
propafenone HCl	Rythmol SR
propofol	Anesthesia S/I-40 (propofol)
propofol	Anesthesia S/I-40A (propofol)
propofol	Anesthesia S/I-40H (propofol)
propofol	Anesthesia S/I-40S (propofol)
propofol	Anesthesia S/I-60 (propofol)
propofol	Diprivan
propofol	propofol
propofol in lipid emulsion MCT/LCT (1:1)/PF	Propofol-Lipuro (PF)
propofol in lipid emulsion MCT/LCT (1:1)/PF	Propoven (EUA) (PF)
propranolol HCl/hydrochlorothiazide	propranolol-hydrochlorothiazid
quetiapine fumarate	quetiapine
quetiapine fumarate	Seroquel
quetiapine fumarate	Seroquel XR
quinapril HCl/hydrochlorothiazide	Accuretic
quinapril HCl/hydrochlorothiazide	quinapril-hydrochlorothiazide
quinidine gluconate	quinidine gluconate
quinidine sulfate	quinidine sulfate
quinine sulfate	Qualaquin
quinine sulfate	quinine sulfate
ranolazine	Aspruzyo Sprinkle
ranolazine	Ranexa
ranolazine	ranolazine
relugolix	Orgovyx
relugolix/estradiol/norethindrone acetate	Myfembree
remdesivir	remdesivir
remdesivir	Veklury
remimazolam besylate	Byfavo
ribociclib succinate	Kisqali
ribociclib succinate/letrozole	Kisqali Femara Co-Pack
rilpivirine	rilpivirine
rilpivirine HCl	Edurant
risperidone	Perseris
risperidone	Risperdal
risperidone	risperidone
risperidone microspheres	Risperdal Consta

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
romidepsin	Istodax
romidepsin	romidepsin
rucaparib camsylate	Rubraca
saquinavir mesylate	Invirase
selpercatinib	Retevmo
sertraline HCl	sertraline
sertraline HCl	Zoloft
sevoflurane	sevoflurane
sevoflurane	Ultane
siponimod	Mayzent
siponimod	Mayzent Starter(for 1mg maint)
siponimod	Mayzent Starter(for 2mg maint)
solifenacin succinate	solifenacin
solifenacin succinate	Vesicare
solifenacin succinate	Vesicare LS
sorafenib tosylate	Nexavar
sorafenib tosylate	sorafenib
sotalol HCl	Betapace
sotalol HCl	Betapace AF
sotalol HCl	Sorine
sotalol HCl	sotalol
sotalol HCl	Sotalol AF
sotalol HCl	Sotylize
spironolactone/hydrochlorothiazide	Aldactazide
spironolactone/hydrochlorothiazide	spironolacton-hydrochlorothiaz
sunitinib malate	sunitinib
sunitinib malate	Sutent
tacrolimus	Astagraf XL
tacrolimus	Envarsus XR
tacrolimus	Prograf
tacrolimus	tacrolimus
tamoxifen citrate	Soltamox
tamoxifen citrate	tamoxifen
tazemetostat hydrobromide	Tazverik
tebentafusp-tebn	Kimmtrak
telavancin HCl	Vibativ
telmisartan/hydrochlorothiazide	Micardis HCT
telmisartan/hydrochlorothiazide	telmisartan-hydrochlorothiazid
terlipressin acetate	Terlivaz
tetrabenazine	tetrabenazine
tetrabenazine	Xenazine
thioridazine HCl	thioridazine
tizanidine HCl	tizanidine
tizanidine HCl	Zanaflex
tizanidine HCl/irritant counter-irritants combination no.2	Comfort Pac-tizanidine
tolterodine tartrate	Detrol
tolterodine tartrate	Detrol LA
tolterodine tartrate	tolterodine
toremifene citrate	Fareston
toremifene citrate	toremifene
torsemide	Soaanz
torsemide	torsemide
tramadol HCl	ConZip
tramadol HCl	Qdolo

Appendix G. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
tramadol HCl	tramadol
tramadol HCl	Ultram
tramadol HCl/acetaminophen	tramadol-acetaminophen
tramadol HCl/acetaminophen	Ultracet
tramadol HCl/celecoxib	Seglantis
TRAMADOL HCL/GLUCOSAMINE SULFATE	Synapryn
trazodone HCl	trazodone
triamcinolone acetonide/moxifloxacin HCl/water/PF	triamcinolon-moxiflox-watr(PF)
triamterene/hydrochlorothiazide	Maxzide
triamterene/hydrochlorothiazide	Maxzide-25mg
triamterene/hydrochlorothiazide	triamterene-hydrochlorothiazid
trifluridine/tipiracil HCl	Lonsurf
trimipramine maleate	trimipramine
valbenazine tosylate	Ingrezza
valbenazine tosylate	Ingrezza Initiation Pack
valsartan/hydrochlorothiazide	Diovan HCT
valsartan/hydrochlorothiazide	valsartan-hydrochlorothiazide
vandetanib	Caprelsa
vardenafil HCl	vardenafil
vemurafenib	Zelboraf
venlafaxine besylate	venlafaxine besylate
venlafaxine HCl	Effexor XR
venlafaxine HCl	venlafaxine
voclosporin	Lupkynis
vonoprazan fumarate/amoxicillin trihydrate/clarithromycin	Voquezna Triple Pak
voriconazole	Vfend
voriconazole	Vfend IV
voriconazole	voriconazole
vorinostat	Zolinza
ziprasidone HCl	Geodon
ziprasidone HCl	ziprasidone HCl
ziprasidone mesylate	Geodon
ziprasidone mesylate	ziprasidone mesylate

Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 1-3)

To describe the incidence rate of hospitalized tachyarrhythmia, defined as principal diagnosis of tachyarrhythmia in the emergency department visit or inpatient hospital setting, overall and by subtype, that occurred between May 13, 2022 (the approval date of Mounjaro in the U.S.) to June 30, 2023 (the end date of the latest available data), in type 2 diabetes mellitus (T2DM) patients who newly initiated tirzepatide or other long-acting glucagon-like peptide 1 (GLP-1) receptor agonists (RAs), by product and patient characteristics including race/ethnicity groups.

- report 01 has a preindex enrollment requirement of 365 days

Query period start date (binds Index Date): May 13, 2022 (tirzepatide approval date in U.S.)

Query period end date (binds Index Date): June 30, 2023

Coverage requirement: Medical & Drug Coverage

Pre-index enrollment requirement: 365 days

Post-index enrollment requirement: N/A

Enrollment gap: 45 days

Age groups: 0-40, 41-64, 65-74, 75-84, ≥85 years old

Sex groups: Male, Female

Race groups: White, Black or African American, Asian, American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, Unknown, Multi-Racial

Stratifications: Age group (0-40, 41-64, 65-74, 75-84, ≥85)

Sex (M F)

Calendar Year

Race (White, Black or African American, Asian, American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, Unknown, Multi-Racial)

Calendar Year * Race

Age group * Race

Arrhythmia at baseline

Other cardiac disease at baseline (heart failure, ischemic heart disease/coronary artery disease/myocardial infarction, hypertension, valvular disease, obstructive sleep apnea, and hypertrophic cardiomyopathy)

Censor output stratifications: Categorical (0-30 31-60 61-90 91-183 184-365 366-455+)

Continuous

Follow up time stratifications: Categorical (0-30 31-60 61-90 91-183 184-365 366-455+)

Continuous

Envelope macro: No reclassification

Features: Censoring table, follow-up time table, exposure/HOI code distribution tables

Plus programming:

- Disease severity risk score and comorbidity score categorical bins

- Report baseline characteristics, effect estimates by race

- Truncation code distribution

Freeze data: No

Notes: N/A

Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 1-3)

		Cohort Group 1	Cohort Group 2	Cohort Group 3
		Tirzepatide (Mounjaro)	Exenatide synthetic (Bydureon, Bydureon BCISE)	Semaglutide (Ozempic)
Drug/Exposure	Exposure	Tirzepatide (Mounjaro)	Exenatide synthetic (Bydureon, Bydureon BCISE)	Semaglutide (Ozempic)
	Code Details (type, days supply, etc.)	Dispensings (Dispensings table only), native days supply	Dispensings (Dispensings table only), native days supply	Dispensings (Dispensings table only), native days supply
	Care Setting	N/A	N/A	N/A
	Incident with respect to:	Long-acting GLP-1 RA (Bydureon, Bydureon BCISE, Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Victoza, Wegovy, Xultophy) (Implemented as exclusion criteria)	Long-acting GLP-1 RA (Bydureon, Bydureon BCISE, Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Victoza, Wegovy, Xultophy) (Implemented as exclusion criteria)	Long-acting GLP-1 RA (Bydureon, Bydureon BCISE, Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Victoza, Wegovy, Xultophy) (Implemented as exclusion criteria)
	Code Details (type, days supply, etc.)	Dispensings (Dispensings table only), native days supply	Dispensings (Dispensings table only), native days supply	Dispensings (Dispensings table only), native days supply
	Care Setting	N/A	N/A	N/A
	Washout (days)	365 days (Implemented as exclusion criteria)	365 days (Implemented as exclusion criteria)	365 days (Implemented as exclusion criteria)
	Exposure Episode Truncation Criteria	*Death *Disenrollment *DP end date *Study period end date *Pregnancy *IP or ED encounter (other than HOI-defining hospitalized tachyarrhythmia) *non-index long-acting GLP-1 RA (see Combo Tool tab for more details on implementation)	*Death *Disenrollment *DP end date *Study period end date *Pregnancy *IP or ED encounter (other than HOI-defining hospitalized tachyarrhythmia) *non-index long-acting GLP-1 RA (see Combo Tool tab for more details on implementation)	*Death *Disenrollment *DP end date *Study period end date *Pregnancy *IP or ED encounter (other than HOI-defining hospitalized tachyarrhythmia) *non-index long-acting GLP-1 RA (see Combo Tool tab for more details on implementation)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)? (This does not apply to index-defining criteria)	No	No	No

Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 1-3)

		Cohort Group 1	Cohort Group 2	Cohort Group 3
		Tirzepatide (Mounjaro)	Exenatide synthetic (Bydureon, Bydureon BCISE)	Semaglutide (Ozempic)
	Forced supply to attach to codes	N/A	N/A	N/A
	Cohort Definition	Only the first valid treatment episode during the query period (01)	Only the first valid treatment episode during the query period (01)	Only the first valid treatment episode during the query period (01)
	Prevalent Cohort creation?	No	No	No
	Exposure Episode Gap	5 days	5 days	5 days
	Exposure Extension Period	5 days	5 days	5 days
	Minimum Episode Duration	1 day	1 day	1 day
	Minimum Days Supplied	1 day	1 day	1 day
	Point Exposure?	No	No	No
	Maximum Episode Duration	N/A	N/A	N/A
Base Cohort Outcome		<i>[out] = all</i>	<i>[out] = all</i>	<i>[out] = all</i>
	Event/Outcome	Hospitalized tachyarrhythmia	Hospitalized tachyarrhythmia	Hospitalized tachyarrhythmia
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect to	N/A	N/A	N/A
	Event Incidence Criteria	N/A	N/A	N/A
	Care Setting / PDX			
	Event washout (days)	0 days	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Start of at-risk period	N/A	N/A	N/A
	Blackout Period	1 day	1 day	1 day

Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 1-3)

		Cohort Group 1	Cohort Group 2	Cohort Group 3
		Tirzepatide (Mounjaro)	Exenatide synthetic (Bydureon, Bydureon BCISE)	Semaglutide (Ozempic)
Outcome	Event/Outcome	Atrial fibrillation and flutter	Atrial fibrillation and flutter	Atrial fibrillation and flutter
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect to	N/A	N/A	N/A
	Event Incidence Criteria Care Setting / PDX	N/A	N/A	N/A
	Event washout (days)	0 days	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Start of at-risk period	N/A	N/A	N/A
	Blackout Period	1 day	1 day	1 day
	Event/Outcome	Sinus tachycardia	Sinus tachycardia	Sinus tachycardia
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect to	N/A	N/A	N/A
	Event Incidence Criteria Care Setting / PDX	N/A	N/A	N/A
	Event washout (days)	0 days	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)

Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 1-3)

		Cohort Group 1	Cohort Group 2	Cohort Group 3
		Tirzepatide (Mounjaro)	Exenatide synthetic (Bydureon, Bydureon BCISE)	Semaglutide (Ozempic)
Outcome	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Start of at-risk period	N/A	N/A	N/A
	Blackout Period	1 day	1 day	1 day
	Event/Outcome	Supraventricular tachycardia	Supraventricular tachycardia	Supraventricular tachycardia
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect to	N/A	N/A	N/A
	Event Incidence Criteria	N/A	N/A	N/A
	Care Setting / PDX			
	Event washout (days)	0 days	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Start of at-risk period	N/A	N/A	N/A
	Blackout Period	1 day	1 day	1 day
	Event/Outcome	Other tachycardia	Other tachycardia	Other tachycardia
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect to	N/A	N/A	N/A

Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 1-3)

		Cohort Group 1	Cohort Group 2	Cohort Group 3
		Tirzepatide (Mounjaro)	Exenatide synthetic (Bydureon, Bydureon BCISE)	Semaglutide (Ozempic)
Outcome	Event Incidence Criteria	N/A	N/A	N/A
	Care Setting / PDX			
	Event washout (days)	0 days	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Start of at-risk period	N/A	N/A	N/A
	Blackout Period	1 day	1 day	1 day
	Event/Outcome	Cardiac arrest	Cardiac arrest	Cardiac arrest
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect to	N/A	N/A	N/A
	Event Incidence Criteria	N/A	N/A	N/A
	Care Setting / PDX			
	Event washout (days)	0 days	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Start of at-risk period	N/A	N/A	N/A
	Blackout Period	1 day	1 day	1 day

Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 1-3)

	Cohort Group 1	Cohort Group 2	Cohort Group 3
	Tirzepatide (Mounjaro)	Exenatide synthetic (Bydureon, Bydureon BCISE)	Semaglutide (Ozempic)
Outcome	Event/Outcome	Ventricular fibrillation and flutter	Ventricular fibrillation and flutter
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*
	Event Incidence with Respect to	N/A	N/A
	Event Incidence Criteria	N/A	N/A
	Care Setting / PDX		
	Event washout (days)	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No
	Forced supply to attach to codes	N/A	N/A
	Start of at-risk period	N/A	N/A
	Blackout Period	1 day	1 day
	Event/Outcome	Ventricular tachycardia	Ventricular tachycardia
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*
	Event Incidence with Respect to	N/A	N/A
	Event Incidence Criteria	N/A	N/A
	Care Setting / PDX		
	Event washout (days)	0 days	0 days

Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 1-3)

		Cohort Group 1	Cohort Group 2	Cohort Group 3
		Tirzepatide (Mounjaro)	Exenatide synthetic (Bydureon, Bydureon BCISE)	Semaglutide (Ozempic)
Inclusion/Exclusion Criteria	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Start of at-risk period	N/A	N/A	N/A
	Blackout Period	1 day	1 day	1 day
	Include or Exclude	Inclusion	Inclusion	Inclusion
	Conditions	Type 2 Diabetes	Type 2 Diabetes	Type 2 Diabetes
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	Any	Any	Any
Inclusion/Exclusion Criteria	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
	AND			
	Include or Exclude	Inclusion	Inclusion	Inclusion
	Conditions	Any oral anti-diabetic drug	Any oral anti-diabetic drug	Any oral anti-diabetic drug
	Code Details (type, days supply, etc.)	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)

Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 1-3)

		Cohort Group 1	Cohort Group 2	Cohort Group 3
		Tirzepatide (Mounjaro)	Exenatide synthetic (Bydureon, Bydureon BCISE)	Semaglutide (Ozempic)
Inclusion/Exclusion Criteria	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
		AND (	AND (	AND (
	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Insulin	Insulin	Insulin
	Code Details (type, days supply, etc.)	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
		AND NOT	AND NOT	AND NOT
	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Any anti-diabetic drug other than insulin	Any anti-diabetic drug other than insulin	Any anti-diabetic drug other than insulin
	Code Details (type, days supply, etc.)	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A

Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 1-3)

		Cohort Group 1	Cohort Group 2	Cohort Group 3
		Tirzepatide (Mounjaro)	Exenatide synthetic (Bydureon, Bydureon BCISE)	Semaglutide (Ozempic)
Inclusion/Exclusion Criteria	Number of Code Occurrences	1x	1x	1x
		) OR	) OR	) OR
	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Type 1 Diabetes	Type 1 Diabetes	Type 1 Diabetes
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
Inclusion/Exclusion Criteria		OR	OR	OR
	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Gestational Diabetes	Gestational Diabetes	Gestational Diabetes
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
		OR	OR	OR
Inclusion/Exclusion Criteria	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Other secondary diabetes illness	Other secondary diabetes illness	Other secondary diabetes illness
	Code Details (type, days supply, etc.)	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes

Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 1-3)

		Cohort Group 1	Cohort Group 2	Cohort Group 3
		Tirzepatide (Mounjaro)	Exenatide synthetic (Bydureon, Bydureon BCISE)	Semaglutide (Ozempic)
Inclusion/Exclusion Criteria	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
		OR	OR	OR
	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Short-acting GLP-1 RA (Byetta, Adlyxin, Soliqua)	Short-acting GLP-1 RA (Byetta, Adlyxin, Soliqua)	Short-acting GLP-1 RA (Byetta, Adlyxin, Soliqua)
	Code Details (type, days supply, etc.)	Dispensing (RX) code	Dispensing (RX) code	Dispensing (RX) code
	Care Setting/PDX	Any	Any	Any
Inclusion/Exclusion Criteria	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
		OR	OR	OR
	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Pregnancy	Pregnancy	Pregnancy
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No

Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 1-3)

		Cohort Group 1	Cohort Group 2	Cohort Group 3
		Tirzepatide (Mounjaro)	Exenatide synthetic (Bydureon, Bydureon BCISE)	Semaglutide (Ozempic)
Inclusion/Exclusion (Washout) Criteria	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
		OR	OR	OR
	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Long-acting GLP-1 RA (Bydureon, Bydureon BCISE, Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Victoza, Wegovy, Xultophy)	Long-acting GLP-1 RA (Bydureon, Bydureon BCISE, Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Victoza, Wegovy, Xultophy)	Long-acting GLP-1 RA (Bydureon, Bydureon BCISE, Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Victoza, Wegovy, Xultophy)
	Code Details (type, days supply, etc.)	Dispensing (RX) code	Dispensing (RX) code	Dispensing (RX) code
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
Stockpiling	Group(s) Affected by Custom Stockpiling Rules	Long or Short-acting GLP-1 RAs by brand name (for Victoza, both brand names consolidated to one stockgroup) (Other RXs by generic name, default stockpiling rules)	Long or Short-acting GLP-1 RAs by brand name (for Victoza, both brand names consolidated to one stockgroup) (Other RXs by generic name, default stockpiling rules)	Long or Short-acting GLP-1 RAs by brand name (for Victoza, both brand names consolidated to one stockgroup) (Other RXs by generic name, default stockpiling rules)
	Same Day Processing (days supply)	Max	Max	Max
	Same Day Processing (amount supply)	Max	Max	Max
	Allowable Range (days supply)	Greater than 0	Greater than 0	Greater than 0
	Allowable Range (amount)	Greater than 0	Greater than 0	Greater than 0

Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 1-3)

		Cohort Group 1	Cohort Group 2	Cohort Group 3
		Tirzepatide (Mounjaro)	Exenatide synthetic (Bydureon, Bydureon BCISE)	Semaglutide (Ozempic)
Baseline	Covariates	Maximum Amount of Percentage Overlap Allowed Prior to Shifting Dispensing Date	0% (No shifting of index date; truncate previous dispensing at any overlap with next dispensing)	0% (No shifting of index date; truncate previous dispensing at any overlap with next dispensing)
		Covariates	(See Appendix I)	(See Appendix I)
		Code Details (type, days supply, etc.)	(See Appendix I)	(See Appendix I)
		Care Setting/PDX	N/A	N/A
	Utilization/ Comorbidity Score	Covariate evaluation window (days)	(See Appendix I)	(See Appendix I)
		Comorbidity Score evaluation window (days)	(-365, -1)	(-365, -1)
		Medical Utilization Evaluation Window	(-365, -1)	(-365, -1)
		Medical Utilization Care setting	IP, IS, AV, OA, ED	IP, IS, AV, OA, ED
		Drug Utilization Evaluation Window	(-365, -1)	(-365, -1)

Abbreviations:

DP: Data Partner

IP: Inpatient

ED: Emergency Department

HOI: Health Outcome of Interest

PDX: Principal Discharge Diagnosis Flag

IPP: Inpatient Hospital Stays, Principal Diagnoses

IS: Non-acute Institutional Stay

AV: Ambulatory Visits

OA: Other Ambulatory Visits

N/A: Not applicable

Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 4-6) (Continued)

		Cohort Group 4	Cohort Group 5	Cohort Group 6
		Semaglutide (Rybelsus)	Semaglutide (Wegovy)	Liraglutide (Saxenda)
Drug/Exposure	Exposure	Semaglutide (Rybelsus)	Semaglutide (Wegovy)	Liraglutide (Saxenda)
	Code Details (type, days supply, etc.)	Dispensings (Dispensings table only), native days supply	Dispensings (Dispensings table only), native days supply	Dispensings (Dispensings table only), native days supply
	Care Setting	N/A	N/A	N/A
	Incident with respect to:	Long-acting GLP-1 RA (Bydureon, Bydureon BCISE, Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Victoza, Wegovy, Xultophy) (Implemented as exclusion criteria)	Long-acting GLP-1 RA (Bydureon, Bydureon BCISE, Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Victoza, Wegovy, Xultophy) (Implemented as exclusion criteria)	Long-acting GLP-1 RA (Bydureon, Bydureon BCISE, Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Victoza, Wegovy, Xultophy) (Implemented as exclusion criteria)
	Code Details (type, days supply, etc.)	Dispensings (Dispensings table only), native days supply	Dispensings (Dispensings table only), native days supply	Dispensings (Dispensings table only), native days supply
	Care Setting	N/A	N/A	N/A
	Washout (days)	365 days (Implemented as exclusion criteria)	365 days (Implemented as exclusion criteria)	365 days (Implemented as exclusion criteria)
	Exposure Episode Truncation Criteria	*Death *Disenrollment *DP end date *Study period end date *Pregnancy *IP or ED encounter (other than HOI- defining hospitalized tachyarrhythmia) *non-index long-acting GLP-1 RA (see Combo Tool tab for more details on implementation)	*Death *Disenrollment *DP end date *Study period end date *Pregnancy *IP or ED encounter (other than HOI- defining hospitalized tachyarrhythmia) *non-index long-acting GLP-1 RA (see Combo Tool tab for more details on implementation)	*Death *Disenrollment *DP end date *Study period end date *Pregnancy *IP or ED encounter (other than HOI- defining hospitalized tachyarrhythmia) *non-index long-acting GLP-1 RA (see Combo Tool tab for more details on implementation)

Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 4-6) (Continued)

		Cohort Group 4	Cohort Group 5	Cohort Group 6
		Semaglutide (Rybelsus)	Semaglutide (Wegovy)	Liraglutide (Saxenda)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)? (This does not apply to index-defining criteria)	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Cohort Definition	Only the first valid treatment episode during the query period (01)	Only the first valid treatment episode during the query period (01)	Only the first valid treatment episode during the query period (01)
	Prevalent Cohort creation?	No	No	No
	Exposure Episode Gap	5 days	5 days	5 days
	Exposure Extension Period	5 days	5 days	5 days
	Minimum Episode Duration	1 day	1 day	1 day
	Minimum Days Supplied	1 day	1 day	1 day
	Point Exposure?	No	No	No
	Maximum Episode Duration	N/A	N/A	N/A
Base Cohort Outcome		<i>[out] = all</i>	<i>[out] = all</i>	<i>[out] = all</i>
	Event/Outcome	Hospitalized tachyarrhythmia	Hospitalized tachyarrhythmia	Hospitalized tachyarrhythmia
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect to	N/A	N/A	N/A
	Event Incidence Criteria	N/A	N/A	N/A
	Care Setting / PDX			
	Event washout (days)	0 days	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Start of at-risk period	N/A	N/A	N/A
	Blackout Period	1 day	1 day	1 day

Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 4-6) (Continued)

	Cohort Group 4	Cohort Group 5	Cohort Group 6
	Semaglutide (Rybelsus)	Semaglutide (Wegovy)	Liraglutide (Saxenda)
Event/Outcome	Atrial fibrillation and flutter	Atrial fibrillation and flutter	Atrial fibrillation and flutter
Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
Event Incidence with Respect to	N/A	N/A	N/A
Event Incidence Criteria	N/A	N/A	N/A
Care Setting / PDX			
Event washout (days)	0 days	0 days	0 days
Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
Forced supply to attach to codes	N/A	N/A	N/A
Start of at-risk period	N/A	N/A	N/A
Blackout Period	1 day	1 day	1 day
Event/Outcome	Sinus tachycardia	Sinus tachycardia	Sinus tachycardia
Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
Event Incidence with Respect to	N/A	N/A	N/A
Event Incidence Criteria	N/A	N/A	N/A
Care Setting / PDX			
Event washout (days)	0 days	0 days	0 days
Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
Forced supply to attach to codes	N/A	N/A	N/A
Start of at-risk period	N/A	N/A	N/A

Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 4-6) (Continued)

	Cohort Group 4	Cohort Group 5	Cohort Group 6
	Semaglutide (Rybelsus)	Semaglutide (Wegovy)	Liraglutide (Saxenda)
Blackout Period	1 day	1 day	1 day
Outcome	Event/Outcome	Supraventricular tachycardia	Supraventricular tachycardia
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*
	Event Incidence with Respect to	N/A	N/A
	Event Incidence Criteria	N/A	N/A
	Care Setting / PDX		
	Event washout (days)	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No
	Forced supply to attach to codes	N/A	N/A
	Start of at-risk period	N/A	N/A
	Blackout Period	1 day	1 day
	Event/Outcome	Other tachycardia	Other tachycardia
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*
	Event Incidence with Respect to	N/A	N/A
	Event Incidence Criteria	N/A	N/A
	Care Setting / PDX		
	Event washout (days)	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No
	Forced supply to attach to codes	N/A	N/A

Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 4-6) (Continued)

	Cohort Group 4	Cohort Group 5	Cohort Group 6
	Semaglutide (Rybelsus)	Semaglutide (Wegovy)	Liraglutide (Saxenda)
Start of at-risk period	N/A	N/A	N/A
Blackout Period	1 day	1 day	1 day
Event/Outcome	Cardiac arrest	Cardiac arrest	Cardiac arrest
Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
Event Incidence with Respect to	N/A	N/A	N/A
Event Incidence Criteria	N/A	N/A	N/A
Care Setting / PDX			
Event washout (days)	0 days	0 days	0 days
Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
Forced supply to attach to codes	N/A	N/A	N/A
Start of at-risk period	N/A	N/A	N/A
Blackout Period	1 day	1 day	1 day
Event/Outcome	Ventricular fibrillation and flutter	Ventricular fibrillation and flutter	Ventricular fibrillation and flutter
Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
Event Incidence with Respect to	N/A	N/A	N/A
Event Incidence Criteria	N/A	N/A	N/A
Care Setting / PDX			
Event washout (days)	0 days	0 days	0 days
Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No

Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 4-6) (Continued)

		Cohort Group 4	Cohort Group 5	Cohort Group 6
		Semaglutide (Rybelsus)	Semaglutide (Wegovy)	Liraglutide (Saxenda)
	Forced supply to attach to codes	N/A	N/A	N/A
	Start of at-risk period	N/A	N/A	N/A
	Blackout Period	1 day	1 day	1 day
	Event/Outcome	Ventricular tachycardia	Ventricular tachycardia	Ventricular tachycardia
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect to	N/A	N/A	N/A
	Event Incidence Criteria	N/A	N/A	N/A
	Care Setting / PDX			
	Event washout (days)	0 days	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Start of at-risk period	N/A	N/A	N/A
	Blackout Period	1 day	1 day	1 day
Inclusion/Exclusion Criteria	Include or Exclude	Inclusion	Inclusion	Inclusion
	Conditions	Type 2 Diabetes	Type 2 Diabetes	Type 2 Diabetes
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
		AND	AND	AND
	Include or Exclude	Inclusion	Inclusion	Inclusion

Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 4-6) (Continued)

		Cohort Group 4	Cohort Group 5	Cohort Group 6
		Semaglutide (Rybelsus)	Semaglutide (Wegovy)	Liraglutide (Saxenda)
Inclusion/Exclusion Criteria	Conditions	Any oral anti-diabetic drug	Any oral anti-diabetic drug	Any oral anti-diabetic drug
	Code Details (type, days supply, etc.)	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
Inclusion/Exclusion Criteria	AND (		AND (	AND (
	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Insulin	Insulin	Insulin
	Code Details (type, days supply, etc.)	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
Inclusion/Exclusion Criteria	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
	AND NOT		AND NOT	AND NOT
	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Any anti-diabetic drug other than insulin	Any anti-diabetic drug other than insulin	Any anti-diabetic drug other than insulin
	Code Details (type, days supply, etc.)	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
	Care Setting/PDX	Any	Any	Any
Inclusion/Exclusion Criteria	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
	OR		OR	OR
	Include or Exclude	Exclusion	Exclusion	Exclusion

Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 4-6) (Continued)

Inclusion/Exclusion Criteria		Cohort Group 4	Cohort Group 5	Cohort Group 6
		Semaglutide (Rybelsus)	Semaglutide (Wegovy)	Liraglutide (Saxenda)
	Conditions	Type 1 Diabetes	Type 1 Diabetes	Type 1 Diabetes
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
Inclusion/Exclusion Criteria	Number of Code Occurrences	1x	1x	1x
		) OR	) OR	) OR
	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Gestational Diabetes	Gestational Diabetes	Gestational Diabetes
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
Inclusion/Exclusion Criteria	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
		OR	OR	OR
	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Other secondary diabetes illness	Other secondary diabetes illness	Other secondary diabetes illness
	Code Details (type, days supply, etc.)	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
Inclusion/Exclusion Criteria	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
		OR	OR	OR
	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Other secondary diabetes illness	Other secondary diabetes illness	Other secondary diabetes illness
	Code Details (type, days supply, etc.)	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
	Care Setting/PDX	Any	Any	Any
Inclusion/Exclusion Criteria	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
		OR	OR	OR
	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Other secondary diabetes illness	Other secondary diabetes illness	Other secondary diabetes illness
	Code Details (type, days supply, etc.)	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
Inclusion/Exclusion Criteria	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
		OR	OR	OR
	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Other secondary diabetes illness	Other secondary diabetes illness	Other secondary diabetes illness
Inclusion/Exclusion Criteria	Code Details (type, days supply, etc.)	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
		OR	OR	OR
	Include or Exclude	Exclusion	Exclusion	Exclusion

Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 4-6) (Continued)

Inclusion/Exclusion Criteria		Cohort Group 4	Cohort Group 5	Cohort Group 6
		Semaglutide (Rybelsus)	Semaglutide (Wegovy)	Liraglutide (Saxenda)
	Conditions	Short-acting GLP-1 RA (Byetta, Adlyxin, Soliqua)	Short-acting GLP-1 RA (Byetta, Adlyxin, Soliqua)	Short-acting GLP-1 RA (Byetta, Adlyxin, Soliqua)
	Code Details (type, days supply, etc.)	Dispensing (RX) code	Dispensing (RX) code	Dispensing (RX) code
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
Inclusion/Exclusion Criteria	Number of Code Occurrences	1x	1x	1x
		OR	OR	OR
	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Pregnancy	Pregnancy	Pregnancy
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
Inclusion/Exclusion (Washout) Criteria	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
		OR	OR	OR
	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Long-acting GLP-1 RA (Bydureon, Bydureon BCISE, Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Victoza, Wegovy, Xultophy)	Long-acting GLP-1 RA (Bydureon, Bydureon BCISE, Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Victoza, Wegovy, Xultophy)	Long-acting GLP-1 RA (Bydureon, Bydureon BCISE, Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Victoza, Wegovy, Xultophy)
	Code Details (type, days supply, etc.)	Dispensing (RX) code	Dispensing (RX) code	Dispensing (RX) code
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)

Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 4-6) (Continued)

		Cohort Group 4	Cohort Group 5	Cohort Group 6
		Semaglutide (Rybelsus)	Semaglutide (Wegovy)	Liraglutide (Saxenda)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
Stockpiling	Group(s) Affected by Custom Stockpiling Rules	Long or Short-acting GLP-1 RAs by brand name (for Victoza, both brand names consolidated to one stockgroup) (Other RXs by generic name, default stockpiling rules)	Long or Short-acting GLP-1 RAs by brand name (for Victoza, both brand names consolidated to one stockgroup) (Other RXs by generic name, default stockpiling rules)	Long or Short-acting GLP-1 RAs by brand name (for Victoza, both brand names consolidated to one stockgroup) (Other RXs by generic name, default stockpiling rules)
	Same Day Processing (days supply)	Max	Max	Max
	Same Day Processing (amount supply)	Max	Max	Max
	Allowable Range (days supply)	Greater than 0	Greater than 0	Greater than 0
	Allowable Range (amount supply)	Greater than 0	Greater than 0	Greater than 0
	Maximum Amount of Percentage Overlap Allowed Prior to Shifting Dispensing Date	0% (No shifting of index date; truncate previous dispensing at any overlap with next dispensing)	0% (No shifting of index date; truncate previous dispensing at any overlap with next dispensing)	0% (No shifting of index date; truncate previous dispensing at any overlap with next dispensing)
Baseline Covariates	Covariates	(See Appendix I)	(See Appendix I)	(See Appendix I)
	Code Details (type, days supply, etc.)	(See Appendix I)	(See Appendix I)	(See Appendix I)
	Care Setting/PDX	N/A	N/A	N/A
	Covariate evaluation window (days)	(See Appendix I)	(See Appendix I)	(See Appendix I)
Utilization/Comorbidity Score	Comorbidity Score evaluation window (days)	(-365, -1)	(-365, -1)	(-365, -1)
	Medical Utilization Evaluation Window	(-365, -1)	(-365, -1)	(-365, -1)
	Medical Utilization Care setting	IP, IS, AV, OA, ED	IP, IS, AV, OA, ED	IP, IS, AV, OA, ED
	Drug Utilization Evaluation Window	(-365, -1)	(-365, -1)	(-365, -1)

Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 4-6) (Continued)

Cohort Group 4	Cohort Group 5	Cohort Group 6
Semaglutide (Rybelsus)	Semaglutide (Wegovy)	Liraglutide (Saxenda)

Abbreviations:

DP: Data Partner

IP: Inpatient

ED: Emergency Department

HOI: Health Outcome of Interest

PDX: Principal Discharge Diagnosis Flag

IPP: Inpatient Hospital Stays, Principal Diagnoses

IS: Non-acute Institutional Stay

AV: Ambulatory Visits

OA: Other Ambulatory Visits

N/A: Not applicable

Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 7-9) (Continued)

		Cohort Group 7	Cohort Group 8	Cohort Group 9
		Liraglutide (Victoza)	Dulaglutide (Trulicity)	Insulin degludec and liraglutide (Xultophy)
Drug/Exposure	Exposure	Liraglutide (Victoza)	Dulaglutide (Trulicity)	Insulin degludec and liraglutide (Xultophy)
	Code Details (type, days supply, etc.)	Dispensings (Dispensings table only), native days supply	Dispensings (Dispensings table only), native days supply	Dispensings (Dispensings table only), native days supply
	Care Setting	N/A	N/A	N/A
	Incident with respect to:	Long-acting GLP-1 RA (Bydureon, Bydureon BCISE, Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Victoza, Wegovy, Xultophy) (Implemented as exclusion criteria)	Long-acting GLP-1 RA (Bydureon, Bydureon BCISE, Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Victoza, Wegovy, Xultophy) (Implemented as exclusion criteria)	Long-acting GLP-1 RA (Bydureon, Bydureon BCISE, Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Victoza, Wegovy, Xultophy) (Implemented as exclusion criteria)
	Code Details (type, days supply, etc.)	Dispensings (Dispensings table only), native days supply	Dispensings (Dispensings table only), native days supply	Dispensings (Dispensings table only), native days supply
	Care Setting	N/A	N/A	N/A
	Washout (days)	365 days (Implemented as exclusion criteria)	365 days (Implemented as exclusion criteria)	365 days (Implemented as exclusion criteria)
Exposure Episode Truncation Criteria		*Death *Disenrollment *DP end date *Study period end date *Pregnancy *IP or ED encounter (other than HOI- defining hospitalized tachyarrhythmia) *non-index long-acting GLP-1 RA (see Combo Tool tab for more details on implementation)	*Death *Disenrollment *DP end date *Study period end date *Pregnancy *IP or ED encounter (other than HOI- defining hospitalized tachyarrhythmia) *non-index long-acting GLP-1 RA (see Combo Tool tab for more details on implementation)	*Death *Disenrollment *DP end date *Study period end date *Pregnancy *IP or ED encounter (other than HOI- defining hospitalized tachyarrhythmia) *non-index long-acting GLP-1 RA (see Combo Tool tab for more details on implementation)

Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 7-9) (Continued)

		Cohort Group 7	Cohort Group 8	Cohort Group 9
		Liraglutide (Victoza)	Dulaglutide (Trulicity)	Insulin degludec and liraglutide (Xultophy)
Drug/Exposure	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)? (This does not apply to index-defining criteria)	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Cohort Definition	Only the first valid treatment episode during the query period (01)	Only the first valid treatment episode during the query period (01)	Only the first valid treatment episode during the query period (01)
	Prevalent Cohort creation?	No	No	No
	Exposure Episode Gap	5 days	5 days	5 days
	Exposure Extension Period	5 days	5 days	5 days
	Minimum Episode Duration	1 day	1 day	1 day
	Minimum Days Supplied	1 day	1 day	1 day
	Point Exposure?	No	No	No
	Maximum Episode Duration	N/A	N/A	N/A
Base Cohort Outcome	Event/Outcome	Hospitalized tachyarrhythmia	Hospitalized tachyarrhythmia	Hospitalized tachyarrhythmia
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect to	N/A	N/A	N/A
	Event Incidence Criteria	N/A	N/A	N/A
	Care Setting / PDX			
	Event washout (days)	0 days	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Start of at-risk period	N/A	N/A	N/A
	Blackout Period	1 day	1 day	1 day
	Event/Outcome	Atrial fibrillation and flutter	Atrial fibrillation and flutter	Atrial fibrillation and flutter

Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 7-9) (Continued)

		Cohort Group 7	Cohort Group 8	Cohort Group 9
		Liraglutide (Victoza)	Dulaglutide (Trulicity)	Insulin degludec and liraglutide (Xultophy)
Outcome	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect to	N/A	N/A	N/A
	Event Incidence Criteria	N/A	N/A	N/A
	Care Setting / PDX			
	Event washout (days)	0 days	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Start of at-risk period	N/A	N/A	N/A
	Blackout Period	1 day	1 day	1 day
Outcome	Event/Outcome	Sinus tachycardia	Sinus tachycardia	Sinus tachycardia
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect to	N/A	N/A	N/A
	Event Incidence Criteria	N/A	N/A	N/A
	Care Setting / PDX			
	Event washout (days)	0 days	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Start of at-risk period	N/A	N/A	N/A
	Blackout Period	1 day	1 day	1 day

Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 7-9) (Continued)

		Cohort Group 7	Cohort Group 8	Cohort Group 9
		Liraglutide (Victoza)	Dulaglutide (Trulicity)	Insulin degludec and liraglutide (Xultophy)
Outcome	Event/Outcome	Supraventricular tachycardia	Supraventricular tachycardia	Supraventricular tachycardia
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect to	N/A	N/A	N/A
	Event Incidence Criteria	N/A	N/A	N/A
	Care Setting / PDX			
	Event washout (days)	0 days	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Start of at-risk period	N/A	N/A	N/A
	Blackout Period	1 day	1 day	1 day
Outcome	Event/Outcome	Other tachycardia	Other tachycardia	Other tachycardia
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect to	N/A	N/A	N/A
	Event Incidence Criteria	N/A	N/A	N/A
	Care Setting / PDX			
	Event washout (days)	0 days	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Start of at-risk period	N/A	N/A	N/A
	Blackout Period	1 day	1 day	1 day
	Event/Outcome	Cardiac arrest	Cardiac arrest	Cardiac arrest

Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 7-9) (Continued)

	Cohort Group 7 Liraglutide (Victoza)	Cohort Group 8 Dulaglutide (Trulicity)	Cohort Group 9 Insulin degludec and liraglutide (Xultophy)
Outcome	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*
	Event Incidence with Respect to	N/A	N/A
	Event Incidence Criteria	N/A	N/A
	Care Setting / PDX		
	Event washout (days)	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No
	Forced supply to attach to codes	N/A	N/A
	Start of at-risk period	N/A	N/A
	Blackout Period	1 day	1 day
Outcome	Event/Outcome	Ventricular fibrillation and flutter	Ventricular fibrillation and flutter
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	IPP, ED*	IPP, ED*
	Event Incidence with Respect to	N/A	N/A
	Event Incidence Criteria	N/A	N/A
	Care Setting / PDX		
	Event washout (days)	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No
	Forced supply to attach to codes	N/A	N/A
	Start of at-risk period	N/A	N/A
	Blackout Period	1 day	1 day
	Event/Outcome	Ventricular tachycardia	Ventricular tachycardia
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes

Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 7-9) (Continued)

		Cohort Group 7	Cohort Group 8	Cohort Group 9
		Liraglutide (Victoza)	Dulaglutide (Trulicity)	Insulin degludec and liraglutide (Xultophy)
Outcome	Care Setting/PDX	IPP, ED*	IPP, ED*	IPP, ED*
	Event Incidence with Respect to Event Incidence Criteria	N/A	N/A	N/A
	Care Setting / PDX	N/A	N/A	N/A
	Event washout (days)	0 days	0 days	0 days
	Event de-duplication	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)	All occurrences of an HOI during an exposure episode are counted for all event characteristics (0)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Start of at-risk period	N/A	N/A	N/A
	Blackout Period	1 day	1 day	1 day
Inclusion/Exclusion Criteria	Include or Exclude	Inclusion	Inclusion	Inclusion
	Conditions	Type 2 Diabetes	Type 2 Diabetes	Type 2 Diabetes
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
		AND	AND	AND
Inclusion/Exclusion Criteria	Include or Exclude	Inclusion	Inclusion	Inclusion
	Conditions	Any oral anti-diabetic drug	Any oral anti-diabetic drug	Any oral anti-diabetic drug
	Code Details (type, days supply, etc.)	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No

Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 7-9) (Continued)

		Cohort Group 7	Cohort Group 8	Cohort Group 9
		Liraglutide (Victoza)	Dulaglutide (Trulicity)	Insulin degludec and liraglutide (Xultophy)
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
Inclusion/Exclusion Criteria		AND (	AND (	AND (
	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Insulin	Insulin	Insulin
	Code Details (type, days supply, etc.)	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
		AND NOT	AND NOT	AND NOT
Inclusion/Exclusion Criteria	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Any anti-diabetic drug other than insulin	Any anti-diabetic drug other than insulin	Any anti-diabetic drug other than insulin
	Code Details (type, days supply, etc.)	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
		OR	OR	OR
	Include or Exclude	Exclusion	Exclusion	Exclusion
Inclusion/Exclusion Criteria	Conditions	Type 1 Diabetes	Type 1 Diabetes	Type 1 Diabetes
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No

Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 7-9) (Continued)

		Cohort Group 7	Cohort Group 8	Cohort Group 9
		Liraglutide (Victoza)	Dulaglutide (Trulicity)	Insulin degludec and liraglutide (Xultophy)
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
Inclusion/Exclusion Criteria		OR	OR	OR
	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Gestational Diabetes	Gestational Diabetes	Gestational Diabetes
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
		OR	OR	OR
Inclusion/Exclusion Criteria	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Other secondary diabetes illness	Other secondary diabetes illness	Other secondary diabetes illness
	Code Details (type, days supply, etc.)	Dispensing (RX) codes	Dispensing (RX) codes	Dispensing (RX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
		OR	OR	OR
	Include or Exclude	Exclusion	Exclusion	Exclusion
Inclusion/Exclusion Criteria	Conditions	Short-acting GLP-1 RA (Bvetta. Adlvxin. Soliqua)	Short-acting GLP-1 RA (Bvetta. Adlvxin. Soliqua)	Short-acting GLP-1 RA (Bvetta. Adlvxin. Soliqua)
	Code Details (type, days supply, etc.)	Dispensing (RX) code	Dispensing (RX) code	Dispensing (RX) code
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No

Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 7-9) (Continued)

		Cohort Group 7	Cohort Group 8	Cohort Group 9
		Liraglutide (Victoza)	Dulaglutide (Trulicity)	Insulin degludec and liraglutide (Xultophy)
Inclusion/Exclusion Criteria	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x
		OR	OR	OR
	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Pregnancy	Pregnancy	Pregnancy
	Code Details (type, days supply, etc.)	Diagnosis (DX) codes	Diagnosis (DX) codes	Diagnosis (DX) codes
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
Inclusion/Exclusion (Washout) Criteria	Number of Code Occurrences	1x	1x	1x
		OR	OR	OR
	Include or Exclude	Exclusion	Exclusion	Exclusion
	Conditions	Long-acting GLP-1 RA (Bydureon, Bydureon BCISE, Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Victoza, Wegovy, Xultophy)	Long-acting GLP-1 RA (Bydureon, Bydureon BCISE, Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Victoza, Wegovy, Xultophy)	Long-acting GLP-1 RA (Bydureon, Bydureon BCISE, Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Victoza, Wegovy, Xultophy)
	Code Details (type, days supply, etc.)	Dispensing (RX) code	Dispensing (RX) code	Dispensing (RX) code
	Care Setting/PDX	Any	Any	Any
	Lookback Period	(-365, -1)	(-365, -1)	(-365, -1)
	Only consider dispensing date when considering washout, i.e. ignore days supply (after stockpiling)?	No	No	No
	Forced supply to attach to codes	N/A	N/A	N/A
	Number of Code Occurrences	1x	1x	1x

Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 7-9) (Continued)

		Cohort Group 7	Cohort Group 8	Cohort Group 9
		Liraglutide (Victoza)	Dulaglutide (Trulicity)	Insulin degludec and liraglutide (Xultophy)
Stockpiling	Group(s) Affected by Custom Stockpiling Rules	Long or Short-acting GLP-1 RAs by brand name (for Victoza, both brand names consolidated to one stockgroup) (Other RXs by generic name, default stockpiling rules)	Long or Short-acting GLP-1 RAs by brand name (for Victoza, both brand names consolidated to one stockgroup) (Other RXs by generic name, default stockpiling rules)	Long or Short-acting GLP-1 RAs by brand name (for Victoza, both brand names consolidated to one stockgroup) (Other RXs by generic name, default stockpiling rules)
	Same Day Processing (days supply)	Max	Max	Max
	Same Day Processing (amount supply)	Max	Max	Max
	Allowable Range (days supply)	Greater than 0	Greater than 0	Greater than 0
	Allowable Range (amount supply)	Greater than 0	Greater than 0	Greater than 0
	Maximum Amount of Percentage Overlap Allowed Prior to Shifting Dispensing Date	0% (No shifting of index date; truncate previous dispensing at any overlap with next dispensing)	0% (No shifting of index date; truncate previous dispensing at any overlap with next dispensing)	0% (No shifting of index date; truncate previous dispensing at any overlap with next dispensing)
Baseline Covariates	Covariates	(See Appendix I)	(See Appendix I)	(See Appendix I)
	Code Details (type, days supply, etc.)	(See Appendix I)	(See Appendix I)	(See Appendix I)
	Care Setting/PDX	N/A	N/A	N/A
	Covariate evaluation window (days)	(See Appendix I)	(See Appendix I)	(See Appendix I)
Utilization/Comorbidity Score	Comorbidity Score evaluation window	(-365, -1)	(-365, -1)	(-365, -1)
	Medical Utilization Evaluation Window	(-365, -1)	(-365, -1)	(-365, -1)
	Medical Utilization Care setting	IP, IS, AV, OA, ED	IP, IS, AV, OA, ED	IP, IS, AV, OA, ED
	Drug Utilization Evaluation Window	(-365, -1)	(-365, -1)	(-365, -1)

Appendix H. Specifications Defining Parameters for this Request (Primary Analysis, Cohorts 7-9) (Continued)

	Cohort Group 7	Cohort Group 8	Cohort Group 9
	Liraglutide (Victoza)	Dulaglutide (Trulicity)	Insulin degludec and liraglutide (Xultophy)

Abbreviations:

DP: Data Partner

IP: Inpatient

ED: Emergency Department

HOI: Health Outcome of Interest

PDX: Principal Discharge Diagnosis Flag

IPP: Inpatient Hospital Stays, Principal Diagnoses

IS: Non-acute Institutional Stay

AV: Ambulatory Visits

OA: Other Ambulatory Visits

N/A: Not applicable

Appendix I. Specifications Defining Parameters for Baseline Characteristics in this Request (Primary Analysis)

							Only consider dispensing date when considering baseline characteristics, i.e. ignore days supply (after stockpiling)?	Forced supply to attach to codes
Group	No.	Covariate	Care Setting	Covariate Window	Code Type	Minimum # of Instances		
Demographic Characteristics	N/A	Continuous age	N/A	Index Day	N/A	N/A	N/A	N/A
	N/A	Age groups (0-40, 41-64, 65-74, 75-84, ≥85)	N/A	Index Day	N/A	N/A	N/A	N/A
	N/A	Race (White, Black or African American, Asian, American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, Unknown, Multi-Racial)	N/A	Index Day	N/A	N/A	N/A	N/A
	N/A	Sex (M F)	N/A	Index Day	N/A	N/A	N/A	N/A
	N/A	Calendar year	N/A	Index Day	N/A	N/A	N/A	N/A
Lifestyle Risk Factor	1	Alcohol use or abuse	Any	(-365, -1)	Diagnosis	1x	No	N/A
	2	Obesity	Any	(-365, -1)	Diagnosis	1x	N/A	N/A
	3	Tobacco Use	Any	(-365, -1)	Diagnosis	1x	No	N/A
Medical History	4	Arrhythmia	Any	(-365, -1)	Diagnosis	1x	No	N/A
	5	Cerebrovascular disease/stroke/transient ischemic attack	Any	(-365, -1)	Diagnosis	1x	No	N/A
	6	Chronic kidney disease	Any	(-365, -1)	Diagnosis	1x	No	N/A
	7	Chronic obstructive pulmonary disease	Any	(-365, -1)	Diagnosis	1x	No	N/A
	8	Congenital heart disease	Any	(-365, -1)	Diagnosis	1x	No	N/A
	9	Heart failure	Any	(-365, -1)	Diagnosis	1x	No	N/A
	10	Hyperlipidemia	Any	(-365, -1)	Diagnosis	1x	No	N/A
	11	Hypertensive disease	Any	(-365, -1)	Diagnosis	1x	No	N/A
	12	Thyroid disease	Any	(-365, -1)	Diagnosis	1x	No	N/A
	13	Ischemic heart disease/coronary artery disease/myocardial infarction	Any	(-365, -1)	Diagnosis	1x	No	N/A
	14	Left ventricular hypertrophy	Any	(-365, -1)	Diagnosis	1x	No	N/A
	15	Peripheral artery disease	Any	(-365, -1)	Diagnosis	1x	No	N/A
	16	Valvular/mitral valve disease	Any	(-365, -1)	Diagnosis	1x	No	N/A
	17	Diseases of veins and lymphatics, and other diseases of circulatory system	Any	(-365, -1)	Diagnosis	1x	No	N/A
	18	Obstructive sleep apnea	Any	(-365, -1)	Diagnosis	1x	No	N/A
	19	Hypertrophic cardiomyopathy	Any	(-365, -1)	Diagnosis	1x	No	N/A

Appendix I. Specifications Defining Parameters for Baseline Characteristics in this Request (Primary Analysis)

							Only consider dispensing date when considering baseline characteristics, i.e. ignore days supply (after stockpiling)?	Forced supply to attach to codes
Group	No.	Covariate	Care Setting	Covariate Window	Code Type	Minimum # of Instances		
	20	Other cardiac disease (heart failure, ischemic heart disease/coronary artery disease/myocardial infarction, hypertension, valvular disease, obstructive sleep apnea, and hypertrophic cardiomyopathy)	N/A	N/A	Complex Covariate	N/A	N/A	N/A
	21	Tachyarrhythmia Day 0	Any	(0, 0)	Diagnosis	1x	No	N/A
	22	Hospitalized Tachyarrhythmia Day 0	ED*, IP*	(0, 0)	Diagnosis	1x	No	N/A
	Risk score	Charlson/Elixhauser combined comorbidity index	N/A	(-365, -1)	N/A	N/A	N/A	N/A
	Risk score (custom)	Charlson/Elixhauser combined comorbidity index (0)	N/A	(-365, -1)	Custom Coding	N/A	N/A	N/A
	Risk score (custom)	Charlson/Elixhauser combined comorbidity index (1 or 2)	N/A	(-365, -1)	Custom Coding	N/A	N/A	N/A
	Risk score (custom)	Charlson/Elixhauser combined comorbidity index (3 or 4)	N/A	(-365, -1)	Custom Coding	N/A	N/A	N/A
	Risk score (custom)	Charlson/Elixhauser combined comorbidity index (5 or greater)	N/A	(-365, -1)	Custom Coding	N/A	N/A	N/A
Severity of Diabetes	Risk score	Diabetes complications severity index	Any	(-365, -1)	Risk Score	1x	No	N/A
	Risk score (custom)	Diabetes complications severity index (0)	Any	(-365, -1)	Custom Coding	1x	No	N/A
	Risk score (custom)	Diabetes complications severity index (1)	Any	(-365, -1)	Custom Coding	1x	No	N/A
	Risk score (custom)	Diabetes complications severity index (2)	Any	(-365, -1)	Custom Coding	1x	No	N/A
	Risk score (custom)	Diabetes complications severity index (3)	Any	(-365, -1)	Custom Coding	1x	No	N/A
	Risk score (custom)	Diabetes complications severity index (4)	Any	(-365, -1)	Custom Coding	1x	No	N/A
	Risk score (custom)	Diabetes complications severity index (5 or greater)	Any	(-365, -1)	Custom Coding	1x	No	N/A

Appendix I. Specifications Defining Parameters for Baseline Characteristics in this Request (Primary Analysis)

							Only consider dispensing date when considering baseline characteristics, i.e. ignore days supply (after stockpiling)?	Forced supply to attach to codes
Group	No.	Covariate	Care Setting	Covariate Window	Code Type	Minimum # of Instances		
Baseline Use of Antidiabetic Drug	25	History of serious hypoglycemia (emergency department visit and/or inpatient care)	ED*, IP*	(-365, -1)	Diagnosis	1x	No	N/A
	26	Alpha-glucosidase inhibitors	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	27	Amylin analogs (Pramlintide)	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	28	Dipeptidyl peptidase 4 (DPP-4) inhibitors	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	29	Incretin mimetics (Dipeptidyl peptidase 4 (DPP-4) inhibitors, Victoza, Byetta, Bydureon, Bydureon BCISE)	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	30	Meglitinides	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	31	Insulin	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	32	Biguanides (metformin)	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	33	SGLT2 Inhibitors	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A

Appendix I. Specifications Defining Parameters for Baseline Characteristics in this Request (Primary Analysis)

							Only consider dispensing date when considering baseline characteristics, i.e. ignore days supply (after stockpiling)?	Forced supply to attach to codes
Group	No.	Covariate	Care Setting	Covariate Window	Code Type	Minimum # of Instances		
Baseline Use of Other Medications	34	Sulfonylurea	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	35	Thiazolidinedione						
	36	No baseline use of any of the above antidiabetic drugs	N/A	N/A	Complex Covariate	N/A	N/A	N/A
	37	Other antidiabetic drugs (bromocriptine, mifepristone)	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	38	Sodium channel blockers	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	39	Beta blockers	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	40	Potassium channel blockers/openers	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	41	Non-dihydropyridine calcium channel blockers	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	42	Digoxin	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A

Appendix I. Specifications Defining Parameters for Baseline Characteristics in this Request (Primary Analysis)

Group	No.	Covariate	Care Setting	Covariate Window	Code Type	Minimum # of Instances	Only consider dispensing date when considering baseline characteristics, i.e. ignore days supply (after stockpiling)?		Forced supply to attach to codes
	43	Other antiarrhythmic agents	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No		N/A
	44	Antiarrhythmic agents (any of the above antiarrhythmic agents)	N/A	N/A	Complex Covariate	N/A	N/A		N/A
	45	Angiotensin-converting-enzyme (ACE) inhibitor	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No		N/A
	46	Angiotensin II receptor blockers (ARB)	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No		N/A
	47	Dihydropyridines	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No		N/A
	48	Diuretics	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No		N/A
	49	Other antihypertensives	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No		N/A
	50	Antihypertensives (any of the above antihypertensives)	N/A	N/A	Complex Covariate	N/A	N/A		N/A
	51	Oral anticoagulants	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No		N/A
	52	Vitamin K antagonists	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No		N/A

Appendix I. Specifications Defining Parameters for Baseline Characteristics in this Request (Primary Analysis)

							Only consider dispensing date when considering baseline characteristics, i.e. ignore days supply (after stockpiling)?	Forced supply to attach to codes
Group	No.	Covariate	Care Setting	Covariate Window	Code Type	Minimum # of Instances		
	53	Other cardiac medications (not including oral anticoagulants or vitamin K antagonists)	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	54	Other cardiac medications (any of above "other" medications")	N/A	N/A	Complex Covariate	N/A	N/A	N/A
	55	Lipid lowering therapy	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	56	Drugs with a known risk of prolonged QT and Torsades de Pointes	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
	57	Drugs with a known/possible/conditional risk of prolonged QT and Torsades de Pointes	N/A	(-365, -1)	Dispensings (Dispensings Table)	1x	No	N/A
Concomitant use of drugs with a risk of prolonged QT and Torsades de Pointes	58	Drugs with a known risk of prolonged QT and Torsades de Pointes	N/A	(0, 0)	Dispensings (Dispensings Table)	1x	No	N/A
	59	Drugs with a known/possible/conditional risk of prolonged QT and Torsades de Pointes	N/A	(0, 0)	Dispensings (Dispensings Table)	1x	No	N/A
Intensity of Health Care Utilization	N/A	Number of inpatient hospital stays	IP*	(-365, -1)	N/A	N/A	N/A	N/A
	N/A	Number of non-acute institutional stays	IS*	(-365, -1)	N/A	N/A	N/A	N/A
	N/A	Number of emergency department visits	ED*	(-365, -1)	N/A	N/A	N/A	N/A
	N/A	Number of ambulatory visits	AV*	(-365, -1)	N/A	N/A	N/A	N/A
	N/A	Number of other ambulatory visits (includes other non overnight ambulatory encounters such as home health visits, telemedicine, telephone and email consultations)	OA*	(-365, -1)	N/A	N/A	N/A	N/A
Intensity of	N/A	Number of dispensings	N/A	(-365, -1)	N/A	N/A	N/A	N/A

Appendix I. Specifications Defining Parameters for Baseline Characteristics in this Request (Primary Analysis)

							Only consider dispensing date when considering baseline characteristics, i.e. ignore days supply (after stockpiling)?	Forced supply to attach to codes
Group	No.	Covariate	Care Setting	Covariate Window	Code Type	Minimum # of Instances		
Drug	N/A	Number of unique generics dispensed	N/A	(-365, -1)	N/A	N/A	N/A	N/A
Utilization	N/A	Number of unique drug classes dispensed	N/A	(-365, -1)	N/A	N/A	N/A	N/A

N/A: Not Applicable

Appendix J. Specifications Defining Combination Code Parameters Used in this Request (Primary Analysis)

Order	Combo description	Purpose	Final Combo	Order within Combo	Base component	Time window between components	AND / AND NOT?	Combined-to component	New Anchor Date	New Episode Length	Details
1	IP encounter Other than Non-HOI Hospitalized Tachyarrhythmia	Truncation	RX (IPENCOUNTER)	1	IP or ED encounter (EN01)	(0, 0)	AND NOT	Pregnancy (any) or Tachyarrhythmia (any)	Start date of base component	Start date of IP encounter	- This will prevent IP/ED encounters from reporting IP/ED pregnancy codes in the code distribution for truncation codes. - All tachyarrhythmia codes in all care settings are excluded in this combo so that hospitalized tachyarrhythmia (IPP, ED*) will be used as truncation criteria for cohorts where the hospitalized tachyarrhythmia code is not used
2	ED encounter Other than Non-HOI Hospitalized Tachyarrhythmia	Truncation	RX (EDENCOUNTER)	1	IP or ED encounter (EN01)	(0, 0)	AND NOT	Pregnancy (any) or Tachyarrhythmia (any)	Start date of base component	Start date of ED encounter	- This will prevent IP/ED encounters from reporting IP/ED pregnancy codes in the code distribution for truncation codes. - All tachyarrhythmia codes in all care settings are excluded in this combo so that hospitalized tachyarrhythmia (IPP, ED*) will be used as truncation criteria for cohorts where the hospitalized tachyarrhythmia code is not used

Abbreviations:


IP: Inpatient

ED: Emergency Department

N/A: Not applicable

Appendix K. Design Diagram for this Request

Type 2 design diagram: Primary analysis



Abbreviations:

DP: Data Partner

ER: Emergency Room

HOI: Health Outcome of Interest

GLP-1 RA: Glucagon-like Peptide 1 Receptor Agonist

Appendix K. Design Diagram for this Request

*Exclusion Criteria

Window 1: use of insulin without other anti-diabetic drugs, type 1 diabetes, gestational diabetes, other secondary diabetes illnesses, short-acting GLP-1 RAs, pregnancy, long-acting GLP-1 RAs

**Inclusion Criteria

Window A: type 2 diabetes, any oral anti-diabetic drug

***Covariates:

Window I: Age, year, race, sex

Window II: Charlson/Elixhauser combined comorbidity index, adapted Diabetes Complications Severity Index (ADCSI), alcohol use or abuse, obesity, tobacco use, arrhythmia, cerebrovascular disease/stroke/transient ischemic attack, chronic kidney disease, COPD, congenital heart disease, heart failure, hyperlipidemia, hypertensive disease, thyroid disease, ischemic heart disease/coronary artery disease/myocardial infarction, left ventricular hypertrophy, peripheral artery disease, valvular/mitral valve disease, diseases of veins and lymphatics and other diseases of circulatory system, obstructive sleep apnea, hypertrophic cardiomyopathy, other cardiac diseases, history of serious hypoglycemia, alpha-glucosidase inhibitor, amylin analogs (pramlintide), DPP-4 inhibitors, incretin mimetics, meglitinides, insulin, biguanides, SGLT-2 inhibitors, sulfonylurea, thiazolidinedione, no baseline use of above mentioned antidiabetic drugs, sodium channel blocker, beta blocker, potassium channel blockers/openers, non-dihydropyridine calcium channel blockers, digoxin, other antiarrhythmic agents, any of the above mentioned antiarrhythmic agents, ACE inhibitor, ARBs, dihydropyridines, diuretic, other antihypertensives, any of the above mentioned antihypertensives, oral anticoagulants, vitamin K antagonists, other cardiac medications (not including oral anticoagulants or vitamin K antagonists), any of the above mentioned "other" medications, lipid lowering therapy, drugs with a known risk of Prolong QT and Torsades de Pointes, drugs with a known/possible/conditional risk of Prolong QT and Torsades de Pointes, healthcare and utilization metrics

Window III: tachyarrhythmia, hospitalized tachyarrhythmia, drugs with a known risk of Prolong QT and Torsades de Pointes, drugs with a known/possible/conditional risk of Prolong QT and Torsades de Pointes